

10/766, 948

EAST Search History

Ref #	Hits	Search Query	DBs	Default Operator	Plurals	Time Stamp
S1	394	544/349 OR 544/350 OR 544/353 OR 544/354 OR 544/355	US-PGPUB; USOCR; EPO; JPO; DERWENT	OR	OFF	2006/02/27 13:37
S2	63	S1 AND (CYCLOPENTA OR DIMETHYLCYCLOHEXYL OR METABOTROPIC OR GLUTAMATE OR MGLUR)	US-PGPUB; USOCR; EPO; JPO; DERWENT	OR	OFF	2006/02/27 13:37
S3	1370	544/349 OR 544/350 OR 544/353 OR 544/354 OR 544/355	USPAT	OR	OFF	2006/02/27 13:37
S4	0	S2 AND (CYCLOPENTA OR DIMETHYLCYCLOHEXYL OR METABOTROPIC OR GLUTAMATE OR MGLUR)	USPAT	OR	OFF	2006/02/27 13:38
S5	133	S3 AND (CYCLOPENTA OR DIMETHYLCYCLOHEXYL OR METABOTROPIC OR GLUTAMATE OR MGLUR)	USPAT	OR	OFF	2006/02/27 13:38
S6	75	S5 AND (GLUTAMATE ADJ RECEPTOR OR NMDA OR MGLUR OR METABOTROPIC)	USPAT	OR	OFF	2006/02/27 13:39

STN SEARCH TRANSCRIPT

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:SSSPTA1613ZCT

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR 7):2

***** Welcome to STN International *****

NEWS 1 Web Page URLs for STN Seminar Schedule - N. America
 NEWS 2 "Ask CAS" for self-help around the clock
 NEWS 3 DEC 05 CASREACT(R) - Over 10 million reactions available
 NEWS 4 DEC 14 2006 MESH terms loaded in MEDLINE/LAGOLINE
 NEWS 5 DEC 14 2006 MESH terms loaded for MEDLINE file segment of TOXCENTER
 NEWS 6 DEC 14 CA/Caplus to be enhanced with updated IPC codes
 NEWS 7 DEC 21 IPC search and display fields enhanced in CA/Caplus with the
 IPC reform
 NEWS 8 DEC 23 New IPC SEARCH, DISPLAY, and SELECT fields in USPATFULL/
 USPAT2
 NEWS 9 JAN 13 IPC 8 searching in IPAT, IPIUDS, and IPIUDS
 NEWS 10 JAN 13 New IPC 8 SEARCH, DISPLAY, and SELECT enhancements added to
 INPADOC
 NEWS 11 JAN 17 Pre-1988 INPI data added to WARPAT
 NEWS 12 JAN 17 IPC 8 in the WPI family of databases including WPIFV
 NEWS 13 JAN 30 Saved answer limit increased
 NEWS 14 JAN 31 Monthly current-awareness alert (SDI) frequency
 added to TULSA
 NEWS 15 FEB 21 STN AnaVist, Version 1.1, lets you share your STN AnaVist
 visualization results
 NEWS 16 FEB 22 Status of current MO (PCT) information on STN
 NEWS 17 FEB 22 The IPC thesaurus added to additional patent databases on STN
 NEWS 18 FEB 22 Updates in EPFULL; IPC 8 enhancements added
 NEWS EXPRESS FEBRUARY 15 CURRENT VERSION FOR WINDOWS IS V8.01a,
 CURRENT MACINTOSH VERSION IS V8.0c(SM) AND V8.01c(JP),
 AND CURRENT DISCOVER FILE IS DATED 19 DECEMBER 2005.
 V8.0 AND V8.01 USERS CAN OBTAIN THE UPGRADE TO V8.01a AT
<http://download.cas.org/express/v8.0-Discover/>
 NEWS HOURS STN Operating Hours Plus Help Desk Availability
 NEWS INTER General Internet Information
 NEWS LOGIN Welcome Banner and News Items
 NEWS PHONE Direct Dial and Telecommunication Network Access to STN
 NEWS WWW CAS World Wide Web Site (general information)

Enter NEWS followed by the item number or name to see news on that
 specific topic.

All use of STN is subject to the provisions of the STN Customer
 agreement. Please note that this agreement limits use to scientific
 research. Use for software development or design or implementation
 of commercial gateways or other similar uses is prohibited and may
 result in loss of user privileges and other penalties.

***** STN Columbus *****

FILE 'HOME' ENTERED AT 08:02:15 ON 28 FEB 2006

5-7 7-9 7-10 10-11 11-12
 ring bonds :
 1-2 1-6 2-3 2-15 3-4 3-15 4-5 5-6
 exact/norm bonds :
 2-15 3-15 5-7 7-9 7-10 10-11 11-12
 normalized bonds :
 1-2 1-6 2-3 3-4 4-5 5-6
 isolated ring systems :
 containing 1 :

G1:O,S

G2:C,O,S,N

Match level :

1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:CLASS 9:CLASS 10:CLASS
 11:CLASS 12:Atom 15:Atom

L1 STRUCTURE UPLOADED


>> que L1

L2 QUE L1

>> D L1

L1 HAS NO ANSWERS

L1 STR



G1 O,S

G2 C,O,S,N

Structure attributes must be viewed using STN Express query preparation.

>> S L1
 SAMPLE SEARCH INITIATED 08:10:35 FILE 'REGISTRY'
 SAMPLE SCREEN SEARCH COMPLETED - 329 TO ITERATE

100.0% PROCESSED 329 ITERATIONS 50 ANSWERS
 INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)
 SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
 BATCH **COMPLETE**
 PROJECTED ITERATIONS: 5492 TO 7668
 PROJECTED ANSWERS: 964 TO 1996

L3 50 SEA SSS SAM L1

>> FILE REQ
 COST IN U.S. DOLLARS
 FULL ESTIMATED COST

SINCE FILE
 ENTRY
 TOTAL
 SESSION
 0.21 0.21

FILE 'REGISTRY' ENTERED AT 08:02:30 ON 28 FEB 2006
 USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
 PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
 COPYRIGHT (C) 2006 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
 provided by InfoChem.

STRUCTURE FILE UPDATES: 26 FEB 2006 HIGHEST RN 875270-69-2
 DICTIONARY FILE UPDATES: 26 FEB 2006 HIGHEST RN 875270-69-2

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH January 6, 2006

Please note that search-term pricing does apply when
 conducting SmartSELECT searches.

 * The CA roles and document type information have been removed from *
 * the IDE default display format and the ED field has been added, *
 * effective March 20, 2005. A new display format, IDERL, is now *
 * available and contains the CA role and document type information. *

Structure search iteration limits have been increased. See HELP SLIMITS
 for details.


REGISTRY includes numerically searchable data for experimental and
 predicted properties as well as tags indicating availability of
 experimental property data in the original document. For information
 on property searching in REGISTRY, refer to:

<http://www.cas.org/ONLINE/UG/regprops.html>

>>Testing the current file.... screen

ENTER SCREEN EXPRESSION OR (END):end

>> Uploading C:\Program Files\Stnexp\Queries\METABOTROPIC GLUTAMATE.str



chain nodes :
 7 9 10 11 12

ring nodes :
 1 2 3 4 5 6 15

chain bonds :

>> S L1 SSS FULL
 FULL SEARCH INITIATED 08:12:01 FILE 'REGISTRY'
 FULL SCREEN SEARCH COMPLETED - 6431 TO ITERATE

100.0% PROCESSED 6431 ITERATIONS 1369 ANSWERS
 SEARCH TIME: 00.00.06

L4 1369 SEA SSS FUL L1

>> FILE CAPLUS
 COST IN U.S. DOLLARS
 FULL ESTIMATED COST

SINCE FILE
 ENTRY
 TOTAL
 SESSION
 173.54 173.75

FILE 'CAPLUS' ENTERED AT 08:12:12 ON 28 FEB 2006
 USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
 PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
 COPYRIGHT (C) 2006 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is
 held by the publishers listed in the PUBLISHER (PB) field (available
 for records published or updated in Chemical Abstracts after December
 26, 1996), unless otherwise indicated in the original publications.
 The CA Lexicon is the copyrighted intellectual property of the
 American Chemical Society and is provided to assist you in searching
 databases on STN. Any dissemination, distribution, copying, or storing
 of this information, without the prior written consent of CAS, is
 strictly prohibited.

FILE COVERS 1907 - 28 Feb 2006 VOL 144 ISS 10
 FILE LAST UPDATED: 27 Feb 2006 (20060227/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply.
 They are available for your review at:

<http://www.cas.org/infopolicy.html>

>> S L4

L5 283 L4

>> FILE REQ
 COST IN U.S. DOLLARS
 FULL ESTIMATED COST

SINCE FILE
 ENTRY
 TOTAL
 SESSION
 0.46 174.21

FILE 'REGISTRY' ENTERED AT 08:12:45 ON 28 FEB 2006
 USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
 PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
 COPYRIGHT (C) 2006 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
 provided by InfoChem.

STRUCTURE FILE UPDATES: 26 FEB 2006 HIGHEST RN 875270-69-2
 DICTIONARY FILE UPDATES: 26 FEB 2006 HIGHEST RN 875270-69-2

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH January 6, 2006

Please note that search-term pricing does apply when
 conducting SmartSELECT searches.

strictly prohibited.

FILE COVERS 1907 - 28 Feb 2006 VOL 144 ISS 10
FILE LAST UPDATED: 27 Feb 2006 (20060227/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply.
They are available for your review at:

<http://www.cas.org/infopolicy.html>

>> D 6-10

L5 ANSWER 6 OF 283 CAPLUS COPYRIGHT 2006 ACS on STN
AN 2005:1251676 CAPLUS
DN 144:150330
TI Design of novel hexahydropyrazinoquinolines as potent and selective
dopamine D1 receptor ligands with improved solubility
Chen, Jianyong; Ding, Ke; Levant, Beth; Wang, Shaocong
CS Departments of Internal Medicine and Medicinal Chemistry, University of
Michigan, Ann Arbor, MI, 48109-0934, USA
SO Bioorganic & Medicinal Chemistry Letters (2006), 16(2), 443-446
CODEN: BMCLB; ISSN: 0960-894X
PB Elsevier B.V.
DT Journal
LA English
RE.CNT 16 THERE ARE 16 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 7 OF 283 CAPLUS COPYRIGHT 2006 ACS on STN
AN 2005:1201037 CAPLUS
DN 143:460276
TI Phosphate/sulfate ester compounds and pharmaceutical compositions for
inhibiting protein interacting NIMA (PIN 1)
IN Dagostino, Eleanor; Dong, Liming; Guo, Chuangxing; Hou, Xijun; Margosiak,
Stephen
PA Pfizer Inc., USA
SO U.S. Pat. Appl. Publ., 82 pp.
CODEN: USXXCO
DT Patent
LA English
FAN.CNT 1


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI US 2005250742	A1	20051110	US 2004-792241	20040303
PRAI US 2004-792241		20040303		
OS MARPAT 143:460276				

L5 ANSWER 8 OF 283 CAPLUS COPYRIGHT 2006 ACS on STN
AN 2005:1103757 CAPLUS
DN 143:387051
TI Preparation of pyrimidine derivatives as MCH antagonists for treatment of
CNS disorders
IN Sekiguchi, Yoshinori; Kanuma, Kousuke; Omodesu, Katsunori; Tran, Thuy-Anh;
Semple, Graeme; Kramer, Bryan A.
PA Taiho Pharmaceutical Co., Ltd., Japan; Arena Pharmaceuticals, Inc
SO PCT Int. Appl., 281 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2005095357	A2	20051013	WO 2005-JP6582	20050329
W: AS, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD,				

IT 774242-66-9P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU
(Therapeutic use); BIOL (Biological study); PREP (Preparation); USES
(Uses)
(preparation of phosphate/sulfate ester compds. and their pharmaceutical
compns. for inhibition of protein interacting nima (PIN 1))
RN 774242-66-9 CAPLUS
CN 2-Quinoxalinecarboxamide, N-((1R)-1-(phenylethyl)-2-(phosphonoxy)ethyl]-
(9CI) (CA INDEX NAME)

Absolute stereochemistry.



>> D 11-15

L5 ANSWER 11 OF 283 CAPLUS COPYRIGHT 2006 ACS on STN
AN 2005:604277 CAPLUS
DN 143:286667
TI One-Head-One-Compound Library of End-Capped Dipeptides and Deconvolution
by Microflow NMR
AU Simon, Rozalyn A.; Schuresko, Laura; Dendukuri, Nagamani; Goers, Emily;
Murphy, Brent; Lokey, R. Scott
CS Department of Chemistry and Biochemistry, University of California, Santa
Cruz, CA, 95064, USA
SO Journal of Combinatorial Chemistry (2005), 7(5), 697-702
CODEN: JCHIFF; ISSN: 1520-4766
PB American Chemical Society
DT Journal
LA English
RE.CNT 17 THERE ARE 17 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 12 OF 283 CAPLUS COPYRIGHT 2006 ACS on STN
AN 2005:479511 CAPLUS
DN 143:172833
TI Process Development of CP-481715, a Novel CCR1 Antagonist
LI, Bryan; Andersen, Brian; Brown, Matthew F.; Buzon, Richard A.; Chiu,
Charles K.-F.; Couturier, Michel; Dias, Eric; Urban, Frank J.; Jasys, V.
John; Kath, John C.; Kissel, William; Le, Tung; Li, Z. Jane; Negri,
Joanna; Poss, John; Christopher S.; Tucker, John; Whritenour, David; Zandi,
Kathleen
CS Gilead Laboratories, Pfizer Global Research and Development, Groton, CT,
06340, USA
SO Organic Process Research & Development (2005), 9(4), 466-471
CODEN: OPDPFK; ISSN: 1083-6160
PB American Chemical Society
DT Journal
LA English
OS CASREACT 143:172833
RE.CNT 20 THERE ARE 20 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 13 OF 283 CAPLUS COPYRIGHT 2006 ACS on STN
AN 2005:470256 CAPLUS

GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,
LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MO, MU, MY, NA, NI,
NO, NZ, OM, OS, PA, PE, PF, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM,
SV, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM,
AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK,
EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT,
RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GO, GW, ML,
MR, NE, SN, TD, TO

PRAI US 2004-557406P P 20040330
OS MARPAT 143:387051

L5 ANSWER 9 OF 283 CAPLUS COPYRIGHT 2006 ACS on STN
AN 2005:1075759 CAPLUS
DN 143:367087
TI Preparation of benzamide and nicotinamide derivatives as opioid receptor
antagonists
IN Chappell, Mark Donald; Mitch, Charles Howard; Quimby, Steven James;
Siegel, Miles Goodman
PA Eli Lilly and Company, USA
SO PCT Int. Appl., 77 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2005095357	A1	20051013	WO 2005-056723	20050303
W: AS, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MO, MU, MY, NA, NI, NO, NZ, OM, OS, PA, PE, PF, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SV, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW RW, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GO, GW, ML, MR, NE, SN, TD, TO				

PRAI US 2004-553175P P 20040315
OS MARPAT 143:367087

RE.CNT 22 THERE ARE 22 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 10 OF 283 CAPLUS COPYRIGHT 2006 ACS on STN
AN 2005:1018895 CAPLUS
DN 143:415566
TI G-Protein-Coupled Receptor Affinity Prediction Based on the Use of a
Profiling Dataset: QSAR Design, Synthesis, and Experimental Validation
AU Rolland, Catherine; Gosalbes, Rafael; Nicolaie, Eric; Paugam,
Marie-France; Coussy, Laurent; Barbosa, Frederique; Horvath, Dragos;
Revah, Frederic
CS Cerop, Rueil-Malmaison, 92500, Fr.
SO Journal of Medicinal Chemistry (2005), 48(21), 6563-6574
CODEN: JMCMAR; ISSN: 0022-2623
PB American Chemical Society
DT Journal
LA English
RE.CNT 26 THERE ARE 26 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

>> D 7 HITSTR

L5 ANSWER 7 OF 283 CAPLUS COPYRIGHT 2006 ACS on STN

DN 143:20052
TI Urea derivatives as kinase modulators
IN Minakov, Zdravko V.; Patel, Hitesh K.; Grotzfeld, Robert M.; Mehta, Shamel
A.; Andili, Lei G.; Lockhart, David J.
PA Ambit Biosciences Corporation, USA
SO PCT Int. Appl., 350 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 2

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2005048948	A2	20050602	WO 2004-US38288	20041115
WO 2005048948	A3	20050728		
W: AS, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MO, MU, MY, NA, NI, NO, NZ, OM, OS, PA, PE, PF, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SV, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW RW, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GO, GW, ML, MR, NE, SN, TD, TO				
US 2005146605	A1	20050707	US 2004-989745	20041115
US 2005165031	A1	20050728	US 2004-989814	20041115
US 2005165024	A1	20050728	US 2004-989824	20041115
US 2005165074	A1	20050728	US 2004-990007	20041115
US 2005171171	A1	20050804	US 2004-989766	20041115
US 2005171172	A1	20050804	US 2004-989823	20041115
US 2005192314	A1	20050901	US 2004-990195	20041115
US 2005197371	A1	20050908	US 2004-990194	20041115
US 2005267182	A1	20051124	US 2004-989623	20041115
US 2005267182	A1	20051120	US 2004-989717	20041115
PRAI US 2003-520273P	P	20031113		
US 2003-527094P	P	20031203		
US 2003-531082P	P	20031218		
US 2003-531243P	P	20031218		
OS MARPAT 143:20052				

L5 ANSWER 14 OF 283 CAPLUS COPYRIGHT 2006 ACS on STN
AN 2005:324151 CAPLUS
DN 142:373847
TI Preparation of [1-(quinolinyl)ethyl]phenyl tetrazoles as P-glycoprotein
inhibitors
IN Sang, Yeuk Chan; Cha, Mi Young; Ahn, Young Gil; Ham, Young Jin; Kim, Maeng
Sup; Lee, Gwan Sun
PA Hammi Pharm. Co., Ltd., S. Korea
SO PCT Int. Appl., 53 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2005031097	A1	20050414	WO 2004-KR2550	20041006
W: AS, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MO, MU, MY, NA, NI, NO, NZ, OM, OS, PA, PE, PF, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SV, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW RW, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK,				

.....
* The CA roles and document type information have been removed from
* the IDE default display format and the ED field has been added.
* effective March 20, 2005. A new display format, IDEAL, is now
* available and contains the CA role and document type information.
.....

Structure search iteration limits have been increased. See HELP SLIMITS
for details.

REGISTRY includes numerically searchable data for experimental and
predicted properties as well as tags indicating availability of
experimental property data in the original document. For information
on property searching in REGISTRY, refer to:

<http://www.cas.org/ONLINE/US/regprops.html>

--> LOG HOLD
COST IN U.S. DOLLARS
FULL ESTIMATED COST

	SINCE FILE	TOTAL
	ENTRY	SESSION
	0.44	174.65

SESSION WILL BE HELD FOR 60 MINUTES
STN INTERNATIONAL SESSION SUSPENDED AT 08:12:48 ON 28 FEB 2006

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:SSSPA16232CT

PASSWORD:

***** RECONNECTED TO STN INTERNATIONAL *****
SESSION RESUMED IN FILE 'REGISTRY' AT 08:16:07 ON 28 FEB 2006
FILE 'REGISTRY' ENTERED AT 08:16:07 ON 28 FEB 2006
COPYRIGHT (C) 2006 American Chemical Society (ACS)

COST IN U.S. DOLLARS
FULL ESTIMATED COST

	SINCE FILE	TOTAL
	ENTRY	SESSION
	0.44	174.65

--> D HIS

(FILE 'HOME' ENTERED AT 08:02:15 ON 28 FEB 2006)

FILE 'REGISTRY' ENTERED AT 08:02:20 ON 28 FEB 2006

L1 STRUCTURE UPLOADED
L2 CUE L1
L3 50 S L1
L4 1369 S L1 SSS FULL

FILE 'CAPLUS' ENTERED AT 08:12:12 ON 28 FEB 2006

283 S L4

FILE 'REGISTRY' ENTERED AT 08:12:45 ON 28 FEB 2006

--> D 1-5

YOU HAVE REQUESTED DATA FROM FILE 'CAPLUS' - CONTINUE? (Y)/N:Y

PA Pharmacia Corporation, USA
SO U.S., 548 pp.
CODEN: USXXKO
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI US 6979686	B1	20051227	US 2001-21780	20011207
PRAI US 2001-21780		20011207		

RE.CNT 87 THERE ARE 87 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 4 OF 283 CAPLUS COPYRIGHT 2006 ACS ON STN
AN 2005:1288708 CAPLUS

DN 144:40787

TI Pharmaceutical compositions with enhanced performance containing
hydroxypropyl methyl cellulose derivatives

IN Babcock, Walter Christian; Priesen, Dwayne Thomas; Lyon, David Keith;

Miller, Warren Kenyon; Smithy, Daniel Tod

PA Pfizer Products Inc., USA

SO PCT Int. Appl., 73 pp.

CODEN: PIXXKD

DT Patent

LA English

FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2005115330	A2	20051208	WO 2005-1B1580	20050518

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH,
CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD,
GE, GH, GM, GR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ,
LC, LK, LR, LS, LT, LU, LV, MA, MD, ME, MG, MH, MI, MN, MO, NA,
NO, NI, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK,
SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU,
ZA, ZM, ZW

RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM,
AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK,
EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT,
RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GN, GQ, GW, ML,
MR, NE, SN, TD, TO

PRAI US 2004-575519 P 20040528
US 2004-586549 P 20040709

L5 ANSWER 5 OF 283 CAPLUS COPYRIGHT 2006 ACS ON STN
AN 2005:1288062 CAPLUS

DN 144:36196

TI Preparation of benzamide derivatives for therapeutic use as cannabinoid
receptor modulators

IN Jin, Shujuan; Liu, Ziping; Milburn, Claire; Tomaszewski, Mirosław;

Walpole, Christopher; Wei, Zhong-Yong; Yang, Hua

PA AstraZeneca AB, Swed.

SO PCT Int. Appl., 112 pp.

CODEN: PIXXKD

DT Patent

LA English

FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2005115972	A1	20051208	WO 2005-SE754	20050520

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH,
CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD,
GE, GH, GM, GR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ,
LC, LK, LR, LS, LT, LU, LV, MA, MD, ME, MG, MH, MI, MN, MO, NA,
NO, NI, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK,
SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU,
ZA, ZM, ZW

L5 ANSWER 1 OF 283 CAPLUS COPYRIGHT 2006 ACS ON STN

AN 2006:103871 CAPLUS

TI Preparation of N-(4-sulfamoylphenyl) amides as inhibitors of voltage-gated
sodium channels

IN Gonzalez, Jesus E.; Termin, Andreas P.; Martinborough, Esther; Zimmerman,
Nicole

PA USA

SO U.S. Pat. Appl. Publ., 353 pp., Cont.-in-part of U.S. Ser. No. 914,988.

CODEN: USXXKO

DT Patent

LA English

FAN.CNT 2

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI US 2006025415	A1	20060202	US 2005-60719	20050217
US 2005137190	A1	20050623	US 2004-914988	20040809
PRAI US 2003-493659P	P	20030808		
US 2004-584717P	P	20040704		
US 2004-914988	A2	20040809		

L5 ANSWER 2 OF 283 CAPLUS COPYRIGHT 2006 ACS ON STN

AN 2005:1351085 CAPLUS

DN 144:88043

TI Preparation of phenylcarboxylic acid derivatives as glucose-stimulated
insulin secretors useful in the treatment of diabetes and related diseases

IN Moisset, Gerard; Botton, Gerard; Kergoat, Micheline

PA Merck Santé, Fr.

SO Fr. Demande, 222 pp.

CODEN: FRXXSL

DT Patent

LA French

FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI FR 2872159	A1	20051230	FR 2004-7076	20040628
WO 2006002088	A1	20060105	WO 2005-EP5868	20050601

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH,
CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD,
GE, GH, GM, GR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ,
LC, LK, LR, LS, LT, LU, LV, MA, MD, ME, MG, MH, MI, MN, MO, NA,
NO, NI, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK,
SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU,
ZA, ZM, ZW

RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE,
IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF,
CG, CI, CM, GN, GQ, GW, ML, MR, NE, SN, TD, TO

KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG,
KZ, MD, RU, TJ, TM

PRAI FR 2004-7076 A 20040628

RE.CNT 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 3 OF 283 CAPLUS COPYRIGHT 2006 ACS ON STN

AN 2005:1345046 CAPLUS

DN 144:69823

TI Preparation of heteroarylpyrazoles as p38 kinase inhibitors

IN Hareian, Ashok S.; Clare, Michael; Collins, Paul W.; Crich, Joyce Zuovu;

Devraj, Rajesh; Flynn, Daniel L.; Geng, Lifeng; Granoto, Matthew J.;

Hanau, Cathleen E.; Hanson, Gunner J.; Hartmann, Susan J.; Hepperle,
Michael; Huang, He; Kowzyk, Francis J.; Liao, Shuyuan; Metz, Suzanne;

Partis, Richard A.; Perry, Thao D.; Rao, Shashidhar N.; Selness, Shaun
Raj; South, Michael S.; Stealey, Michael A.; Talley, John Jeffrey;

Vazquez, Michael L.; Weiser, Richard M.; Xu, Xiangdong; Khanna, Ish K.; Yu,
Yi; Naing, Win; Walker, John; Yang, Syaulan

SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU,
ZA, ZM, ZW

RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM,
AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK,
EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT,
RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GN, GQ, GW, ML,
MR, NE, SN, TD, TO

PRAI SE 2004-1342 A 20040525

OS MARPAT 144:36196

RE.CNT 13 THERE ARE 13 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

--> D 3 HITSTR

YOU HAVE REQUESTED DATA FROM FILE 'CAPLUS' - CONTINUE? (Y)/N:Y

L5 ANSWER 3 OF 283 CAPLUS COPYRIGHT 2006 ACS ON STN

IT 216518-34-2P

RL: CPN (Combinatorial preparation); PAC (Pharmacological activity); SPN
(Synthetic preparation); THU (Therapeutic use); BIOL (Biological study);


CHBI (Combinatorial study); PREP (Preparation); USES (Uses)

(p38 kinase inhibitor; preparation of heteroarylpyrazole p38 kinase
inhibitors by cyclocondensation of hydrazines with ketones)

RN 216518-34-2 CAPLUS

CN 2-Quinoxalinecarboxamide, N-((1R)-1-[5-(4-fluorophenyl)-4-(4-pyridinyl)-1H-
pyrazol-3-yl]-2-phenylethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



--> FILE CAPLUS

COST IN U.S. DOLLARS
FULL ESTIMATED COST

	SINCE FILE	TOTAL
	ENTRY	SESSION
	0.44	188.48

FILE 'CAPLUS' ENTERED AT 08:23:01 ON 28 FEB 2006

USE 19 SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE 'HELP USAGETERMS' FOR DETAILS.

COPYRIGHT (C) 2006 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is
held by the publishers listed in the PUBLISHER (PB) field (available
for records published or updated in Chemical Abstracts after December
26, 1996), unless otherwise indicated in the original publications.
The CA Lexicon is the copyrighted intellectual property of the
American Chemical Society and is provided to assist you in searching
databases on STN. Any dissemination, distribution, copying, or storing
of this information, without the prior written consent of CAS, is

EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE,
SI, SK, TR, BF, BJ, CP, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE,
SN, TD, TG

PRAI KR 2003-69582 A 20031007

OS MARPAT 142:373847

RE.CNT 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 15 OF 283 CAPLUS COPYRIGHT 2006 ACS ON STN
AN 2005:324132 CAPLUS

DN 142:392427

TI Preparation of N-heterocyclyl amides and sulfonamides as p38 kinase
inhibitors

IN Dugar, Sundee; McEnroe, Glen

PA Scios Inc., USA

SO PCT Int. Appl., 195 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2005031072	A2	20050414	WO 2004-032403	20040930
W:	AS, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, ME, MG, MK, MN, MW, MX, MY, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CP, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			

PRAI US 2003-507633P P 20030930

OS MARPAT 142:392427

=> D 13-15 HITSTR


L5 ANSWER 13 OF 283 CAPLUS COPYRIGHT 2006 ACS ON STN

IT 852669-46-6

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(urea deriva. as kinase modulators for treatment of cellular
proliferative disorders)

RN 852669-46-6 CAPLUS

CN 2-Quinoxalinecarboxamide, N-[[4-[[[5-(1,1-dimethylethyl)-3-
isoxazolyl]amino]carbonyl]amino]phenyl]- (9CI) (CA INDEX NAME)



L5 ANSWER 14 OF 283 CAPLUS COPYRIGHT 2006 ACS ON STN

IT 849675-53-2P. Quinoxaline-2-carboxylic acid N-[2-[4-[2-(6,7-
dimethoxy-3,4-dihydro-1H-isoquinolin-2-yl)ethyl]phenyl]-2H-tetrazol-5-yl]-
4,5-dimethoxyphenyl]amide

PA Methylgene, Inc., Can.

SO PCT Int. Appl., 559 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 2

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 20050310705	A1	20050407	WO 2004-031591	20040924
W:	AS, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, ME, MG, MK, MN, MW, MX, MY, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CP, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			

PRAI US 2003-505884P P 20030924

US 2003-532973P P 20031229

US 2004-561082P P 20040409

OS MARPAT 142:355054

RE.CNT 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 17 OF 283 CAPLUS COPYRIGHT 2006 ACS ON STN

AN 2005:300394 CAPLUS

DN 142:373563

TI Preparation of amide derivatives as inhibitors of histone deacetylase

IN Moradei, Oscar; Paquin, Isabelle; Leit, Silvana; Frechette, Sylvie;
Vaisburg, Arkadii; Besterman, Jeffrey M.; Tessier, Pierre; Mallais, Tammy C.

PA Methylgene, Inc., Can.

SO PCT Int. Appl., 389 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 2

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 20050310704	A1	20050407	WO 2004-031590	20040924
W:	AS, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, ME, MG, MK, MN, MW, MX, MY, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CP, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			

PRAI US 2003-505884P P 20030924

US 2003-532973P P 20031229

US 2004-561082P P 20040409

OS MARPAT 142:373563

RE.CNT 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 18 OF 283 CAPLUS COPYRIGHT 2006 ACS ON STN

AN 2005:281801 CAPLUS

DN 142:355169


TI Preparation of 3,5-diaminopiperidine-substituted hetero/aromatic compounds

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of [(isoquinolinyl)ethyl]phenyl tetrazoles as P-glycoprotein
inhibitors)

RN 849675-53-2 CAPLUS

CN 2-Quinoxalinecarboxamide, N-[2-[2-[4-[2-(3,4-dihydro-6,7-dimethoxy-2(1H)-
isoquinolinyl)ethyl]phenyl]-2H-tetrazol-5-yl]-4,5-dimethoxyphenyl]- (9CI)
(CA INDEX NAME)



L5 ANSWER 15 OF 283 CAPLUS COPYRIGHT 2006 ACS ON STN

IT 849744-54-3P


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of N-heterocyclyl amides and sulfonamides as p38 kinase
inhibitors)

RN 849744-54-3 CAPLUS

CN 2-Quinoxalinecarboxamide, N-[[4-(fluorophenyl)methyl]-N-[2-[[[1S]-1-
phenylethyl]amino]-4-pyridinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



=> D 16-20

L5 ANSWER 16 OF 283 CAPLUS COPYRIGHT 2006 ACS ON STN

AN 2005:300395 CAPLUS

DN 142:355054

TI Preparation of amide derivatives as inhibitors of histone deacetylase

IN Moradei, Oscar; Paquin, Isabelle; Leit, Silvana; Frechette, Sylvie;
Vaisburg, Arkadii; Besterman, Jeffrey M.; Tessier, Pierre; Mallais, Tammy C.

as antibacterial agents

IN Zhou, Yuefen; Vourloumis, Dionisio; Gregor, Vlad E.; Winters, Geoff;
Hermann, Thomas; Ayida, Benjamin; Sun, Zhongxiang; Murphy, Douglas;
Simonsen, Klaus Baek

PA Anadys Pharmaceuticals, Inc., USA

SO PCT Int. Appl., 270 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2005028467	A1	20050331	WO 2004-031064	20040915
W:	AS, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, ME, MG, MK, MN, MW, MX, MY, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CP, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			

US 2005239827

PRAI US 2003-502612P P 20030915

US 2004-548852P P 20040302

OS MARPAT 142:355169

RE.CNT 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD

ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 19 OF 283 CAPLUS COPYRIGHT 2006 ACS ON STN

AN 2005:259646 CAPLUS

DN 142:291408

TI Method of treating obesity and metabolic disorders related to excess
adipose tissue by administration of natriuretic peptide receptor c
inhibitors

IN Chada, Kiran K.; Chouinard, Roland; Ashar, Hena; Sayed, Abu

PA USA

SO U.S. Pat. Appl. Publ., 14 pp., Cont.-in-part of U.S. Ser. No. 768,566.

CODEN: USXXCO

DT Patent

LA English

FAN.CNT 2

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI US 2005065092	A1	20050324	US 2004-898490	20040722
US 2004-258789	A1	20041223	US 2004-768566	20040129
PRAI US 2002-398785P	P	20020729		
US 2003-478206P	P	20030612		
US 2003-630423	A1	20030729		
US 2004-768566	A2	20040129		

L5 ANSWER 20 OF 283 CAPLUS COPYRIGHT 2006 ACS ON STN

AN 2005:141021 CAPLUS

DN 142:261788

TI Preparation of aryl and heteroaryl amino acid derivatives as antagonists
of factor IX and/or factor XI

IN Mjallil, Adnan M. A.; Andrews, Robert C.; Guo, Xiao-Chuan; Christen, Daniel
Peter; Gohimukula, Devi Reddy; Huang, Guoxiang; Rothlein, Robert; Tyagi,
Sameer; Yaramana, Tripura; Behme, Christopher

PA Transtech Pharma, Inc., USA

SO PCT Int. Appl., 313 pp.

CODEN: PIXXD2

DT Patent


LA English

FAN.CNT 4


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI MO 2005014533	A2	20050217	MO 2004-US25463	20040806
MO 2005014533	A3	20050407		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MY, NA, NI, NO, NZ, OM, PA, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RN:	EW, GE, GM, KE, LS, MW, MZ, NA, SD, SI, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, EG, GZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, ML, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, CA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
US 2005049310	A1	20050303	US 2004-913882	20040806
US 2005059713	A1	20050317	US 2004-913216	20040806
PRAI US 2003-493878P	P	20030808		
US 2003-493879P	P	20030808		
US 2003-493903P	P	20030808		
OS MARPAT 142:261788				

-- D 16-20 HITSTR

L5 ANSWER 16 OF 283 CAPLUS COPYRIGHT 2006 ACS ON STN
 IT 849233-41-6P
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (preparation of amide deriva. as inhibitors of histone deacetylase)
 RN 849233-41-6 CAPLUS
 CN 2-Quinoxalinecarboxamide, N-[2-amino-5-(2-thienyl)phenyl]- (9CI) (CA INDEX NAME)




L5 ANSWER 17 OF 283 CAPLUS COPYRIGHT 2006 ACS ON STN
 IT 849233-41-6P
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (preparation of amide deriva. as inhibitors of histone deacetylase)
 RN 849233-41-6 CAPLUS
 CN 2-Quinoxalinecarboxamide, N-[2-amino-5-(2-thienyl)phenyl]- (9CI) (CA INDEX NAME)



L5 ANSWER 18 OF 283 CAPLUS COPYRIGHT 2006 ACS ON STN
 IT 849152-15-4P, N-(3-Chloro-4-[[[(3-hydroxyquinoxalin-2-yl)carbonyl]amino]phenyl]-4,6-bis-(cis-3,5-diaminopiperidin-1-yl)-1,3,5-triazin-2-amine monohydrochloride 849154-56-9P
 849158-51-6P
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (antibacterial; preparation of 3,5-diaminopiperidine-substituted hetero/aromatic compds. as antibacterial agents)
 RN 849152-15-4 CAPLUS
 CN 2-Quinoxalinecarboxamide, N-[4-[[[4,6-bis[(3R,5S)-3,5-diamino-1-piperidinyl]-1,3,5-triazin-2-yl]amino]-2-chlorophenyl]-3,4-dihydro-3-oxo-, monohydrochloride, rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



● HCl


RN 849154-56-9 CAPLUS
 CN 2-Quinoxalinecarboxamide, N-[4-[[[4,6-bis[(3R,5S)-3,5-diamino-1-piperidinyl]-1,3,5-triazin-2-yl]amino]-2-hydroxyphenyl]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 849158-51-6 CAPLUS
 CN 2-Quinoxalinecarboxamide, N-[4-[[[4,6-bis[(3R,5S)-3,5-diamino-1-piperidinyl]-1,3,5-triazin-2-yl]amino]phenyl]-3,4-dihydro-3-oxo-, monohydrochloride, rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.




● HCl

L5 ANSWER 19 OF 283 CAPLUS COPYRIGHT 2006 ACS ON STN
 IT 301838-48-2P 301839-08-7P 301839-95-2P
 301839-97-4P 301840-15-3P
 RL: PAC (Pharmacological activity); PKT (Pharmacokinetics); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (method of treating obesity and metabolic disorders related to excess adipose tissue by administration of natriuretic peptide receptor c inhibitors)
 RN 301838-48-2 CAPLUS
 CN L-isoleucinamide, N-[(2S,3S)-3-methyl-2-[(3R)-3-[methyl[[4-[(2-quinoxalinylyl)amino]phenyl]acetyl]amino]-2-oxo-1-pyrrolidinyl]-1-oxopentyl]-L-α-aspartyl-D-arginyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



PAGE 1-A




PAGE 2-A


RN 301839-08-7 CAPLUS
 CN L-isoleucinamide, N-[(2S,3S)-3-methyl-2-[(3R)-3-[methyl[[4-[(2-quinoxalinylyl)amino]phenyl]acetyl]amino]-2-oxo-1-pyrrolidinyl]-1-oxopentyl]-L-α-aspartyl-D-arginyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 2-A




RN 301839-95-2 CAPLUS
 CN L-isoleucinamide, N-[(2S,3S)-3-methyl-1-oxo-2-[(3R)-2-oxo-3-[[[4-[(2-quinolalinylylcarbonyl)amino]phenyl]acetyl]amino]-1-pyrrolidinyl]pentyl]-L-α-aspartyl-N-methylglycyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 1-B




RN 301839-97-4 CAPLUS
 CN L-isoleucinamide, N-[(2S,3S)-3-methyl-1-oxo-2-[(3R)-2-oxo-3-[[[4-[(2-quinolalinylylcarbonyl)amino]phenyl]acetyl]amino]-1-pyrrolidinyl]pentyl]-L-α-aspartyl-D-ornithyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 2-A




RN 301840-15-3 CAPLUS
 CN D-argininamide, N-[(2S,3S)-3-methyl-1-oxo-2-[(3R)-2-oxo-3-[[[4-[(2-quinolalinylylcarbonyl)amino]phenyl]acetyl]amino]-1-pyrrolidinyl]pentyl]-L-α-aspartyl-N-(cyclohexylmethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 1-B



L5 ANSWER 20 OF 283 CAPLUS COPYRIGHT 2006 ACS ON STN
 IT 845679-13-2P
 RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
 (preparation of aryl and heteroaryl amino acid derivs. as antagonists of factor IX and/or factor XI)
 RN 845679-13-2 CAPLUS
 CN [1,1'-Biphenyl]-4-propanoic acid, α-[[[6-[4-(1,1-dimethylethyl)phenoxy]-3-(ethylthio)-2-quinolalinylyl]carbonyl]amino]-, methyl ester, (αS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




IT 845679-12-1P 845679-14-3P 845679-15-4P
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(Uses)

(preparation of aryl and heteroaryl amino acid derivs. as antagonists of factor IX and/or factor XI)


RN 845679-12-1 CAPLUS
CN [1,1'-Biphenyl]-4-propanoic acid, α -[[[6-[[4-(1,1'-quinoxalinyloxy)phenyl]-2-quinoxalinyloxy]amino]-, methyl ester, (S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 845679-14-3 CAPLUS
CN [1,1'-Biphenyl]-4-propanoic acid, α -[[[6-[[4-(1,1'-dimethylethylphenoxy)-2-quinoxalinyloxy]amino]-, (S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 845679-15-4 CAPLUS
CN [1,1'-Biphenyl]-4-propanoic acid, α -[[[6-[[4-(1,1'-dimethylethylphenoxy)-2-quinoxalinyloxy]amino]-, methyl ester, (S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



=> D 21-25

L5 ANSWER 21 OF 283 CAPLUS COPYRIGHT 2006 ACS on STN
AN 2005:136505 CAPLUS
DN 142:240421
TI Preparation of N-(4-sulfamoylphenyl) amides as inhibitors of voltage-gated sodium channels
IN Gonzalez, Jesus E.; III; Termin, Andreas P.; Martinborough, Esther; Zimmerman, Nicole

PA Vertex Pharmaceuticals Incorporated, USA

SO PCT Int. Appl., 332 pp.

COGN: PIXKD2

DT Patent

LA English

FAN.CNT 2

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2005013914	A2	20050217	WO 2004-US25827	20040809
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MO, MX, MY, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TO				

PRAI US 2003-493699P

US 2004-084717P

OS MARPAT 142:240421

L5 ANSWER 21 OF 283 CAPLUS COPYRIGHT 2006 ACS on STN

AN 2005:76258 CAPLUS

DN 142:148826

TI Chromatinic remedies

IN Itai, Akiko; Muto, Susumu

PA Institute of Medicinal Molecular Design, Inc., Japan

SO PCT Int. Appl., 130 pp.

COGN: PIXKD2

DT Patent

LA Japanese

FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2005007151	A1	20050127	WO 2004-JP10558	20040716
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MO, MX, MY, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TO				

PRAI JP 2003-197807

OS MARPAT 142:148826

RE.CNT 13 THERE ARE 13 CITED REFERENCES AVAILABLE FOR THIS RECORD

ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 21 OF 283 CAPLUS COPYRIGHT 2006 ACS on STN

AN 2005:14357 CAPLUS

DN 142:114079

TI Preparation of heterocyclic compounds containing 3-substituted cycloalkenecarboxylic acid derivative moiety as cysteine protease inhibitors

IN Hiratake, Akira; Tatsuzuki, Makoto; Susujima, Tsuyoshi

PA Taisho Pharmaceutical Co., Ltd., Japan

SO PCT Int. Appl., 120 pp.

COGN: PIXKD2

DT Patent

LA Japanese

FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 200500793	A1	20050106	WO 2004-JP9360	20040625
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MO, MX, MY, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TO				

PRAI JP 2003-182727

JP 2004-09250

OS MARPAT 142:114079

RE.CNT 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD

ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 24 OF 283 CAPLUS COPYRIGHT 2006 ACS on STN

AN 2004:106085 CAPLUS

DN 142:1728

TI Branched compounds containing bioactive molecules and targeting moieties for cellular delivery

IN Vergeese, Chandra; Haeblerli, Peter; Wang, Weimin; Chen, Tongqian

PA Sirna Therapeutics, Inc., USA

SO U.S. Pat. Appl. Publ., 143 pp., Cont.-in-part of U.S. Ser. No. 427.160.

COGN: USXXCO

DT Patent

LA English

FAN.CNT 232

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI US 2004249178	A1	20041209	US 2004-780447	20040213
US 9851819	A1	19980611	AU 1998-51819	19980112
AU 729657	B2	20010208		
AU 9939188	A1	19990916	AU 1999-39188	19990713
AU 769175	B2	20040115	AU 2000-56616	20000911
WO 2002094185	A2	20021128	WO 2002-US15876	20020520
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MO, MX, MY, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TO				
WO 2003070918	A2	20030828	WO 2003-US5346	20030220
WO 2003070918	A3	20040708		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MO, MX, MY, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TO				

US 2004110296

A1 20040610

US 2003-427160

20030430

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004111337	A1	20041223	WO 2004-US11848	20040416
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MO, MX, MY, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TO				

US 2005012713

WO 2005041859

A2 20050512

WO 2004-US13456

20040416

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MO, MX, MY, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW

	LK,	GH,	OH,	HR,	HU,	ID,	IL,	IN,	IS,	JP,	KE,	KO,	KP,	KZ,	LC,
	LR,	LS,	LT,	LV,	LU,	MA,	MD,	DZ,	EC,	EG,	MM,	MX,	MK,	NZ,	NA,
	NO,	NZ,	OM,	PG,	PH,	PL,	PT,	RO,	RU,	SC,	SD,	SE,	SG,	SK,	SL,
RW:	TJ,	TM,	TN,	TR,	TT,	TZ,	UA,	UG,	UZ,	VC,	VN,	YU,	ZA,	ZM,	ZW
	BW,	GH,	GM,	KE,	LS,	MM,	MZ,	NA,	SD,	SL,	SZ,	TZ,	UG,	ZM,	ZW
	AZ,	BY,	KG,	KZ,	MO,	RU,	TJ,	TM,	AT,	BE,	BO,	CH,	CY,	CZ,	DE,
	SE,	ES,	FI,	FR,	GB,	GR,	HU,	IE,	IT,	LU,	MC,	NL,	PL,	PT,	RO,
	SI,	SK,	TR,	BF,	BJ,	CF,	CG,	CI,	CM,	GA,	GN,	OQ,	QM,	ML,	MR,
	SN,	TD,	TO												NE
WO 2005045035				A3	20050519				BA	2004-US26930					20040820
WO 2005045035				A2	20051208				BB,	BG,	BR,	BW,	BY,	BZ,	CA,
W:	AE,	AG,	AL,	AM,	AT,	AU,	AZ,	BA,	BB,	BG,	BR,	BW,	BY,	BZ,	CA,
	CH,	CO,	CR,	CU,	CZ,	DE,	DK,	DZ,	EC,	EG,	ES,	FI,	FR,	GB,	GH,
	GM,	GH,	GM,	HR,	HU,	ID,	IL,	IN,	IS,	JP,	KE,	KO,	KP,	KZ,	LC,
	LK,	LR,	LS,	LT,	LV,	LU,	MA,	MD,	MX,	MY,	MM,	MX,	MK,	NZ,	NA,
	NO,	NZ,	OM,	PG,	PH,	PL,	PT,	RO,	RU,	SC,	SD,	SE,	SG,	SK,	SL,
	TJ,	TM,	TN,	TR,	TT,	TZ,	UA,	UG,	UZ,	VC,	VN,	YU,	ZA,	ZM,	ZW
RW:	BW,	GH,	GM,	KE,	LS,	MM,	MZ,	NA,	SD,	SL,	SZ,	TZ,	UG,	ZM,	ZW
	AZ,	BY,	KG,	KZ,	MO,	RU,	TJ,	TM,	AT,	BE,	BO,	CH,	CY,	CZ,	DE,
	SE,	ES,	FI,	FR,	GB,	GR,	HU,	IE,	IT,	LU,	MC,	NL,	PL,	PT,	RO,
	SI,	SK,	TR,	BF,	BJ,	CF,	CG,	CI,	CM,	GA,	GN,	OQ,	QM,	ML,	MR,
	SN,	TD,	TO												NE
WO 2005045037				A3	20050519				BA	2004-US27169					20040820
WO 2005045037				A3	20051103										
WO 2005045037				B1	20051129										
W:	AE,	AG,	AL,	AM,	AT,	AU,	AZ,	BA,	BB,	BG,	BR,	BW,	BY,	BZ,	CA,
	CH,	CO,	CR,	CU,	CZ,	DE,	DK,	DM,	DZ,	EC,	EG,	ES,	FI,	FR,	GB,
	GM,	GH,	GM,	HR,	HU,	ID,	IL,	IN,	IS,	JP,	KE,	KO,	KP,	KZ,	LC,
	LK,	LR,	LS,	LT,	LV,	LU,	MA,	MD,	MX,	MY,	MM,	MX,	MK,	NZ,	NA,
	NO,	NZ,	OM,	PG,	PH,	PL,	PT,	RO,	RU,	SC,	SD,	SE,	SG,	SK,	SL,
	TJ,	TM,	TN,	TR,	TT,	TZ,	UA,	UG,	UZ,	VC,	VN,	YU,	ZA,	ZM,	ZW
RW:	BW,	GH,	GM,	KE,	LS,	MM,	MZ,	NA,	SD,	SL,	SZ,	TZ,	UG,	ZM,	ZW
	AZ,	BY,	KG,	KZ,	MO,	RU,	TJ,	TM,	AT,	BE,	BO,	CH,	CY,	CZ,	DE,
	SE,	ES,	FI,	FR,	GB,	GR,	HU,	IE,	IT,	LU,	MC,	NL,	PL,	PT,	RO,
	SI,	SK,	TR,	BF,	BJ,	CF,	CG,	CI,	CM,	GA,	GN,	OQ,	QM,	ML,	MR,
	SN,	TD,	TO												NE
WO 2005045038				A3	20050519				BA	2004-US27231					20040820
WO 2005045038				C1	20050714										
W:	AE,	AG,	AL,	AM,	AT,	AU,	AZ,	BA,	BB,	BO,	BR,	BW,	BY,	BZ,	CA,
	CH,	CO,	CR,	CU,	CZ,	DE,	DK,	DM,	DZ,	EC,	EG,	ES,	FI,	FR,	GB,
	GM,	GH,	GM,	HR,	HU,	ID,	IL,	IN,	IS,	JP,	KE,	KO,	KP,	KZ,	LC,
	LK,	LR,	LS,	LT,	LV,	LU,	MA,								

	GE, GH, GM, HR, HU, DL, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LV, LU, MD, ME, MK, MN, MM, MX, MY, NZ, OM, NZ, ON, PO, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RM:	BW, OH, OM, KE, LS, MW, KZ, MA, SD, SL, SE, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, MG, MO, MU, MY, NI, NG, NU, PA, PE, PG, PH, PK, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
	SE, ES, FI, FR, GB, GR, HU, IS, IT, LU, MK, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CO, CI, CM, CA, GN, GQ, GW, ML, MR, NE, SN, TD, TO			
WO 2005044981	A2	20050519	WO 2004-1527403	20040820
WO 2005044981	A1	20050522		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GR, HU, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LV, LU, MD, ME, MK, MN, MM, MX, MY, NZ, OM, NZ, ON, PO, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RM:	BW, OH, OM, KE, LS, MW, KZ, MA, SD, SL, SE, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IS, IT, LU, MK, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CO, CI, CM, CA, GN, GQ, GW, ML, MR, NE, SN, TD, TO			
US 2005153916	A1	20050574	US 2004-923330	20040820
US 2005153916	A1	20050721	US 2004-923522	20040820
US 2005164968	A1	20050728	US 2004-923329	20040820
US 2005170371	A1	20050804	US 2004-922340	20040820
US 2005176666	A1	20050811	US 2004-923182	20040820
US 2005176024	A1	20050811	US 2004-923354	20040820
US 2005176024	A1	20050811	US 2004-923354	20040820
US 2005182007	A1	20050818	US 2004-923675	20040820
US 2005182008	A1	20050818	US 2004-923142	20040820
US 2005182009	A1	20050818	US 2004-923201	20040820
US 2005187174	A1	20050825	US 2004-923181	20040820
US 2005191618	A1	20050901	US 2004-923473	20040820
US 2005191618	A1	20050908	US 2004-923890	20040820
US 2005227935	A1	20051013	US 2004-923470	20040820
US 2005227936	A1	20051013	US 2004-923475	20040820
US 2005233344	A1	20051020	US 2004-923270	20040820
US 2005239731	A1	20051027	US 2004-923379	20040820
US 2005250668	A1	20051117	US 2004-923761	20040820
US 2005250668	A1	20051117	US 2004-923761	20040820
US 2005282642	A1	20051229	US 2004-923476	20040820
WO 2005028650	A2	20050331	WO 2004-1051012	20040915
WO 2005028650	A1	20051122		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GR, HU, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LV, LU, MD, ME, MK, MN, MM, MX, MY, NZ, OM, NZ, ON, PO, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RM:	BW, OH, OM, KE, LS, MW, KZ, MA, SD, SL, SE, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IS, IT, LU, MK, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CO, CI, CM, CA, GN, GQ, GW, ML, MR, NE, SN, TD, TO			
US 2005029180	A1	20050532	US 2004-942560	20040915
WO 2005028649	A1	20050531		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GR, HU, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LV, LU, MD, ME, MK, MN, MM, MX, MY, NZ, OM, NZ, ON, PO, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RM:	BW, OH, OM, KE, LS, MW, KZ, MA, SD, SL, SE, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IS, IT, LU, MK, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CO, CI, CM, CA, GN, GQ, GW, ML, MR, NE, SN, TD, TO			

EK, ES, FI, FR, GB, GR, HU, IE, IT, LJ, MC, NL, PL, PT, RD, SE,
 SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE,
 SN, TD, TG

US 2005233998 A1 20051020 US 2004-944611 20040916
 US 200522066 A1 20051006 US 2004-962898 20041012
 US 2005241219 A1 20051124 US 2004-1347 20041130
 US 2005196781 A1 20050908 US 2004-14373 20041215
 US 2006019913 A1 20060126 US 2005-14668 20050106
 US 2006025361 A1 20060202 US 2005-15813 20050114
 US 2005287128 A1 20051229 US 2005-54047 20050209
 US 2005260620 A1 20051124 US 2005-58582 20050215
 US 2005277131 A1 20051215 US 2005-63415 20050222
 US 2005282188 A1 20051222 US 2005-98303 20050404
 US 2006019917 A1 20060126 US 2005-140328 20050527

PRAI US 2002-162016P P 20020306
 US 2002-163124P P 20020311
 WO 2002-US15876 A2 20020520
 US 2002-186782P P 20020606
 US 2002-406784P P 20020829
 US 2002-408378P P 20020905
 US 2002-409293P P 20020909
 US 2003-440129P P 20030115
 WO 2003-US5346 A2 20030220
 US 2003-427160 A2 20030430
 AU 1995-26422 A3 19950518
 US 1996-623891 A 19960325
 AU 1996-76662 A3 19961025
 US 2000-181797P P 20000211
 US 2001-780533 B2 20010209
 WO 2001-US4273 A2 20010209
 US 2001-827395 B2 20010405
 US 2001-292217P P 20010518
 US 2001-294140P P 20010529
 US 2001-296249P P 20010606
 US 2001-306883P P 20010720
 US 2001-916466 B1 20010725
 US 2001-311865P P 20010813
 US 2001-930423 B2 20010815
 US 2001-318471P P 20010910
 US 2001-334461P P 20011130
 US 2002-358580P P 20020220
 US 2002-336124P P 20020311
 WO 2002-US9187 A2 20020326
 WO 2002-US10512 A2 20020403
 US 2002-374722P P 20020422
 US 2002-151116 A2 20020517
 US 2002-157580 A2 20020529
 WO 2002-US16840 A2 20020529
 WO 2002-US17674 A1 20020529
 US 2002-163552 A2 20020606
 US 2002-393796P P 20020703
 US 2002-393924P P 20020703
 US 2002-396600P P 20020717
 US 2002-396805P P 20020718
 US 2002-201394 A2 20020722
 US 2002-398036P P 20020723
 US 2002-205309 A2 20020725
 US 2002-206705 A2 20020726
 US 2002-399348P P 20020729
 US 2002-401093P P 20020805
 US 2002-401104P P 20020805
 US 2002-404039P P 20020815
 US 2002-225023 A2 20020821
 US 2002-409493P P 20020909
 US 2002-238700 A2 20020910

US 2002-409785P P 20020911
 US 2002-411275P P 20020917
 US 2002-411707P P 20020918
 US 2002-251117 A2 20020919
 US 2002-412304P P 20020920
 US 2002-417745P P 20020926
 US 2002-418655P P 20021015
 US 2002-27794 A B2 20021021
 US 2002-287949 A2 20021104
 US 2002-425559P P 20021112
 US 2002-427467P P 20021119
 US 2003-306747 A2 20021127
 US 2002-429359P P 20021128
 US 2002-431105P P 20021205
 US 2003-439922P P 20030114
 WO 2003-US2510 A2 20030128
 WO 2003-US3473 A2 20030205
 WO 2003-US3662 A2 20030206
 WO 2003-US4034 A2 20030211
 WO 2003-US4088 A2 20030211
 WO 2003-US4123 A2 20030211
 WO 2003-US4347 A2 20030211
 WO 2003-US4566 A2 20030211
 WO 2003-US7273 A2 20030211
 WO 2003-US4250 A2 20030213
 WO 2003-US4317 A2 20030213
 WO 2003-US4397 A2 20030213
 WO 2003-US4402 A2 20030213
 WO 2003-US4448 A2 20030213
 WO 2003-US4710 A2 20030218
 WO 2003-US4738 A2 20030218
 WO 2003-US4907 A2 20030218
 WO 2003-US4908 A2 20030218
 WO 2003-US4909 A2 20030218
 WO 2003-US4741 A2 20030220
 WO 2003-US4951 A2 20030220
 WO 2003-US5022 A2 20030220
 WO 2003-US5028 A2 20030220
 WO 2003-US5043 A2 20030220
 WO 2003-US5044 A2 20030220
 WO 2003-US5045 A2 20030220
 WO 2003-US5162 A2 20030220
 WO 2003-US5190 A 20030220
 WO 2003-US5234 A2 20030220
 WO 2003-US5326 A2 20030220
 US 2003-417012 A 20030416
 US 2003-420194 A2 20030422
 WO 2003-US12626 A2 20030422
 US 2003-422704 A 20030424
 US 2003-424339 A2 20030425
 US 2003-430882 A2 20030506
 US 2003-444853 A 20030523
 US 2003-407933 A 20030627
 US 2003-486729P P 20030711
 US 2003-487214P P 20030714
 US 2003-493561P P 20030808
 US 2003-496555P P 20030820
 US 2003-652791 A 20030829
 US 2003-664767 A 20030916
 US 2003-665255 A 20030916
 US 2003-667271 A 20030916
 US 2003-670011 A 20030923
 US 2003-683990 A2 20031010
 US 2003-512701P P 20031020
 US 2003-693059 A 20031023

US 2003-698311 A 20031031
 US 2003-712633 A2 20031113
 US 2003-720448 A 20031124
 US 2003-724270 A2 20031126
 US 2003-726236 A2 20031202
 US 2003-727780 A2 20031203
 US 2003-736128 A2 20031218
 US 2004-757803 A 20040114
 US 2004-764957 A 20040126
 US 2004-843480P P 20040210
 US 2004-780447 A 20040213
 US 2004-798090 A2 20040311
 US 2004-800487 A2 20040315
 US 2004-824036 A2 20040414
 US 2004-825485 A2 20040415
 US 2004-826966 A 20040416
 WO 2004-US11848 A2 20040416
 US 2004-830569 A2 20040423
 US 2004-831620 A 20040423
 WO 2004-US12517 A2 20040423
 US 2004-832522 A2 20040426
 US 2004-13456 A 20040430
 WO 2004-US13456 W 20040430
 US 2004-570086P P 20040511
 US 2004-844076 A 20040511
 US 2004-844072 A 20040512
 US 2004-16390 A 20040524
 WO 2004-US16390 W 20040524
 US 2004-863973 A2 20040609
 US 2004-864044 A 20040609
 US 2004-894475 A2 20040719
 US 2004-919866 A 20040817
 US 2004-922675 A2 20040820
 US 2004-923475 A2 20040820
 US 2004-923536 A2 20040820
 US 2004-944611 A2 20040916
 US 2005-11668 A1 20050106
 US 2005-39680 A2 20050118
 WO 2005-US4270 A2 20050209
 US 2005-98303 A2 20050404

OS MARPAT 142:1728


L5 ANSWER 25 OF 283 CAPLUS COPYRIGHT 2006 ACS ON STN
 AN 2004:989258 CAPLUS
 DN 142:93713
 TI Azole-N-acetonitriles as carbonyl synthons: A one-pot preparation of heteroaryl amides from halides
 AU Zhang, Zhongxing; Yin, Zhiveli; Kadow, John F.; Meanwell, Nicholas A.; Wang, Tao
 CS Department of Chemistry, The Bristol-Myers Squibb Pharmaceutical Research Institut, Wallingford, CT, 06492, USA
 SO Synlett (2004), (13), 2323-2326
 CODEN: SYNL88; ISSN: 0936-5214
 PB Georg Thieme Verlag
 DT Journal
 LA English
 OS CASREACT 142:93713
 RE.CNT 26 THERE ARE 26 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

--> D 21-24 HITSTR


L5 ANSWER 21 OF 283 CAPLUS COPYRIGHT 2006 ACS ON STN
 IT 845260-99-2P 845260-99-3P 845261-00-9P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (preparation of N-(4-sulfamoylphenyl) amides as inhibitors of voltage-gated sodium channels)


RN 845260-98-2 CAPLUS
 CN 2-Quinoxalinecarboxamide, N-[4-[[[4-methyl-2-pyrimidinyl]amino]sulfonyl]phenyl]- (9CI) (CA INDEX NAME)




RN 845260-99-3 CAPLUS
 CN 2-Quinoxalinecarboxamide, N-[4-[[[5-methyl-1,3,4-thiadiazol-2-yl]amino]sulfonyl]phenyl]- (9CI) (CA INDEX NAME)



RN 845261-00-9 CAPLUS
 CN 2-Quinoxalinecarboxamide, N-[4-[[[2-thiazolylamino]sulfonyl]phenyl]- (9CI) (CA INDEX NAME)




L5 ANSWER 22 OF 283 CAPLUS COPYRIGHT 2006 ACS ON STN
 IT 439144-03-3
 RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (trifluoromethylphenylchlorohydroxybenzamide analogs as chromatosis and skin cancer remedies and skin whitening cosmetics)
 RN 439144-03-3 CAPLUS
 CN 2-Quinoxalinecarboxamide, N-[3,5-bis(trifluoromethyl)phenyl]-3,4-dihydro-3-oxo- (9CI) (CA INDEX NAME)




L5 ANSWER 23 OF 283 CAPLUS COPYRIGHT 2006 ACS ON STN
 IT 820989-89-7P
 RL: PAC (Pharmacological activity); SPN (Synthetic Preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (Preparation of heterocyclic compds. containing 2-substituted cycloalkancarboxylic acid derivative moiety as cysteine protease inhibitors for treatment of cerebral infarction, Alzheimer's disease, etc.)
 RN 820989-89-7 CAPLUS
 CN 2-Quinoxalinecarboxamide, N-[[[1,4-dihydro-2-[[[1,4-dihydro-2-phenylethyl]amino]carbonyl]cyclohexyl]-1-formyl-3-phenylethyl]amino]carbonyl]cyclohexyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L5 ANSWER 24 OF 283 CAPLUS COPYRIGHT 2006 ACS ON STN
 IT 700863-20-3
 RL: RCT (Reactant); RACT (Reactant or reagent)
 (branched compds. containing bioactive mole. and targeting moieties for cellular delivery)
 RN 700863-20-3 CAPLUS
 CN Benzoic acid, 4-[[[1,4-dihydro-2-[[[1-methyl-1-oxopropyl]amino]-4-oxo-6-pteridinyl]carbonyl]cyclohexyl]amino]- (9CI) (CA INDEX NAME)



-- D 26-30

L5 ANSWER 26 OF 283 CAPLUS COPYRIGHT 2006 ACS ON STN
 AN 2004:963181 CAPLUS

DN 141:379941
 TI Preparation of quinoxaline-2,4-diamines as melanin concentrating hormone (MCH) receptor antagonists
 IN Sekiguchi, Yoshikatsu; Kanuma, Yukihiko; Omodera, Katsunori; Tran, Thuy-Anh; Gramer, Bryan Aubrey; Bealey, Nigel Robert Arnold
 PA Taisho Pharmaceutical Co., Ltd., Japan
 SO Jpn. Kokai Tokkyo Koho, 988 pp.
 CODEN: JKKXAP
 DT Patent
 LA Japanese
 FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI JP 2004-315511	A2	20041111	JP 2004-95046	20040329
PRAI JP 2003-93418	A	20030331		
OS MARPAT 141:379941				

L5 ANSWER 27 OF 283 CAPLUS COPYRIGHT 2006 ACS ON STN
 AN 2004:927005 CAPLUS
 DN 141:395806
 TI Preparation of quinoxaliny macrocyclic hepatitis C serine protease inhibitors
 IN Nakajima, Suanne; Sun, Ying; Tang, Datong; Xu, Gouyou; Porter, Brian; Or, Yat Sun; Wang, Zhe; Miao, Zhenwei
 PA Shanta Pharmaceuticals, Inc., USA
 SO PCT Int. Appl., 131 pp.
 CODEN: PIKX2
 DT Patent
 LA English
 FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2004093798	A2	20041104	WO 2004-US11841	20040416
WO 2004093798	A3	20051208		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MY, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SV, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BM, GH, GM, KE, LS, MW, MZ, SD, SI, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
CA 2522551	AA	20041104	CA 2004-2522551	20040416
US 2004266668	A1	20041130	US 2004-826743	20040416
EP 1615613	A2	20060118	EP 2004-750236	20040416
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, HR				
PRAI US 2003-418759	A	20030418		
US 2003-509071P	P	20030418		
WO 2004-US11841	W	20040416		
OS MARPAT 141:395806				

L5 ANSWER 28 OF 283 CAPLUS COPYRIGHT 2006 ACS ON STN
 AN 2004:925864 CAPLUS
 DN 142:56428
 TI Heterocyclic Trost's ligands. Synthesis and applications in asymmetric allylic alkylation
 AU Sinou, Denis; Percine-Pichon, Nathalie; Konovets, Angelica; Iourtchenko, Alexander
 CS Laboratoire de Synthèse Asymétrique, associé au CNRS, CPE Lyon, Université Claude. Villeurbanne, 69622, F.
 SO ARKIVOC (Gainesville, FL, United States) (2004), (14), 103-109

CODEN: AQFUAR
 URL: http://www.arkat-usa.org/ark/journal/2004/114_General/1179/04-1179C.pdf
 PB Arkat USA Inc.
 DT Journal; (online computer file)
 LA English
 OS CASREACT 142:56428
 RE.CNT 15 THERE ARE 15 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 29 OF 283 CAPLUS COPYRIGHT 2006 ACS ON STN
 AN 2004:911919 CAPLUS
 DN 142:298075
 TI Pharmacophore based synthesis of 3-chloroquinoxaline-2-carboxamides as serotonin (5-HT3) receptor antagonist
 AU Mahesh, Radhakrishnan; Perumal, Ramachandran Venkatesha; Pandi, Pandi Vijaya
 CS Pharmacy Group, Birla Institute of Technology and Science, Pilani, 333 031, India
 SO Biological & Pharmaceutical Bulletin (2004), 27(9), 1403-1405
 CODEN: BPBLBO; ISSN: 0918-6158
 PB Pharmaceutical Society of Japan
 DT Journal
 LA English
 OS CASREACT 142:298075
 RE.CNT 16 THERE ARE 16 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 30 OF 283 CAPLUS COPYRIGHT 2006 ACS ON STN
 AN 2004:857609 CAPLUS
 DN 141:350270
 TI Phosphate/sulfate ester compounds and pharmaceutical compositions for inhibiting protein interacting NIMA (PIN 1)
 IN Guo, Chuangxing; Dagoatino, Sleanor Ferronyalka; Dong, Liming; Hou, Xijun; Margosiak, Stephen Anthony
 PA Pfizer Inc., USA
 SO PCT Int. Appl., 128 pp.
 CODEN: PIKX2
 DT Patent
 LA English
 FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2004087720	A1	20041014	WO 2004-1B574	20040323
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MY, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SV, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BM, GH, GM, KE, LS, MW, MZ, SD, SI, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2517281	AA	20041014	CA 2004-2517281	20040323
EP 1603926	A1	20051214	EP 2004-713610	20040323
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
PRAI US 2003-453163P	P	20030310		
WO 2004-1B574	W	20040323		
OS MARPAT 141:350270				
RE.CNT 11 THERE ARE 11 CITED REFERENCES AVAILABLE FOR THIS RECORD ALL CITATIONS AVAILABLE IN THE RE FORMAT				

-- D 31-35
 L5 ANSWER 31 OF 283 CAPLUS COPYRIGHT 2006 ACS ON STN
 AN 2004:857323 CAPLUS
 DN 141:350041
 TI Preparation of benzamide modulators of metabotropic glutamate receptors
 IN Duggan, Mark E.; Lindsey, Craig W.; Wisniewski, David D.
 PA Merck & Co. Inc., USA
 SO PCT Int. Appl., 65 pp.
 CODEN: PIKX2
 DT Patent
 LA English
 FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2004087048	A2	20041014	WO 2004-US8627	20040322
WO 2004087048	A3	20041223		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MY, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SV, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BM, GH, GM, KE, LS, MW, MZ, SD, SI, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2519954	AA	20041014	CA 2004-2519954	20040322
EP 1611096	A2	20060104	EP 2004-758170	20040322
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK				
PRAI US 2003-457734P	P	20030326		
WO 2004-US8627	W	20040322		
OS MARPAT 141:350041				

L5 ANSWER 32 OF 283 CAPLUS COPYRIGHT 2006 ACS ON STN
 AN 2004:822842 CAPLUS
 DN 141:314346
 TI Preparation of quinoline, tetrahydroquinazoline, and pyrimidine derivatives as MCH antagonists for treatment of CNS disorders
 IN Sekiguchi, Yoshinori; Kanuma, Koukai; Omodera, Katsunori; Busujima, Tsuyoshi; Tran, Thuy-Anh; Han, Sangdon; Casper, Martin; Kramer, Bryan A.; Semple, Gramme; Zou, Ning
 PA Taisho Pharmaceutical Co. Ltd., Japan; Arena Pharmaceuticals, Inc.
 SO Sur. Pat. Appl., 586 pp.
 CODEN: EPKX2W
 DT Patent
 LA English
 FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI EP 1464335	A2	20041006	EP 2004-7651	20040330
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK				
US 2005197350	A1	20050908	US 2004-812075	20040330
CA 2518913	AA	20041014	CA 2004-2518913	20040331
WO 2004087669	A1	20041014	WO 2004-JP4624	20040331
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MY, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SV, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BM, GH, GM, KE, LS, MW, MZ, SD, SI, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				

PATENT NO.		KIND	DATE	APPLICATION NO.	DATE
PI	WO 2004069813	A1	20040819	WO 2004-US2131	20040126
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DB, EC, EE, EG, ES, FI, GB, GD, GE, GR, GU, HK, HN, HU, IL, IN, JP, KE, KG, KH, KR, KZ, LA, LB, LC, LI, LU, LV, LY, MA, MG, MK, MN, MU, MV, MW, MY, MZ, NA, NG, NI, NL, NO, NZ, OM, PA, PE, PG, PH, PK, PL, PT, QA, RO, RU, RW, SA, SC, SD, SE, SG, SI, SK, SL, SM, SN, SR, ST, SV, SW, SY, SZ, TD, TH, TJ, TK, TL, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VE, VG, VI, VN, YU, ZA, ZM, ZW				

[illegible]

SP	EN, TD, TO	A2	20060208	SP	2004-775924	20040430
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, HR					
US	2005137153	A1	20050623	US	2004-840731	20040506
US	2005171039	A1	20050884	US	2004-844078	20040511
US	2005171076	A1	20050721	US	2004-844072	20040512
US	2005171755	A1	20050623	US	2004-851060	20040603
US	2005143333	A1	20050630	US	2004-863973	20040609
US	2005171040	A1	20050804	US	2004-854004	20040609
US	2005119211	A1	20050602	US	2004-869638	20040616
US	2005119212	A1	20050602	US	2004-871222	20040618
US	2005120779	A1	20050921	US	2004-877849	20040628
US	2005124566	A1	20050609	US	2004-879867	20040628
US	2005130181	A1	20050616	US	2004-881118	20040630
US	2005124567	A1	20050609	US	2004-883218	20040701
US	2005124568	A1	20050609	US	2004-888226	20040709
US	2005124569	A1	20050609	US	2004-892922	20040716
US	2005147124	A1	20050721	US	2004-903203	20040716
US	2005070497	A1	20050331	US	2004-894475	20040719
US	2005176663	A1	20050811	US	2004-897902	20040723
US	2005196765	A1	20050908	US	2004-898660	20040723
US	2005277608	A1	20051215	US	2004-898311	20040723
US	2005182008	A1	20050818	US	2004-903128	20040730
US	2005151740	A1	20050721	US	2004-915896	20040811
US	2005193179	A1	20050721	US	2004-916030	20040811
US	2005158735	A1	20050721	US	2004-916095	20040811
US	2005153914	A1	20050714	US	2004-918969	20040816
US	2005164966	A1	20050728	US	2004-918896	20040816
US	2005203604	A1	20050915	US	2004-918987	20040816
US	2005171668	A1	20050811	US	2004-919866	20040817
US	2005176665	A1	20050811	US	2004-919964	20040817
US	2005231997	A1	20051020	US	2004-919584	20040817
US	2005136436	A1	20050623	US	2004-923660	20040819
US	2005153915	A1	20050714	US	2004-922544	20040819
US	2005151740	A1	20050721	US	2004-923626	20040820
US	2005159382	A1	20050721	US	2004-923580	20040819
US	2005164967	A1	20050728	US	2004-922034	20040819
US	2005079610	A1	20050414	US	2004-923115	20040820
US	2005153916	A1	20050714	US	2004-923330	20040820
US	2005193981	A1	20050721	US	2004-923522	20040820
US	2005164968	A1	20050728	US	2004-923329	20040820
US	2005170371	A1	20050804	US	2004-922340	20040820
US	2005176666	A1	20050811	US	2004-923182	20040820
US	2005176024	A1	20050811	US	2004-923354	20040820
US	2005176025	A1	20050811	US	2004-923516	20040820
US	2005182607	A1	20050818	US	2004-923675	20040820
US	2005181208	A1	20050818	US	2004	

US 2006025361 A1 20060202 US 2005-35813 20050114
US 2005287128 A1 20051229 US 2005-54047 20050209
US 2005260620 A1 20051124 US 2005-58582 20050215
US 2005271133 A1 20051215 US 2005-63415 20050222
US 2005202108 A1 20051222 US 2005-59303 20050404
US 2006019817 A1 20060126 US 2005-140328 20050527
PRAI US 2002-362016P P 20020306
US 2002-363124P P 20020311
WO 2002-US15876 A2 20020520
US 2002-366782P P 20020606
US 2002-406784P P 20020629
US 2002-408378P P 20020905
US 2002-409293P P 20020909
US 2002-440129P P 20030115
WO 2002-US5028 A2 20030220
WO 2002-US5346 A2 20030220
AU 1995-26422 A3 19950518
US 1996-621891 A 19960325
AU 1996-76662 A3 19961025
US 2000-181797P P 20000211
US 2001-780533 B2 20010209
WO 2001-US4273 A2 20010209
US 2001-027395 B2 20010405
US 2001-292179P P 20010518
US 2001-294140P P 20010529
US 2001-296249P P 20010606
US 2001-306883P P 20010720
US 2001-916466 B1 20010725
US 2001-311865P P 20010813
US 2001-930423 B2 20010815
US 2001-318471P P 20010910
US 2001-334461P P 20011130
US 2002-358580P P 20020220
US 2002-336124P P 20020311
WO 2002-US9187 A2 20020326
WO 2002-US10512 A2 20020403
US 2002-374722P P 20020422
US 2002-151116 A2 20020517
US 2002-157580 A2 20020529
WO 2002-US16840 A2 20020529
WO 2002-US17674 A2 20020529
US 2002-163552 A2 20020606
US 2002-393796P P 20020703
US 2002-393924P P 20020703
US 2002-396600P P 20020717
US 2002-396905P P 20020718
US 2002-201394 A2 20020722
US 2002-398036P P 20020723
US 2002-205309 A2 20020725
US 2002-206705 A2 20020726
US 2002-399348P P 20020729
US 2002-401039P P 20020805
US 2002-401104P P 20020805
US 2002-404039P P 20020815
US 2002-225023 A2 20020821
US 2002-409493P P 20020909
US 2002-238700 A2 20020910
US 2002-409785P P 20020911
US 2002-411275P P 20020917
US 2002-411707P P 20020918
US 2002-251117 A2 20020919
US 2002-412304P P 20020920
US 2002-413714P P 20020926
US 2002-418655P P 20021015
US 2002-277494 B2 20021021


US 2002-287949 A2 20021104
US 2002-425599P P 20021112
US 2002-427467P P 20021119
US 2002-306747 A2 20021127
US 2002-439589P P 20021128
US 2002-431105P P 20021205
US 2002-439922P P 20030114
WO 2002-US2510 A2 20030128
WO 2002-US3473 A2 20030205
WO 2002-US3662 A2 20030206
WO 2002-US4034 A2 20030211
WO 2002-US4088 A2 20030211
WO 2002-US4123 A2 20030211
WO 2002-US4347 A2 20030211
WO 2002-US4566 A2 20030211
WO 2002-US97273 A2 20030211
WO 2002-US4250 A2 20030213
WO 2002-US4317 A2 20030213
WO 2002-US4397 A2 20030213
WO 2002-US4402 A2 20030213
WO 2002-US4448 A2 20030213
WO 2002-US4710 A2 20030218
WO 2002-US4718 A2 20030218
WO 2002-US4907 A2 20030218
WO 2002-US4908 A2 20030218
WO 2002-US4909 A2 20030218
WO 2002-US4741 A2 20030220
WO 2002-US4951 A2 20030220
WO 2002-US5022 A2 20030220
WO 2002-US5043 A2 20030220
WO 2002-US5044 A2 20030220
WO 2002-US5045 A2 20030220
WO 2002-US5162 A2 20030220
WO 2002-US5190 A 20030220
WO 2002-US5214 A2 20030220
WO 2002-US5326 A2 20030220
US 2002-462874P P 20030415
US 2002-417012 A1 20030416
US 2002-420194 A2 20030422
WO 2002-US12626 A2 20030422
US 2002-422704 A2 20030424
US 2002-424339 A 20030425
US 2002-427160 A2 20030430
US 2002-430882 A2 20030506
US 2002-444853 A2 20030523
US 2002-607933 A2 20030627
US 2002-486729P P 20030711
US 2002-652791 A2 20030829
US 2002-664767 B2 20030916
US 2002-665255 A2 20030916
US 2002-667271 A2 20030916
US 2002-664668 A2 20030918
US 2002-665951 A2 20030918
US 2002-670011 A2 20030923
US 2002-683990 A2 20031010
US 2002-512701P P 20031020
US 2002-693059 A2 20031023
US 2002-698311 A2 20031031
US 2002-712633 A2 20031111
US 2002-720448 A2 20031124
US 2002-724270 A2 20031126
US 2002-726236 A2 20031202
US 2002-727780 A2 20031203
US 2002-738128 A2 20031218
US 2004-758155 A2 20040112

US 2004-757803 A2 20040114
US 2004-764957 A2 20040126
US 2004-543480P P 20040210
US 2004-780447 A 20040213
US 2004-783128 A2 20040220
US 2004-798090 A2 20040311
US 2004-800487 A2 20040315
US 2004-824036 A2 20040414
US 2004-825485 A2 20040415
US 2004-826966 A2 20040416
WO 2004-US11848 A2 20040416
US 2004-830569 A2 20040423
US 2004-831620 A2 20040423
WO 2004-US12517 A2 20040423
US 2004-832522 A2 20040426
WO 2004-US13456 W 20040430
US 2004-570086P P 20040511
US 2004-844076 A2 20040511
US 2004-844072 A2 20040512
WO 2004-US16390 A2 20040524
US 2004-863973 A2 20040609
US 2004-894475 A2 20040719
US 2004-922675 A2 20040820
US 2004-922475 A2 20040820
US 2004-923536 A2 20040820
US 2004-944611 A2 20040916
US 2005-31668 A1 20050106
US 2005-39680 A2 20050118
WO 2005-US4270 A2 20050209
US 2005-98303 A2 20050404
OS MARPAT 141:34630

--> D 31-33 HITSTR

L5 ANSWER 31 OF 283 CAPLUS COPYRIGHT 2006 ACS ON STN
IT 774549-08-5P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(Preparation of benzamide modulators of metabotropic glutamate receptors)
RN 774549-08-5 CAPLUS
CN 2-Quinoxalinecarboxamide, N-[[5-fluoro-2-[(2-pyridinylcarbonyl)amino]phenyl]methyl]- (9CI) (CA INDEX NAME)




L5 ANSWER 32 OF 283 CAPLUS COPYRIGHT 2006 ACS ON STN
IT 769176-66-1P, N-[cis-4-[[4-(Dimethylamino)quinolin-2-yl]amino]cyclohexyl]quinoxaline-2-carboxamide 769178-84-9P, N-[cis-4-[[4-(Dimethylamino)pyrimidin-2-yl]amino]cyclohexyl]quinoxaline-2-carboxamide 769181-01-3P, N-[cis-4-[[4-(Dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino]cyclohexyl]quinoxaline-2-carboxamide
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(MCH antagonist; preparation of quinolines, quinoxalines, and pyrimidines as MCH antagonist for treatment of CNS disorders)


RN 769176-66-1 CAPLUS
CN 2-Quinoxalinecarboxamide, N-[cis-4-[[4-(dimethylamino)-2-quinolinyl]amino]cyclohexyl]- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 769178-84-9 CAPLUS
CN 2-Quinoxalinecarboxamide, N-[cis-4-[[4-(dimethylamino)-2-pyrimidinyl]amino]cyclohexyl]- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 769181-01-3 CAPLUS
CN 2-Quinoxalinecarboxamide, N-[cis-4-[[4-(dimethylamino)-5,6,7,8-tetrahydroquinazolin-2-yl]amino]cyclohexyl]- (9CI) (CA INDEX NAME)


Relative stereochemistry.




L5 ANSWER 33 OF 283 CAPLUS COPYRIGHT 2006 ACS ON STN
IT 773070-27-2P 773070-28-3P 773070-29-4P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(Preparation of benzamide compds. as phosphorus transport inhibitors)
RN 773070-27-2 CAPLUS
CN Benzoic acid, 5-chloro-2-[[2-(quinoxalinylylcarbonyl)amino]-[(3-fluorophenyl)methylene]hydrazide (9CI) (CA INDEX NAME)



RN 773070-28-3 CAPLUS
 CN Benzoic acid, 5-chloro-2-[(2-quinoxalinylylcarbonyl)amino]-, [(3,4-dimethylphenyl)methylene]hydrazide (9C1) (CA INDEX NAME)



RN 773070-29-4 CAPLUS
 CN Benzoic acid, 5-chloro-2-[(2-quinoxalinylylcarbonyl)amino]-, [(4-chloro-3-(trifluoromethyl)phenyl)methylene]hydrazide (9C1) (CA INDEX NAME)



-- D 36-40

L5 ANSWER 36 OF 283 CAPLUS COPYRIGHT 2006 ACS ON STN
 AN 2004:462860 CAPLUS
 DN 141:33797
 TI Substituted heterocyclic acyl-tripeptides useful as thrombin receptor modulators
 IN McComsey, David P.; Maryanoff, Bruce E.; Hawkins, Michael J.
 PA Ortho-McNeil Pharmaceutical, Inc., USA

SO U.S., 14 pp., Cont.-in-part of U.S. Ser. No. 444,327, abandoned.

CODEN: USXKAM
 DT Patent
 LA English
 FAM.CNT 2

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI US 6747127	B1	20040608	US 2000-565715	20000505
TR 200102502	T2	20020521	TR 2001-200102502	19991119
US 2004063803	A1	20040401	US 2003-606422	20030626
PRAI US 1998-112313P	P	19981214		
US 1999-444327	B2	19991119		
US 2000-565715	A3	20000505		

OS MARPAT 141:33797

RE.CNT 25 THERE ARE 25 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 37 OF 283 CAPLUS COPYRIGHT 2006 ACS ON STN
 AN 2004:454723 CAPLUS
 DN 141:174149
 TI Synthesis and reactivity of a new pyranoquinoline
 AU Hamel, Lamouri; Fodili, Mokhtar; Amari, Mohamed; Khier, Nawel; Medjar-Kolli, Bellara; Andre, Chantal; Hoffmann, Pascal; Peric, Jacques
 CS Institut de Chimie, USTHB, Algiers, 16111, Algeria
 SO Heterocycles (2004), 63(6), 1409-1416
 CODEN: HTCYAM; ISSN: 0385-5414
 PB Japan Institute of Heterocyclic Chemistry
 DT Journal
 LA English
 OS CASREACT 141:174149
 RE.CNT 13 THERE ARE 13 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 38 OF 283 CAPLUS COPYRIGHT 2006 ACS ON STN
 AN 2004:412926 CAPLUS
 DN 140:423706

TI Preparation of phenylalkyl and pyridylalkyl piperazine derivatives as antagonists of dopamine D2 receptors and of serotonin 2A (5HT2A) receptors
 IN Cho, Stephen Sung Yong; Davis, Jamie Marie; Graham, James Michael; Gregory, Tracey Fay; Howard, Harry Ralph, Jr.; Nikam, Sham Shridhar; Walters, Michael Anthony
 PA Warner-Lambert Company LLC, USA
 SO PCT Int. Appl., 185 pp.
 CODEN: PIXXD2

DT Patent
 LA English
 FAM.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2004041793	A1	20040521	WO 2003-184805	20031027
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GR, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MY, NZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CP, CO, CI, CM, CA, GN, GO, GW, ML, MR, NE, SN, TD, TO				
CA 2505397	AA	20040521	CA 2003-2505397	20031027
EP 1562919	A1	20050817	EP 2003-753871	20031027
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
BR 2003016108	A	20050927	BR 2003-16108	20031027

US 2004186108 A1 20040923 US 2003-703333 20031107
 PRAI US 2002-425219P P 20021108
 WO 2003-184805 W 20031027
 OS MARPAT 140:423706

L5 ANSWER 39 OF 283 CAPLUS COPYRIGHT 2006 ACS ON STN
 AN 2004:412920 CAPLUS
 DN 140:423590
 TI Preparation of 4-(phenylpiperidin-4-ylidenemethyl)benzamides for treatment of pain, anxiety, or gastrointestinal disorders
 IN Brown, William; Griffin, Andrew
 PA AstraZeneca AB, Sweden
 SO PCT Int. Appl., 96 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 FAM.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2004041784	A1	20040521	WO 2003-SR1705	20031105
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GR, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MY, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CP, CO, CI, CM, CA, GN, GO, GW, ML, MR, NE, SN, TD, TO				
EP 1567496	A1	20050831	EP 2003-759165	20031105
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
US 2006014789	A1	20060119	US 2005-513838	20050504
PRAI SE 2002-1301	A	20021107		
WO 2003-621705	W	20031105		
OS MARPAT 140:423590				

L5 ANSWER 40 OF 283 CAPLUS COPYRIGHT 2006 ACS ON STN
 AN 2004:390233 CAPLUS
 DN 140:406322
 TI A preparation of heteroaryl-hexanoic acid amide derivatives as immunomodulatory agents
 IN Brown, Matthew Frank; Gavenco, Anderson See; Gladue, Ronald Paul; Kath, John Charles; Poss, Christopher Stanley
 PA Pfizer Products Inc., USA
 SO PCT Int. Appl., 66 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 FAM.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2004039787	A1	20040513	WO 2003-184626	20031020
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GR, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MY, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CP, CO, CI, CM, CA, GN, GO, GW, ML, MR, NE, SN, TD, TO				
US 2004097554	A1	20040520	US 2003-667380	20031016

CA 2503770 AA 20040513 CA 2003-2503770 20031020
 AU 2003269374 A1 20040525 AU 2003-269374 20031020
 EP 1558587 A1 20050803 EP 2003-751155 20031020
 R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK
 BR 2003015837 A 20050920 BR 2003-15837 20031020
 JP 2006056393 T2 20060223 JP 2004-547879 20031020
 PRAI US 2002-422574P P 20021030
 WO 2003-184626 W 20031020
 OS MARPAT 140:406822

-- D 40 HITSTR

L5 ANSWER 40 OF 283 CAPLUS COPYRIGHT 2006 ACS ON STN


IT 689254-88-4P	689254-99-7P	689255-04-7P
689255-10-1P	689255-16-1P	689255-23-0P
689255-28-5P	689255-34-3P	689255-40-1P
689255-46-7P	689255-51-4P	689255-55-8P
689255-58-1P	689255-61-6P	689255-64-9P
689255-67-2P	689255-70-7P	689255-73-0P
689255-76-3P	689255-78-5P	689255-80-9P
689255-81-0P	689255-82-1P	689255-84-3P
689255-86-5P	689255-87-6P	689255-89-8P
689255-90-1P	689255-91-2P	689255-92-3P
689255-93-4P	689255-95-6P	689255-96-7P
689255-97-8P	689255-99-0P	689256-02-8P
689256-04-0P	689256-05-1P	689256-06-2P
689256-07-3P	689256-09-5P	689256-14-2P
689256-16-4P	689256-18-6P	689256-19-7P
689256-21-1P	689256-23-3P	689256-25-5P
689256-27-7P	689256-29-9P	689256-30-2P
689256-31-3P	689256-32-4P	689256-34-6P
689256-36-8P	689256-38-0P	689256-40-4P
689256-42-6P	689256-44-8P	689256-46-0P
689256-48-2P	689256-50-6P	

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(Preparation of heteroaryl-hexanoic acid amide deriva. useful as immunomodulatory agents)

RN 689254-88-4 CAPLUS
 CN Butanedioic acid, mono[(1S,3R)-3-(aminocarbonyl)-1-[(1R)-2-(3-fluorophenyl)-1-[(2-quinoxalinylylcarbonyl)amino]ethyl]-6-hydroxy-6-methylheptyl] ester (9C1) (CA INDEX NAME)


Absolute stereochemistry.



RN 689254-99-7 CAPLUS

CN 2-Quinoxalinecarboxamide, N-[(1S,2S,4R)-2-(acetyloxy)-4-(aminocarbonyl)-1-[(3-fluorophenyl)methyl]-7-hydroxy-7-methyloctyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 689255-04-7 CAPLUS

CN 2-Quinoxalinecarboxamide, N-[(1S,2S,4R)-4-(aminocarbonyl)-1-[(3-fluorophenyl)methyl]-7-hydroxy-7-methyl-2-(phosphonoxy)octyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 689255-08-1 CAPLUS

CN 2-Quinoxalinecarboxamide, N-[(1S,2S,4R)-4-(aminocarbonyl)-1-[(3-fluorophenyl)methyl]-7-hydroxy-7-methyl-2-(sulfoxy)octyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 689255-16-1 CAPLUS

CN 2-Quinoxalinecarboxamide, N-[(1S,2S,4R)-4-(aminocarbonyl)-1-[(3-fluorophenyl)methyl]-2-hydroxy-7-methyl-7-(phosphonoxy)octyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 689255-23-0 CAPLUS

CN 2-Quinoxalinecarboxamide, N-[(1S,2S,4R)-4-(aminocarbonyl)-1-[(3-fluorophenyl)methyl]-2-hydroxy-7-methyl-7-(sulfoxy)octyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 689255-28-5 CAPLUS

CN 2-Quinoxalinecarboxamide, N-[(1S,2S,4R)-4-(aminocarbonyl)-1-[(3-

[fluorophenyl)methyl]-7-methyl-2,7-bis(phosphonoxy)octyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 689255-34-3 CAPLUS

CN 2-Quinoxalinecarboxamide, N-[(1S,2S,4R)-4-(aminocarbonyl)-1-[(3-fluorophenyl)methyl]-7-methyl-2,7-bis(sulfoxy)octyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 689255-40-1 CAPLUS

CN 2-Quinoxalinecarboxamide, N-[(1S,2S,4R)-4-(aminocarbonyl)-1-[(3-fluorophenyl)methyl]-2,7-dihydroxy-7-methyloctyl]-, 1-oxide (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 689255-46-7 CAPLUS

CN 2-Quinoxalinecarboxamide, N-[(1S,2S,4R)-4-(aminocarbonyl)-1-[(3-fluorophenyl)methyl]-2,7-dihydroxy-7-methyloctyl]-, 4-oxide (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 689255-51-4 CAPLUS

CN 2-Quinoxalinecarboxamide, N-[(1S,2S,4R)-4-(aminocarbonyl)-1-[(3-fluorophenyl)methyl]-2,7-dihydroxy-7-methyloctyl]-, 1,4-dioxide (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 689255-55-8 CAPLUS

CN Glycine, (1S,3R)-3-(aminocarbonyl)-1-[(1S)-2-(3-fluorophenyl)-1-[(2-quinoxalinylicarbonyl)amino]ethyl]-6-hydroxy-6-methylheptyl ester (9CI)
(CA INDEX NAME)


Absolute stereochemistry.



RN 689255-58-1 CAPLUS

CN L-Alanine, (1S,3R)-3-(aminocarbonyl)-1-[(1S)-2-(3-fluorophenyl)-1-[(2-quinoxalinylicarbonyl)amino]ethyl]-6-hydroxy-6-methylheptyl ester (9CI)
(CA INDEX NAME)


Absolute stereochemistry.



RN 689255-61-6 CAPLUS

CN L-Lysine, (1S,3R)-3-(aminocarbonyl)-1-[(1S)-2-(3-fluorophenyl)-1-[(2-quinoxalinylicarbonyl)amino]ethyl]-6-hydroxy-6-methylheptyl ester (9CI)
(CA INDEX NAME)


Absolute stereochemistry.



RN 689255-64-9 CAPLUS

CN L-Arginine, (1S,3R)-3-(aminocarbonyl)-1-[(1S)-2-(3-fluorophenyl)-1-[(2-quinoxalinylicarbonyl)amino]ethyl]-6-hydroxy-6-methylheptyl ester (9CI)
(CA INDEX NAME)


Absolute stereochemistry.



RN 689255-67-2 CAPLUS

CN L-Histidine, (1S,3R)-3-(aminocarbonyl)-1-[(1S)-2-(3-fluorophenyl)-1-[(2-quinoxalinylicarbonyl)amino]ethyl]-6-hydroxy-6-methylheptyl ester (9CI)
(CA INDEX NAME)


Absolute stereochemistry.



RN 689255-70-7 CAPLUS


CN L-Aspartic acid, bis[(1S,3R)-3-(aminocarbonyl)-1-[(1S)-2-(3-fluorophenyl)-1-[(2-quinoxalinylicarbonyl)amino]ethyl]-6-hydroxy-6-methylheptyl ester (9CI)
(CA INDEX NAME)

Absolute stereochemistry.



PAGE 1-A


PAGE 1-B



RN 689255-73-0 CAPLUS

CN L-Glutamic acid, bis[(1S,3R)-3-(aminocarbonyl)-1-[(1S)-2-(3-fluorophenyl)-1-[(2-quinoxalinylicarbonyl)amino]ethyl]-6-hydroxy-6-methylheptyl ester (9CI)
(CA INDEX NAME)

Absolute stereochemistry.



PAGE 1-A


PAGE 1-B

Me

RN 689255-76-3 CAPLUS


CN L-Asparagine, (1S,3R)-3-(aminocarbonyl)-1-[(1S)-2-(3-fluorophenyl)-1-[(2-quinoxalinylicarbonyl)amino]ethyl]-6-hydroxy-6-methylheptyl ester (9CI)
(CA INDEX NAME)

Absolute stereochemistry.





RN 689255-78-5 CAPLUS
CN L-Glutamine, (1S,3R)-3-(aminocarbonyl)-1-[(1S)-2-(3-fluorophenyl)-1-[(2-quinoxalinylicarbonyl)amino]ethyl]-6-hydroxy-6-methylheptyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.





RN 689255-80-9 CAPLUS
CN Benzenepropanoic acid, $\beta,\beta,2,4$ -tetramethyl-6-(phosphonooxy)-, α -[(1S,3R)-3-(aminocarbonyl)-1-[(1S)-2-(3-fluorophenyl)-1-[(2-quinoxalinylicarbonyl)amino]ethyl]-6-hydroxy-6-methylheptyl] ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 689255-81-0 CAPLUS
CN Benzoic acid, 2-[(acetyloxy)methyl]-, (1S,3R)-3-(aminocarbonyl)-1-[(1S)-2-(3-fluorophenyl)-1-[(2-quinoxalinylicarbonyl)amino]ethyl]-6-hydroxy-6-methylheptyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 689255-82-1 CAPLUS
CN Butanedioic acid, (1S,3R)-3-(aminocarbonyl)-1-[(1S)-2-(3-fluorophenyl)-1-[(2-quinoxalinylicarbonyl)amino]ethyl]-6-hydroxy-6-methylheptyl ethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 689255-84-3 CAPLUS
CN Pentanedioic acid, mono[(1S,3R)-3-(aminocarbonyl)-1-[(1S)-2-(3-fluorophenyl)-1-[(2-quinoxalinylicarbonyl)amino]ethyl]-6-hydroxy-6-methylheptyl] ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 689255-86-5 CAPLUS
CN Pentanedioic acid, [(1S,3R)-3-(aminocarbonyl)-1-[(1S)-2-(3-fluorophenyl)-1-[(2-quinoxalinylicarbonyl)amino]ethyl]-6-hydroxy-6-methylheptyl ethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 689255-87-6 CAPLUS
CN Glycine, (4R,6S,7S)-4-(aminocarbonyl)-8-(3-fluorophenyl)-6-hydroxy-1,1-


dimethyl-7-[(2-quinoxalinylicarbonyl)amino]octyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 689255-89-8 CAPLUS
CN L-Alanine, (4R,6S,7S)-4-(aminocarbonyl)-8-(3-fluorophenyl)-6-hydroxy-1,1-dimethyl-7-[(2-quinoxalinylicarbonyl)amino]octyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 689255-90-1 CAPLUS
CN L-Lysine, (4R,6S,7S)-4-(aminocarbonyl)-8-(3-fluorophenyl)-6-hydroxy-1,1-dimethyl-7-[(2-quinoxalinylicarbonyl)amino]octyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 689255-91-2 CAPLUS
CN L-Arginine, (4R,6S,7S)-4-(aminocarbonyl)-8-(3-fluorophenyl)-6-hydroxy-1,1-dimethyl-7-[(2-quinoxalinylicarbonyl)amino]octyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 689255-92-3 CAPLUS
CN L-Histidine, (4R,6S,7S)-4-(aminocarbonyl)-8-(3-fluorophenyl)-6-hydroxy-1,1-dimethyl-7-[(2-quinoxalinylicarbonyl)amino]octyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 689255-93-4 CAPLUS
CN L-Aspartic acid, bis[(4R,6S,7S)-4-(aminocarbonyl)-8-(3-fluorophenyl)-6-hydroxy-1,1-dimethyl-7-[(2-quinoxalinylicarbonyl)amino]octyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




PAGE 1-A




RN 689255-95-6 CAPLUS
CN L-Glutamic acid, bis[(4R,6S,7S)-4-(aminocarbonyl)-8-(3-fluorophenyl)-6-hydroxy-1,1-dimethyl-7-[(2-quinoxalinylicarbonyl)amino]octyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 1-B




RN 689255-96-7 CAPLUS
CN Butanedioic acid, mono[(4R,6S,7S)-4-(aminocarbonyl)-8-(3-fluorophenyl)-6-hydroxy-1,1-dimethyl-7-[(2-quinoxalinylicarbonyl)amino]octyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 689255-97-8 CAPLUS
CN Butanedioic acid, mono[(4R,6S,7S)-4-(aminocarbonyl)-8-(3-fluorophenyl)-6-hydroxy-1,1-dimethyl-7-[(2-quinoxalinylicarbonyl)amino]octyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 689255-99-0 CAPLUS
CN Pentanedioic acid, mono[(4R,6S,7S)-4-(aminocarbonyl)-8-(3-fluorophenyl)-6-hydroxy-1,1-dimethyl-7-[(2-quinoxalinylicarbonyl)amino]octyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 689256-02-8 CAPLUS
CN Pentanedioic acid, (4R,6S,7S)-4-(aminocarbonyl)-8-(3-fluorophenyl)-6-hydroxy-1,1-dimethyl-7-[(2-quinoxalinylicarbonyl)amino]octyl ethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 689256-04-0 CAPLUS
CN Glycine, [(1S,3R)-3-(aminocarbonyl)-1-[(1S)-2-(3-fluorophenyl)-1-[(2-quinoxalinylicarbonyl)amino]ethyl]-6-hydroxy-6-methylheptyloxy]methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 689256-05-1 CAPLUS
CN L-Alanine, [(1S,3R)-3-(aminocarbonyl)-1-[(1S)-2-(3-fluorophenyl)-1-[(2-quinoxalinylicarbonyl)amino]ethyl]-6-hydroxy-6-methylheptyloxy]methyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 689256-06-2 CAPLUS

CN Glycine, [[[(4R,6S,7S)-4-(aminocarbonyl)-8-(3-fluorophenyl)-6-hydroxy-1,1-dimethyl-7-[(2-quinoxalinylylcarbonyl)amino]octyl]oxy]methyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 689256-07-3 CAPLUS

CN L-Alanine, [[[(4R,6S,7S)-4-(aminocarbonyl)-8-(3-fluorophenyl)-6-hydroxy-1,1-dimethyl-7-[(2-quinoxalinylylcarbonyl)amino]octyl]oxy]methyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 689256-09-5 CAPLUS

CN Butanedioic acid, mono[[[(1S,3R)-3-(aminocarbonyl)-1-[(1S)-2-(3-fluorophenyl)-1-[(2-quinoxalinylylcarbonyl)amino]ethyl]-6-hydroxy-6-methylheptyl]oxy]methyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 689256-14-2 CAPLUS

CN Butanedioic acid, [[[(1S,3R)-3-(aminocarbonyl)-1-[(1S)-2-(3-fluorophenyl)-1-[(2-quinoxalinylylcarbonyl)amino]ethyl]-6-hydroxy-6-methylheptyl]oxy]methyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 689256-16-4 CAPLUS

CN Pentanedioic acid, mono[[[(1S,3R)-3-(aminocarbonyl)-1-[(1S)-2-(3-fluorophenyl)-1-[(2-quinoxalinylylcarbonyl)amino]ethyl]-6-hydroxy-6-methylheptyl]oxy]methyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 689256-18-6 CAPLUS

CN Pentanedioic acid, [[[(1S,3R)-3-(aminocarbonyl)-1-[(1S)-2-(3-fluorophenyl)-1-[(2-quinoxalinylylcarbonyl)amino]ethyl]-6-hydroxy-6-methylheptyl]oxy]methyl ethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 689256-19-7 CAPLUS

CN Butanedioic acid, mono[[[(4R,6S,7S)-4-(aminocarbonyl)-8-(3-fluorophenyl)-6-hydroxy-1,1-dimethyl-7-[(2-quinoxalinylylcarbonyl)amino]octyl]oxy]methyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 689256-21-1 CAPLUS

CN Butanedioic acid, [[[(4R,6S,7S)-4-(aminocarbonyl)-8-(3-fluorophenyl)-6-hydroxy-1,1-dimethyl-7-[(2-quinoxalinylylcarbonyl)amino]octyl]oxy]methyl ethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 689256-23-3 CAPLUS

CN Pentanedioic acid, mono[[[(4R,6S,7S)-4-(aminocarbonyl)-8-(3-fluorophenyl)-6-hydroxy-1,1-dimethyl-7-[(2-quinoxalinylylcarbonyl)amino]octyl]oxy]methyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 689256-25-5 CAPLUS


CN Pentanedioic acid, [[[(4R,6S,7S)-4-(aminocarbonyl)-8-(3-fluorophenyl)-6-hydroxy-1,1-dimethyl-7-[(2-quinoxalinylylcarbonyl)amino]octyl]oxy]methyl ethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 689256-27-7 CAPLUS

CN Acetic acid, [[[(1S,3R)-3-(aminocarbonyl)-1-[(1S)-2-(3-fluorophenyl)-1-[(2-quinoxalinylylcarbonyl)amino]ethyl]-6-hydroxy-6-methylheptyl]oxy]carbonyl]oxy]- (9CI) (CA INDEX NAME)




Absolute stereochemistry.




RN 689256-29-9 CAPLUS
CN Propanoic acid, 3-[[[[(1S,3R)-3-(aminocarbonyl)-1-[(1S)-2-(3-fluorophenyl)-1-[(2-quinoxalinylylcarbonyl)amino]ethyl]-6-hydroxy-6-methylheptyl]oxy]carbonyl]oxy]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 689256-30-2 CAPLUS
CN Carbonic acid, (1S,3R)-3-(aminocarbonyl)-1-[(1S)-2-(3-fluorophenyl)-1-[(2-quinoxalinylylcarbonyl)amino]ethyl]-6-hydroxy-6-methylheptyl 2-aminoethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 689256-36-8 CAPLUS
CN 2-Butenedioic acid, mono[(1S,3R)-3-(aminocarbonyl)-1-[(1S)-2-(3-fluorophenyl)-1-[(2-quinoxalinylylcarbonyl)amino]ethyl]-6-hydroxy-6-methylheptyl] ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.



RN 689256-38-0 CAPLUS
CN Ethanedioic acid, mono[(1S,3R)-3-(aminocarbonyl)-1-[(1S)-2-(3-fluorophenyl)-1-[(2-quinoxalinylylcarbonyl)amino]ethyl]-6-hydroxy-6-methylheptyl] ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 689256-40-4 CAPLUS
CN Glycine, [[[(1S,3R)-3-(aminocarbonyl)-1-[(1S)-2-(3-fluorophenyl)-1-[(2-quinoxalinylylcarbonyl)amino]ethyl]-6-hydroxy-6-methylheptyl]oxy]carbonyl]oxy]methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.


RN 689256-31-3 CAPLUS
CN Acetic acid, [[[(4R,6S,7S)-4-(aminocarbonyl)-8-(3-fluorophenyl)-6-hydroxy-1,1-dimethyl-7-[(2-quinoxalinylylcarbonyl)amino]octyl]oxy]carbonyl]oxy]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 689256-32-4 CAPLUS
CN Propanoic acid, 3-[[[[(4R,6S,7S)-4-(aminocarbonyl)-8-(3-fluorophenyl)-6-hydroxy-1,1-dimethyl-7-[(2-quinoxalinylylcarbonyl)amino]octyl]oxy]carbonyl]oxy]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 689256-34-6 CAPLUS
CN Carbonic acid, (4R,6S,7S)-4-(aminocarbonyl)-8-(3-fluorophenyl)-6-hydroxy-1,1-dimethyl-7-[(2-quinoxalinylylcarbonyl)amino]octyl 2-aminoethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 689256-42-6 CAPLUS
CN Carbonic acid, (1S,3R)-3-(aminocarbonyl)-1-[(1S)-2-(3-fluorophenyl)-1-[(2-quinoxalinylylcarbonyl)amino]ethyl]-6-hydroxy-6-methylheptyl 2,3-dihydroxypropyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 689256-44-8 CAPLUS
CN 2-Butenedioic acid (2Z), mono[(4R,6S,7S)-4-(aminocarbonyl)-8-(3-fluorophenyl)-6-hydroxy-1,1-dimethyl-7-[(2-quinoxalinylylcarbonyl)amino]octyl] ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.
Double bond geometry as shown.



RN 689256-46-0 CAPLUS


CN Ethanedioic acid, mono[[(4R,6S,7S)-4-(aminocarbonyl)-8-(3-fluorophenyl)-6-hydroxy-1,1-dimethyl-7-[(2-quinoxalinylylcarbonyl)amino]octyl] ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 689256-48-2 CAPLUS
CN 2-Butenedioic acid (3E)-, mono[[(4R,6S,7S)-4-(aminocarbonyl)-8-(3-fluorophenyl)-6-hydroxy-1,1-dimethyl-7-[(2-quinoxalinylylcarbonyl)amino]octyl] ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.




RN 689256-49-3 CAPLUS
CN Glycine, [([[(4R,6S,7S)-4-(aminocarbonyl)-8-(3-fluorophenyl)-6-hydroxy-1,1-dimethyl-7-[(2-quinoxalinylylcarbonyl)amino]octyl]oxycarbonyl)oxymethyl] ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 689256-50-6 CAPLUS
CN Carbonic acid, (4R,6S,7S)-4-(aminocarbonyl)-8-(3-fluorophenyl)-6-hydroxy-1,1-dimethyl-7-[(2-quinoxalinylylcarbonyl)amino]octyl 2,3-dihydroxypropyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



IT 212790-31-3
RL: RCT (Reactant); RACT (Reactant or reagent)
(reactant; preparation of heteroaryl-hexanoic acid amide derivs. useful as immunomodulatory agents)

RN 212790-31-3 CAPLUS
CN 2-Quinoxalinecarboxamide, N-[(1S,2S,4R)-4-(aminocarbonyl)-1-[(3-fluorophenyl)methyl]-2,7-dihydroxy-7-methyloctyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




>> D 36 HITSTR

L5 ANSWER 36 OF 283 CAPLUS COPYRIGHT 2006 ACS ON STN

IT 231408-75-6
RL: BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(heterocyclic acyl-tripeptide derive. for thrombin receptor modulators)
RN 231408-75-6 CAPLUS
CN L-Phenylalaninamide, 3-cyclohexyl-N-(2-quinoxalinylylcarbonyl)-L-alanyl-L-arginyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



>> D 41-45

L5 ANSWER 41 OF 283 CAPLUS COPYRIGHT 2006 ACS ON STN
AN 2004:372867 CAPLUS
DN 140:375193
TI Preparation of heteroaryl-hexanoic acid amides which are CCR1 antagonists useful as immunomodulatory agents
IN Brown, Matthew F.; Gaweco, Anderson S.; Gladue, Ronald P.; Kath, John C.; Poss, Christopher S.
PA Pfizer Inc, USA
SO U.S. Pat. Appl. Publ., 63 pp.
CODEN: USXXCO
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI US 2004087571	A1	20040506	US 2003-687015	20031016
WO 2004039375	A1	20040513	WO 2003-184614	20031020
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MY, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CO, CI, CM, GA, GN, GO, GW, ML, MR, NE, NG, TD, TG				
AU 2003267800	A1	20040525	AU 2003-267800	20031020
PRAI US 2002-422579P	P	20021030		
WO 2003-184614	W	20031020		
OS MARPAT 140:375193				

L5 ANSWER 42 OF 283 CAPLUS COPYRIGHT 2006 ACS ON STN
AN 2004:331784 CAPLUS
DN 140:339193
TI Preparation of indole nitriles as cysteine protease, in particular cathepsin K inhibitors
IN Samberg, Joe Timothy; Gabriel, Tobias; Krauss, Nancy Elisabeth; Mirzadegan, Taraneh; Palmer, Wylie Solang; Smith, David Bernard
PA Roche Palo Alto, LLC, USA
SO U.S. Pat. Appl. Publ., 141 pp., Cont.-in-part of U.S. Ser. No. 308,963.
CODEN: USXXCO
DT Patent
LA English

FAN.CNT 2

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI US 2004077646	A1	20040422	US 2003-453112	20030602
US 6759428	B2	20040706		
US 2003212097	A1	20031113	US 2002-308963	20021203
US 6747053	B2	20040608		
PRAI US 2001-336750P	P	20011204		
US 2002-308963	A2	20021203		
OS MARPAT 140:339193				

RE.CNT 23 THERE ARE 23 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 43 OF 283 CAPLUS COPYRIGHT 2006 ACS ON STN
AN 2004:303285 CAPLUS
DN 141:64382
TI Novel CCR1 antagonists with improved metabolic stability
AU Brown, Matthew F.; Avery, Mike; Brissette, William H.; Chang, J. H.; Colizza, Kevin; Conklyn, Maryrose; Dirico, Amy P.; Gladue, Ronald P.; Kath, John C.; Krueger, Suzanne S.; Lira, Paul D.; Lillie, Brett M.; Lundquist, Greg D.; Mairs, Erin N.; McElroy, Eric B.; McGlynn, Molly A.; Paradis, Timothy J.; Poss, Christopher S.; Rossulek, Michelle I.; Shepard, Richard M.; Sims, Jeff; Strelevitz, Timothy J.; Truesdell, Susan; Tylaska, Laurie A.; Yoon, Kwansik; Zheng, Deyu
CS Pfizer Global Research and Development, Groton, CT, 06340, USA
SO Bioorganic & Medicinal Chemistry Letters (2004), 14(9), 2175-2179
CODEN: BMCLB8; ISSN: 0960-894X
PB Elsevier Science B.V.
DT Journal
LA English
RE.CNT 12 THERE ARE 12 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 44 OF 283 CAPLUS COPYRIGHT 2006 ACS ON STN
AN 2004:303284 CAPLUS
DN 141:64381
TI Potent small molecule CCR1 antagonists
AU Kath, John C.; Brissette, William H.; Brown, Matthew F.; Conklyn, Maryrose; Dirico, Amy P.; Dorff, Peter; Gladue, Ronald P.; Lillie, Brett M.; Lira, Paul D.; Mairs, Erin N.; Martin, William H.; McElroy, Eric B.; McGlynn, Molly A.; Paradis, Timothy J.; Poss, Christopher S.; Stock, Ingrid A.; Tylaska, Laurie A.; Zheng, Deyu
CS Pfizer Global Research and Development, Groton, CT, 06340, USA
SO Bioorganic & Medicinal Chemistry Letters (2004), 14(9), 2169-2173
CODEN: BMCLB8; ISSN: 0960-894X
PB Elsevier Science B.V.
DT Journal
LA English
RE.CNT 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 45 OF 283 CAPLUS COPYRIGHT 2006 ACS ON STN
AN 2004:205969 CAPLUS
DN 142:93707
TI Product class 15: quinoxalines
AU Gobec, S.; Urleb, U.
CS Germany
SO Science of Synthesis (2004), 16, 845-911
CODEN: SSCYJ9
PB Georg Thieme Verlag
DT Journal; General Review
LA English
RE.CNT 408 THERE ARE 408 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

-- D 46-50

L5 ANSWER 46 OF 283 CAPLUS COPYRIGHT 2006 ACS ON STN
AN 2004:182843 CAPLUS
DN 140:235498
TI Preparation of antibacterial benzoic acid derivatives
IN Thorenansen, Atli; Ruble, Craig J.; Fisher, Jed F.; Romero, Donna L.;
Beauchamp, Thomas J.; Northuis, Jill M.
PA Pharmacia & Upjohn Company, USA
SO PCT Int. Appl., 500 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2004018428	A1	20040304	WO 2003-US24796	20030822
W: AS, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GR, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RM: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GO, GW, ML, MR, NE, SN, TD, TO				
US 2004110802	A1	20040610	US 2003-645802	20030820
US 2003264005	A1	20040311	AU 2003-264005	20030822
PRAI US 2002-405429P	P	20020823		
US 2002-430592P	P	20021203		
WO 2003-US24796	W	20030822		

OS MARPAT 140:235498
RE.CNT 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 47 OF 283 CAPLUS COPYRIGHT 2006 ACS ON STN
AN 2004:173258 CAPLUS
DN 140:418328
TI Metabotropic glutamate 1 receptor distribution and occupancy in the rat brain: a quantitative autoradiographic study using [3H]RB214127
AU Lavreyen, Hilde; Pereira, Sandrine Nobrega; Leyeen, Josee S.; Langlois, Xavier; Leage, Anne S. J.
CS CNS Discovery Research, Johnson and Johnson Pharmaceutical Research and Development, Beerse, B-2340, Belg.
IN Neuropharmacology (2004), 46(5), 609-619
CODEN: NEPHW; ISSN: 0028-3908
PB Elsevier Science B.V.
DT Journal
LA English
RE.CNT 40 THERE ARE 40 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 48 OF 283 CAPLUS COPYRIGHT 2006 ACS ON STN
AN 2004:143121 CAPLUS
DN 140:187486
TI Crystal forms of a quinoxaline-2-carboxylic acid derivative
IN Kach, John Charles; Li, Zhongong Bryen; McIlroy, Eric Brock; Meltz, Clifford Nathaniel; Poas, Christopher Stanley
PA Pfizer Products Inc., USA
SO PCT Int. Appl., 48 pp.
CODEN: PIXXD2
DT Patent
LA English

ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 50 OF 283 CAPLUS COPYRIGHT 2006 ACS ON STN
AN 2004:41604 CAPLUS
DN 140:105238
TI Antibacterial inhibitors of FtsZ protein
IN White, Lucile S.; Reynolds, Robert C.; Suling, William
PA Southern Research Institute, USA
SO PCT Int. Appl., 117 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2004005472	A2	20040115	WO 2003-US20984	200310702
WO 2004005472	A3	20040923		
W: AS, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GR, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RM: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GO, GW, ML, MR, NE, SN, TD, TO				
CA 2491680	AA	20040115	CA 2003-2491680	20030702
EP 1538907	AA	20050615	EP 2003-756780	20030702
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, HU, IE, IT, LU, NL, SE, MC, PT, IS, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
JP 2005535662	T2	20051124	JP 2004-519843	20030702
PRAI US 2002-393680P	P	20020702		
US 2003-US20984	W	20030702		

-- D 51-55

L5 ANSWER 51 OF 283 CAPLUS COPYRIGHT 2006 ACS ON STN
AN 2004:36264 CAPLUS
DN 141:260621
TI Interaction of bromomalonate acid N,N'-dibenzylamide with bifunctional amines - A pathway to the new pharmacologically active substances
AU Georgiyants, V. A.; Sych, I. A.
CS National Pharmaceutical University, Ukraine
SO Medicyna Khimiya (2003), 5(3), 95-99
CODEN: MKHIA7
PB Vidavnistetvo "Ukrmedkniga"
DT Journal
LA Ukrainian
OS CASREACT 141:260621

L5 ANSWER 52 OF 283 CAPLUS COPYRIGHT 2006 ACS ON STN
AN 2003:991345 CAPLUS
DN 140:42216
TI Preparation of phenol or phenyl acetate derivatives for treatment of allergic diseases
IN Muto, Susumu; Itai, Akiko
PA Institute of Medicinal Molecular Design, Inc., Japan
SO PCT Int. Appl., 418 pp.
CODEN: PIXXD2
DT Patent
LA Japanese
FAN.CNT 1

FAN.CNT 1
PATENT NO. KIND DATE APPLICATION NO. DATE
PI WO 2004018475 A1 20040219 WO 2003-183464 20030731
W: AS, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GR, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RM: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GO, GW, ML, MR, NE, SN, TD, TO
CA 2494776 AA 20040219 CA 2003-2494776 20030731
AU 2003250450 A1 20040225 AU 2003-250450 20030731
EP 1539715 A1 20050615 EP 2003-784381 20030731
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IS, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK
BR 2003013378 A 20050712 BR 2003-13378 20030731
JP 2005538130 T2 20051215 JP 2004-527195 20030731
US 2004072834 A1 20040415 US 2003-637475 20030805
PRAI US 2002-403216P P 20020812 NO 2005-540 20050131
WO 2003-183464 W 20030731
RE.CNT 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 49 OF 283 CAPLUS COPYRIGHT 2006 ACS ON STN
AN 2004:142932 CAPLUS
DN 140:187358
TI Pharmaceutical compositions of semi-ordered drugs and polymers
IN Babcock, Walter Christian; Caldwell, William Brett; Crew, Marshall David; Friesen, Dwayne Thomas; Smithey, Daniel Tod; Shanker, Ravi Mysore
PA Pfizer Products Inc., USA
SO PCT Int. Appl., 117 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2004014342	A1	20040219	WO 2003-183465	20030731
W: AS, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GR, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RM: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GO, GW, ML, MR, NE, SN, TD, TO				
CA 2496441 AA 20040219 CA 2003-2496441 20030731				
AU 2003249474 A1 20040225 AU 2003-249474 20030731				
EP 1530457 A1 20050518 EP 2003-784384 20030731				
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IS, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
BR 2003013428 A 20050628 BR 2003-13428 20030731				
JP 2006500349 T2 20060105 JP 2004-527196 20030731				
US 2004156905 A1 20040812 US 2003-636834 20030805				
NO 2005000419 A 20050404 NO 2005-419 20050125				
PRAI US 2002-403087P P 20020812				
WO 2003-183465 W 20030731				

RE.CNT 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2003103665	A1	20031218	WO 2003-JP7120	20030605
W: AS, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GR, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RM: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GO, GW, ML, MR, NE, SN, TD, TO				
CA 2488367 AA 20031218 CA 2003-2488367 20030605				
AU 2003242103 A1 20031222 AU 2003-242103 20030605				
EP 1514544 A1 20050316 EP 2003-730831 20030605				
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IS, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
PRAI JP 2002-165141 W 20030605				
WO 2003-JP7120 W 20030605				

OS MARPAT 140:42216
RE.CNT 24 THERE ARE 24 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 53 OF 283 CAPLUS COPYRIGHT 2006 ACS ON STN
AN 2003:991339 CAPLUS
DN 140:42204
TI Preparation of immunity-related protein kinase inhibitors
IN Muto, Susumu; Itai, Akiko
PA Institute of Medicinal Molecular Design, Inc., Japan
SO PCT Int. Appl., 401 pp.
CODEN: PIXXD2
DT Patent
LA Japanese
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2003103658	A1	20031218	WO 2003-JP7130	20030605
W: AS, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GR, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RM: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GO, GW, ML, MR, NE, SN, TD, TO				
CA 2487900 AA 20031218 CA 2003-2487900 20030605				
AU 2003242131 A1 20031222 AU 2003-242131 20030605				
EP 1510210 A1 20050302 EP 2003-730840 20030605				
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IS, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
US 2004019958 A1 20040126 US 2005-515343 20050801				
PRAI JP 2002-164525 A 20020605				
WO 2003-JP7130 W 20030605				

OS MARPAT 140:42204
RE.CNT 20 THERE ARE 20 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 54 OF 283 CAPLUS COPYRIGHT 2006 ACS ON STN
AN 2003:991338 CAPLUS
DN 140:42203
TI Preparation of hydroxybenzamide, naphthalenecarboxamide, and hydroxyheterocycliccarboxamide derivatives for preventive and/or


therapeutic drugs for neurodegenerative diseases and epilepsy
IN Muto, Susumu; Itai, Akiko
PA Institute of Medicinal Molecular Design, Inc., Japan
SO PCT Int. Appl., 278 pp.
CODEN: PIXXD2
DT Patent
LA Japanese
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	MO	2003103657	A1	20031218
W:	AS, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SJ, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW	MO 2003-JP7121	MO 2003-JP7121	20030605
RW:	GH, GM, KE, LS, MM, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, NG, TD, TO	CA 2488979	AA 20031228	CA 2003-2488979
CA 2488979	AA	20031228	CA 2003-2488979	20030605
EP 1555018	A1	20050720	EP 2003-730838	20030605
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK	US 2006035944	A1	20060216
PRAI JP 2002-169640	A	20020611	US 2005-516293	20050810
MO 2003-JP7121	W	20030605		
OS	MARPAT 140:42203			
RE.CNT 44	THERE ARE 44 CITED REFERENCES AVAILABLE FOR THIS RECORD ALL CITATIONS AVAILABLE IN THE RE FORMAT			

L5 ANSWER 55 OF 283 CAPLUS COPYRIGHT 2006 ACS ON STN
AN 2003:991336 CAPLUS
DN 140:42202
TI Preparation of hydroxybenzamide, naphthalenecarboxamide, and hydroxyheterocycliccarboxamide derivatives as anticancer agents
IN Muto, Susumu; Itai, Akiko
PA Institute of Medicinal Molecular Design, Inc., Japan
SO PCT Int. Appl., 265 pp.
CODEN: PIXXD2
DT Patent
LA Japanese
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	MO	2003103655	A1	20031218
W:	AS, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW	MO 2003-JP7121	MO 2003-JP7121	20030605
RW:	GH, GM, KE, LS, MM, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, NG, TD, TO	CA 2488974	AA 20031218	CA 2003-2488974
CA 2488974	AA	20031218	CA 2003-2488974	20030605
EP 1535610	A1	20050601	EP 2003-730832	20030605
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK	US 2006014811	A1	20060119
PRAI JP 2002-168332	A	20020610	US 2005-516292	20050705

PUBLISHER: Vidavnitstvo "Ukrmedkniga"
DOCUMENT TYPE: Journal
LANGUAGE: Ukrainian
OTHER SOURCE(S): CASREACT 141:260621
OI




AB Reactions of α -bromomalonate acid N,N'-dibenzylamide BrCH(CONHCH₂Ph)₂ (I) with bifunctional amines, such as 2-aminopyridine, 2-aminothiazole or o-phenylenediamine, were studied. The reaction of I with 2-aminopyridine gives the corresponding pyridine yields, which cyclize on heating in DMF to afford imidazo[1,2-a]pyridines II (R = H, Me) in 75-80% yields. The reaction of I with 4-phenyl-2-aminothiazole occurs similarly giving the corresponding benzylcarbamoyl-substituted imidazo[1,2-b]thiazole. On treatment of I with o-phenylenediamine, benzylcarbamoyl quinoxaline III was obtained in 92% yield. When α , ω -dibromomalonate acid N,N'-dibenzylamide was used as alkylating agent instead of I, the formation of benzimidazole-2,2-dicarboxylic acid N,N'-dibenzylamide was observed. Pharmacol. screening of the products showed that III possess a moderate neuroleptic and high diuretic, analgesic and anti-inflammatory activity comparable to the reference compds.

IT 753471-46-4P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of carbamoyl-substituted imidazopyridines, imidazothiazole, quinoxaline and other heterocycles via heterocyclization of dibenzyl α -bromomalonate with bifunctional amines)

RN 753471-46-4 CAPLUS

CN 2-Quinoxalinecarboxamide, 3,4-dihydro-1-oxo-N-(phenylmethyl)- (9CI) (CA INDEX NAME)




L5 ANSWER 52 OF 283 CAPLUS COPYRIGHT 2006 ACS ON STN
ACCESSION NUMBER: 2003:991345 CAPLUS
DOCUMENT NUMBER: 140:42216
TITLES: Preparation of phenol or phenyl acetate derivatives for treatment of allergic diseases
INVENTOR(S): Muto, Susumu; Itai, Akiko
PATENT ASSIGNEE(S): Institute of Medicinal Molecular Design, Inc., Japan
SOURCE: PCT Int. Appl., 418 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent

MO 2003-JP7121 W 20030605
OS MARPAT 140:42202
RE.CNT 11 THERE ARE 11 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT


==> D 50 HITSTR

L5 ANSWER 50 OF 283 CAPLUS COPYRIGHT 2006 ACS ON STN
IT 83269-14-1
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(inhibitors of ftx and uses thereof)
RN 83269-14-1 CAPLUS
CN Carbanic acid, [5-amino-3-[(methylphenylamino)carbonyl]pyrido[3,4-b]pyrazin-7-yl]-, ethyl ester (9CI) (CA INDEX NAME)



==> D 46 HITSTR

L5 ANSWER 46 OF 283 CAPLUS COPYRIGHT 2006 ACS ON STN
IT 668974-93-4P
RL: BSU (Biological study, unclassified); PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of benzoic acid derivs. as antibacterial agents)
RN 668974-93-4 CAPLUS
CN Benzoic acid, 5-bromo-2-[(2-quinoxalinylylcarbonyl)amino]- (9CI) (CA INDEX NAME)




==> D 51-283 IBIB ABS HITSTR

L5 ANSWER 51 OF 283 CAPLUS COPYRIGHT 2006 ACS ON STN
ACCESSION NUMBER: 2004:26264 CAPLUS
DOCUMENT NUMBER: 141:260621
TITLES: Interaction of bromomalonate acid N,N'-dibenzylamide with bifunctional amines - A pathway to the new pharmacologically active substances
Georgiyants, V. A.; Sych, I. A.
NATIONAL PHARMACEUTICAL UNIVERSITY, UKRAINE
MEDICINA KHIMIIYA (2003), 5(3), 95-99
AUTHOR(S):
CORPORATE SOURCE:
SOURCE:

LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
MO	2003103665	A1	20031218	MO 2003-JP7120
W:	AS, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW	CA 2488977	AA 20031218	CA 2003-2488977
CA 2488977	AA	20031218	CA 2003-2488977	20030605
EP 1514544	A1	20050216	EP 2003-730831	20030605
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK	JP 2002-165148	A	20020606
PRIORITY APPLN. INFO.:	JP 2002-165148 A 20020606			
OTHER SOURCE(S):	MARPAT 140:42216 MO 2003-JP7120 W 20030605			
OI				



AB The title compds. I [wherein X = a connecting group; A = H or acetyl; E = (un)substituted aryl or heteroaryl; ring Z = (un)substituted arene or heteroarene] and pharmaceutically acceptable salts, hydrates, and solvates thereof are prepared for the treatment of allergic diseases, endometriosis, and/or hysteromyoma (no date). A total of approx. 500 I including N-phenylhydroxybenzamidines (N-phenylacetylamides), N-heterocyclylhydroxybenzamidines, N-phenylhydroxycarboxylcarboxamides, N-phenylhydroxynaphthalenecarboxamides, N-phenylhydroxypyridinecarboxamides, N-phenylhydroxyquinoxalinecarboxamides, and N-phenylhydroxyindolecarboxamides were prepared. The compds. I exhibited inhibitory activities against IgE production, cell proliferation, and cell degranulation.

IT 439244-03-1P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of phenol or Ph acetate derivs. for treatment of allergic diseases)

RN 439244-03-3 CAPLUS
CN 2-Quinoxalinecarboxamide, N-[3,5-bis(trifluoromethyl)phenyl]-3,4-dihydro-1-oxo- (9CI) (CA INDEX NAME)




REFERENCE COUNT: 24 THERE ARE 24 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 53 OF 283 CAPLUS COPYRIGHT 2006 ACS ON STN
 ACCESSION NUMBER: 2003:991339 CAPLUS
 DOCUMENT NUMBER: 140:42204
 TITLE: Preparation of immunity-related protein kinase inhibitors
 INVENTOR(S): Muto, Susumu; Itai, Akiko
 PATENT ASSIGNER(S): Institute of Medicinal Molecular Design, Inc., Japan
 SOURCE: PCT Int. Appl., 401 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: Japanese
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
MO 2003103658	A1	20031218	MO 2003-JP7130	20030605
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MY, NZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CO, CI, CM, GA, GN, GO, GW, ML, MR, NE, NG, TD, TO				
CA 2487900	AA	20031218	CA 2003-2487900	20030605
AU 2003242131	A1	20031222	AU 2003-242131	20030605
EP 1510210	A1	20050302	EP 2003-730840	20030605
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
US 2006019958	A1	20060126	US 2005-515343	20050601
PRIORITY APPLN. INFO.:			JP 2002-164525	A 20020605
			MO 2003-JP7130	W 20030605

OTHER SOURCE(S): MARPAT 140:42204
 GI



EP 1555018 A1 20050720 EP 2003-730838 20030605
 R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK
 US 2006035944 A1 20060216 US 2005-516293 20050810
 PRIORITY APPLN. INFO.: JP 2002-169640 A 20020611
 MO 2003-JP7128 W 20030605
 OTHER SOURCE(S): MARPAT 140:42203
 GI



AB Disclosed are preventive and/or therapeutic drugs for (1) neurodegenerative diseases including Alzheimer's disease and (2) epilepsy, which contain as the active ingredient substances selected from the group consisting of comds. represented by the general formula (I), pharmaceutically acceptable salts thereof, and hydrates and solvates of both [wherein A is hydrogen or acetyl; E is 2,5- or 3,5-disubstituted Ph or an optionally substituted monocyclic or fused-polycyclic heteroaryl group (exclusive of (1) fused -polycyclic heteroaryl whose benzene ring is bonded directly to the -CONH- group, (2) unsubstituted thiazol-2-yl, and (3) unsubstituted benzothiazol-2-yl); and Z is arene which may have a substituent in addition to the groups represented by the general formula: -O-A (wherein A is as defined above) and -CONH-E (wherein E is as defined above) or heteroarene which may have a substituent in addition to the groups represented by the general formula: -O-A (wherein A is as defined above) and -CONH-E (wherein E is as defined above)]. These comds. I are effective for the prevention and/or treatment of Alzheimer's disease and (2) epilepsy based on the simultaneous inhibition of activated protein 1 (AP-1) and transcription factor NF-κB activation. The comds. I including N-phenylhydroxybenzamide (N-phenylisalicylamide), N-phenylhydroxynaphthalenecarboxamide, N-heterocyclylsalicylamide, N-phenylpyridinylcarboxamide, N-phenylhydroxythiophenecarboxamide, N-phenylquinolinylcarboxamide, and N-phenylindolylcarboxamide derivs. exhibited the inhibition of (1) TNF-α-stimulated activation of NF-κB in HepG2 cells, (2) TNF-α-stimulated activation of Hela cells, and (3) the activation of AP-1 in HepG2 cells transfected with MEK1-1 expression plasmid. In an Alzheimer's model animal assay, N-[3,5-bis(trifluoromethyl)phenyl]-5-chloro-2-hydroxybenzamide inhibited the memory formation failure in rats injected with human β-amyloid to the hippocampus.


IT 439144-03-3P
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of hydroxybenzamide, naphthalenecarboxamide, and hydroxyheterocyclohexanecarboxamide preventive and/or therapeutic drugs for Alzheimer's disease and epilepsy)
 RN 439144-03-3 CAPLUS
 CN 2-Quinoxalinecarboxamide, N-[3,5-bis(trifluoromethyl)phenyl]-3,4-dihydro-3-oxo- (9CI) (CA INDEX NAME)

AB The title comds. I [X is a connecting group whose main chain has 2 to 5 atoms and which may have a substituent; A is hydrogen or acetyl; E is optionally substituted aryl or optionally substituted heteroaryl; and Z is arene which may have a substituent in addition to the groups represented by the general formulae O-A (wherein A is as defined above) and X-E (wherein X and E are as defined above) or heteroarene which may have a substituent in addition to the groups represented by the general formulae O-A (wherein A is as defined above) and X-E (wherein X and E are as defined above)] are prepared. Comds. of this invention in vitro at 1 μg/mL gave 90% to 92.6% inhibition of NF-κB activation.

IT 439144-03-3P
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)


(preparation of immunity-related protein kinase inhibitors)
 RN 439144-03-3 CAPLUS
 CN 2-Quinoxalinecarboxamide, N-[3,5-bis(trifluoromethyl)phenyl]-3,4-dihydro-3-oxo- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 20 THERE ARE 20 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 54 OF 283 CAPLUS COPYRIGHT 2006 ACS ON STN
 ACCESSION NUMBER: 2003:991338 CAPLUS
 DOCUMENT NUMBER: 140:42203
 TITLE: Preparation of hydroxybenzamide, naphthalenecarboxamide, and hydroxyheterocyclohexanecarboxamide derivatives for preventive and/or therapeutic drugs for neurodegenerative diseases and epilepsy
 INVENTOR(S): Muto, Susumu; Itai, Akiko
 PATENT ASSIGNER(S): Institute of Medicinal Molecular Design, Inc., Japan
 SOURCE: PCT Int. Appl., 278 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: Japanese
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
MO 2003103657	A1	20031218	MO 2003-JP7128	20030605
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MY, NZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CO, CI, CM, GA, GN, GO, GW, ML, MR, NE, NG, TD, TO				
CA 2488974	AA	20031218	CA 2003-2488974	20030605
AU 2003242124	A1	20031222	AU 2003-242124	20030605



REFERENCE COUNT: 44 THERE ARE 44 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 55 OF 283 CAPLUS COPYRIGHT 2006 ACS ON STN
 ACCESSION NUMBER: 2003:991336 CAPLUS
 DOCUMENT NUMBER: 140:42202
 TITLE: Preparation of hydroxybenzamide, naphthalenecarboxamide, and hydroxyheterocyclohexanecarboxamide derivatives as anticancer agents
 INVENTOR(S): Muto, Susumu; Itai, Akiko
 PATENT ASSIGNER(S): Institute of Medicinal Molecular Design, Inc., Japan
 SOURCE: PCT Int. Appl., 265 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: Japanese
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
MO 2003103655	A1	20031218	MO 2003-JP7121	20030605
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MY, NZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CO, CI, CM, GA, GN, GO, GW, ML, MR, NE, NG, TD, TO				
CA 2488974	AA	20031218	CA 2003-2488974	20030605
AU 2003242108	A1	20031222	AU 2003-242108	20030605
EP 1535610	A1	20050601	EP 2003-730832	20030605
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
US 2006014811	A1	20060119	US 2005-516292	20050705
PRIORITY APPLN. INFO.:			JP 2002-168332	A 20020610
			MO 2003-JP7121	W 20030605

OTHER SOURCE(S): MARPAT 140:42202
 GI



AB Disclosed are drugs for the prevention and/or treatment of cancer, which contain as the active ingredient substances selected from the group consisting of compds. represented by the general formula (I), pharmacol. acceptable salts thereof, and hydrates and solvates of both (wherein A is hydrogen or acetyl; E is 2,5- or 3,5-disubstituted Ph or an optionally substituted monocyclic or fused-polycyclic heteroaryl group (exclusive of (1) fused-polycyclic heteroaryl whose benzene ring is bonded directly to the -CONH- group, (2) unsubstituted thiazol-2-yl, and (3) unsubstituted benzothiazol-2-yl); and Z is arene which may have a substituent in addition to the groups represented by the general formula: -O-A (wherein A is as defined above) and -CONH-E (wherein E is as defined above) or heteroarene which may have a substituent in addition to the groups represented by the general formula: -O-A (wherein A is as defined above) and -CONH-E (wherein E is as defined above). The compds. I including N-phenylhydroxybenzamide (N-phenylalicylamide), N-phenylhydroxynaphthalenecarboxamide, N-heterocyclylacylamide, N-phenylpyridinecarboxamide, N-phenylhydroxythiophenecarboxamide, N-phenylquinolinecarboxamide, and N-phenylindolecarboxamide derivs. in vitro inhibited the proliferation of Jurkat, MIA PACA-2, RD, HepG2, and A549 human cancer cells. N-[3,5-bis(trifluoromethyl)phenyl]-4-chloro-2-hydroxybenzamide in vitro inhibited the proliferation of B16 melanoma, HT-1080 fibrosarcoma, NB-1 neuroblastoma, and HMC-1-8 breast cancer cells and in vivo metastasis of B16 melanoma in mice.


IT 439144-03-3P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(Preparation of hydroxybenzamide, naphthalenecarboxamide, and hydroxyheterocyclohexanecarboxamide derivs. as anticancer agents)

RN 439144-03-3 CAPLUS

CN 2-Quinoxalinecarboxamide, N-[3,5-bis(trifluoromethyl)phenyl]-3,4-dihydro-3-oxo- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 11 THERE ARE 11 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 56 OF 283 CAPLUS COPYRIGHT 2006 ACS ON STN

ACCESSION NUMBER: 2003:991335 CAPLUS

DOCUMENT NUMBER: 140:42201

TITLE: Preparation of hydroxybenzamide, naphthalenecarboxamide, and hydroxyheterocyclohexanecarboxamide derivatives as transcription factor NF- κ B activation inhibitors

INVENTOR(S): Muto, Susumu; Itai, Akiko

PATENT ASSIGNEE(S): Institute of Medicinal Molecular Design, Inc., Japan

SOURCE: PCT Int. Appl., 286 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: Japanese

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
MO 2003103648	A1	20031218	MO 2003-JP7111	20030605

W: AS, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, GR, GU, HK, HU, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MY, NZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW

RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CO, CI, CM, GN, GW, GM, ML, MR, NE, SN, TD, TO

CA 2488342 AA 20031218 CA 2003-2488342 20030605

AU 2003242137 A1 20031222 AU 2003-242137 20030605

EP 1510207 A1 20050302 EP 2003-730841 20030605

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IS, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK

PRIORITY APPL. INFO.: JP 2002-164524 A 20020605

OTHER SOURCE(S): MARPAT 140:27850


IT 439144-03-3P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(Preparation of hydroxybenzamide, naphthalenecarboxamide, and hydroxyheterocyclohexanecarboxamide derivs. as transcription factor NF- κ B activation inhibitors)

RN 439144-03-3 CAPLUS

CN 2-Quinoxalinecarboxamide, N-[3,5-bis(trifluoromethyl)phenyl]-3,4-dihydro-3-oxo- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 23 THERE ARE 23 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 57 OF 283 CAPLUS COPYRIGHT 2006 ACS ON STN

ACCESSION NUMBER: 2003:991330 CAPLUS

DOCUMENT NUMBER: 140:27850

TITLE: Preparation of phenol or phenyl acetate derivatives as therapeutic drugs for prevention or treatment of diabetes and/or diabetes complications

INVENTOR(S): Muto, Susumu; Itai, Akiko

PATENT ASSIGNEE(S): Institute of Medicinal Molecular Design, Inc., Japan

SOURCE: PCT Int. Appl., 396 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: Japanese

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
MO 2003103648	A1	20031218	MO 2003-JP7111	20030605

W: AS, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, GR, GU, HK, HU, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MY, NZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW

RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CO, CI, CM, GN, GW, GM, ML, MR, NE, SN, TD, TO

CA 2488342 AA 20031218 CA 2003-2488342 20030605

AU 2003242137 A1 20031222 AU 2003-242137 20030605

EP 1510207 A1 20050302 EP 2003-730841 20030605


R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IS, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK

PRIORITY APPL. INFO.: JP 2002-164524 A 20020605


OTHER SOURCE(S): MARPAT 140:27850

OI

MO 2003103648	A1	20031218	MO 2003-JP7111	20030605
W: AS, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, GR, GU, HK, HU, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MY, NZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CO, CI, CM, GN, GW, GM, ML, MR, NE, SN, TD, TO				
CA 2488342	AA	20031218	CA 2003-2488342	20030605
AU 2003242137	A1	20031222	AU 2003-242137	20030605
EP 1510207	A1	20050302	EP 2003-730841	20030605
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IS, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
PRIORITY APPL. INFO.: JP 2002-164524 A 20020605				
OTHER SOURCE(S): MARPAT 140:42201				
OI				



AB Disclosed are drugs having an inhibitory activity against transcription factor NF- κ B activation, which contain as the active ingredient substances selected from the group consisting of compds. represented by the general formula (I), pharmacol. acceptable salts thereof, and hydrates and solvates of both (wherein A is hydrogen or acetyl; E is 2,5- or 3,5-disubstituted Ph or an optionally substituted monocyclic or fused-polycyclic heteroaryl group (exclusive of (1) fused-polycyclic heteroaryl whose benzene ring is bonded directly to the -CONH- group, (2) unsubstituted thiazol-2-yl, and (3) unsubstituted benzothiazol-2-yl); and Z is arene which may have a substituent in addition to the groups represented by the general formula: -O-A (wherein A is as defined above) and -CONH-E (wherein E is as defined above) or heteroarene which may have a substituent in addition to the groups represented by the general formula: -O-A (wherein A is as defined above) and -CONH-E (wherein E is as defined above). Also disclosed are (1) inhibitors against production and release of inflammatory mediators and immunosuppressants and (2) drugs for prevention and/or treatment of chronic articular rheumatism. The compds. I including N-phenylhydroxybenzamide (N-phenylalicylamide), N-phenylhydroxynaphthalenecarboxamide, N-heterocyclylacylamide, N-phenylpyridinecarboxamide, N-phenylhydroxythiophenecarboxamide, N-phenylquinolinecarboxamide, and N-phenylindolecarboxamide derivs. exhibited the inhibition of (1) TNF- α -stimulated activation of NF- κ B (2) TNF- α -stimulated production of IL-6, IL-8, and PGE2 in human synovial cells (RA-pos.) cells. (3) collagen-induced inflammation in mice, (4) myocardial ischemic reperfusion disorder in rats, and (5) proliferation of smooth muscle cells of normal coronary artery blood vessel. Some com. available compds. were selected as NF- κ B inhibitors (ligands) by virtual screening using a three-dimensional database automated retrieval software based on a protein structure of NF- κ B. The activity of the selected compds. were confirmed by reporter assay for inhibition of TNF- α -stimulated activation of



AB Disclosed are medicines for the prevention and/or treatment of diabetes and/or diabetes complications, containing as the active ingredient substances selected from the group consisting of compds. represented by the general formula (I) and pharmacol. acceptable salts thereof, and hydrates and solvates of both (wherein X is a connecting group whose main chain has 2 to 5 carbon atoms and which may have a substituent; A is hydrogen or acetyl; E is optionally substituted aryl or optionally substituted heteroaryl; and the ring Z is arene which may have a substituent in addition to the groups represented by the general formula: -O-A and -X-E, or heteroarene which may have a substituent in addition to the groups represented by the general formula: -O-A and -X-E). Also disclosed are medicines possessing insulin-resistance improving, hyperinsulinemia improving, and/or hyperglycemia improving activity. A total of approx. 500 I including N-phenylhydroxybenzamide (N-phenylalicylamide), N-heterocyclylhydroxybenzamide, N-phenylhydroxycarboxylic acid derivatives, N-phenylhydroxynaphthalenecarboxamide, N-phenylhydroxypyridinecarboxamide, N-phenylhydroxyquinolinecarboxamide, and N-phenylhydroxyindolecarboxamide were prepared. The compds. I improve insulin resistance by specifically inhibiting I κ B- β (I κ B kinase β).


IT 439144-03-3P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(Preparation of phenol or Ph acetate derivs. as therapeutic drugs for prevention or treatment of diabetes and/or diabetes complications)

RN 439144-03-3 CAPLUS

CN 2-Quinoxalinecarboxamide, N-[3,5-bis(trifluoromethyl)phenyl]-3,4-dihydro-3-oxo- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 8 THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 58 OF 283 CAPLUS COPYRIGHT 2006 ACS ON STN

ACCESSION NUMBER: 2003:991329 CAPLUS

DOCUMENT NUMBER: 140:27849


TITLE: Preparation of phenol or phenyl acetate derivatives as inhibitors against the activation of activator protein-1 (AP-1) and nuclear factor of activated T-cells (NFAT)

INVENTOR(S): Muto, Susumu; Itai, Akiko

PATENT ASSIGNEE(S): Institute of Medicinal Molecular Design, Inc., Japan


SOURCE: PCT Int. Appl., 401 pp.
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO. KIND DATE APPLICATION NO. DATE
WO 2003103647 A1 20031218 WO 2003-JP7129 20030605
N: AS, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, GR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MY, NZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, CA, GN, GQ, GW, ML, MR, NE, SN, TD, TO
CA 2487891 AA 20031218 CA 2003-2487891 20030605
AU 2003242127 A1 20031222 AU 2003-242127 20030605
EP 1512396 A1 20050109 EP 2001-730819 20030605
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK
PRIORITY APPLN. INFO.: JP 2002-164526 A 20020605
WO 2003-JP7129 W 20030605
OTHER SOURCE(S): MARPAT 140:27849
GI



AB Disclosed are medicines for inhibiting the activation of AP-1 or NFAT, containing as the active ingredient substances selected from the group consisting of compds. represented by the general formula (I) and pharmaceut. acceptable salts thereof, and hydrates and solvates of both (wherein X is a substituent group whose main chain has 2 to 5 carbon atoms and which may have a substituent; A is hydrogen or acetyl; E is optionally substituted aryl or optionally substituted heteroaryl; and the ring Z is arene which may have a substituent in addition to the groups represented by the general formulae: -O-A and -X-E, or heteroarene which may have a substituent in addition to the groups represented by the general formulae: -O-A and -X-E). A total of approx. 500 including N-phenylhydroxybenzamide (N-phenylisoleucylamide), N-heterocyclylhydroxybenzamide, N-phenylhydroxycarbazolecarboxamide, N-phenylhydroxynaphthalenebenzamide, N-phenylhydroxypyridinecarboxamide, N-phenylhydroxyquinolinecarboxamide, and N-phenylhydroxyindolecarboxamide were prepared. The compds. I can exhibit the inhibitory activity against releasing inflammatory cytokine, inflammatory activity, immunosuppressant activity, and antiallergic activity based on inhibiting the activation of AP-1 or NFAT.
IT 439144-03-3P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)


the prevention or treatment of eating disorders, weight gain, obesity, abnormalities in reproduction and sexual behavior, thyroid hormone secretion, diabetes and water/electrolyte homeostasis, sensory processing, memory, sleeping, arousal, anxiety, depression, seizures, neurodegeneration and psychiatric disorders. Approx. 450 synthetic examples of I are given.
For instance, reaction of N-(7-chloroquinolin-4-yl)cyclohexane-1,4-diamine (cis isomer) with 4-chloro-2,6-bis(trifluoromethyl)quinoline in N-methylpyrrolidinone the presence of Et3N at 150° gave title compound II. In a fluorescence assay for release of intracellular Ca²⁺ induced by activation of MCHR, a more preferred group of compds. I inhibited MCH-induced fluorescence in a range of 90-100% at 10 μM. A more preferred group of I also gave 90-100% inhibition of 125I-MCH binding to human MCHR1 at 2 μM (no addn. data).
IT 589493-04-9P, cis-N-[4-((7-chloroquinolin-4-yl)amino)cyclohexyl]quinoline-2-carboxamide
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(drug candidate; preparation of quinolinylcyclohexanediamine deriva. as MCH receptor antagonist)
RN 589493-04-9 CAPLUS
CN 2-Quinoxalinecarboxamide, N-[cis-4-((7-chloro-4-quinolinyl)amino)cyclohexyl]- (9CI) (CA INDEX NAME)
Relative stereochemistry.



REFERENCE COUNT: 14 THERE ARE 14 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT
LS ANSWER 60 OF 283 CAPLUS COPYRIGHT 2006 ACS ON STN
ACCESSION NUMBER: 2003:913160 CAPLUS
DOCUMENT NUMBER: 139:399863
TITLE: Process for the preparation of a hydrate of an anthranilic acid derivative
INVENTOR(S): Heyman, David Frank; Wright, Michael
PATENT ASSIGNER(S): Xenova Limited, UK
SOURCE: PCT Int. Appl., 37 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO. KIND DATE APPLICATION NO. DATE
WO 2003095447 A1 20031120 WO 2003-GB2060 20030513
N: AS, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, GR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,

(preparation of phenol or Ph acetate deriva. as inhibitors against activation of activator protein-1 (AP-1) and nuclear factor of activated T-cells (NFAT))
RN 439144-03-3 CAPLUS
CN 2-Quinoxalinecarboxamide, N-[3,5-bis(trifluoromethyl)phenyl]-3,4-dihydro-3-oxo- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 26 THERE ARE 26 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

LS ANSWER 59 OF 283 CAPLUS COPYRIGHT 2006 ACS ON STN
ACCESSION NUMBER: 2003:971716 CAPLUS
DOCUMENT NUMBER: 140:16656
TITLE: cis-N-(Quinolin-4-yl)cyclohexane-1,4-diamine derivatives as antagonists of melanin concentrating hormone (MCH) and their pharmaceutical compositions and therapeutic uses, e.g., for treatment of obesity
INVENTOR(S): Kym, Philip R.; Hartand, Kresna; Geo, Ju; Phelan, Kathleen M.; Akritopoulou-Zanze, Irini; Collins, Christine A.; Vasudevan, Anil; Verzel, Mary K.
PATENT ASSIGNER(S): Abbott Laboratories, USA
SOURCE: U.S. Pat. Appl. Publ., 89 pp.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO. KIND DATE APPLICATION NO. DATE
US 2003229119 A1 20031211 US 2003-372359 20030221
US 6818772 B2 20041116
PRIORITY APPLN. INFO.: US 2002-359081P P 20020222
OTHER SOURCE(S): MARPAT 140:16656
GI


* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB The invention is directed to the compds. of formula I, or therapeutically suitable salts, esters, prodrugs, or zwitterions thereof [R1, R2, R3 = H, alkyl, alkoxy, halo, haloalkyl, haloalkoxy, OH, NH2 and deriva.; R4 = H, alkyl; R5 = -(CH2)mAYB; m = 0-6; A = bond, alkoxyalkylene, alkylene, or hydroxyalkylene; B = H, alkyl, aryl, acryl, arylalkenyl, aralkenyl, aryloxyalkyl, biaryl, biarylalkyl, cycloalkyl, heterocyclyl, heterocyclylcarbonyl, heterocyclylalkenyl, haloalkyl, NH2 or deriva., carbamoyl or deriva., OH or deriva., SH or deriva.; Y = CO, S, SO, SO2, or bond; R6 = H, alkyl, arylcarboxyalkyl; R7, R8, R9, R10 = H, alkyl, alkoxy, halo, haloalkyl, haloalkoxy, OH; or R7R8 = exo; with 4 proviso(s)]. The invention further relates to the antagonism of the effects of melanin-concentrating hormone (MCH) through the MCH receptor, which is useful for

LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MY, NZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SO, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, CA, GN, GQ, GW, ML, MR, NE, SN, TD, TO
AU 2003233899 A1 20031111 AU 2003-233899 20030513
CA 2485430 AA 20031120 CA 2003-2485430 20030513
EP 1506188 A1 20050216 EP 2003-727661 20030513
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK
BR 2003009990 A 20050222 BR 2003-9990 20030513
CN 1665806 A 20050907 CN 2003-815929 20030513
JP 2005538051 T2 20051215 JP 2004-503463 20030513
US 2005222199 A1 20051006 US 2005-513986 20050408
PRIORITY APPLN. INFO.: US 2002-379759P P 20020514
WO 2003-GB2060 W 20030513
OTHER SOURCE(S): MARPAT 139:399863

AB A hydrate of an acid addition salt of an anthranilic acid derivative is produced by a process, which comprises: (a) combining, in any order, the anthranilic acid derivative, a pharmaceutically acceptable organic solvent, an excess of water and a pharmaceutically acceptable strong acid to form a mixture; (b) warming the mixture until a clear solution forms; (c) filtering the solution while it is warm, to yield a filtrate; and (d) recovering the hydrate as defined above from the filtrate. The hydrate has a defined number of moles of water of crystallization and possesses better storage stability and dissoln. characteristics than conventionally produced hydrates of such acid addition salts. Anthranilic acid deriva. and hydrates of their bis-salts are useful as inhibitors of P-glycoprotein for modulating P-glycoprotein mediated multidrug resistance in tumor treatment. For example, bis-mesylate hexahydrate of quinoline-3-carboxylic acid [2-{4-[2-(6,7-dimethoxy-3,4-dihydro-1H-isoquinolin-2-yl)-ethyl]-phenyl}carbamoyl]-4,5-dimethoxy-phenyl)-amide was prepared, using acetone as antisolvent for recovery of hydrate from the filtrate.
IT 206872-43-7
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(anthranilic acid deriva. and their salt hydrates as modulators of multidrug resistance in tumor treatment)

REFERENCE COUNT: 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT
LS ANSWER 61 OF 283 CAPLUS COPYRIGHT 2006 ACS ON STN
ACCESSION NUMBER: 2003:913154 CAPLUS
DOCUMENT NUMBER: 139:381369



TITLE: Process for preparation of 5-(1-amino-2-arylethyl)-3-(3-hydroxy-3-methylbutyl)dihydrofuran-2-ones via treatment of 5-(1-protected-amino-2-arylethyl)-3-(3-methyl-2-butenyl)dihydrofuran-2-ones with phosphoric acid

INVENTOR(S): Urban, Frank John; Jaeye, Vytautas John; Li, Zhongong

PATENT ASSIGNEE(S): Bryan, Kath, John Charles

SOURCE: Pfizer Products Inc., USA

DOCUMENT TYPE: PCT Int. Appl., 62 pp.

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION: Patent

PATENT NO. KIND DATE APPLICATION NO. DATE

WO 2003095440 A1 20031120 WO 2003-181840 20030505

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MY, NZ, OM, PH, PL, PT, RU, SD, SE, SG, SI, SK, SL, SM, ST, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW

RM: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GN, GW, GM, ML, MR, NE, SN, TD, TO

AU 2003223052 A1 20031111 AU 2003-223052 20030505

CA 2484860 A 20031120 CA 2003-2484860 20030505

BR 200309930 A 20050209 BR 2003-9930 20030505

EP 1503999 A1 20050209 EP 2003-719022 20030505

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK

JP 2005530775 T2 20051013 JP 2004-503456 20030505

US 2004019217 A1 20040129 US 2003-431276 20030507

US 6858744 B2 20050222


PRIORITY APPLN. INFO.: US 2002-380694P P 20020514

US 2002-397138P P 20020718

WO 2003-181840 W 20030505


OTHER SOURCE(S): MARPAT 139:381369

GI



AB Title compds. [I; R2 = (substituted) Ph(CH2)m, naphthyl(CH2)m, cycloalkyl(CH2)m, alkyl(CH2)m, heteroaryl(CH2)m; m = 0-4] were prepared by treatment of alkenes (II; P = protecting group; R2 as above) with H3PO4. Thus, [2-(3-fluorophenyl)-1-[4-(3-methylbut-2-enyl)-5-oxotetrahydrofuran-2-yl]ethyl]carbamate tert-Bu ester (preparation given) was stirred with CHCl2 and 85% H3PO4 for 7h followed by cooling to 0°, dilution with water, and addition of 20% NaOH to pH 7-8.5 to give 5-[1-amino-2-(3-fluorophenyl)ethyl]-3-(3-hydroxy-3-methylbutyl)dihydrofuran-2-one. The latter was used to prepare quinoxaline-2-carboxylic acid [2-(3-fluorophenyl)-1-[4-(3-hydroxy-3-methylbutyl)-5-oxotetrahydrofuran-2-yl]ethyl]amide.

IT 624736-63-6



RM: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GN, GW, GM, ML, MR, NE, SN, TD, TO

CA 2481369 AA 20031023 CA 2003-2481369 20030411

AU 2003223602 A1 20031027 AU 2003-223602 20030411

EP 1497282 A2 20050119 EP 2003-719741 20030411

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK

JP 2005535574 T2 20051124 JP 2003-584048 20030411


NO 2004004889 A 20050110 NO 2004-4889 20041110

PRIORITY APPLN. INFO.: NO 2003-371846P P 20030411

WO 2003-US11459 W 20030411

OTHER SOURCE(S): MARPAT 139:338195

GI



REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

LS ANSWER 62 OF 283 CAPLUS COPYRIGHT 2006 ACS ON STN

ACCESSION NUMBER: 2003:837079 CAPLUS

DOCUMENT NUMBER: 139:338195

TITLE: Preparation of peptides as inhibitors of serine proteases, particularly HCV NS3-NS4A protease

INVENTOR(S): Pitlik, Janos; Cottrell, Kevin M.; Farmer, Luc J.; Berni, Robert B.; Courtney, Lawrence F.; Van Drie, John H.; Murecho, Mark A.

PATENT ASSIGNEE(S): Vertex Pharmaceuticals, Inc., USA

SOURCE: PCT Int. Appl., 210 pp.

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 3

PATENT INFORMATION: Patent

PATENT NO. KIND DATE APPLICATION NO. DATE

WO 2003087093 A3 20031023 WO 2003-US11459 20030411

WO 2003087093 A3 20040910

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MY, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW


RL: RCT (Reactant); RACT (Reactant or reagent)

(preparation of aminoarylethylhydroxymethylbutyldihydrofuranones via treatment of protected aminoarylethylmethylbutenyldihydrofuranones with phosphoric acid)

RM 624736-63-6 CAPLUS

CN 2-Quinoxalinecarboxamide, N-[(1S)-2-(3-fluorophenyl)-1-[(2S,4R)-tetrahydro-4-(3-methyl-2-butenyl)-5-oxo-2-furanyl]ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 624736-64-7P


RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation of aminoarylethylhydroxymethylbutyldihydrofuranones via treatment of protected aminoarylethylmethylbutenyldihydrofuranones with phosphoric acid)

RM 624736-64-7 CAPLUS

CN Acetic acid, trifluoro-, 3-[(3R,5S)-5-[(1S)-2-(3-fluorophenyl)-1-[(2-quinoxalinyloxy)amino]ethyl]tetrahydro-2-oxo-3-furanyl]-1,1-dimethylpropyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 212790-31-3P 624736-60-3P

RL: SPN (Synthetic preparation); PREP (Preparation)

(preparation of aminoarylethylhydroxymethylbutyldihydrofuranones via treatment of protected aminoarylethylmethylbutenyldihydrofuranones with phosphoric acid)

RM 212790-31-3 CAPLUS

CN 2-Quinoxalinecarboxamide, N-[(1S,2S,4R)-4-(aminocarbonyl)-1-[(3-fluorophenyl)methyl]-2,7-dihydroxy-7-methyloctyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

RM: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GN, GW, GM, ML, MR, NE, SN, TD, TO

CA 2481369 AA 20031023 CA 2003-2481369 20030411

AU 2003223602 A1 20031027 AU 2003-223602 20030411

EP 1497282 A2 20050119 EP 2003-719741 20030411


R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK

JP 2005535574 T2 20051124 JP 2003-584048 20030411

NO 2004004889 A 20050110 NO 2004-4889 20041110

PRIORITY APPLN. INFO.: NO 2003-371846P P 20030411

WO 2003-US11459 W 20030411



AB The invention relates to compds. I [A together with X and Y is a 3- to 6-membered aromatic or non-aromatic ring having up to 3 heteroatoms; R1, R3 are aliphatic, (un)substituted (cyclo)alk(en)yl, (hetero)aryl, etc.; R2, R4 are H, (un)substituted aliphatic, cycloalkyl or aryl aliphatic; R5 is (un)substituted aliphatic; W is COOR6, COOR6, or COCONR6, where R6 is H, aliphatic, (hetero)aryl, etc.; V is CONR8, SONR8, SO2NR8, where R8 is H or aliphatic; T is (hetero)aryl, aliphatic, sulfonylaminoalkyl, etc.] that inhibit serine protease activity, particularly the activity of hepatitis C virus NS3-NS4A protease. Thus, peptide II was prepared via coupling reactions in solution and showed Ki and IC50 values < 0.5 μM.

IT 615583-77-3P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of peptides as inhibitors of serine proteases, particularly HCV NS3-NS4A protease)

RM 615583-77-2 CAPLUS

CN 1H-Indole-2-carboxamide, (2S)-2-cyclohexyl-N-(2-quinoxalinyloxy)glycyl-3-methyl-L-valyl-N-[(1S)-1-[(cyclopropylamino)oxoacetyl]butyl]octahydro-, (2S,3S,7S) - (9CI) (CA INDEX NAME)

AB The invention relates to compds. I [A together with X and Y is a 3- to 6-membered aromatic or non-aromatic ring having up to 3 heteroatoms; R1, R3 are aliphatic, (un)substituted (cyclo)alk(en)yl, (hetero)aryl, etc.; R2, R4 are H, (un)substituted aliphatic, cycloalkyl or aryl aliphatic; R5 is (un)substituted aliphatic; W is COOR6, COOR6, or COCONR6, where R6 is H, aliphatic, (hetero)aryl, etc.; V is CONR8, SONR8, SO2NR8, where R8 is H or aliphatic; T is (hetero)aryl, aliphatic, sulfonylaminoalkyl, etc.] that inhibit serine protease activity, particularly the activity of hepatitis C virus NS3-NS4A protease. Thus, peptide II was prepared via coupling reactions in solution and showed Ki and IC50 values < 0.5 μM.

IT 615583-77-3P


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of peptides as inhibitors of serine proteases, particularly HCV NS3-NS4A protease)

RM 615583-77-2 CAPLUS

CN 1H-Indole-2-carboxamide, (2S)-2-cyclohexyl-N-(2-quinoxalinyloxy)glycyl-3-methyl-L-valyl-N-[(1S)-1-[(cyclopropylamino)oxoacetyl]butyl]octahydro-, (2S,3S,7S) - (9CI) (CA INDEX NAME)



Absolute stereochemistry.



LS ANSWER 63 OF 283 CAPLUS COPYRIGHT 2006 ACS ON STN
 ACCESSION NUMBER: 2003:83605 CAPLUS
 DOCUMENT NUMBER: 139:323346
 TITLE: Preparation of naphthalene amides as potassium channel openers
 INVENTOR(S): Turner, Sean C.; Castle, Neil A.; Carroll, William A.; White, Tammie K.
 PATENT ASSIGNER(S): USA
 SOURCE: U.S. Pat. Appl. Publ., 32 pp.
 CODEN: USKXCO
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2003195578	A1	20031023	US 2002-125899	20020419
WO 2003089404	A1	20031030	WO 2003-US12023	20030417

W: CA, JP, MX
 RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR
 PRIORITY APPL. INFO.: MARPAT 139:323346
 OTHER SOURCE(S):
 OT




AB The title compds. [I; X = (un)substituted OH, SH, NH2; R1, R2 = H, alkyl, alkylcarbonyl, etc.; R3, R4 = H, alkyl, aryl, etc.; R5 = H, alkenyl, alkoxyalkyl, etc.; n = 0-6] that have ability to act as potassium channel openers, were prepared. Thus, reacting 1-aminonaphthalene with hexafluoroacetone.3H2O in the presence of p-TsOH followed by treating the

resulting 2-(1-aminonaphthalen-2-yl)-1,1,1,3,3,3-hexafluoropropan-2-ol with Ac2O afforded II. The compds. I exhibited a 50% maximum response of membrane hyperpolarization in Guinea pig bladder cells at doses > 1000 nM. Pharmacological composition comprising the compound I is claimed.

IT 571166-29-5
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

RN {preparation of naphthalene amides as potassium channel openers}

CN 2-Quinoxalinecarboxamide, N-[2-[2,2,2-trifluoro-1-hydroxy-1-(trifluoromethyl)ethyl]-1-naphthalenyl]- (9CI) (CA INDEX NAME)



LS ANSWER 64 OF 283 CAPLUS COPYRIGHT 2006 ACS ON STN
 ACCESSION NUMBER: 2003:81288 CAPLUS
 DOCUMENT NUMBER: 140:35552

TITLE: CP-481,715, A Potent and Selective CCR1 Antagonist with Potential Therapeutic Implications for Inflammatory Diseases
 AUTHOR(S): Gladue, Ronald P.; Tylaska, Laurie A.; Brissette, William H.; Lira, Paul D.; Kath, John C.; Rose, Christopher S.; Brown, Matthew P.; Paradis, Timothy J.; Conklyn, Maryrose J.; Osborne, Kevin T.; McGlynn, Molly A.; Lillie, Brett M.; DiRico, Amy P.; Mairs, Erin N.; McElroy, Eric B.; Martin, William H.; Stock, Ingrid A.; Shepard, Richard M.; Showell, Henry J.; Noote, Kuldewp

CORPORATE SOURCE: Pfizer Global Research and Development, Groton, CT, 06340, USA

SOURCE: Journal of Biological Chemistry (2003), 278(42), 40473-40480

CODEN: JBCHA3; ISSN: 0021-9258

PUBLISHER: American Society for Biochemistry and Molecular Biology

DOCUMENT TYPE: Journal

LANGUAGE: English

AB The chemokines CCL3 and CCL5, as well as their shared receptor CCR1, are believed to play a role in the pathogenesis of several inflammatory diseases including rheumatoid arthritis, multiple sclerosis, and transplant rejection. In this study we describe the pharmacol. properties of a novel small mol. weight CCR1 antagonist, CP-481,715 (quinoxaline-2-carboxylic acid 4(R)-carbamoyl-1(S)-(3-fluorobenzyl)-2(S)-7-dihydroxy-7-methyloctylamide). Radiolabeled binding studies indicate that CP-481,715 binds to human CCR1 with a Kd of 9.3 nM and displaces 125I-labeled CCL3 from CCR1-transfected cells with an IC50 of 74 nM. CP-481,715 lacks intrinsic agonist activity but fully blocks the ability of CCL3 and CCL5 to stimulate receptor signaling (guanosine 5'-O-(thiotriphosphate) incorporation; IC50 = 210 nM), calcium mobilization (IC50 = 71 nM), monocyte chemotaxis (IC50 = 55 nM), and matrix metalloproteinase 9 release (IC50 = 54 nM). CP-481,715 retains activity in human whole blood, inhibiting CCL3-induced CD11b up-regulation and actin polymerization (IC50 =

165

and 57 nM, resp.) on monocytes. Furthermore, it behaves as a competitive and reversible antagonist. CP-481,715 is >100-fold selective for CCR1 as compared with a panel of G-protein-coupled receptors including related chemokine receptors. Evidence for its potential use in human disease is suggested by its ability to inhibit 90% of the monocyte chemotactic activity present in 11/15 rheumatoid arthritis synovial fluid samples. These data illustrate that CP-481,715 is a potent and selective antagonist for CCR1 with therapeutic potential for rheumatoid arthritis and other inflammatory diseases.


IT 212790-31-3, CP 481715
 RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

RN (CP-481715 a potent and selective CCR1 antagonist with potential therapeutic implications for inflammatory diseases)

CN 212790-31-3 CAPLUS

2-Quinoxalinecarboxamide, N-[(1S,2S,4R)-4-(aminocarbonyl)-1-[(3-fluorophenyl)methyl]-2,7-dihydroxy-7-methyloctyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 41 THERE ARE 41 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

LS ANSWER 65 OF 283 CAPLUS COPYRIGHT 2006 ACS ON STN
 ACCESSION NUMBER: 2003:678662 CAPLUS
 DOCUMENT NUMBER: 139:214342

TITLE: cis-N-(Quinololin-4-yl)cyclohexane-1,4-diamine derivatives as antagonists of melanin concentrating hormone (MCH) and their pharmaceutical compositions and therapeutic uses, e.g., for treatment of obesity
 INVENTOR(S): Kym, Philip R.; Hertandi, Kresna; Geo, Ju; Phelan, Kathleen M.; Akritopoulou-Zanze, Irini; Collins, Christine A.; Vasudevan, Anil; Venzal, Mary K.

PATENT ASSIGNER(S): Abbott Laboratories, USA

SOURCE: PCT Int. Appl., 207 pp.

CODEN: PIXND2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003070244	A1	20030828	WO 2003-US5510	20030221

W: CA, JP, MX
 RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR

PRIORITY APPL. INFO.: MARPAT 139:214342 US 2002-81675 A 20020222

OTHER SOURCE(S):

OT

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB The invention is directed to the compds. of formula I, or therapeutically suitable salts, esters, prodrugs, or zwitterions thereof [R1, R2, R3 = H, alkyl, alkoxy, halo, haloalkyl, haloalkoxy, OH, NH2 and derivs.; R4 = H, alkyl; R5 = -(CH2)mYAB; m = 0-6; A = bond, alkoxyalkylene, alkylene, or hydroxyalkylene; B = H, alkyl, aryl, eroyl, arylsulfonyl, aralkenyl, arylalkoxy, biaryl, biarylalkyl, cycloalkyl, heterocyclyl, heterocyclylcarbonyl, heterocyclylsulfonyl, haloalkyl, NH2 or derivs., carbamoyl or derivs., OH or derivs., SH or derivs.; Y = CO, S, SO, SO2, or bond; R6 = H, alkyl, arylcarboxyalkyl; R7, R8, R9, R10 = H, alkyl, alkoxy, halo, haloalkyl, haloalkoxy, OH; or R7R8 = oxo; with 4 proviso(s). The invention further relates to the antagonism of the effects of melanin-concentrating hormone (MCH) through the MCH receptor, which is useful

for

the prevention or treatment of eating disorders, weight gain, obesity, abnormalities in reproduction and sexual behavior, thyroid hormone secretion, diuresis and water/electrolyte homeostasis, sensory processing, memory, sleeping, arousal, anxiety, depression, seizures, neurodegeneration and psychiatric disorders. Approx. 450 synthetic examples of I are given. For instance, reaction of N-(7-chloroquinolin-4-yl)cyclohexane-1,4-diamine (cis isomer) with 4-chloro-2,8-bis(trifluoromethyl)quinoline in N-methylpyrrolidinone the presence of Et3N at 150° gave title compound II. In a fluorescence assay for release of intracellular Ca++ induced by activation of MCHR, a more preferred group of compds. I inhibited MCH-induced fluorescence in a range of 90-100% at 10 μM. A more preferred group of I also gave 90-100% inhibition of 125I-MCH binding to human MCHR1 at 2 μM (no addnl. data).

IT 589493-04-9P, cis-N-4-[(7-Chloroquinolin-4-yl)amino]cyclohexylquinoxaline-2-carboxamide


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(drug candidate; preparation of quinolinylcyclohexanediimine derivs. as MCH receptor antagonists)

RN 589493-04-9 CAPLUS

CN 2-Quinoxalinecarboxamide, N-[cis-4-[(7-chloro-4-quinolinyl)amino]cyclohexyl]- (9CI) (CA INDEX NAME)

Relative stereochemistry.



REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

LS ANSWER 66 OF 283 CAPLUS COPYRIGHT 2006 ACS ON STN

ACCESSION NUMBER: 2003:633358 CAPLUS
DOCUMENT NUMBER: 139:179892
TITLE: Preparation of N-biphenylmethyl cycloalkanecarboxamides as bradykinin B1 antagonists or inverse agonists useful in the treatment of pain and inflammation
INVENTOR(S): Wood, Michael R.; Anthony, Neville J.; Bock, Mark G.; Feng, Dong-mei; Kuduk, Scott D.; Su, Dai-shi; Mai, Jenny Miu-chun
PATENT ASSIGNEE(S): Merck & Co., Inc., USA
SOURCE: PCT Int. Appl., 72 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003065789	A2	20030814	WO 2003-US5782	20030204
WO 2003065789	A3	20040311		

W: AB, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MY, NZ, OM, PH, PL, PT, RD, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW


RM: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR, BF, BJ, CP, CG, CI, CM, GA, GN, GW, GM, ML, MR, NE, SN, TD, TG

CA 2473778 AA 20030814 CA 2003-2473778 20030204
EP 1476419 A2 20041117 EP 2003-713689 20030204
EP 1476419 B1 20060201

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK

US 2005085667 A1 20050421 US 2003-503502 20030204
JP 2005516979 T2 20050609 JP 2003-565227 20030204
US 2002-355062P P 20020208
US 2002-410775P P 20020912
WO 2003-US5782 W 20030204


PRIORITY APPLN. INFO.:
OTHER SOURCE(S): MARPAT 139:179892
GI



AB Title compds. [I; R1, R2 = H, alkyl; R4, R41 = H, halo, (substituted)

alkyl; R5 = alkynyl, (substituted) alkyl, cycloalkyl, alkenyl, aryl(alkyl), heterocyclyl(alkyl), etc.; R6 = halo, cyano, NO2, cycloalkyl, (substituted) alkyl, alkenyl, amino, acylamino, heterocyclyl, etc.; R61, R62 = H, R6; R7, R71 = H, halo, cyano, NO2, OR, CO2R, alkyl, haloalkyl, etc.; with proviso), were prepared for treatment of pain and inflammation (no data). Thus, a mixture of THF, H2O, K2CO3, Me 2-iodobenzoate, 4-cyanophenylboronic acid, and bis(tri-o-tolylphosphine)palladium(II) chloride was refluxed 3.5 h, cooled to ambient temperature, and stirred overnight to give Me 4'-cyano-1,1'-biphenyl-2-carboxylate. The latter in 2 M NH3 in MeOH with a 50% aqueous slurry of Raney Ni was stirred under H2 for 9 h to give a residue which was dissolved in Et2O/EtOAc prior to introduction of HCl to give Me 4'-(aminomethyl)-1,1'-biphenyl-2-carboxylate hydrochloride. To the free base of the above in THF was added 1-((tert-butoxycarbonyl)amino)cyclopropanecarboxylic acid, Et3N, HOBT, H2O, and EDCI and the mixture was stirred overnight to provide Me 4'-[[[1-((tert-butoxycarbonyl)amino)cyclopropyl]carbonyl]amino]methyl]-1,1'-biphenyl-2-carboxylate. The latter was treated with HCl in CH2Cl2/MeOH to give the deprotected amine which was treated with HOBT, H2O, 3,3,3-trifluoropropionic acid, Et3N, and EDCI in DMF to give 78% Me 4'-[[[1-((3,3,3-trifluoropropionyl)amino)cyclopropyl]carbonyl]amino]methyl]-1,1'-biphenyl-2-carboxylate.

IT 578766-97-99
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(Preparation of N-biphenylmethyl cycloalkanecarboxamides as bradykinin B1 antagonists or inverse agonists useful in the treatment of pain and inflammation)
RN 578766-97-9 CAPLUS
CN [1,1'-Biphenyl]-2-carboxylic acid, 4'-[[[1-((2-quinoxalinyloxy)amino)cyclopropyl]carbonyl]amino]methyl]-, methyl ester (9CI) (CA INDEX NAME)



LS ANSWER 67 OF 283 CAPLUS COPYRIGHT 2006 ACS ON STN
ACCESSION NUMBER: 2003:491039 CAPLUS
DOCUMENT NUMBER: 139:69255
TITLE: Preparation of hydroxyphenyl-pyrazoles as kinase inhibitors and pharmaceutical compositions comprising them for treating cancer and other disorders
INVENTOR(S): Casasucelli, Francesco; D'Alessio, Roberto; Felder, Eduard; Vulpatti, Anna
PATENT ASSIGNEE(S): Pharmacia Italia SPA, Italy
SOURCE: PCT Int. Appl., 291 pp.

DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003051358	A1	20030626	WO 2002-EP14087	20021211

W: AB, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MY, NZ, OM, PH, PL, PT, RD, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW


RM: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR, BF, BJ, CP, CG, CI, CM, GA, GN, GW, GM, ML, MR, NE, SN, TD, TG

US 2004010027 A1 20040115 US 2001-15630 20011211
CA 2470616 AA 20030626 CA 2002-2470616 20021211
AU 2002358676 A1 20030630 AU 2002-358676 20021211
EP 1458379 A1 20040922 EP 2002-792973 20021211

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK

BR 2002015063 A 20041019 BR 2002-15063 20021211
JP 2005515209 T2 20050526 JP 2003-552291 20021211
US 2001-15630 A 20011211
WO 2002-EP14087 W 20021211

PRIORITY APPLN. INFO.:
OTHER SOURCE(S): MARPAT 139:69255
GI




AB The present invention provides a method for treating diseases caused by and/or associated with an altered protein kinase activity which comprises administering to a mammal in need thereof an effective amount of 3-(o-hydroxyphenyl)pyrazoles (shown as I; variables defined below; e.g. 3-(o-hydroxyphenyl)-3-[2-hydroxy-4-(4-methoxybenzoylamino)phenyl]pyrazole-1-carboxylic acid butylamide). The invention also provides some new compounds, a library comprising at least two of them, a process for their preparation and the pharmaceutical compns. containing them, which are useful in the treatment of diseases caused by and/or associated with an altered protein kinase activity such as cancer, cell proliferative disorders, viral infections, autoimmune diseases and neurodegenerative disorders. Pharmacol. test methods are described but no results are reported. For I: R1 to R4 = H, halogen, hydroxy, nitro or NR8R9 (R8 and R9 = H or (un)substituted C1-C6 alkyl, aryl, C3-C7 cycloalkyl and (un)saturated heterocyclyl), or COR10, CONHR10 or SO2R10 (R10 is H atom or (un)substituted C1-C6 alkyl, aryl, C3-C7 cycloalkyl, (un)saturated C3-C7 cycloalkyl or (un)saturated heterocyclyl), or an (un)substituted straight or branched C1-C6 alkyl, aryl, C1-C6 alkyl, (un)saturated C3-C7 cycloalkyl

or cycloalkoxy, (un)saturated heterocyclyl, C1-C6 alkoxy, aryloxy, aryl C1-C6 alkoxy, R5 and R6 = H or (un)substituted C1-C6 alkyl, aryl, aryl C1-C6 alkyl, C3-C7 cycloalkyl and (un)saturated heterocyclyl; R7 is a substituent attached at one of the two N atoms of the pyrazole ring and is CONHR10, CSNHR10, SO2R10, COR10 or COOR10. The example preparation of 5-cyclopropyl-3-[2-hydroxy-4-(4-methoxybenzoylamino)phenyl]pyrazole-1-carboxylic acid butylamide is provided starting from 4-amino-2-hydroxyacetophenone and involving attachment to a polystyrene derivative, amidation using p-anisoyl chloride, coupling with Et cyclopropanecarboxylate, cyclocondensation with hydrazine, addition reaction with BUNCO and removal of the polymer using 50% CF3CO2H in CH2Cl2. Characterization data are provided for approx. 30 examples of I and approx. 2700 examples of I are tabulated without data.


IT 550325-85-4P 550325-86-5P 550325-87-6P
550325-88-7P 550325-89-8P 550325-90-1P
550325-91-2P 550325-92-3P 550325-93-4P
550325-94-5P 550325-95-6P 550325-96-7P
550325-97-8P 550325-98-9P 550325-99-0P
550326-00-6P 550326-01-7P 550326-02-8P
550326-03-9P 550326-04-0P 550326-05-1P
550326-06-2P 550326-07-3P 550326-08-4P
550326-09-5P 550326-10-6P 550326-11-7P
550326-12-8P 550326-13-9P 550326-14-2P
550326-15-3P 550326-16-4P 550326-17-5P
550326-18-6P 550326-19-7P 550326-20-8P
550326-21-1P 550326-22-2P 550326-23-3P
550326-24-4P 550326-25-5P 550326-26-6P
550326-27-7P 550326-28-8P 550326-29-9P
550326-30-2P 550326-31-3P 550326-33-5P
550326-35-7P 550326-37-9P 550326-39-1P
550340-02-8P 550340-03-9P 550340-04-0P
550340-05-1P 550340-06-2P 550340-07-3P
550340-08-4P 550340-09-5P 550340-10-6P
550340-11-7P 550340-12-8P 550340-13-9P
550340-14-2P 550340-15-3P 550340-16-4P
550340-17-5P 550340-18-6P 550340-19-7P
550340-20-8P 550340-21-1P 550340-22-2P
550340-23-3P 550340-24-4P 550340-25-5P
550340-26-6P 550340-27-7P 550340-28-8P
550340-29-9P 550340-30-2P 550340-31-3P
550340-32-4P 550340-33-5P 550340-34-6P
550340-35-7P 550340-36-8P 550340-37-9P
550340-38-0P 550340-39-1P 550340-40-4P
550340-41-5P 550340-42-6P 550340-43-7P
550340-44-8P 550340-45-9P 550340-46-0P
550340-47-1P 550340-48-2P 550340-49-3P
550340-50-6P 550340-51-7P 550340-52-8P

RL: CPN (Combinatorial preparation); PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); CNBI (Combinatorial study); PREP (Preparation); USES (Uses)
(drug candidate; preparation of hydroxyphenyl-pyrazoles as kinase inhibitors and pharmaceutical compns. comprising them for treating cancer and other disorders)


RN 550325-85-4 CAPLUS
CN 2-Quinoxalinecarboxamide, N-[4-[5-cyclopropyl-1-[[[1-methyl(ethyl)amino]carbonyl]-1H-pyrazol-3-yl]-3-hydroxyphenyl]- (9CI) (CA INDEX NAME)




RN 550325-86-5 CAPLUS
CN 2-Quinoxalinecarboxamide, N-[4-[5-cyclopropyl-1-[(ethylamino)carbonyl]-1H-pyrazol-3-yl]-3-hydroxyphenyl]- (9CI) (CA INDEX NAME)




RN 550325-87-6 CAPLUS
CN 2-Quinoxalinecarboxamide, N-[4-[5-cyclopropyl-1-[(2-propenylamino)carbonyl]-1H-pyrazol-3-yl]-3-hydroxyphenyl]- (9CI) (CA INDEX NAME)




RN 550325-88-7 CAPLUS
CN 2-Quinoxalinecarboxamide, N-[4-[5-cyclopropyl-1-[(propylamino)carbonyl]-1H-pyrazol-3-yl]-3-hydroxyphenyl]- (9CI) (CA INDEX NAME)




RN 550325-89-8 CAPLUS
CN 2-Quinoxalinecarboxamide, N-[4-[5-cyclopropyl-1-[(phenylmethylamino)carbonyl]-1H-pyrazol-3-yl]-3-hydroxyphenyl]- (9CI) (CA INDEX NAME)




RN 550325-90-1 CAPLUS
CN 2-Quinoxalinecarboxamide, N-[4-[5-cyclopropyl-1-[(2-phenylethylamino)carbonyl]-1H-pyrazol-3-yl]-3-hydroxyphenyl]- (9CI) (CA INDEX NAME)



RN 550325-91-2 CAPLUS
CN 2-Quinoxalinecarboxamide, N-[4-[5-cyclopropyl-1-[(2-methylphenylmethylamino)carbonyl]-1H-pyrazol-3-yl]-3-hydroxyphenyl]- (9CI) (CA INDEX NAME)




RN 550325-92-3 CAPLUS
CN 2-Quinoxalinecarboxamide, N-[4-[5-cyclopropyl-1-[(3-methylphenylmethylamino)carbonyl]-1H-pyrazol-3-yl]-3-hydroxyphenyl]- (9CI) (CA INDEX NAME)




RN 550325-93-4 CAPLUS


CN 2-Quinoxalinecarboxamide, N-[4-[5-cyclopropyl-1-[(4-methylphenylmethylamino)carbonyl]-1H-pyrazol-3-yl]-3-hydroxyphenyl]- (9CI) (CA INDEX NAME)




RN 550325-94-5 CAPLUS
CN 2-Quinoxalinecarboxamide, N-[4-[1-[(2-chlorophenyl)methylamino]carbonyl]-5-cyclopropyl-1H-pyrazol-3-yl]-3-hydroxyphenyl]- (9CI) (CA INDEX NAME)




RN 550325-95-6 CAPLUS
CN 2-Quinoxalinecarboxamide, N-[4-[5-cyclopropyl-1-[(4-fluorophenyl)methylamino]carbonyl]-1H-pyrazol-3-yl]-3-hydroxyphenyl]- (9CI) (CA INDEX NAME)




RN 550325-96-7 CAPLUS
CN 2-Quinoxalinecarboxamide, N-[4-[5-cyclopropyl-1-[(3,4-dichlorophenyl)methylamino]carbonyl]-1H-pyrazol-3-yl]-3-hydroxyphenyl]- (9CI) (CA INDEX NAME)




RN 550325-97-8 CAPLUS
CN 2-Quinoxalinecarboxamide, N-[4-[5-cyclopropyl-1-[(4-methoxyphenyl)methylamino]carbonyl]-1H-pyrazol-3-yl]-3-hydroxyphenyl]- (9CI) (CA INDEX NAME)




RN 550325-98-9 CAPLUS
CN 2-Quinoxalinecarboxamide, N-[4-[5-cyclopropyl-1-[(1-methylpropylamino)carbonyl]-1H-pyrazol-3-yl]-3-hydroxyphenyl]- (9CI) (CA INDEX NAME)




RN 550325-99-0 CAPLUS
CN 2-Quinoxalinecarboxamide, N-[4-[5-cyclopropyl-1-[(2-fluorophenyl)methylamino]carbonyl]-1H-pyrazol-3-yl]-3-hydroxyphenyl]- (9CI) (CA INDEX NAME)




RN 550326-00-6 CAPLUS
CN 2-Quinoxalinecarboxamide, N-[4-[5-cyclopropyl-1-[(3-fluorophenyl)methylamino]carbonyl]-1H-pyrazol-3-yl]-3-hydroxyphenyl]- (9CI) (CA INDEX NAME)




RN 550326-01-7 CAPLUS
CN 2-Quinoxalinecarboxamide, N-[4-{5-cyclopropyl-1-[(cyclopropylamino)carbonyl]-1H-pyrazol-3-yl]-3-hydroxyphenyl]- (9CI) (CA INDEX NAME)




RN 550326-02-8 CAPLUS
CN 2-Quinoxalinecarboxamide, N-[4-{5-cyclobutyl-1-[(1-methylethylamino)carbonyl]-1H-pyrazol-3-yl]-3-hydroxyphenyl]- (9CI) (CA INDEX NAME)




RN 550326-03-9 CAPLUS
CN 2-Quinoxalinecarboxamide, N-[4-{5-cyclobutyl-1-[(ethylamino)carbonyl]-1H-pyrazol-3-yl]-3-hydroxyphenyl]- (9CI) (CA INDEX NAME)




RN 550326-04-0 CAPLUS
CN 2-Quinoxalinecarboxamide, N-[4-{5-cyclobutyl-1-[(2-propenylamino)carbonyl]-1H-pyrazol-3-yl]-3-hydroxyphenyl]- (9CI) (CA INDEX NAME)




RN 550326-05-1 CAPLUS
CN 2-Quinoxalinecarboxamide, N-[4-{5-cyclobutyl-1-[(propylamino)carbonyl]-1H-pyrazol-3-yl]-3-hydroxyphenyl]- (9CI) (CA INDEX NAME)



RN 550326-06-2 CAPLUS
CN 2-Quinoxalinecarboxamide, N-[4-{5-cyclobutyl-1-[(phenylethylamino)carbonyl]-1H-pyrazol-3-yl]-3-hydroxyphenyl]- (9CI) (CA INDEX NAME)




RN 550326-07-3 CAPLUS
CN 2-Quinoxalinecarboxamide, N-[4-{5-cyclobutyl-1-[(2-phenylethylamino)carbonyl]-1H-pyrazol-3-yl]-3-hydroxyphenyl]- (9CI) (CA INDEX NAME)




RN 550326-08-4 CAPLUS
CN 2-Quinoxalinecarboxamide, N-[4-{5-cyclobutyl-1-[(2-propenylamino)carbonyl]-1H-pyrazol-3-yl]-3-hydroxyphenyl]- (9CI) (CA INDEX NAME)


methylphenyl)methylamino]carbonyl]-1H-pyrazol-3-yl]-3-hydroxyphenyl]- (9CI) (CA INDEX NAME)




RN 550326-09-5 CAPLUS
CN 2-Quinoxalinecarboxamide, N-[4-{5-cyclobutyl-1-[(3-methylphenyl)methylamino]carbonyl]-1H-pyrazol-3-yl]-3-hydroxyphenyl]- (9CI) (CA INDEX NAME)




RN 550326-10-8 CAPLUS
CN 2-Quinoxalinecarboxamide, N-[4-{5-cyclobutyl-1-[(4-methylphenyl)methylamino]carbonyl]-1H-pyrazol-3-yl]-3-hydroxyphenyl]- (9CI) (CA INDEX NAME)




RN 550326-11-9 CAPLUS
CN 2-Quinoxalinecarboxamide, N-[4-{5-cyclobutyl-1-[(2-chlorophenyl)methylamino]carbonyl]-1H-pyrazol-3-yl]-3-hydroxyphenyl]- (9CI) (CA INDEX NAME)




RN 550326-12-0 CAPLUS
CN 2-Quinoxalinecarboxamide, N-[4-{5-cyclobutyl-1-[(4-fluorophenyl)methylamino]carbonyl]-1H-pyrazol-3-yl]-3-hydroxyphenyl]- (9CI) (CA INDEX NAME)




RN 550326-13-1 CAPLUS
CN 2-Quinoxalinecarboxamide, N-[4-{5-cyclobutyl-1-[(3,4-dichlorophenyl)methylamino]carbonyl]-1H-pyrazol-3-yl]-3-hydroxyphenyl]- (9CI) (CA INDEX NAME)




RN 550326-14-2 CAPLUS
CN 2-Quinoxalinecarboxamide, N-[4-{5-cyclobutyl-1-[(4-methoxyphenyl)methylamino]carbonyl]-1H-pyrazol-3-yl]-3-hydroxyphenyl]- (9CI) (CA INDEX NAME)




RN 550326-15-3 CAPLUS
CN 2-Quinoxalinecarboxamide, N-[4-{5-cyclobutyl-1-[(1-methylpropylamino)carbonyl]-1H-pyrazol-3-yl]-3-hydroxyphenyl]- (9CI) (CA INDEX NAME)




RN 550326-16-4 CAPLUS
CN 2-Quinoxalinecarboxamide, N-[4-[5-cyclobutyl-1-[[[(2-fluorophenyl)methyl]amino]carbonyl]-1H-pyrazol-3-yl]-3-hydroxyphenyl]- (9CI) (CA INDEX NAME)



RN 550326-17-5 CAPLUS
CN 2-Quinoxalinecarboxamide, N-[4-[5-cyclobutyl-1-[[[(3-fluorophenyl)methyl]amino]carbonyl]-1H-pyrazol-3-yl]-3-hydroxyphenyl]- (9CI) (CA INDEX NAME)




RN 550326-18-6 CAPLUS
CN 2-Quinoxalinecarboxamide, N-[4-[5-cyclobutyl-1-[[[(cyclopropylamino)carbonyl]-1H-pyrazol-3-yl]-3-hydroxyphenyl]- (9CI) (CA INDEX NAME)




RN 550326-19-7 CAPLUS
CN 2-Quinoxalinecarboxamide, N-[4-[5-cyclopentyl-1-[[[(1-


methylethyl)amino]carbonyl]-1H-pyrazol-3-yl]-3-hydroxyphenyl]- (9CI) (CA INDEX NAME)




RN 550326-20-0 CAPLUS
CN 2-Quinoxalinecarboxamide, N-[4-[5-cyclopentyl-1-[[[(ethylamino)carbonyl]-1H-pyrazol-3-yl]-3-hydroxyphenyl]- (9CI) (CA INDEX NAME)




RN 550326-21-1 CAPLUS
CN 2-Quinoxalinecarboxamide, N-[4-[5-cyclopentyl-1-[[[(2-propenylamino)carbonyl]-1H-pyrazol-3-yl]-3-hydroxyphenyl]- (9CI) (CA INDEX NAME)




RN 550326-22-2 CAPLUS
CN 2-Quinoxalinecarboxamide, N-[4-[5-cyclopentyl-1-[[[(propylamino)carbonyl]-1H-pyrazol-3-yl]-3-hydroxyphenyl]- (9CI) (CA INDEX NAME)




RN 550326-23-3 CAPLUS
CN 2-Quinoxalinecarboxamide, N-[4-[5-cyclopentyl-1-[[[(2-phenylethyl)amino]carbonyl]-1H-pyrazol-3-yl]-3-hydroxyphenyl]- (9CI) (CA INDEX NAME)




RN 550326-24-4 CAPLUS
CN 2-Quinoxalinecarboxamide, N-[4-[5-cyclopentyl-1-[[[(2-phenylethyl)amino]carbonyl]-1H-pyrazol-3-yl]-3-hydroxyphenyl]- (9CI) (CA INDEX NAME)




RN 550326-25-5 CAPLUS
CN 2-Quinoxalinecarboxamide, N-[4-[5-cyclopentyl-1-[[[(2-methylphenyl)methyl]amino]carbonyl]-1H-pyrazol-3-yl]-3-hydroxyphenyl]- (9CI) (CA INDEX NAME)




RN 550326-26-6 CAPLUS
CN 2-Quinoxalinecarboxamide, N-[4-[5-cyclopentyl-1-[[[(3-methylphenyl)methyl]amino]carbonyl]-1H-pyrazol-3-yl]-3-hydroxyphenyl]- (9CI) (CA INDEX NAME)




RN 550326-27-7 CAPLUS
CN 2-Quinoxalinecarboxamide, N-[4-[5-cyclopentyl-1-[[[(4-methylphenyl)methyl]amino]carbonyl]-1H-pyrazol-3-yl]-3-hydroxyphenyl]- (9CI) (CA INDEX NAME)




RN 550326-28-8 CAPLUS
CN 2-Quinoxalinecarboxamide, N-[4-[1-[[[(2-chlorophenyl)methyl]amino]carbonyl]-5-cyclopentyl-1H-pyrazol-3-yl]-3-hydroxyphenyl]- (9CI) (CA INDEX NAME)




RN 550326-29-9 CAPLUS
CN 2-Quinoxalinecarboxamide, N-[4-[5-cyclopentyl-1-[[[(2-fluorophenyl)methyl]amino]carbonyl]-1H-pyrazol-3-yl]-3-hydroxyphenyl]- (9CI) (CA INDEX NAME)




RN 550326-30-2 CAPLUS
CN 2-Quinoxalinecarboxamide, N-[4-[5-cyclopentyl-1-[[[(3,4-dichlorophenyl)methyl]amino]carbonyl]-1H-pyrazol-3-yl]-3-hydroxyphenyl]- (9CI) (CA INDEX NAME)




RN 550326-31-3 CAPLUS
CN 2-Quinoxalinecarboxamide, N-[4-[5-cyclopentyl-1-[[[(4-methoxyphenyl)methyl]amino]carbonyl]-1H-pyrazol-3-yl]-3-hydroxyphenyl]- (9CI) (CA INDEX NAME)




RN 550326-33-5 CAPLUS
CN 2-Quinoxalinecarboxamide, N-[4-[5-cyclopentyl-1-[[[(1-methylpropyl)amino]carbonyl]-1H-pyrazol-3-yl]-3-hydroxyphenyl]- (9CI) (CA INDEX NAME)




RN 550326-35-7 CAPLUS
CN 2-Quinoxalinecarboxamide, N-[4-[5-cyclopentyl-1-[[[(2-fluorophenyl)methyl]amino]carbonyl]-1H-pyrazol-3-yl]-3-hydroxyphenyl]- (9CI) (CA INDEX NAME)




RN 550326-37-9 CAPLUS
CN 2-Quinoxalinecarboxamide, N-[4-[5-cyclopentyl-1-[[[(3-fluorophenyl)methyl]amino]carbonyl]-1H-pyrazol-3-yl]-3-hydroxyphenyl]- (9CI) (CA INDEX NAME)




RN 550326-39-1 CAPLUS
CN 2-Quinoxalinecarboxamide, N-[4-[5-cyclopentyl-1-[[[(cyclopropylamino)carbonyl]-1H-pyrazol-3-yl]-3-hydroxyphenyl]- (9CI) (CA INDEX NAME)




RN 550340-02-8 CAPLUS
CN 2-Quinoxalinecarboxamide, N-[3-[5-cyclopropyl-1-[[[(1-methylethyl)amino]carbonyl]-1H-pyrazol-3-yl]-4-hydroxyphenyl]- (9CI) (CA INDEX NAME)




RN 550340-03-9 CAPLUS
CN 2-Quinoxalinecarboxamide, N-[3-[5-cyclopropyl-1-[[[(ethylamino)carbonyl]-1H-pyrazol-3-yl]-4-hydroxyphenyl]- (9CI) (CA INDEX NAME)




RN 550340-04-0 CAPLUS
CN 2-Quinoxalinecarboxamide, N-[3-[5-cyclopropyl-1-[[[(2-propenylamino)carbonyl]-1H-pyrazol-3-yl]-4-hydroxyphenyl]- (9CI) (CA INDEX NAME)




RN 550340-05-1 CAPLUS
CN 2-Quinoxalinecarboxamide, N-[3-[5-cyclopropyl-1-[[[(propylamino)carbonyl]-1H-pyrazol-3-yl]-4-hydroxyphenyl]- (9CI) (CA INDEX NAME)




RN 550340-06-2 CAPLUS
CN 2-Quinoxalinecarboxamide, N-[3-[5-cyclopropyl-1-[[[(phenylethyl)amino]carbonyl]-1H-pyrazol-3-yl]-4-hydroxyphenyl]- (9CI) (CA INDEX NAME)




RN 550340-07-3 CAPLUS
CN 2-Quinoxalinecarboxamide, N-[3-[5-cyclopropyl-1-[[[(2-phenylethyl)amino]carbonyl]-1H-pyrazol-3-yl]-4-hydroxyphenyl]- (9CI) (CA INDEX NAME)




RN 550340-08-4 CAPLUS
CN 2-Quinoxalinecarboxamide, N-[3-[5-cyclopropyl-1-[[[(2-methylphenyl)methyl]amino]carbonyl]-1H-pyrazol-3-yl]-4-hydroxyphenyl]- (9CI) (CA INDEX NAME)




RN 550340-09-5 CAPLUS
CN 2-Quinoxalinecarboxamide, N-[3-[5-cyclopropyl-1-[[[(3-methylphenyl)methyl]amino]carbonyl]-1H-pyrazol-3-yl]-4-hydroxyphenyl]- (9CI) (CA INDEX NAME)




RN 550340-10-8 CAPLUS
CN 2-Quinoxalinecarboxamide, N-[3-[5-cyclopropyl-1-[[[(4-methylphenyl)methyl]amino]carbonyl]-1H-pyrazol-3-yl]-4-hydroxyphenyl]- (9CI) (CA INDEX NAME)




RN 550340-11-9 CAPLUS
CN 2-Quinoxalinecarboxamide, N-[3-[1-[[[(2-chlorophenyl)methyl]amino]carbonyl]-5-cyclopropyl-1H-pyrazol-3-yl]-4-hydroxyphenyl]- (9CI) (CA INDEX NAME)




RN 550340-12-0 CAPLUS
CN 2-Quinoxalinecarboxamide, N-[3-[5-cyclopropyl-1-[[[(4-fluorophenyl)methyl]amino]carbonyl]-1H-pyrazol-3-yl]-4-hydroxyphenyl]- (9CI) (CA INDEX NAME)




RN 550340-13-1 CAPLUS
CN 2-Quinoxalinecarboxamide, N-[3-[5-cyclopropyl-1-[[[(3,4-dichlorophenyl)methyl]amino]carbonyl]-1H-pyrazol-3-yl]-4-hydroxyphenyl]- (9CI) (CA INDEX NAME)




RN 550340-14-2 CAPLUS
CN 2-Quinoxalinecarboxamide, N-[3-[5-cyclopropyl-1-[[[(4-methoxyphenyl)methyl]amino]carbonyl]-1H-pyrazol-3-yl]-4-hydroxyphenyl]- (9CI) (CA INDEX NAME)




RN 550340-15-3 CAPLUS
CN 2-Quinoxalinecarboxamide, N-[3-[5-cyclopropyl-1-[[[(1-methylpropyl)amino]carbonyl]-1H-pyrazol-3-yl]-4-hydroxyphenyl]- (9CI) (CA INDEX NAME)




RN 550340-16-4 CAPLUS
CN 2-Quinoxalinecarboxamide, N-[3-[5-cyclopropyl-1-[[[(3-fluorophenyl)methyl]amino]carbonyl]-1H-pyrazol-3-yl]-4-hydroxyphenyl]- (9CI) (CA INDEX NAME)




RN 550340-17-5 CAPLUS
CN 2-Quinoxalinecarboxamide, N-[3-[5-cyclopropyl-1-[[[(1-phenylmethyl)amino]carbonyl]-1H-pyrazol-3-yl]-4-hydroxyphenyl]- (9CI) (CA INDEX NAME)




RN 550340-18-6 CAPLUS
CN 2-Quinoxalinecarboxamide, N-[3-[5-cyclobutyl-1-[[[(3,4-dichlorophenyl)methyl]amino]carbonyl]-1H-pyrazol-3-yl]-4-hydroxyphenyl]- (9CI) (CA INDEX NAME)




RN 550340-19-7 CAPLUS
CN 2-Quinoxalinecarboxamide, N-[3-[5-cyclobutyl-1-[[[(1-methylethyl)amino]carbonyl]-1H-pyrazol-3-yl]-4-hydroxyphenyl]- (9CI) (CA INDEX NAME)




RN 550340-20-0 CAPLUS
CN 2-Quinoxalinecarboxamide, N-[3-[5-cyclobutyl-1-[[[(2-propenyl)amino]carbonyl]-1H-pyrazol-3-yl]-4-hydroxyphenyl]- (9CI) (CA INDEX NAME)




RN 550340-21-1 CAPLUS
CN 2-Quinoxalinecarboxamide, N-[3-[5-cyclobutyl-1-[[[(2-propenyl)amino]carbonyl]-1H-pyrazol-3-yl]-4-hydroxyphenyl]- (9CI) (CA INDEX NAME)




RN 550340-22-2 CAPLUS
CN 2-Quinoxalinecarboxamide, N-[3-[5-cyclobutyl-1-[[[(propylamino)carbonyl]-1H-pyrazol-3-yl]-4-hydroxyphenyl]- (9CI) (CA INDEX NAME)




RN 550340-23-3 CAPLUS
CN 2-Quinoxalinecarboxamide, N-[3-[5-cyclobutyl-1-[[[(phenylmethyl)amino]carbonyl]-1H-pyrazol-3-yl]-4-hydroxyphenyl]- (9CI) (CA INDEX NAME)




RN 550340-24-4 CAPLUS
CN 2-Quinoxalinecarboxamide, N-[3-[5-cyclobutyl-1-[[[(2-phenylethyl)amino]carbonyl]-1H-pyrazol-3-yl]-4-hydroxyphenyl]- (9CI) (CA INDEX NAME)




RN 550340-25-5 CAPLUS
CN 2-Quinoxalinecarboxamide, N-[3-[5-cyclobutyl-1-[[[(2-phenylethyl)amino]carbonyl]-1H-pyrazol-3-yl]-4-hydroxyphenyl]- (9CI) (CA INDEX NAME)




RN 550340-26-6 CAPLUS
CN 2-Quinoxalinecarboxamide, N-[3-[[5-cyclobutyl-1-[[[(3-methylphenyl)methyl]amino]carbonyl]-1H-pyrazol-3-yl]-4-hydroxyphenyl]- (9CI) (CA INDEX NAME)




RN 550340-27-7 CAPLUS
CN 2-Quinoxalinecarboxamide, N-[3-[[5-cyclobutyl-1-[[[(4-methylphenyl)methyl]amino]carbonyl]-1H-pyrazol-3-yl]-4-hydroxyphenyl]- (9CI) (CA INDEX NAME)




RN 550340-28-8 CAPLUS
CN 2-Quinoxalinecarboxamide, N-[3-[[5-cyclobutyl-1-[[[(2-chlorophenyl)methyl]amino]carbonyl]-1H-pyrazol-3-yl]-4-hydroxyphenyl]- (9CI) (CA INDEX NAME)




RN 550340-29-9 CAPLUS
CN 2-Quinoxalinecarboxamide, N-[3-[[5-cyclobutyl-1-[[[(4-fluorophenyl)methyl]amino]carbonyl]-1H-pyrazol-3-yl]-4-hydroxyphenyl]- (9CI) (CA INDEX NAME)




RN 550340-30-2 CAPLUS
CN 2-Quinoxalinecarboxamide, N-[3-[[5-cyclobutyl-1-[[[(3,4-dichlorophenyl)methyl]amino]carbonyl]-1H-pyrazol-3-yl]-4-hydroxyphenyl]- (9CI) (CA INDEX NAME)




RN 550340-31-3 CAPLUS
CN 2-Quinoxalinecarboxamide, N-[3-[[5-cyclobutyl-1-[[[(1-methoxyphenyl)methyl]amino]carbonyl]-1H-pyrazol-3-yl]-4-hydroxyphenyl]- (9CI) (CA INDEX NAME)




RN 550340-32-4 CAPLUS
CN 2-Quinoxalinecarboxamide, N-[3-[[5-cyclobutyl-1-[[[(1-methylpropyl)amino]carbonyl]-1H-pyrazol-3-yl]-4-hydroxyphenyl]- (9CI) (CA INDEX NAME)




RN 550340-33-5 CAPLUS
CN 2-Quinoxalinecarboxamide, N-[3-[[5-cyclobutyl-1-[[[(2-fluorophenyl)methyl]amino]carbonyl]-1H-pyrazol-3-yl]-4-hydroxyphenyl]- (9CI) (CA INDEX NAME)




RN 550340-34-6 CAPLUS
CN 2-Quinoxalinecarboxamide, N-[3-[[5-cyclobutyl-1-[[[(3-fluorophenyl)methyl]amino]carbonyl]-1H-pyrazol-3-yl]-4-hydroxyphenyl]- (9CI) (CA INDEX NAME)




RN 550340-35-7 CAPLUS
CN 2-Quinoxalinecarboxamide, N-[3-[[5-cyclobutyl-1-[[[(cyclopropylamino)carbonyl]-1H-pyrazol-3-yl]-4-hydroxyphenyl]- (9CI) (CA INDEX NAME)




RN 550340-36-8 CAPLUS
CN 2-Quinoxalinecarboxamide, N-[3-[[5-cyclopentyl-1-[[[(1-methylethyl)amino]carbonyl]-1H-pyrazol-3-yl]-4-hydroxyphenyl]- (9CI) (CA INDEX NAME)




RN 550340-37-9 CAPLUS
CN 2-Quinoxalinecarboxamide, N-[3-[[5-cyclopentyl-1-[[[(ethylamino)carbonyl]-1H-pyrazol-3-yl]-4-hydroxyphenyl]- (9CI) (CA INDEX NAME)




RN 550340-38-0 CAPLUS
CN 2-Quinoxalinecarboxamide, N-[3-[[5-cyclopentyl-1-[[[(2-propenylamino)carbonyl]-1H-pyrazol-3-yl]-4-hydroxyphenyl]- (9CI) (CA INDEX NAME)



RN 550340-39-1 CAPLUS
CN 2-Quinoxalinecarboxamide, N-[3-[[5-cyclopentyl-1-[[[(propylamino)carbonyl]-1H-pyrazol-3-yl]-4-hydroxyphenyl]- (9CI) (CA INDEX NAME)




RN 550340-40-4 CAPLUS
CN 2-Quinoxalinecarboxamide, N-[3-[[5-cyclopentyl-1-[[[(phenylethyl)amino]carbonyl]-1H-pyrazol-3-yl]-4-hydroxyphenyl]- (9CI) (CA INDEX NAME)




RN 550340-41-5 CAPLUS
CN 2-Quinoxalinecarboxamide, N-[3-[[5-cyclopentyl-1-[[[(2-phenylethyl)amino]carbonyl]-1H-pyrazol-3-yl]-4-hydroxyphenyl]- (9CI) (CA INDEX NAME)


INDEX NAME)




RN 550340-42-6 CAPLUS
CN 2-Quinoxalinecarboxamide, N-[3-[[5-cyclopentyl-1-[[[2-methylphenyl)methyl]amino]carbonyl]-1H-pyrazol-3-yl]-4-hydroxyphenyl]- (9CI) (CA INDEX NAME)



RN 550340-43-7 CAPLUS
CN 2-Quinoxalinecarboxamide, N-[3-[[5-cyclopentyl-1-[[[3-methylphenyl)methyl]amino]carbonyl]-1H-pyrazol-3-yl]-4-hydroxyphenyl]- (9CI) (CA INDEX NAME)




RN 550340-44-8 CAPLUS
CN 2-Quinoxalinecarboxamide, N-[3-[[5-cyclopentyl-1-[[[4-methylphenyl)methyl]amino]carbonyl]-1H-pyrazol-3-yl]-4-hydroxyphenyl]- (9CI) (CA INDEX NAME)




RN 550340-45-9 CAPLUS


CN 2-Quinoxalinecarboxamide, N-[3-[[1-[[[2-chlorophenyl)methyl]amino]carbonyl]-5-cyclopentyl-1H-pyrazol-3-yl]-4-hydroxyphenyl]- (9CI) (CA INDEX NAME)




RN 550340-46-0 CAPLUS
CN 2-Quinoxalinecarboxamide, N-[3-[[5-cyclopentyl-1-[[[4-fluorophenyl)methyl]amino]carbonyl]-1H-pyrazol-3-yl]-4-hydroxyphenyl]- (9CI) (CA INDEX NAME)




RN 550340-47-1 CAPLUS
CN 2-Quinoxalinecarboxamide, N-[3-[[5-cyclopentyl-1-[[[3,4-dichlorophenyl)methyl]amino]carbonyl]-1H-pyrazol-3-yl]-4-hydroxyphenyl]- (9CI) (CA INDEX NAME)




RN 550340-48-2 CAPLUS
CN 2-Quinoxalinecarboxamide, N-[3-[[5-cyclopentyl-1-[[[4-methoxyphenyl)methyl]amino]carbonyl]-1H-pyrazol-3-yl]-4-hydroxyphenyl]- (9CI) (CA INDEX NAME)




RN 550340-49-3 CAPLUS
CN 2-Quinoxalinecarboxamide, N-[3-[[5-cyclopentyl-1-[[[1-methylpropyl]amino]carbonyl]-1H-pyrazol-3-yl]-4-hydroxyphenyl]- (9CI) (CA INDEX NAME)



RN 550340-50-6 CAPLUS
CN 2-Quinoxalinecarboxamide, N-[3-[[5-cyclopentyl-1-[[[2-fluorophenyl)methyl]amino]carbonyl]-1H-pyrazol-3-yl]-4-hydroxyphenyl]- (9CI) (CA INDEX NAME)




RN 550340-51-7 CAPLUS
CN 2-Quinoxalinecarboxamide, N-[3-[[5-cyclopentyl-1-[[[3-fluorophenyl)methyl]amino]carbonyl]-1H-pyrazol-3-yl]-4-hydroxyphenyl]- (9CI) (CA INDEX NAME)



RN 550340-52-8 CAPLUS
CN 2-Quinoxalinecarboxamide, N-[3-[[5-cyclopentyl-1-[[[cyclopropylamino]carbonyl]-1H-pyrazol-3-yl]-4-hydroxyphenyl]- (9CI) (CA INDEX NAME)

INDEX NAME)




REFERENCE COUNT: 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

LS ANSWER 68 OF 283 CAPLUS COPYRIGHT 2006 ACS ON STN
ACCESSION NUMBER: 2003:454289 CAPLUS
DOCUMENT NUMBER: 139:36449
TITLE: Substituted 2-aminocycloalkancarboxamides for use as cysteine protease inhibitors
INVENTOR(S): Gabriel, Thomas; Krausa, Nancy Elisabeth; Mirzadegan, Taraneh; Palmer, Wylie Solang; Smith, David Bernard
PATENT ASSIGNEE(S): F. Hoffmann-La Roche Ag, Switz.
SOURCE: PCT Int. Appl., 84 pp.
DOCUMENT TYPE: CODEN: PIXXD2
LANGUAGE: Patent
FAMILY ACC. NUM. COUNT: 2 English
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003048123	A1	20030612	WO 2002-EPI3221	20021125
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GR, GM, GU, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MY, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZM, ZW				
RM: OH, OM, KE, LS, MM, ME, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CO, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2467435	AA	20030612	CA 2002-2467435	20021125
AU 2002352126	A1	20030617	AU 2002-352126	20021125
EP 1453801	A1	20040908	EP 2002-787799	20021125
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK				
BR 2002014642	A	20041103	BR 2002-14642	20021125
JP 2005517640	T2	20050616	JP 2003-549315	20021125
NO 2004002719	A	20040628	NO 2004-2719	20040628
PRIORITY APPL. INFO.: US 2001-336750P P 20011204 W 20021125				
OTHER SOURCE(S): MARPAT 139:36449				


GI



AB Title compds. I [R1 = heteroaryl, (CH₂)_nCO₂R, S(O)₂R; R2-R4, R6-R8 = H, alkyl; R5 = H, alkyl, heterocyclic, cycloalkyl, cycloalkylalkyl, alkoxy, carbonylalkyl, aryl, aralkyl, heteroaryl, heteroarylalkyl; R9 = heteroaryl, heteroarylalkyl, heteroarylalkoxy; n = 0, 1; n = 1-3; p = 1, 2] were prepared for use as cysteine protease inhibitors. The compds. are useful for the treatment of diseases which are associated with cysteine proteases such as osteoporosis, osteoarthritis, rheumatoid arthritis, tumor metastasis, glomerulonephritis, atherosclerosis, myocardial infarction, angina pectoris, unstable angina pectoris, stroke, plaque rupture, transient ischemic attacks, amaurosis fugax, peripheral arterial occlusive disease, restenosis after angioplasty and stent placement, abdominal aortic aneurysm formation, inflammation, autoimmune disease, malaria, ocular fundus tissue cytopathy and respiratory disease. Thus, Et [(1R,2S)-2-aminocyclohexanecarboxylate-1R] was treated with indole-2-carboxylic acid, followed by ester hydrolysis and amidation with (R,8)-amino(cyclopropyl)acetonitrile to give the amide II which had IC50 for inhibition of cathepsin K of 0.018 nM.


IT 541524-14-5P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (Preparation of substituted 2-aminocycloalkancarboxamides for use as cysteine protease inhibitors)
RN 541524-14-5 CAPLUS
CN Cyclohexanecarboxylic acid, 2-[(2-quinoxalinylylcarbonyl)amino]-, (1R,2S)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.




IT 541523-58-4P 541523-71-1P
RL: SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (Preparation of substituted 2-aminocycloalkancarboxamides for use as cysteine protease inhibitors)
RN 541523-58-4 CAPLUS
CN 2-Quinoxalincarboxamide, N-[(1S,2R)-2-[[[(1S)-cyanocyclopropylmethyl]amino]carbonyl]cyclohexyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 541523-71-1 CAPLUS
CN 2-Quinoxalincarboxamide, N-[(1S,2R)-2-[[[(1S)-1-cyano-2-phenylethyl]amino]carbonyl]cyclohexyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 69 OF 283 CAPLUS COPYRIGHT 2006 ACS ON STN
ACCESSION NUMBER: 2003:417614 CAPLUS
DOCUMENT NUMBER: 139:6678
TITLE: Preparation of benzoic acid and benzenealkanoic acid dual inhibitors of adipocyte fatty acid binding protein and keratinocyte fatty acid binding protein
INVENTOR(S): Maguin, David R.; Sulsky, Richard B.; Robl, Jeffrey A.; Caulfield, Thomas J.; Parker, Rex A.
PATENT ASSIGNEE(S): Bristol-Myers Squibb Company, USA
SOURCE: PCT Int. Appl., 236 pp.
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003043624	A1	20030530	WO 2002-053680	20021115
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GR, HU, IL, IN, JP, KE, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MY, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RM: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CV, CO, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SH, TD, TO				
AU 2002348276	A1	20030610	AU 2002-348276	20021115
US 2003225091	A1	20031204	US 2002-295819	20021115
US 6984645	B2	20060110		20021115
EP 1443919	A1	20040811	EP 2002-783300	20021115
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,				


IR, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, ES, SK
PRIORITY APPL. INFO.: US 2001-333194P P 20011116
 WO 2002-053680 W 20021115
OTHER SOURCE(S): MARPAT 139:6678
GI




AB Title compds. I [wherein A = a bond or (un)substituted alkylene or alkenylene; B = CO₂H or tetrazole; X and Y = independently (un)substituted O(CH₂)₂q, (CH₂)₂qO, (CH₂)₂qNCO, NHC(O)(CH₂)₂q, NHC(O)(CH₂)₂qCO₂, NHC(O)CH₂CH₂CH₂qNHSO₂, NHC(O)(CH₂)₂q, OCO(CH₂)₂q, O(CH₂)₂qCO, (CH₂)₂qOCO, or (CH₂)₂qSO₂; R1 and R2 = independently (un)substituted (hetero)aryl, (cyclo)alkyl, (hetero)alkyl, cycloalkenyl, or heterocyclyl; R3 = H, OH, (hydroxy)alkyl, aryl, MD₂, halo, (alkyl)amino, alkoxy, CN, thioalkyl, CO₂H, CO₂R, NR₂CO₂R, or NR₂CO₂R; R4 = H or (un)substituted (halo)alkyl, aminoalkyl, alkoxyalkyl, hydroxyalkyl, or (hetero)aryl; R5 = H, OH, CN, or (un)substituted alkoxy, alkyl, alkenyl, hydroxyalkyl, (hetero)aryl, (hetero)alkyl, alkythio, or (hetero)aryloxy; q = 0-5; t = 0-2; with proviso; and pharmaceutically acceptable salts, prodrug esters, stereoisomers, or solvates thereof] were prepared as dual inhibitors of adipocyte fatty acid binding protein (aP2) and keratinocyte fatty acid binding protein (k-FABP). For example, reaction of 2,3-dihydroxybenzaldehyde with 2-chlorobenzyl chloride in the presence of K₂CO₃ in EtOH provided the bis ether (71b), which was oxidized using trimethylsilyl cyanide, trimethylsilyl chloride, and TEA in EtOH to give the Et α-hydroxybenzeneacetate (84a). Deacetylation with NaOH in THF and recrystn. afforded the free acid II (87a). I, alone or in combination with at least one other antidiabetic agent, are useful for the treatment of diabetes and related diseases, especially Type II diabetes (no data).

IT 533898-29-6P, 3-(Phenylmethoxy)-2-[(2-quinoxalinylylcarbonyl)amino]benzoic acid 533898-29-2P, 3-[(2-Bromophenyl)methoxy]-2-[(2-quinoxalinylylcarbonyl)amino]benzoic acid 533898-35-0P, 3-[(2-Methylphenyl)methoxy]-2-[(2-quinoxalinylylcarbonyl)amino]benzoic acid 533898-43-0P, 3-[(3-Methylphenyl)methoxy]-2-[(2-quinoxalinylylcarbonyl)amino]benzoic acid 533898-55-4P, 3-[(4-Bromophenyl)methoxy]-2-[(2-quinoxalinylylcarbonyl)amino]benzoic acid 533898-65-6P, 3-[(4-Methylphenyl)methoxy]-2-[(2-quinoxalinylylcarbonyl)amino]benzoic acid 533898-76-9P, 2-[(2-Quinoxalinylylcarbonyl)amino]-3-[[4-(trifluoromethyl)phenyl]methoxy]benzoic acid 533898-95-2P, 3-[(2-Chlorophenyl)methoxy]-2-[(2-quinoxalinylylcarbonyl)amino]benzoic acid 533898-13-7P, 3-[[[1,1'-Biphenyl]-4-yl]methoxy]-2-[(2-quinoxalinylylcarbonyl)amino]benzoic acid 533898-24-0P, 3-Butoxy-2-[(2-quinoxalinylylcarbonyl)amino]benzoic acid 533898-36-4P, 3-(Cyclohexylmethoxy)-2-[(2-quinoxalinylylcarbonyl)amino]benzoic acid 533898-49-9P, 3-(1-Naphthalenylmethoxy)-2-[(2-quinoxalinylylcarbonyl)amino]benzoic acid


533898-59-1P, 3-(2-Naphthalenylmethoxy)-2-[(2-quinoxalinylylcarbonyl)amino]benzoic acid 533898-68-2P, 3-[(4-Chlorophenyl)methoxy]-2-[(2-quinoxalinylylcarbonyl)amino]benzoic acid 533898-78-4P, 3-[(3-Phenoxyphenyl)methoxy]-2-[(2-quinoxalinylylcarbonyl)amino]benzoic acid 533898-87-5P, 3-[(3-Methoxyphenyl)methoxy]-2-[(2-quinoxalinylylcarbonyl)amino]benzoic acid
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (antidiabetic agent; preparation of benzoic acid and benzenealkanoic acid dual aP2/k-FABP inhibitors as antidiabetic agents)
RN 533898-29-2 CAPLUS
CN Benzoic acid, 3-[(2-bromophenyl)methoxy]-2-[(2-quinoxalinylylcarbonyl)amino]- (9CI) (CA INDEX NAME)




RN 533898-29-2 CAPLUS
CN Benzoic acid, 3-[(2-bromophenyl)methoxy]-2-[(2-quinoxalinylylcarbonyl)amino]- (9CI) (CA INDEX NAME)




RN 533898-35-0 CAPLUS
CN Benzoic acid, 3-[(2-methylphenyl)methoxy]-2-[(2-quinoxalinylylcarbonyl)amino]- (9CI) (CA INDEX NAME)




RN 533898-43-0 CAPLUS
CN Benzoic acid, 3-[(3-methylphenyl)methoxy]-2-[(2-quinoxalinylylcarbonyl)amino]- (9CI) (CA INDEX NAME)




RN 533898-55-4 CAPLUS
CN Benzoic acid, 3-[(4-bromophenyl)methoxy]-2-[(2-quinoxalinylylcarbonyl)amino]- (9CI) (CA INDEX NAME)




RN 533898-55-6 CAPLUS
CN Benzoic acid, 3-[(4-methylphenyl)methoxy]-2-[(2-quinoxalinylylcarbonyl)amino]- (9CI) (CA INDEX NAME)




RN 533898-76-9 CAPLUS
CN Benzoic acid, 2-[(2-quinoxalinylylcarbonyl)amino]-3-[(4-(trifluoromethyl)phenyl)methoxy]- (9CI) (CA INDEX NAME)




RN 533898-95-2 CAPLUS
CN Benzoic acid, 3-[(2-chlorophenyl)methoxy]-2-[(2-quinoxalinylylcarbonyl)amino]- (9CI) (CA INDEX NAME)




RN 533899-13-7 CAPLUS
CN Benzoic acid, 3-[(1,1'-biphenyl)-4-ylmethoxy]-2-[(2-quinoxalinylylcarbonyl)amino]- (9CI) (CA INDEX NAME)




RN 533899-24-0 CAPLUS
CN Benzoic acid, 3-butoxy-2-[(2-quinoxalinylylcarbonyl)amino]- (9CI) (CA INDEX NAME)




RN 533899-36-4 CAPLUS
CN Benzoic acid, 3-(cyclohexylmethoxy)-2-[(2-quinoxalinylylcarbonyl)amino]- (9CI) (CA INDEX NAME)




RN 533899-49-9 CAPLUS
CN Benzoic acid, 3-(1-naphthalenylmethoxy)-2-[(2-quinoxalinylylcarbonyl)amino]- (9CI) (CA INDEX NAME)




RN 533899-59-1 CAPLUS
CN Benzoic acid, 3-(2-naphthalenylmethoxy)-2-[(2-quinoxalinylylcarbonyl)amino]- (9CI) (CA INDEX NAME)




RN 533899-68-2 CAPLUS
CN Benzoic acid, 3-[(4-chlorophenyl)methoxy]-2-[(2-quinoxalinylylcarbonyl)amino]- (9CI) (CA INDEX NAME)



RN 533899-78-4 CAPLUS
CN Benzoic acid, 3-[(3-phenoxyphenyl)methoxy]-2-[(2-quinoxalinylylcarbonyl)amino]- (9CI) (CA INDEX NAME)



RN 533899-87-5 CAPLUS
CN Benzoic acid, 3-[(3-methoxyphenyl)methoxy]-2-[(2-quinoxalinylylcarbonyl)amino]- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 70 OF 283 CAPLUS COPYRIGHT 2006 ACS ON STN

ACCESSION NUMBER: 2003:412773 CAPLUS

DOCUMENT NUMBER: 139:381448

TITLE: Some reactions with ketene dithioacetals. Part II: Novel synthesis of quinoxaline, pyrrole and pyrrolo[3,4-b]quinoxaline derivatives using ketene dithioacetals as antimicrobial activity

AUTHOR(S): El-Sharief, A. M. Sh.; Zahran, M. A.; El-Gaby, M. S. A.; Ammar, Y. A.; El-Said, U. H.

CORPORATE SOURCE: Chemistry Department, Faculty of Science, Al-Azhar University, Naser City, Cairo, Egypt

SOURCE: Afinidad (2003), 60(503), 81-87

CODEN: AFINAB; ISSN: 0001-9704

PUBLISHER: Asociacion de Quimicos del Instituto Quimico de Sarria

DOCUMENT TYPE: Journal


LANGUAGE: English

OTHER SOURCE(S): CASREACT 139:381448


AB The key compound, [(4-aminophenylaminomethylthio)methylene]malonitrile (I) was synthesized by condensation of ketene dithioacetals and 1,4-phenylenediamine. The reactivity of quinoxaline-2,3-dicarboxylic anhydride (II) towards compound I as nitrogen nucleophile was investigated. Thus, treatment of compound II with I in refluxing ethanol afforded the quinoxaline carboxylic acid derivative (III). On the other hand, fusion of compound II and I at 160°C yielded the corresponding quinoxaline carboxamide (IV). Fusion of comds. III and IV with hydrazine hydrate at 150°C produced the novel corresponding substituted pyrazoles. Refluxing of compound III with acetic anhydride furnished the novel pyrrolo[3,4-b]quinoxaline. By treatment of compound I with aromatic sulfonyl chloride followed by fusion with hydrazine, the novel pyrazole was obtained. The anti-microbial activity of some selected compound was also reported.

IT 623934-60-1P 623934-61-2P 623934-63-4P


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
(multi-step preparation of quinoxaline, pyrazole and pyrroloquinoxaline
deriva. using ketene dithioacetals and their antimicrobial activity)
RN 623934-60-1 CAPLUS
CN 2-Quinoxalinecarboxylic acid, 3-[[[4-[(5-amino-4-cyano-1H-pyrazol-3-yl)amino]phenyl]amino]carbonyl]- (9CI) (CA INDEX NAME)




RN 623934-61-2 CAPLUS
CN 2-Quinoxalinecarboxamide, N-[4-[(5-amino-4-cyano-1H-pyrazol-3-yl)amino]phenyl]- (9CI) (CA INDEX NAME)




RN 623934-63-4 CAPLUS
CN 2,3-Quinoxalinecarboxamide, N-[4-[[[2,2-dicyano-1-[[4-methylphenyl]amino]ethenyl]amino]phenyl]-N'-(4-methylphenyl)- (9CI) (CA INDEX NAME)



IT 623934-58-7P 623934-59-8P
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation); RACT (Reactant or Reagent)
(ring closure of: multi-step preparation of quinoxaline, pyrazole and pyrroloquinoxaline deriva. using ketene dithioacetals and their antimicrobial activity)
RN 623934-58-7 CAPLUS
CN 2-Quinoxalinecarboxylic acid, 3-[[[4-[[2,2-dicyano-1-(methylthio)ethenyl]amino]phenyl]amino]carbonyl]- (9CI) (CA INDEX NAME)



RN 623934-59-8 CAPLUS
CN 2-Quinoxalinecarboxamide, N-[4-[[[2,2-dicyano-1-(methylthio)ethenyl]amino]phenyl]- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 26 THERE ARE 26 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT


L5 ANSWER 71 OF 283 CAPLUS COPYRIGHT 2006 ACS ON STN
ACCESSION NUMBER: 2003:376819 CAPLUS
DOCUMENT NUMBER: 138:385173
TITLE: Preparation of N,N'-substituted-1,3-diamino-2-hydroxypropanes for treating Alzheimer's disease
INVENTOR(S): Varghese, John; Maillard, Michel; Jagodzinski, Barbara; Beck, James P.; Gailunas, Andrea; Fang, Larry; Sealy, Jennifer; Tenbrink, Ruth; Preskos, John; Mickelson, John; Samala, Lakshman; Hom, Roy
PATENT ASSIGNER(S): Elian Pharmaceuticals, Inc., USA; Pharmacia & Upjohn Company
SOURCE: PCT Int. Appl., 1243 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003040096	A2	20030515	WO 2002-US36072	20021108
WO 2003040096	A3	20040506		
W: AS, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GR, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MX, MY, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, SF, BJ, CP, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, NG, SN, TD, TG				
CA 2466284	AA	20030515	CA 2002-2466284	20021108
WO 2003040096	A2	20030515	WO 2002-2466284	20021108
W: AS, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GR, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MX, MY, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, SF, BJ, CP, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, NG, SN, TD, TG				

GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MX, MY, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, SF, BJ, CP, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

US 2004171881 A1 20040902 US 2002-291318 20021108
EP 1453789 A2 20040908 EP 2002-793909 20021108
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IS, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK
BR 2002014035 A 20050426 BR 2002-14035 20021108
JP 2005520791 T2 20050714 JP 2003-542142 20021108
NO 2004002359 A 20040806 NO 2004-2359 20040607
US 2001-337122P P 20011108
US 2001-344086P P 20011228
US 2002-345635P P 20020103
WO 2002-US36072 W 20021108


PRIORITY APPLN. INFO.:
OTHER SOURCE(S): MARPAT 138:385173
GI



AB The title compds. [I; R1 = (un)substituted alkyl, alkenyl, alkynyl, etc.; R2 = H, alkyl, haloalkyl, alkenyl, etc.; R3 = H, alkyl, haloalkyl, alkenyl, etc.; or R2 and R3 are taken together with the carbon to which they are attached to form a carbocycle of 3-7 carbon atoms, optionally where one carbon atom is replaced by a heteroatom selected from the group consisting of O, S, SO2, (un)substituted NH; R4 = alkyl, haloalkyl, hydroxyalkyl, etc.; R5 = R6X (wherein X = CO, SO2, (un)substituted CH2; R6 = (un)substituted Ph, naphthyl, indenyl, etc.); R25 = H, alkyl, alkoxy, etc.] which have activity as inhibitors of β -secretase and are therefore useful in treating a variety of disorders such as Alzheimer's disease, were prepared E.g., a multi-step synthesis of (1S,2R)-II, starting from (2S)-2-[(tert-butoxycarbonyl)amino]-3-[(3,5-difluorophenyl)propionic acid, was given. The compds. I showed IC50 of < 20 μ M in cell free inhibition assay utilizing a synthetic APP substrate. This is a Part 1 of 1-2 series.
IT 527722-15-2P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(Preparation of N,N'-substituted-1,3-diamino-2-hydroxypropanes for treating Alzheimer's disease)
RN 527722-15-2 CAPLUS
CN 2-Quinoxalinecarboxamide, N-[[[1S,2R]-1-[[[3,5-difluorophenyl]methyl]-3-[[[1-ethoxyphenyl]methyl]amino]-2-hydroxypropyl]-3,4-dihydro-3-oxo- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



L5 ANSWER 72 OF 283 CAPLUS COPYRIGHT 2006 ACS ON STN
ACCESSION NUMBER: 2003:356431 CAPLUS
DOCUMENT NUMBER: 138:368915
TITLE: Preparation of 2(1H)-quinoxalinones as analgesics
INVENTOR(S): Settlegger, Michael; Buschmann, Helmut; Przewosny, Michael; Enlberger, Werner; Koegel, Babette-Ivonne; Schick, Hans
PATENT ASSIGNER(S): Gruenthal G.m.b.H., Germany
SOURCE: PCT Int. Appl., 89 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: German
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003037879	A1	20030508	WO 2002-EP1812	20021023
W: AS, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GR, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MX, MY, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, SF, BJ, CP, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, NG, SN, TD, TG				
DE 10153345	A1	20030508	DE 2001-10153345	20011029
CA 2465061	AA	20030508	CA 2002-2465061	20021023
EP 1444212	A1	20040811	EP 2002-785285	20021023
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IS, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK				
JP 2005512986	T2	20050512	JP 2003-540161	20021023
US 2004224954	A1	20041111	US 2004-832205	20040426
PRIORITY APPLN. INFO.: DE 2001-10153345 A 20011029				


G1



AB Title compds. [I: R1-R4 = H, halo, OR, (branched) (saturated) C1-10 aliphatic group, C3-7 cycloaliph. group; whereby the both aliphatic and cycloaliph. groups are bonded by an ether bridge; A = (CH2)n-2, (CH2)nCH=CH, (CH2)nCO2, (CH2)nCOOH, (CH2)n-10(CH2)pCO, (CH2)n-10, (CH2)n-1NH2, NH(CH2)2, p = 0, 1; n = 0-3; r = 0-2; R5 = H, (branched) (saturated) C1-10 aliphatic group, C3-7 cycloaliph. group (heteroaryl); X = (substituted) phenylcyclohexyl, etc.], were prepared Thua, 6,7-dimethyl-3-oxo-3,4-dihydroquinoxaline-2-carboxylic acid (preparation given) was reacted with 4-amino-2-(N,N-dimethylaminomethyl)-1-(3-methoxyphenyl)cyclohexan-1-ol in the presence of N-methylmorpholine, dicyclohexylcarbodiimide, and hydroxybenzotriazole in DMF to give 69% (6,7-dimethyl-3-oxo-3,4-dihydroquinoxaline-2-yl)-N-[3-(N,N-dimethylaminomethyl)-4-hydroxy-4-(3-methoxyphenyl)cyclohexyl]carboxamide. The latter at 10 mg/kg i.v. in mice gave 72% inhibition of phenylquinone-induced writhing.


IT 521292-62-6P 521292-63-7P 521292-71-7P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USSES (Uses)
(preparation of quinoxalines as analgesics)

RN 521292-62-6 CAPLUS
CN 2-Quinoxalinecarboxamide, N-[3-[(dimethylamino)methyl]-4-hydroxy-4-(3-methoxyphenyl)cyclohexyl]-3,4-dihydro-6,7-dimethyl-3-oxo-, hydrochloride (9CI) (CA INDEX NAME)




● x HCl

RN 521292-63-7 CAPLUS
CN 2-Quinoxalinecarboxamide, 6,7-dichloro-N-[3-[(dimethylamino)methyl]-4-hydroxy-4-(3-methoxyphenyl)cyclohexyl]-3,4-dihydro-3-oxo- (9CI) (CA INDEX NAME)



RN 521292-71-7 CAPLUS
CN 2-Quinoxalinecarboxamide, N-[3-[(dimethylamino)methyl]-4-hydroxy-4-(3-methoxyphenyl)cyclohexyl]-3,4-dihydro-6,7-dimethyl-3-oxo- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT


L5 ANSWER 73 OF 283 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2003:329697 CAPLUS
DOCUMENT NUMBER: 139:128326
TITLE: [3H]R214127: A novel high-affinity radioligand for the mGluR receptor reveals a common binding site shared by multiple allosteric antagonists
AUTHOR(S): Lavreyaen, Hilde; Janasen, Cor; Biachoff, Francois; Langlois, Xavier; Leyaen, Joaee E.; Leage, Anne S. J.
CORPORATE SOURCE: CNS Discovery Research, Johnson and Johnson Pharmaceutical Research and Development, Beerse, B-2340, Belg.
SOURCE: Molecular Pharmacology (2003), 63(5), 1082-1093
CODEN: MOPMA3; ISSN: 0026-895X
PUBLISHER: American Society for Pharmacology and Experimental Therapeutics
DOCUMENT TYPE: Journal
LANGUAGE: English

AB R214127 was shown to be a potent and noncompetitive metabotropic glutamate 1 (mGluR) receptor-selective antagonist. The kinetics and pharmacol. of [3H]1-(3,4-dihydro-2H-pyran-2,3-b)quinolin-7-yl)-2-phenyl-1-ethanone (R214127) binding to rat mGluR receptor Chinese hamster ovary (CHO)-dhr-membranes was investigated, as well as the distribution of [3H]R214127 binding in rat brain tissue and sections. Specific binding to rat mGluR receptor CHO-dhr-membranes was approx. 92% of total and was optimal at 4°. Full association was reached within 5 min, and [3H]R214127 bound to a single binding site with an apparent KD of 0.90 nM and a Bmax of 6512 fmol/mg of protein. Inhibition expts. showed that [3H]R214127 binding was completely blocked by 2-quinoxaline-carboxamide-N-adamantan-1-yl (NPS 2390), (2a), (6a), 6a-naphthalen-2-ylmethyl-5-methyliden-hexahydro-cyclopenta[c] furan-1-yl (BAY 36-7620), and 7-(hydroxymethyl)cyclopropyl(b)chromen-1a-carboxylate Et ester (CPCCOEt), but

was not displaced by competitive mGluR receptor ligands such as glutamate and quisqualate, suggesting that R214127, NPS 2390, BAY 36-7620, and CPCCOEt bind to the same site or mutually exclusive sites. Expts. using rat cortex, striatum, hippocampus and cerebellum revealed that [3H]R214127 labeled a single high-affinity binding site (KD approx. 1 nM). Bmax values were highest in the cerebellum (4302 fmol/mg of protein) and were 741, 688, and 471 fmol/mg of protein in the striatum, hippocampus, and cortex, resp. The distribution of [3H]R214127 binding in rat brain was investigated in more detail by radioligand autoradiog. A high d. of binding sites was detected in the mol. layer of the cerebellum. Moderate labeling was seen in the CA3 and dentate gyrus of the hippocampus, thalamus, olfactory tubercle, amygdala, and substantia nigra reticulata. The cerebral cortex, caudate putamen, ventral pallidum, and nucleus accumbens showed lower labeling. The high affinity and selectivity of [3H]R214127 for mGluR receptors renders this compound the ligand of choice to study the native mGluR receptor in brain.

IT 226878-01-9 NPS 2390
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(characterization of R214127 as high-affinity radioligand for mGluR receptor reveals common binding site shared by multiple allosteric antagonists)

RN 226878-01-9 CAPLUS
CN 2-Quinoxalinecarboxamide, N-tricyclo[3.3.1.1.3,7]dec-1-yl- (9CI) (CA INDEX NAME)




REFERENCE COUNT: 29 THERE ARE 29 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 74 OF 283 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2003:326027 CAPLUS
DOCUMENT NUMBER: 139:143355
TITLE: Structure-activity relationship of a novel class of naphthyl amide KATP channel openers
AUTHOR(S): Turner, Sean C.; Carroll, William A.; White, Tammie K.; Brune, Michael E.; Buckner, Steven A.; Gopalakrishnan, Murali; Fabiyi, Adebola; Coghen, Michael J.; Scott, Victoria E.; Castle, Neil A.; Daza, Anthony V.; Milicic, Iven; Sullivan, James P.
CORPORATE SOURCE: Global Pharmaceutical Research and Development, Neuroscience Research, Abbott Laboratories, Abbott Park, IL, 60064, USA
SOURCE: Bioorganic & Medicinal Chemistry Letters (2003), 13(10), 1741-1744
CODEN: BMCLB; ISSN: 0960-894X
PUBLISHER: Elsevier Science B.V.
DOCUMENT TYPE: Journal
LANGUAGE: English
OTHER SOURCE(S): CASREACT 139:143355
AB We have discovered a novel series of N-[2-(2,2,2-trifluoro-1-hydroxy-1-(trifluoromethyl)ethyl)-naphthalen-1-yl] amides that are potent openers of KATP channels and investigated structure-activity relationships (SAR) around the 1,2-disubstituted naphthyl core. A-151892, a prototype compound of this series, was found to be a potent and efficacious potassium channel opener in vitro in transfected Kir6.2/SUR2B cells and pig bladder strips. Addnl., A-151892 was found to selectively inhibit unstable bladder contractions in vivo in an obstructed rat model of myogenic bladder

(function.
IT 571166-29-5P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USSES (Uses)
(structure-activity relationship of a novel class of naphthyl amide KATP channel openers)

RN 571166-29-5 CAPLUS
CN 2-Quinoxalinecarboxamide, N-[2-(2,2,2-trifluoro-1-hydroxy-1-(trifluoromethyl)ethyl)-1-naphthalenyl]- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 20 THERE ARE 20 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT


L5 ANSWER 75 OF 283 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2003:311209 CAPLUS
DOCUMENT NUMBER: 139:190619
TITLE: Synthesis and antimycobacterial activity of new quinoxaline-2-carboxamide 1,4-di-N-oxide derivatives
AUTHOR(S): Zarranz, Belen; Jaso, Andrea; Aldana, Ignacio; Monge, Antonio
CORPORATE SOURCE: Centro de Investigacion en Farmacobiología Aplicada (CIPA), Unidad en Investigación y Desarrollo de Medicamentos, Universidad de Navarra, Pamplona, Spain
SOURCE: Bioorganic & Medicinal Chemistry (2003), 11(10), 2149-2156
CODEN: BMCLB; ISSN: 0960-8996
PUBLISHER: Elsevier Science Ltd.
DOCUMENT TYPE: Journal
LANGUAGE: English
OTHER SOURCE(S): CASREACT 139:190619

AB As a continuation of our research and with the aim of obtaining new antituberculous agents which can improve the current chemotherapeutic antituberculous treatments, new series of quinoxaline-2-carboxamide 1,4-di-N-oxide deriva. were synthesized and evaluated for in vitro antituberculous activity against Mycobacterium tuberculosis strain H37Rv, using the radiometric BACTEC 460-Tb methodol. Active compds. were also screened by serial dilution to assess toxicity to a VERO cell line. The results indicate that some compds. exhibited a good antituberculous activity and the arylcarboxamide analogs 3, 8, and 9 were the most active compds. (EC50/MIC1). Also, the cytotoxic effects indicate that these compds. have a good Selectivity Index (SI).


IT 31983-89-6P 111888-46-1P 585527-84-0P 585527-85-1P 585527-86-2P 585527-87-3P 585527-88-4P 585527-89-5P 585527-90-8P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USSES (Uses)
(synthesis and antimycobacterial activity of new quinoxaline-2-carboxamide 1,4-di-N-oxide deriva.)

RN 31983-89-6 CAPLUS
CN 2-Quinoxalinecarboxamide, 3-methyl-N-phenyl-, 1,4-dioxide (9CI) (CA INDEX NAME)


NAME)




RN 111888-46-1 CAPLUS
CN 2-Quinoxalinecarboxamide, 3-methyl-N-(2-methylphenyl)-, 1,4-dioxide (9CI)
(CA INDEX NAME)




RN 585527-84-0 CAPLUS
CN 2-Quinoxalinecarboxamide, 3,6,7-trimethyl-N-phenyl-, 1,4-dioxide (9CI)
(CA INDEX NAME)




RN 585527-85-1 CAPLUS
CN 2-Quinoxalinecarboxamide, 3,7-dimethyl-N-phenyl-, 1,4-dioxide (9CI) (CA INDEX NAME)




RN 585527-86-2 CAPLUS
CN 2-Quinoxalinecarboxamide, 7-chloro-3-methyl-N-phenyl-, 1,4-dioxide (9CI)
(CA INDEX NAME)




RN 585527-87-3 CAPLUS
CN 2-Quinoxalinecarboxamide, 6,7-dichloro-3-methyl-N-phenyl-, 1,4-dioxide (9CI) (CA INDEX NAME)




RN 585527-88-4 CAPLUS
CN 2-Quinoxalinecarboxamide, 3,6,7-trimethyl-N-(2-methylphenyl)-, 1,4-dioxide (9CI) (CA INDEX NAME)




RN 585527-89-5 CAPLUS
CN 2-Quinoxalinecarboxamide, 3,7-dimethyl-N-(2-methylphenyl)-, 1,4-dioxide (9CI) (CA INDEX NAME)



RN 585527-90-8 CAPLUS
CN 2-Quinoxalinecarboxamide, 7-chloro-3-methyl-N-(2-methylphenyl)-, 1,4-dioxide (9CI) (CA INDEX NAME)



RN 585527-91-9 CAPLUS
CN 2-Quinoxalinecarboxamide, 6,7-dichloro-3-methyl-N-(2-methylphenyl)-, 1,4-dioxide (9CI) (CA INDEX NAME)



REFERENCE COUNT: 16 THERE ARE 16 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 76 OF 283 CAPLUS COPYRIGHT 2006 ACS ON STN
ACCESSION NUMBER: 2003:282325 CAPLUS
DOCUMENT NUMBER: 138:321285
TITLE: Preparation of quinoxaline-2,4-diamines as MCH receptor antagonists
INVENTOR(S): Sekiguchi, Yoshinori; Kanuma, Kouke; Omodere, Katsunori; Tran, Thuy-anh; Kramer, Bryan Aubrey; Beeley, Nigel Robert Arnold
PATENT ASSIGNEE(S): Taiho Pharmaceutical Co., Ltd., Japan
SOURCE: PCT Int. Appl., 1171 pp.
CODEN: PIXX2
DOCUMENT TYPE: Patent
LANGUAGES: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003028641	A2	20030410	WO 2002-US31059	20020930
WO 2003028641	A3	20030828		
W:	AB, AD, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, EC, EE, ES, FI, GB, GD, GR, GU, HM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MY, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW			
RW:	GH, GM, KE, LS, MW, MZ, SD, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CO, CI, CM, GA, GN, GQ, GW, ML, MR, NE, NG, TD, TG			
CA 2460594	AA	20030410	CA 2002-2460594	20020930
EP 1432693	A2	20040630	EP 2002-800388	20020930
R:	AT, BE, CH, DE, DK, EE, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IS, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, ES, SK			


JP 2005523237 T2 20050804 JP 2003-511977 20020930
PRIORITY APPLN. INFO.: US 2001-326463P P 20011001
US 2001-326758P P 20011002
WO 2002-US31059 W 20020930
OTHER SOURCE(S): MARPAT 138:321285
OI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB The title compds. QLYR1[O = 1, C(=NH)NH2; R1 = (un)substituted alkyl, alkenyl, cycloalkyl, etc.; L = II-IV (wherein R4 = H, alkyl; R5 = H, alkyl, alkyl substituted by a substituted carbocyclic aryl, etc.; Y = SO2, CO, (CH2)m; m = 0-1] which act as MCH receptor antagonists, and are useful for prophylaxis or treatment of obesity, obesity related disorders, anxiety, or depression, were prepared. Thus, hydrogenation of benzyl cis-[4-(4-dimethylaminoquinazolin-2-ylamino)cyclohexylmethyl]carbamate followed by reacting the resulting intermediate with 4-bromo-2-trifluoromethoxybenzaldehyde in the presence of NaBH(OAc)3 and AcOH in CH2Cl2, and treatment of the product with 4N HCl in EtOAc afforded 344 cis-V.2HCl which showed IC50 of 6 nM against MCH receptor.


IT 509145-80-6P 510739-53-4P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of quinoxaline-2,4-diamines as MCH receptor antagonists)
RN 509145-80-6 CAPLUS
CN 2-Quinoxalinecarboxamide, N-[[cis-4-[[4-(dimethylamino)-2-quinazolinyl]amino]cyclohexyl]methyl]- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 510739-53-4 CAPLUS
CN 2-Quinoxalinecarboxamide, N-[[cis-4-[[4-(dimethylamino)-2-quinazolinyl]amino]cyclohexyl]methyl]- (9CI) (CA INDEX NAME)

Relative stereochemistry.



L5 ANSWER 77 OF 283 CAPLUS COPYRIGHT 2006 ACS ON STN
ACCESSION NUMBER: 2003:150531 CAPLUS
DOCUMENT NUMBER: 138:187765

TITLE: Preparation of heteroarylpyrazoles as p38 kinase inhibitors

INVENTOR(S): Anantanarayan, Ashok; Clare, Michael; Collins, Paul M.; Crich, Joyce Zuowu; Devraj, Rajesh; Flynn, Daniel L.; Geng, Lifeng; Graneto, Matthew J.; Hanau, Cathleen E.; Hanson, Gunner J.; Hartmann, Susan J.; Hepperle, Michael; Huang, He; Koszyk, Francis J.; Liao, Shuyuan; Metz, Suzanne; Partis, Richard A.; Perry, Thao D.; Rao, Shashidhar N.; Selness, Shaun Raj; South, Michael S.; Stealey, Michael A.; Talley, John Jeffrey; Vazquez, Michael L.; Weier, Richard M.; Xu, Xiangdong; Khanna, Ish K.; Yu, Yi

PATENT ASSIGNEE(S): O.D. Searle and Co., USA

SOURCE: U.S., 415 pp., Cont.-in-part of U.S. Ser. No. 196,623. CODEN: USXXAM

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 4

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 6525059	B1	20030225	US 2000-513351	20000224
US 6514977	B1	20030204	US 1998-196623	19981120
WO 2000031063	A1	20000602	WO 1999-US26007	19991117

W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, ES, FI, GB, GD, GE, GH, GM, GR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM


RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, NG, SN, TD, TO

PRIORITY APPL. INFO.:

US 1998-196623	A2	19981120
WO 1999-US26007	A1	19991117
US 1997-47570P	P	19970522
US 1998-83670	A2	19980522

OTHER SOURCE(S): MARPAT 138:167765

CI



AB Title compds. [I; R1 = H, OH, NH2, (cyclo)alk(en)yl, acyl, aryl, etc.; R2 = (un)substituted piperidinyl; R3 = (un)substituted pyridinyl; R4 = (un)substituted phenyl; and pharmaceutically acceptable salts or tautomers thereof] were prepared by solution phase and solid phase parallel array reactions of ketones with hydrazines. Thus, R3CH2C(=O)Me (R3 = 4-pyridinyl) was condensed with 3,4-F(MeO)C6H3CHO to give the butenone (80%), which was cyclocondensed with TeNHNH2 to afford the title compound II (20.7%). The latter inhibited human p38 kinase activity in vitro with IC50 of 4.6 µM and inhibited tumor necrosis factor α (TNFα) and interleukin


1β (IL-1β) release from human peripheral blood mononuclear cells following stimulation with lipopolysaccharide with IC50 of 0.5 µM. Thus, I are useful for the treatment of inflammation, arthritis, asthma, and other disorders mediated by p38 kinase and TNF α.

IT 216518-34-2P
RL: CPM (Combinatorial preparation); PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); CMBI (Combinatorial study); PREP (Preparation); USES (Uses)
 [p38 kinase inhibitor; preparation of heteroarylpyrazole p38 kinase inhibitors by cyclocondensation of hydrazines with ketones]

RN 216518-34-2 CAPLUS

CN 2-Quinoxalinecarboxamide, N-[(1R)-1-(5-(4-fluorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl)-2-phenylethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 75 THERE ARE 75 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 79 OF 283 CAPLUS COPYRIGHT 2006 ACS ON STN
ACCESSION NUMBER: 2003:126021
DOCUMENT NUMBER: 139:85305

TITLE: On the reactivity of 1H-pyrazino[2,3-c][1,2,6]thiadiazine 2,2-dioxide and derivatives: nucleophilic substitution, amination, aldol-type condensation, oxidation, and hydrolysis

AUTHOR(S): Campillo, Nuria; Paes, Juan Antonio; Goya, Pilar

CORPORATE SOURCE: Inst. de Química Médica (CSIC), Madrid, E-28006, Spain

SOURCE: Helvetica Chimica Acta (2003), 86(1), 139-146

PUBLISHER: Verlag Helvetica Chimica Acta

DOCUMENT TYPE: Journal

LANGUAGE: English


OTHER SOURCE(S): CASREACT 139:85305

AB The reactivity of the 1H-pyrazino[2,3-c][1,2,6]thiadiazine 2,2-dioxide system, structurally related to pteridine, was studied, and a number of novel derivs. were synthesized. The chemical behaviors of these two related fused polycyclic systems were compared.

IT 556019-76-2P
RL: SPN (Synthetic preparation); PREP (Preparation)
 (reactivity of 1H-pyrazino[2,3-c][1,2,6]thiadiazine 2,2-dioxide and derivs.)

RN 556019-76-2 CAPLUS

CN 1H-Pyrazino[2,3-c][1,2,6]thiadiazine-6-carboxamide, 4-amino-7-phenyl-N-(phenylethyl)-, 2,2-dioxide (9CI) (CA INDEX NAME)



REFERENCE COUNT: 19 THERE ARE 19 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 79 OF 283 CAPLUS COPYRIGHT 2006 ACS ON STN
ACCESSION NUMBER: 2003:92403
DOCUMENT NUMBER: 138:137307

TITLE: Preparation of heteroarylpyrazoles as p38 kinase inhibitors

INVENTOR(S): Anantanarayan, Ashok; Clare, Michael; Collins, Paul M.; Crich, Joyce Zuowu; Devraj, Rajesh; Flynn, Daniel L.; Geng, Lifeng; Graneto, Matthew J.; Hanau, Cathleen E.; Hanson, Gunner J.; Hartmann, Susan J.; Hepperle, Michael; Huang, He; Koszyk, Francis J.; Liao, Shuyuan; Metz, Suzanne; Partis, Richard A.; Perry, Thao D.; Rao, Shashidhar N.; Selness, Shaun Raj; South, Michael S.; Stealey, Michael A.; Talley, John Jeffrey; Vazquez, Michael L.; Weier, Richard M.; Xu, Xiangdong; Khanna, Ish K.; Yu, Yi

PATENT ASSIGNEE(S): O.D. Searle and Co., USA

SOURCE: U.S., 541 pp., Cont.-in-part of U.S. Ser. No. 83,670. CODEN: USXXAM

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 4

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 6514977	B1	20030204	US 1998-196623	19981120
CA 2351725	AA	20000602	US 1999-2351725	19991117
WO 2000031063	A1	20000602	WO 1999-US26007	19991117

W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, ES, FI, GB, GD, GE, GH, GM, GR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, NG, SN, TD, TO

EP 1144403 A1 20011017 EP 1999-965756 19991117

EP 1144403 B1 20041006

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO

TR 200102001 T2 20011221 TR 2001-200102001 19991117

BR 9915420 A 20020122 BR 1999-15420 19991117

SE 200100268 A 20021216 SE 2001-268 19991117

NZ 512344 A 20031128 NZ 1999-512344 19991117

AU 774262 B2 20040624 AU 2000-21454 19991117

AT 278685 E 20041015 AT 1999-965756 19991117

EP 1500657 A1 20050126 EP 2004-23186 19991117

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI, CY

PT 1144403 T 20050131 PT 1999-965756 19991117


ES 2329809	T3	20050416	ES 1999-965756	19991117
US 6525059	B1	20030225	US 2000-513351	20000224
ZA 2001003882	A	20021014	ZA 2001-3882	20010514
NO 2001002456	A	20010719	NO 2001-2456	20010518
BG 105620	A	20020131	BG 2001-105620	20010619
US 6423713	B1	20020723	US 2001-918481	20010731
HK 1040705	A1	20050304	HK 2003-102213	20020322
US 6617324	B2	20030909	US 2002-114297	20020402
US 2004176433	A1	20040909	US 2003-374781	20030225

PRIORITY APPL. INFO.:

US 1997-47570P	P	19970522
US 1998-83670	A2	19980522
US 1998-196623	A	19981120
EP 1999-965756	A3	19991117
WO 1999-US26007	W	19991117
US 2001-918481	A3	20010731
US 2002-114297	A3	20020402

OTHER SOURCE(S): MARPAT 138:137307

CI




AB Title compds. [I; R1 = H, OH, NH2, (cyclo)alk(en)yl, acyl, aryl, etc.; R2 = (un)substituted piperidinyl or piperazinyl; R3 = (un)substituted pyridinyl; R4 = (un)substituted phenyl; and pharmaceutically acceptable salts or tautomers thereof] were prepared by solution phase and solid phase parallel array reactions of ketones with hydrazines. Thus, R3CH2C(=O)Me (R3 = 4-pyridinyl) was condensed with 3,4-F(MeO)C6H3CHO to give the butenone (80%), which was cyclocondensed with TeNHNH2 to afford the title compound II (20.7%). The latter inhibited human p38 kinase activity in vitro with IC50 of 4.6 µM and inhibited tumor necrosis factor α (TNFα) and interleukin 1β (IL-1β) release from human peripheral blood mononuclear cells following stimulation with lipopolysaccharide with IC50 of 0.5 µM. Thus, I are useful for the treatment of inflammation, arthritis, asthma, and other disorders mediated by p38 kinase and TNFα.

IT 216518-34-2P
RL: CPM (Combinatorial preparation); PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); CMBI (Combinatorial study); PREP (Preparation); USES (Uses)
 [p38 kinase inhibitor; preparation of heteroarylpyrazole p38 kinase inhibitors by cyclocondensation of hydrazines with ketones]

RN 216518-34-2 CAPLUS

CN 2-Quinoxalinecarboxamide, N-[(1R)-1-(5-(4-fluorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl)-2-phenylethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 76 THERE ARE 76 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 80 OF 283 CAPLUS COPYRIGHT 2006 ACS ON STN
 ACCESSION NUMBER: 2003:5811 CAPLUS
 DOCUMENT NUMBER: 138:78458
 TITLE: Pharmaceutical compositions containing a solid dispersion of a poorly-soluble drug in a matrix and a solubility-enhancing polymer
 INVENTOR(S): Babcock, Walter Christian; Curatolo, William John; Friesen, Dwayne Thomas; Ketter, Rodney James; Lo, Julian Belknap; Nightingale, James Alan Schriver; Shanker, Ravi Mysore; West, James Blair
 PATENT ASSIGNEE(S): Pfizer Products Inc., USA
 SOURCE: PCT Int. Appl., 212 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003000294	A1	20030103	WO 2002-181800	20020513
WO 2003000294	C1	20031106		
W: AS, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW				
RM: GH, GM, KE, LS, MG, MW, MY, NA, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW				
CA 2448864	AA	20030103	CA 2002-2448864	20020513
EP 1401503	A1	20040311	EP 2002-733019	20020513
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
BR 2002010520	A	20040622	BR 2002-10520	20020513
JP 200500313	T2	20050106	JP 2003-506936	20020513
US 2003104063	A1	20030605	US 2002-175640	20020619
PRIORITY APPLN. INFO.:			US 2001-300261P	P 20010622
			WO 2002-181800	W 20020513

AB A pharmaceutical composition comprises a dispersion containing a low-solubility drug and a matrix combined with a concentration-enhancing polymer. At least a major portion of the drug is amorphous in the dispersion. The compns. improve the stability of the drug in the dispersion, and/or the concentration of drug in a use environment. For example, a solid drug/matrix dispersion comprised

RM: GH, GM, KE, LS, MG, MW, MY, NA, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW

CA 2450762

AA

20030103

CA 2002-2450762

20020508

NZ 529608

A

20031219

NZ 2002-529608

20020508

EP 1399190

A1

20040324

EP 2002-730571

20020508

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR

BR 200400033

A

20040615

BR 2004-33

20020508

BR 2002010530

A

20040622

BR 2002-10530

20020508

CN 1545421

A

20041110

CN 2002-816333

20020508

JP 2004514822

T2

20041118

JP 2003-506934

20020508

US 2003054038

A

20030320

US 2002-175566

20020617

ZA 2003008989

A

20041119

ZA 2003-8989

20031119

BG 108488

A

20050131

BG 2003-108488

20031122

US 2006003011

A1

20060105

US 2005-213118

20050826

US 2001-300256P

A1

20010622

WO 2002-181710

W 20020508

US 2002-175566

A1


20020617

AB Pharmaceutical compns. comprised of low-solubility and/or acid-sensitive drugs and neutralized acidic polymers are disclosed. A dispersion of the acid-sensitive drug quinoxaline-5,2-carboxylic acid (4(R)-carbamoyl-1-(S)-3-(fluorobenzyl)-2(S)-7-dihydroxy-7-methyloctyl) amide (I) 1.25%, neutralized acidic enteric polymer hydroxypropyl Me cellulose acetate succinate (II) 1.75%, and sodium acetate 0.51% in methanol/water (9/1) was prepared. Stability of I in the dispersions was determined after storage for five days at 40° and 75% RH. The stability of I was significantly improved in comparison to the stability of the dispersion with unneutralized II.

IT 212790-31-3
 RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses) (pharmaceutical compns. comprising low-solubility and/or acid-sensitive drugs and neutralized acidic polymers)

RM 212790-31-3 CAPLUS
 CN 2-Quinoxalinecarboxamide, N-[(1S,2S,4R)-4-(aminocarbonyl)-1-[(3-fluorophenyl)methyl]-2,7-dihydroxy-7-methyloctyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT


L5 ANSWER 82 OF 283 CAPLUS COPYRIGHT 2006 ACS ON STN
 ACCESSION NUMBER: 2003:5760 CAPLUS
 DOCUMENT NUMBER: 138:78451
 TITLE: Pharmaceutical compositions of adsorbates of amorphous drug
 INVENTOR(S): Babcock, Walter Christian; Friesen, Dwayne Thomas; Shanker, Ravi Mysore; Smithy, Daniel Tod; Tedday,

of 10% 3,5-dimethyl-4-(3'-pentoxy)-2-(2',4',6'-trimethylphenoxy)pyridine and 90% polyethylene glycol was prepared by a melt-congeal process. The solid drug/matrix dispersion was then combined with the concentration-enhancing polymer hydroxypropyl Me cellulose acetate succinate (HPMCAS). Addition of HPMCAS increased maximum concentration of drug in solution during the first 90 min (Cmax90) and the area under the aqueous concentration vs. time curve after 90 min (AUC90) by 1.12-fold and 1.19-fold, resp., compared to the solid drug/matrix dispersion with no concentration-enhancing polymer and by 2.36-fold and 2.25-fold, resp., compared to pure drug.

IT 212790-31-3
 RL: PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses) (compns. containing poorly-soluble drug/matrix solid dispersion and solubility-enhancing polymer)

RM 212790-31-3 CAPLUS
 CN 2-Quinoxalinecarboxamide, N-[(1S,2S,4R)-4-(aminocarbonyl)-1-[(3-fluorophenyl)methyl]-2,7-dihydroxy-7-methyloctyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 81 OF 283 CAPLUS COPYRIGHT 2006 ACS ON STN
 ACCESSION NUMBER: 2003:5809 CAPLUS
 DOCUMENT NUMBER: 138:61352
 TITLE: Pharmaceutical compositions comprising low-solubility and/or acid-sensitive drugs and neutralized acidic polymers

INVENTOR(S): Crew, Marshall David; Friesen, Dwayne Thomas; Ketter, Rodney James; Shanker, Ravi Mysore; West, James Blair
 PATENT ASSIGNEE(S): Pfizer Products Inc., USA
 SOURCE: PCT Int. Appl., 203 pp.
 CODEN: PIXXD2

DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003000292	A1	20030103	WO 2002-181710	20020508
W: AS, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW				

PATENT ASSIGNEE(S): Pfizer Products Inc., USA
 SOURCE: PCT Int. Appl., 218 pp.
 CODEN: PIXXD2

DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003000238	A1	20030103	WO 2002-181792	20020521
W: AS, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW				

RM: GH, GM, KE, LS, MG, MW, MY, NA, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW

CA 2448825

AA

20030103

CA 2002-2448825

20020521

EP 1404302

A1

20040407

EP 2002-730596

20020521

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR

BR 200400034

A

20040615

BR 2004-34

20020521

BR 2002010519

A

20040622

BR 2002-10519

20020521

CN 1521979

A

20040825

CN 2002-813503

20020521

JP 200501820

T2

20050120

JP 2003-506885

20020521

NZ 529490

A

20050826

NZ 2002-529490

20020521

US 2003054037

A1

20030320

US 2002-173987

20020617

ZA 2003008735

A

20040915

ZA 2003-8735

20031110

BG 108489

A

20040730

BG 2003-108489

20031222


PRIORITY APPLN. INFO.:
 | | US 2001-300260P | P 20010622 |

AB Pharmaceutical compns. comprise a low-solubility drug adsorbed onto a high surface area substrate to form an adsorbate. The compns. in some embodiments include a concentration-enhancing polymer. A drug/adsorbate adsorbate comprising quinoxaline-2-carboxylic acid(4(R)-carbamoyl-1-(S)-3-(fluorobenzyl)-2(S)-7-dihydroxy-7-methyloctyl)amide 10, and zinc oxide 90% (the substrate) was prepared. The Cmax,90 provided by the above adsorbate was 3.3-fold that of the crystalline control, while the AUC90 was 2.6-fold that of the control.

IT 212790-30-2 212790-31-3 479541-07-6
 RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses) (pharmaceutical compns. of adsorbates of amorphous drug)

RM 212790-30-2 CAPLUS
 CN 2-Quinoxalinecarboxamide, N-[(1S,2S,4R)-4-(aminocarbonyl)-1-[(3-fluorophenyl)methyl]-2,7-dihydroxy-7-methyloctyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RM 212790-31-3 CAPLUS
 CN 2-Quinoxalinecarboxamide, N-[(1S,2S,4R)-4-(aminocarbonyl)-1-[(3-

RN 474331-59-4 CAPLUS
CN 2-Quinoxalinecarboxamide, N-[2-(1-piperazinyl)-5-(trifluoromethyl)phenyl]-
(9CI) (CA INDEX NAME)

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2002161050	A1	20021031	US 2001-23288	20011217
US 6624196	B2	20030923		
US 6541531	B1	20030401	US 1999-351549	19990712
PRIORITY ASSIGN. INFO.:			US 1999-351549	A3 19990712
OTHER SOURCE(S):	MARPAT	137:337683		
GI				



AB The title compds. with general formula of I (wherein R1 = H, (cyclo)alkyl, (hetero)aryl, (hetero)aryalkyl, or heterocyclyl(alkyl); R2, R3a, R3, and R3a = independently H, P, RS, NR7CO-alkyl, alkanoyl(oxy), alkoxyarabonyl, alkanoylthio, NR7-alkyl, alkylsulfinyl, alkylsulfonyl(amino), CN, CF3, or (un)substituted alkyl-R5; R5 = H, (hetero)aryl, heterocyclyl,


N-naphthalimide, N-2,3-naphthylimide, indol-3-yl, imidazol-4-yl, pyridyl, 2,4-dioxo-1,5,5-triazolymethylimidazolidin-3-yl, or a side chain of an (un)naturally occurring amino acid; R₄ = SH, ORAc, or NSORAc; R₅a = H, (aryl)alkyl, cycloalkyl, or aryl(methoxy)methyl; R₆, ORAc, CSNR₆c, R₆dCO, CO₂R₆e, CO₂H, CH(OH), CO, CH(ORt)₂, C(CH₃)₂, OCSNR₆f, OCSNR₆g, OCSNR₆h, OCSNR₆i, OCSNR₆j, OCSNR₆k, OCSNR₆l, OCSNR₆m, OCSNR₆n, OCSNR₆o, OCSNR₆p, OCSNR₆q, OCSNR₆r, OCSNR₆s, OCSNR₆t, OCSNR₆u, OCSNR₆v, OCSNR₆w, OCSNR₆x, OCSNR₆y, OCSNR₆z, OCSNR₆aa, OCSNR₆ab, OCSNR₆ac, OCSNR₆ad, OCSNR₆ae, OCSNR₆af, OCSNR₆ag, OCSNR₆ah, OCSNR₆ai, OCSNR₆aj, OCSNR₆ak, OCSNR₆al, OCSNR₆am, OCSNR₆an, OCSNR₆ao, OCSNR₆ap, OCSNR₆aq, OCSNR₆ar, OCSNR₆as, OCSNR₆at, OCSNR₆au, OCSNR₆av, OCSNR₆aw, OCSNR₆ax, OCSNR₆ay, OCSNR₆az, OCSNR₆ba, OCSNR₆bb, OCSNR₆bc, OCSNR₆bd, OCSNR₆be, OCSNR₆bf, OCSNR₆bg, OCSNR₆bh, OCSNR₆bi, OCSNR₆bj, OCSNR₆bk, OCSNR₆bl, OCSNR₆bm, OCSNR₆bn, OCSNR₆bo, OCSNR₆bp, OCSNR₆bq, OCSNR₆br, OCSNR₆bs, OCSNR₆bt, OCSNR₆bu, OCSNR₆bv, OCSNR₆bw, OCSNR₆bx, OCSNR₆by, OCSNR₆bz, OCSNR₆ca, OCSNR₆cb, OCSNR₆cc, OCSNR₆cd, OCSNR₆ce, OCSNR₆cf, OCSNR₆cg, OCSNR₆ch, OCSNR₆ci, OCSNR₆cj, OCSNR₆ck, OCSNR₆cl, OCSNR₆cm, OCSNR₆cn, OCSNR₆co, OCSNR₆cp, OCSNR₆cq, OCSNR₆cr, OCSNR₆cs, OCSNR₆ct, OCSNR₆cu, OCSNR₆cv, OCSNR₆cw, OCSNR₆cx, OCSNR₆cy, OCSNR₆cz, OCSNR₆da, OCSNR₆db, OCSNR₆dc, OCSNR₆dd, OCSNR₆de, OCSNR₆df, OCSNR₆dg, OCSNR₆dh, OCSNR₆di, OCSNR₆dj, OCSNR₆dk, OCSNR₆dl, OCSNR₆dm, OCSNR₆dn, OCSNR₆do, OCSNR₆dp, OCSNR₆dq, OCSNR₆dr, OCSNR₆ds, OCSNR₆dt, OCSNR₆du, OCSNR₆dv, OCSNR₆dw, OCSNR₆dx, OCSNR₆dy, OCSNR₆dz, OCSNR₆ea, OCSNR₆eb, OCSNR₆ec, OCSNR₆ed, OCSNR₆ee, OCSNR₆ef, OCSNR₆eg, OCSNR₆eh, OCSNR₆ei, OCSNR₆ej, OCSNR₆ek, OCSNR₆el, OCSNR₆em, OCSNR₆en, OCSNR₆eo, OCSNR₆ep, OCSNR₆eq, OCSNR₆er, OCSNR₆es, OCSNR₆et, OCSNR₆eu, OCSNR₆ev, OCSNR₆ew, OCSNR₆ex, OCSNR₆ey, OCSNR₆ez, OCSNR₆fa, OCSNR₆fb, OCSNR₆fc, OCSNR₆fd, OCSNR₆fe, OCSNR₆ff, OCSNR₆fg, OCSNR₆fh, OCSNR₆fi, OCSNR₆fj, OCSNR₆fk, OCSNR₆fl, OCSNR₆fm, OCSNR₆fn, OCSNR₆fo, OCSNR₆fp, OCSNR₆fq, OCSNR₆fr, OCSNR₆fs, OCSNR₆ft, OCSNR₆fu, OCSNR₆fv, OCSNR₆fw, OCSNR₆fx, OCSNR₆fy, OCSNR₆fz, OCSNR₆ga, OCSNR₆gb, OCSNR₆gc, OCSNR₆gd, OCSNR₆ge, OCSNR₆gf, OCSNR₆gg, OCSNR₆gh, OCSNR₆gi, OCSNR₆gj, OCSNR₆gk, OCSNR₆gl, OCSNR₆gm, OCSNR₆gn, OCSNR₆go, OCSNR₆gp, OCSNR₆gq, OCSNR₆gr, OCSNR₆gs, OCSNR₆gt, OCSNR₆gu, OCSNR₆gv, OCSNR₆gw, OCSNR₆gx, OCSNR₆gy, OCSNR₆gz, OCSNR₆ha, OCSNR₆hb, OCSNR₆hc, OCSNR₆hd, OCSNR₆he, OCSNR₆hf, OCSNR₆hg, OCSNR₆hi, OCSNR₆hj, OCSNR₆hk, OCSNR₆hl, OCSNR₆hm, OCSNR₆hn, OCSNR₆ho, OCSNR₆hp, OCSNR₆hq, OCSNR₆hr, OCSNR₆hs, OCSNR₆ht, OCSNR₆hu, OCSNR₆hv, OCSNR₆hw, OCSNR₆hx, OCSNR₆hy, OCSNR₆hz, OCSNR₆ia, OCSNR₆ib, OCSNR₆ic, OCSNR₆id, OCSNR₆ie, OCSNR₆if, OCSNR₆ig, OCSNR₆ih, OCSNR₆ii, OCSNR₆ij, OCSNR₆ik, OCSNR₆il, OCSNR₆im, OCSNR₆in, OCSNR₆io, OCSNR₆ip, OCSNR₆iq, OCSNR₆ir, OCSNR₆is, OCSNR₆it, OCSNR₆iu, OCSNR₆iv, OCSNR₆iw, OCSNR₆ix, OCSNR₆iy, OCSNR₆iz, OCSNR₆ja, OCSNR₆jb, OCSNR₆jc, OCSNR₆jd, OCSNR₆je, OCSNR₆jf, OCSNR₆jj, OCSNR₆jh, OCSNR₆ji, OCSNR₆jj, OCSNR₆jk, OCSNR₆jl, OCSNR₆jm, OCSNR₆jn, OCSNR₆jo, OCSNR₆jp, OCSNR₆jq, OCSNR₆jr, OCSNR₆js, OCSNR₆jt, OCSNR₆ju, OCSNR₆jv, OCSNR₆jw, OCSNR₆jx, OCSNR₆ji, OCSNR₆jj, OCSNR₆jk, OCSNR₆jl, OCSNR₆jm, OCSNR₆jn, OCSNR₆jo, OCSNR₆jp, OCSNR₆jq, OCSNR₆jr, OCSNR₆js, OCSNR₆jt, OCSNR₆ju, OCSNR₆jv, OCSNR₆jw, OCSNR₆jx, OCSNR₆ji, OCSNR₆jj, OCSNR₆jk, OCSNR₆jl, OCSNR₆jm, OCSNR₆jn, OCSNR₆jo, OCSNR₆jp, OCSNR₆jq, OCSNR₆jr, OCSNR₆js, OCSNR₆jt, OCSNR₆ju, OCSNR₆jv, OCSNR₆jw, OCSNR₆jx, OCSNR₆ka, OCSNR₆kb, OCSNR₆kc, OCSNR₆kd, OCSNR₆ke, OCSNR₆kf, OCSNR₆kg, OCSNR₆kh, OCSNR₆ki, OCSNR₆kj, OCSNR₆kl, OCSNR₆km, OCSNR₆kn, OCSNR₆ko, O

by 1.0 M aqueous HCl to give 4-(4-aminophenyl)-4-oxobutyric acid. Subsequent esterification, amidation, and hydrolysis of the above compound afforded 4-(4-(4-methylbenzenesulfonyl)phenyl)-4-oxobutyric acid (II). It showed the activity vs. MPP-2CD, MPP-3CD, and MPP-13CD with IC50 values of 0.22 μM, 1.55 μM, and 5.0 μM, resp. It are useful for the treatment of multiple sclerosis, atherosclerotic plaque rupture, aortic aneurysms, heart failure, left ventricular dilation, restenosis, periodontal disease, corneal ulceration, treatment of burns, decubital ulcers, wound healing, cancer, inflammation, pain, arthritis, osteoporosis, renal disease, or other autoimmune or inflammatory disorders dependent upon tissue invasion by leukocytes or other activated migrating cells, acute and chronic neurodegenerative diseases including atrophic lateral sclerosis, amyotrophic lateral sclerosis, Alzheimer's disease, amyotrophic lateral sclerosis, cerebral aneurysm, angiodysplasia, AIDS, Parkinson's disease, Huntington's disease, prion diseases, myasthenia gravis, and Duchenne's muscular dystrophy (no date).

IT 474019-14-2P
RL: PAC (pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIO (Biological study); PREP (Preparation); USES (Uses)

(MPP inhibitor; preparation of benzenesulfonyl acids as inhibitors of matrix metalloproteinases)

RU 474019-14-2 CAPLUS
CN Benzenesulfonyl acid, γ-oxo-4-[(2-quinoxalinyloxy)amino]- (9CI)
CN (CA INDEX NAME)



L5 ANSWER 86 OF 283	CAPLUS COPYRIGHT 2006 ACS ON STN
ACCESSION NUMBER:	2002:754361 CAPLUS
DOCUMENT NUMBER:	137:729208
TITLE:	Preparation of [indazol-5-ylamino]quinazolinone as Rho-kinase inhibitors
INVENTOR(S):	Negerathnam, Dhanaapalan; Aegari, Davoud; Shao, Jianxing; Liu, Xiao-Gao; Khire, Uday; Wang, Chunguang; Licht, Barry; Boyer, Stephen; Weber, Olaf; Lynch, Mark; Bankston, Donald
PATENT ASSIGNEE(S):	Bayer Corporation, USA
SOURCE:	PCT Int. Appl., 74 pp. CODEN: PIXDD2
DOCUMENT TYPE:	PATENT

LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002076976	A2	20021003	WO 2002-US8659	20020322
WO 2002076976	A3	20021212		
W: AS, AO, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GR, GM, HR, HU, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MY, NZ, PH, PL, PT, RU, RV, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW				
RM: GH, GM, KE, LS, MG, MO, MT, MU, NI, NL, NO, NZ, OM, PA, PG, PH, PK, PY, RE, RW, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW				
CA 2441492	AA	20021003	CA 2002-2441492	20020322
US 2003125344	A1	20030703	US 2002-103566	20020322
EP 1370593	A2	20031127	EP 2002-719303	20020322
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
JP 2004524350	T2	20040812	JP 2002-576234	20020322
US 2003220357	A1	20031127	US 2002-252369	20020924
CA 2507381	AA	20040808	CA 2003-2507381	20020924
WO 2004029045	A2	20040407	WO 2003-US29538	20020924
WO 2004029045	A3	20040722		
W: AS, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GR, GM, HR, HU, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MY, NZ, OM, PA, PG, PH, PL, PT, RU, RV, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RM: GH, GM, KE, LS, MG, MT, SD, SL, SZ, TJ, TM, TR, TT, UA, UG, US, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IL, IT, LU, MC, NL, PT, RO, SE, SI, SK, SL, TR, TT, BF, BJ, CF, CG, CI, CM, GN, GQ, GT, HT, IG, LI, LU, NL, SE, SN, TO, TZ, UG, UZ, VN, YU, ZA, ZM, ZW				
AU 2003270785	A1	20040419	AU 2003-270785	20030924
EP 1542992	A2	20050622	EP 2003-752497	20030924
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, DE, HU, KG, NO, OM, PA, PG, PH, PK, PY, RE, RW, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW				
PRIORITY APPL. INFO.:				
			US 2001-115341P	20010829
			WO 2002-US8659	W 20020322
			US 2002-252369	A 20020924
			WO 2003-US29538	N 20030924
OTHER SOURCE(S):		CASREACT 137:729208	MARPAT 137:729208	
Q1				

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB Title compds. I [Y = N, CR17; X = alkyl, alkoxy, thialkoxy, amido, etc.; p = 0-3; a, c = CRS, NR6, etc.; b = CRS, N; A = H, halo, carboxy, cyano, alkoxy, etc.]; B = (un)substituted up to 3 times in any position by RS; R = H, alkyl, aryl, alkoxy, thioalkoxy, etc.; CR18 = 1-4, 1,3,5-trisubstituted benzene provisions) were prepared. For instance, 2,4-Dichloroquinazoline (preparation given) was reacted with 5-aminoindazole (TSP/H₂O, KOAc) to give 2,4-Dichloro-5-amino-6-methylquinazoline which was chloromethylated with SOCl₂. This coupled to 2,4-dichlorophenylboronic acid (ethylene glycol Di Me ether, Pd(dppf)Cl₂, NaHCO₃, reflux) to give II. I are rho-kinase inhibitors and are useful for inhibiting tumor growth. treating erectile dysfunction and



IT 461036-92-0P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
(Reactant or reagent)
(intermediate; preparation of (indazol-5-ylamino)quinazolines as Rho-kinase
inhibitors)

RN 461036-92-0 CAPLUS
CN 2-Quinoxalinecarboxamide, N-(2-cyanophenyl)- (9CI) (CA INDEX NAME)



L5	ANSWER 87 OF 263	CAPLUS	COPYRIGHT 2006 ACS ON STN
ACCESSION NUMBER:	2002:754339	CAPLUS	
DOCUMENT NUMBER:	137:29100		
TITLE:	Preparation of non-imidazole aryl alkylamines as histamine H3 receptor antagonists		
INVENTOR(S):	Beavers, Lisa Selman; Oadeki, Robert Alan; Hipekind, Philip Arthur; Lindseley, Craig William; Lobb, Karen Lynn; Nixon, James Arthur; Pickard, Richard Todd; Schaus, John Mehmet; Takakuwa, Takako; Watson, Brian Morgan		
PATENT ASSIGNEE(S):	Eli Lilly and Company, USA		
SOURCE:	PCT Int. Appl., 202 pp. CODEN: PIXXD2		
DOCUMENT TYPE:	Patent		
LANGUAGE:	English		
FAMILY ACC. NUM. COUNT:	1		
PATENT INFORMATION:			


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002076925	A2	20021003	WO 2002-US6644	20020321
WO 2002076925	A3	20030918		
W:	AS, AG, AI, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, C1, DE, DK, DM, DZ, ES, FI, GB, GD, GE, GR, HK, HR, HU, ID, IL, IN, IS, JP, KE, KP, KR, KZ, LG, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MM, MX, MZ, NO, NZ, OM, PH, PL, PT, RU, RD, SE, SG, SO, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW			
RM:	GR, GM, KG, KM, KW, KX, MW, ME, MC, MD, ME, MG, MK, MN, MM, MU, MV, MY, NZ, OM, PA, PE, PG, PH, PK, PL, PT, RU, RD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW			
GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BP, CB, CP, CO, CI, CM, CA, GN, GO, GW, ML, MR, NE, SN, TD, TG				
CA 2441080	AA	20021003	CA 2002-2441080	20020321
EP 1379493	AA	20040114	EP 2002-723329	20020321
R: AT, BR, CH, DE, DK, ES, FR, GB, GR, IT, IL, LU, NL, SE, MC, PT, SI, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
JP 2004532834	T2	20041028	JP 2002-576188	20020321
US 2004110748		US 2003-472675	US 2001-278210P	20020318
PRIORITY APPLN. INFO.:			WO 2002-US6644	W 20020321
OTHER SOURCE(S):		HARPAT 137:279100		
GI				




AB The title compds. [I: X = O, NR7; S; R1 = H, alkyl, haloalkyl, etc.; R2 = R1, COR1; or NR1R2 = (un)substituted 4-6 membered carbon ring wherein one of said carbons is optionally replaced by one of O, S, NR1 or CO; R3 = cycloalkylene, (un)substituted alkylene; R4 = H, halo, alkyl, etc.; R5 = H, alkyl; R6 = H, halo, etc.; R7 = H, alkyl, haloalkyl, etc.; R8 = R, a bond, alkyl, etc.] and their pharmaceutically acceptable salts which have selective histamine-H3 receptor antagonist activity (biol. data given), and are useful in treating obesity and other histamine H3 receptor-related diseases, were prepared. Thus, reacting p-hydroxyacetophenone with 3-chloro-N,N-diethyl-N-propylamine in the presence of NaH in THF and DMF (92% yield) followed by reductive amination of the resulting intermediate with 2-(dimethylamino)ethylamine in the presence of MeCN/H3 in EtOH afforded 93% II.

IT 464898-03-1P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
[preparation of non-imidazole aryl alkylamines as histamine H3 receptor antagonists]

RN 464898-03-1 CAPLUS
CN 2-Quinoxalylcarboxamide, N-[[4-(3-(diethylamino)propoxy)phenyl]methyl]-(9CI) (CA INDEX NAME)




L5 ANSWER 88 OF 283 CAPLUS COPYRIGHT 2006 ACS ON STN
ACCESSION NUMBER: 2002:675985 CAPLUS
DOCUMENT NUMBER: 137:201606
TITLE: Preparation of bicyclic excitatory amino acid derivatives
INVENTOR(S): Massey, Steven Marc; Monn, James Allen; Prieto, Lourdes; Valli, Matthew John
PATENT ASSIGNEE(S): Eli Lilly and Company, USA
SOURCE: PCT Int. Appl., 187 pp.
CODEN: PIXXD2



RN 452976-51-1 CAPLUS
CN Bicyclo[3.1.0]hexane-2,6-dicarboxylic acid, 2-amino-4-[(2-quinoxalylcarbonyl)amino]-, hydrochloride (5:2), (1R,2R,4R,5S,6R)-rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



● 2/5 HCl

IT 452976-38-4P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
[preparation of bicyclic excitatory amino acid derivs.]
RN 452976-38-4 CAPLUS
CN Bicyclo[3.1.0]hexane-2,6-dicarboxylic acid, 2-[(1,1-dimethylethoxy)carbonyl]amino-4-[(2-quinoxalylcarbonyl)amino]-, diethyl ester, (1R,2R,4R,5S,6R)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



REFERENCE COUNT: 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT


L5 ANSWER 89 OF 283 CAPLUS COPYRIGHT 2006 ACS ON STN
ACCESSION NUMBER: 2002:674636 CAPLUS

DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002068380	A1	20020906	WO 2002-US1247	20020212
WO 2002068380	C1	20050623		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GR, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MY, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW				
RM: GH, GM, KE, LS, MW, MG, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GO, GW, ML, MR, NE, NG, SN, TD, TG				
EP 1370519	A1	20031217	EP 2002-705812	20020212
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
US 2004116489	A1	20040617	US 2003-467429	20031208
PRIORITY APPL. INFO.: US 2001-270512P P 20010222				
US 2001-340607P P 20010300				
WO 2002-US1247 W 20020212				

OTHER SOURCE(S): MARPAT 137:201606

GI



AB Bicyclic amino acids I [X = CH2, O, NH; Y = O, S, N, H2; A = a bond, O, N, C1-10 alkyl, C2-10 alkenyl or alkynyl, (un)substituted aryl, heterocyclyl or the group XC(Y)AR is 2-benzothiazolylmethyl, 2-benzothiazolylmethyl, or 2-benzimidazolylmethyl] or their pharmaceutically acceptable salts were prepared as modulators of metabotropic glutamate receptor function and are useful in the treatment of neural and psychiatric disorders. Thus, (1S*,2S*,4S*,5R*,6S*)-2-amino-4-[3-(3-chlorophenyl)ureido]bicyclo[3.1.0]hexane-2,6-dicarboxylic acid [I: XC(Y)AR = 3-(3-chlorophenyl)ureido] (claimed compound) was prepared by treatment of (1S*,2S*,4S*,5R*,6S*)-2-[(tert-butoxycarbonyl)amino]-4-aminobicyclo[3.1.0]hexane-2,6-dicarboxylic acid di-tert-butyl ester (preparation given) with 3-chlorophenyl isocyanate in CH2Cl2 and then HCl gas in EtOAc. Comps. of the invention have improved affinity for the mGlu3 receptors when compared to compds. of United States patent 5,958,960.

IT 452974-70-8P 452976-51-1P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
[preparation of bicyclic excitatory amino acid derivs.]

RN 452974-70-8 CAPLUS
CN Bicyclo[3.1.0]hexane-2,6-dicarboxylic acid, 2-amino-4-[(2-quinoxalylcarbonyl)amino]-, (1R,2R,4R,5S,6R)-rel- (9CI) (CA INDEX NAME)



Relative stereochemistry.

DOCUMENT NUMBER: 137:185515
TITLE: Preparation of acylated indenyl amines and their use as remedies in upregulation of endothelial nitric oxide synthase
INVENTOR(S): Strobel, Hartmut; Mohlfart, Paulus; Seferova, Alene; Walsae, Armin; Suzuki, Teri; Dharanipragada, Ramalinga M.
PATENT ASSIGNEE(S): Aventis Pharma Deutschland GmbH, Germany
SOURCE: PCT Int. Appl., 137 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002084545	A1	20020822	WO 2002-EP1444	20020212
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GR, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MY, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GO, GW, ML, MR, NE, NG, SN, TD, TG				
CA 2437944	AA	20020822	CA 2002-2437944	20020212
SE 200300369	A	20031015	SE 2003-169	20020212
EP 1373191	A1	20040102	EP 2002-722067	20020212
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
BR 2002007211	A	20040127	BR 2002-7211	20020212
CN 1491207	A	20040421	CN 2002-804836	20020212
JP 2004518719	T2	20040624	JP 2002-564478	20020212
NZ 527470	A	20050429	NZ 2002-527470	20020212
US 2003050959	A1	20030320	US 2002-73160	20020212
ZA 2003005413	A	20040428	ZA 2003-5413	20030714
BO 108076	A	20050531	BO 2003-108076	20030807
NO 2003003565	A	20031013	NO 2003-3565	20030812
PRIORITY APPL. INFO.: EP 2001-102850 A 20010213				
WO 2002-EP1444 W 20020212				

OTHER SOURCE(S): MARPAT 137:185515

GI




II

AB Title compds. [1; R1-R4 =; A = CH₂, CHOR, CH(C1-C3-alkyl); B = CH₂, CH(C1-C3-alkyl); R5 = aryl, heteroaryl] are prepared and are useful in the upregulation of endothelial nitric oxide synthase (eNOS). Title compds. 1 may therefore be useful for the manufacture of medicaments for the treatment of cardiovascular diseases, stable or unstable angina pectoris, coronary heart disease, Prinzmetal angina, acute coronary syndrome, heart failure, myocardial infarction, stroke, thrombosis, peripheral artery occlusive disease, endothelial dysfunction, atherosclerosis, restenosis, endothelial damage after PTCA (percutaneous transluminal coronary angioplasty), hypertension, essential hypertension, pulmonary hypertension, secondary hypertension, renovascular hypertension, chronic glomerulonephritis, erectile dysfunction, ventricular arrhythmia, diabetes or diabetes complications, nephropathy or retinopathy, angiogenesis, asthma bronchial, chronic renal failure, cirrhosis of the liver, osteoporosis, restricted memory performance, a restricted ability to learn, or for the lowering of cardiovascular risk of postmenopausal women or after intake of contraceptives. Thus, the title compound 11 was prepared from 2-amino-4-methylindane and 4-fluorobenzoyl chloride, purified by HPLC and was in vitro tested on human umbilical vein cord endothelial cells for activation effect of eNOS transcription with EC-50 (μM) = 6.0 and TIR(max) = 2.80.

IT 226878-15-5P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); TRU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(Preparation method of acylated indanyl amines and use as remedies in upregulation of endothelial nitric oxide synthase)

RN 226878-15-5 CAPLUS
CN 2-Quinoxalinecarboxamide, N-(2,3-dihydro-1H-inden-2-yl)- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

LS ANSWER 90 OF 283 CAPLUS COPYRIGHT 2006 ACS ON STN

ACCESSION NUMBER: 2002:560149 CAPLUS

DOCUMENT NUMBER: 138:24692

TITLE: Some reactions with quinoxaline-2,3-dicarboxylic acid anhydride: Novel synthesis of thieno[2,3-d]pyrimidines and pyrrolo[3,4-b]quinoxalines as antimicrobial agents
AUTHOR(S): Ammar, Y. A.; Ismail, M. M. F.; El-Gaby, M. S. A.; Zahran, M. A.

CORPORATE SOURCE: Chemistry Department, Faculty of Science, Al-Azhar University, Nasr City, Egypt

SOURCE: Indian Journal of Chemistry, Section B: Organic Chemistry Including Medicinal Chemistry (2002), 41B(7), 1485-1491
CODEN: IJSCDH; ISSN: 0376-4699

PUBLISHER: National Institute of Science Communication

DOCUMENT TYPE: Journal


LANGUAGE: English

OTHER SOURCE(S): CASREACT 138:24692

AB The reactivity of quinoxaline-2,3-dicarboxylic anhydride (I) towards some heterocyclic amines as N nucleophiles was studied. E.g., treatment of I with 2-aminobenzothiophenes led to preparation of polyheterocyclic compds.


such as pyrroloquinoxalines and thieno[2,3-d]pyrimidines. Some quinoxaline derivs. were tested for their antibacterial and antifungal activity. None of the tested compds. showed activity superior to that of Streptomycin or Mycoatatin.

IT 478060-41-2P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
(Preparation and antimicrobial activity of benzothienylaminocarbonylquinoxalines)
RN 478060-41-2 CAPLUS
CN Benzo[b]thiophene-3-carboxylic acid, 4,5,6,7-tetrahydro-2-[[[3-[[[4-methylphenyl]amino]carbonyl]-2-quinoxaliny]carbonyl]amino]-, ethyl ester (9CI) (CA INDEX NAME)




IT 478060-43-4P 478060-45-6P
RL: SPN (Synthetic preparation); PREP (Preparation)
(reaction of quinoxaline-2,3-dicarboxylic anhydride with aminobenzothiophenes)

RN 478060-43-4 CAPLUS
CN Benzo[b]thiophene-3-carboxylic acid, 4,5,6,7-tetrahydro-2-[[[3-[[[4-methylphenyl]amino]carbonyl]-2-quinoxaliny]carbonyl]amino]-, ethyl ester (9CI) (CA INDEX NAME)



RN 478060-45-6 CAPLUS
CN Benzo[b]thiophene-3-carboxylic acid, 2-[[[3-[[[4-chlorophenyl]amino]carbonyl]-2-quinoxaliny]carbonyl]amino]-4,5,6,7-tetrahydro-, ethyl ester (9CI) (CA INDEX NAME)



REFERENCE COUNT: 18 THERE ARE 18 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

LS ANSWER 91 OF 283 CAPLUS COPYRIGHT 2006 ACS ON STN

ACCESSION NUMBER: 2002:560146 CAPLUS

DOCUMENT NUMBER: 138:24691

TITLE: Synthesis of novel quinoxaline carboxylic acid derivatives for antimicrobial investigation

AUTHOR(S): El-Gaby, M. S. A.; Ismail, M. M. F.; Ammar, Y. A.; Zahran, M. A.; Shmeiss, N. A. M. M.

CORPORATE SOURCE: Chemistry Department, Faculty of Science, Al-Azhar University at Assiut, Assiut, 71524, Egypt

SOURCE: Indian Journal of Chemistry, Section B: Organic Chemistry Including Medicinal Chemistry (2002), 41B(7), 1480-1485
CODEN: IJSCDH; ISSN: 0376-4699

PUBLISHER: National Institute of Science Communication

DOCUMENT TYPE: Journal

LANGUAGE: English

OTHER SOURCE(S): CASREACT 138:24691


AB Treatment of 6,7-dimethylquinoxaline-2,3-dicarboxylic acid anhydride with binucleophiles such as phenylenediamines and aminophenols led to 2-aminocarbonylquinoxaline-3-carboxylic acid derivs. such as quinoxalinecarboxamides and pyrrolo[3,4-b]quinoxalines. Some of the prepared compds. were tested in vitro for their antimicrobial activities. 6,7-Dimethyl-2-(4-chlorobenzylideneaminophenylamino)carbonylquinoxaline-3-carboxylic acid exhibited the best bactericidal and fungicidal activity.

IT 478048-93-0P 478049-01-1P 478049-09-1P
478049-13-7P 478049-15-9P 478049-17-1P
478049-23-9P 478049-25-1P


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)

(Preparation and antimicrobial activity of quinoxaline derivs.)



RN 478048-93-0 CAPLUS
CN 2-Quinoxalinecarboxylic acid, 3,3'-[[1,4-phenylenebis(iminocarbonyl)]bis[6,7-dimethyl- (9CI) (CA INDEX NAME)




RN 478049-01-3 CAPLUS
CN 2-Quinoxalinecarboxylic acid, 3-[[[2-(acetylamino)phenyl]amino]carbonyl]-6,7-dimethyl- (9CI) (CA INDEX NAME)




RN 478049-09-1 CAPLUS
CN 2,3-Quinoxalinecarboxamide, N-[4-(acetylamino)phenyl]-6,7-dimethyl-N'-(4-methylphenyl)- (9CI) (CA INDEX NAME)




RN 478049-13-7 CAPLUS
CN 2-Quinoxalinecarboxylic acid, 3-[[[4-[[[4-chlorophenyl]methylene]amino]phenyl]amino]carbonyl]-6,7-dimethyl- (9CI) (CA INDEX NAME)




RN 478049-15-9 CAPLUS
CN 2-Quinoxalinecarboxamide, N-[4-[[[4-methoxyphenyl]methylene]amino]phenyl]-6,7-dimethyl- (9CI) (CA INDEX NAME)




RN 478049-17-1 CAPLUS
CN 2-Quinoxalinecarboxamide, N-[4-[[[4-chlorophenyl]methylene]amino]phenyl]-6,7-dimethyl- (9CI) (CA INDEX NAME)




RN 478049-23-9 CAPLUS
CN 2-Quinoxalinecarboxylic acid, 3-[[[4-aminophenyl]amino]carbonyl]-6,7-dimethyl- (9CI) (CA INDEX NAME)




RN 478049-25-1 CAPLUS
CN 2-Quinoxalinecarboxylic acid, 3-[[[2-aminophenyl]amino]carbonyl]-6,7-dimethyl- (9CI) (CA INDEX NAME)




IT 478048-85-0P 478048-87-2P 478048-89-4P
478048-91-6P 478048-99-6P 478049-07-9P
478049-11-5P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of pyrroloquinoxalines and quinoxalinecarboxamides)
RN 478048-85-0 CAPLUS
CN 2-Quinoxalinecarboxylic acid, 3-[[[2-amino-5-methylphenyl]amino]carbonyl]-6,7-dimethyl- (9CI) (CA INDEX NAME)




RN 478048-87-2 CAPLUS
CN 2-Quinoxalinecarboxylic acid, 3-[[[2-hydroxyphenyl]amino]carbonyl]-6,7-dimethyl- (9CI) (CA INDEX NAME)




RN 478048-89-4 CAPLUS
CN 2-Quinoxalinecarboxylic acid, 3-[[[5-chloro-2-hydroxyphenyl]amino]carbonyl]-6,7-dimethyl- (9CI) (CA INDEX NAME)




RN 478048-91-6 CAPLUS
CN 2-Quinoxalinecarboxylic acid, 3,3'-[[1,2-phenylenebis(iminocarbonyl)]bis]-6,7-dimethyl- (9CI) (CA INDEX NAME)




RN 478048-99-6 CAPLUS
CN 2-Quinoxalinecarboxylic acid, 3-[[[4-(acetylamino)phenyl]amino]carbonyl]-6,7-dimethyl- (9CI) (CA INDEX NAME)



RN 478049-07-9 CAPLUS
CN 2,3-Quinoxalinedicarboxamide, N-[4-(acetylamino)phenyl]-N'-(4-chlorophenyl)-6,7-dimethyl- (9CI) (CA INDEX NAME)



RN 478049-11-5 CAPLUS
CN 2-Quinoxalinecarboxylic acid, 3-[[[4-((4-methoxyphenyl)methylene)amino]phenyl]amino]carbonyl]-6,7-dimethyl- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 12 THERE ARE 12 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT


L5 ANSWER 92 OF 283 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2002:487387 CAPLUS
DOCUMENT NUMBER: 137:63257
TITLE: Preparation of benzamides as inhibitors of production and release of inflammatory cytokines
INVENTOR(S): Muto, Susumu; Nagano, Tatsu; Saitome, Tomomi; Itai, Akiko
PATENT ASSIGNEE(S): Institute of Medicinal Molecular Design Inc., Japan
SOURCE: PCT Int. Appl., 313 pp.
CODEN: PIKX2
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002049632	A1	20020627	WO 2001-JP11084	20011218
W: AS, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, ME, MG, MK, MN, MX, MY, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, RW, GH, GM, KE, LS, MW, MZ, SD, SI, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CP, CO, CI, CN, GA, GN, GD, GW, ML, MR, NE, SN, TD, TG				
CA 2431083	A1	20020627	CA 2001-2631083	20011218
AU 2002022683	A5	20020701	AU 2002-22683	20011218
EP 1352650	A1	20031015	EP 2001-271124	20011218
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
US 2004259877	A1	20041223	US 2004-433619	20040219

PRIORITY APPLN. INFO.:

JP 2000-383202 A 20001218
WO 2001-JP11084 W 20011218

OTHER SOURCE(S): MARPAT 137:63257
OI




AB The title compds. 1 (wherein X is a connecting group; A is hydrogen or acetyl; E is aryl or heteroaryl; and Z is arene or heteroarene) are prepared in an in vitro test using cells, 5-chloro-2-hydroxy-N-(4-methoxynaphthalen-2-yl)benzamide at 1 µg/mL gave 95.1% inhibition of NF-κB activation.

IT 439144-03-3P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of benzamides as inhibitors of production and release of inflammatory cytokines)

RN 439144-03-3 CAPLUS
CN 2-Quinoxalinecarboxamide, N-[3,5-bis(trifluoromethyl)phenyl]-3,4-dihydro-3-oxo- (9CI) (CA INDEX NAME)




REFERENCE COUNT: 15 THERE ARE 15 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 93 OF 283 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2002:424638 CAPLUS
DOCUMENT NUMBER: 137:140770
TITLE: A Novel Peptide-Based Encoding System for "One-Bead One-Compound" Peptidomimetic and Small Molecule Combinatorial Libraries
AUTHOR(S): Liu, Ruiwu; Merik, Jan; Lam, Kit S.
CORPORATE SOURCE: Division of Hematology & Oncology Department of Internal Medicine, UC Davis Cancer Center University of California Davis, Sacramento, CA, 95817, USA
SOURCE: Journal of the American Chemical Society (2002), 124(26), 7678-7680
CODEN: JACSAT; ISSN: 0002-7863
PUBLISHER: American Chemical Society
DOCUMENT TYPE: Journal
LANGUAGE: English
AB The "one-bead one-compound" (OBOC) combinatorial library method is highly efficient, especially when used with well-established on-bead binding or functional assays. Literally, millions of compds. can be screened concurrently within 1 to 2 days. However, structure determination of

peptidomimetic and small mol. compds. on one single bead is not trivial. A novel, highly efficient, and robust peptide-based encoding system has been developed for OBOC peptidomimetic and small mol. combinatorial libraries. In this system, topol. segregated bifunctional beads, which are made by a simple biphasic solvent strategy, are employed for the preparation and screening of an OBOC combinatorial peptidomimetic and small mol. libraries. Testing mols. are on the outer layer, and the coding tags in the interior of the bead do not interfere with screening. The coding tag is a peptide containing a large number of unnatural α -amino acids derived from different building blocks used for generating the peptidomimetic or small mol. By coupling common building blocks simultaneously to the scaffold of the testing compound and to the side chains of the α -amino acids on the coding peptide, extra synthetic steps are eliminated and the amount of undesirable side products is minimized. Pos. bead decoding is easy and straightforward as there is no need for cleavage and retrieval of the coding tag, and pos. beads can be sequenced directly with Edman degradation. The authors demonstrate the efficiency and simplicity of their peptidyl encoding system by generating an encoded 158 400-member model peptidomimetic library and screening it for ligands that bind to streptavidin. Potent and novel ligands with clear motifs have been identified.

IT 444795-41-9
 RL: CUS (Combinatorial use); PRP (Properties); CMGI (Combinatorial study);
 USES (Uses)
 (HPLC retention times of aminophenylalanine phenylisothiocyanate
 deriva. used in the encoding system for the "one-bead one-compound"
 combinatorial peptide library)
 RN 444795-41-9 CAPLUS
 CN 2-Quinoxalinecarboxamide, 3,4-dihydro-3-oxo-N-[4-[[[4(5)-5-oxo-1-phenyl-2-thioxo-4-imidazolidinyl]methyl]phenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.





REFERENCE COUNT: 11 THERE ARE 11 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 94 OF 283 CAPLUS COPYRIGHT 2006 ACS ON STN
 ACCESSION NUMBER: 2002:348242 CAPLUS
 DOCUMENT NUMBER: 137:63231
 TITLE: Synthesis of Zwitterionic Compounds: Fully Saturated Pyrimidinyl and 1,3-Diazepinyl Derivatives via the Novel Rearrangement of 3-Oxobutanoic Acid Thioamide Derivatives
 AUTHOR(S): Zaleska, Barbara; Bazanek, Tomasz; Socha, Robert; Karelus, Marcin; Grochowaki, Jacek; Serda, Paweł
 CORPORATE SOURCE: Department of Organic Chemistry and Regional Laboratory of Physicochemical Analyses and Structural Research, Jagiellonian University, Krakow, PL 30-060, Pol.
 SOURCE: Journal of Organic Chemistry (2002), 67(13), 4526-4529


INVENTOR(S): Sakurai, Minoru; Washizuka, Kenichi; Hamashima, Hitoshi; Tomishima, Yasuo; Imanishi, Masashi; Nakajima, Yutaka; Ohtake, Hiroaki; Korada, Satoru; Murata, Masayoshi; Kayakiri, Hiroshi; Fujii, Naoki; Taniguchi, Kiyoshi
 PATENT ASSIGNEE(S): Fujisawa Pharmaceutical Co., Ltd., Japan
 SOURCE: PCT Int. Appl., 112 pp.
 CODEN: PIXK02
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002024635	A2	20020328	WO 2001-JP8155	20010919
WO 2002024635	A3	20020328		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GR, HU, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW				
RW: GH, GM, KE, LG, MH, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2001090246	A5	20020402	AU 2001-90246	20010919
JP 20040509162	T2	20040325	JP 2002-528649	20010919
US 2004037022	A1	20040226	US 2003-380627	20030321
US 6826033	B2	20041130		
PRIORITY APPL. INFO.: AU 2000-340 A 20000925 WO 2001-JP8155 W 20010919				
OTHER SOURCE(S): MARPAT 136:279196				
OI				




AB Title compds. I [X1 = bond, OCH2; X2 = (NR2CO)n, NHCOY1; R2 = H, alkyl; n = 1-2; Y1 = NR3; R3 = H, alkyl, etc.; R1 = H, amino protective group; A = Ph, indolyl, carbazolyl; B = H, halo, alkyl, alkoxy, carbonyl, cycloalkyl, heterocyclic, naphthyl, 1,2,3,4-tetrahydronaphthyl, benzyl, phenyl] were prepared. For instance, (2S)-2-(phenoxyethyl)oxirane was reacted with


PUBLISHER: CODEN: JOCEAH; ISSN: 0022-3263
 American Chemical Society
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 OTHER SOURCE(S): CASREACT 137:63231
 AB An unusual rearrangement following cyclization of 2-anilino-2-ethoxy-3-oxothiobutanoic acid with aliphatic 1,3- as well as 1,4-diamine leads to zwitterionic deriva. of 2-hydroxypropanoic acid. Moreover, with aromatic 1,2-diamines, fused heterocyclic systems such as pteridine, quinoxaline, and pyrido[2,3-b]pyrazine are obtained.
 IT 439863-91-9
 RL: SPM (Synthetic preparation); PREP (Preparation)
 (preparation of zwitterionic deriva. of pyrimidine and diazepine compds. from reaction of 2-anilino-2-ethoxy-3-oxothiobutanoic acid and aliphatic diamines)
 RN 439863-91-9 CAPLUS
 CN 2-Quinoxalinecarboxamide, 3-methyl-N-phenyl- (9CI) (CA INDEX NAME)



RN 439863-92-0 CAPLUS
 CN Pyrido[2,3-b]pyrazine-3-carboxamide, 2-methyl-N-phenyl- (9CI) (CA INDEX NAME)



RN 439863-93-1 CAPLUS
 CN 7-Pteridinecarboxamide, 1,2,3,4-tetrahydro-1,3,6-trimethyl-2,4-dioxo-N-phenyl- (9CI) (CA INDEX NAME)




REFERENCE COUNT: 28 THERE ARE 28 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 95 OF 283 CAPLUS COPYRIGHT 2006 ACS ON STN
 ACCESSION NUMBER: 2002:240716 CAPLUS
 DOCUMENT NUMBER: 136:279196
 TITLE: Preparation and use of amino alcohol derivatives for treatment of urinary incontinence

(2S)-2-amino-3-(4-nitrophenyl)-1-propanol to give (2S)-3-(4-nitrophenyl)-2-[[[(2S)-2-hydroxy-3-phenoxypropyl]amino]-1-propanol. This intermediate was protected as the N-Boc derivative which was then reduced (MeOH, 10% Pd-C, H2-1 atm) to give the corresponding aminophenyl derivative Carbodiimide coupling of this amine with 3-carboxypyrrole followed by deprotection provided 11. 11 showed 2.6 ± 0.05 mm Hg increase in intravesical pressure (compared to 7.0 ± 1.0 mm Hg control) induced by carbachol in anesthetized dog. 1 are useful for the prophylactic and/or the therapeutic treatment of pollakiures or urinary incontinence.
 IT 406168-15-8P
 RL: PAC (Pharmacological activity); SPM (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (drug: preparation and use of amino alc. deriva. for treatment of urinary incontinence)
 RN 406168-15-8 CAPLUS
 CN 2-Quinoxalinecarboxamide, N-[[[(2S)-2-[[[(2R)-2-(3-chlorophenyl)-2-hydroxyethyl]amino]-3-hydroxypropyl]phenyl]-, mono(trifluoroacetate) (salt) (9CI) (CA INDEX NAME)

CM 1
 CRN 406168-14-7
 CMF C26 H25 Cl N4 O3

Absolute stereochemistry.



CM 2
 CRN 76-05-1
 CMF C2 H F3 O2



L5 ANSWER 96 OF 283 CAPLUS COPYRIGHT 2006 ACS ON STN
 ACCESSION NUMBER: 2002:182202 CAPLUS
 DOCUMENT NUMBER: 136:222317
 TITLE: Preparation of heterocyclylbenzenes as herbicides and defoliants
 INVENTOR(S): Gupta, Sandeep; Wu, Shao-Yong; Tsukamoto, Masamitsu; Pulman, David A.; Ying, Bai-Ping
 PATENT ASSIGNEE(S): ISK America Incorporated, USA

SOURCE: U.S., 74 pp., Cont.-in-part of U.S. Ser. No. 958,313.
CODEN: USXXAM
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 6355799	B1	20020312	US 2000-530373	20000427
WO 9921837	A1	19990506	WO 1998-US17197	19980821

W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GR, GM, HR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VM, YU, ZW, AM, AZ, BY, BD, KE, MD, RU, TJ, TM, CH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SF, BJ, CF, CO, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

US 2002133007 A1 20020919 US 2001-930149 20010816
US 6545161 B2 20030408

PRIORITY APPLN. INFO.: US 1997-958313 A2 19971027
WO 1998-US17197 W 19980821
US 2000-530373 A3 20000427

OTHER SOURCE(S): MARPAT 136:212317
GI



AB Title compds. I: X = H, halo, NO2, amino, NHR, NR2, amide, thioamide, cyano, alkylcarbonyl, alkoxy, haloalkoxy, alkoxy, heteroalkoxy, aryloxy, heteroaryloxy; Y = H, halo, NO2; W = H, OR, SR, NHR, NR2, CH2R, CHR2, CR3, halo, NO2, cyano; R = H, (substituted) alkyl, alkenyl, alkynyl, cycloalkyl, aryl, heteroaryl, alkoxy, cycloalkoxy, aryloxy, heteroaryloxy, alkylsulfonyl, PhCH2, alkylcarbonyl, aryloxy, etc.; Q = (substituted) heterocyclyl; Z = amino, OH, SH, CHO, CO2H, cyano, alkylcarbonyl, arylcarbonyl, H3, etc. were prepared. Thus, 3-(4-chloro-6-fluoro-3-methoxy-2-nitrophenyl)-1-methyl-6-trifluoromethyl-2,4-(1H,3H)-pyrimidinedione (preparation given) was stirred with Fe powder in H2OAc to give title compound (II). II at 7.8 g/ha post-emergent gave 100% control of *Amaranthus retroflexus* and *Abutilon theophrasti*.

IT 224164-07-2P. 2-Quinoxalinecarboxamide, N-[3-chloro-6-[3,6-dihydro-3-methyl-2,6-dioxo-4-(trifluoromethyl)-1(2H)-pyrimidinyl]-5-fluoro-2-methoxyphenyl]- (preparation of heterocyclylbenzenes as herbicides and defoliants)

RN 224164-07-2 CAPLUS

CN 2-Quinoxalinecarboxamide, N-[3-chloro-6-[3,6-dihydro-3-methyl-2,6-dioxo-4-(trifluoromethyl)-1(2H)-pyrimidinyl]-5-fluoro-2-methoxyphenyl]- (9CI) (CA INDEX NAME)

Tablets containing II were also formulated.


IT 400004-35-5P 400004-39-9P 400004-40-2P
400004-49-1P 400004-65-1P 400004-96-8P
400004-97-9P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of thiazole compds. as selective protein kinase C γ inhibitors for sedatives)


RN 400004-35-5 CAPLUS

CN 2-Quinoxalinecarboxamide, N-[3-[2-[[2'-(acetylamino)-4'-methyl[4,5'-bithiazol]-2-yl]amino]-2-oxoethyl]phenyl]- (9CI) (CA INDEX NAME)




RN 400004-39-9 CAPLUS

CN 2-Quinoxalinecarboxamide, N-[3-[2-oxo-2-[[4-(4-pyridinyl)-2-thiazolyl]amino]ethyl]phenyl]- (9CI) (CA INDEX NAME)




RN 400004-40-2 CAPLUS

CN 2-Quinoxalinecarboxamide, N-[3-[2-[methyl[4-(4-pyridinyl)-2-thiazolyl]amino]-2-oxoethyl]phenyl]- (9CI) (CA INDEX NAME)



RN 400004-49-1 CAPLUS

CN 2-Quinoxalinecarboxamide, N-[3-[2-[[2'-(cyclohexylacetyl)amino]-4'-methyl[4,5'-bithiazol]-2-yl]amino]-2-oxoethyl]phenyl]- (9CI) (CA INDEX NAME)




REFERENCE COUNT: 37 THERE ARE 37 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT


L5 ANSWER 97 OF 283 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2002126362 CAPLUS
DOCUMENT NUMBER: 136:177998
TITLE: Thiazole compounds as selective protein kinase C γ inhibitors and sedatives containing them
INVENTOR(S): Inaba, Takayuki; Sogawa, Shoichi; Okamoto, Yoshihisa
PATENT ASSIGNER(S): Japan Tobacco, Inc., Japan
SOURCE: Jpn. Kokai Tokkyo Koho, 113 pp.
CODEN: JKKXAF
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 2002053566	A2	20020219	JP 2000-244080	20000811

PRIORITY APPLN. INFO.: JP 2000-244080 20000811
OTHER SOURCE(S): MARPAT 136:177998
GI




AB Protein kinase C inhibitors contain thiazole compds. I [R1 = H, halo, Cl-6 alkyl; R2 = H, (un)substituted Cl-6 alkyl (substituents are given); R3, R4 = H, (un)substituted Cl-6 alkyl, ORal (R1 = H, Cl-6 alkyl, Cl-6 alkylcarbonyl), NR2R3 (R2, R3 = H, Cl-6 alkyl, Cl-6 alkylcarbonyl); NR2R3 may be a ring; R2 and R3 may be bonded together with HCO2R4 to form a (hetero)cyclo; X = direct bond, Cl-4 alkylene, O, S, CO2, OCO, NR4, CONR4, NR4CO (R4 = H, (un)substituted Cl-6 alkyl); ring Hy = (un)substituted heterocyclyl containing 1-4 O, N, and/or S; Z = H, (un)substituted Cl-6 alkyl, C6-14 aryl, C3-7 cycloalkyl, C3-7 cycloalkenyl, heterocyclyl; ring Cy = C6-14 aryl, C3-7 cycloalkyl, heterocyclyl or their pharmaceutically acceptable salts. Drug compds. and sedatives containing I or their salts are also claimed. I selectively inhibit protein kinase C γ -isozyme. IC50 values of N-[4-[2-(cyclopropylcarbonylamino)-4-methylthiazol-5-yl]thiazol-2-yl]-N-[2-(dimethylamino)ethyl]-2-(2-fluorophenyl)acetamide (II, preparation given) to PKC α , PKC β 1, and PKC γ were 0.8691, 2.9062, and 0.0369 μ M, resp. Sedative effect of II was shown in formalin test for rats.




RN 400004-65-1 CAPLUS

CN 2-Quinoxalinecarboxamide, N-[3-[2-[[2'-(acetylamino)-4'-methyl[4,5'-bithiazol]-2-yl]methylamino]-2-oxoethyl]phenyl]- (9CI) (CA INDEX NAME)




RN 400004-96-8 CAPLUS

CN 2-Quinoxalinecarboxamide, N-[3-[2-[[2'-amino-4'-methyl[4,5'-bithiazol]-2-yl]amino]-2-oxoethyl]phenyl]- (9CI) (CA INDEX NAME)




RN 400004-97-9 CAPLUS


CN 2-Quinoxalinecarboxamide, N-[3-[2-[[2'-((cyclopropylcarbonyl)amino)-4'-methyl[4,5'-bithiazol]-2-yl]amino]-2-oxoethyl]phenyl]- (9CI) (CA INDEX NAME)



L5 ANSWER 98 OF 283 CAPLUS COPYRIGHT 2006 ACS ON STM
 ACCESSION NUMBER: 2002:71116 CAPLUS
 DOCUMENT NUMBER: 136:369341
 TITLE: Reductive cleavage of N-substituted aromatic amides as tert-butyl acylcarbamates
 AUTHOR(S): Ragnarsen, Ulf; Grehn, Leif; Maia, Hernani L. S.; Monteiro, Luis S.
 CORPORATE SOURCE: Department of Biochemistry, Biomedical Center, University of Uppsala, Uppsala, SE-751 23, Swed.
 SOURCE: Journal of the Chemical Society, Perkin Transactions 1 (2002), (1), 97-101
 CODEN: JCSPDC; ISSN: 1472-7781
 PUBLISHER: Royal Society of Chemistry
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 OTHER SOURCE(S): CASREACT 136:369341
 AB Synthetic and spectroscopic details relating to a set of heteroatom acylcarbamates and in particular the corresponding tert-Bu acylcarbamates are reported. These compts. were required to study the postulated effect of various heterocycles (pyridine and pyrazine with and without condensed benzene rings) on the cleavage of acyl-N bonds by reduction. All compts. were initially characterized by cyclic voltammetry (CV) which indicated various degrees of facilitated reduction, reflecting a direct influence of the heterocyclic component. Selected acylcarbamates were studied with respect to acyl-N bond cleavage by mild reducing agents, and selectively deacylated by activated Al and Na borohydride. Conversion to acylcarbamates followed by reduction might therefore be a mild, efficient two-step procedure to effect cleavage of amides, allowing isolation of carbamates and with Na borohydride also the corresponding alcs.
 IT 7066-32-2P 423158-16-1P
 RL: CPS (Chemical process); PEP (Physical, engineering or chemical process); PRP (Properties); RCT (Reactant); SPN (Synthetic preparation); PRSP (Preparation); PROC (Process); RACT (Reactant or reagent) (reductive cleavage of N-substituted aromatic amides as tert-Bu acylcarbamates)
 RN 7066-32-2 CAPLUS
 CN 2-Quinoxalinecarboxamide, N-(phenylmethyl)- (9CI) (CA INDEX NAME)



RN 423158-16-1 CAPLUS
 CN Carbamic acid, (phenylmethyl) (2-quinoxalinylylcarbonyl)-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)





REFERENCE COUNT: 37 THERE ARE 37 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 99 OF 283 CAPLUS COPYRIGHT 2006 ACS ON STM


ACCESSION NUMBER: 2001:923748 CAPLUS
 DOCUMENT NUMBER: 136:53544
 TITLE: β -amino acid nitrile derivs. useful for the treatment of diseases which are associated with cysteine proteases
 INVENTOR(S): Gabriel, Tobias; Pech, Michael; Rodrigues Sarmiento, Rosa Maria
 PATENT ASSIGNEE(S): F. Hoffmann-La Roche A.-G., Switz.
 SOURCE: PCT Int. Appl., 91 pp.
 CODEN: PIXX22
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001096285	A1	20011220	WO 2001-EP6541	20010608
M: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CO, CU, CZ, DE, DK, EC, EE, ES, FI, GB, GD, GE, GM, GR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MO, MP, MQ, MR, MU, NA, NZ, NI, NO, NU, NZ, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZA, ZW				
RN: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GN, GW, ML, MR, NE, SN, TD, TG				
US 2002016361	A1	20020207	US 2001-672927	20010601
US 6462076	B2	20021008		
CA 2410303	AA	20011220	CA 2001-2410303	20010608
EP 1294679	A1	20030326	EP 2001-943489	20010608
EP 1294679	B1	20050921		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
BR 20011733	A	20030527	BR 2001-11733	20010608
JP 2004505255	T2	20040305	JP 2002-510429	20010608
NZ 522587	A	20040730	NZ 2001-522587	20010608
RU 2245871	C2	20050210	RU 2002-135634	20010608
AT 304997	E	20051015	AT 2001-943489	20010608
ZA 2002009415	A	20040219	ZA 2001-9415	20021119
NO 2002005823	A	20021204	NO 2002-5823	20021204
PRIORITY APPL. INFO.:			EP 2000-112577	A 20000614
			WO 2001-EP6541	M 20010608


OTHER SOURCE(S): MARPAT 136:53544
 GI



AB Compts. of formula I [R1 = H, aryl, C(O)Ra, or SO2Rb (Ra = lower alkyl, lower-alkoxy, cycloalkyl, cycloalkyl-lower-alkyl, cycloalkyl-lower alkoxy, cycloalkoxy, aryl, aryloxy, etc.; Rb = aryl, aryl-lower-alkyl, or heteroaryl); R2, R3, R4 = H or lower-alkyl; R5 = H, lower-alkyl, cycloalkyl, or aryl; n = 1,2] were prepared. Thus, (1R,2R)-2-[(S)-[cyano(3-hydroxyphenyl)methyl]carbamoyl]cyclohexyl]carbamate benzyl ester (II) was produced from (1R,2R)-2-benzoyloxycarbonylamino-cyclohexane carboxylic acid and (S)-2-amino-2-(3-hydroxyphenyl)acetonitrile. II was assayed against cathepsins K, S, L, and B and the inhibitory activity (IC50) was determined to be 0.005, >10, 4.7, and 4.6 μ Mol/L, resp. The compts. and pharmaceutically acceptable salts and/or pharmaceutically acceptable esters thereof are useful for the treatment of diseases which are associated with cysteine proteases such as osteoporosis, osteoarthritis, rheumatoid arthritis, tumor metastasis, glomerulonephritis, atherosclerosis, myocardial infarction, angina pectoris, instable angina pectoris, stroke, plaque rupture, transient ischemic attacks, aneurysms, fugal, peripheral arterial occlusive disease, restenosis after angioplasty and stent placement, abdominal aortic aneurysm formation, inflammation, autoimmune disease, malaria, ocular fundus tissue cytopathy and respiratory disease. A discussion of pharmaceutical compts. is also included.
 IT 381241-65-2
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PRSP (Preparation); USRS (Uses)
 (preparation of beta-amino acid nitrile derivs. useful for the treatment of diseases which are associated with cysteine proteases)
 RN 381241-65-2 CAPLUS
 CN 2-Quinoxalinecarboxamide, N-[(1R,2R)-2-[[[cyano(3-hydroxyphenyl)methyl]amino]carbonyl]cyclohexyl]-, rel- (9CI) (CA INDEX NAME)
 Relative stereochemistry.



IT 381241-65-2
 RL: RCT (Reactant); RACT (Reactant or reagent)
 (preparation of beta-amino acid nitrile derivs. useful for the treatment of diseases which are associated with cysteine proteases)
 RN 381241-65-2 CAPLUS
 CN Cyclohexanecarboxylic acid, 2-[(2-quinoxalinylylcarbonyl)amino]-, (1R,2R)-rel- (9CI) (CA INDEX NAME)
 Relative stereochemistry.




REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 100 OF 283 CAPLUS COPYRIGHT 2006 ACS ON STM
 ACCESSION NUMBER: 2001:851126 CAPLUS
 DOCUMENT NUMBER: 135:371760
 TITLE: Preparation of pyrazolylpyrimidines and analogs as TNF- α signaling modulators
 INVENTOR(S): Snaddon, Scott F.; Kane, John L.; Hirth, Bradford H.; Vinick, Fred; Qiao, Shuang; Nahill, Sharon R.
 PATENT ASSIGNEE(S): Genzyme Corporation, USA
 SOURCE: PCT Int. Appl., 108 pp.
 CODEN: PIXX22
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001087849	A2	20011122	WO 2001-US15027	20010510
WO 2001087849	A3	20020606		
M: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GR, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW				
RN: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GN, GW, ML, MR, NE, SN, TD, TG				
CA 2408408	AA	20011122	CA 2001-2408408	20010510

US 2002119988 A1 20020829 US 2001-652965 20010510
 US 6969728 B2 20051129
 EP 1294699 A2 20030326 EP 2001-933253 20010510
 R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, SI, SK, TR, CY, AL, TR
 JP 2003533515 T2 20031111 JP 2001-584245 20010510
 BR 2001011158 A 20040406 BR 2001-11158 20010510
 NO 2002005405 A 20030109 NO 2002-5405 20021111
 US 2004171617 A1 20040902 US 2004-797244 20040310
 PRIORITY APPL. INFO.: US 2000-203784P P 20000512
 US 2001-852965 A3 20010510
 WO 2001-US15027 W 20010510


OTHER SOURCE(S): MARPAT 135:371760
 GI



AB Title compds. [I; R1 = H or NH2; R2 = Z3(CH2)nR; R = (un)substituted Ph or -heterocyclyl; R4 = (alkyl-substituted) 2-pyridinyl or -pyrazinyl; Z = (un)substituted pyrazole-1,4-diyl; Z1, Z2 = N or CH; Z3 = O, CH2, S, SO2; n = 0-2] were prepared. Thus, 4-(Me2HC)C6H4OH was condensed with (MeCO)2CHN2 and the product cyclocondensed with 4-(3-pyridinyl)-2-pyrimidinylhydrazine to give title compound II. Data for biol. activity of I were given.


IT 374080-51-OP 374080-57-6P
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USRS (Uses) (preparation of pyrazolopyrimidines and analogs as TNF- α signaling modulators)

RN 374080-51-0 CAPLUS
 CN 2-Quinoxalinecarboxamide, N-[1-(3-cyanophenyl)-2-[(2-(4-methoxyphenyl)ethyl)amino]-2-oxoethyl]-N-[2-(1H-imidazol-4-yl)ethyl]- (9CI) (CA INDEX NAME)



RN 374080-57-6 CAPLUS


CN 2-Quinoxalinecarboxamide, N-[1-(3-cyanophenyl)-2-[(2,2-diphenylethyl)amino]-2-oxoethyl]-N-[2-(1H-imidazol-4-yl)ethyl]- (9CI) (CA INDEX NAME)



L5 ANSWER 101 OF 283 CAPLUS COPYRIGHT 2006 ACS on STN
 ACCESSION NUMBER: 2001:597979 CAPLUS
 DOCUMENT NUMBER: 135:167035
 TITLE: Preparation of tyrosine derivatives having anti-leukotriene activity
 INVENTOR(S): Makovec, Francesco; Peris, Walter; Rovati, Lucio Claudio
 PATENT ASSIGNEE(S): Rott Research Laboratorium S.P.A., Italy
 SOURCE: PCT Int. Appl., 27 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001058892	A1	20010816	WO 2001-EP1315	20010207
W: AU, CA, JP, US				
RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR				
IT 1320162	B1	20031118	IT 2000-TO127	20000209
CA 2399451	AA	20010816	CA 2001-2399451	20010207
EP 1255749	A1	20021113	EP 2001-905744	20010207
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, SI, SK, TR, CY, AL, TR				
JP 2003523768	T2	20030729	JP 2001-558442	20010207
AU 776214	B2	20040902	AU 2001-33742	20010207
US 2003087910	A1	20030508	US 2002-203424	20020808
US 6605722	B2	20030812		


PRIORITY APPL. INFO.: IT 2000-TO127 A 20000209
 WO 2001-EP1315 W 20010207
 OTHER SOURCE(S): MARPAT 135:167035
 GI



AB Compds. I [R1, R2 = H, Cl-4 alkyl, halo, MeO, cyano, CF3; R3 = (un)substituted Ph, pyridyl or (iso)quinolinyl, 1- or 2-naphthyl, 2- or 3-indolyl or N-alkyl derivs., 3-, 5- or 6-quinolyl, cinnolyl, benzimidazolyl], which may have the L- or D-configuration or be racemic, were prepared and are useful in the treatment of pathol. conditions sensitive to leukotriene inhibition. Thus, O-(2-quinolinylmethyl)-N-quinolaldehyde-DL-tyrosine was prepared by acylation of DL-tyrosine Me ester with quinaldic acid. O-alkylation with 2-chloromethylquinoline hydrochloride, and saponification. The product showed IC50x10-9 M = 20.0 for inhibition of binding of [3H]-LTD4 to guinea pig lung membranes.

IT 353798-99-9P
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USRS (Uses) (preparation of tyrosine derivs. having anti-leukotriene activity)

RN 353798-99-9 CAPLUS
 CN Tyrosine, O-(2-quinolinylmethyl)-N-(2-quinoxalinyllcarbonyl)- (9CI) (CA INDEX NAME)




REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 102 OF 283 CAPLUS COPYRIGHT 2006 ACS on STN
 ACCESSION NUMBER: 2001:581874 CAPLUS
 DOCUMENT NUMBER: 135:152821
 TITLE: Preparation of N-(hydroxyalkyl)quinoxaline-2-carboxamides and analogs as CCR1 antagonists for treatment of inflammation and other immune disorders
 INVENTOR(S): Brown, Matthew Frank; Posa, Christopher Stanley
 PATENT ASSIGNEE(S): Pfizer Products Inc., USA
 SOURCE: PCT Int. Appl., 70 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001057023	A1	20010809	WO 2001-IB107	20010126
W: AS, AO, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GR, GM, HR,				

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
CA 2399214	AA	20010809	CA 2001-2399214	20010126
AU 2001026997	A5	20010814	AU 2001-26997	20010126
BR 2001008002	A	20021029	BR 2001-8002	20010126
EP 1252154	A1	20021030	EP 2001-901328	20010126
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, SI, SK, TR, CY, AL, TR				
JP 2003522164	T2	20030722	JP 2001-557855	20010126
EE 200200432	A	20031215	EE 2002-432	20010126
NZ 520075	A	20040227	NZ 2001-520075	20010126
EP 1498417	A1	20050119	EP 2004-21270	20010126
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, SI, SK, TR, CY, AL, TR				
US 2002132810	A1	20020919	US 2001-774871	20010131
US 6548671	B2	20030415		
BG 106922	A	20030331	BG 2002-106922	20020715
ZA 2002006140	A	20030801	ZA 2002-6140	20020801
NO 2002003675	A	20020910	NO 2002-3675	20020802
US 2003024086	A1	20031030	US 2003-360059	20030206
US 6689866	B2	20040210		

PRIORITY APPL. INFO.: US 2000-180159P P 20000204
 EP 2001-901328 A3 20010126
 WO 2001-18107 W 20010126
 US 2001-774871 A3 20010131
 OTHER SOURCE(S): MARPAT 135:152821
 GI



II



III

AB The title compds. R1CONHCHR2CH(OH)CH2CHR3R4 [I; wherein R1 = (un)substituted heterocyclyl; R2 = (un)substituted Ph(CH2)m, naphthyl-(CH2)m, (cyclo)alkyl-(CH2)m, or heterocyclyl-(CH2)m; m = 0-4; R3 = H, D, or (un)substituted alkyl, cycloalkyl-(CH2)n, heterocycloalkyl-(CH2)n, or (heterocyclyl)-(CH2)n; n = 0-6; or R3 and the C to which it is

attached form a 5-7 membered (un)substituted ring; R4 = heteroaryl, heterocycloalkyl, or (un)substituted sulfonyl, thiocarbonyl, or carboximidamide; stereoisomers or pharmaceutically acceptable salt thereof] were prepared as CCR1 antagonists for the treatment of inflammation and other immune disorders. For example, ring opening and amidation of the lactone II with semioctaldehyde di-Me acetal (91%), O-protection (96%), conversion to the imidazole using ammonium acetate in the presence of AcOH (17%), and deprotection (100%) gave III. All of the compds. of the invention that were tested for inhibition of chemotaxis of various chemokines exhibited $IC_{50} < 25 \mu M$.


IT 352536-96-0P 352536-97-1P 352536-98-2P
352537-00-9P 352537-02-1P 352537-03-2P
352537-07-6P 352537-10-1P 352537-11-2P
352537-12-3P 352537-13-4P 352537-20-3P
352537-22-5P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(intermediate; preparation of N-(hydroxyalkyl)quinoxalinecarboxamide CCR1 antagonists from lactones for treatment of inflammation and other immune disorders)


RN 352536-96-0 CAPLUS

CN 2-Quinoxalinecarboxamide, N-[2-(acetyloxy)-4-[[[(2,2-dimethoxyethyl)amino]carbonyl]-1-[(3-fluorophenyl)methyl]-7-hydroxy-7-methyloctyl]-9CI] (CA INDEX NAME)




RN 352536-97-1 CAPLUS

CN 2-Quinoxalinecarboxamide, N-[4-[[[(2,2-dimethoxyethyl)amino]carbonyl]-1-[(3-fluorophenyl)methyl]-2,7-dihydroxy-7-methyloctyl]-9CI] (CA INDEX NAME)




RN 352536-98-2 CAPLUS

CN 2-Quinoxalinecarboxamide, N-[2-(acetyloxy)-1-[(3-fluorophenyl)methyl]-7-hydroxy-4-[(1H-imidazol-2-yl)-7-methyloctyl]-9CI] (CA INDEX NAME)




RN 352537-00-9 CAPLUS

CN 2-Quinoxalinecarboxamide, N-[2-(acetyloxy)-4-(aminocarbonyl)-7-fluoro-7-methyl-1-(phenylmethyl)octyl]-9CI] (CA INDEX NAME)




RN 352537-02-1 CAPLUS

CN 2-Quinoxalinecarboxamide, N-[2-(acetyloxy)-4-[[[(dimethylamino)methylene]amino]carbonyl]-7-fluoro-7-methyl-1-(phenylmethyl)octyl]-9CI] (CA INDEX NAME)




RN 352537-03-2 CAPLUS

CN 2-Quinoxalinecarboxamide, N-[2-(acetyloxy)-7-fluoro-7-methyl-1-(phenylmethyl)-4-[(1H-1,2,4-triazol-3-yl)octyl]-9CI] (CA INDEX NAME)




RN 352537-07-6 CAPLUS

CN Benzenehexanoic acid, α -(3-fluoro-3-methylbutyl)- γ -hydroxy-5-[[2-quinoxaliny]carbonyl]amino]-, hydrazide (9CI] (CA INDEX NAME)




RN 352537-10-1 CAPLUS

CN Benzenehexanoic acid, α -(3-fluoro-3-methylbutyl)- γ -hydroxy-5-[[2-quinoxaliny]carbonyl]amino]- (9CI] (CA INDEX NAME)




RN 352537-11-2 CAPLUS

CN Benzenehexanoic acid, γ -[[[(1,1-dimethylethyl)dimethylsilyl]oxy]-7-fluoro-7-methyl-4-[[2-oxoethyl]amino]carbonyl]-1-(phenylmethyl)octyl]-9CI] (CA INDEX NAME)




RN 352537-12-3 CAPLUS

CN 2-Quinoxalinecarboxamide, N-[2-[[[(1,1-dimethylethyl)dimethylsilyl]oxy]-7-fluoro-4-[[2-hydroxyethyl]amino]carbonyl]-7-methyl-1-(phenylmethyl)octyl]-9CI] (CA INDEX NAME)




RN 352537-13-4 CAPLUS

CN 2-Quinoxalinecarboxamide, N-[4-(4,5-dihydro-2-oxazolyl)-2-[[[(1,1-dimethylethyl)dimethylsilyl]oxy]-7-fluoro-7-methyl-1-(phenylmethyl)octyl]-9CI] (CA INDEX NAME)




RN 352537-20-3 CAPLUS

CN 2-Quinoxalinecarboxamide, N-[2-[[[(1,1-dimethylethyl)dimethylsilyl]oxy]-7-fluoro-7-methyl-4-[[2-oxoethyl]amino]carbonyl]-1-(phenylmethyl)octyl]-9CI] (CA INDEX NAME)



RN 352537-22-5 CAPLUS

CN 2-Quinoxalinecarboxamide, N-[2-[[[(1,1-dimethylethyl)dimethylsilyl]oxy]-7-fluoro-7-methyl-4-[[2-oxazolyl]-1-(phenylmethyl)octyl]-9CI] (CA INDEX NAME)




IT 352536-94-8P 352536-99-3P 352537-04-3P

352537-06-5P 352537-08-7P 352537-09-8P
352537-16-7P 352537-25-8P 352537-28-1P
352537-29-2P 352537-30-5P 352537-31-6P
352537-32-7P 352537-33-8P 352537-34-9P
352537-35-0P 352537-36-1P 352537-37-2P
352537-38-3P 352537-39-4P 352537-40-7P
352537-41-8P 352537-43-0P 352537-44-1P
352537-45-2P 352537-46-3P 352542-82-6P


RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use);

BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of N-(hydroxyalkyl)quinoxalinecarboxamide CCR1 antagonists from
lactones for treatment of inflammation and other immune disorders)


RN 352536-94-8 CAPLUS
CN 2-Quinoxalinecarboxamide, N-[1-[(3-fluorophenyl)methyl]-2,7-dihydroxy-4-(1H-imidazol-2-yl)-7-methyloctyl]- (9CI) (CA INDEX NAME)




RN 352537-99-3 CAPLUS
CN 2-Quinoxalinecarboxamide, N-[7-fluoro-2-hydroxy-7-methyl-1-(phenylmethyl)-4-(1H-1,2,4-triazol-3-yl)octyl]- (9CI) (CA INDEX NAME)




RN 352537-04-3 CAPLUS
CN 2-Quinoxalinecarboxamide, N-[4-(4,5-dihydro-1H-imidazol-2-yl)-7-fluoro-2-hydroxy-7-methyl-1-(phenylmethyl)octyl]- (9CI) (CA INDEX NAME)




RN 352537-06-5 CAPLUS
CN 2-Quinoxalinecarboxamide, N-[4-(5-amino-1,3,4-oxadiazol-2-yl)-7-fluoro-2-hydroxy-7-methyl-1-(phenylmethyl)octyl]- (9CI) (CA INDEX NAME)




RN 352537-08-7 CAPLUS
CN 2-Quinoxalinecarboxamide, N-[4-(4,5-dihydro-5-oxo-1,3,4-oxadiazol-2-yl)-7-fluoro-2-hydroxy-7-methyl-1-(phenylmethyl)octyl]- (9CI) (CA INDEX NAME)



RN 352537-09-8 CAPLUS
CN 2-Quinoxalinecarboxamide, N-[4-(4,5-dihydro-2-oxazolyl)-7-fluoro-2-hydroxy-7-methyl-1-(phenylmethyl)octyl]- (9CI) (CA INDEX NAME)




RN 352537-16-7 CAPLUS
CN 2-Quinoxalinecarboxamide, N-[7-fluoro-2-hydroxy-7-methyl-4-(2-oxazolyl)-1-(phenylmethyl)octyl]- (9CI) (CA INDEX NAME)




RN 352537-25-8 CAPLUS
CN 2-Quinoxalinecarboxamide, N-[(1S,2S,4R)-1-[(3-fluorophenyl)methyl]-2,7-dihydroxy-4-(1H-imidazol-2-yl)-7-methyloctyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 352537-28-1 CAPLUS
CN 2-Quinoxalinecarboxamide, N-[(1S,2S,4R)-2,7-dihydroxy-4-(1H-imidazol-2-yl)-7-methyl-1-(phenylmethyl)octyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 352537-29-2 CAPLUS
CN 2-Quinoxalinecarboxamide, N-[(1S,2S,4R)-7-fluoro-1-[(3-fluorophenyl)methyl]-2-hydroxy-4-(1H-imidazol-2-yl)-7-methyloctyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 352537-30-5 CAPLUS
CN 2-Quinoxalinecarboxamide, N-[(1S,2S,4R)-7-fluoro-2-hydroxy-4-(1H-imidazol-2-yl)-7-methyl-1-(phenylmethyl)octyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 352537-31-6 CAPLUS
CN 2-Quinoxalinecarboxamide, N-[(1S,2S,4R)-4-(aminosulfonyl)-1-[(3-fluorophenyl)methyl]-2,7-dihydroxy-7-methyloctyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 352537-32-7 CAPLUS
CN 2-Quinoxalinecarboxamide, N-[(1S,2S,4R)-4-(aminosulfonyl)-2,7-dihydroxy-7-methyl-1-(phenylmethyl)octyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 352537-33-8 CAPLUS
CN 2-Quinoxalinecarboxamide, N-[(1S,2S,4R)-4-(aminosulfonyl)-7-fluoro-1-[(3-fluorophenyl)methyl]-2-hydroxy-7-methyloctyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 352537-34-9 CAPLUS
CN 2-Quinoxalinecarboxamide, N-[(1S,2S,4R)-4-(aminosulfonyl)-7-fluoro-2-hydroxy-7-methyl-1-(phenylmethyl)octyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 352537-35-0 CAPLUS
CN 2-Quinoxalinecarboxamide, N-[(1S,2S,4R)-1-[(3-fluorophenyl)methyl]-2,7-dihydroxy-7-methyl-4-[(methylamino)sulfonyl]octyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 352537-36-1 CAPLUS
CN 2-Quinoxalinecarboxamide, N-[(1S,2S,4R)-2,7-dihydroxy-7-methyl-4-[(methylamino)sulfonyl]-1-(phenylmethyl)octyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 352537-37-2 CAPLUS
CN 2-Quinoxalinecarboxamide, N-[(1S,2S,4R)-7-fluoro-2-hydroxy-7-methyl-4-[(methylamino)sulfonyl]-1-(phenylmethyl)octyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 352537-38-3 CAPLUS
CN 2-Quinoxalinecarboxamide, N-[(1S,2S,4R)-4-(4-chloro-1H-imidazol-2-yl)-1-[(3-fluorophenyl)methyl]-2,7-dihydroxy-7-methyloctyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 352537-39-4 CAPLUS
CN 2-Quinoxalinecarboxamide, N-[(1S,2S,4R)-4-(4-chloro-1H-imidazol-2-yl)-2,7-dihydroxy-7-methyl-1-(phenylmethyl)octyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 352537-40-7 CAPLUS
CN 2-Quinoxalinecarboxamide, N-[(1S,2S,4R)-4-(4-chloro-1H-imidazol-2-yl)-7-fluoro-1-[(3-fluorophenyl)methyl]-2-hydroxy-7-methyloctyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 352537-41-8 CAPLUS
CN 2-Quinoxalinecarboxamide, N-[(1S,2S,4R)-4-(4-chloro-1H-imidazol-2-yl)-7-fluoro-2-hydroxy-7-methyl-1-(phenylmethyl)octyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 352537-43-0 CAPLUS
CN 2-Quinoxalinecarboxamide, N-[(1S,2S,4R)-4-(4-fluoro-1H-imidazol-2-yl)-1-[(3-fluorophenyl)methyl]-2,7-dihydroxy-7-methyloctyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 352537-44-1 CAPLUS
CN 2-Quinoxalinecarboxamide, N-[(1S,2S,4R)-4-(4-fluoro-1H-imidazol-2-yl)-2,7-dihydroxy-7-methyl-1-(phenylmethyl)octyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 352537-45-2 CAPLUS
CN 2-Quinoxalinecarboxamide, N-[(1S,2S,4R)-7-fluoro-4-[(4-fluoro-1H-imidazol-2-yl)-1-[(3-fluorophenyl)methyl]-2-hydroxy-7-methyloctyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 352537-46-3 CAPLUS
CN 2-Quinoxalinecarboxamide, N-[(1S,2S,4R)-7-fluoro-4-[(4-fluoro-1H-imidazol-2-yl)-1-[(3-fluorophenyl)methyl]-2-hydroxy-7-methyl-1-(phenylmethyl)octyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 352542-82-6 CAPLUS
CN 2-Quinoxalinecarboxamide, N-[(1S,2S,4R)-7-fluoro-1-[(3-fluorophenyl)methyl]-2-hydroxy-7-methyl-4-[(methylamino)sulfonyl]octyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.




IT 352536-95-9 352537-01-0 352537-05-4
RL: RCT (Reactant); RACT (Reactant or reagent)
(reactant; preparation of N-(hydroxyalkyl)quinoxalinecarboxamide CCR1 antagonists from lactones for treatment of inflammation and other immune disorders)
RN 352536-95-9 CAPLUS
CN Acetic acid, trifluoro-, 3-[5-[2-(3-fluorophenyl)-1-[(2-quinoxalinyloxy)amino]ethyl]tetrahydro-2-oxo-3-furanyl]-1,1-dimethylpropyl ester (9CI) (CA INDEX NAME)



RN 352537-01-0 CAPLUS
CN 2-Quinoxalinecarboxamide, N-[(4-(aminocarbonyl)-7-fluoro-2-hydroxy-7-methyl-1-(phenylmethyl)octyl]- (9CI) (CA INDEX NAME)




RN 352537-05-4 CAPLUS
CN 2-Quinoxalinecarboxamide, N-[1-[4-(3-fluoro-3-methylbutyl)tetrahydro-5-oxo-2-furanyl]-2-phenylethyl]- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 103 OF 283 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2001:565014 CAPLUS
DOCUMENT NUMBER: 135:152826
TITLE: Preparation of benz-fused heterocycle derivatives and remedies containing the same as cysteine proteases inhibitors
INVENTOR(S): Ohmoto, Kazuyuki; Itagaki, Iori
PATENT ASSIGNEE(S): Ono Pharmaceutical Co., Ltd., Japan
SOURCE: PCT Int. Appl., 273 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001055118	A1	20010802	WO 2001-JP473	20010125
W: AE, AO, AL, AM, AT, AU, AZ, BA, BB, BO, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, SE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KS, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, ME, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KO, KZ, MD, RU, TJ, TM				
RM: GH, GM, KE, LS, MM, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CP, CO, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TO				
AU 2001028810	A5	20010807	AU 2001-28810	20010125
EP 1254898	A1	20021106	EP 2001-946856	20010125
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
US 2003162964	A1	20030828	US 2002-181713	20020722
US 5809092	B2	20041026		
US 2005009755	A1	20050113	US 2004-901263	20040729
PRIORITY APPL. INFO.:			JP 2000-17045	A 20000126
			WO 2001-JP473	W 20010125
			US 2002-181713	A3 20020722
OTHER SOURCE(S):				
OT				




AB Title compds. (RAA1AA2NR9CR7R8CO(CH2)2m2(R10)n; R = H, Cl-alkyl, NO2, CF3, alkylsulfonyl, alkoxycarbonyl, alkylcarbonyl; AA1 = single bond, carbonylalkylamino, heterocyclylamino, heterocycle; AA2 = single bond, carbonylalkylamino, carbonylcycloalkylamino; R7, R8 independently = H, Cl-alkyl; R9 = H, Cl-alkyl, aryl; Z = benzazepine; R10 = Cl-alkyl, cycloalkyl, amino, alkoxy, OH) and nontoxic salts are prepared. Title compds. exhibit inhibitory activities against cysteine proteases (no data) and are useful as preventive and/or therapeutic drugs for immune disorders (such as autoimmune diseases and infectious diseases), inflammatory diseases (such as inflammatory diseases of intestine, multiple endophthalosclerosis, and arthritis), nerve degeneration diseases (such as Alzheimer's disease and muscular dystrophy), bone resorptive diseases (such as osteoporosis), respiratory diseases, diabetes, shock, etc. Thus, the title compound I was prepared

IT 352355-40-99
RL: SPM (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of benzazepine derivs. and remedies as cysteine proteases inhibitors)

RN 352355-40-9 CAPLUS
CN 2-Quinoxalinecarboxamide, N-[(1S,2R)-2-[[[(1S)-3-methyl-1-[(1,3,4,5-tetrahydro-2H-2-benzazepin-2-yl)acetyl]butyl]amino]carbonyl]cyclohexyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT


L5 ANSWER 104 OF 283 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2001:545674 CAPLUS
DOCUMENT NUMBER: 135:137516
TITLE: Synthesis of heteroarylbenzamides and analogs used for inhibiting protein kinases
INVENTOR(S): Bender, Steven Lee; Bhuralkar, Dilip; Collins, Michael Raymond; Cripps, Stephan James; Deal, Judith

PATENT ASSIGNEE(S):
SOURCE:
DOCUMENT TYPE:
LANGUAGE:
FAMILY ACC. NUM. COUNT: 1
PCT Int. Appl., 237 pp.
CODEN: PIXKD2
Patent
English

PATENT NO. KIND DATE APPLICATION NO. DATE
WO 2001053274 A1 20010726 WO 2001-US1723 20010119
M: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NZ, NL, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZM, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, MG, SD, SL, SZ, TZ, UG, ZM, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG
CA 2394703 A1 20010726 CA 2001-2394703 20010119
US 2002103203 A1 20020801 US 2001-764306 20010119
US 6635641 B2 20011021
EP 1252146 A1 20021030 EP 2001-906592 20010119
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR
BR 2001008025 A 20021105 BR 2001-8025 20010119
JP 2003529558 T2 20031007 JP 2001-553276 20010119
US 2004092747 A1 20040513 US 2003-621979 20030717
PRIORITY APPL. INFO.: US 2000-177059P P 20000121
US 2001-764306 A3 20010119
WO 2001-US1723 W 20010119
OTHER SOURCE(S): MARPAT 135:137516
GI


* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB Title compds. I [Z = CH, NH; Q = moiety such that ring A is (un)substituted mono- or bicyclic heteroaryl which has at least 2 carbon atoms in the heteroaryl ring system; X = CH₂, O, S, NH; Y = CH₂, O, S, provided at least one of X and Y = CH₂ or X and Y form a cyclopropyl ring; R₂-3 = H, Me, halo, CF₃, CN, R₄ = CONHR₅, NHCOHR₅; where R₅ = (un)substituted aryl, heteroaryl, cycloalkyl, etc.; R₆ = (un)substituted aryl, heteroaryl, cycloalkyl, etc.] are prepared. Examples include synthetic procedures for over 150 compds., 11 biol. assays and 3 sample formulations. For instance, 3-mercaptopropionic acid was treated with α-chloro-N-methoxy-N-methylacetamide followed by carbodiimide coupling to 2-methyl-6-aminocyclohexanone to give II. II was converted to a β-thiono-ketone with thioacetamide/N-BuLi followed by treatment with hydrazine to give pyrazole III. III gave 85% inhibition of an lck protein tyrosine kinase at 5 μM and had Ki = 2.21 nM for VEGF-R2Δ50. Treatment of cancer as well as other disease states associated with unwanted angiogenesis and/or cellular proliferation, such as diabetic retinopathy, neovascular glaucoma, rheumatoid arthritis, and psoriasis are claimed uses of the invention.
IT 351323-60-9P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USSS (Uses) (synthesis of heteroarylbenzamide used for inhibiting protein kinases)




AB The title compds. I [R represents hydrogen, alkyl, etc.; AA1 represents a single bond, an amino acid residue, etc.; AA2 represents a single bond, an amino acid residue, etc.; R7 and R8 represent each hydrogen, alkyl, etc.; R9 represents hydrogen or alkyl; and R10 represents each hydrogen, alkyl, etc.; ring Z is 2-oxo-1,3,4-oxadiazoline, etc.] are prepared. I are useful in the treatment of inflammatory diseases, autoimmune diseases, etc. In an in vitro test for inhibiting activity against cathepsin K, one compound of this invention showed the Ki value of 1.3 nM. Formulations are given.
IT 345214-16-6P 345215-25-6P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USSS (Uses) (preparation of dipeptide analogs containing oxadiazole derive. as cysteine protease inhibitors)
RN 345214-16-6 CAPLUS
CN 2-Quinoxalinecarboxamide, N-[(1S,2R)-2-[[[(1S)-1-[[4,5-dihydro-4-(2-methylpropyl)-5-oxo-1,3,4-oxadiazol-2-yl]carbonyl]-3-methylbutyl]amino]carbonyl]cyclohexyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 345215-25-0 CAPLUS
CN 2-Quinoxalinecarboxamide, N-[(1S,2R)-2-[[[(1S)-1-[[4,5-dihydro-4-(2-methylthio)-1,3,4-oxadiazol-2-yl]carbonyl]butyl]amino]carbonyl]cyclohexyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 106 OF 283 CAPLUS COPYRIGHT 2006 ACS ON STM

RN 351323-60-9 CAPLUS
CN 2-Quinoxalinecarboxamide, 3,4-dihydro-3-oxo-N-[(1R-pyrazolo[3,4-d]pyrimidin-6-ylthio)methyl]phenyl]- (9CI) (CA INDEX NAME)





REFERENCE COUNT: 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 105 OF 283 CAPLUS COPYRIGHT 2006 ACS ON STM
ACCESSION NUMBER: 2001:453041 CAPLUS
DOCUMENT NUMBER: 135:46457
TITLE: Preparation of dipeptide analogs containing oxadiazole derivatives as cysteine protease inhibitors
INVENTOR(S): Ohmoto, Kazuyuki; Itagaki, Iori
PATENT ASSIGNEE(S): Ono Pharmaceutical Co., Ltd., Japan
SOURCE: PCT Int. Appl., 424 pp.
CODEN: PIXKD2
Patent
Japanese
FAMILY ACC. NUM. COUNT: 1
PCT INFORMATION:

PATENT NO. KIND DATE APPLICATION NO. DATE
WO 2001044214 A1 20010621 WO 2000-JP8514 20001201
M: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NZ, NL, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZM, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, MG, SD, SL, SZ, TZ, UG, ZM, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG
AU 2001016504 A5 20010625 AU 2001-16504 20001201
EP 1234820 A1 20020828 EP 2000-979048 20001201
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR
US 2003166573 A1 20030904 US 2002-148612 20020821
PRIORITY APPL. INFO.: JP 1999-344389 A 19991203
WO 2000-JP8514 W 20001201
OTHER SOURCE(S): MARPAT 135:46457
GI

ACCESSION NUMBER: 2001:416917 CAPLUS
DOCUMENT NUMBER: 135:5823
TITLE: Preparation of dipeptide analogs containing 1,3,4-oxadiazoline derivatives as cysteine protease inhibitors and drugs containing these derivatives as the active ingredient
INVENTOR(S): Ohmoto, Kazuyuki; Itagaki, Iori
PATENT ASSIGNEE(S): Ono Pharmaceutical Co., Ltd., Japan
SOURCE: PCT Int. Appl., 154 pp.
CODEN: PIXKD2
Patent
Japanese
FAMILY ACC. NUM. COUNT: 1
PCT INFORMATION:

PATENT NO. KIND DATE APPLICATION NO. DATE
WO 2001040204 A1 20010607 WO 2000-JP8515 20001201
M: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NZ, NL, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZM, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, MG, SD, SL, SZ, TZ, UG, ZM, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG
AU 2001016505 A5 20010625 AU 2001-16505 20001201
EP 1234821 A1 20020828 EP 2000-979049 20001201
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR
US 2003166574 A1 20030904 US 2002-148613 20020828
US 6797720 B2 20040528
PRIORITY APPL. INFO.: JP 1999-344451 A 19991203
WO 2000-JP8515 W 20001201
OTHER SOURCE(S): MARPAT 135:5823
GI




AB 1,3,4-Oxadiazoline derive. represented by general formula (I) and nontoxic salt thereof (wherein W represents O or S; R represents hydrogen, alkyl, CycA, (un)substituted alkyl, R16OC, R16O2C, R16N(R17)CO, R16SO2, R16COCH2, etc. (R16 = C1-8-alkyl, C2-8 alkenyl, C2-8 alkynyl; R17 = H, C1-4 alkyl); AA1 represents a single bond, an amino acid residue, etc.; AA2 represents a single bond, an amino acid residue, etc.; R7 and R8 represent each hydrogen, alkyl, CycA, substituted C1-8 alkyl; or R7 and R8

are combined together to represent C2-8 alkylene optionally substituted by (un)substituted OH or NH2 and optionally replacing one of the carbons of alkylene with O, S, (un)substituted (un)substituted NH; R9 represents hydrogen, alkyl, Ph, phenyl-C1-8 alkyl; or R9 and R7 combined together to represent C2-8 alkylene optionally substituted by (un)substituted OH or NH2 and optionally replacing one of the carbons of alkylene with O, S, (un)substituted (un)substituted NH are prepared. Because of having a cysteine protease inhibitory activity, the compds. of general formula I are useful as preventives and/or remedies for inflammatory diseases, diseases induced by apoptosis, diseases induced in immune response failure, autoimmune diseases, diseases induced by the degradation of biol. constituting proteins, shock, circulatory disorder, blood coagulation system disorder, malignant tumor, acquired immune deficiency syndrome (AIDS) and AIDS-related complex (ARC), parasitosis, neurodegenerative diseases, lung disorder, bone resorption diseases, endocrine hyperenergetic diseases, etc. These compds. I at 10 μ M inhibited 250% cysteine protease and more specifically 2-oxo-1,3,4-oxadiazoline-containing dipeptide analog (II) at 1 μ M inhibited 99% cysteine protease. An analog containing N-[(1S)-2-(2-oxo-1,3,4-oxadiazolin-5-yl)-1-(2-methylpropyl)-2-oxoethyl]- (2S,1R)-2-(phenylcarboxylamino)cyclohexane-1-carboxamide. was formulated.

IT 341973-22-6P
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPM (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (Preparation of dipeptide analogs containing oxadiazoline derive. as cysteine protease inhibitors and preventives and/or remedies for diseases such as inflammatory, autoimmune, and apoptosis-induced diseases.)

RN 341973-22-6 CAPLUS
 CN 2-Quinoxalinecarboxamide, N-[(1S,2R)-2-[[[(1S)-1-[[4,5-dihydro-5-oxo-1,3,4-oxadiazol-2-yl]carbonyl]-3-methylbutyl]amino]carbonyl]cyclohexyl]- (9CI)
 (CA INDEX NAME)

Absolute stereochemistry.





REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 107 OF 283 CAPLUS COPYRIGHT 2006 ACS on STN
 ACCESSION NUMBER: 2001:360562 CAPLUS
 DOCUMENT NUMBER: 134:366881
 TITLE: Preparation of triazoles as farnesyl transferase inhibitors
 INVENTOR(S): Saha, Ashis Kumar; End, David William; De Corte, Bart
 PATENT ASSIGNEE(S): Lieven Daniel; Breslin, Henry Joseph; Liu, Li
 SOURCE: Janssen Pharmaceutica N.V., Belg.
 PCT Int. Appl. 78 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001036395	A1	20010525	WO 2000-EP11393	20001115
W: AS, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, ES, FI, GB, GR, HU, ID, IL, IN, IS, JP, KR, KZ, LC, LR, LS, LU, LV, MA, MD, MG, MK, MN, MU, MY, NZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
KH: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NR, SN, TD, TG				
CA 2389280	AA	20010525	CA 2000-2389280	20001115
EP 1232147	A1	20020821	EP 2000-988714	20001115
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
JP 2003514804	T2	20030422	JP 2001-538884	20001115
AU 779426	B2	20050127	AU 2001-25063	20001115
US 2005234117	A1	20051020	US 2005-143814	20050602
PRIORITY APPL. INFO.:			US 1999-165434P	P 19991115
			WO 2000-EP11393	M 20001115
			US 2002-130322	A3 20020513

OTHER SOURCE(S): MARPAT 134:366881
 GI



AB The title compds. [I; L1, L2 = YR1; R1 = H, CN, aryl, (un)substituted heterocyclyl; Z1Z2Z3 = NH, CH, NCH, N; X = SO2, (CH2)n (n = 1-4), CO, etc.; R2 = aryl, (un)substituted cycloalkyl, etc.; R3 = aryl, NR5R6, (un)substituted heterocyclyl, etc.; R4 = H, aryl, cycloalkyl, etc.; R5, R6 = H, (un)substituted heterocyclyl, aryl, etc.) and their N-oxides, addition salts, quaternary amines which are useful as novel class of peptidomimetic FTPase inhibitors and also show antiviral activity against RSV, were prepared e.g., a 4-step synthesis of the triazole II which showed an inhibition of FTPase activity of at least 10% at 10⁻⁷ M, was given.


IT 340730-10-1P 340732-17-4P
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological

study, unclassified); SPM (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (Preparation of triazoles as farnesyl transferase inhibitors)

RN 340730-10-1 CAPLUS
 CN Quinoxalinium, 3-[[[2-(4-bromophenyl)ethyl][4-[(4-cyanophenyl)methyl]-4H-1,2,4-triazol-3-yl]methyl]amino]carbonyl]-1-[[[4-cyanophenyl)methyl]-, salt with trifluoroacetic acid (1:1) (9CI) (CA INDEX NAME)

CM 1
 CRN 340730-09-8
 CMF C36 H28 Br N8 O

PAGE 1-A



PAGE 2-A


CM 2
 CRN 14477-72-6
 CMF C2 F3 O2



RN 340732-17-4 CAPLUS
 CN 2-Quinoxalinecarboxamide, N-[[[4-[(4-cyanophenyl)methyl]-4H-1,2,4-triazol-3-

yl]methyl]-N-[(2,4-difluorophenyl)methyl]-3,4-dihydro-3-oxo-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1
 CRN 340732-16-3
 CMF C27 H19 F2 N7 O2




CM 2
 CRN 76-05-1
 CMF C2 H F3 O2



REFERENCE COUNT: 12 THERE ARE 12 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT


L5 ANSWER 108 OF 283 CAPLUS COPYRIGHT 2006 ACS on STN
 ACCESSION NUMBER: 2001:340055 CAPLUS
 DOCUMENT NUMBER: 136:102343
 TITLE: Synthesis and anticancer activity of some novel 2-(quinoxalin-2-yl)-5,6,7,8-tetrahydrobenzo[4,5]thieno[2,3-d]pyrimidine derivatives
 AUTHOR(S): Iemal, M. M. F.; Zahran, Medhat A.; El-Gaby, M. S. A.; Ammar, Y. A.
 CORPORATE SOURCE: Chemistry Department, Faculty of Pharmacy (Girl's), Al-Azhar University, Naser City, Egypt
 SOURCE: Al-Azhar Bulletin of Science (1999), 10(1), 41-50
 CODEN: ABSCE7; ISSN: 1110-2535
 PUBLISHER: Al-Azhar University, Faculty of Science
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 OTHER SOURCE(S): CASREACT 136:102343
 GI




AB 2-Carboxamide derivative I was obtained by a fusion reaction and refluxing of I in acetic anhydride afforded thieno[2,3-d]pyrimidine II (Q = 2-quinoxaliny). Cyclization of the intermediate I with hydrazine hydrate in refluxing butanol furnished a thieno[2,3-d]pyrimidine derivative III (Q = 2-quinoxaliny). Reaction of III with aromatic aldehydes led to the formation of Schiff's bases. A thiourea derivative was obtained by refluxing of III with Ph isothiocyanate in pyridine. Preliminary pharmacol. screening revealed that some of the new comds. exhibited anticancer activity.

IT 389085-83-OP 389085-84-IP 389085-85-2P
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (preparation and anticancer activity of [quinoxaliny]tetrahydrobenzo[4,5]thieno[2,3-d]pyrimidine derivate.)


RN 389085-83-0 CAPLUS
 CN 2,3-Quinoxalinedicarboxamide, N-(3-cyano-4,5,6,7-tetrahydrobenzo[b]thien-2-yl)-N'-phenyl- (9CI) (CA INDEX NAME)



RN 389085-84-1 CAPLUS
 CN 2,3-Quinoxalinedicarboxamide, N-(3-cyano-4,5,6,7-tetrahydrobenzo[b]thien-2-yl)-N'-(4-methylphenyl)- (9CI) (CA INDEX NAME)



RN 389085-85-2 CAPLUS
 CN 2,3-Quinoxalinedicarboxamide, N-(4-chlorophenyl)-N'-(3-cyano-4,5,6,7-tetrahydrobenzo[b]thien-2-yl)- (9CI) (CA INDEX NAME)




REFERENCE COUNT: 22 THERE ARE 22 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 109 OF 283 CAPLUS COPYRIGHT 2006 ACS on STN
 ACCESSION NUMBER: 2001:22885 CAPLUS
 DOCUMENT NUMBER: 134:252339
 TITLE: Preparation of benzimidazole derivatives as poly(ADP-ribose) polymerase (PARP) inhibitors
 INVENTOR(S): Takayama, Kazuhisa; Koga, Yuji; Masuda, Naoyuki; Miyazaki, Toji; Kimura, Takenori; Nagashima, Shinya; Okamoto, Yoshinori; Okada, Yohei; Takeuchi, Makoto
 Yamanouchi Pharmaceutical Co., Ltd., Japan
 PATENT ASSIGNEE(S): PCT Int. Appl., 49 pp.
 SOURCE: CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: Japanese
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001021615	A1	20010329	WO 2000-JP6319	20000914
W: AS, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MM, MX, MY, NZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY,				


DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SP, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TO
 PRIORITY APPL. INFO.: JP 1999-264431 A 19990917
 JP 2000-170715 A 20000607
 OTHER SOURCE(S): MARPAT 134:252339
 GI



AB Benzimidazole derive. having heterocyclic groups at the 2-position and carbamoyl at the 4-position as represented by general formula (I) or (II) or salts thereof (wherein R1 is H, lower alkyl, halo, or halo-lower alkyl; R2 is H, lower alkyl, or lower alkyl-carbonyl; and A is an optionally substituted heterocyclic group), which are useful in the prevention or the treatment of various PARP-related diseases such as inflammations (in particular chronic articular rheumatism), autoimmune diseases, and ischemic reperfusion disorders, are prepared. Thus, 3.58 g Me 2-(pyridin-4-yl)-1H-benzimidazole-4-carboxylate was added to 35 mL NH4(l) at -50° in a metal sealed tube and heated at 140° for 3 days to give 2.58 g 2-(pyridin-4-yl)-1H-benzimidazole-4-carboxamide (III). III and 15 other comds. of I and II in vitro showed IC50 of 7-50 nM against PARP.

IT 330948-40-8P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (preparation of benzimidazole derive. as poly(ADP-ribose) polymerase (PARP) inhibitors in prevention or treatment of various PARP-related diseases)

RN 330948-40-8 CAPLUS
 CN Benzoic acid, 2-amino-3-[(2-quinoxaliny)carbonyl]amino-, methyl ester (9CI) (CA INDEX NAME)



REFERENCE COUNT: 12 THERE ARE 12 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 110 OF 283 CAPLUS COPYRIGHT 2006 ACS on STN
 ACCESSION NUMBER: 2001:152650 CAPLUS
 DOCUMENT NUMBER: 134:207831
 TITLE: Preparation, composition and use of heterocyclic aromatic amides as fungicides
 INVENTOR(S): Ricks, Michael John; Dent, William Hunter, III; Rogers, Richard Brewer; Yao, Chenglin; Nader, Bassem Salim; Miesel, John Louis; Fitzpatrick, Gina Marie; Meyer, Kevin Gerald; Niyaz, Moormohamed Mohamed; Morrison, Irene Mae; Henry, Matthew James; Adamski,

PATENT ASSIGNEE(S): Buts Jennifer Lynn; Gajewski, Robert Peter
 Dow Agrosciences LLC, USA
 SOURCE: PCT Int. Appl., 200 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 2
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001014339	A2	20010301	WO 2000-US21523	20000804
WO 2001014339	A3	20011119		
W: AS, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MM, MX, MY, NZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SP, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TO				
US 6521622	B1	20030218	US 2000-620662	20000720
CA 2376275	A1	20030301	CA 2000-2376275	20000804
AU 2000065267	A5	20030319	AU 2000-65267	20000804
AU 778108	B2	20041118		
US 6355660	B1	20020312	US 2000-632930	20000804
EP 1204643	A2	20020515	EP 2000-952599	20000804
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL				
EP 1234823	A2	20030618	EP 2002-9583	20000804
EP 1234823	A3	20030618		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL				
EP 1234824	A1	20020828	EP 2002-9584	20000804
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL				
EP 1234825	A2	20020828	EP 2002-9585	20000804
EP 1234825	A3	20030618		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL				
EP 1234826	A2	20020828	EP 2002-9586	20000804
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL				
EP 1234827	A2	20020828	EP 2002-9590	20000804
EP 1234827	A3	20030618		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL				
TR 200200409	T2	20030321	TR 2002-200200409	20000804
EP 2000013469	A1	20030429	BR 2000-13469	20000804
JP 2003527324	T2	20030916	JP 2001-518428	20000804
EP 1486489	A2	20041215	EP 2004-22082	20000804
EP 1486489	A3	20050511		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI, CY				
EP 1493733	A2	20050105	EP 2004-22081	20000804
EP 1493733	A3	20050126		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI, CY				
US 2002177578	A1	20021128	US 2001-22413	20011213
US 2003018052	A1	20030123	US 2001-22207	20011213
US 2003018012	A1	20030123	US 2001-22511	20011213
US 6706740	B2	20040316		
US 2003022902	A1	20030130	US 2001-22483	20011213

US 2003022903 A1 20030130 US 2001-23497 20011213
 ZA 2002000435 A 20030117 ZA 2002-435 20020117
 US 2004034025 A1 20040219 US 2002-307844 20021202
 US 2004048864 A1 20040311 US 2002-307710 20021202
 US 6927225 B2 20050809

PRIORITY APPLN. INFO.:
 US 1999-149777P P 19990820
 US 1999-150248P P 19990823
 US 2000-620662 A 20000720
 US 1999-144676P P 19990720
 EP 2000-950599 A3 20000804
 US 2000-632930 A3 20000804
 MD 2000-US1523 W 20000804


OTHER SOURCE(S): MARPAT 134:207831
 GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *


AB Title compds. [I; wherein X1-X4 independently = O, S, NR1, N, CR2, bond; R1 = H, C1-3 alkyl, C2-3 alkenyl, C3-3 alkynyl, OR, CHF2, C1-4 alkoxy; R2 = H, P, Cl, Br, CN, OM, C1-3 alkyl, C1-3 haloalkyl cyclopropyl, C1-3 alkoxy; Z = O, S, NOR3, NOR3; R3 = C1-3 alkyl, A = C1-14 alkyl, C1-14 alkenyl, C1-14 cycloalkyl, aryl, heteroaryl, Q; M = H, Si(t-Bu)Me2, Si(Ph)Me2, SiEt3, C2R4, SO2R5; R4 = H, C1-6 alkyl, C2-6 alkenyl, C3-6 alkynyl; R5 = aryl, heteroaryl, C1-6 alkyl, C2-6 alkenyl, C3-6 alkynyl, C3-6 cycloalkyl, C1-6 cycloalkyl; X, Y independently = O, S; W = O, CH2, bond; R = C1-8 alkyl, C2-8 alkenyl, C2-8 alkynyl, C1-8 cycloalkyl, aryl, heteroaryl; R11 = H, C1-3 alkyl, C2-5 alkenyl, C2-5 alkynyl; R10 = H, R, OR, OOR, OCOOR; R8, R9 independently = H, C1-6 alkyl, C2-6 alkenyl; R6, R7 independently = H, C1-6 alkyl, C2-6 alkenyl, C2-5 alkenyl, C3-6 cycloalkyl] are prepared as fungicides involving application methods of effective usage of title compds. to control fungi, particularly plant pathogens and wood decaying fungi. The invention also encompasses hydrates, salts and complexes thereof. The title compound II was prepared and tested as fungicide.

IT 321601-18-7P
 RL: AGR (Agricultural use); BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PRP (Preparation); USES (Uses) (preparation and fungicidal activity of heterocyclic aromatic amides)

RN 321601-18-7 CAPLUS
 CN 2-Quinoxalinecarboxamide, 3,4-dihydro-3-oxo-N-(3,3,5,5-tetramethylcyclohexyl)- (9CI) (CA INDEX NAME)




L5 ANSWER 111 OF 283 CAPLUS COPYRIGHT 2006 ACS ON STN
 ACCESSION NUMBER: 2001:63978 CAPLUS
 DOCUMENT NUMBER: 134:131431
 TITLE: Fungicidal heterocyclic aromatic amides and their compositions, methods of use and preparation
 INVENTOR(S): Rickes, Michael John; Dent, William Hunter, III; Rogers, Richard Brewer; Yao, Chenglin; Nader, Bassam Salim; Miesel, John Louis; Fitzpatrick, Gina Marie;



AB Title compds. I [W, X, Y, Z are selected from S, O, NR1, N, CR2 or bond and comprise a 5-6 membered (un)substituted heterocyclic ring; R1 = H, alkyl, alkenyl, alkynyl, OR, acyloxy, alkoxy, CHF2, cyclopropyl, or alkoxy; R2 = H, halo, CN, OR, alkyl, haloalkyl, cyclopropyl, alkoxy, haloalkoxy, etc.; O = O, S or NOR3 where R3 = H or alkyl; A = (un)substituted alkyl, alkenyl, alkynyl, cycloalkyl, unsatd. cycloalkyl, heterocycle, bi or tricyclic ring system which may contain heteroatoms, aryl or heteroaryl, etc.] bearing a hydroxy group adjacent to the amide functionality are prepared and disclosed as antifungal agents, particularly for plants. Thus, benzoyl carbamate II was prepared via amidation of 3-benzoyloxy-6-bromo-4-methoxy-pyridin-2-carbonyl chloride with 4-(4-trifluoromethylphenoxy)aniline with subsequent deprotection. The preferred fungicidal composition consists of a compound of formula I with a phytol, acceptable carrier. Activity has been demonstrated against a variety of fungi, e.g., *Plasmopara viticola* (Downy Mildew of Grape), *Phytophthora infestans* (Late Blight of Tomato), and *Venturia inaequalis* (Apple Scab). I is both useful for eradication and prevention of fungal attack.

IT 321601-18-7P
 RL: AGR (Agricultural use); BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PRP (Preparation); USES (Uses) (preparation and fungicidal activity of heterocyclic aromatic amides)


RN 321601-18-7 CAPLUS
 CN 2-Quinoxalinecarboxamide, 3,4-dihydro-3-oxo-N-(3,3,5,5-tetramethylcyclohexyl)- (9CI) (CA INDEX NAME)



L5 ANSWER 112 OF 283 CAPLUS COPYRIGHT 2006 ACS ON STN
 ACCESSION NUMBER: 2000:894633 CAPLUS
 DOCUMENT NUMBER: 134:157715
 TITLE: The discovery of orally-active pseudopeptide antagonists of the atrial natriuretic peptide clearance receptor
 AUTHOR(S): Jacobs, Robert T.; Aharony, David; Alford, Vernon; Bialecki, Russell A.; Cook, Steven E.; Dantzman, Cathy L.; Davenport, Timothy W.; Dock, Steven T.; Edwards, Philip D.; Hostetler, Greg A.; Kirschner, Alan; Mauger, Russell C.; Murphy, Megan; Palmer, William E.; Pine, Kara K.; Rumsey, William L.; Steelman, Gary B.;

Patent Assignee(s):
 SOURCE: Meyer, Kevin Gerald; Niyas, Noormohamed Mohamed; Morrison, Irene Mae; Gajewski, Robert Peter
 Dow Agrosciences LLC, USA
 PCT Int. Appl., 159 pp.
 CODEN: P1IXD2
 Patent
 English
 FAMILY ACC. NUM. COUNT: 2
 PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
MD 2001005769	A2	20010125	MD 2000-US19794	20000720
MD 2001005769	A3	20011122		
W: AS, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CZ, DE, DK, DM, DZ, ES, FI, GB, GD, GE, GH, GR, GU, HA, HD, HE, HF, HG, HK, HN, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MO, MQ, MC, MZ, NL, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, CG, CZ, DE, DK, DM, DZ, ES, FI, GB, GD, GE, GH, GR, GU, HA, HD, HE, HF, HG, HK, HN, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MO, MQ, MC, MZ, NL, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, CG, CZ, DE, DK, DM, DZ, ES, FI, GB, GD, GE, GH, GR, GU, HA, HD, HE, HF, HG, HK, HN, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MO, MQ, MC, MZ, NL, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, CG, CZ, DE, DK, DM, DZ, ES, FI, GB, GD, GE, GH, GR, GU, HA, HD, HE, HF, HG, HK, HN, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MO, MQ, MC, MZ, NL, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, CG, CZ, DE, DK, DM, DZ, ES, FI, GB, GD, GE, GH, GR, GU, HA, HD, HE, HF, HG, HK, HN, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MO, MQ, MC, MZ, NL, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, CG, CZ, DE, DK, DM, DZ, ES, FI, GB, GD, GE, GH, GR, GU, HA, HD, HE, HF, HG, HK, HN, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MO, MQ, MC, MZ, NL, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, CG, CZ, DE, DK, DM, DZ, ES, FI, GB, GD, GE, GH, GR, GU, HA, HD, HE, HF, HG, HK, HN, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MO, MQ, MC, MZ, NL, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, CG, CZ, DE, DK, DM, DZ, ES, FI, GB, GD, GE, GH, GR, GU, HA, HD, HE, HF, HG, HK, HN, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MO, MQ, MC, MZ, NL, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, CG, CZ, DE, DK, DM, DZ, ES, FI, GB, GD, GE, GH, GR, GU, HA, HD, HE, HF, HG, HK, HN, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MO, MQ, MC, MZ, NL, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, CG, CZ, DE, DK, DM, DZ, ES, FI, GB, GD, GE, GH, GR, GU, HA, HD, HE, HF, HG, HK, HN, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MO, MQ, MC, MZ, NL, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, CG, CZ, DE, DK, DM, DZ, ES, FI, GB, GD, GE, GH, GR, GU, HA, HD, HE, HF, HG, HK, HN, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MO, MQ, MC, MZ, NL, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, CG, CZ, DE, DK, DM, DZ, ES, FI, GB, GD, GE, GH, GR, GU, HA, HD, HE, HF, HG, HK, HN, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MO, MQ, MC, MZ, NL, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, CG, CZ, DE, DK, DM, DZ, ES, FI, GB, GD, GE, GH, GR, GU, HA, HD, HE, HF, HG, HK, HN, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MO, MQ, MC, MZ, NL, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, CG, CZ, DE, DK, DM, DZ, ES, FI, GB, GD, GE, GH, GR, GU, HA, HD, HE, HF, HG, HK, HN, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MO, MQ, MC, MZ, NL, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, CG, CZ, DE, DK, DM, DZ, ES, FI, GB, GD, GE, GH, GR, GU, HA, HD, HE, HF, HG, HK, HN, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MO, MQ, MC, MZ, NL, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, CG, CZ, DE, DK, DM, DZ, ES, FI, GB, GD, GE, GH, GR, GU, HA, HD, HE, HF, HG, HK, HN, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MO, MQ, MC, MZ, NL, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, CG, CZ, DE, DK, DM, DZ, ES, FI, GB, GD, GE, GH, GR, GU, HA, HD, HE, HF, HG, HK, HN, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MO, MQ, MC, MZ, NL, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, CG, CZ, DE, DK, DM, DZ, ES, FI, GB, GD, GE, GH, GR, GU, HA, HD, HE, HF, HG, HK, HN, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MO, MQ, MC, MZ, NL, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, CG, CZ, DE, DK, DM, DZ, ES, FI, GB, GD, GE, GH, GR, GU, HA, HD, HE, HF, HG, HK, HN, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MO, MQ, MC, MZ, NL, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, CG, CZ, DE, DK, DM, DZ, ES, FI, GB, GD, GE, GH, GR, GU, HA, HD, HE, HF, HG, HK, HN, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MO, MQ, MC, MZ, NL, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, CG, CZ, DE, DK, DM, DZ, ES, FI, GB, GD, GE, GH, GR, GU, HA, HD, HE, HF, HG, HK, HN, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MO, MQ, MC, MZ, NL, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, CG, CZ, DE, DK, DM, DZ, ES, FI, GB, GD, GE, GH, GR, GU, HA, HD, HE, HF, HG, HK, HN, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MO, MQ, MC, MZ, NL, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, CG, CZ, DE, DK, DM, DZ, ES, FI, GB, GD, GE, GH, GR, GU, HA, HD, HE, HF, HG, HK, HN, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MO, MQ, MC, MZ, NL, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, CG, CZ, DE, DK, DM, DZ, ES, FI, GB, GD, GE, GH, GR, GU, HA, HD, HE, HF, HG, HK, HN, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MO, MQ, MC, MZ, NL, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, CG, CZ, DE, DK, DM, DZ, ES, FI, GB, GD, GE, GH, GR, GU, HA, HD, HE, HF, HG, HK, HN, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MO, MQ, MC, MZ, NL, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, CG, CZ, DE, DK, DM, DZ, ES, FI, GB, GD, GE, GH, GR, GU, HA, HD, HE, HF, HG, HK, HN, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MO, MQ, MC, MZ, NL, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, CG, CZ, DE, DK, DM, DZ, ES, FI, GB, GD, GE, GH, GR, GU, HA, HD, HE, HF, HG, HK, HN, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MO, MQ, MC, MZ, NL, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, CG, CZ, DE, DK, DM, DZ, ES, FI, GB, GD, GE, GH, GR, GU, HA, HD, HE, HF, HG, HK, HN, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MO, MQ, MC, MZ, NL, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, CG, CZ, DE, DK, DM, DZ, ES, FI, GB, GD, GE, GH, GR, GU, HA, HD, HE, HF, HG, HK, HN, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MO, MQ, MC, MZ, NL, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, CG, CZ, DE, DK, DM, DZ, ES, FI, GB, GD, GE, GH, GR, GU, HA, HD, HE, HF, HG, HK, HN, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MO, MQ, MC, MZ, NL, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, CG, CZ, DE, DK, DM, DZ, ES, FI, GB, GD, GE, GH, GR, GU, HA, HD, HE, HF, HG, HK, HN, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MO, MQ, MC, MZ, NL, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, CG, CZ, DE, DK, DM, DZ, ES, FI, GB, GD, GE, GH, GR, GU, HA, HD, HE, HF, HG, HK, HN, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MO, MQ, MC, MZ, NL, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, CG, CZ, DE, DK, DM, DZ, ES, FI, GB, GD, GE, GH, GR, GU, HA, HD, HE, HF, HG, HK, HN, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MO, MQ, MC, MZ, NL, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, CG, CZ, DE, DK, DM, DZ, ES, FI, GB, GD, GE, GH, GR, GU, HA, HD, HE, HF, HG, HK, HN, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MO, MQ, MC, MZ, NL, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, CG, CZ, DE, DK, DM, DZ, ES, FI, GB, GD, GE, GH, GR, GU, HA, HD, HE, HF, HG, HK, HN, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MO, MQ, MC, MZ, NL, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, CG, CZ, DE, DK, DM, DZ, ES, FI, GB, GD, GE, GH, GR, GU, HA, HD, HE, HF, HG, HK, HN, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MO, MQ, MC, MZ, NL, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, CG, CZ, DE, DK, DM, DZ, ES, FI, GB, GD, GE, GH, GR, GU, HA, HD, HE, HF, HG, HK, HN, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MO, MQ, MC, MZ, NL, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, CG, CZ, DE, DK, DM, DZ, ES, FI, GB, GD, GE, GH, GR, GU, HA, HD, HE, HF, HG, HK, HN, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MO, MQ, MC, MZ, NL, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, CG, CZ, DE, DK, DM, DZ, ES, FI, GB, GD, GE, GH, GR, GU, HA, HD, HE, HF, HG, HK, HN, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MO, MQ, MC, MZ, NL, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, CG, CZ, DE, DK, DM, DZ, ES, FI, GB, GD, GE, GH, GR, GU, HA, HD, HE, HF, HG, HK, HN, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MO, MQ, MC, MZ, NL, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, CG, CZ, DE, DK, DM, DZ, ES, FI, GB, GD, GE, GH, GR, GU, HA, HD, HE, HF, HG, HK, HN, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MO, MQ, MC, MZ, NL, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, CG, CZ, DE, DK, DM, DZ, ES, FI, GB, GD, GE, GH, GR, GU, HA, HD, HE, HF, HG, HK, HN, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MO, MQ, MC, MZ, NL, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, CG, CZ, DE, DK, DM, DZ, ES, FI, GB, GD, GE, GH, GR, GU, HA, HD, HE, HF, HG, HK, HN, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MO, MQ, MC, MZ, NL, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, CG, CZ, DE, DK, DM, DZ, ES, FI, GB, GD, GE, GH, GR, GU, HA, HD, HE, HF, HG, HK, HN, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MO, MQ, MC, MZ, NL, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, CG, CZ, DE, DK, DM, DZ, ES, FI, GB, GD, GE, GH, GR, GU, HA, HD, HE, HF, HG, HK, HN, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MO, MQ, MC, MZ, NL, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, CG, CZ, DE, DK, DM, DZ, ES, FI, GB, GD, GE, GH, GR, GU, HA, HD, HE, HF, HG, HK, HN, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MO, MQ, MC, MZ, NL, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, CG, CZ, DE, DK, DM, DZ, ES, FI, GB, GD, GE, GH, GR, GU, HA, HD, HE, HF, HG, HK, HN, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MO, MQ, MC, MZ, NL, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, CG, CZ, DE, DK, DM, DZ, ES, FI, GB, GD, GE, GH, GR, GU, HA, HD, HE, HF, HG, HK, HN, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MO, MQ, MC, MZ, NL, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, CG, CZ, DE, DK, DM, DZ, ES, FI, GB, GD, GE, GH, GR, GU, HA, HD, HE, HF, HG, HK, HN, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MO, MQ, MC, MZ, NL, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, CG, CZ, DE, DK, DM, DZ, ES, FI, GB, GD, GE, GH, GR, GU, HA, HD, HE, HF, HG, HK, HN, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MO, MQ, MC, MZ, NL, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, CG, CZ, DE, DK, DM, DZ, ES, FI, GB, GD, GE, GH, GR, GU, HA, HD, HE, HF, HG, HK, HN, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MO, MQ, MC, MZ, NL, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, CG, CZ, DE, DK, DM, DZ, ES, FI, GB, GD, GE, GH, GR, GU, HA, HD, HE, HF, HG, HK, HN, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MO, MQ, MC, MZ, NL, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, CG, CZ, DE, DK, DM, DZ, ES, FI, GB, GD, GE, GH, GR, GU, HA, HD, HE, HF, HG, HK, HN, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MO, MQ, MC, MZ, NL, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, CG, CZ, DE, DK, DM, DZ, ES, FI, GB, GD, GE, GH, GR, GU, HA, HD, HE, HF, HG, HK, HN, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MO, MQ, MC, MZ, NL, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, CG, CZ, DE, DK, DM, DZ, ES, FI, GB, GD, GE, GH, GR, GU, HA, HD, HE, HF, HG, HK, HN, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MO, MQ, MC, MZ, NL, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, CG, CZ, DE, DK, DM, DZ, ES, FI, GB, GD, GE, GH, GR, GU, HA, HD, HE, HF, HG, HK, HN, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MO, MQ, MC, MZ, NL, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, CG, CZ, DE, DK, DM, DZ, ES, FI, GB, GD, GE, GH, GR, GU, HA, HD, HE, HF, HG, HK, HN, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MO, MQ, MC, MZ, NL, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, CG, CZ, DE, DK, DM, DZ, ES, FI, GB, GD, GE, GH, GR, GU, HA, HD, HE, HF, HG, HK, HN, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MO, MQ, MC, MZ, NL, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, CG, CZ, DE, DK, DM, DZ, ES, FI, GB, GD, GE, GH, GR, GU, HA, HD, HE, HF, HG, HK, HN, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MO, MQ, MC, MZ, NL, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, CG, CZ, DE, DK, DM, DZ, ES, FI, GB, GD, GE, GH, GR, GU, HA, HD, HE, HF, HG, HK, HN, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MO, MQ, MC, MZ, NL, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM,				



REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT


LS ANSWER 113 OF 283 CAPLUS COPYRIGHT 2006 ACS ON STN
 ACCESSION NUMBER: 2000:861662 CAPLUS
 DOCUMENT NUMBER: 134:29325
 TITLE: Preparation of metabotropic glutamate receptor antagonists and their use for treating central nervous system diseases
 INVENTOR(S): Van Wagenen, Bradford C.; Moe, Scott T.; Smith, Daryl L.; Sheehan, Susan M.; Shcherbakova, Irina; Travato, Richard; Walton, Ruth; Barmore, Robert; Delmar, Eric G.; Stornemann, Thomas M.
 PATENT ASSIGNEE(S): NPS Pharmaceuticals, Inc., USA
 SOURCE: PCT Int. Appl., 61 pp.
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 2
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000073183	A1	20001207	WO 2000-US15222	20000602
W: AS, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
CA 2376024	AA	20001207	CA 2000-2376024	20000602
EP 1196397	A1	20020417	EP 2000-936465	20000602
EP 1196397	B1	20050817		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IS, SI, LT, LV, FI, RO, MK, CY, AL				
JP 2003500480	T2	20030107	JP 2000-621349	20000602
NZ 515894	A	20030926	NZ 2000-515894	20000602
AU 778063	B2	20041111	AU 2000-51780	20000602
AT 302194	E	20050915	AT 2000-936465	20000602
EP 1595871	A2	20051116	EP 2005-17791	20000602
EP 1595871	A3	20051130		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IS, SI, LT, LV, FI, RO, MK, CY, AL				
PRIORITY APPL. INFO.: US 1999-137272P P 19990602 EP 2000-936465 A3 20000602 WO 2000-US15222 W 20000602				
OTHER SOURCES(S): MARPAT 134:29325				
GI				




AB Title compds. [R1NHCOR; R = quinolinyl, quinoxalinyl, thiazolidinyl, Ph, benzimidazolyl, pyridyl, naphthyridinyl; R1 = phenylpropyl, cyclopentyl, pentyl, cyclohexyl, quinolinyl], stereoisomers, and pharmaceutically acceptable salts are prepared and are active as metabotropic glutamate receptor antagonists (no date). Title compds. are useful for treating neurol. diseases and disorders in pharmaceutical compns. Thus, the title compound 1 was prepared for treating disease associated with glutamate-induced neuronal damage.
 IT 311346-58-4P
 RL: SPH (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (preparation of mGluR antagonists for treating central nervous system diseases)
 RN 311346-58-4 CAPLUS
 CN 2-Quinoxalinecarboxamide, N-(trans-1-methyl-4-phenylcyclohexyl)- (9CI) (CA INDEX NAME)


Relative stereochemistry.



IT 311346-84-6P 311346-87-9P 311346-91-5P
 311346-96-0P 311346-97-1P 311347-11-2P
 311347-24-7P 311347-25-8P 311347-26-9P
 311347-27-0P 311347-30-5P 311347-31-6P
 311347-32-7P 311347-33-8P 311347-38-3P
 RL: SPH (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (preparation of mGluR antagonists for treating ophthalmol. disorder)
 RN 311346-84-6 CAPLUS
 CN 2-Quinoxalinecarboxamide, N-[2-(2-fluorophenyl)propyl]- (9CI) (CA INDEX NAME)




RN 311346-87-9 CAPLUS
 CN 2-Quinoxalinecarboxamide, N-cyclopentyl- (9CI) (CA INDEX NAME)




RN 311346-91-5 CAPLUS
 CN 2-Quinoxalinecarboxamide, N-(trans-4-phenylcyclohexyl)- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 311346-96-0 CAPLUS
 CN 2-Quinoxalinecarboxamide, N-(1-methyl-4-phenylcyclohexyl)- (9CI) (CA INDEX NAME)




RN 311346-97-1 CAPLUS
 CN 2-Quinoxalinecarboxamide, N-[(1S)-1-phenylethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 311347-11-2 CAPLUS
 CN 2-Quinoxalinecarboxamide, N-[2-(2,6-difluorophenyl)ethyl]- (9CI) (CA INDEX NAME)



RN 311347-24-7 CAPLUS


CN 2-Quinoxalinecarboxamide, 6-fluoro-N-(trans-4-methylcyclohexyl)- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 311347-25-8 CAPLUS
 CN 2-Quinoxalinecarboxamide, 5-fluoro-N-(trans-4-methylcyclohexyl)- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 311347-26-9 CAPLUS
 CN 2-Quinoxalinecarboxamide, N-(trans-4-methylcyclohexyl)-5-(trifluoromethyl)- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 311347-27-0 CAPLUS
 CN 2-Quinoxalinecarboxamide, 6-methoxy-N-(trans-4-methylcyclohexyl)- (9CI) (CA INDEX NAME)


Relative stereochemistry.




RN 311347-30-5 CAPLUS
CN 2-Quinoxalinecarboxamide, N-[2-(2,3-difluorophenyl)ethyl]- (9CI) (CA INDEX NAME)




RN 311347-31-6 CAPLUS
CN 2-Quinoxalinecarboxamide, N-[2-(2,4-difluorophenyl)ethyl]- (9CI) (CA INDEX NAME)




RN 311347-32-7 CAPLUS
CN 2-Quinoxalinecarboxamide, N-[2-(2,5-difluorophenyl)ethyl]- (9CI) (CA INDEX NAME)



RN 311347-33-8 CAPLUS
CN 2-Quinoxalinecarboxamide, N-[2-(3,4-difluorophenyl)ethyl]- (9CI) (CA INDEX NAME)




RN 311347-36-3 CAPLUS
CN 2-Quinoxalinecarboxamide, N-[2-(3,5-difluorophenyl)ethyl]- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 114 OF 283 CAPLUS COPYRIGHT 2006 ACS on STM
ACCESSION NUMBER: 2000:113403 CAPLUS
DOCUMENT NUMBER: 134:115915


TITLE: Some reactions with quinoxaline-2,3-dicarboxylic acid anhydride. Synthesis of quinoxalinoquinoxalines and quinoxalino [2,3:6,1]pyridazino[4,5-b]quinoxalines
AUTHOR(S): Zahran, Medhat A.
CORPORATE SOURCE: Chemistry Department, Faculty of Science, Al-Azhar University, Nasr City, Egypt
SOURCE: Journal of the Indian Chemical Society (2000), 77(10), 494-496
CODEN: JICSAH; ISSN: 0019-4522
PUBLISHER: Indian Chemical Society
DOCUMENT TYPE: Journal
LANGUAGE: English
OTHER SOURCE(S): CASREACT 134:115915
OI




AB Quinoxalinoquinoxalines, e.g. I (R = H, NH2, 4-ClC6H4CH2N, 4-MeOC6H4CH2N, PhCONH, 4-MeC6H4SO2NH, 4-BrC6H4SO2NH, PhNHCONH, 4-ClC6H4NHCONH, 4-MeOC6H4, 4-ClC6H4), and quinoxalinoquinoxalines II have been prepared starting from quinoxaline-2,3-dicarboxylic acid anhydride.

IT 320590-45-2P 320590-46-3P 320590-47-4P
320590-48-5P 320590-50-3P 320590-51-0P
320590-52-1P 320590-53-2P 320590-56-5P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of quinoxalinoquinoxalines and quinoxalinoquinoxalines II via condensation of quinoxalinedicarboxylic acid anhydride with anthranilic acid or Me anthranilate)


RN 320590-45-2 CAPLUS
CN 2-Quinoxalinecarboxylic acid, 3-[[[2-carboxyphenyl]amino]carbonyl]- (9CI) (CA INDEX NAME)




RN 320590-46-3 CAPLUS
CN 2-Quinoxalinecarboxylic acid, 3-[[[2-(methoxycarbonyl)phenyl]amino]carbonyl]- (9CI) (CA INDEX NAME)





RN 320590-47-4 CAPLUS
CN Benzoic acid, 2-[[[2-(quinoxalinylyl)carbonyl]amino]- (9CI) (CA INDEX NAME)





RN 320590-48-5 CAPLUS
CN Benzoic acid, 2-[[[2-(quinoxalinylyl)carbonyl]amino]-, methyl ester (9CI) (CA INDEX NAME)




RN 320590-50-9 CAPLUS
CN Benzoic acid, 2-[[[3-[[[4-methoxyphenyl]amino]carbonyl]-2-quinoxalinylyl]carbonyl]amino]- (9CI) (CA INDEX NAME)




RN 320590-51-0 CAPLUS
CN Benzoic acid, 2-[[[3-[[[4-methoxyphenyl]amino]carbonyl]-2-quinoxalinylyl]carbonyl]amino]- (9CI) (CA INDEX NAME)




RN 320590-52-1 CAPLUS
CN Benzoic acid, 2-[[[3-[[[4-methoxyphenyl]amino]carbonyl]-2-quinoxalinylyl]carbonyl]amino]-, methyl ester (9CI) (CA INDEX NAME)




RN 320590-53-2 CAPLUS
CN Benzoic acid, 2-[[[3-[[[4-methoxyphenyl]amino]carbonyl]-2-quinoxalinylyl]carbonyl]amino]-, methyl ester (9CI) (CA INDEX NAME)




RN 320590-56-5 CAPLUS
CN 2-Quinoxalinecarboxamide, N-(4-methoxyphenyl)-3-(4-oxo-4H-3,1-benzoxazin-2-yl)- (9CI) (CA INDEX NAME)




IT 320590-54-3P 320590-58-7P 320590-59-8P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of quinoxalinoquinoxalines and quinoxalinopyridazinoquinoxaline
a via condensation of quinoxalinedicarboxylic acid anhydride with
anthranilic acid or Me anthranilate)
RN 320590-54-3 CAPLUS
CN Benzoic acid, 2-[[[3-(4-morpholinylcarbonyl)-2-
quinoxaliny]carbonyl]amino]-, methyl ester (9CI) (CA INDEX NAME)



RN 320590-58-7 CAPLUS
CN 2-Quinoxalinecarboxamide, 3-(3-amino-3,4-dihydro-4-oxo-2-quinoxaliny)-N-(4-methoxyphenyl)- (9CI) (CA INDEX NAME)



RN 320590-59-8 CAPLUS
CN 2-Quinoxalinecarboxamide, 3-(3-amino-3,4-dihydro-4-oxo-2-quinoxaliny)-N-(4-chlorophenyl)- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 10 THERE ARE 10 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 115 OF 263 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2000:742139 CAPLUS
DOCUMENT NUMBER: 133:310145
TITLE: Preparation of modified pentapeptide antagonists of the atrial natriuretic peptide clearance receptor
INVENTOR(S): Vcale, Chris Allan; Edwards, Philip Duke; Jacobs, Robert Toms; Davenport, Timothy Wayne; Warwick, Paul James
PATENT ASSIGNEE(S): AstraZeneca AB, Swed.
SOURCE: PCT Int. Appl., 52 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000061631	A1	20001019	WO 2000-GB1319	20000407


W: JP, US
RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE
PRIORITY APPL. INFO.: US 1999-128690P P 19990412
OTHER SOURCE(S): MARPAT 133:310145
AB Comps. R5-R4-R3-CH2CONR2-X-NR1CHR6CO[NHCH(CH2CO2H)CO-R7-R8-(S)] [X = CR1:CH, CHR1CO (I), or CR1CO; R12 = CH2CH2, CH2CH2CH2, :CHCH:CH, N:CH; R2 = H, Me; R3 = CH2CH2CH2, (S)-CH:CHCONH, CH2CH2CONH, phenylene, or a single bond; R4 = NHCO, CONH, SO2NH; R5 = 1- or 2-naphthyl, CH2CH2NHCH2CH:CHPh, CH2CH2Ph, CH:CHPh, 2-, 3-, 4-, or 6-quinolyl, 3-isoquinolyl, 2-quinoxaline, 5-chloro-2-indolyl, 2-indolyl, (un)substituted Ph,

CH2CH2CH2Ph, 6-quinolylcarbonyl, 2-quinoxalinecarbonyl, 5-chloro-2-benzimidazolyl, fluorenylmethoxycarbonyl, 4-chlorobenzyl, 4-methylbenzyl, 3-quinoxaliny, 3,4-difluorophenyl, 4-fluorophenyl; R6 = iso-Bu, sec-butyl; R7 = N-methylglycine, NHCH2CH2NHCO, L- or D-arginine or -ornithine, histidine, citrulline, proline, etc.; R8 = L- or D-isoleucine-NH2, CH2-cyclopentyl, CH2-2-furanyl, tert-butylglycine-NH2, Bu, etc.) were prepared as antagonists of the atrial natriuretic peptide clearance receptor. Thus, inhibitory test data are tabulated for 156 compds. of the invention, including I [R12 = CH2CH2 (S-configuration); R2 = H; R3 = p-phenylene; R4 = CONH; R5 = 2-naphthyl; R6 = sec-Bu (S-configuration); R7 = N-MeGly; R8 = Ile-NH2] (Ki = 2.17 nM).


IT 301839-48-2P 301839-08-7P 301839-95-2P
301839-97-4P 301840-15-3P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of modified pentapeptide antagonists of the atrial natriuretic peptide clearance receptor)

RN 301839-48-2 CAPLUS
CN L-Isoleucinamide, N-[(2S,3S)-3-methyl-2-[(3R)-3-[methyl[[4-[(2-quinoxaliny]carbonyl]amino]phenyl]acetyl]amino]-2-oxo-1-pyrrolidinyl]pentyl]-L-α-aspartyl-D-arginyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




PAGE 2-A




RN 301839-08-7 CAPLUS

CN L-Isoleucinamide, N-[(2S,3S)-3-methyl-1-oxo-2-[(3R)-2-oxo-3-[[[4-[(2-quinoxaliny]carbonyl]amino]phenyl]acetyl]amino]-1-pyrrolidinyl]pentyl]-L-α-aspartyl-D-arginyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.





PAGE 2-A





RN 301839-95-2 CAPLUS
CN L-Isoleucinamide, N-[(2S,3S)-3-methyl-1-oxo-2-[(3R)-2-oxo-3-[[[4-[(2-quinoxaliny]carbonyl]amino]phenyl]acetyl]amino]-1-pyrrolidinyl]pentyl]-L-α-aspartyl-N-methylglycyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 301839-97-4 CAPLUS
CN L-Isoleucinamide, N-[(2S,3S)-3-methyl-1-oxo-2-[(3R)-2-oxo-3-[[[4-[(2-quinoxalinylylcarbonyl)amino]phenyl]acetyl]amino]-1-pyrrolidinyl]pentyl]-L-α-aspartyl-D-ornithyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.





IT 301840-52-8P 301840-53-9P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of modified pentapeptide antagonists of the atrial natriuretic peptide clearance receptor)

RN 301840-52-8 CAPLUS
CN Benzenesacetic acid, 4-[(2-quinoxalinylylcarbonyl)amino]- (9CI) (CA INDEX NAME)




RN 301840-53-9 CAPLUS
CN Benzenesacetic acid, 4-[(2-quinoxalinylylcarbonyl)amino]-, ethyl ester (9CI) (CA INDEX NAME)



RN 301840-15-3 CAPLUS
CN D-Argininamide, N-[(2S,3S)-3-methyl-1-oxo-2-[(3R)-2-oxo-3-[[[4-[(2-quinoxalinylylcarbonyl)amino]phenyl]acetyl]amino]-1-pyrrolidinyl]pentyl]-L-α-aspartyl-N-(cyclohexylmethyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 116 OF 283 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2000:658115 CAPLUS
DOCUMENT NUMBER: 133:238010
TITLE: Preparation of pyrazole derivatives as blockers of calcium release-activated calcium channel (CRACC)
INVENTOR(S): Kubota, Koichi; Yoshimura, Noriko; Okamoto, Yoshinori; Yonetoku, Yasuhiro; Naito, Makoto; Ishikawa, Atsushi; Takeuchi, Makoto
PATENT ASSIGNER(S): Yamanouchi Pharmaceutical Co., Ltd., Japan
SOURCE: Jpn. Kokai Tokkyo Koho, 22 pp.
CODEN: JKKXAF
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 2000256358	A2	20000919	JP 1999-62900	19990310
PRIORITY APPLN. INFO.:			JP 1999-62900	19990310
OTHER SOURCE(S):		MARPAT 133:238010		



AB The title compds. (I; ring D = pyrazolyl optionally substituted with 1-3 substituents selected from lower alkyl, alkenyl, alkynyl, or haloalkyl, lower alkylene-cycloalkyl, lower alkylene-O-lower alkyl, cycloalkyl, O-lower alkyl, CO₂H, lower alkoxy, carbonyl, and halo; ring B = phenylene or optionally lower-substituted bivalent monocyclic aromatic heterocyclic ring; X = NR₁CO, CONR₁, NR₁SO₂, SO₂NR₁; wherein R₁ = H, OH, lower alkyl, O-lower alkyl, lower alkyl-carbonyl; Y = bond, CO, lower alkylene, or lower alkenylene; ring A = Ph having at least one substituent selected from HO, O-lower alkyl, and F, or optionally substituent mono-, bi-, or tricyclic condensed heteroaryl; provided that when Y is a bond, ring A represents a group other than heteroaryl selected from thienyl, pyrrolyl, imidazolyl, thiazolyl, oxazolyl, thiadiazolyl, pyridyl, pyrazinyl, and isoquinolyl) and pharmaceutically acceptable salts thereof are prepared. These compds. exhibit the inhibitory activity against CRACC and the production of interleukin-2 and are useful for the prevention or treatment of allergies, inflammations, and autoimmune diseases. Thus, 2,1,3-benzoxadiazole-5-carbonyl chloride and Et₃N were successively added to a mixture of 4-[3,5-bis(trifluoromethyl)-1H-pyrazol-1-yl]aniline and CH₂Cl₂ and stirred at room temperature for 8.5 h to give N-[(2,1,3-benzoxadiazol-5-yl)carbonyl]-4-[3,5-bis(trifluoromethyl)-1H-pyrazol-1-yl]aniline. Preferred compds. I


inhibited thapsigargin-stimulated increase in calcium concentration with IC50 of 51 µM and the production of interleukin-2 with IC50 of ≤0.1 µM in Jurkat cell.

IT 292610-57-2P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USSS (Usses) (preparation of pyrazole derivs. as blockers of calcium release-activated calcium channel and inhibitors of interleukin-2 production)

RN 292610-57-2 CAPLUS

CN 2-Quinoxalinecarboxamide, N-[4-[3,5-bis(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]-3,4-dihydro-3-oxo- (9CI) (CA INDEX NAME)



L5 ANSWER 117 OF 283 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2000:409841 CAPLUS

DOCUMENT NUMBER: 133:309882

TITLE: New pyrazolo[3,4-b]pyrazines: synthesis and biological activity

AUTHOR(S): El-Kashef, H. S.; El-Emary, T. I.; Gaequet, M.; Timon-David, P.; Maldonado, J.; Vanelle, P.

CORPORATE SOURCE: Faculty of Science, Assiut University, Assiut, Egypt

SOURCE: Pharmazie (2000), 55(6), 572-576

CODEN: PHARAT; ISSN: 0031-7144


PUBLISHER: Govi-Verlag Pharmazeutischer Verlag

DOCUMENT TYPE: Journal

LANGUAGE: English

OTHER SOURCE(S): CASREACT 133:309882

GI



AB Some new pyrazolo[3,4-b]pyrazines and related heterocycles were synthesized and evaluated for their antifungal and antiparasitic activities. The key intermediate, 6-amino-3-methyl-1-phenyl-1H-pyrazolo[3,4-b]pyrazine-5-carbonitrile (I), was obtained in a one-pot synthesis from the reaction of 5-amino-3-methyl-4-nitroso-1-phenylpyrazole (II) with malononitrile.

IT 302584-69-6P


RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)

(preparation of pyrazole derivs. as blockers of calcium release-activated calcium channel and inhibitors of interleukin-2 production)

pyrazolo[3,4-b]pyrazines)

RN 302584-69-6 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyrazine-5-carboxamide, 6-amino-3-methyl-N,1-diphenyl- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 24 THERE ARE 24 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 116 OF 283 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2000:452347 CAPLUS

DOCUMENT NUMBER: 133:49798

TITLE: Preparation of peptidyl boronic ester and acid compounds as proteasome inhibitors

INVENTOR(S): Adams, Julian; Ma, Yu-Ting; Stein, Ross; Baevsky, Matthew; Grenier, Louis; Plamondon, Louis

PATENT ASSIGNER(S): Leukosite, Inc., USA

SOURCE: U.S., 38 pp., Cont.-in-part of U.S. Ser. No. 330,525, abandoned.

CODEN: USXXAM

Patent

English

FAMILY ACC. NUM. COUNT: 3

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 6081903	A	20000704	US 1995-442581	19950516
CA 2203936	AA	19960509	CA 1995-2203936	19951027
CA 2203936	C	20050412		
CA 2496538	AA	19960509	CA 1995-2496538	19951027
WO 9613266	A1	19960509	WO 1995-US14117	19951027
M: AL, AM, AT, AU, BB, BO, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK				
RW, KE, LS, MW, SD, SZ, UO, AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TO				
AU 9641398	A1	19960523	AU 1996-41398	19951027
AU 710564	B2	19990923		
ZA 9509119	A	19960527	ZA 1995-9119	19951027
EP 788160	A1	19970813	EP 1995-939670	19951027
EP 788160	B1	20000528		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE				
CN 1168633	A	19971224	CN 1995-196590	19951027
US 5780454	A	19980714	US 1995-549318	19951027
JP 10510245	T2	19981006	JP 1996-514834	19951027
JP 3717934	B2	20051116		
NZ 337211	A	20001222	NZ 1995-337211	19951027
IL 115790	A1	20021201	IL 1995-115790	19951027
EP 1312609	A1	20030521	EP 2001-4280	19951027
EP 1312609	B1	20051228		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, NL, SE, MC, PT, IE				
AT 241631	E	20030615	AT 1995-939670	19951027
PT 788160	T	20031031	PT 1995-939670	19951027

ES 2199257 T3 20040216 ES 1995-939670 19951027

IL 133831 A1 20040328 IL 1995-133831 19951027

IL 137726 A1 20040831 IL 1995-137726 19951027

AT 314378 E 20060115 AT 2003-4280 19951027

SP 1627880 A1 20060222 EP 2005-21462 19951027

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, NL, SE, MC, PT, IE

FI 9701746 A 19970606 FI 1997-1746 19970423

NO 9701929 A 19970612 NO 1997-1929 19970425

NO 310556 B1 20010723

HK 1002059 A1 20010905 HK 1998-100951 19980207

US 6066730 A 20000523 US 1998-85404 19980526

US 6297217 B1 20011002 US 2000-490511 20000125

US 6465433 B1 20021015 US 2001-953540 20010914

US 2002173488 A1 20021121 US 2002-100295 20020318

US 6548668 B2 20010415

US 6617317 B1 20030909 US 2002-125997 20020419

US 2003199561 A1 20031023 US 2003-392165 20030319

US 6747150 B2 20040608

US 2004167332 A1 20040826 US 2003-730231 20031208

PRIORITY APPL. INFO.: MARPAT 133:89798

US 1994-330525 B2 19941028

US 1995-442581 A 19950516

CA 1995-2203936 A3 19951027

EP 1995-939670 A3 19951027

EP 2003-4280 A3 19951027

IL 1995-115790 A3 19951027

NZ 1995-296717 A1 19951027

US 1995-549318 A3 19951027

WO 1995-US14117 W 19951027

US 1998-85404 A3 19980526

US 2000-490511 A1 20000125

US 2001-953540 A1 20010914

US 2002-100295 A1 20020318

US 2002-125997 A1 20020419

US 2003-392165 A1 20030319

OTHER SOURCE(S): MARPAT 133:89798

AB Peptidyl boronic acid and ester compds. P-NRCH2R2-X2-CHR3B2122 [P = 2- or 8-quinolyl-, 2-quinolalyl-, 2- or 3-pyridyl-, piperazinyl-, 3-furanyl-, or 3-pyrrolylcarbonyl, or -sulfonyl, or morpholinylcarbonyl; X2 = CONH, CH2NH, CH(OH)CH2, CH(OH)CH(OH), CH(OH)CH2NH, CH(OH)COCH2, SO2NH, SO2CH2, or CH(OH)CH2CONH; R = H or alkyl; R2, R3 = H, alkyl, cycloalkyl, aryl, heterocyclyl, CH2-R5 (R5 = aryl, alkyl, alkaryl, cycloalkyl, heterocyclyl) or alkyl-chalcogen; Z1, Z2 = alkyl, hydroxy, alkoxy, aryloxy, or together form a dihydroxy compound] were prepared as proteasome inhibitors. Thus, coupling of (1S,2S,3R,5S)-pinenediol leucine boronate trifluoroacetate salt with N-Boc-β-(1-naphthyl)-L-alanine, followed by deprotection, acylation with 4-morpholinylcarbonyl chloride and cleavage of the pinenediol moiety afforded N-(4-morpholine)carbonyl-β-(1-naphthyl)-L-alanine-L-leucine boronic acid [MO-273], which inhibited 20S proteasome with Ki = 0.18 nM.

IT 179324-42-6P, MO 299

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USSS (Usses) (preparation of peptidyl boronic ester and acid compds. as proteasome inhibitors)

RN 179324-42-6 CAPLUS

CN Boronic acid, [(1R)-3-methyl-1-[(2S)-3-(1-naphthalenyl)-1-oxo-2-[(2-quinolalyl)carbonyl]amino]propyl]amino]butyl]- (9CI) (CA INDEX NAME)

AB Peptidyl boronic acid and ester compds. P-NRCH2R2-X2-CHR3B2122 [P = 2- or 8-quinolyl-, 2-quinolalyl-, 2- or 3-pyridyl-, piperazinyl-, 3-furanyl-, or 3-pyrrolylcarbonyl, or -sulfonyl, or morpholinylcarbonyl; X2 = CONH, CH2NH, CH(OH)CH2, CH(OH)CH(OH), CH(OH)CH2NH, CH(OH)COCH2, SO2NH, SO2CH2, or CH(OH)CH2CONH; R = H or alkyl; R2, R3 = H, alkyl, cycloalkyl, aryl, heterocyclyl, CH2-R5 (R5 = aryl, alkyl, alkaryl, cycloalkyl, heterocyclyl) or alkyl-chalcogen; Z1, Z2 = alkyl, hydroxy, alkoxy, aryloxy, or together form a dihydroxy compound] were prepared as proteasome inhibitors. Thus, coupling of (1S,2S,3R,5S)-pinenediol leucine boronate trifluoroacetate salt with N-Boc-β-(1-naphthyl)-L-alanine, followed by deprotection, acylation with 4-morpholinylcarbonyl chloride and cleavage of the pinenediol moiety afforded N-(4-morpholine)carbonyl-β-(1-naphthyl)-L-alanine-L-leucine boronic acid [MO-273], which inhibited 20S proteasome with Ki = 0.18 nM.


IT 179324-42-6P, MO 299

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USSS (Usses) (preparation of peptidyl boronic ester and acid compds. as proteasome inhibitors)

RN 179324-42-6 CAPLUS

CN Boronic acid, [(1R)-3-methyl-1-[(2S)-3-(1-naphthalenyl)-1-oxo-2-[(2-quinolalyl)carbonyl]amino]propyl]amino]butyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 119 OF 283 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2000:431292 CAPLUS

DOCUMENT NUMBER: 133:164438

TITLE: A new polymer-bound N-hydroxy succinimide active ester linker

AUTHOR(S): Shao, Rui; Zhang, Qiang; Goodnow, Robert; Chen, Li; Tam, Steve

CORPORATE SOURCE: Department of Discovery Chemistry, Roche Research Center, Hoffmann-La Roche, Inc., Nutley, NJ, 07110, USA

SOURCE: Tetrahedron Letters (2000), 41(22), 4257-4260

CODEN: TETLEA; ISSN: 0040-4039

PUBLISHER: Elsevier Science Ltd.

DOCUMENT TYPE: Journal

LANGUAGE: English

AB Synthesis of a new N-hydroxy succinimide resin is described and the N-acylation with this resin provides amide products in high yields and excellent purities. This new linker is suitable for combinatorial library synthesis.


IT 287945-56-6P 287945-57-7P

RL: SPN (Synthetic preparation); PREP (Preparation)

(preparation of polymer-bound N-hydroxy succinimide active ester linker for N-acylation)


RN 287945-56-6 CAPLUS

CN 2-Quinoxalinecarboxamide, N-[(4-methoxyphenyl)methyl]- (9CI) (CA INDEX NAME)



RN 287945-57-7 CAPLUS

CN 2-Quinoxalinecarboxamide, N-[2-(2,5-dimethoxyphenyl)ethyl]- (9CI) (CA INDEX NAME)




REFERENCE COUNT: 21 THERE ARE 21 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 120 OF 283 CAPLUS COPYRIGHT 2006 ACS ON STN
 ACCESSION NUMBER: 2000:421161 CAPLUS
 DOCUMENT NUMBER: 133:53708
 TITLE: Substituted heterocyclic acyl-tripeptides useful as thrombin receptor modulators
 INVENTOR(S): McComsey, David F.; Maryanoff, Bruce E.; Hawkins, Michael J.
 PATENT ASSIGNEE(S): Ortho-McNeil Pharmaceutical, Inc., USA
 SOURCE: PCT Int. Appl., 57 pp.
 CODEN: PLEXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 2
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000035942	A1	20000622	WO 1999-US27570	19991119
W: AS, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GR, GU, HK, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RU, RO, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SF, BJ, CP, CO, CI, CM, GA, GN, GW, HR, HU, IL, IN, IS, IT, KE, KP, KR, KZ, LC, LK, LR, LS, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RU, RO, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
CA 2355818	AA	20000622	CA 1999-2355818	19991119
EP 1140985	A1	20011010	EP 1999-961738	19991119
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IS, SI, LT, LV, FI, RO				
BR 9916811	A	20020115	BR 1999-16811	19991119
TR 200102502	T2	20020521	TR 2001-200102502	19991119
AU 771844	B2	20040401	AU 2000-18256	19991119
NO 2001002939	A	20010609	NO 2001-2939	20010614
US 1998-112311P P 19981214				
US 1999-444327 A 19991119				
WO 1999-US27570 W 19991119				

OTHER SOURCE(S): MARPAT 133:53708
 AB Substituted heterocyclic acyl-tripeptides, useful as thrombin receptor modulators, are disclosed, as is their use in wound healing and preventing platelet aggregation. Pharmaceutical compns. comprising the substituted heterocyclic acyl-tripeptides of the invention, as well as methods of treating conditions mediated by the thrombin receptor, are also disclosed.
 IT 231608-75-6
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (heterocyclic acyl-tripeptide deriva. for thrombin receptor modulators)
 RN 231608-75-6 CAPLUS
 CN L-Phenylalaninamide, 3-cyclohexyl-N-(2-quinoloxalinyloxycarbonyl)-L-alanyl-L-

arganyl- (9CI) (CA INDEX NAME)
 Absolute stereochemistry.



REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT


L5 ANSWER 121 OF 283 CAPLUS COPYRIGHT 2006 ACS ON STN
 ACCESSION NUMBER: 2000:368337 CAPLUS
 DOCUMENT NUMBER: 133:4656
 TITLE: Preparation of heteroarylpyrazoles as p38 kinase inhibitors
 INVENTOR(S): Anantaraman, Ashok; Clare, Michael; Collins, Paul W.; Crich, Joyce Z.; Devraj, Rajesh; Flynn, Daniel L.; Geng, Lifeng; Graneto, Matthew J.; Hanau, Cathleen E.; Hanson, Gunner J.; Hartmann, Susan J.; Hepperle, Michael; Huang, He; Kanne, Ish K.; Koszyk, Francis J.; Liu, Shuyuan; Metz, Suzanne; Partis, Richard A.; Perry, Thao D.; Rao, Shashidhar M.; Selness, Shaun Raj; South, Michael S.; Stealey, Michael A.; Talley, John Jeffrey; Vazquez, Michael L.; Weier, Richard M.; Xu, Xiangdong; Yu, Yi
 PATENT ASSIGNEE(S): G.D. Searle and Co., USA
 SOURCE: PCT Int. Appl., 1210 pp.
 CODEN: PLEXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 4
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000031063	A1	20000602	WO 1999-US26007	19991117
W: AS, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GR, GU, HK, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MW, MX, NO, NZ, PL, PT, RU, RO, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SF, BJ, CP, CO, CI, CM, GA, GN, GW, HR, HU, IL, IN, IS, IT, KE, KP, KR, KZ, LC, LK, LR, LS, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RU, RO, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
US 6514977	B1	20010204	US 1998-136623	19981120
CA 2351725	AA	20000602	CA 1999-2351725	19991117
EP 1144403	A1	20011017	EP 1999-965756	19991117
EP 1144403	B1	20041006		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IS, SI, LT, LV, FI, RO				
BR 9915420	A	20020122	BR 1999-15420	19991117

EE 200100268 A 20021216 EE 2001-268 19991117
 NZ 512344 A 20031128 NZ 1999-512344 19991117
 AU 774262 B2 20040624 AU 2000-21454 19991117
 AT 276685 E 20041015 AT 1999-965756 19991117
 ES 2229809 T3 20050416 ES 1999-965756 19991117
 US 6520509 B1 20020225 US 2000-513351 20000224
 NO 2001002456 A 20010719 NO 2001-2456 20010518
 BG 105620 A 20020131 BG 2001-105620 20010619
 HK 1040705 A1 20050304 HK 2002-102213 20020322
 US 1998-196623 A 19981120
 US 1997-47570P P 19970522
 US 1998-83670 A2 19980522
 WO 1999-US26007 W 19991117
 OTHER SOURCE(S): MARPAT 133:4656
 GI



AB Title compds. [I: R1 = H, OH, NH2, (cyclo)alk(en)yl, acyl, aryl, etc.; R2 = H, halo, alkyl, alkoxy, (un)substituted piperidinyl, etc.; R3 = pyridyl, pyrimidinyl, quinolyl, etc.; R4 = H, alkyl, heterocycl, aryl, etc.] were prepared by reaction of ketones with hydrazines. Thus, R3CH2COMe (R3 = 4-pyridinyl) was condensed with 3,4-F(MeO)C6H3CHO and the product cyclized with TBAH to give title compound II. Data for biol. activity of I were given.
 IT 216518-34-2P
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (Preparation of heteroarylpyrazole p38 kinase inhibitors by cyclocondensation of hydrazines with ketones)
 RN 216518-34-2 CAPLUS
 CN 2-Quinoxalinecarboxamide, N-[(1R)-1-{5-(4-fluorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl}-2-phenylethyl]- (9CI) (CA INDEX NAME)
 Absolute stereochemistry.




REFERENCE COUNT: 10 THERE ARE 10 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 122 OF 283 CAPLUS COPYRIGHT 2006 ACS ON STN


ACCESSION NUMBER: 2000:242342 CAPLUS
 DOCUMENT NUMBER: 133:37715
 TITLE: Quinoxaline chemistry. Part 13: 3-carboxy-2-benzylamino-substituted quinoxalines and N-[4-[(3-carboxyquinoxalin-2-yl)aminomethyl]benzoyl]-L-glutamate: synthesis and evaluation of in vitro anticancer activity
 AUTHOR(S): Corona, Paola; Vitale, Gabriella; Loriga, Mario; Paglietti, Giuseppe
 CORPORATE SOURCE: Dipartimento Farmaco Chimico Tossicologico, Universita di Sassari, Sassari, 07100, Italy
 SOURCE: Farmaco (2000), 55(3), 77-86
 CODEN: FRMCEB; ISSN: 0014-827X
 PUBLISHER: Elsevier Science S.A.
 DOCUMENT TYPE: Journal
 LANGUAGE: English

AB Among a new series of 28 3-carboxy or carbethoxy quinoxalines bearing a substituted benzylamino or N-[4-(aminomethyl)benzoyl]glutamate group on position 2 of the ring and various substituents at C-6, 7 positions, 21 were selected at the National Cancer Institute for evaluation of their in vitro anticancer activity. The results obtained seem to confirm that the carboxy or carbethoxy group on position 3 is not helpful, with a few exceptions, for the anticancer activity.

IT 274686-94-1P 274686-95-2P
 RL: BVP (Byproduct); PREP (Preparation)
 (synthesis and evaluation of in vitro anticancer activity of carboxybenzylamino-substituted quinoxalines and [4-[(3-carboxyquinoxalin-2-yl)aminomethyl]benzoyl]-L-glutamates in relation to structure)
 RN 274686-94-1 CAPLUS
 CN 2-Quinoxalinecarboxamide, N-[(3,4-dichlorophenyl)methyl]-3-[[[3,4-dichlorophenyl)methyl]amino]- (9CI) (CA INDEX NAME)



RN 274686-95-2 CAPLUS
 CN 2-Quinoxalinecarboxamide, N-[(4-methoxyphenyl)methyl]-3-[[[4-methoxyphenyl)methyl]amino]-6-(trifluoromethyl)- (9CI) (CA INDEX NAME)




REFERENCE COUNT: 12 THERE ARE 12 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 123 OF 283 CAPLUS COPYRIGHT 2006 ACS ON STN
 ACCESSION NUMBER: 2000:227634 CAPLUS
 DOCUMENT NUMBER: 132:265091
 TITLE: Preparation of N-(benzamidophenyl)pyridinecarboxamides and analogs as cytokine production inhibitors
 INVENTOR(S): Brown, Deary Sutherland; Brown, George Robert
 PATENT ASSIGNER(S): Zeneca Limited, UK
 SOURCE: PCT Int. Appl., 138 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000018738	A1	20000406	WO 1999-GB3144	19990921
W: AS, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, ES, FI, GB, GD, GE, GH, GM, GR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW				
RM: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, NI, TD, TO				
CA 2340454	AA	20000406	CA 1999-2340454	19990921
AU 9961034	A1	20000417	AU 1999-61034	19990921
AU 761361	B2	20000605		19990921
BR 9913947	A	20010612	BR 1999-13947	19990921
EP 1115707	A1	20010718	EP 1999-947653	19990921
EP 1115707	B1	20031112		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
TR 200100840	T2	20011022	TR 2001-200100840	19990921
JP 2002525358	T2	20020813	JP 2000-572198	19990921
NZ 509836	A	20030630	NZ 1999-509836	19990921
AT 254105	E	20031115	AT 1999-947653	19990921
RU 2219171	C2	20031220	RU 2001-111320	19990921
PT 1115707	T	20040430	PT 1999-947653	19990921
ES 2211172	T3	20040901	ES 1999-947653	19990921
ZA 2001002185	A	20020618	ZA 2001-2185	20010315
NO 2001001492	A	20010525	NO 2001-1492	20010323
US 318800	B1	20050509		
US 6455520	B1	20020924	US 2001-787882	20010323
HK 1038556	A1	20040430	HK 2001-107980	20011113
PRIORITY APPL. INFO.:			GB 1998-26938	A 19981209
			GB 1999-5969	A 19990317
			WO 1999-GB3144	W 19990921

OTHER SOURCE(S): MARPAT 132:265091
 GI




AB R4Z4ZCONH21NHCOZ2R2 [I: R2 = 23R3; R3 = (un)substituted heteroaryl; R4 =

(di)alkylamino(alkyl), heterocyclyl(alkyl), heteroaryl(alkyl), etc.; Z = (un)substituted phenylene; Z1 = 2-halo- or -alkyl-1,5-phenylene; Z2 = bond or (CH2)1-4; Z3 = bond, O, NH, alkyleneoxy, alkyleneamino, etc.; Z4 = bond, alkylene(oxy), alkyleneamino, etc. were prepared as p38 kinase inhibitors. Thus, 3-(C1C2C3C4C5C6) was amidated by 2-methyl-5-nitroaniline and the product amidated by 1-methylpiperazine to give, after reduction and pyridine-3-carbonyl chloride amidation, title compound II. Data for biol. activity of I were given.

IT 263267-83-0P
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (preparation of N-(benzamidophenyl)pyridinecarboxamides and analogs as cytokine production inhibitors)

RM 263267-83-0 CAPLUS
 CN 2-Quinoxalinecarboxamide, N-[4-methyl-3-[[3-[[4-methyl-1-piperazinyl)methyl]benzoyl]aminophenyl]- (9CI) (CA INDEX NAME)




REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 124 OF 283 CAPLUS COPYRIGHT 2006 ACS ON STN
 ACCESSION NUMBER: 2000:133728 CAPLUS
 DOCUMENT NUMBER: 132:175808
 TITLE: Hepatitis C inhibitor peptides
 INVENTOR(S): Llinas-Brunet, Montse; Bailey, Murray D.; Cameron, Dale; Ghio, Elise; Goudreau, Nathalie; Poupard, Marc-Andre; Rancourt, Jean; Teantrizos, Youla S. Boehringer Ingelheim (Canada) Ltd., Can.
 PATENT ASSIGNER(S): PCT Int. Appl., 113 pp.
 SOURCE: CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 2
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000005558	A1	20000224	WO 1999-CA737	19990809
W: AS, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, GR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MW, MX, MY, NZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW				
RM: GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, NI, TD, TO				
US 6767991	B1	20040727	US 1999-368670	19990805
CA 2336597	AA	20000224	CA 1999-2336597	19990809
CA 2336597	C	20060214		
AU 9952732	A1	20000306	AU 1999-52732	19990809
AU 764655	B2	20030828		
BR 9912943	A	20010508	BR 1999-12943	19990809
EP 1105422	A1	20010613	EP 1999-938085	19990809
EP 1105422	B1	20060214		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
TR 200100438	T2	20010621	TR 2001-200100438	19990809
JP 200252557	T2	20020723	JP 2000-565004	19990809
EE 200100080	A	20020815	EE 2001-80	19990809
NZ 510395	A	20021219	NZ 1999-510395	19990809
TW 577895	B	20040301	TW 1999-88113587	19990809
NO 2001000604	A	20010205	NO 2001-604	20010205
ZA 2001000972	A	20020718	ZA 2001-972	20010205
BG 105230	A	20011031	BG 2001-105230	20010208
HR 2001000101	A1	20020228	HR 2001-101	20010208
HK 1039947	A1	20050225	HK 2002-101472	20020226
PRIORITY APPL. INFO.:			US 1998-959459	P 19980610
			US 1997-55186P	P 19970811
			US 1998-131758	B2 19980810
			US 1998-219939	B1 19981223
			WO 1999-CA737	W 19990809

OTHER SOURCE(S): MARPAT 132:175808
 GI



AB The invention provides peptides I (a, b = 0, 1; Y = H, C1-6 alkyl; B = H, acyl derivative, sulfonyl derivative; W = OH, N-substituted amino), or a pharmaceutically acceptable salt or ester thereof, for use in the treatment of hepatitis C virus infection. Preparation of peptides is included.

IT 259221-54-0P
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (hepatitis C inhibitor peptides and preparation thereof)

RM 259221-54-0 CAPLUS
 CN Cyclopropanecarboxylic acid, (2S)-2-cyclohexyl-N-(2-quinoloxalinyloxy)-L-prolyl-1-amino-2-ethenyl-, [(1R,2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 125 OF 283 CAPLUS COPYRIGHT 2006 ACS ON STN
 ACCESSION NUMBER: 2000:117025 CAPLUS
 DOCUMENT NUMBER: 132:166125
 TITLE: Preparation of heteroarylcarboxamides as inhibitors of the production of cytokines
 INVENTOR(S): Brown, Deary Sutherland; Brown, George Robert
 PATENT ASSIGNER(S): Zeneca Limited, UK
 SOURCE: PCT Int. Appl., 118 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 200007991	A1	20000217	WO 1999-GB2489	19990729
W: AS, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, GR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MW, MX, MY, NZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW				
RM: GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, NI, TD, TO				
CA 2338121	AA	20000217	CA 1999-2338121	19990729
AU 9951788	A1	20000228	AU 1999-51788	19990729
AU 753741	B2	20021024		
BR 9912729	A	20010502	BR 1999-12729	19990729
EP 1102750	A1	20010530	EP 1999-936810	19990729
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
TR 200100300	T2	20010723	TR 2001-200100300	19990729
JP 200252421	T2	20020723	JP 2000-563625	19990729
NZ 509318	A	20021025	NZ 1999-509318	19990729
RU 2216541	C2	20031120	RU 2001-105961	19990729
NO 2001000534	A	20010315	NO 2001-534	20010311
NO 320289	B1	20051121		
US 6432949	B1	20020813	US 2001-762107	20010202

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9902885	A1	19991209	CA 1999-US12295	19990603
N: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DK, DR, ES, SE, FI, GB, GE, GR, GU, HK, HR, HU, ID, IL, IN, JP, KR, KZ, KG, KP, KX, LA, LV, MD, MG, MK, MN, MX, MY, NZ, PL, PT, RU, RO, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZW	AA	19991209	CA 1999-2332957	19990603
CA 2332957	AA	19991220	CA 1999-2332957	19990603
US 6042299	T2	20000202	US 99-232957	19990603
US 6042299	B1	20000202	US 99-232957	19990603

PRIORITY APPLN. INFO.:

US 1998-08154P P 19980605
WO 1999-US12295 W 19990603


OTHER SOURCE(S): MARPAT 132:22963
GI



AB Title compds. [I; R = R4212; R1, R2 = halo, CF3, alkyl, alkoxy, etc.; R2 = H, halo, Me; R4 = (cyclo)alkyl, alkoxy, alkylamino, etc.; Z = 1,4-phenylene; Z1 = CONH, CO2NH, NH, etc.] were prepared. Thus, I [R = 4-(R5HN)C6H4, R1 = R3 = CF3, R2 = H] (I1; R5 = H) was amidated by cyclohexanecarboxylic acid to give I1 (R5 = cyclohexylcarbonyl). Data for biol. activity of I were given.

IT 251655-89-7P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of 1-(4-aminophenyl)pyrazoles and their use as anti-inflammatory agents)

RN 251655-89-7 CAPLUS
CN 2-Quinoxalinecarboxamide, N-[4-(3,5-bis(trifluoromethyl)-1H-pyrazol-1-yl)phenyl]- (9CI) (CA INDEX NAME)




REFERENCE COUNT: 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 129 OF 283 CAPLUS COPYRIGHT 2006 ACS ON STN
ACCESSION NUMBER: 1999-737917 CAPLUS
DOCUMENT NUMBER: 132:93285
TITLE: Synthesis of new fluorine-containing derivatives of quinoxaline 1,4-dioxides and condensed systems derived from them
AUTHOR(S): Chupekhin, O. N.; Kotovskaya, S. K.; Perova, N. M.; Basakova, Z. M.; Charushin, V. N.
CORPORATE SOURCE: Ural's State Technical University, Yekaterinburg, 620002, Russia
SOURCE: Chemistry of Heterocyclic Compounds (New York) (Translation of Khimiya Geterotsiklicheskikh Soedinenii) (1999), 35(4), 459-469
CODEN: CHCCAL; ISSN: 0009-3122
PUBLISHER: Consultants Bureau
DOCUMENT TYPE: Journal
LANGUAGE: English
OTHER SOURCE(S): CASREACT 132:93285
AB The Beirut reaction of 5,6-difluorobenzofuroxan with 1,3-diketones, β -keto esters, and β -keto amides produces 6,7-


difluoroquinoxaline 1,4-dioxides. The condensation of 2-ethoxycarbonyl-6,7-difluoro-3-methylquinoxaline 1,4-dioxide is studied. Fluorinated furo[3,4-b]- and pyrrolo[3,4-b]quinoxaline 4,9-dioxides are synthesized and further functionalized by nucleophilic substitution of fluorine and reduction of the N-O bond.

IT 254754-85-3P 254754-89-7P 254754-95-5P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(fluorinated quinoxaline 1,4-dioxides and condensed systems derived from them)


RN 254754-85-3 CAPLUS
CN 2-Quinoxalinecarboxamide, 6,7-difluoro-3-methyl-N-phenyl-, 1,4-dioxide (9CI) (CA INDEX NAME)



RN 254754-89-7 CAPLUS
CN 2-Quinoxalinecarboxamide, 6,7-difluoro-3-methyl-N-phenyl- (9CI) (CA INDEX NAME)




RN 254754-95-5 CAPLUS
CN 2-Quinoxalinecarboxamide, 7-fluoro-3-methyl-6-(4-morpholinyl)-N-phenyl-, 1,4-dioxide (9CI) (CA INDEX NAME)




IT 254755-05-0P 254755-06-1P 254755-07-2P
RL: SPN (Synthetic preparation); PREP (Preparation)
(fluorinated quinoxaline 1,4-dioxides and condensed systems derived from them)


RN 254755-05-0 CAPLUS
CN 2-Quinoxalinecarboxamide, 7-fluoro-3-methyl-6-(4-morpholinyl)-N-phenyl- (9CI) (CA INDEX NAME)



RN 254755-06-1 CAPLUS
CN 2-Quinoxalinecarboxamide, 7-fluoro-3-methyl-6-(4-methyl-1-piperazinyl)-N-phenyl- (9CI) (CA INDEX NAME)



RN 254755-07-2 CAPLUS
CN 2-Quinoxalinecarboxamide, 7-fluoro-3-methyl-N-phenyl-6-(1-pyrrolidinyl)- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 15 THERE ARE 15 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 130 OF 283 CAPLUS COPYRIGHT 2006 ACS ON STN
ACCESSION NUMBER: 1999-511130 CAPLUS
DOCUMENT NUMBER: 131:157767
TITLE: Preparation of quinoxalinecarboxylic acid 4-carbamoyl-2,7-dihydroxy-7-methyloltylamides for treatment of inflammation and immune disorders.
INVENTOR(S): Kach, John Charles; Brown, Matthew Frank; Poss, Christopher Stanley
PATENT ASSIGNEE(S): Pfizer Products Inc., USA
SOURCE: PCT Int. Appl., 23 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9940061	A2	19990812	WO 1999-1B67	19990118
WO 9940061	A3	19991021		

N: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GR, HR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZM, AM, AZ, BY, BG, BR, RU, TJ, TH

RN: GH, GM, KE, LS, MW, SD, SZ, UG, ZM, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SF, BJ, CF, CG, CI, CM, QA, ON, OW, ML, MR, NE, SN, TD, TG

CA 2320388	AA	19990812	CA 1999-2320388	19990118
CA 2320388	C	20050503		
AU 9917789	A1	19990823	AU 1999-17789	19990118
AU 752407	B2	20020919		
BR 9907655	A	20001024	BR 1999-7655	19990118
EP 1051405	A2	20001115	EP 1999-900098	19990118

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE, SI, LT, LV, FI, RO

TR 200002248	T2	20001321	TR 2000-200002248	19990118
JP 2002502819	T2	20020129	JP 2000-530493	19990118
JP 3693916	B2	20050914		
NZ 505724	A	20030228	NZ 1999-505724	19990118
NZ 523610	A	20040827	NZ 1999-523610	19990118
TM 470744	B	20020101	TM 1999-08101505	19990201
ZA 9900873	A	20000804	ZA 1999-073	19990204
AP 992	A	20010806	AP 1999-1457	19990204


N: BM, GM, GH, KE, MW, SD, UG, ZM, ZW

US 6673801	B1	20040106	US 2000-403218	20000302
NO 2000003965	A	20001003	NO 2000-3965	20000804
HR 200000529	A1	20010831	HR 2000-529	20000804
HR 20000529	B1	20041231		
BO 104726	A	20010430	BO 2000-104726	20000829
HK 1034969	A1	20050708	HK 2001-105717	20010815
US 2003018033	A1	20030123	US 2002-200844	20020722

PRIORITY APPLN. INFO.:

US 1998-73801P P 19980205
NZ 1999-505724 A1 19990118
WO 1999-1B67 W 19990118
US 2000-403218 A1 20000302

GI




AB Title compds. (I; all variables undefined), were prepared as antagonists of CCR1 receptors. Thus, [1(S)-[5-oxotetrahydrofuran-2(S)-yl]-2-phenylethyl]carbamoyl-tert-butyl ester in THF was added dropwise to a mixture of BuLi and HN(SiMe3)2 in THF at -78°; 4-bromo-2-methyl-2-butene in THF was added after 30 min. and the mixture was stirred 3h to -60° to give 77% [1(S)-[4(R)-[3-methylbut-2-enyl]-5-oxotetrahydrofuran-2(S)-yl]-2-phenylethyl]carbamoyl-tert-butyl ester. The latter was stirred with CF3CO2H and the residue was stirred with 2-quinoxalyl chloride and Et3N in CH2Cl2 to give 72% quinoxaline-2-carboxylic acid 1(S)-benzyl-4(R)-carbamoyl-2(S),7-dihydroxy-7-methyloltylamide. Tested I inhibited chemotaxis with IC50 <25 μ M.

IT 212790-10-2P 212790-31-3P 212790-33-5P
212790-38-0P 212790-42-6P 212790-44-6P
212790-45-9P 212790-46-0P 212790-47-1P
212790-48-9P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of quinoxalinecarboxylic acid 4-carbamoyl-2,7-dihydroxy-7-


methyloctylamides for treatment of inflammation and immune disorders)
 RN 212790-30-2 CAPLUS
 CN 2-Quinoxalinecarboxamide, N-[(1S,2S,4R)-4-(aminocarbonyl)-2,7-dihydroxy-7-methyl-1-(phenylmethyl)octyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 212790-31-3 CAPLUS
 CN 2-Quinoxalinecarboxamide, N-[(1S,2S,4R)-4-(aminocarbonyl)-1-[(3-fluorophenyl)methyl]-2,7-dihydroxy-7-methyloctyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 212790-33-5 CAPLUS
 CN 2-Quinoxalinecarboxamide, N-[(1S,2S,4R)-4-(aminocarbonyl)-1-[(3-chlorophenyl)methyl]-2,7-dihydroxy-7-methyloctyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 212790-38-0 CAPLUS
 CN 2-Quinoxalinecarboxamide, N-[(1S,2S,4R)-2,7-dihydroxy-4-(hydroxyamino)carbonyl]-7-methyl-1-(phenylmethyl)octyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 212790-46-0 CAPLUS
 CN 2-Quinoxalinecarboxamide, N-[(1S,2S,4R)-4-(aminocarbonyl)-1-[(3,4-difluorophenyl)methyl]-2,7-dihydroxy-7-methyloctyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 212790-47-1 CAPLUS
 CN 2-Quinoxalinecarboxamide, N-[(1S,2S,4R)-4-(aminocarbonyl)-2,7-dihydroxy-7-methyl-1-(1-naphthalenylmethyl)octyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 236733-84-9 CAPLUS
 CN 2-Quinoxalinecarboxamide, N-[(1S,2S,4R)-4-(aminocarbonyl)-1-[(2-chlorophenyl)methyl]-2,7-dihydroxy-7-methyloctyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 212790-42-6 CAPLUS
 CN 2-Quinoxalinecarboxamide, N-[(1S,2S,4R)-1-[(2-fluorophenyl)methyl]-2,7-dihydroxy-4-[(hydroxyamino)carbonyl]-7-methyloctyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 212790-44-8 CAPLUS
 CN 2-Quinoxalinecarboxamide, N-[(1S,2S,4R)-4-(aminocarbonyl)-1-[(2-fluorophenyl)methyl]-2,7-dihydroxy-7-methyloctyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 212790-45-9 CAPLUS
 CN 2-Quinoxalinecarboxamide, N-[(1S,2S,4R)-1-[(3,4-difluorophenyl)methyl]-2,7-dihydroxy-4-[(hydroxyamino)carbonyl]-7-methyloctyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



LS ANSWER 131 OF 283 CAPLUS COPYRIGHT 2006 ACS ON STM
 ACCESSION NUMBER: 1999:388171 CAPLUS
 DOCUMENT NUMBER: 131:44827
 TITLE: Preparation of N-[(imidazolyl- and triazolylalkyl)phenyl]acetamides and analogs as retinoid metabolism inhibitors
 INVENTOR(S): Mabire, Dominique; Adelinet, Christophe Denis; Csoka, Imre Christian; Venet, Marc Gaston
 PATENT ASSIGNEE(S): Janssen Pharmaceutica N.V., Belg.
 SOURCE: PCT Int. Appl., 75 pp.
 DOCUMENT TYPE: CODEN: PIXXD2
 LANGUAGE: Patent
 FAMILY ACC. NUM. COUNT: English
 PATENT INFORMATION: 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9929674	A1	19990617	WO 1998-EP8126	19981208
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, RW: GH, GM, KE, LG, MW, SD, SZ, US, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SF, BJ, CP, CO, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
CA 2312720	AA	19990617	CA 1998-2312720	19981208
AU 9921608	A1	19990628	AU 1999-21608	19981208
EP 1037880	A1	20000927	EP 1998-965820	19981208
EP 1037880	B1	20040630		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
TR 200001645	T2	200001221	TR 2000-200001645	19981208
JP 2001525400	T2	20011211	JP 2000-524271	19981208
AT 270277	B	20040715	AT 1998-965820	19981208
PT 1037880	T	20041130	PT 1998-965820	19981208
ES 2224462	T3	20050301	ES 1998-965820	19981208
TW 523503	B	20030311	TW 1998-87120384	19981208
ZA 9811351	A	20000612	ZA 1998-11351	19981210
US 6319939	B1	20011120	US 2000-555775	20000601
BG 104499	A	20010831	BG 2000-104499	20000602
US 2002115653	A1	20020822	US 2001-962551	20010925
US 6936626	B2	20050830		
US 2005165018	A1	20050728		
PRIORITY APPL. INFO.:				
US 2005-81393			US 2005-81393	20050316
EP 1997-203886	A	19971211		
WO 1998-EP8126			WO 1998-EP8126	19981208
US 2000-555775	A3	20000601		

OTHER SOURCE(S): MARPAT 131:44827
US 2001-962551 A3 20010925
AB R4C(X)KR3ZCRR1R2 [I; R = pyrrolyl, imidazolyl, triazolyl, pyridinyl, etc.; R1 = H, OH, alkyl, aryl; R2 = H, (un)substituted alkyl, (hetero)aryl, etc.; R3 = H, (ar)alkyl, (hetero)aryl, etc.; R4 = H, OH, (un)substituted alkyl, alkoxy, etc.; Z = O, S, NR3; X = 1,4-phenylene] were prepared. Thus, 4-(ACHN)C6H4C(R)CH2Me2 (II; R = OH) was O-mesylated and the product condensed with 1H-1,2,4-triazole to give I (R = 1H-1,2,4-triazol-1-yl). Data for biol. activity of I were given.
IT 227281-65-4P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses) (preparation of N-[(imidazolyl- and triazolyl)alkyl]phenyl]acetamides and analogs as retinoid metabolism inhibitors)
RN 227281-65-4 CAPLUS
CN 2-Quinoxalinecarboxamide, N-[4-[(1H-imidazol-1-yl)-2-methylpropyl]phenyl]- (9CI) (CA INDEX NAME)




REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

LS ANSWER 132 OF 283 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 1999:354484 CAPLUS
DOCUMENT NUMBER: 131:31954
TITLE: Preparation of quinoxalinecarboxamides and analogs as metabotropic glutamate receptor antagonists
INVENTOR(S): Van Wagenen, Bradford C.; Moe, Scott T.; Smith, Daryl L.; Sheehan, Susan M.; Shcherbakova, Irina; Travato, Richard; Walton, Ruth; Barmore, Robert; Delmar, Eric G.; Stormann, Thomas M.
PATENT ASSIGNER(S): NPS Pharmaceuticals, Inc., USA
SOURCE: PCT Int. Appl., 63 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9926927	A2	19990603	WO 1998-US24833	19981120
WO 9926927	A3	19991021		
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW				
RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TO				
CA 2311131	AA	19990603	CA 1998-2311131	19981120
AU 9915317	A1	19990615	AU 1999-15317	19981120
AU 771356	B2	20040318		
EP 1037878	A2	20000927	EP 1998-959535	19981120

RN 226877-99-2 CAPLUS
CN 2-Quinoxalinecarboxamide, N-tricyclo[3.3.1.1.3,7]dec-2-yl- (9CI) (CA INDEX NAME)




RN 226878-00-8 CAPLUS
CN 2-Quinoxalinecarboxamide, N-[[[1R,2R,3R,5S]-2,6,6-trimethylbicyclo[3.1.1]hept-3-yl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 226878-01-9 CAPLUS
CN 2-Quinoxalinecarboxamide, N-tricyclo[3.3.1.1.3,7]dec-1-yl- (9CI) (CA INDEX NAME)



RN 226878-03-1 CAPLUS
CN 2-Quinoxalinecarboxamide, N-(1R,2R,4S)-bicyclo[2.2.1]hept-2-yl-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 226878-04-2 CAPLUS
CN 2-Quinoxalinecarboxamide, N-[(1R,2S,4R)-1,7,7-trimethylbicyclo[2.2.1]hept-2-yl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO
JP 2001524468 T2 20011204 JP 2000-522085 19981120
NZ 505207 A 20011031 NZ 1998-505207 19981120
CN 1554648 A 20041215 CN 2004-10047499 19981120
US 6429207 B1 20020806 US 2000-573347 20000519
US 2003013715 A1 20030116 US 2002-211523 20020805
US 1997-667589 P 19971121
WO 1998-US24833 W 19981120
US 1999-137272P P 19990602
US 2000-573347 A3 20000519


OTHER SOURCE(S): MARPAT 131:31954
AB RZR1 [R = (ar)alkyl, (alkyl)cycloalkyl; R1 = (hetero)aryl(alkyl); Z = (CO- and heteroatom-interrupted)(CH2)2-6, -alkenylene, -alkynylene] were prepared as metabotropic glutamate receptor antagonists (no data). Thus, 2-Quinoxalinecarboxylic acid was amidated by 2-adamantanamine to give N-(2-adamantyl)-2-quinoxalinecarboxamide.
IT 88996-81-0P 226877-99-3P 226877-99-2P
226878-00-8P 226878-01-9P 226878-03-1P
226878-04-2P 226878-05-3P 226878-06-4P
226878-07-5P 226878-08-6P 226878-09-7P
226878-10-0P 226878-11-1P 226878-12-2P
226878-13-3P 226878-14-4P 226878-15-5P
226878-16-6P 226878-17-7P 226878-18-8P
226878-21-3P 226878-22-4P 226878-23-5P
226878-24-6P 226878-25-7P 226878-26-8P
226878-27-9P 226878-28-0P 226878-29-1P
226878-30-4P 226878-31-5P 226878-32-6P
226878-40-6P 226878-57-5P 226878-82-6P
226878-83-7P 226878-86-0P 226878-88-2P
226878-89-3P 226878-90-6P 226878-92-8P
226878-93-9P 226878-94-0P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses) (preparation of quinoxalinecarboxamides and analogs as metabotropic glutamate receptor antagonists)
RN 88996-81-0 CAPLUS
CN 2-Quinoxalinecarboxamide, 3-methyl-N-tricyclo[3.3.1.1.3,7]dec-1-yl- (9CI) (CA INDEX NAME)




RN 226877-90-3 CAPLUS
CN 2-Quinoxalinecarboxamide, N-(trans-4-methylcyclohexyl)- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 226878-05-3 CAPLUS
CN 2-Quinoxalinecarboxamide, N-(hexahydro-2,5-methanopentalen-3a(1H)-yl)- (9CI) (CA INDEX NAME)




RN 226878-06-4 CAPLUS
CN 2-Quinoxalinecarboxamide, N-[(1R,2R,3R,5S)-2,6,6-trimethylbicyclo[3.1.1]hept-3-yl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 226878-07-5 CAPLUS
CN 2-Quinoxalinecarboxamide, N-[(1S,2S,3S,5R)-2,6,6-trimethylbicyclo[3.1.1]hept-3-yl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 226878-08-6 CAPLUS
CN 2-Quinoxalinecarboxamide, N-(5-chlorotricyclo[2.2.1.0.2,6]hept-3-yl)- (9CI) (CA INDEX NAME)




RN 226878-09-7 CAPLUS
CN 2-Quinoxalinecarboxamide, N-(tricyclo[4.3.1.1.3,8]undec-3-yl)- (9CI) (CA INDEX NAME)




RN 226878-10-0 CAPLUS
CN 2-Quinoxalinecarboxamide, N-([(1S,2R,5S)-6,6-dimethylbicyclo[3.1.1]hept-2-yl)methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 226878-11-1 CAPLUS
CN 2-Quinoxalinecarboxamide, N-([(1R,2R,4R)-1,7,7-trimethylbicyclo[2.2.1]hept-2-yl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 226878-12-2 CAPLUS
CN 2-Quinoxalinecarboxamide, N-(1R,2S,4S)-bicyclo[2.2.1]hept-2-yl-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 226878-13-3 CAPLUS
CN 2-Quinoxalinecarboxamide, N-[(2R)-2-phenylpropyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 226878-14-4 CAPLUS
CN 2-Quinoxalinecarboxamide, N-[(2S)-2-phenylpropyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.




RN 226878-15-5 CAPLUS
CN 2-Quinoxalinecarboxamide, N-(2,3-dihydro-1H-inden-2-yl)- (9CI) (CA INDEX NAME)




RN 226878-16-6 CAPLUS
CN 2-Quinoxalinecarboxamide, N-cyclooctyl- (9CI) (CA INDEX NAME)




RN 226878-17-7 CAPLUS
CN 2-Quinoxalinecarboxamide, N-cycloheptyl- (9CI) (CA INDEX NAME)




RN 226878-18-8 CAPLUS
CN 2-Quinoxalinecarboxamide, N-spiro[4.5]dec-2-yl- (9CI) (CA INDEX NAME)




RN 226878-21-3 CAPLUS
CN 2-Quinoxalinecarboxamide, N-(1,1-dimethyl-2-phenylethyl)- (9CI) (CA INDEX NAME)




RN 226878-22-4 CAPLUS
CN 2-Quinoxalinecarboxamide, N-[2-(2-chlorophenyl)-1,1-dimethylethyl]- (9CI) (CA INDEX NAME)




RN 226878-23-5 CAPLUS
CN 2-Quinoxalinecarboxamide, N-[2-(4-fluorophenyl)-1,1-dimethylethyl]- (9CI) (CA INDEX NAME)




RN 226878-24-6 CAPLUS
CN 2-Quinoxalinecarboxamide, N-(2-phenylpropyl)- (9CI) (CA INDEX NAME)



RN 226878-25-7 CAPLUS
CN 2-Quinoxalinecarboxamide, N-(3-methylcyclohexyl)- (9CI) (CA INDEX NAME)




RN 226878-26-8 CAPLUS
CN 2-Quinoxalinecarboxamide, N-(2,3-dimethylcyclohexyl)- (9CI) (CA INDEX NAME)




RN 226878-27-9 CAPLUS
CN 2-Quinoxalinecarboxamide, N-([(1S,2S,3S,5R)-2,6,6-trimethylbicyclo[3.1.1]hept-3-yl)methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 226878-28-0 CAPLUS
CN 2-Quinoxalinecarboxamide, N-(tricyclo[3.3.1.1.3,7]dec-1-ylmethyl)- (9CI) (CA INDEX NAME)




RN 226878-29-1 CAPLUS
CN 2-Quinoxalinecarboxamide, N-(4-methylcyclohexyl)- (9CI) (CA INDEX NAME)




RN 226878-30-4 CAPLUS
CN 2-Quinoxalinecarboxamide, N-[(1S,2S,5S)-6,6-dimethylbicyclo[3.1.1]hept-2-yl)methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 226878-31-5 CAPLUS
CN 2-Quinoxalinecarboxamide, N-[(1R,2R,5R)-6,6-dimethylbicyclo[3.1.1]hept-2-yl)methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 226878-39-3 CAPLUS
CN 2-Quinoxalinecarboxamide, 3-chloro-N-tricyclo[3.3.1.1^{3,7}]dec-1-yl- (9CI) (CA INDEX NAME)




RN 226878-40-6 CAPLUS
CN 2-Quinoxalinecarboxamide, N-tricyclo[3.3.1.1^{3,7}]dec-1-yl-, 4-oxide (9CI) (CA INDEX NAME)




RN 226878-57-5 CAPLUS
CN 2-Quinoxalinecarboxamide, N-(cis-4-methylcyclohexyl)- (9CI) (CA INDEX NAME)


Relative stereochemistry.




RN 226878-82-6 CAPLUS
CN 2-Quinoxalinecarboxamide, 3-[(1-piperazinyl)-N-tricyclo[3.3.1.1^{3,7}]dec-1-yl-6-(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 226878-83-7 CAPLUS
CN 2-Quinoxalinecarboxamide, 3-[(2-aminoethyl)amino]-N-tricyclo[3.3.1.1^{3,7}]dec-1-yl-6-(trifluoromethyl)- (9CI) (CA INDEX NAME)



RN 226878-86-0 CAPLUS
CN 2-Quinoxalinecarboxamide, 3-methoxy-N-tricyclo[3.3.1.1^{3,7}]dec-1-yl- (9CI) (CA INDEX NAME)




RN 226878-88-2 CAPLUS
CN 2-Quinoxalinecarboxamide, 6,7-dimethyl-N-tricyclo[3.3.1.1^{3,7}]dec-1-yl- (9CI) (CA INDEX NAME)




RN 226878-89-3 CAPLUS
CN 2-Quinoxalinecarboxamide, N-[(1S)-1,2,3,4-tetrahydro-1-naphthalenyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.




RN 226878-90-6 CAPLUS
CN 2-Quinoxalinecarboxamide, N-[2-(4-chlorophenyl)ethyl]- (9CI) (CA INDEX NAME)




RN 226878-92-8 CAPLUS
CN 2-Quinoxalinecarboxamide, N-[(1,2,3,4-tetrahydro-1-naphthalenyl)methyl]- (9CI) (CA INDEX NAME)



RN 226878-93-9 CAPLUS
CN 2-Quinoxalinecarboxamide, N-[(2,3-dihydro-1H-inden-1-yl)methyl]- (9CI) (CA INDEX NAME)



RN 226878-94-0 CAPLUS
CN 2-Quinoxalinecarboxamide, N-(4,4-dimethylcyclohexyl)- (9CI) (CA INDEX NAME)




L5 ANSWER 133 OF 283 CAPLUS COPYRIGHT 2006 ACS ON STN
ACCESSION NUMBER: 1999:348254 CAPLUS
DOCUMENT NUMBER: 131:102532
TITLE: Heterocycle-peptide hybrid compounds.
Aminotriazole-containing agonists of the thrombin receptor (PAR-1)
AUTHOR(S): McComsey, David P.; Hawkins, Michael J.; Andrade-Gordon, Patricia; Addo, Michael F.; Oksenberg, Donna; Maryanoff, Bruce E.
CORPORATE SOURCE: Drug Discovery, The R. W. Johnson Pharmaceutical Research Institute, Spring House, PA, 19477, USA
SOURCE: Bioorganic & Medicinal Chemistry Letters (1999), 9(10), 1423-1428
CODEN: BMCLE8; ISSN: 0960-894X
PUBLISHER: Elsevier Science Ltd.
DOCUMENT TYPE: Journal
LANGUAGE: English
AB The thrombin receptor PAR-1 is activated by α -thrombin to stimulate cells, including platelets, through the tethered-ligand sequence SFLRRN.

The authors have discovered a novel series of heterocycle-peptide hybrids comprised of a tripeptide segments, such as Cha-Arg-Phe (Cha = cyclohexylalanine), and an N-terminal heterocyclic group, many of which behave as full PAR-1 agonists. Certain compounds with an aminotriazole group, such as RCO-Cha-Arg-Phe-NH₂ (R = 5-amino-1,2,4-triazole-3-yl) and RCO-Phe-Arg-Phe-NH₂ (R = 5-amino-1,2,4-triazole-3-yl), are nearly as potent as SPFLRN-NH₂ in inducing platelet aggregation. Also, some arylethenyl "N-capped" compounds, such as RCO-Cha-Arg-Phe-NH₂ (R = 5-(o-chlorocinnamido)-1,2,4-triazol-3-yl; 5-(2-thienyl)acrylamido-1,2,4-triazol-3-yl), exhibit mixed PAR-1 agonist-antagonist activity.

IT 231608-75-6P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
(Preparation of aminotriazole-containing tripeptides as agonists of the thrombin receptor (PAR-1))

RN 231608-75-6 CAPLUS
CN L-Phenylalaninamide, 3-cyclohexyl-N-(2-quinazolinylcarbonyl)-L-alanyl-L-arginyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 28 THERE ARE 28 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT


L5 ANSWER 134 OF 283 CAPLUS COPYRIGHT 2006 ACS ON STM
ACCESSION NUMBER: 1999:327924 CAPLUS
DOCUMENT NUMBER: 131:141312
TITLE: Structure-based discovery and in-parallel optimization of novel competitive inhibitors of thymidylate synthase
AUTHOR(S): Tondl, Donatella; Slomczynska, Ursula; Costi, M. Paola; Watterson, D. Martin; Ghelli, Stefano; Sholichet, Brian K.
CORPORATE SOURCE: Department of Molecular Pharmacology and Biological Chemistry, Northwestern University, Chicago, IL, 60611-3008, USA
SOURCE: Chemistry & Biology (1999), 6(5), 319-331
CODEN: CBOLB; ISSN: 1074-5521
PUBLISHER: Current Biology Publications
DOCUMENT TYPE: Journal
LANGUAGE: English
AB The substrate sites of enzymes are attractive targets for structure-based inhibitor design. Two difficulties hinder efforts to discover and elaborate new (nonsubstrate-like) inhibitors for these sites. First, novel inhibitors often bind at nonsubstrate sites. Second, a novel scaffold introduces a chemical that is frequently unfamiliar, making synthetic elaboration challenging. In an effort to discover and elaborate a novel

scaffold for a substrate site, we combined structure-based screening with in-parallel synthetic elaboration. These techniques were used to find new inhibitors that bound to the folate site of *Lactobacillus casei* thymidylate synthase (LTS), an enzyme that is a potential target for proliferative diseases, and is highly studied. The available chemical directory was screened, using a mol-docking computer program, for compounds that complemented the three-dimensional structure of this site. Five high-ranking compounds were selected for testing. Activity and docking studies led to a derivative of one of these, danalyltyrosine (Ki 65 μM). Using solid-phase in-parallel techniques 33 derivatives of this lead were synthesized and tested. These analogs are dissimilar to the substrate but bind competitively with it. The most active analog had a Ki of 1.3 μM. The tighter binding inhibitors were also the most specific for LTS vs. related enzymes. TS can recognize inhibitors that are dissimilar to, but that bind competitively with, the folate substrate. Combining structure-based discovery with in-parallel synthetic techniques allowed the rapid elaboration of this series of compounds. More automated versions of this approach can be envisaged.

IT 236430-18-5P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
(Structure-based discovery and in-parallel optimization of novel competitive inhibitors of thymidylate synthase)

RN 236430-18-5 CAPLUS
CN L-Tyrosine, N-[2-(2-quinazolinylcarbonyl)-, 5-(dimethylamino)-1-naphthalenesulfonyl] (ester) (9CI) (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 55 THERE ARE 55 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 135 OF 283 CAPLUS COPYRIGHT 2006 ACS ON STM
ACCESSION NUMBER: 1999:325961 CAPLUS
DOCUMENT NUMBER: 130:352553
TITLE: Synthesis of dipeptide nitriles as inhibitors of cysteine cathepsins
INVENTOR(S): Altman, Eva; Bettschart, Claudia; Gohde, Keigo; Horiuchi, Miyuki; Lattmann, Rene; Miesbach, Martin; Sakaki, Junichi; Takai, Michihiro; Teno, Naoki; Cowen, Scott Douglas; Greenspan, Paul David; McGuire, Leslie; Wighton, Tommasi; Ruben Alberto; Van Duzer, John Henry
PATENT ASSIGNEE(S): Novartis AG, Switz.; Novartis-Erfindungen
SOURCE: PCT Int. Appl., 137 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9924460	A2	19990520	WO 1998-EP6937	19981103
WO 9924460	A3	19990902		
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GR, HU, ID, IL, IS, JP, KR, KG, KP, KZ, LC, LR, LS, LT, LU, LV, MD, MG, MK, MN, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, RM: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IR, IT, LU, MC, NL, PT, SE, BF, BJ, CP, CO, CI, CM, GA, GN, GW, ML, MR, NS, SN, TD, TG				
CA 2306313	A1	19990520	CA 1998-2306313	19981103
AU 9914873	A1	19990531	AU 1999-14873	19981103
AU 751669	B2	20020822		
EP 1028942	A2	20000823	EP 1998-958887	19981103
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
BR 9813197	A	20000829	BR 1998-13197	19981103
TR 200001189	T2	20000921	TR 2000-200001189	19981103
JP 2001522862	T2	20011120	JP 2000-520468	19981103
RU 2201420	C2	20010327	RU 2000-114821	19981103
ZA 9810073	A	19990505	ZA 1998-10073	19981104
TW 527162	B	20010411	TW 1998-87118553	19981105
WO 200002320	A	20000704	WO 2000-2320	20000502
US 6353017	B1	20020305	US 2000-643639	20000822
US 2004029814	A1	20040212	US 2003-342872	20030115
US 2004110806	A1	20040610	US 2003-694672	20031028
PRIORITY APPL. INFO.: GB 1997-23407 A 19971105 US 1997-108160P P 19971208 US 1997-965973 A 19971205 WO 1998-EP6937 W 19981103 US 1998-186223 B1 19981104 US 2000-643639 A1 20000822 US 2002-54590 B1 20020122 US 2003-342872 A1 20030115				

OTHER SOURCE(S): MARPAT 130:352553
AB N-terminal substituted dipeptide nitriles R(LX)XNHC(R2)R3C(Y)NHC(R4)R5CN (R is optionally substituted aryl, alkyl, alkenyl, alkynyl, heterocyclyl; R2, R3 = H, optionally substituted alkyl, cycloalkyl, bicycloalkyl, or aryl-, biaryl-, cycloalkyl, bicycloalkyl; R4 and R5 together represent alkylene, optionally interrupted by O, S, or NR6, where R6 is H, alkyl, arylalkyl; or R2 or R3 are linked by alkylene to the adjacent nitrogen to form a ring; R4, R5 = H, optionally substituted alkyl, arylalkyl, CO₂R7, CONHR7 (R7 is optionally substituted alkyl, aryl, arylalkyl, cycloalkyl, bicycloalkyl, or heterocyclyl and R8 is H or optionally substituted alkyl, aryl, arylalkyl, cycloalkyl, bicycloalkyl, heterocyclyl), etc.; R4 and R5 together represent alkylene, optionally interrupted by O, S, or NR6; X1 = CO, CS, SO, SO₂, P(O)OR6; Y = O, S; L is optionally substituted Het, Het=CH₂, CH₂-Het (Het = O, N, or S); x = zero or 1) were prepared as inhibitors of cysteine cathepsins, e.g., cathepsins B, K, L and S, and can be used for the treatment of cysteine cathepsin dependent diseases and conditions. Thus, N-[2-[(13-carboxyphenyl)methoxy]-1(18)-cyanomethyl]-3-methyl-Nu-(2,2-diphenylacetyl)-L-phenylalaninamide was prepared and shown to have IC₅₀ = 5 nM for inhibition of cathepsin B.

IT 225121-86-8P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USBS (Uses)
(Synthesis of dipeptide nitriles as inhibitors of cysteine cathepsins)

RN 225121-86-8 CAPLUS
CN Benzoic acid, 3-[(2R)-2-cyano-2-[(2S)-3-cyclohexyl-1-oxo-2-[(2-quinazolinylcarbonyl)amino]propyl]amino]ethoxymethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L5 ANSWER 136 OF 283 CAPLUS COPYRIGHT 2006 ACS ON STM
ACCESSION NUMBER: 1999:297407 CAPLUS
DOCUMENT NUMBER: 130:338118
TITLE: Preparation of heterocyclylbenzenes as herbicides and defoliants
INVENTOR(S): Gupta, Sandeep; Tsukamoto, Masamitsu; Pulman, David A.; Ying, Bei-ping; Wu, Shao-yong
PATENT ASSIGNEE(S): I&K Americas Incorporated, USA
SOURCE: PCT Int. Appl., 139 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9921837	A1	19990506	WO 1998-US17197	19980821
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GR, HU, ID, IL, IS, JP, KR, KP, KR, KZ, LC, LR, LS, LT, LU, LV, MD, MG, MK, MN, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, RM: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IR, IT, LU, MC, NL, PT, SE, BF, BJ, CP, CO, CI, CM, GA, GN, GW, ML, MR, NS, SN, TD, TG				
CA 2307815	A1	19990506	CA 1998-2307815	19980821
AU 9695650	A1	19990517	AU 1998-95650	19980821
UA 749237	B2	20020620		
EP 1030843	A1	20000830	EP 1998-949302	19980821
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
JP 2001521027	T2	20011106	JP 2000-517949	19980821
BR 9814104	A	20011226	BR 1998-14104	19980821
ZA 9809639	A	19990426	ZA 1998-9639	19981022
TW 533200	B	20010521	TW 1998-87117635	19981023
EG 22047	A	20020630	EG 1998-1309	19981027
US 6355799	B1	20020312	US 2000-530373	20000427
US 2002133007	A1	20020919	US 2001-930149	20010816
US 6545161	B2	20030408		
PRIORITY APPL. INFO.: US 1997-958313 A2 19971027 WO 1998-US17197 W 19980821 US 2000-530373 A3 20000427				

OTHER SOURCE(S): MARPAT 130:338118

OI

L5	ANSWER 137 OF 283	CAPLUS COPYRIGHT 2006 ACS ON STN
ACCESSION NUMBER:	1999:256079	CAPLUS
DOCUMENT NUMBER:	130:267770	
TITLE:	Synthesis of N,N-disubstituted amino acids as endothelin inhibitors with pharmaceutical effects	
INVENTOR(S):	Puhl, Michael; Zechel, Johann-Christian; Dietrich, Klaus; Hillen, Heins; Kohl, Tanja; Eberhardt, Melanie; Hergenroeder, Stefan; Markert, Claus Otto	
PATENT ASSIGNEE(S):	BASF A.-O., Germany	
SOURCE:	Ger. Offen., 12 pp. CODEN: GWXXBX	
DOCUMENT TYPE:	Patent	
LANGUAGE:	German	
FAMILY ACC. NUM. COUNT:	1	

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
DE 19745146	A1	19990415	DE 1997-27545146	19971014
2305499	AA	19990422	CA 1998-2305499	19980918
WO 9913120	A1	19990422	WO 99/05945	19980918
W: AL, AU, BG, BR, BY, CA, CN, CZ, GE, HU, ID, IL, JP, KR, KZ, LT, LV, MK, MX, NO, NZ, PL, RO, RU, SG, SI, SK, TR, UA, US, AM, AZ, BY, KO, KZ, MO, KU, TJ, TM				
RM: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
AO 9910235	A1	19990503	AO 1999-10235	19980918
EP 1020282	A1	20000402	EP 1998-925597	19980918
R: AT, BG, CH, DE, ES, FR, GB, IT, LI, NL, SE, VI				
BR 9811037	A	20000815	BR 1998-13037	19980918
JP 2001519427	T2	20011023	JP 2000-515692	19980918
ZA 9809312	A	20000413	ZA 1998-9312	19981013
MX 200003357	A	20001113	MX 2000-3357	20000406
NO 200001846	A	20000410	NO 2000-1846	20000410
US 6469056	B1	20021022	US 2000-529181	20000401


OTHER SOURCE(S) :

OTHER SOURCES(8):
 AB Titration: C(0)(OH)1:R1:R2:R3:R4:R5:R6:R7:R8:R9:R10:R11:R12:R13:R14:R15:R16:R17:R18:R19:R20:R21:R22:R23:R24:R25:R26:R27:R28:R29:R30:R31:R32:R33:R34:R35:R36:R37:R38:R39:R40:R41:R42:R43:R44:R45:R46:R47:R48:R49:R50:R51:R52:R53:R54:R55:R56:R57:R58:R59:R60:R61:R62:R63:R64:R65:R66:R67:R68:R69:R70:R71:R72:R73:R74:R75:R76:R77:R78:R79:R80:R81:R82:R83:R84:R85:R86:R87:R88:R89:R90:R91:R92:R93:R94:R95:R96:R97:R98:R99:R100:R101:R102:R103:R104:R105:R106:R107:R108:R109:R110:R111:R112:R113:R114:R115:R116:R117:R118:R119:R120:R121:R122:R123:R124:R125:R126:R127:R128:R129:R130:R131:R132:R133:R134:R135:R136:R137:R138:R139:R140:R141:R142:R143:R144:R145:R146:R147:R148:R149:R150:R151:R152:R153:R154:R155:R156:R157:R158:R159:R160:R161:R162:R163:R164:R165:R166:R167:R168:R169:R170:R171:R172:R173:R174:R175:R176:R177:R178:R179:R180:R181:R182:R183:R184:R185:R186:R187:R188:R189:R190:R191:R192:R193:R194:R195:R196:R197:R198:R199:R200:R201:R202:R203:R204:R205:R206:R207:R208:R209:R210:R211:R212:R213:R214:R215:R216:R217:R218:R219:R220:R221:R222:R223:R224:R225:R226:R227:R228:R229:R230:R231:R232:R233:R234:R235:R236:R237:R238:R239:R240:R241:R242:R243:R244:R245:R246:R247:R248:R249:R250:R251:R252:R253:R254:R255:R256:R257:R258:R259:R260:R261:R262:R263:R264:R265:R266:R267:R268:R269:R270:R271:R272:R273:R274:R275:R276:R277:R278:R279:R280:R281:R282:R283:R284:R285:R286:R287:R288:R289:R290:R291:R292:R293:R294:R295:R296:R297:R298:R299:R300:R301:R302:R303:R304:R305:R306:R307:R308:R309:R310:R311:R312:R313:R314:R315:R316:R317:R318:R319:R320:R321:R322:R323:R324:R325:R326:R327:R328:R329:R330:R331:R332:R333:R334:R335:R336:R337:R338:R339:R340:R341:R342:R343:R344:R345:R346:R347:R348:R349:R350:R351:R352:R353:R354:R355:R356:R357:R358:R359:R360:R361:R362:R363:R364:R365:R366:R367:R368:R369:R370:R371:R372:R373:R374:R375:R376:R377:R378:R379:R380:R381:R382:R383:R384:R385:R386:R387:R388:R389:R390:R391:R392:R393:R394:R395:R396:R397:R398:R399:R400:R401:R402:R403:R404:R405:R406:R407:R408:R409:R410:R411:R412:R413:R414:R415:R416:R417:R418:R419:R420:R421:R422:R423:R424:R425:R426:R427:R428:R429:R430:R431:R432:R433:R434:R435:R436:R437:R438:R439:R440:R441:R442:R443:R444:R445:R446:R447:R448:R449:R450:R451:R452:R453:R454:R455:R456:R457:R458:R459:R460:R461:R462:R463:R464:R465:R466:R467:R468:R469:R470:R471:R472:R473:R474:R475:R476:R477:R478:R479:R480:R481:R482:R483:R484:R485:R486:R487:R488:R489:R490:R491:R492:R493:R494:R495:R496:R497:R498:R499:R500:R501:R502:R503:R504:R505:R506:R507:R508:R509:R510:R511:R512:R513:R514:R515:R516:R517:R518:R519:R520:R521:R522:R523:R524:R525:R526:R527:R528:R529:R530:R531:R532:R533:R534:R535:R536:R537:R538:R539:R540:R541:R542:R543:R544:R545:R546:R547:R548:R549:R550:R551:R552:R553:R554:R555:R556:R557:R558:R559:R560:R561:R562:R563:R564:R565:R566:R567:R568:R569:R570:R571:R572:R573:R574:R575:R576:R577:R578:R579:R580:R581:R582:R583:R584:R585:R586:R587:R588:R589:R590:R591:R592:R593:R594:R595:R596:R597:R598:R599:R600:R601:R602:R603:R604:R605:R606:R607:R608:R609:R610:R611:R612:R613:R614:R615:R616:R617:R618:R619:R620:R621:R622:R623:R624:R625:R626:R627:R628:R629:R630:R631:R632:R633:R634:R635:R636:R637:R638:R639:R640:R641:R642:R643:R644:R645:R646:R647:R648:R649:R650:R651:R652:R653:R654:R655:R656:R657:R658:R659:R660:R661:R662:R663:R664:R665:R666:R667:R668:R669:R670:R671:R672:R673:R674:R675:R676:R677:R678:R679:R680:R681:R682:R683:R684:R685:R686:R687:R688:R689:R690:R691:R692:R693:R694:R695:R696:R697:R698:R699:R700:R701:R702:R703:R704:R705:R706:R707:R708:R709:R710:R711:R712:R713:R714:R715:R716:R717:R718:R719:R720:R721:R722:R723:R724:R725:R726:R727:R728:R729:R730:R731:R732:R733:R734:R735:R736:R737:R738:R739:R740:R741:R742:R743:R744:R745:R746:R747:R748:R749:R750:R751:R752:R753:R754:R755:R756:R757:R758:R759:R760:R761:R762:R763:R764:R765:R766:R767:R768:R769:R770:R771:R772:R773:R774:R775:R776:R777:R778:R779:R780:R781:R782:R783:R784:R785:R786:R787:R788:R789:R790:R791:R792:R793:R794:R795:R796:R797:R798:R799:R800:R801:R802:R803:R804:R805:R806:R807:R808:R809:R810:R811:R812:R813:R814:R815:R816:R817:R818:R819:R820:R821:R822:R823:R824:R825:R826:R827:R828:R829:R830:R831:R832:R833:R834:R835:R836


1T 220203-61-2P
 study: RAC (Biological activity or effector, except adverse); BSU (Biological
 study: unclassified); SPN (Synthetic preparation); THU (Therapeutic use);
 BIOL (Biological study); PREP (Preparation); USSS (Uses)
 (Preparation of α -endothelin inhibitors with pharmaceutical effects)
 RN 220203-61-2 CAPLUS
 CN L-Phenylalanine, N-[(2S)-2-[[[(9S)-fluoren-9-ylmethoxy]carbonyl]amino]-3-
 phenylpropionyl]-N-(2-guanyldimethylammonio)-9-glycine] [CA INDEX NAME]

Absolute stereochemistry.

PAGE 1-A




PAGE 2-A



L5 ANSWER 138 OF 283 CAPLUS COPYRIGHT 2006 ACS ON STN
 ACCESSION NUMBER: 1999:188605 CAPLUS
 DOCUMENT NUMBER: 131:340
 TITLE: Reversal of P-glycoprotein mediated multidrug resistance by novel anthranilamide derivatives
 AUTHOR(S): Roe, Michael; Folker, Adrian; Aebworth, Philip; Brunwell, Julie; Chima, Lal; Nunjen, Sukhjit; Pretswell, Ian; Dangerfield, Wendy; Ryder, Hamish; Charlton, Peter
 CORPORATE SOURCE: Xenova Ltd., Stough, SL1 4EP, UK
 SOURCE: Biogenic & Molecular Chemistry Letters (1999), 9(4), 595-600
 CODEN: BMCLES; ISSN: 0960-894X
 PUBLISHER: Elsevier Science Ltd.
 JOURNAL: English
 LANGUAGE: English
 AB We have synthesized and evaluated a series of anthranilamide based modulators of P-glycoprotein. These studies have identified XR957a, a potent inhibitor of P-glycoprotein in vitro and in vivo. The general synthesis and the SAR of these compounds are described.
 IT 206873-50-9
 RU: RAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (preparation of novel anthranilamide derivative for reversal of P-glycoprotein mediated multidrug resistance)
 RN 206873-50-9 CAPLUS

CN 2-Quinoxalinecarboxamide, N-[2-[[[4-[2-(3,4-dihydro-6,7-dimethoxy-2(1H)-isquinolinyl)ethyl]phenyl]amino]carbonyl]phenyl]- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 12 THERE ARE 12 CITED REFERENCES AVAILABLE FOR THIS
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 139 OF 283 CAPLUS COPYRIGHT 2006 ACS ON STN
ACCESSION NUMBER: 1999:176102 CAPLUS
DOCUMENT NUMBER: 130:267404
TITLE: Exceptional products of the desulfurization of
N,2-diaryl-5-(arylimino)-2,5-dihydro-4-nitrosothiazol-
3-amines
AUTHOR(S): Moya Argilegos, Dally; Linden, Anthony; Heimgartner,
Heinz
CORPORATE SOURCE: Organisch-Chemisches Institut, Universitaet Zuerich,
Zurich, CH-8057, Switz.
SOURCE: Helvetica Chimica Acta 1999, 82(2), 238-260
CODEN: HCACAV; ISSN: 0018-019X
PUBLISHER: Verlag Helvetica Chimica Acta
DOCUMENT TYPE: Journal
LANGUAGE: English

OTHER SOURCE(S): CASREACT 130:267404


AB The desulfurization of several N,2-diaryl-5-(arylimino)-2,5-dihydro-4-nitroisothiazol-3-amines with Ph3P led to complex mixts. of products in low yields by desulfurization and subsequent rearrangement. For instance, quinoline-2-imine, 2-phenyl-4-nitro-5-(phenylimino)-2,5-dihydroisothiazol-3-amine and 2-phenyl-4-nitro-5-(2-phenylvinylimino)-2,5-dihydroisothiazol-3-amine were isolated with a different substitution pattern from that expected from the starting materials. Reaction mechanisms involving intermediate ketene imines and O transfer from the NO2 group to the neighboring ketene imine are proposed.

neighboring ketene imine are proposed.


IT 222056-37-3P 222056-53-3P 222056-55-5P
RL: PRP (Properties); SPN (Synthetic preparation); PREP (Preparation)
(crystal structure)

RN 222056-37-3 CAPLUS


CN 2-Quinoxalinelcarboxamide, N-phenyl-3-(phenylamino)-, 1-oxide (9CI) (CA
INDEX NAME)




RN 222056-53-3 CAPLUS
CN 2-Quinoxalinecarboxamide, 7-methoxy-3-[(4-methoxyphenyl)amino]-N-phenyl-,
1-oxide (9CI) (CA INDEX NAME)




RN 222056-55-5 CAPLUS
CN 2-Quinoxalinecarboxamide, N-(4-methoxyphenyl)-3-(phenylamino)-, 1-oxide (9CI) (CA INDEX NAME)




IT 222056-39-5P 222056-41-5P 222056-43-1P
222056-45-3P 222056-47-5P 222056-49-7P
222056-51-1P 222056-52-2P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of quinoxalinecarboxamide oxides and nitroquinolines by desulfurization and rearrangement of arylaminohydronitroisothiazolamine)s
RN 222056-39-5 CAPLUS
CN 2-Quinoxalinecarboxamide, N-(4-nitrophenyl)-3-(phenylamino)-, 1-oxide (9CI) (CA INDEX NAME)




RN 222056-41-9 CAPLUS
CN 2-Quinoxalinecarboxamide, N-(4-fluorophenyl)-3-(phenylamino)-, 1-oxide (9CI) (CA INDEX NAME)



RN 222056-43-1 CAPLUS
CN 2-Quinoxalinecarboxamide, N-(4-methoxyphenyl)-3-(phenylamino)-, 1-oxide (9CI) (CA INDEX NAME)




RN 222056-52-2 CAPLUS
CN 2-Quinoxalinecarboxamide, N-(4-fluorophenyl)-3-(phenylamino)-, 1-oxide (9CI) (CA INDEX NAME)




REFERENCE COUNT: 51 THERE ARE 51 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 140 OF 283 CAPLUS COPYRIGHT 2006 ACS ON STN
ACCESSION NUMBER: 1999:96109 CAPLUS
DOCUMENT NUMBER: 130:172992
TITLE: Indan muscarinic agonists
INVENTOR(S): Hollinshead, Sean Patrick; Huff, Bret Eugene; Hughes, Philip Floyd; Mendoza, Jose Serafin; Mitch, Charles Howard; Staszak, Michael Alexander; Ward, John Stanley; Wilson, Joseph Wendell
PATENT ASSIGNEE(S): Eli Lilly and Company, USA
SOURCE: PCT Int. Appl., 96 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9904778	A1	19990204	WO 1998-US15475	19980721
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GR, GM, HR, HU, ID, IL, IS, JP, KR, KZ, KP, KR, KZ, LC, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, RM: GH, GM, KE, LS, MW, SD, SZ, UD, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SF, BJ, CF, CO, CI, CM, GA, GN, GW, MD, MR, NE, SN, TD, TG				
CA 2297906	AA	19990204	CA 1998-2297906	19980721
AU 9685918	A1	19990216	AU 1998-85918	19980721
EP 1003495	A1	20000531	EP 1998-937136	19980721
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE, SI, LT, LV, FI, RO				
JP 2001510797	T2	20010807	JP 2000-503635	19980721
US 2001012848	A1	20010809	US 2000-740380	20001219
US 6395735	B2	20020528		
PRIORITY APPLN. INFO.:			US 1997-53404P	P 19970722
			US 1998-116408	B3 19980716




RN 222056-45-3 CAPLUS
CN 2-Quinoxalinecarboxamide, N-(4-methoxyphenyl)-3-[(4-methoxyphenyl)amino]-N-phenyl-, 1-oxide (9CI) (CA INDEX NAME)



RN 222056-47-5 CAPLUS
CN 2-Quinoxalinecarboxamide, N-(4-methoxyphenyl)-3-(phenylamino)-, 1-oxide (9CI) (CA INDEX NAME)




RN 222056-49-7 CAPLUS
CN 2-Quinoxalinecarboxamide, N-(4-fluorophenyl)-3-[(4-fluorophenyl)amino]-N-phenyl-, 1-oxide (9CI) (CA INDEX NAME)



RN 222056-51-1 CAPLUS
CN 2-Quinoxalinecarboxamide, N-(4-fluorophenyl)-3-[(4-fluorophenyl)amino]-, 1-oxide (9CI) (CA INDEX NAME)


OTHER SOURCE(S): MARPAT 130:172992
GI



AB The present invention provides novel indan-like compds. which can be useful for treating psychosis and other conditions associated with the modulation of a muscarinic receptor. Examples are given for formulations of the compds. Among a large number of compds. prepared was 1. Muscarinic receptor binding data are also given.

IT 194028-33-6P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses) (indan muscarinic agonist pharmaceuticals)
RN 194028-33-6 CAPLUS
CN 2-Quinoxalinecarboxamide, N-[(1R,2R)-2,3-dihydro-2-hydroxy-6-[(1-pyrrolidinylmethylene)amino]-1H-inden-1-yl]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry unknown.




REFERENCE COUNT: 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 141 OF 283 CAPLUS COPYRIGHT 2006 ACS ON STN
ACCESSION NUMBER: 1999:13562 CAPLUS
DOCUMENT NUMBER: 130:139152
TITLE: Unsolvated vic-tricarbonyl compounds via ozonation. Part 4. Ozonation of acylamines without C-C cleavage
AUTHOR(S): Schank, Kurt; Beck, Horst; Himbert, Gerhard
CORPORATE SOURCE: Fachrichtung 11.2 Organische Chemie, Univ. Saarland, Saarbrücken, D-66041, Germany
SOURCE: Synthesis (1998), (12), 1718-1720
CODEN: SYNTHF; ISSN: 0039-7881
PUBLISHER: Georg Thieme Verlag
DOCUMENT TYPE: Journal
LANGUAGE: English
OTHER SOURCE(S): CASREACT 130:139152
AB Acylketimines RPHN(CO)2C(OR)2 (R = Me; R1 = 4-MeOC6H4, 4-ClC6H4, 4-O2NC6H4, Me3CCH2 or R = Ph, R1 = cyclohexylamino) and O3/O2 react at -50° in CH2Cl2 yielding the corresponding unsolvated 1,2-dioxo carboxamides RPHN(CO)3R1 as exclusive reaction products. Two important details of this conversion are emphasized. Neither peroxidic intermediates which usually must be reduced before workup are detected

after O3 is consumed nor is any evidence for a C-C cleavage of the triple bond found. Ph2N(CO)3CH4-4-NO2 partially loses its NO2-substituent during ozonization and was fully characterized by derivatization with 1,2-C6H4(NH2)2 and formation of its quinoxaline-2-carboxamide.

IT 220079-38-9P
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (preparation of)
 RN 220079-38-9 CAPLUS
 CN 2-Quinoxalinecarboxamide, N-methyl-3-(4-nitrophenyl)-N-phenyl- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 22 THERE ARE 22 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 142 OF 283 CAPLUS COPYRIGHT 2006 ACS ON STN
 ACCESSION NUMBER: 1998:789144 CAPLUS
 DOCUMENT NUMBER: 130:38377
 TITLE: Preparation of heteroarylpyrazoles as p38 kinase inhibitors
 INVENTOR(S): Anantanarayan, Ashok; Clare, Michael; Collins, Paul M.; Crich, Joyce Zuowu; Devraj, Rajesh; Flynn, Daniel L.; Geng, Lifeng; Hanson, Gunnar J.; Koszyk, Francis J.; Liao, Shuyuan; Partis, Richard A.; Rao, Shashidhar N.; Selness, Shaun Raj; South, Michael S.; Stealey, Michael A.; Weiler, Richard M.; Xu, Xiangdong
 PATENT ASSIGNEE(S): G.D. Searle and Co., USA; et al.
 SOURCE: PCT Int. Appl., 828 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 4
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9853940	A1	19981126	WO 1998-US10436	19980522
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZM, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, RW, GH, GM, KE, LS, MW, SD, SZ, UG, ZM, AT, BE, BG, CH, CY, DE, DK, EE, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SF, SJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TO				
CA 2291115	AA	19981126	CA 1998-2291115	19980522
AU 9875803	A1	19981211	AU 1998-75803	19980522
AU 754830	B2	20021128		
ZA 9804358	A1	19980524	ZA 1998-4358	19980522
EP 1000055	A1	20000517	EP 1998-923642	19980522
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
TR 200000235	T2	20000522	TR 2000-200000235	19980522
BR 9900527	A	20000615	BR 1999-527	19980522
BR 9809147	A	20000801	BR 1998-9147	19980522

JP 2002508754 T2 20020319 JP 1998-550650 19980522
 NZ 501112 A 20021025 NZ 1998-501112 19980522
 AP 1246 A 20040207 AP 1999-1715 19980522
 W: GM, GH, KE, LS, MW, SD, SZ, UG, ZW
 MX 9905695 A 20000121 MX 1999-5695 19991119
 MX 9910759 A 20000531 MX 1999-10759 19991122
 BO 64313 B1 20040930 BO 1999-103964 19991208
 PRIORITY APPL. INFO.: US 1997-47570P P 19970522
 WO 1998-US10436 W 19980522
 OTHER SOURCE(S): MARPAT 130:38377
 GI




AB Title compds. [I; R1 = H, NH2, (cyclo)alk(en)yl, acyl, aryl, etc.; R2 = H, halo, alkyl, alkoxy, etc.; R3 = pyridyl, pyrimidinyl, quinolyl, etc.; R4 = H, alkyl, heterocyclyl, aryl, etc.] were prepared. Thus, R3CH2COOMe (R3 = 4-pyridinyl) was condensed with 3,4-(OMe)2C6H3CHO and the product cyclized with TeNBH2 to give title compound II. Data for biol. activity of I were given.

IT 216518-34-2P
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (preparation of heteroarylpyrazoles as p38 kinase inhibitors)

RN 216518-34-2 CAPLUS
 CN 2-Quinoxalinecarboxamide, N-[(R)-1-[5-(4-fluorophenyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]-2-phenylethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




REFERENCE COUNT: 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 143 OF 283 CAPLUS COPYRIGHT 2006 ACS ON STN
 ACCESSION NUMBER: 1998:686792 CAPLUS
 DOCUMENT NUMBER: 130:25029
 TITLE: Reactions of fluoroalkyl-containing 2-hydroxyimino-1,3-dicarbonyl compounds with o-phenylenediamine
 AUTHOR(S): Burgart, A. V.; Kusueva, O. O.; Kodess, M. I.;

CORPORATE SOURCE: Saloutin, V. I.
 Institute of Organic Synthesis, Ural Division, Russian Academy of Sciences, Yekaterinburg, 620219, Russia
 SOURCE: Russian Journal of Organic Chemistry (Translation of Zhurnal Organicheskoi Khimii) (1998), 34(3), 375-380
 CODEN: RUOCCO; ISSN: 1070-4280
 PUBLISHER: MAIK Nauka/Interperiodica Publishing
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 AB Fluoroalkyl-containing 2-hydroxyimino-3-oxo esters react with o-phenylenediamine in methanol (benzene, toluene) with formation of substituted quinoxalines. The same reaction in di-Et ether affords the corresponding 4-fluoroalkyl-4-hydroxy-3-hydroxyimino-2,3,4,5-tetrahydro-1,5-benzodiazepin-2-one. The reaction of 1,1,1-trifluoro-3-hydroxyimino-4-phenyl-2,4-butanedione in methanol results in cleavage of the latter and formation of 3-trifluoromethylquinoxalin-2-one; the same reactants in di-Et ether give rise to 2-hydroxy-3-hydroxyimino-4-phenyl-2-trifluoromethyl-2,3-dihydro-1H-1,5-benzodiazepine.

IT 216307-09-4P
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (reactions of fluoroalkyl-containing (hydroxyimino)-substituted 1,3-dicarbonyl compds. with phenylenediamine)
 RN 216307-09-4 CAPLUS
 CN 2-Quinoxalinecarboxamide, N-(2-aminophenyl)-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)




REFERENCE COUNT: 17 THERE ARE 17 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 144 OF 283 CAPLUS COPYRIGHT 2006 ACS ON STN
 ACCESSION NUMBER: 1998:608600 CAPLUS
 DOCUMENT NUMBER: 129:230740
 TITLE: Heteroaryl-hexanoic acid amide derivatives, their preparation and their use as selective inhibitors of MIP-1α binding to its CCR1 receptor
 INVENTOR(S): Brown, Matthew Frank; Kath, John Charles; Poes, Christopher Stanley
 PATENT ASSIGNEE(S): Pfizer Inc., USA
 SOURCE: PCT Int. Appl., 106 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9808167	A1	19980903	WO 1998-US1568	19980205
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZM, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, RW, GH, GM, KE, LS, MW, SD, SZ, UG, ZM, AT, BE, BG, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SF, SJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TO				

AU 9861354 A1 19980918 AU 1998-61354 19980205
 AU 745687 B2 20020328
 EP 664443 A1 19991229 EP 1998-906013 19980205
 R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IR, LI, LU, NL, SE, PT, IE, SI, LT, LV, FI, RO
 TR 9902056 T2 20000121 TR 1999-9902056 19980205
 BR 9807858 A 20000222 BR 1998-7858 19980205
 JP 2000513740 T2 20001017 JP 1998-537644 19980205
 CA 2282834 C 20041005 CA 1998-2282834 19980205
 CA 2282834 AA 19980903
 IL 131163 A1 20050619 IL 1998-131163 19980205
 ZA 9801602 A1 19980921 ZA 1998-1602 19980226
 AP 1056 A 20020405 AP 1998-1200 19980226
 W: BW, GM, KE, MW, UG, ZM, ZW
 BO 10368 A 20001130 BO 1999-10368 19990824
 NO 9904101 A 19990825 NO 1999-4101 19990825
 NO 313877 B1 20021216
 US 6403587 B1 20020611
 US 2002198207 A1 20021226
 PRIORITY APPL. INFO.: US 1997-39169P P 19970226
 WO 1998-US1568 W 19980205
 US 2000-380269 A3 20000518
 OTHER SOURCE(S): MARPAT 129:230740
 GI



AB I [R1 = optionally substituted (C2-C9)heteroaryl; R2 = optionally substituted phenyl-(CH2)m-, (C3-C10)cycloalkyl-(CH2)n-, (C1-C6)alkyl or (C2-C9)heteroaryl-(CH2)m-, m = integer from zero to four; R3 = H, optionally substituted (C1-C10)alkyl, (C3-C10)cycloalkyl-(CH2)n-, (C2-C9)heterocycloalkyl-(CH2)n-, (C2-C9)heteroaryl-(CH2)n-, aryl-(CH2)n-, n = integer from zero to six; R4 and the carbon to which it is attached form an optionally substituted and/or fused five to seven membered carbocyclic ring; R4 = H, (C1-C6)alkyl, hydroxy, (C1-C6)alkoxy, hydroxy-(C1-C6)alkyl, (C1-C6)alkoxyCO, (C3-C10)cycloalkyl-(CH2)p-, optionally substituted (C2-C9)heterocycloalkyl-(CH2)p-, (C2-C9)heteroaryl-(CH2)p-, phenyl-(CH2)p- or naphthyl-(CH2)p-, p = integer from zero to four; R5 and R6 together with the nitrogen atom to which they are attached form an optionally substituted (C2-C9)heterocycloalkyl group; R5 = H, (C1-C6)alkyl, amino] were prepared. The present compds. are potent and selective inhibitors of MIP-1α binding to its receptor CCR1, and are thus useful to treat inflammation and other immune disorders. E.g., quinoxaline-2-carboxylic acid [1(S)-benzyl-4(R)-benzylcarbamoyl-7-fluoro-2(S)-hydroxy-7-methyloctylamide was prepared


IT 212787-53-6P 212787-54-7P 212787-55-8P
 212787-56-9P 212787-59-3P 212787-62-7P
 212787-64-9P 212787-70-7P 212787-81-0P
 212787-84-3P 212787-84-5P 212787-96-7P
 212787-98-9P 212788-06-2P 212788-10-8P
 212788-11-9P 212788-13-1P 212788-15-3P
 212788-17-5P 212788-24-4P 212788-27-7P
 212788-35-7P 212788-43-7P 212788-47-1P
 212788-50-6P 212788-52-8P 212788-53-9P
 212788-54-0P 212788-55-1P 212788-56-2P
 212788-57-3P 212788-58-4P 212788-59-5P
 212788-60-8P 212788-65-3P 212788-67-5P
 212788-68-6P 212788-69-7P 212788-70-0P

212788-71-1P 212788-72-2P 212788-73-3P
 212788-74-4P 212788-75-5P 212788-76-6P
 212788-77-7P 212788-78-8P 212788-79-9P
 212788-80-2P 212788-82-4P 212788-83-5P
 212788-84-6P 212788-85-7P 212788-86-8P
 212788-90-4P 212788-91-5P 212788-94-8P
 212788-95-9P 212788-96-0P 212788-97-1P
 212788-98-2P 212788-99-3P 212789-01-0P
 212789-03-2P 212789-04-3P 212789-05-4P
 212789-06-5P 212789-07-6P 212789-08-7P
 212789-09-8P 212789-12-3P 212789-13-4P
 212789-16-7P 212789-19-0P 212789-20-3P
 212789-21-4P 212789-22-5P 212789-23-6P
 212789-24-7P 212789-25-8P 212789-26-9P
 212789-27-0P 212789-28-1P 212789-29-2P
 212789-30-5P 212789-31-6P 212789-32-7P
 212789-33-8P 212789-34-9P 212789-35-0P
 212789-36-1P 212789-37-2P 212789-38-3P
 212789-39-4P 212789-40-7P 212789-41-8P
 212789-42-9P 212789-43-0P 212789-44-1P
 212789-45-2P 212789-46-3P 212789-47-4P
 212789-48-5P 212789-49-6P 212789-50-9P
 212789-51-0P 212789-52-1P 212789-53-2P
 212789-55-4P 212789-56-5P 212789-57-6P
 212789-58-7P 212789-59-8P 212789-60-1P
 212789-61-2P 212789-62-3P 212789-63-4P
 212789-64-5P 212789-65-6P 212789-66-7P
 212789-67-8P 212789-68-9P 212789-69-0P
 212789-70-1P 212789-71-4P 212789-72-5P
 212789-73-6P 212789-74-7P 212789-75-8P
 212789-76-9P 212789-81-6P 212789-90-7P
 212789-95-2P 212789-96-3P 212789-98-5P
 212790-01-7P 212790-02-8P 212790-03-9P
 212790-04-0P 212790-05-1P 212790-06-2P
 212790-07-3P 212790-08-4P 212790-13-1P
 212790-14-2P 212790-15-3P 212790-16-4P
 212790-17-5P 212790-18-6P 212790-19-7P
 212790-20-0P 212790-21-1P 212790-22-2P
 212790-23-3P 212790-24-4P 212790-25-5P
 212790-26-6P 212790-27-7P 212790-28-8P
 212790-29-9P 212790-30-2P 212790-31-3P
 212790-32-4P 212790-33-5P 212790-34-6P
 212790-37-9P 212790-38-0P 212790-42-6P
 212790-44-8P 212790-45-9P 212790-46-0P
 212790-47-1P 212790-49-3P 212790-50-6P
 212790-52-8P 212835-27-3P 212835-28-4P
 212835-29-5P 212835-30-8P 212835-32-0P
 212835-33-1P 212835-34-2P 212835-35-3P
 212835-36-4P 212835-37-5P 212835-38-6P
 212835-39-7P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USSS (Uses)
 (preparation of heteroaryl-substituted hexanamides and their use as selective inhibitors of MIP-1 α binding to its CCR1 receptor)


RN 212787-53-6 CAPLUS
 CN 2-Quinoxalinecarboxamide, N-[(1S,2S,4R)-7-fluoro-2-hydroxy-7-methyl-1-(phenylmethyl)-4-[(phenylmethyl)amino]carbonyl]octyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 212787-54-7 CAPLUS
 CN 2-Quinoxalinecarboxamide, N-[(1S,2S,4R)-7-fluoro-2-hydroxy-4-[(hydroxyamino)carbonyl]-7-methyl-1-(phenylmethyl)octyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 212787-55-8 CAPLUS
 CN 2-Quinoxalinecarboxamide, N-[(1S,2S,4R)-4-(aminocarbonyl)-2-hydroxy-7-methyl-1-(phenylmethyl)octyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 212787-56-9 CAPLUS
 CN 2-Quinoxalinecarboxamide, N-[(1S,2S,4R)-1-(cyclohexylmethyl)-2-hydroxy-6-methyl-4-[(methylamino)carbonyl]heptyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 212787-59-2 CAPLUS
 CN 2-Quinoxalinecarboxamide, N-[(1S,2S,4R)-1-(cyclohexylmethyl)-2-hydroxy-6-methyl-4-[(methylamino)carbonyl]-6-heptyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 212787-62-7 CAPLUS
 CN 2-Quinoxalinecarboxamide, N-[(1S,2S,4R)-1-(cyclohexylmethyl)-4-[(dimethylamino)carbonyl]-2-hydroxy-6-methyl-6-heptyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 212787-64-9 CAPLUS
 CN 2-Quinoxalinecarboxamide, N-[(1S,2S,4R)-1-(cyclohexylmethyl)-2-hydroxy-6-methyl-4-[(methylamino)carbonyl]heptyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 212787-70-7 CAPLUS
 CN 2-Quinoxalinecarboxamide, N-[(1S,2S,4R)-1-(cyclohexylmethyl)-2-hydroxy-5-(methylamino)-5-oxo-4-(phenylmethyl)pentyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 212787-81-0 CAPLUS
 CN 2-Quinoxalinecarboxamide, N-[(1S,2S,4R)-2-hydroxy-6-methyl-4-[(methylamino)carbonyl]-1-(phenylmethyl)heptyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 212787-84-3 CAPLUS
 CN 2-Quinoxalinecarboxamide, N-[(1S,2S,4R)-4-[(butylamino)carbonyl]-2-hydroxy-6-methyl-1-[(4-(phenylmethoxy)phenyl)methyl]heptyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 212787-94-5 CAPLUS
CN 2-Quinoxalinecarboxamide, N-[(1S,2S,4S)-2-hydroxy-6-methyl-4-[(methylamino)carbonyl]-1-(phenylmethyl)heptyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 212787-96-7 CAPLUS
CN Methanesulfonic acid, trifluoro-, 4-[(2S,3S,5R)-3-hydroxy-7-methyl-5-[(methylamino)carbonyl]-2-[(2-quinoxalinyloxy)amino]octyl]phenyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 212787-98-9 CAPLUS
CN 2-Quinoxalinecarboxamide, N-[(1S,2S,4R)-4-(cyclohexylmethyl)-2-hydroxy-5-(methylamino)-5-oxo-1-(phenylmethyl)pentyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 212788-06-2 CAPLUS
CN 2-Quinoxalinecarboxamide, N-[(1S,2S,4R)-2-hydroxy-1-[(4-methoxyphenyl)methyl]-6-methyl-4-[(methylamino)carbonyl]heptyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 212788-10-8 CAPLUS
CN 2-Quinoxalinecarboxamide, N-[(1S,2S,4R)-2-hydroxy-1-[(4-hydroxyphenyl)methyl]-6-methyl-4-[(methylamino)carbonyl]heptyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 212788-11-9 CAPLUS
CN 2-Quinoxalinecarboxamide, N-[(1S,2S,4R)-1,4-bis(cyclohexylmethyl)-2-hydroxy-5-(methylamino)-5-oxopentyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 212788-13-1 CAPLUS
CN 2-Quinoxalinecarboxamide, N-[(1S,2S,4R)-1-[(4-chlorophenyl)methyl]-2-hydroxy-6-methyl-4-[(methylamino)carbonyl]heptyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 212788-15-3 CAPLUS
CN 2-Quinoxalinecarboxamide, N-[(1S,2S,4R)-1-(cyclohexylmethyl)-2-hydroxy-7-methyl-4-[(methylamino)carbonyl]octyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 212788-17-5 CAPLUS
CN 2-Quinoxalinecarboxamide, N-[(1S,2S,4R)-1-[(4-chlorophenyl)methyl]-2-hydroxy-5-(methylamino)-5-oxopentyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 212788-24-4 CAPLUS
CN 2-Quinoxalinecarboxamide, N-[(1S,2S,4R)-2-hydroxy-7-methyl-4-[(methylamino)carbonyl]-1-(phenylmethyl)octyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 212788-27-7 CAPLUS
CN 2-Quinoxalinecarboxamide, N-[(1S,2S,4R)-1-[(3,4-dichlorophenyl)methyl]-2-hydroxy-6-methyl-4-[(methylamino)carbonyl]heptyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 212788-35-7 CAPLUS
CN 2-Quinoxalinecarboxamide, N-[(1S,2S,4R)-1-[(4-fluorophenyl)methyl]-2-hydroxy-6-methyl-4-[(methylamino)carbonyl]heptyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 212788-43-3 CAPLUS
CN 2-Quinoxalinecarboxamide, N-[(1S,2S,4R)-4-[(butylamino)carbonyl]-2-hydroxy-7-methyl-1-(phenylmethyl)octyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 212788-47-1 CAPLUS
CN 2-Quinoxalinecarboxamide, N-[(1S,2S,4R)-4-(cyclopentylmethyl)-2-hydroxy-5-(methylamino)-5-oxo-1-(phenylmethyl)pentyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 212788-50-6 CAPLUS
CN 2-Quinoxalinecarboxamide, N-[(1S,2S,4R)-5-amino-4-(cyclopentylmethyl)-2-hydroxy-5-oxo-1-(phenylmethyl)pentyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 212788-53-8 CAPLUS


CN 2-Quinoxalinecarboxamide, N-[(1S,2S,4R)-1-[(4,4-difluorocyclohexyl)methyl]-2-hydroxy-6-methyl-4-[(methylamino)carbonyl]heptyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 212788-53-9 CAPLUS
CN 2-Quinoxalinecarboxamide, N-[(1S,2S,4R)-1-[(4,4-difluorocyclohexyl)methyl]-2-hydroxy-7-methyl-4-[(methylamino)carbonyl]octyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 212788-54-0 CAPLUS
CN 2-Quinoxalinecarboxamide, N-[(1S,2S,4R)-4-[(ethylamino)carbonyl]-2-hydroxy-7-methyl-1-(phenylmethyl)octyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 212788-55-1 CAPLUS
CN 2-Quinoxalinecarboxamide, N-[(1S,2S,4R)-2-hydroxy-7-methyl-1-(phenylmethyl)-4-[(propylamino)carbonyl]octyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 212788-56-2 CAPLUS
CN 2-Quinoxalinecarboxamide, N-[(1S,2S,4R)-4-[(cyclopropylamino)carbonyl]-2-hydroxy-7-methyl-1-(phenylmethyl)octyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 212788-57-3 CAPLUS
CN 2-Quinoxalinecarboxamide, N-[(1S,2S,4R)-4-[(cyclobutylamino)carbonyl]-2-hydroxy-7-methyl-1-(phenylmethyl)octyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 212788-58-4 CAPLUS
CN 2-Quinoxalinecarboxamide, N-[(1S,2S,4R)-1-[(4-(difluoromethoxy)phenyl)methyl]-2-hydroxy-7-methyl-4-[(methylamino)carbonyl]octyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 212788-59-5 CAPLUS
CN Benzoic acid, 4-[(2S,3S,5R)-3-hydroxy-7-methyl-5-[(methylamino)carbonyl]-2-[(2-quinoxalinyloxy)amino]octyl]-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 212788-60-8 CAPLUS
CN 2-Quinoxalinecarboxamide, N-[(1S,2S)-5-amino-2-hydroxy-5-oxo-1-(phenylmethyl)pentyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 212788-65-3 CAPLUS
CN 2-Quinoxalinecarboxamide, N-[(1S,2S,4R)-5-(butylamino)-4-(cyclopentylmethyl)-2-hydroxy-5-oxo-1-(phenylmethyl)pentyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 212788-67-5 CAPLUS
CN 2-Quinoxalinecarboxamide, N-[(1S,2S,4R)-2-hydroxy-8-methyl-4-[(methylamino)carbonyl]-1-(phenylmethyl)nonyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 212788-68-6 CAPLUS
CN 2-Quinoxalinecarboxamide, N-[(1S,2S,4R)-2-hydroxy-6-methyl-4-[(methylamino)carbonyl]-1-(phenylmethyl)heptyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 212788-69-7 CAPLUS
CN 2-Quinoxalinecarboxamide, N-[(1S,2S,4R)-1-[(1,1'-biphenyl)-4-ylmethyl]-2-hydroxy-7-methyl-4-[(methylamino)carbonyl]octyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 212788-70-0 CAPLUS


CN 2-Quinoxalinecarboxamide, N-[(1S,2S,4R)-4-(aminocarbonyl)-2-hydroxy-7-methyl-1-(phenylmethyl)-6-octenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 212788-71-1 CAPLUS
CN 2-Quinoxalinecarboxamide, N-[(1S,2S,4R)-2-hydroxy-6-methyl-4-[(methylamino)carbonyl]-1-(2-naphthalenylmethyl)heptyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 212788-72-2 CAPLUS
CN 2-Quinoxalinecarboxamide, N-[(1S,2S,4R)-2-hydroxy-7,7-dimethyl-1-(phenylmethyl)octyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 212788-73-3 CAPLUS
CN 2-Quinoxalinecarboxamide, N-[(1S,2S,4R)-2-hydroxy-7,7-dimethyl-4-[(methylamino)carbonyl]-1-(phenylmethyl)octyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 212788-74-4 CAPLUS
CN 2-Quinoxalinecarboxamide, N-[(1S,2S,4R)-5-amino-2-hydroxy-5-oxo-1,4-bis(phenylmethyl)pentyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 212788-75-5 CAPLUS
CN 2-Quinoxalinecarboxamide, N-[(1S,2S,4R)-4-(aminocarbonyl)-1-[(1,1'-biphenyl)-4-ylmethyl]-2-hydroxy-7-methyloctyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 212788-76-6 CAPLUS
CN 2-Quinoxalinecarboxamide, N-[(1S,2S,4R)-4-[(4,4-difluorocyclohexyl)methyl]-2-hydroxy-5-(methylamino)-5-oxo-1-(phenylmethyl)pentyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 212788-77-7 CAPLUS
CN 2-Quinoxalinecarboxamide, N-[(1S,2S,4R)-5-amino-4-[(4,4-difluorocyclohexyl)methyl]-2-hydroxy-5-oxo-1-(phenylmethyl)pentyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 212788-78-8 CAPLUS
CN 2-Quinoxalinecarboxamide, N-[(1S,2S,4R)-1-[(3-fluorophenyl)methyl]-2-hydroxy-7-methyl-4-[(methylamino)carbonyl]octyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 212788-79-9 CAPLUS
CN 2-Quinoxalinecarboxamide, N-[(1S,2S,4R)-4-(aminocarbonyl)-1-[(3-fluorophenyl)methyl]-2-hydroxy-7-methyloctyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 212788-80-2 CAPLUS
CN 2-Quinoxalinecarboxamide, N-[(1S,2S,4R)-2-hydroxy-7-methyl-4-[(methylamino)carbonyl]-1-(phenylmethyl)-6-octenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 212788-82-4 CAPLUS
CN 2-Quinoxalinecarboxamide, N-[(1S,2S,4R,7S)-4-[(dimethylamino)carbonyl]-2-hydroxy-7-methyl-1-(phenylmethyl)nonyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 212788-83-5 CAPLUS
CN 2-Quinoxalinecarboxamide, N-[(1S,2S,4R)-7-fluoro-2-hydroxy-7-methyl-4-[(methylamino)carbonyl]-1-(phenylmethyl)octyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 212788-91-5 CAPLUS
CN 2-Quinoxalinecarboxamide, N-[(1S,2S,4R)-4-(aminocarbonyl)-2-hydroxy-1-(phenylmethyl)-6-nonenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.




RN 212788-94-8 CAPLUS
CN 2-Quinoxalinecarboxamide, N-[(1S,2S,4R)-4-(aminocarbonyl)-2-hydroxy-1-(phenylmethyl)nonyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 212788-95-9 CAPLUS
CN Butanediamide, 2-[(2S,3S)-2-hydroxy-4-phenyl-3-[(2-quinoxalinyloxy)amino]butyl]-N,N'-dimethyl-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 212788-96-0 CAPLUS
CN 2-Quinoxalinecarboxamide, N-[(1S,2S,4R)-4-[(ethylamino)carbonyl]-7-fluoro-2-hydroxy-7-methyl-1-(phenylmethyl)octyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


RN 212788-84-6 CAPLUS
CN 2-Quinoxalinecarboxamide, N-[(1S,2S,4R)-4-(aminocarbonyl)-7-fluoro-2-hydroxy-7-methyl-1-(phenylmethyl)octyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 212788-85-7 CAPLUS
CN 2-Quinoxalinecarboxamide, N-[(1S,2S,4R)-2-hydroxy-7-methyl-4-[(methylamino)carbonyl]-1-(phenylmethyl)nonyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 212788-86-8 CAPLUS
CN 2-Quinoxalinecarboxamide, N-[(1S,2S,4R)-4-[(dimethylamino)carbonyl]-2-hydroxy-6-methyl-1-(phenylmethyl)heptyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 212788-90-4 CAPLUS
CN 2-Quinoxalinecarboxamide, N-[(1S,2S,4R)-2-hydroxy-4-[(methylamino)carbonyl]-1-(phenylmethyl)-6-nonenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.




RN 212788-97-1 CAPLUS
CN 2-Quinoxalinecarboxamide, N-[(1S,2S,4R)-4-[(butylamino)carbonyl]-7-fluoro-2-hydroxy-7-methyl-1-(phenylmethyl)octyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 212788-98-2 CAPLUS
CN 2-Quinoxalinecarboxamide, N-[(1S,2S,4R)-7-fluoro-1-[(4-fluorophenyl)methyl]-2-hydroxy-7-methyl-4-[(methylamino)carbonyl]octyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 212788-99-3 CAPLUS
CN 2-Quinoxalinecarboxamide, N-[(1S,2S,4R)-4-(aminocarbonyl)-1-[(3,4-dichlorophenyl)methyl]-7-fluoro-2-hydroxy-7-methyloctyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 212789-01-0 CAPLUS
CN 2-Quinoxalinecarboxamide, N-[(1S,2S,4R)-4-(aminocarbonyl)-2-hydroxy-7-methyl-1-(2-phenylethyl)octyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 212789-03-2 CAPLUS
CN 2-Quinoxalinecarboxamide, N-[(1S,2S,4R)-4-(aminocarbonyl)-7-fluoro-1-[(4-fluorophenyl)methyl]-2-hydroxy-7-methyloctyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 212789-04-3 CAPLUS
CN 2-Quinoxalinecarboxamide, N-[(1S,2S,4R)-7-fluoro-2-hydroxy-7-methyl-4-[(4-methyl-1-piperazinyl)carbonyl]-1-(phenylmethyl)octyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 212789-05-4 CAPLUS
CN 2-Quinoxalinecarboxamide, N-[(1S,2S,4R)-5-amino-2-hydroxy-5-oxo-1-(phenylmethyl)-4-[(tetrahydro-2H-pyran-4-yl)methyl]pentyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 212789-06-5 CAPLUS
CN 2-Quinoxalinecarboxamide, N-[(1S,2S,4R)-7-fluoro-2-hydroxy-7-methyl-1-(phenylmethyl)-4-(1-piperidinylcarbonyl)octyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 212789-07-6 CAPLUS
CN 2-Quinoxalinecarboxamide, N-[(1S,2S,4R)-7-fluoro-2-hydroxy-7-methyl-4-(4-morpholinylcarbonyl)-1-(phenylmethyl)octyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 212789-08-7 CAPLUS
CN 2-Quinoxalinecarboxamide, N-[(1S,2S)-3-[2-(aminocarbonyl)-2,3-dihydro-1H-inden-2-yl]-2-hydroxy-1-(phenylmethyl)propyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 212789-09-8 CAPLUS
CN 2-Quinoxalinecarboxamide, N-[(1S,2S,4R)-2-hydroxy-4-[(methylamino)carbonyl]-7-phenyl-1-(phenylmethyl)-6-heptenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.




RN 212789-12-3 CAPLUS
CN 2-Quinoxalinecarboxamide, N-[(1S,2S,4S)-5-amino-4-cyclohexyl-2-hydroxy-5-oxo-1-(phenylmethyl)pentyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 212789-13-4 CAPLUS
CN 2-Quinoxalinecarboxamide, N-[(1S,2S,4S)-5-amino-4-cyclopentyl-2-hydroxy-5-oxo-1-(phenylmethyl)pentyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 212789-16-7 CAPLUS
CN 2-Quinoxalinecarboxamide, N-[(1S,2S,4R)-4-(aminocarbonyl)-1-(2-(fluorophenyl)methyl)-2-hydroxy-7-methyloctyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 212789-19-0 CAPLUS
CN 2-Quinoxalinecarboxamide, N-[(1S,2S,4S)-5-amino-2-hydroxy-5-oxo-1-(phenylmethyl)-4-(3,3,5,5-tetramethylcyclohexyl)pentyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 212789-20-3 CAPLUS
CN 2-Quinoxalinecarboxamide, N-[(1S,2S,4S)-5-amino-4-(2,3-dihydro-1H-inden-2-yl)-2-hydroxy-5-oxo-1-(phenylmethyl)pentyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 212789-21-4 CAPLUS
CN 2-Quinoxalinecarboxamide, N-[(1S,2S,4S)-5-amino-4-cycloheptyl-2-hydroxy-5-oxo-1-(phenylmethyl)pentyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 212789-22-5 CAPLUS
CN 2-Quinoxalinecarboxamide, N-[(1S,2S,4R)-4-(aminocarbonyl)-2-hydroxy-1-(phenylmethyl)-5-propyloctyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 212789-23-6 CAPLUS
CN 2-Quinoxalinecarboxamide, N-[(1S,2S,4R)-7-chloro-2-hydroxy-4-[(methylamino)carbonyl]-1-(phenylmethyl)-6-heptynyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.




RN 212789-24-7 CAPLUS
CN 2-Quinoxalinecarboxamide, N-[(1S,2S,4R)-6-chloro-2-hydroxy-4-[(methylamino)carbonyl]-1-(phenylmethyl)-6-heptynyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 212789-25-8 CAPLUS
CN 2-Quinoxalinecarboxamide, N-[(1S,2S,4R)-4-(aminocarbonyl)-6-chloro-2-hydroxy-1-(phenylmethyl)-6-heptynyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 212789-26-9 CAPLUS
CN 2-Quinoxalinecarboxamide, N-[(1S,2S,4S)-4-(aminocarbonyl)-6-cyclopropyl-2-hydroxy-1-(phenylmethyl)hexyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 212789-27-0 CAPLUS
CN 2-Quinoxalinecarboxamide, N-[(1S,2S,4R)-6-cyclopropyl-2-hydroxy-4-[(methylamino)carbonyl]-1-(phenylmethyl)hexyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 212789-28-1 CAPLUS
CN 2-Quinoxalinecarboxamide, N-[(1S,2S,4R)-5-amino-2-hydroxy-5-oxo-1-(phenylmethyl)-4-[[4-(trifluoromethoxy)phenyl]methyl]pentyl]- (9CI) (CA INDEX NAME)


INDEX NAME)

Absolute stereochemistry.




RN 212789-29-2 CAPLUS
CN 2-Quinoxalinecarboxamide, N-[(1S,2S,4R)-5-amino-4-[(4-fluorophenyl)methyl]-2-hydroxy-5-oxo-1-(phenylmethyl)pentyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 212789-30-5 CAPLUS
CN 2-Quinoxalinecarboxamide, N-[(1S,2S,4R)-4-(aminocarbonyl)-7-chloro-2-hydroxy-1-(phenylmethyl)-6-heptynyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.




RN 212789-31-6 CAPLUS
CN 2-Quinoxalinecarboxamide, N-[(1S,2S,4R)-4-(aminocarbonyl)-7-fluoro-2-hydroxy-7-methyl-1-(phenylmethyl)octyl]-3,4-dihydro-3-oxo- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 212789-32-7 CAPLUS
CN 2-Quinoxalinecarboxamide, N-[(1S,2S,4R)-7-fluoro-2-hydroxy-7-methyl-1-(phenylmethyl)-4-[[3-pyridinylmethyl]amino]carbonyl]octyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 212789-33-8 CAPLUS
CN 2-Quinoxalinecarboxamide, N-[(1S,2S,4R)-8,8,8-trifluoro-2-hydroxy-4-[(methylamino)carbonyl]-1-(phenylmethyl)-7-(trifluoromethyl)octyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 212789-34-9 CAPLUS
CN 2-Quinoxalinecarboxamide, N-[(1S,2S,4R)-4-(aminocarbonyl)-8,8,8-trifluoro-2-hydroxy-1-(phenylmethyl)-7-(trifluoromethyl)octyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 212789-35-0 CAPLUS
CN 2-Quinoxalinecarboxamide, N-[(1S,2S,4R)-2-hydroxy-7-methyl-4-[(methylamino)carbonyl]-1-[[4-[(methylamino)carbonyl]phenyl]methyl]octyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 212789-36-1 CAPLUS
CN 2-Quinoxalinecarboxamide, N-[(1S,2S,4S)-4-(aminocarbonyl)-5-ethyl-2-hydroxy-1-(phenylmethyl)heptyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 212789-37-2 CAPLUS
CN 2-Quinoxalinecarboxamide, N-[(1S,2S,4S)-5-amino-2-hydroxy-5-oxo-1-(phenylmethyl)-4-(tetrahydro-2H-pyran-4-yl)pentyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 212789-38-3 CAPLUS
CN 2-Quinoxalinecarboxamide, N-[(1S,2S,4R)-7-fluoro-2-hydroxy-7-methyl-1-(phenylmethyl)-4-[[2-(2-pyridinyl)ethyl]amino]carbonyloctyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 212789-39-4 CAPLUS
CN 2-Quinoxalinecarboxamide, N-[(1S,2S,4R)-4-[[[3,4-dimethoxyphenyl]methyl]amino]carbonyl]-7-fluoro-2-hydroxy-7-methyl-1-(phenylmethyl)octyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 212789-40-7 CAPLUS
CN 2-Quinoxalinecarboxamide, N-[(1S,2S,4R)-4-(aminocarbonyl)-2-hydroxy-6-methoxy-1-(phenylmethyl)hexyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 212789-41-8 CAPLUS
CN 2-Quinoxalinecarboxamide, N-[(1S,2S,4R)-4-(aminocarbonyl)-7-chloro-2-hydroxy-1-(phenylmethyl)-6-octenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.




RN 212789-42-9 CAPLUS
CN 2-Quinoxalinecarboxamide, N-[(1S,2S,4R)-7-chloro-2-hydroxy-4-[(methylamino)carbonyl]-1-(phenylmethyl)-6-octenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.




RN 212789-43-0 CAPLUS
CN 2-Quinoxalinecarboxamide, N-[(1S,2S,4R)-7-fluoro-2-hydroxy-7-methyl-1-(phenylmethyl)-4-[[2-(2-pyridinylmethyl)amino]carbonyloctyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 212789-44-1 CAPLUS
CN 2-Quinoxalinecarboxamide, N-[(1S,2S,4R)-7-fluoro-2-hydroxy-4-[[2-(4-hydroxyphenyl)ethyl]amino]carbonyl]-7-methyl-1-(phenylmethyl)octyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 212789-45-2 CAPLUS
CN 2-Quinoxalinecarboxamide, N-[(1S,2S,4R)-7-fluoro-2-hydroxy-7-methyl-1-(phenylmethyl)-4-[[2-(thienylmethyl)amino]carbonyloctyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 212789-46-3 CAPLUS
CN 2-Quinoxalinecarboxamide, N-[(1S,2S,4R)-4-(aminocarbonyl)-2-hydroxy-6-phenoxy-1-(phenylmethyl)hexyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 212789-47-4 CAPLUS
CN 2-Quinoxalinecarboxamide, N-[(1S,2S,4R)-4-(aminocarbonyl)-2-hydroxy-6-(1-methylethoxy)-1-(phenylmethyl)hexyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 212789-48-5 CAPLUS
CN 2-Quinoxalinecarboxamide, N-[(1S,2S,4R)-7-fluoro-2-hydroxy-7-methyl-1-((phenylmethyl)octyl)-4-((2-((4-aminosulfonyl)phenyl)ethyl)amino)carbonyl)-7-fluoro-2-hydroxy-7-methyl-1-(phenylmethyl)octyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 212789-49-6 CAPLUS
CN 2-Quinoxalinecarboxamide, N-[(1S,2S,4R)-7-fluoro-2-hydroxy-7-methyl-1-(phenylmethyl)octyl)-4-((2-((4-pyridinylmethyl)amino)carbonyl)octyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 212789-50-9 CAPLUS
CN 2-Quinoxalinecarboxamide, N-[(1S,2S,4R)-7-fluoro-2-hydroxy-7-methyl-1-(phenylmethyl)octyl)-4-((2-((4-pyridinylmethyl)amino)carbonyl)octyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 212789-51-0 CAPLUS
CN 2-Quinoxalinecarboxamide, N-[(1S,2S,4R)-7-fluoro-2-hydroxy-7-methyl-1-(phenylmethyl)octyl)-4-((2-((4-methoxyphenyl)methyl)amino)carbonyl)-7-methyl-1-(phenylmethyl)octyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 212789-52-1 CAPLUS
CN 2-Quinoxalinecarboxamide, N-[(1S,2S,4R)-7-fluoro-2-hydroxy-7-methyl-1-(phenylmethyl)octyl)-4-((2-((4-pyridinylmethyl)amino)carbonyl)octyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 212789-53-2 CAPLUS
CN 2-Quinoxalinecarboxamide, N-[(1S,2S,4R)-7-fluoro-2-hydroxy-7-methyl-1-(phenylmethyl)octyl)-4-((2-((4-pyridinylmethyl)amino)carbonyl)octyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 212789-55-4 CAPLUS
CN 2-Quinoxalinecarboxamide, N-[(1S,2S,4R)-7-fluoro-2-hydroxy-7-methyl-1-(phenylmethyl)octyl)-4-((2-((4-pyridinylmethyl)amino)carbonyl)octyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 212789-56-5 CAPLUS
CN 2-Quinoxalinecarboxamide, N-[(1S,2S,4R)-7-fluoro-2-hydroxy-7-methyl-1-(phenylmethyl)octyl)-4-((2-((4-pyridinylmethyl)amino)carbonyl)octyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 212789-57-6 CAPLUS
CN 2-Quinoxalinecarboxamide, N-[(1S,2S,4R)-7-fluoro-2-hydroxy-7-methyl-1-(phenylmethyl)octyl)-4-((2-((4-pyridinylmethyl)amino)carbonyl)octyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 212789-58-7 CAPLUS
CN 2-Quinoxalinecarboxamide, N-[(1S,2S,4R)-7-fluoro-2-hydroxy-7-methyl-1-(phenylmethyl)octyl)-4-((2-((4-pyridinylmethyl)amino)carbonyl)octyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 212789-59-8 CAPLUS
CN 2-Quinoxalinecarboxamide, N-[(1S,2S,4R)-7-fluoro-2-hydroxy-7-methyl-1-(phenylmethyl)octyl)-4-((2-((4-pyridinylmethyl)amino)carbonyl)octyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 212789-60-1 CAPLUS
CN 2-Quinoxalinecarboxamide, N-[(1S,2S,4R)-7-fluoro-2-hydroxy-7-methyl-1-(phenylmethyl)octyl)-4-((2-((4-pyridinylmethyl)amino)carbonyl)octyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 212789-61-2 CAPLUS
CN 2-Quinoxalinecarboxamide, N-[(1S,2S,4R)-7-fluoro-2-hydroxy-7-methyl-1-(phenylmethyl)-4-[[[2-(2-thienyl)ethyl]amino]carbonyl]octyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 212789-62-3 CAPLUS
CN 2-Quinoxalinecarboxamide, N-[(1S,2S,4R)-7-fluoro-2-hydroxy-4-[[[2-(1H-indol-3-yl)ethyl]amino]carbonyl]-7-methyl-1-(phenylmethyl)octyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 212789-63-4 CAPLUS
CN 2-Quinoxalinecarboxamide, N-[(1S,2S,4R)-7-fluoro-2-hydroxy-4-[[[2-(4-aminophenyl)ethyl]amino]carbonyl]-7-fluoro-2-hydroxy-7-methyl-1-(phenylmethyl)octyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 212789-64-5 CAPLUS
CN 2-Quinoxalinecarboxamide, N-[(1S,2S,4R)-4-[[[2-(3,5-dimethoxyphenyl)ethyl]amino]carbonyl]-7-fluoro-2-hydroxy-7-methyl-1-(phenylmethyl)octyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 212789-65-6 CAPLUS
CN 2-Quinoxalinecarboxamide, N-[(1S,2S,4R)-4-[[[2-(3,4-dimethoxyphenyl)ethyl]amino]carbonyl]-7-fluoro-2-hydroxy-7-methyl-1-(phenylmethyl)octyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 212789-66-7 CAPLUS
CN 2-Quinoxalinecarboxamide, N-[(1S,2S,4R)-7-fluoro-4-[[[2-(4-methoxyphenyl)ethyl]amino]carbonyl]-2-hydroxy-7-methyl-1-(phenylmethyl)octyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 212789-67-8 CAPLUS
CN 2-Quinoxalinecarboxamide, N-[(1S,2S,4R)-4-[[[2-(2,5-dimethoxyphenyl)ethyl]amino]carbonyl]-7-fluoro-2-hydroxy-7-methyl-1-(phenylmethyl)octyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 212789-68-9 CAPLUS
CN 2-Quinoxalinecarboxamide, N-[(1S,2S,4R)-7-fluoro-4-[[[2-(4-methoxyphenyl)ethyl]amino]carbonyl]-7-fluoro-2-hydroxy-7-methyl-1-(phenylmethyl)octyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 212789-69-0 CAPLUS
CN 2-Quinoxalinecarboxamide, N-[(1S,2S,4R)-4-((aminocarbonyl)-6-(cyclohexyloxy)-2-hydroxy-1-(phenylmethyl)hexyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 212789-70-3 CAPLUS
CN 2-Quinoxalinecarboxamide, N-[(1S,2S,4R)-4-[[[1H-benzimidazol-2-ylmethyl]amino]carbonyl]-7-fluoro-2-hydroxy-7-methyl-1-(phenylmethyl)octyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 212789-71-4 CAPLUS
CN 2-Quinoxalinecarboxamide, N-([1S,2S,4R]-7-fluoro-2-hydroxy-4-[[[(2S)-2-(hydroxymethyl)-1-pyrrolidinyl]carbonyl]-7-methyl-1-(phenylmethyl)octyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 212789-72-5 CAPLUS
CN 2-Quinoxalinecarboxamide, N-([1S,2S,4S]-7-fluoro-2-hydroxy-7-methyl-1-(phenylmethyl)-4-[[[(tetrahydro-2-furanyl)methyl]amino]carbonyl]octyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 212789-73-6 CAPLUS
CN 2-Quinoxalinecarboxamide, N-([1S,2S,4S]-5-amino-4-(4,4-difluorocyclohexyl)-2-hydroxy-5-oxo-1-(phenylmethyl)pentyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 212789-74-7 CAPLUS
CN 2-Quinoxalinecarboxamide, N-([1S,2S,4R]-4-[[[(2,3-dimethoxyphenyl)methyl]amino]carbonyl]-7-fluoro-2-hydroxy-7-methyl-1-(phenylmethyl)octyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 212789-75-8 CAPLUS
CN 2-Quinoxalinecarboxamide, N-([1S,2S,4S]-5-amino-2-hydroxy-4-(1-hydroxycyclohexyl)-5-oxo-1-(phenylmethyl)pentyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 212789-76-9 CAPLUS
CN 2-Quinoxalinecarboxamide, N-([1S,2S,4R]-4-(aminocarbonyl)-7-fluoro-1-(3-fluorophenyl)methyl)-2-hydroxy-7-methyloctyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 212789-81-6 CAPLUS
CN 2-Quinoxalinecarboxamide, N-([1S,2S,4R]-4-(aminocarbonyl)-7-fluoro-2-hydroxy-1-[[4-iodophenyl)methyl]-7-methyloctyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 212789-90-7 CAPLUS
CN 2-Quinoxalinecarboxamide, N-([1S,2S,4R]-5-amino-2-hydroxy-5-oxo-1-(phenylmethyl)-4-(3-pyridinylmethyl)pentyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 212789-95-2 CAPLUS
CN 2-Quinoxalinecarboxamide, N-([1S,2S,4R]-4-(aminocarbonyl)-7-fluoro-2-hydroxy-7-methyl-1-phenyloctyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 212789-96-3 CAPLUS
CN 2-Quinoxalinecarboxamide, N-([1S,2S,4R]-5-amino-2-hydroxy-5-oxo-1-(phenylmethyl)-4-(2-pyridinylmethyl)pentyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 212789-98-5 CAPLUS
CN 2-Quinoxalinecarboxamide, N-([1S,2S,4S]-5-amino-2-hydroxy-5-oxo-1-(phenylmethyl)-4-(tetrahydro-4-hydroxy-2H-thiopyran-4-yl)pentyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 212790-01-7 CAPLUS
CN 2-Quinoxalinecarboxamide, N-([1S,2S,4R]-5-amino-4-[(2-chlorophenyl)methyl]-2-hydroxy-5-oxo-1-(phenylmethyl)pentyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 212790-02-8 CAPLUS
CN 2-Quinoxalinecarboxamide, N-([1S,2S,4R]-5-amino-2-hydroxy-4-[(2-methylphenyl)methyl]-5-oxo-1-(phenylmethyl)pentyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 212790-01-9 CAPLUS
CN 2-Quinoxalinecarboxamide, N-[(1S,2S,4R)-2-hydroxy-5-(hydroxyamino)-5-oxo-1,4-bis(phenylmethyl)pentyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 212790-04-0 CAPLUS
CN 2-Quinoxalinecarboxamide, N-[(1S,2S,4S)-5-amino-2-hydroxy-4-(1-hydroxycyclopentyl)-5-oxo-1-(phenylmethyl)pentyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 212790-05-1 CAPLUS
CN 2-Quinoxalinecarboxamide, N-[(1S,2S,4S)-5-amino-4-[(3,4-dichlorophenyl)methyl]-2-hydroxy-5-oxo-1-(phenylmethyl)pentyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 212790-06-2 CAPLUS


CN 2-Quinoxalinecarboxamide, N-[(1S,2S,4R)-5-amino-4-[(2-fluorophenyl)methyl]-2-hydroxy-5-oxo-1-(phenylmethyl)pentyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 212790-07-3 CAPLUS
CN 2-Quinoxalinecarboxamide, N-[(1S,2S,4S)-2-hydroxy-5-(hydroxyamino)-4-(1-hydroxycyclopentyl)-5-oxo-1-(phenylmethyl)pentyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 212790-08-4 CAPLUS
CN 2-Quinoxalinecarboxamide, N-[(1S,2S,4S)-5-amino-2-hydroxy-4-(1-hydroxy-3-methylcyclopentyl)-5-oxo-1-(phenylmethyl)pentyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 212790-13-1 CAPLUS
CN 2-Quinoxalinecarboxamide, N-[(1S,2S,4S)-5-amino-2-hydroxy-4-(1-hydroxycycloheptyl)-5-oxo-1-(phenylmethyl)pentyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 212790-14-2 CAPLUS


CN 2-Quinoxalinecarboxamide, N-[(1S,2S,4S)-2-hydroxy-5-(hydroxyamino)-4-(1-hydroxycycloheptyl)-5-oxo-1-(phenylmethyl)pentyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 212790-15-3 CAPLUS
CN 2-Quinoxalinecarboxamide, N-[(1S,2S,4R)-5-amino-4-[(3-fluorophenyl)methyl]-2-hydroxy-5-oxo-1-(phenylmethyl)pentyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 212790-16-4 CAPLUS
CN 2-Quinoxalinecarboxamide, N-[(1S,2S,4R)-5-amino-2-hydroxy-4-[(3-methylphenyl)methyl]-5-oxo-1-(phenylmethyl)pentyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 212790-17-5 CAPLUS
CN 2-Quinoxalinecarboxamide, N-[(1S,2S)-2-hydroxy-5-[(2-methylpropyl)amino]-5-oxo-1-(phenylmethyl)pentyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 212790-18-6 CAPLUS


CN 2-Quinoxalinecarboxamide, N-[(1S,2S,4S)-5-amino-2-hydroxy-4-(2-hydroxytricyclo[3.3.1.1.3,7]dec-2-yl)-5-oxo-1-(phenylmethyl)pentyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 212790-19-7 CAPLUS
CN 2-Quinoxalinecarboxamide, N-[(1S,2S,4S)-5-amino-2-hydroxy-4-(9-hydroxybicyclo[3.3.1]non-9-yl)-5-oxo-1-(phenylmethyl)pentyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 212790-20-0 CAPLUS
CN 2-Quinoxalinecarboxamide, N-[(1S,2S,4S)-2-hydroxy-5-(hydroxyamino)-4-(2-hydroxytricyclo[3.3.1.1.3,7]dec-2-yl)-5-oxo-1-(phenylmethyl)pentyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 212790-21-1 CAPLUS
CN 2-Quinoxalinecarboxamide, N-[(1S,2S,4S)-2-hydroxy-5-(hydroxyamino)-4-(9-hydroxybicyclo[3.3.1]non-9-yl)-5-oxo-1-(phenylmethyl)pentyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 212790-22-2 CAPLUS
CN 2-Quinoxalinecarboxamide, N-[(1S,2S,4R)-5-amino-2-hydroxy-4-[(3-methoxyphenyl)methyl]-5-oxo-1-(phenylmethyl)pentyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 212790-23-3 CAPLUS
CN 2-Quinoxalinecarboxamide, N-[(1S,2S,4S)-5-amino-2-hydroxy-4-[(4-methoxyphenyl)methyl]-5-oxo-1-(phenylmethyl)pentyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 212790-24-4 CAPLUS
CN 2-Quinoxalinecarboxamide, N-[(1S,2S,4S)-5-amino-2-hydroxy-4-[(1-hydroxy-4,4-dimethylcyclohexyl)-5-oxo-1-(phenylmethyl)pentyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 212790-25-5 CAPLUS


CN 2-Quinoxalinecarboxamide, N-[(1S,2S,4S)-2-hydroxy-5-(hydroxyamino)-4-(1-hydroxy-4,4-dimethylcyclohexyl)-5-oxo-1-(phenylmethyl)pentyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 212790-26-6 CAPLUS
CN 2-Quinoxalinecarboxamide, N-[(1S,2S,4S)-2-hydroxy-5-(hydroxyamino)-4-(4,4-difluoro-1-hydroxycyclohexyl)-5-oxo-1-(phenylmethyl)pentyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 212790-27-7 CAPLUS
CN 2-Quinoxalinecarboxamide, N-[(1S,2S,4S)-2-hydroxy-5-(hydroxyamino)-4-(4,4-difluoro-1-hydroxycyclohexyl)-5-oxo-1-(phenylmethyl)pentyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 212790-28-8 CAPLUS
CN 2-Quinoxalinecarboxamide, N-[(1S,2S,4R)-7-fluoro-2-hydroxy-7-methyl-1-(phenylmethyl)-4-(1-pyrrolidinylcarbonyl)octyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 212790-29-9 CAPLUS
CN Benzenehexanoic acid, alpha-(3-fluoro-3-methylbutyl)-gamma-hydroxy-5-[(2-quinoxalinylylcarbonyl)amino]-, hydrazide, (alpha,gamma,S,S) (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 212790-30-3 CAPLUS
CN 2-Quinoxalinecarboxamide, N-[(1S,2S,4R)-4-(aminocarbonyl)-2,7-dihydroxy-7-methyl-1-(phenylmethyl)octyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 212790-31-3 CAPLUS
CN 2-Quinoxalinecarboxamide, N-[(1S,2S,4R)-4-(aminocarbonyl)-1-[(3-fluorophenyl)methyl]-2,7-dihydroxy-7-methyloctyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 212790-32-4 CAPLUS
CN 2-Quinoxalinecarboxamide, N-[(1S,2S,4R)-4-(aminocarbonyl)-1-[(3,5-difluorophenyl)methyl]-2,7-dihydroxy-7-methyloctyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 212790-33-5 CAPLUS
CN 2-Quinoxalinecarboxamide, N-[(1S,2S,4R)-4-(aminocarbonyl)-1-[(3-chlorophenyl)methyl]-2,7-dihydroxy-7-methyloctyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 212790-34-6 CAPLUS
CN 2-Quinoxalinecarboxamide, N-[(1S,2S,4R)-1-[(3-chlorophenyl)methyl]-2,7-dihydroxy-4-[(hydroxyamino)carbonyl]-7-methyloctyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 212790-37-9 CAPLUS
CN 2-Quinoxalinecarboxamide, N-[(1S,2S,4R)-1-[(3,5-difluorophenyl)methyl]-2,7-dihydroxy-4-[(hydroxyamino)carbonyl]-7-methyloctyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 212790-38-0 CAPLUS
CN 2-Quinoxalinecarboxamide, N-[(1S,2S,4R)-2,7-dihydroxy-4-[(hydroxyamino)carbonyl]-7-methyl-1-(phenylmethyl)octyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 212790-42-6 CAPLUS
CN 2-Quinoxalinecarboxamide, N-[(1S,2S,4R)-1-[(2-fluorophenyl)methyl]-2,7-dihydroxy-4-[(hydroxyamino)carbonyl]-7-methyloctyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 212790-44-8 CAPLUS
CN 2-Quinoxalinecarboxamide, N-[(1S,2S,4R)-4-(aminocarbonyl)-1-[(2-fluorophenyl)methyl]-2,7-dihydroxy-7-methyloctyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 212790-45-9 CAPLUS
CN 2-Quinoxalinecarboxamide, N-[(1S,2S,4R)-1-[(3,4-difluorophenyl)methyl]-2,7-dihydroxy-4-[(hydroxyamino)carbonyl]-7-methyloctyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 212790-46-0 CAPLUS
CN 2-Quinoxalinecarboxamide, N-[(1S,2S,4R)-4-(aminocarbonyl)-1-[(3,4-difluorophenyl)methyl]-2,7-dihydroxy-7-methyloctyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 212790-47-1 CAPLUS
CN 2-Quinoxalinecarboxamide, N-[(1S,2S,4R)-4-(aminocarbonyl)-2,7-dihydroxy-7-methyl-1-(1-naphthalenylmethyl)octyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 212790-49-3 CAPLUS
CN 2-Quinoxalinecarboxamide, N-[(1S,2S,4R)-4-(aminocarbonyl)-2,7-dihydroxy-7-methyl-1-(2-naphthalenylmethyl)octyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 212790-50-6 CAPLUS
CN 2-Quinoxalinecarboxamide, N-[(1S,2S,4R)-2,7-dihydroxy-4-[(hydroxyamino)carbonyl]-7-methyl-1-(2-naphthalenylmethyl)octyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 212790-52-8 CAPLUS
CN 2-Quinoxalinecarboxamide, N-[5-amino-2-hydroxy-4-[(4-hydroxyphenyl)methyl]-5-oxo-1-(phenylmethyl)pentyl]- (9CI) (CA INDEX NAME)




RN 212835-27-3 CAPLUS
CN 2-Quinoxalinecarboxamide, N-[(1S,2S,4S)-5-amino-2-hydroxy-4-[(1-methylethyl)cyclohexyl]-5-oxo-1-(phenylmethyl)pentyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 212835-28-4 CAPLUS
CN 2-Quinoxalinecarboxamide, N-[(1S,2S)-5-amino-2-hydroxy-4-(4-methylcyclohexyl)-5-oxo-1-(phenylmethyl)pentyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 212835-29-5 CAPLUS
CN 2-Quinoxalinecarboxamide, N-[(1S,2S,4R)-5-amino-4-(3,5-dimethylcyclohexyl)-5-oxo-1-(phenylmethyl)pentyl]- (9CI) (CA INDEX NAME)


2-hydroxy-5-oxo-1-(phenylmethyl)pentyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 212835-30-8 CAPLUS
CN 2-Quinoxalinecarboxamide, N-[(1S,2S,4S)-5-amino-2-hydroxy-5-oxo-1-(phenylmethyl)-4-(tetrahydro-2,6-dimethyl-2H-pyran-4-yl)pentyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 212835-32-0 CAPLUS
CN 2-Quinoxalinecarboxamide, N-[(1S,2S,4S)-5-amino-2-hydroxy-5-oxo-1-(phenylmethyl)-4-(1-hydroxy-4-methylcyclohexyl)-5-oxo-1-(phenylmethyl)pentyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 212835-33-1 CAPLUS
CN 2-Quinoxalinecarboxamide, N-[(1S,2S,4S)-5-amino-2-hydroxy-5-oxo-1-(phenylmethyl)-4-(1-hydroxy-4-methylcyclohexyl)-5-oxo-1-(phenylmethyl)pentyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 212835-34-2 CAPLUS
CN 2-Quinoxalinecarboxamide, N-[(1S,2S,4S)-5-amino-2-hydroxy-5-oxo-1-(phenylmethyl)-4-(1-hydroxy-3,5-dimethylcyclohexyl)-5-oxo-1-(phenylmethyl)pentyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 212835-35-3 CAPLUS
CN 2-Quinoxalinecarboxamide, N-[(1S,2S,4S)-5-amino-2-hydroxy-5-oxo-1-(phenylmethyl)-4-(1-hydroxy-3,5-dimethylcyclohexyl)-5-oxo-1-(phenylmethyl)pentyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 212835-36-4 CAPLUS
CN 2-Quinoxalinecarboxamide, N-[(1S,2S,4S)-5-amino-2-hydroxy-5-oxo-1-(phenylmethyl)-4-(1-hydroxy-4-propylcyclohexyl)-5-oxo-1-(phenylmethyl)pentyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 212835-37-5 CAPLUS
CN 2-Quinoxalinecarboxamide, N-[(1S,2S,4S)-5-amino-2-hydroxy-5-oxo-1-(phenylmethyl)-4-(1-hydroxy-4-propylcyclohexyl)-5-oxo-1-(phenylmethyl)pentyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 212835-38-6 CAPLUS
CN 2-Quinoxalinecarboxamide, N-[(1S,2S,4S)-5-amino-2-hydroxy-5-oxo-1-(phenylmethyl)-4-(1-hydroxy-4-propylcyclohexyl)-5-oxo-1-(phenylmethyl)pentyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 212835-39-7 CAPLUS
CN 2-Quinoxalinecarboxamide, N-[(1S,2S,4S)-5-amino-2-hydroxy-5-oxo-1-(phenylmethyl)-4-(1-hydroxy-4-(trifluoromethyl)cyclohexyl)-5-oxo-1-(phenylmethyl)pentyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



IT 212790-56-2P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of heteroaryl-substituted hexanamides and their use as selective inhibitors of MIP-1 binding to its CCR1 receptor)

RN 212790-56-2 CAPLUS
CN 2-Quinoxalinecarboxamide, N-[(1S,2S,4S)-5-amino-2-hydroxy-5-oxo-1-(phenylmethyl)-4-(1-hydroxy-4-(trifluoromethyl)cyclohexyl)-5-oxo-1-(phenylmethyl)pentyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



REFERENCE COUNT: 10 THERE ARE 10 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 145 OF 283 CAPLUS COPYRIGHT 2006 ACS ON STN
ACCESSION NUMBER: 1998:509179 CAPLUS
DOCUMENT NUMBER: 129:148906
TITLE: Preparation of 1-acylamino-2-hydroxy-6-iminoindanes and related compounds having muscarinic receptor activity.
INVENTOR(S): Huff, Bret E.; Staszak, Michael A.; Ward, John S.
PATENT ASSIGNEE(S): Eli Lilly and Co., USA
SOURCE: PCT Int. Appl., 72 pp.
CODEN: PIXX2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9831660	A1	19980723	WO 1998-US1145	19980121
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GR, GM, GU, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MX, NO, NZ, PL, PT, RD, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KZ, MD, RU, TJ, TM, RM: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TO				
CA 2278424	AA	19980723	CA 1998-2278424	19980121
AU 9859266	A1	19980807	AU 1998-59266	19980121
EP 971885	A1	20000119	EP 1998-902664	19980121
EP 971885	B1	20031210		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE, FI				
JP 2001510481	T2	20010731	JP 1998-534672	19980121
AT 256104	B	20031215	AT 1998-902664	19980121
ES 2212263	B	20040716	ES 1998-902664	19980121
US 6211364	B1	20010403	US 1999-319652	19990610
PRIORITY APPLN. INFO.:			US 1997-35428P	P 19970122
OTHER SOURCE(S):			WO 1998-US1145	W 19980121
GI				



AB Title compds. [I; R1 = OR4, SR5, alkyl, alkenyl, halo, cyano, acyl(oxy); R20 = protecting group; R4, R5 = H, alkyl; R10 = H, carbonyl, halo, alkyl; R11 = H, alkyl; R12, R13 = H, alkyl, aryl; R12R13 = specified (substituted) heterocyclyl; R11R12N = 3-6 membered ring; R14 = H, halo, alkyl, alkoxy, etc.; Q = (CH2)n; n = 0-3], were prepared by reaction of [II; R21, R22 = H, O, R23 = protecting group; R = OR4, SR5, alkyl, alkenyl, halo, cyano, acyl(oxy)] with R13R12NCR11(OMe)2 (variables as above). I stimulated cAMP production in CHO-m4 cells by <20 % to 214% compared to oxotremorine-M.

IT 194028-33-6P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); IMP (Industrial manufacture); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of 1-acylamino-2-hydroxy-6-iminoindanes and related compds. having muscarinic receptor activity)
RN 194028-33-6 CAPLUS
CN 2-Quinoxalylmethylcarbamate, N-[(1R,2R)-2,3-dihydro-2-hydroxy-6-[(1-pyrrolidinyl)methylene]amino]-1H-inden-1-yl]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry unknown.



REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT



L5 ANSWER 146 OF 283 CAPLUS COPYRIGHT 2006 ACS ON STN
ACCESSION NUMBER: 1998:479021 CAPLUS
DOCUMENT NUMBER: 129:122868
TITLE: Preparation of peptidylboronic ester and acid compounds as proteasome inhibitors
INVENTOR(S): Adams, Julian; Ma, Yu-Ting; Stein, Ross; Baevesky, Matthew; Grenier, Louis; Diamond, Louis
PATENT ASSIGNER(S): Proscript, Inc., USA
SOURCE: U.S., 37 pp., Cont.-in-part of U.S. Ser. No. 442,581. CODEN: USXXAM
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 3
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 5780454	A	19980714	US 1995-549316	19951027

US	A	20000704	US	1995-442581	19950516
US 6066730	A	20000523	US 1998-45404	19980526	
US 6297217	B1	20011002	US 2000-490511	20000125	
US 6465433	B1	20021015	US 2001-953540	20010914	
US 2003173488	A1	20021121	US 2002-100295	20020318	
US 6546668	B2	20030415			
US 6617317	B1	20030909	US 2002-125997	20020419	
US 2003199561	A1	20031023	US 2003-392165	20030319	
US 6747150	B2	20040608			
US 2004167332	A1	20040826	US 2003-730231	20031208	

PRIORITY APPLN. INFO.:

OTHER SOURCE(S): MARPAT 129:122868
OI




AB Disclosed herein is a method for reducing the rate of degradation of proteins in an animal comprising contacting cells of the animal with certain boronic ester and acid compds I [P = aryl-, aralkyl-, heteroaryl-, or heteroarylalkylcarbonyl or -sulfonyl; R1 = H, CH3; R2 = CONH2, CH(OMe)CH2, COCH3; n = 0, 1, 2; R = H, alkyl; R3 or R22 (for n = 0) may form a ring; R1, R2, R3 = H, alkyl, cycloalkyl, aryl, etc.; Z1, Z2 = alkyl, hydroxy, alkoxy, aryloxy; Z1Z2 may form a moiety derived from a dihydroxy compound]. Also disclosed herein are novel boronic ester and acid compds., their synthesis and uses. Thus, peptidylboronic acid II was prepared by coupling pinanedil leucine boronate ester III with N-Boc-β-(1-naphthyl)-L-alanine, followed by deprotection, acylation with 4-morpholinecarbonyl chloride, and cleavage of the pinanedil moiety. II inhibited proteasome 20S with Ki = 0.16 nM.

IT 179324-42-6P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of peptidylboronic ester and acid compds. as proteasome inhibitors)

RN 179324-42-6 CAPLUS
CN Boronic acid, [(1R)-3-methyl-1-[(2S)-3-(1-naphthalenyl)-1-oxo-2-[(2-quinoxalylmethyl)amino]propyl]amino]butyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 19 THERE ARE 19 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT


L5 ANSWER 147 OF 283 CAPLUS COPYRIGHT 2006 ACS ON STN
ACCESSION NUMBER: 1998:450918 CAPLUS
DOCUMENT NUMBER: 129:197559
TITLE: Synthesis and Structure-Activity Relationships of 2-Pyrazinylcarboxamidobenzates and β-Ionylideneacetamidobenzates with Retinoidal Activity
AUTHOR(S): Jones, Paul; Villeneuve, Gerald B.; Fei, Chengpei; DeMarte, Josie; Haggarty, Allison J.; Nwe, Khin Than; Martin, Deborah A.; Lebois, Anne-Marie; Finkelstein, Joshua M.; Gour-Salini, Barbara J.; Chan, Tak Hang; Leyland-Jones, Brian R.
CORPORATE SOURCE: Department of Oncology, McGill University, Montreal, QC, H3G 1Y6, Can.
SOURCE: Journal of Medicinal Chemistry (1998), 41(16), 3062-3077. CODEN: JMCMAR; ISSN: 0022-2623
PUBLISHER: American Chemical Society
DOCUMENT TYPE: Journal
LANGUAGE: English
OTHER SOURCE(S): CASREACT 129:197559

AB The structure-activity relationships of two series of novel retinoids (2-pyrazinylcarboxamidobenzates and β-ionylideneacetamidobenzates) have been investigated by evaluating their ability to induce differentiation in both human promyelocytic leukemia (HL60) cells and mouse embryonal carcinoma (P19) cells. The most active compound (ED50 = 8.3x10-9 M) of the 2-pyrazinylcarboxamidobenzates is 4-[2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethylquinoxalyl)carboxamido]benzoic acid, while the most active analog of the β-ionylideneacetamidobenzates is 4-[3-methyl-5-(2',6',6'-trimethyl-1'-cyclohexen-1'-yl)-(2E,4E)-pentadienyl]benzoic acid (ED50 = 3.2x10-8 M). The authors studies identify an absolute requirement for the carboxylic acid moiety on the aromatic ring to be para relative to the amide linkage for activity. Benzoate substitutions in the ortho position relative to the terminal carboxylate are well-tolerated; however, a methoxy substituent meta relative to the terminal carboxylate gives rise to only weakly active analogs. Conformational studies (NMR, x-ray crystallog.) of the 2-pyrazinylcarboxamidobenzates indicate that the preferred conformation exhibits a trans-amide bond and an internal

hydrogen bond between the quinoxaline N1 and NH amide which locks the torsional angle between C2 and CO in the s-trans conformation. N-methylation results in loss of activity. Studies indicate that there is now a cis-amide bond present which redirects the carboxylate toward the pharmacophoric gem-di-Me groups. The distance between the gem-di-Me group and the terminal carboxylate appears to be too short to activate the retinoid receptor. N-Methylation in the β-ionylideneacetamidobenzate series also results in the formation of a cis-amide bond and loss of activity.

IT 212118-16-8P
RL: PRP (Properties); RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(intermediate; synthesis and structure-activity relationships of 2-pyrazinylcarboxamidobenzates and β-ionylideneacetamidobenzates with retinoidal activity in inducing differentiation in cancer)


RN 212118-16-8 CAPLUS
CN Benzoic acid, 4-[[[(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-quinoxalyl)carbonyl]amino]-, 2-(trimethylsilyl)ethyl ester (9CI) (CA INDEX NAME)




IT 212118-19-9P 212118-20-2P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(intermediate; synthesis and structure-activity relationships of 2-pyrazinylcarboxamidobenzates and β-ionylideneacetamidobenzates with retinoidal activity in inducing differentiation in cancer)

RN 212118-19-9 CAPLUS
CN Benzoic acid, 3-methoxy-4-[[[(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-quinoxalyl)carbonyl]amino]-, 2-(trimethylsilyl)ethyl ester (9CI) (CA INDEX NAME)



RN 212118-20-2 CAPLUS
CN Benzoic acid, 4-[methyl[(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-quinoxalyl)carbonyl]amino]-, 2-(trimethylsilyl)ethyl ester (9CI) (CA INDEX NAME)




IT 187401-11-2P 212118-23-5P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); PRP (Properties); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PRSP (Preparation); USES (Uses)

(synthesis and structure-activity relationships of 2-pyrazinylcarboxamidobenzoates and β -ionylideneacetamidobenzoates with retinoidal activity in inducing differentiation in cancer)


RN 187401-11-2 CAPLUS

CN Benzoic acid, 4-[[[5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-quinoxalinyloxy]carbonyl]amino]- (9CI) (CA INDEX NAME)



RN 212118-23-5 CAPLUS

CN Benzoic acid, 4-[[[5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-quinoxalinyloxy]carbonyl]amino]- (9CI) (CA INDEX NAME)




IT 212117-89-0P 212117-90-3P 212117-91-4P
212117-92-5P 212117-94-7P 212117-95-8P
212117-96-9P 212117-97-0P 212117-98-1P
212117-99-2P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PRSP (Preparation); RACT (Reactant or reagent); USES (Uses)

(synthesis and structure-activity relationships of 2-pyrazinylcarboxamidobenzoates and β -ionylideneacetamidobenzoates with retinoidal activity in inducing differentiation in cancer)


RN 212117-89-0 CAPLUS

CN Benzoic acid, 4-[[[6,7-dihydro-5,5,7,7-tetramethyl-5H-cyclopentapyrazin-2-yl]carbonyl]amino]-, methyl ester (9CI) (CA INDEX NAME)




RN 212117-90-3 CAPLUS

CN Benzoic acid, 3-[[[6,7-dihydro-5,5,7,7-tetramethyl-5H-cyclopentapyrazin-2-yl]carbonyl]amino]-, methyl ester (9CI) (CA INDEX NAME)




RN 212117-91-4 CAPLUS

CN 1,3-Benzenedicarboxylic acid, 5-[[[6,7-dihydro-5,5,7,7-tetramethyl-5H-cyclopentapyrazin-2-yl]carbonyl]amino]-, dimethyl ester (9CI) (CA INDEX NAME)



RN 212117-92-5 CAPLUS


CN Benzoic acid, 2-chloro-4-[[[6,7-dihydro-5,5,7,7-tetramethyl-5H-cyclopentapyrazin-2-yl]carbonyl]amino]-, methyl ester (9CI) (CA INDEX NAME)



RN 212117-94-7 CAPLUS


CN Benzoic acid, 4-chloro-3-[[[6,7-dihydro-5,5,7,7-tetramethyl-5H-cyclopentapyrazin-2-yl]carbonyl]amino]-, methyl ester (9CI) (CA INDEX NAME)

NAME)




RN 212117-95-8 CAPLUS

CN Benzoic acid, 3-[[[6,7-dihydro-5,5,7,7-tetramethyl-5H-cyclopentapyrazin-2-yl]carbonyl]amino]-4-methoxy-, methyl ester (9CI) (CA INDEX NAME)




RN 212117-96-9 CAPLUS

CN Benzoic acid, 4-[[[6,7-dihydro-5,5,7,7-tetramethyl-5H-cyclopentapyrazin-2-yl]carbonyl]amino]-3-methoxy-, methyl ester (9CI) (CA INDEX NAME)




RN 212117-97-0 CAPLUS

CN Benzoic acid, 4-[[[5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-quinoxalinyloxy]carbonyl]amino]-, methyl ester (9CI) (CA INDEX NAME)




RN 212117-98-1 CAPLUS

CN Benzoic acid, 3-[[[5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-quinoxalinyloxy]carbonyl]amino]-, methyl ester (9CI) (CA INDEX NAME)



RN 212117-99-2 CAPLUS

CN 1,3-Benzenedicarboxylic acid, 5-[[[5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-quinoxalinyloxy]carbonyl]amino]-, dimethyl ester (9CI) (CA INDEX NAME)



IT 187401-12-3P 212118-00-8P 212118-01-9P

212118-02-0P 212118-03-1P 212118-04-2P

212118-05-3P 212118-06-4P 212118-07-5P

212118-08-6P 212118-09-7P 212118-10-0P


212118-22-4P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PRSP (Preparation); USES (Uses)

(synthesis and structure-activity relationships of 2-pyrazinylcarboxamidobenzoates and β -ionylideneacetamidobenzoates with retinoidal activity in inducing differentiation in cancer)


RN 187401-12-3 CAPLUS

CN Benzoic acid, 4-[[[6,7-dihydro-5,5,7,7-tetramethyl-5H-cyclopentapyrazin-2-yl]carbonyl]amino]- (9CI) (CA INDEX NAME)




RN 212118-00-8 CAPLUS


CN Benzoic acid, 2-chloro-4-[[[5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-quinoxalinyloxy]carbonyl]amino]-, methyl ester (9CI) (CA INDEX NAME)




RN 212118-01-9 CAPLUS
CN Benzoic acid, 4-chloro-3-[[[5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-quinoxaliny]carbonyl]amino]-, methyl ester (9CI) (CA INDEX NAME)




RN 212118-02-0 CAPLUS
CN Benzoic acid, 4-methoxy-3-[[[5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-quinoxaliny]carbonyl]amino]-, methyl ester (9CI) (CA INDEX NAME)




RN 212118-03-1 CAPLUS
CN Benzoic acid, 3-[[[6,7-dihydro-5,5,7,7-tetramethyl-5H-cyclopentapyrazin-2-yl]carbonyl]amino]- (9CI) (CA INDEX NAME)




RN 212118-04-2 CAPLUS
CN 1,3-Benzenedicarboxylic acid, 5-[[[6,7-dihydro-5,5,7,7-tetramethyl-5H-cyclopentapyrazin-2-yl]carbonyl]amino]- (9CI) (CA INDEX NAME)




RN 212118-05-3 CAPLUS
CN Benzoic acid, 3-chloro-5-[[[6,7-dihydro-5,5,7,7-tetramethyl-5H-cyclopentapyrazin-2-yl]carbonyl]amino]- (9CI) (CA INDEX NAME)




RN 212118-06-4 CAPLUS
CN Benzoic acid, 4-chloro-3-[[[6,7-dihydro-5,5,7,7-tetramethyl-5H-cyclopentapyrazin-2-yl]carbonyl]amino]- (9CI) (CA INDEX NAME)




RN 212118-07-5 CAPLUS
CN Benzoic acid, 3-[[[6,7-dihydro-5,5,7,7-tetramethyl-5H-cyclopentapyrazin-2-yl]carbonyl]amino]-4-methoxy- (9CI) (CA INDEX NAME)




RN 212118-08-6 CAPLUS
CN Benzoic acid, 4-[[[6,7-dihydro-5,5,7,7-tetramethyl-5H-cyclopentapyrazin-2-yl]carbonyl]amino]-3-methoxy- (9CI) (CA INDEX NAME)




RN 212118-09-7 CAPLUS
CN Benzoic acid, 3-[[[5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-quinoxaliny]carbonyl]amino]- (9CI) (CA INDEX NAME)



RN 212118-10-0 CAPLUS
CN Benzoic acid, 3-[[[6,7-dihydro-5,5,7,7-tetramethyl-5H-cyclopentapyrazin-2-yl]carbonyl]methylamino]-, methyl ester (9CI) (CA INDEX NAME)



RN 212118-22-4 CAPLUS
CN Benzoic acid, 3-methoxy-4-[[[5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-quinoxaliny]carbonyl]amino]- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 68 THERE ARE 68 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 148 OF 283
ACCESSION NUMBER: 1998:424263 CAPLUS
DOCUMENT NUMBER: 129:95714
TITLE: Preparation of new heterocyclic amides as nitric oxide production inhibitors
INVENTOR(S): Yatabe, Takumi; Inoue, Takayuki; Hamashima, Toshiaki; Shima, Ichiro; Ohno, Kazuhiko; Yoshihara, Kousei; Oku, Teruo
PATENT ASSIGNEE(S): Fujisawa Pharmaceutical Co., Ltd., Japan; Itoh,

SOURCE: Yoshikuni
PCT Int. Appl., 533 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9827108	A2	19980625	WO 1997-JP4243	19971120
WO 9827108	A3	19980730		
W: AU, CA, CN, HU, IL, JP, KR, MX, US, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
AU 9749680	A1	19980715	AU 1997-49680	19971120
EP 946587	A2	19991006	EP 1997-912529	19971120
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
JP 2001505585	T2	20010424	JP 1998-527528	19971120
ZA 9710603	A	19980625	ZA 1997-10603	19971125
PRIORITY APPLN. INFO.:				
			AU 1996-4219	A 19961216
			AU 1997-5929	A 19970401
			AU 1997-9030	A 19970909
			WO 1997-JP4243	W 19971120

OTHER SOURCE(S): MARPAT 129:95714
OI


* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB Title compds. I [X = S, NR9; Y = CHR], (un)substituted phenylene; R1 = (un)substituted indolyl, (un)substituted benzofuranyl; R2 = H, phenyl-lower alkyl; R3 = H, (CH2)NR6; R4 = H, (un)substituted Ph, (un)substituted pyridyl; R5 = H, imidazolyl, Ph, nitrophenyl, phenyl-lower alkyl, optionally esterified carboxy, CONR7R8; R4R5 = CH:CHCH:CH; R6 = optionally protected OH, acyl, carboxy, acylamino, lower alkoxy, phenyl-lower alkoxy, lower alkylthio, (un)substituted Ph; R7, R8 = independently H, Ph, phenyl-lower alkyl, lower alkoxy, lower alkoxy; R9 = H, lower alkyl, lower cycloalkyl, (un)substituted benzyl; m = 0, 1; n = 0-3 and pharmaceutically acceptable salts thereof are described as strong inhibitors of the production of nitric oxide. Compds. I are useful for prevention and treatment of nitric oxide-mediated diseases such as adult respiratory distress syndrome, cardiovascular ischemia, myocarditis, heart failure, synovitis, shock, diabetes, diabetic nephropathy, diabetic retinopathy, diabetic neuropathy, glomerulonephritis, peptic ulcer, inflammatory bowel disease, cerebral infarction, cerebral ischemia, cerebral hemorrhage, migraine, rheumatoid arthritis, gout, neuritis, post-herpetic neuralgia, osteoarthritis, osteoporosis, systemic lupus erythematosus, rejection by organ transplantation, asthma, metastasis, Alzheimer's disease, arthritis, CNS disorders, dermatitis, hepatitis, liver cirrhosis, multiple sclerosis, pancreatitis, atherosclerosis, and the like in humans and animals. Thus, 2-step cyclocondensation of amino ketone II (preparation given) with protected 3-(2-pyridyl)-L-alanine and methylamine gave protected imidazole III (Boc = Me3CO2C). Deprotection of III followed by acylation with indole-2-carboxylic acid gave desired compound IV. IV inhibited nitric oxide production 100% in murine macrophage cell line RAW264.7 at 10-5 M.

IT 209523-39-7P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOI (Biological study); PRSP (Preparation); USES (Uses)
inhibitors)


RN 209523-39-7 CAPLUS
CN 2-Quinoxalinecarboxamide, N-[[[4-(5-(4-bromophenyl)-1-methyl-1H-imidazol-2-yl]-2-(4-methoxyphenyl)ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L5 ANSWER 149 OF 263 CAPLUS COPYRIGHT 2006 ACS ON STN
ACCESSION NUMBER: 1998:402403 CAPLUS
DOCUMENT NUMBER: 129:81964
TITLE: Preparation and use of ketobenzamides as calpain inhibitors
INVENTOR(S): Lubisch, Wilfried; Moller, Achim; Treiber, Hans-Jorg
PATENT ASSIGNEE(S): BASF A.-G., Germany; Lubisch, Wilfried; Moller, Achim; Treiber, Hans-Jorg
SOURCE: PCT Int. Appl., 64 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: German
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9625883	A1	19980618	WO 1997-EP6655	19971128
W: AL, AU, BG, BR, BY, CA, CN, CZ, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR, UA, US, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
CA 2274464	AA	19980618	CA 1997-2274464	19971128
EP 9457523	A1	19980703	AU 1998-57523	19971128
AU 721420	B2	20000713		
EP 944582	A1	19980929	EP 1997-953714	19971128
EP 944582	B1	20030702		
R: AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SI, FI, RO				
CN 1245486	A	20000223	CN 1997-181748	19971128
NZ 335981	A	20000428	NZ 1997-335981	19971128
BR 9713704	A	20000509	BR 1997-13704	19971128
JP 2001506614	T2	20010522	JP 1998-526156	19971128
RU 2190599	C2	20021010	RU 1999-115765	19971128
SK 282680	B6	20021106	SK 1999-745	19971128
AT 244216	E	20030715	AT 1997-953714	19971128
ES 2202663	T3	20040401	ES 1997-953714	19971128



REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 150 OF 263 CAPLUS COPYRIGHT 2006 ACS ON STN
ACCESSION NUMBER: 1998:268469 CAPLUS
DOCUMENT NUMBER: 128:321568
TITLE: Anthranilic acid derivatives as multi drug resistance modulators
INVENTOR(S): Ryder, Hamish; Ashworth, Philip Anthony; Roe, Michael John; Brunwell, Julie Elizabeth; Hunjan, Sukhjot; Folkes, Adrian John; Sanderson, Jason Terry; Williams, Susanah; Maximen, Levi Michael; et al.
PATENT ASSIGNEE(S): Xenova Ltd., UK; Ryder, Hamish; Ashworth, Philip Anthony; Roe, Michael John; Brunwell, Julie Elizabeth; Hunjan, Sukhjot; Folkes, Adrian John; Sanderson, Jason Terry; Williams, Susanah; Maximen, Levi Michael
SOURCE: PCT Int. Appl., 203 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9817648	A1	19980430	WO 1997-GB2885	19971017
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GR, HU, ID, IL, IN, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LV, MD, MG, MK, MN, MW, MX, MY, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, BG, GR, IE, IT, LU, MC, NL, PT, SE, SF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
RW: GH, KE, LS, MW, SD, UG, ZW, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
CA 2264403	AA	19980430	CA 1997-2264403	19971017
AU 9746339	A1	19980515	AU 1997-46339	19971017
AU 741922	B2	20011213		
ZA 9709329	A	19990419	ZA 1997-9329	19971017
EP 934276	A1	19990811	EP 1997-945030	19971017
EP 934276	B1	20031217		
R: AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
BR 9711935	A	19990824	BR 1997-11935	19971017
GB 2334521	A1	19990825	GB 1999-8193	19971017
GB 2334521	B2	20001004		
CN 1241181	A	20000112	CN 1997-180708	19971017
JP 2001502683	T2	20010227	JP 1998-519108	19971017
RU 2195454	C2	20021227	RU 1999-109990	19971017
AT 256663	E	20040115	AT 1997-945030	19971017
PT 934276	T	20040531	PT 1997-945030	19971017
ES 2210586	T3	20040701	ES 1997-945030	19971017
SK 284649	B6	20050804	SK 1999-509	19971017


HR 970680 B1 20020631 HR 1997-970680 19971210
ZA 971141 A 19990611 ZA 1997-1141 19971211
TW 536530 B 20030611 TW 1997-86118865 19971211
US 6103720 A 20000815 US 1999-319511 19990608
NO 990281 A 19990611 NO 1999-281 19990610
KR 2000057495 A 20000915 KR 1999-705172 19990610
BG 63382 B1 20011231 BG 1999-103485 19990611
DE 1996-19651316 A 19961211
WO 1997-EP6655 W 19971128

PRIORITY APPL. INFO.:

OTHER SOURCE(S): MARPAT 129:81964
AB The invention concerns ketobenzamides of formula R1(R2)n-C6H3-CO-NH(R3)COCOR4 ([I] R1 = Ph, naphthyl, (substituted) heterocycle; R2 = Cl, Br, F, NO2, NH2, NHR5, CO2H, (substituted) alkyl, -alkenyl, -alkynyl; R3 = CO-alkyl, C(=O)H, CO-alkoxy, SO2-alkyl, CO-alkoxy, ureido, alkoxy; R4 = (substituted) alkyl; X = (substituted) functionalized chain from 0-10 atoms, or R2-substituted-C6H3; R4 = OH, (substituted)alkoxy, (substituted)NH2, heterocyclic ring), useful as calpain inhibitors. The invention further concerns their preparation. The novel compds. are suitable for combating diseases. Thus, 3(S)-3-amino-2-hydroxy-4-phenylbutyric acid Me ester was condensed with 2-phenylbenzoic acid to give (S)-I [R1 = Ph; X = null; n = 0; R3 = CH2Ph; R4 = OMe(II)]. In vitro calpain-inhibition tests, I had Ki of <10 µM.

IT 209174-18-SP
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
(Preparation and use of ketobenzamides as calpain inhibitors)
RN 209174-18-5 CAPLUS
CN 2-Quinoxalinecarboxamide, N-[[[4-[[[1(S)-3-amino-2,3-dioxo-1-phenylmethyl]propyl]amino]carbonyl]phenyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 209174-17-4P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(Preparation and use of ketobenzamides as calpain inhibitors)
RN 209174-17-4 CAPLUS
CN 2-Quinoxalinecarboxamide, N-[[[4-[[[1(S)-3-amino-2-hydroxy-3-oxo-1-phenylmethyl]propyl]amino]carbonyl]phenyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

TW 498074 B 20020811 TW 1997-86115402 19971018
BG 103327 A 20001130 BG 1999-103327 19990413
NO 9901836 A 19990617 NO 1999-1836 19990416
NO 313591 B1 20021028
KR 2000049278 A 20000725 KR 1999-703389 19990417
US 6218393 B1 20010417 US 1999-284642 19990608
HK 1018310 A1 20010112 HK 1999-103773 19990901
WO 1996-GB2552 A 19961018
GB 1997-17576 A 19970819
WO 1997-GB2885 W 19971017

PRIORITY APPL. INFO.:


OTHER SOURCE(S): MARPAT 128:321568
OI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB Anthranilic acid derivs. I [R, R1, R2 = H, alkyl, OH, alkoxy, halo, NO2, amino; or R1R2 = OCH2O or OCH2CH2O; R3 = H, alkyl; R4 = alkyl, or CH2 or CH2CH2 bridged to either Ph ring; R5 = H, OH, alkyl; X = bond, O, S, S(CH2)p, O(CH2)p; p = 1-6; R6 = H, alkyl, alkoxy; q = 0 or 1; Ar = (unsaturated carbo- or heterocyclic); R7, R8 = H, (unsubstituted) alkyl, alkoxy, OH, halo, Ph, NHOH, NO2, amino, SH, alkylthio; or R7R8 = CH(CN)(CH3) or OCH2O; n = 0, 1; m = 0-6] and their pharmaceutically acceptable salts are disclosed. The compds. are inhibitors of P-glycoprotein, and may thus be used, inter alia, as modulators of multidrug resistance in the treatment of multidrug-resistant cancers, for example, to potentiate the cytotoxicity of a cancer drug. For instance, amidation of 3-quinolinecarboxylic acid with the corresponding aminothiophene derivative via the acid chloride gave title compound II in 44% yield. In a test for potentiation of doxorubicin toxicity to AR 1.0 cells, II had a potentiation index of 142 at 30 nM.


IT 206872-36-EP 206872-43-7P 206872-45-SP
206872-58-4P 206872-43-OP 206872-50-SP
206872-51-OP 206872-52-1P 206872-52-2P
206872-54-3P 206872-55-4P 206872-56-SP
206872-57-6P 206872-58-7P 206872-59-EP
206874-28-4P 206874-29-5P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(Preparation of anthranilic acid derivs. as multi-drug resistance modulators)

RN 206872-36-8 CAPLUS
CN 2-Quinoxalinecarboxamide, N-2-[[[4-[2-(3,4-dihydro-6,7-dimethoxy-2(1H)-isquinolinyl)ethyl]phenyl]amino]carbonyl]-4-(dimethylamino)phenyl]- (9CI) (CA INDEX NAME)





RN 206872-43-7 CAPLUS
CN 2-Quinoxalinecarboxamide, N-2-[[[4-[2-[[[3,4-


dimethoxyphenyl)methyl]methylamino]ethyl]phenyl]amino]carbonyl]phenyl]- (9CI) (CA INDEX NAME)





RN 206873-45-9 CAPLUS
CN 2-Quinoxalinecarboxamide, N-[2-[[[4-(2,4-dimethoxyphenyl)methyl]methyl]amino]ethyl]phenyl]amino]carbonyl]phenyl]- (9CI) (CA INDEX NAME)




RN 206873-58-4 CAPLUS
CN 2-Quinoxalinecarboxamide, N-[2-[[[4-(2,4-dihydro-6,7-dimethoxy-2(1H)-isoquinolinyl)ethoxy]phenyl]amino]carbonyl]phenyl]- (9CI) (CA INDEX NAME)




RN 206873-43-0 CAPLUS
CN 2-Quinoxalinecarboxamide, N-[2-[[[4-(2,4-dihydro-6,7-dimethoxy-2(1H)-isoquinolinyl)ethyl]amino]carbonyl]phenyl]- (9CI) (CA INDEX NAME)




RN 206873-50-9 CAPLUS
CN 2-Quinoxalinecarboxamide, N-[2-[[[4-(2,4-dihydro-6,7-dimethoxy-2(1H)-isoquinolinyl)ethyl]phenyl]amino]carbonyl]phenyl]- (9CI) (CA INDEX NAME)




RN 206873-51-0 CAPLUS
CN 2-Quinoxalinecarboxamide, N-[2-[[[4-(2,4-dihydro-6,7-dimethoxy-2(1H)-isoquinolinyl)ethyl]phenyl]amino]carbonyl]-5-(hydroxyamino)phenyl]- (9CI) (CA INDEX NAME)




RN 206873-52-1 CAPLUS
CN 2-Quinoxalinecarboxamide, N-[2-[[[4-(2,4-dihydro-6,7-dimethoxy-2(1H)-isoquinolinyl)ethyl]phenyl]amino]carbonyl]-4-methylphenyl]- (9CI) (CA INDEX NAME)




RN 206873-53-2 CAPLUS
CN 2-Quinoxalinecarboxamide, N-[2-[[[4-(2,4-dihydro-6,7-dimethoxy-2(1H)-isoquinolinyl)ethyl]phenyl]amino]carbonyl]-4-hydroxyphenyl]- (9CI) (CA INDEX NAME)




RN 206873-54-3 CAPLUS
CN 2-Quinoxalinecarboxamide, N-[2-[[[4-(2,4-dihydro-6,7-dimethoxy-2(1H)-isoquinolinyl)ethyl]phenyl]amino]carbonyl]-5-nitrophenyl]- (9CI) (CA INDEX NAME)




RN 206873-55-4 CAPLUS
CN 2-Quinoxalinecarboxamide, N-[2-[[[4-(2,4-dihydro-6,7-dimethoxy-2(1H)-isoquinolinyl)ethyl]phenyl]amino]carbonyl]-5-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 206873-56-5 CAPLUS
CN 2-Quinoxalinecarboxamide, N-[2-[[[4-(2,4-dihydro-6,7-dimethoxy-2(1H)-isoquinolinyl)ethyl]phenyl]amino]carbonyl]-5-fluorophenyl]- (9CI) (CA INDEX NAME)




RN 206873-57-6 CAPLUS
CN 2-Quinoxalinecarboxamide, N-[2-[[[4-(2,4-dihydro-6,7-dimethoxy-2(1H)-isoquinolinyl)ethyl]phenyl]amino]carbonyl]-3-fluorophenyl]- (9CI) (CA INDEX NAME)




RN 206873-58-7 CAPLUS
CN 2-Quinoxalinecarboxamide, N-[2-[[[4-(2,4-dihydro-6,7-dimethoxy-2(1H)-isoquinolinyl)ethyl]phenyl]amino]carbonyl]-4-fluorophenyl]- (9CI) (CA INDEX NAME)




RN 206873-59-8 CAPLUS
CN 2-Quinoxalinecarboxamide, N-[2-[[[4-(3,4-dihydro-6,7-dimethoxy-2(1H)-isoquinolinyl)ethyl]phenyl]amino]carbonyl]-4,5-dimethoxyphenyl- (9CI) (CA INDEX NAME)



RN 206874-28-4 CAPLUS
CN 2-Quinoxalinecarboxamide, N-[2-[[[4-(3,4-dihydro-6,7-dimethoxy-2(1H)-isoquinolinyl)propyl]phenyl]amino]carbonyl]phenyl- (9CI) (CA INDEX NAME)




RN 206874-29-5 CAPLUS
CN 2-Quinoxalinecarboxamide, N-[2-[[[4-(3,4-dihydro-6,7-dimethoxy-2(1H)-isoquinolinyl)methyl]phenyl]amino]carbonyl]phenyl- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT


L5 ANSWER 152 OF 283 CAPLUS COPYRIGHT 2006 ACS ON STN
ACCESSION NUMBER: 1998:38306 CAPLUS
DOCUMENT NUMBER: 128:114786
TITLE: Substituted benzoic acid derivatives for use in treating type II diabetes
INVENTOR(S): Hemmerle, Horst; Below, Peter; Burger, Hans-Joerg; Herling, Andreas; Jaehne, Gerhard
PATENT ASSIGNEE(S): Hoechst A.-G., Germany
SOURCE: Ger. Offen., 74 pp.
CODEN: GWXXBX
DOCUMENT TYPE: Patent
LANGUAGE: German
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
DE 19624155	A1	19980108	DE 1996-19624155	19960618
EP 816329	A1	19980107	EP 1997-108869	19970603
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE, FI				
JP 1014251	A2	19980707	JP 1997-175170	19970617
PRIORITY APPL. INPO. 1			DE 1996-19624155	A 19960618
OTHER SOURCE(S):			MARPAT 128:114786	




AB 2,5-R1R2C6H3CO2R3 [R1 = alkyl, perfluoroalkyl, hydroxyalkyl, alkenyl, aralkyl, aralkenyl, aryl, heteroaryl, alkoxy, aralkoxy; R2 = alkyl, alkenyl, alkenyl, aralkyl, aralkenyl, aryl, cycloalkenylalkenyl, heteroaryl, acylamino, sulfonamino, acyl; R3 = H, alkyl] were prepared by solution or solid-phase methods for use in treating type II diabetes. The acid I caused 93% glucose-6-phosphatase inhibition at 100 μM in vitro.
IT 201660-59-5P 201660-73-3P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of substituted benzoic acid derive. for use in treating type II diabetes)

RN 201660-59-5 CAPLUS
CN Benzoic acid, 2-(2-furyl)-5-[(2-quinoxalinyloxy)amino]- (9CI) (CA INDEX NAME)




IT 206874-80-8P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of anthranilic acid derive. as multi-drug resistance modulators)
RN 206874-80-8 CAPLUS
CN 2-Quinoxalinecarboxamide, N-[2-[[[4-(3,4-dihydro-6,7-dimethoxy-2(1H)-isoquinolinyl)ethyl]phenyl]amino]carbonyl]-4-[(1,1-dimethylethyl)dimethylsilyloxy]phenyl- (9CI) (CA INDEX NAME)




REFERENCE COUNT: 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 151 OF 283 CAPLUS COPYRIGHT 2006 ACS ON STN
ACCESSION NUMBER: 1998:224554 CAPLUS
DOCUMENT NUMBER: 128:243871
TITLE: Side chain reactions of 6-acetyl-1,3,7-trimethylxanthine
AUTHOR(S): Kim, Yoonhee; Kim, Jaesung; Kang, Yonghan
CORPORATE SOURCE: Department of Chemistry, Hanyang University, Kyungki-Do, 425-791, S. Korea
SOURCE: Chemistry and Biology of Pteridines and Folates 1997, Proceedings of the International Symposium on Pteridines and Folates, 11th, Berchtesgaden, Germany, June 15-20, 1997 (1997), 41-44. Editor(s): Pfeleiderer, Wolfgang; Roke, Hartmut. Blackwell Wissenschafts-Verlag GmbH: Berlin, Germany.
CODEN: 65VBAF
DOCUMENT TYPE: Conference
LANGUAGE: English
AB Reactions of the 6-acetyl-1,3,7-trimethylxanthine side chain are explored.
IT 109879-41-6P
RL: SPN (Synthetic preparation); PREP (Preparation)
(side chain reactions of acetyltrimethylxanthine)
RN 109879-41-6 CAPLUS
CN 6-Pteridinecarboxamide, 1,2,3,4-tetrahydro-1,3,7-trimethyl-2,4-dioxo-N-(phenylmethyl)- (9CI) (CA INDEX NAME)




RN 201660-73-3 CAPLUS
CN Benzoic acid, 2-[(4-methylphenyl)ethynyl]-5-[(2-quinoxalinyloxy)amino]- (9CI) (CA INDEX NAME)




IT 201661-37-2P 201661-80-5P 201661-89-4P
201662-04-6P
RL: SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of substituted benzoic acid derive. for use in treating type II diabetes)


RN 201661-37-2 CAPLUS
CN [1,1'-Biphenyl]-2-carboxylic acid, 4'-[(1,1-dimethylethyl)-4-[(2-quinoxalinyloxy)amino]- (9CI) (CA INDEX NAME)




RN 201661-80-5 CAPLUS
CN Benzoic acid, 2-(1,3-benzodioxol-5-yl)-5-[(2-quinoxalinyloxy)amino]- (9CI) (CA INDEX NAME)




RN 201661-89-4 CAPLUS
CN Benzoic acid, 2-(6-methoxy-2-naphthalenyl)-5-[(2-quinoxalinyloxy)amino]- (9CI) (CA INDEX NAME)




RN 201662-04-6 CAPLUS
CN Benzoic acid, 2-(2-methylpropyl)-5-[(2-quinoxalinyloxy)amino]- (9CI) (CA INDEX NAME)




L5 ANSWER 153 OF 283 CAPLUS COPYRIGHT 2006 ACS ON STN
 ACCESSION NUMBER: 1997:620417 CAPLUS
 DOCUMENT NUMBER: 127:318935
 TITLE: Behavior of N-benzenesulfonyloxy- and N-acetoxy-2,3-quinoxalinedicarboximides towards some nucleophiles
 AUTHOR(S): Yousef, Mohamed Salah Kamel; Abbedy, Mohamed Saad
 CORPORATE SOURCE: Chem. Dep., Faculty Science, Assiut University, Assiut, Egypt
 SOURCE: Heterocycles (1997), 45(9), 1671-1678
 CODEN: HETCYM; ISSN: 0360-6341
 PUBLISHER: Japan Institute of Heterocyclic Chemistry
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 AB The reactions of N-(benzenesulfonyloxy)2,3-quinoxalinedicarboximide (I) and N-acetoxy-2,3-quinoxalinedicarboximide (II) with different nucleophilic reagents have been investigated. Thus, treatment of I with aromatic amines gave N-aryl-3-(arylsulfonyl)-2-quinoxalinedicarboximides via ring opening followed by Lossen rearrangement with the loss of sulfonate ion to give an intermediate isocyanate which adds another mole of aromatic amine. II failed to undergo Lossen rearrangement when treated with aromatic amines; it reacted with PhNH₂ to give N-phenylquinoxaline-2,3-dicarboxylic acid imide and AcNHPh.
 IT 197641-25-1P 197641-26-2P 197641-27-3P
 RL: SPN (Synthetic preparation); PREP (Preparation) (addition of nucleophiles to N-acetoxy- and N-(benzenesulfonyloxy)quinoxalinedicarboximides)
 RN 197641-25-1 CAPLUS
 CN 2-Quinoxalinedicarboxamide, N-phenyl-3-[[[(phenylamino)carbonyl]amino]- (9CI) (CA INDEX NAME)



RN 197641-26-2 CAPLUS
 CN 2-Quinoxalinedicarboxamide, N-(4-methylphenyl)-3-[[[(4-methylphenyl)amino]carbonyl]amino]- (9CI) (CA INDEX NAME)



RN 197641-27-3 CAPLUS
 CN 2-Quinoxalinedicarboxamide, N-(4-methoxyphenyl)-3-[[[(4-methoxyphenyl)amino]carbonyl]amino]- (9CI) (CA INDEX NAME)




REFERENCE COUNT: 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT


L5 ANSWER 154 OF 283 CAPLUS COPYRIGHT 2006 ACS ON STN
 ACCESSION NUMBER: 1997:499097 CAPLUS
 DOCUMENT NUMBER: 127:176278
 TITLE: Preparation of indanes as antipsychotics
 INVENTOR(S): Hollinshead, Sean P.; Huff, Bret E.; Hughes, Philip F.; Mendosa, Jose S.; Mitch, Charles H.; Sussak, Michael A.; Ward, John S.; Wilson, Joseph W.; et al.
 PATENT ASSIGNEE(S): Eli Lilly and Co., USA
 SOURCE: PCT Int. Appl., 70 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 2
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9725983	A1	19970724	WO 1997-05997	19970122
WO 9725983	A	19970724		
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, US, UZ				
RW: KE, LS, MW, SD, SE, TJ, UG, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SF, BF, CF, CO, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
CA 2243500	AA	19970724	CA 1997-2243500	19970122
CA 2243717	AA	19970724	CA 1997-2243717	19970122
AU 9718349	A1	19970811	AU 1997-18349	19970122
EP 874625	A1	19981104	EP 1997-903904	19970122
EP 874625	B1	20050316		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE, FI				
JP 20000504320	T2	20000411	JP 1997-526290	19970122
AT 290859	S	20050415	AT 1997-903904	19970122
PT 874625	T	20050729	PT 1997-903904	19970122
ES 2237788	T3	20050801	ES 1997-903904	19970122

US 6429317 B1 20020806 US 2000-117089 20000905
 PRIORITY APPLN. INFO.: US 1996-10287P P 19960122
 WO 1997-05997 W 19970122
 OTHER SOURCE(S): MARPAT 127:176278
 GI



AB The title compds. [I; R₁ = H, C1-3 alkyl, C2-3 alkenyl, etc.; R₂ = C1-10 alkyl, C2-10 alkenyl, aryl, etc.; R₁₀ = H, halo, C1-3 alkyl, C(O); R₁₁ = H, C1-3 alkyl; R₁₂ = R₁₃ = H, C1-10 alkyl, aryl; R₁₂R₁₃ = II (wherein X = C, O, S, etc.; n = 0-2; R₁₇ = H, halo, C1-3 alkyl, etc.); R₁₁R₁₂ = 3-6-membered ring; R₁₄ = H, halo, C1-3 alkyl, etc.], useful for treating psychosis and other conditions associated with the modulation of a muscarinic receptor, were prepared and formulated. For example, the title compound III showed 34% maximum stimulation of cAMP production in CHO m4 cells compared to Oxotremorine-M.
 IT 194028-31-6P
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses) (preparation of indanes as antipsychotics)
 RN 194028-33-6 CAPLUS
 CN 2-Quinoxalinedicarboxamide, N-[(1R,2R)-2,3-dihydro-2-hydroxy-6-[(1-pyrrolidinylmethylene)amino]-1H-inden-1-yl]-, rel- (9CI) (CA INDEX NAME)




L5 ANSWER 155 OF 283 CAPLUS COPYRIGHT 2006 ACS ON STN

ACCESSION NUMBER: 1997:189938 CAPLUS
 DOCUMENT NUMBER: 126:186111
 TITLE: Preparation of heterocyclic carboxylic acid derivatives as retinoid receptor agonists
 INVENTOR(S): Kikuchi, Kouichi; Tagami, Katsuya; Yoshimura, Hiroyuki; Iishi, Shigeki; Nagai, Mitsuaki; Abe, Shinya; Okita, Makoto; Hida, Takayuki; Higashi, Seiko; Tokuhara, Naoki; Kobayashi, Seiichi; et al.
 PATENT ASSIGNEE(S): Eisai Co., Ltd., Japan
 SOURCE: PCT Int. Appl., 160 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: Japanese
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9702444	A1	19970123	WO 1996-01782	19960627
W: AU, CA, CN, HU, KR, MX, NO, NZ, RU, US				
RW: AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
JP 09071566	A2	19970318	JP 1996-141433	19960604
AU 9662422	A1	19970205	AU 1996-62422	19960627
EP 838453	A1	19980429	EP 1996-921104	19960627
EP 838453	B1	20050427		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE, FI				
AT 294160	E	20050515	AT 1996-921104	19960627
EP 1559709	A1	20050803	EP 2005-1823	19960627
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE, FI				
US 5977108	A	19991102	US 1997-981770	19971230
US 6329402	B1	20011211	US 1999-313087	19990517
US 2002032202	A1	20020314	US 2001-910012	20010723
US 6541474	B2	20030401		
US 2002103234	A1	20020801	US 2001-910068	20010723
US 6630463	B2	20031007		
US 2003144276	A1	20030731	US 2003-336756	20030106
US 6884808	B2	20050426		

PRIORITY APPLN. INFO.: JP 1995-166004 A 19950630
 JP 1996-141433 A 19960604
 EP 1996-921104 A3 19960627
 WO 1996-JP1782 W 19960627
 US 1997-981770 A3 19971230
 US 1999-313087 XX 19990517
 US 2001-910068 A3 20010723
 OTHER SOURCE(S): MARPAT 126:186111
 GI




AB Heterocyclic carboxylic acid deriv. AB(D)NCOM [A is a heteroaryl group which has at least one nitrogen atom and may be substituted, or the like; B is heteroarylene, CONH, CR₆CR₇ (R₆ and R₇ being each H, lower alkyl or the like) or the like; D is arylene, heteroarylene or the like; n is 0 or 1; and M is hydroxyl, lower alkoxy or the like] are prepared. In an in vitro retinoid receptor binding assay, tetrahydroquinoxaline derivative I showed IC₅₀ of 1.6 nM, vs. IC₅₀ of 1.1 nM shown by all-trans-retinoic acid.


IT 187400-38-0P 187401-11-2P 187401-12-3P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of heterocyclic carboxylic acid derivs. as retinoid receptor agonists)
RN 187400-38-0 CAPLUS
CN Benzoic acid, 4-[[[6,7-dihydro-5-(1-methylethyl)-5H-pyrrolo[2,3-b]pyrazin-3-yl]carbonyl]amino]- (9CI) (CA INDEX NAME)



RN 187401-11-2 CAPLUS
CN Benzoic acid, 4-[[[5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-quinoxaliny]carbonyl]amino]- (9CI) (CA INDEX NAME)




RN 187401-12-3 CAPLUS
CN Benzoic acid, 4-[[[6,7-dihydro-5,5,7,7-tetramethyl-5H-cyclopentapyrazin-2-yl]carbonyl]amino]- (9CI) (CA INDEX NAME)



IT 187402-00-2P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of heterocyclic carboxylic acid derivs. as retinoid receptor agonists)
RN 187402-00-2 CAPLUS
CN Benzoic acid, 4-[[[6,7-dihydro-5-(1-methylethyl)-5H-pyrrolo[2,3-b]pyrazin-3-yl]carbonyl]amino]-, methyl ester (9CI) (CA INDEX NAME)


RN 187402-00-2 CAPLUS
CN Benzoic acid, 4-[[[6,7-dihydro-5-(1-methylethyl)-5H-pyrrolo[2,3-b]pyrazin-3-yl]carbonyl]amino]-, methyl ester (9CI) (CA INDEX NAME)




L5 ANSWER 157 OF 283 CAPLUS COPYRIGHT 2006 ACS ON STN
ACCESSION NUMBER: 1996:466915 CAPLUS
DOCUMENT NUMBER: 125:143315
TITLE: Boronic ester and acid compounds, synthesis and uses
INVENTOR(S): Adams, Julian; Ma, Yu-Ting; Stein, Ross; Baevek, Matthew; Grenier, Louis; Plamondon, Louis
PATENT ASSIGNEE(S): Proscript, Inc., USA
SOURCE: PCT Int. Appl., 144 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 3
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9613266	A1	19960509	WO 1995-US14117	19951027
W: AL, AM, AT, AU, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GR, HU, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MX, MY, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK				
RN: KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GU, MR, NE, SN, TD, TG				
US 6083903	A	20000704	US 1995-442581	19950516
AU 9641398	A1	19960523	AU 1996-41398	19951027
AU 710564	B2	19990923		
EP 788360	A1	19970813	EP 1995-939670	19951027
EP 788360	B1	20030528		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE				
JP 10510245	T2	19981006	JP 1996-514834	19951027
JP 3717934	B2	20051116		
AT 241631	S	20030615	AT 1995-939670	19951027
FI 9701746	A	19970606	FI 1997-1746	19970423
NO 9701929	A	19970612	NO 1997-1929	19970425
NO 310558	B1	20010723		
HK 1002059	A1	20030905	HK 1998-100951	19980207
FI 2004001415	A	20041103	FI 2004-1415	20041103
PRIORITY APPLN. INFO.:			US 1994-330525	A 19941028
			US 1995-442581	A 19950516
			WO 1995-US14117	W 19951027

OTHER SOURCE(S): MARPAT 125:143315
AB Peptidyl boronic acids and esters PNR[B1R1X1]ACHR2X2CHR3B2I2Z [P = aryl-, alkyl-, heteroaryl-, or heteroarylaalkylcarbonyl or -sulfonyl; B1 = N,




L5 ANSWER 156 OF 283 CAPLUS COPYRIGHT 2006 ACS ON STN
ACCESSION NUMBER: 1996:570269 CAPLUS
DOCUMENT NUMBER: 125:247762
TITLE: Synthesis of biscarbonyl side chain substituted quinoxaline-1,4-dioxides
AUTHOR(S): Wang, Jiliang; Liu, Fuchu
CORPORATE SOURCE: Dep. Chem., Yunnan Univ., Kunming, 650091, Peop. Rep. China
SOURCE: Hecheng Huaxue (1996), 4(2), 171-173
CODEN: HEHUE2; ISSN: 1005-1511
PUBLISHER: Hecheng Huaxue Bianjibu
DOCUMENT TYPE: Journal
LANGUAGE: Chinese
GI



AB Reaction of benzofuran 1-oxide with CO(CH2COR)2 (R = PhNH, 4-MeC6H4NH, MeO, EtO, PrO) in THF in the presence of KOR gave 9,4-59% the title compds. 1.

IT 182006-89-9P 182006-92-4P
RL: SPN (Synthetic preparation); PREP (Preparation)
(synthesis of biscarbonyl side chain substituted quinoxaline-1,4-dioxides)

RN 182006-89-9 CAPLUS
CN 2-Quinoxalineacetamide, N-phenyl-3-[[phenylamino]carbonyl]-, 1,4-dioxide (9CI) (CA INDEX NAME)




RN 182006-92-4 CAPLUS
CN 2-Quinoxalineacetamide, N-(4-methylphenyl)-3-[[4-methylphenyl]amino]carbonyl]-, 1,4-dioxide (9CI) (CA INDEX NAME)


CH: X1, X2 = CONH, CH(OH)CH2, COCH2; A = 0, 1, 2; R = H, alkyl; RR1 or RR2 (for A = 0) may form a ring; R1, R2, R3 = H, alkyl, cycloalkyl, aryl, etc.; Z1, Z2 = alkyl, hydroxy, alkoxy, aryloxy; Z1Z2 may form a moiety derived from a dihydroxy compound and their pharmaceutically acceptable salts were prepared. The rate of degradation of proteins of an animal can be reduced by contacting cells of the animal with these boronic compds.
Title, H-(4-morpholinecarbonyl)-B-(1-naphthyl)-L-alanine-L-leucine boronic acid was prepared by coupling (1S,2S,3R,5S)-pinanediol leucine boronate trifluoroacetate salt with N-Boc-B-(1-naphthyl)-L-alanine, followed by deprotection, acylation with 4-morpholinecarbonyl chloride, and cleavage of the pinanediol moiety.

IT 179324-42-6
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); BIOL (Biological study)
(synthesis of peptidyl boronic acids and esters as proteolytic enzyme inhibitors)
RN 179324-42-6 CAPLUS
CN Boronic acid, [(1R)-3-methyl-1-[[[(2S)-3-(1-naphthalenyl)-1-oxo-2-[[3-quinoxaliny]carbonyl]amino]propyl]amino]butyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L5 ANSWER 158 OF 283 CAPLUS COPYRIGHT 2006 ACS ON STN
ACCESSION NUMBER: 1996:433850 CAPLUS
DOCUMENT NUMBER: 125:114563
TITLE: Synthesis and antibacterial properties of quinoxaline 1,4-dioxide derivatives
AUTHOR(S): Takabatake, Tohru; Takabatake, Yumiko; Miyazawa, Tomoyuki; Hasegawa, Minoru
CORPORATE SOURCE: College Pharmacy, Nihon Univ., Funabashi, 274, Japan
SOURCE: Yakugaku Zasshi (1996), 116(6), 491-496
CODEN: YKXZAJ; ISSN: 0031-6903
PUBLISHER: Pharmaceutical Society of Japan
DOCUMENT TYPE: Journal
LANGUAGE: Japanese
GI




AB Title compds. I (R1, R2, R4 = H, Me; R3 = H, Me, MeO; R5 = Me, CH2CO2Me, Ph, 4-O2NC6H4; R6 = Me, MeO, EtO, Ph, PhNH, 2-, 4-MeOC6H4NH, 4-ClC6H4, 2-MeC6H4) were prepared from benzofuroxans II and R5OCH2COR6 catalyzed by silica gel or mol. sieves and their antibacterial activities. I showed strong in vitro activities against *Bacteroides fragilis*.


IT 23433-48-9P 11888-89-EP 104705-39-7P
11888-44-9P 11888-45-OP 11888-46-1P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation) (synthesis and antibacterial properties of quinoxaline 1,4-dioxide deriva.)


RN 23433-48-9 CAPLUS
CN 2-Quinoxalinecarboxamide, N-(2-methoxyphenyl)-3-methyl-, 1,4-dioxide (9CI) (CA INDEX NAME)




RN 11983-89-8 CAPLUS
CN 2-Quinoxalinecarboxamide, 3-methyl-N-phenyl-, 1,4-dioxide (9CI) (CA INDEX NAME)




RN 104705-39-7 CAPLUS
CN 2-Quinoxalinecarboxamide, N,3-diphenyl-, 1,4-dioxide (9CI) (CA INDEX NAME)




RN 11888-44-9 CAPLUS
CN 2-Quinoxalinecarboxamide, N-(4-methoxyphenyl)-3-methyl-, 1,4-dioxide (9CI) (CA INDEX NAME)





RN 11888-45-0 CAPLUS
CN 2-Quinoxalinecarboxamide, N-(4-chlorophenyl)-3-methyl-, 1,4-dioxide (9CI) (CA INDEX NAME)



RN 11888-46-1 CAPLUS
CN 2-Quinoxalinecarboxamide, 3-methyl-N-(2-methylphenyl)-, 1,4-dioxide (9CI) (CA INDEX NAME)




L5 ANSWER 159 OF 283 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 1996:365426 CAPLUS
DOCUMENT NUMBER: 125:114564
TITLE: New synthesis of 2,3-disubstituted quinoxaline derivatives
AUTHOR(S): Zaleska, B.; Bialas, B.
CORPORATE SOURCE: Department Organic Chemistry, Jagiellonian University, Krakow, 30-060, Pol.
SOURCE: Pharmazie (1996), 51(6), 428-429
CODEN: PHARAT; ISSN: 0031-7144
PUBLISHER: Govi-Verlag Pharmazeutischer Verlag
DOCUMENT TYPE: Journal
LANGUAGE: English
OTHER SOURCE(S): CASREACT 125:114564
OI




AB The title compds. I (R = Me, Ph; R1 = Ph, 4-ClC6H4) and II were prepared from 1,2-diaminocyclohexane by reaction with the corresponding anilides and thioanilides by cyclocondensation.

IT 179116-56-4P 179116-60-OP 179116-64-4P
RL: SPN (Synthetic preparation); PREP (Preparation) (preparation of quinoxalines)


RN 179116-56-4 CAPLUS
CN 2-Quinoxalinecarboxamide, 5,6,7,8-tetrahydro-3-methyl-N-phenyl- (9CI) (CA INDEX NAME)



RN 179116-60-0 CAPLUS
CN 2-Quinoxalinecarboxamide, 5,6,7,8-tetrahydro-N,3-diphenyl- (9CI) (CA INDEX NAME)



RN 179116-64-4 CAPLUS
CN 2-Quinoxalinecarboxamide, N-(4-chlorophenyl)-5,6,7,8-tetrahydro-3-phenyl- (9CI) (CA INDEX NAME)




L5 ANSWER 160 OF 283 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 1996:264958 CAPLUS
DOCUMENT NUMBER: 124:317209
TITLE: Preparation of heterobicyclic derivatives as phosphodiesterase IV inhibitors and tumor necrosis factors

INVENTOR(S): Hemmi, Keiji Di; Shimazaki, Norihiko; Watanabe, Shinya; Sawada, Akihiko
PATENT ASSIGNEE(S): Fujisawa Pharmaceutical Co., Ltd., Japan
SOURCE: PCT Int. Appl., 65 pp.
CODEN: PIXX02
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9601825	A1	19960125	WO 1995-JP1366	19950710
W: AU, BR, CA, CN, FI, HU, JP, KR, MX, NO, NZ, RU, UA, US				
RM: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
CA 2194872	AA	19960125	CA 1995-2194872	19950710
AU 9528992	A1	19960209	AU 1995-28992	19950710
AU 698133	B2	19981022		
EP 770079	A1	19970502	EP 1995-924526	19950710
EP 770079	B1	20030212		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, NL, PT, SE				
CN 1157617	A	19970820	CN 1995-194959	19950710
CN 1051548	B	20000419		
JP 10502630	T2	19980310	JP 1995-504226	19950710
HU 77353	A2	19980330	HU 1997-68	19950710
EP 920867	A1	19990609	EP 1996-120297	19950710
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, NL, SE, PT, IE				
RU 2170737	C2	20010720	RU 1997-101882	19950710
JP 3206003	B2	20010904	JP 1996-504226	19950710
AT 232531	B	20030215	AT 1995-924526	19950710
ES 2187561	T3	20030616	ES 1995-924526	19950710
PT 770079	T	20030630	PT 1995-924526	19950710
TW 383307	B	20000301	TW 1995-84107168	19950711
US 6426345	B1	20020730	US 1998-793451	19980130
BK 1004483	A1	20011024	BK 1998-103728	19980501
CN 1250776	A	20000419	CN 1989-111945	19990729
US 2002107251	A1	20020808	US 2002-50855	20020118
US 6727245	B2	20040427		

PRIORITY APPLN. INFO.:


OTHER SOURCE(S): MARPAT 124:317209
OI



AB Heterobicyclic derivs. [I; R1 = (un)substituted aryl, aralkyl, haloalkyl, protected carboxyalkyl, acylalkyl, heterocyclyl, etc.; R2 = (un)substituted aryl, heterocyclyl; R3 = H, alkoxy, alkylthio] and their salts are prepared. A mixture of amino compound II and 1-naphthyl isocyanate in dry dioxane was stirred at room temperature to give the ureido compound III, which showed IC50 of 3.1×10^{-8} M against phosphodiesterase IV and IC50 of 5.6×10^{-8} M against human mononuclear cells.


IT 176031-50-6P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of heterobicyclic derivs. as phosphodiesterase IV inhibitors and tumor necrosis factors.)

RN 176031-50-6 CAPLUS
CN 2-Quinoxalinecarboxamide, N-[3'-[3-oxo-2-(3-pyridinylmethyl)pyrido[2,3-b]pyrazin-4(3H)-yl][1,1'-biphenyl]-3-yl]- (9CI) (CA INDEX NAME)



L5 ANSWER 161 OF 283 CAPLUS COPYRIGHT 2006 ACS ON STN
ACCESSION NUMBER: 1996:242753 CAPLUS


DOCUMENT NUMBER: 125:10756
TITLE: Synthesis and hypoxia-selective cytotoxicity of benzofuraxane and quinoxaline di-N-oxides
AUTHOR(S): Zhang, Wensheng; Wu, Yanfen; Lu, Wei; Li, Wuling; Sun, Xiaoping; Shen, Kun; Li, Xinyuan; Tang, Lixia
CORPORATE SOURCE: School Pharmaceutical Sciences, Beijing Medical University, Beijing, 100083, Peop. Rep. China
SOURCE: Zhongguo Yaowu Huaxue Zazhi (1995), 5(4), 242-4, 270
CODEN: ZYHZEJ; ISSN: 1005-0108
PUBLISHER: Zhongguo Yaowu Huaxue Zazhi Bianjibu
DOCUMENT TYPE: Journal
LANGUAGE: Chinese
GI



AB Title compds. I (R = H, H; H, MeO; NO2, H) and II (R2 = CO2Et, CONHOK, CONHOK, COMe, CONHPh) were synthesized. E.g., reaction of 4-methoxy-2-nitroaniline with aqueous NaOCl in aqueous HCl gave 59.8% I (R = H, R1 = MeO). II (R2 = CONHOK) showed remarkable hypoxia-selective cytotoxicity and radiosensitivity in vitro. The relationships of hypoxia-selective cytotoxicity, and radiosensitization in vitro with their chemical structure were discussed.


IT 31983-89-8
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); BIOL (Biological study)
(synthesis and hypoxia-selective cytotoxicity of benzofuraxane and quinoxaline di-N-oxides)

RN 31983-89-8 CAPLUS
CN 2-Quinoxalinecarboxamide, 3-methyl-N-phenyl-, 1,4-dioxide (9CI) (CA INDEX NAME)



L5 ANSWER 162 OF 283 CAPLUS COPYRIGHT 2006 ACS ON STN
ACCESSION NUMBER: 1996:162161 CAPLUS
DOCUMENT NUMBER: 124:317104
TITLE: Chemistry of diazopolycarbonyl compounds. II. Synthesis of acrylacetyl derivatives of diazopyruvic acid esters and their reaction with ammonia and o-phenylenediamine
AUTHOR(S): Zalesov, V. V.; Vyaznikova, N. G.; Andreichikov, Yu. S.
CORPORATE SOURCE: Perm. Farm. Inst., Russia


SOURCE: Zhurnal Organicheskoi Khimii (1995), 31(8), 1213-17
CODEN: ZORKAE; ISSN: 0514-7492
PUBLISHER: Nauka
DOCUMENT TYPE: Journal
LANGUAGE: Russian
GI



AB (Z)-R1OCCOC((N2))COCH:C(OH)C6H4R2-4 (I; R1 = Et, Pr, Bu; R2 = H, Me, OMe, Cl, Br) were prepared by reaction of 5-aryl-2,3-furandiones with R1OCCOCN2. Reaction of I with NH4OH gave pyrazoles, e.g., II, and reaction with o-phenylenediamine gave pyrazoloquinoxalines, e.g., III. Other quinoxalines were prepared from the arylfurandiones and o-phenylenediamine.

IT 176375-09-0P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)

RN 176375-09-0 CAPLUS
CN 2-Quinoxalinecarboxamide, N-(2-aminophenyl)- (9CI) (CA INDEX NAME)




L5 ANSWER 163 OF 283 CAPLUS COPYRIGHT 2006 ACS ON STN
ACCESSION NUMBER: 1996:138846 CAPLUS
DOCUMENT NUMBER: 124:289449
TITLE: Synthesis and reactions of 6,7-dimethyl-N-(carboxyphenyl)quinoxaline-2,3-dicarboximide
Zahrán, M. A.
CORPORATE SOURCE: Faculty Science, Al-Azhar University, Cairo, Egypt
SOURCE: Al-Azhar Journal of Pharmaceutical Sciences (1994), 13, 60-5
CODEN: AAJPPT; ISSN: 1110-1644
PUBLISHER: Al-Azhar University, Faculty of Pharmacy
DOCUMENT TYPE: Journal
LANGUAGE: English

AB Condensation of 6,7-dimethylquinoxaline-2,3-dicarboxylic anhydride with m-aminobenzoic acid, p-aminobenzoic acid and p-aminophenyl acetic acid in ethanol yielded the corresponding carboxamide derivs. Cyclodehydration of these in acetic anhydride gave the carboximides (I) which on treatment


with sodium hydroxide caused opening of the ring to again afford the amides. Fusion of I with primary and secondary amines gave 6,7-dimethylquinoxaline-2,3-dicarboxamides. 6,7-Dimethyl-N-(4-chlorocarbonylphenyl)quinoxaline-2,3-dicarboximide was prepared and reacted with amines, ethanol and sodium azide to give amides, an imide, and the acid azide. The acid azide was reacted with ammonia and ethanol by Curtius rearrangement to afford ureas and carbamate derivs.

IT 175609-77-5P 175609-78-6P 175609-79-7P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation and reactions of N-(carboxyphenyl)quinoxalinecarboximides)


RN 175609-77-5 CAPLUS
CN 2-Quinoxalinecarboxylic acid, 3-[[[4-(carboxyphenyl)amino]carbonyl]-6,7-dimethyl- (9CI) (CA INDEX NAME)



RN 175609-78-6 CAPLUS
CN 2-Quinoxalinecarboxylic acid, 3-[[[4-(carboxyphenyl)amino]carbonyl]-6,7-dimethyl- (9CI) (CA INDEX NAME)




RN 175609-79-7 CAPLUS
CN 2-Quinoxalinecarboxylic acid, 3-[[[4-(carboxymethyl)phenyl]amino]carbonyl]-6,7-dimethyl- (9CI) (CA INDEX NAME)




IT 175609-83-3P 175609-84-4P 175609-85-5P
175609-86-6P 175609-87-7P 175609-88-8P
175609-89-9P 175609-90-2P 175609-91-3P
175609-92-4P 175609-93-5P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation and reactions of N-(carboxyphenyl)quinoxalinecarboximides)


RN 175609-83-3 CAPLUS
CN Benzoic acid, 3-[[[6,7-dimethyl-2-quinoxaliny]carbonyl]amino]- (9CI) (CA INDEX NAME)




RN 175609-84-4 CAPLUS
CN Benzoic acid, 4-[[[6,7-dimethyl-2-quinoxaliny]carbonyl]amino]- (9CI) (CA INDEX NAME)




RN 175609-85-5 CAPLUS
CN Benzoic acid, 4-[[[6,7-dimethyl-2-quinoxaliny]carbonyl]amino]- (9CI) (CA INDEX NAME)




RN 175609-86-6 CAPLUS
CN Benzoic acid, 3-[[[6,7-dimethyl-3-[[4-methylphenyl]amino]carbonyl]-2-quinoxaliny]carbonyl]amino]- (9CI) (CA INDEX NAME)




RN 175609-87-7 CAPLUS
CN Benzoic acid, 3-[[[3-[[4-methoxyphenyl]amino]carbonyl]-6,7-dimethyl-2-quinoxaliny]carbonyl]amino]- (9CI) (CA INDEX NAME)




RN 175609-88-8 CAPLUS
CN Benzoic acid, 4-[[[6,7-dimethyl-3-[[4-methylphenyl]amino]carbonyl]-2-quinoxaliny]carbonyl]amino]- (9CI) (CA INDEX NAME)




RN 175609-89-9 CAPLUS
CN Benzoic acid, 4-[[[3-[[4-methoxyphenyl]amino]carbonyl]-6,7-dimethyl-2-quinoxaliny]carbonyl]amino]- (9CI) (CA INDEX NAME)




RN 175609-90-2 CAPLUS
CN Benzoic acid, 3-[[[3-[[4-chlorophenyl]amino]carbonyl]-6,7-dimethyl-2-quinoxaliny]carbonyl]amino]- (9CI) (CA INDEX NAME)




RN 175609-91-3 CAPLUS
CN Benzoic acid, 3-[[[6,7-dimethyl-3-(4-morpholinylcarbonyl)-2-quinoxaliny]carbonyl]amino]- (9CI) (CA INDEX NAME)



RN 175609-92-4 CAPLUS
CN Benzoic acid, 4-[[[3-[[4-chlorophenyl]amino]carbonyl]-6,7-dimethyl-2-quinoxaliny]carbonyl]amino]- (9CI) (CA INDEX NAME)




RN 175609-93-5 CAPLUS
CN Benzoic acid, 4-[[[6,7-dimethyl-3-(4-morpholinylcarbonyl)-2-quinoxaliny]carbonyl]amino]- (9CI) (CA INDEX NAME)



L5 ANSWER 164 OF 283 CAPLUS COPYRIGHT 2006 ACS ON STM
ACCESSION NUMBER: 1995:997446 CAPLUS
DOCUMENT NUMBER: 124:175840
TITLE: Preparation of spiro heterocyclic compounds as tachykinin antagonists
INVENTOR(S): Kubota, Hirokazu; Okamoto, Yoshinori; Fujii, Masahiro; Kakefuda, Akio; Yamamoto, Osamu; Nagaoka, Mitoshi; Ikeda, Ken; Isomura, Yasuo
PATENT ASSIGNEE(S): Yamanouchi Pharmaceutical Co., Ltd., Japan
SOURCE: PCT Int. Appl., 142 pp.
CODEN: PIXK23
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9528389	A1	19951026	WO 1995-JP713	19950412
W: AM, AU, BB, BG, BR, BY, CA, CN, CZ, SE, FI, GE, HU, IS, JP, KE, KG, KR, KZ, LK, LR, LT, LV, MD, MG, MN, MM, MX, NO, NZ, PL, RO, RU, SD, SG, SI, SK, TJ, TT, UA, US, UZ, VN				
RW: KE, MM, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT,				

LU, MC, NL, PT, SE, BF, BJ, CP, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG
AU 9522234 A1 19951110 AU 1995-22234 19950412
PRIORITY APPLN. INFO.: JP 1994-101936 A 19940415
JP 1994-255382 A 19941020
WO 1995-JP713 W 19950412
OTHER SOURCE(S): MARPAT 124:175840
OI



AB The title compds. I [Na = N (which may form a quaternary ammonium salt with alkyl, etc.), or N-oxide; Z = C(R8R9)Z1, etc.; Z1 = O, etc.; R = (un)substituted aryl; n = 0 - 5; p, q = 0 or 1 (a proviso is given); X1 = CO, etc. (a proviso is given); X2 = O, S, etc. (a proviso is given); R1 = R4 = H, alkyl; further details on R1 and R2 are given; R5 = H, (un)substituted alkyl, etc.; R6, R9 = H, alkyl, etc.; ring Bz = (un)substituted benzene] are claimed. In an in vitro test for NK-1 receptor antagonism, the title compound II (preparation given) showed IC50 of 2 nM.
IT 173942-84-2P
RL: BAC (Biological activity or effector, except adverse): BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PRSP (Preparation); USES (Uses)
(preparation of spiro heterocyclic compds. as tachykinin antagonists)
RN 173942-84-2 CAPLUS
CN 2-Quinoxalinecarboxamide, N-[2-(3,4-dichlorophenyl)-4-spiro[isobenzofuran-1(3H),4'-piperidin]-1'-yl]butyl]-N-methyl-, (2E)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)


CM 1
CRN 173942-83-1
CMF C32 H32 Cl2 N4 O2



CN 2

CRN 110-17-8
CNP C4 H4 O4


Double bond geometry as shown.



L5 ANSWER 165 OF 283 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 1995:904618 CAPLUS
DOCUMENT NUMBER: 124:146062
TITLE: 6-Fluoro-7-(1-piperazinyl)quinoxaline 1,4-dioxides.
Part 1. 2-(N-(2-hydroxyalkyl)carbamoyl) derivatives
AUTHOR(S): El-Abadlah, Mustafa M.; Kazer, Musa Z.; El-Abadla, Naser S.; Meier, Herbert
CORPORATE SOURCE: Chemistry Dep., University of Jordan, Amman, Jordan
SOURCE: Heterocycles (1995), 41(10), 2203-19
CODEN: HETCYH; ISSN: 0365-5414
PUBLISHER: Japan Institute of Heterocyclic Chemistry
DOCUMENT TYPE: Journal
LANGUAGE: English
OTHER SOURCE(S): CASREACT 124:146062
AB A series of N-(6-fluoro-7-(4-methyl-1-piperazinyl)-3-methyl-2-quinoloxyl)-β-aminokanol 1,4-dioxides was synthesized for bioassay via the Beirut reaction of 5-(6-fluoro-6(5)-(4-methyl-1-piperazinyl)benzofuroxan with the appropriate N-acetoacetyl-β-aminokanol in the presence of triethylamine. Preliminary in vitro investigations have indicated that none of the title compds. exhibits any significant antibacterial potency at concns. ≤ 200 µg/mL.
IT 173029-89-5P 173029-84-OP 173029-89-5P
173029-92-OP
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
(preparation and bactericidal and fungicidal activity of fluoro(piperazinyl)quinoxaline dioxides)
RN 173029-80-6 CAPLUS

CN 2-Quinoxalinecarboxamide, 6-fluoro-N-[1-(hydroxymethyl)-2-phenylethyl]-3-methyl-7-(4-methyl-1-piperazinyl)-, 1,4-dioxide, (S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 173029-84-0 CAPLUS

CN 2-Quinoxalinecarboxamide, 6-fluoro-N-(2-hydroxy-1-methyl-2-phenylethyl)-N,3-dimethyl-7-(4-methyl-1-piperazinyl)-, 1,4-dioxide, [R-(R*,S*)]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 173029-89-5 CAPLUS

CN 2-Quinoxalinecarboxamide, 6-fluoro-N-[1-(hydroxymethyl)-2-phenylethyl]-3-methyl-7-(4-methyl-1-piperazinyl)-, 1,4-dioxide, monohydrochloride, (S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 173029-92-0 CAPLUS


CN 2-Quinoxalinecarboxamide, 6-fluoro-N-(2-hydroxy-1-methyl-2-phenylethyl)-N,3-dimethyl-7-(4-methyl-1-piperazinyl)-, 1,4-dioxide, monohydrochloride, [R-(R*,S*)]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

L5 ANSWER 166 OF 283 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 1995:794453 CAPLUS
DOCUMENT NUMBER: 124:8750
TITLE: Synthesis and chemistry of 3-aminocarbonyl- and 3-hydrazinocarbonylquinoxaline derivatives
AUTHOR(S): Badr, M. Z. A.; Mahgoub, S. A.; Atta, F. M.; Moustafa, O. S.; El-Latif, F. M. Abd
CORPORATE SOURCE: Faculty of Science, Assiut University, Assiut, Egypt
SOURCE: Journal of the Indian Chemical Society (1994), 71(10), 617-19
CODEN: JICSAH; ISSN: 0019-4522
PUBLISHER: Indian Chemical Society
DOCUMENT TYPE: Journal
LANGUAGE: English
OTHER SOURCE(S): CASREACT 124:8750
GI




AB 3-Ethoxycarbonyl-2(1H)-quinoxalinone (I) (shown as structure I) reacts with nucleophiles, namely, dimethylamine, diethylamine, o-phenylenediamine and/or p-phenylenediamine to produce the corresponding 3-N-substituted-aminocarbonyl-2(1H)-quinoxalinones. Treatment of I with hydrazine hydrate produces 2(1H)-quinoxalinone-3-carbohydrazide (2) which with acylating reagents, namely, acetic anhydride, HDAc or acetyl chloride/pyridine, Ph isothiocyanate, p-toluenesulfonyl chloride and/or di-Et malonate produce the corresponding 3-β-N-substituted-hydrazinocarbonyl-2(1H)-quinoxalinones. Condensation of 2 with benzaldehyde, p-anisaldehyde, p-N-dimethylaminobenzaldehyde and/or p-nitrobenzaldehyde gives the corresponding 3-arylidenehydrazinocarbonyl-2(1H)-quinoxalinones. Treatment of 2 with acetylacetone gives 3-(3,5-dimethylpyrazol-1-yl)carbonyl-2(1H)-quinoxalinone (13). Diazotization of 2 produces 2(1H)-quinoxalinone-3-carbozide (14) which when treated with absolute EtOH and/or t-BuOH produces the corresponding 3-alkoxycarbonylaminoquinoxalinones which cyclize on treatment with hydrazine hydrate into triazinoquinoxaline II.
IT 171254-29-8P 171254-30-1P
RL: SPN (Synthetic preparation); PREP (Preparation)

(preparation of)
RN 171254-29-8 CAPLUS
CN 2-Quinoxalinecarboxamide, N-(2-aminophenyl)-3,4-dihydro-3-oxo- (9CI) (CA INDEX NAME)



RN 171254-30-1 CAPLUS


CN 2-Quinoxalinecarboxamide, N-(4-aminophenyl)-3,4-dihydro-3-oxo- (9CI) (CA INDEX NAME)



L5 ANSWER 167 OF 283 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 1995:716813 CAPLUS
DOCUMENT NUMBER: 123:112079
TITLE: Preparation of quinoxaline-2-carboxamides as antidiabetics
INVENTOR(S): Komatsu, Makoto; Sato, Hideaki; Taira, Shinichi; Miyake, Masahiro; Magata, Kiyohiko; Yoshida, Hidehiro; Ueyama, Atsunori; Nishi, Takao
PATENT ASSIGNER(S): Otsuka Pharmaceutical Co. Ltd., Japan
SOURCE: PCT Int. Appl., 507
CODEN: PIKX02
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9509159	A1	19950406	WO 1994-JP1559	19940922
W: AU, CA, CN, KR, US				
RM: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
CA 2150345	AA	19950406	CA 1994-2150345	19940922
AU 9476660	A1	19950418	AU 1994-76660	19940922
AU 674613	B2	19970102		
EP 670831	A1	19950913	EP 1994-927085	19940922
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE				
CN 1114834	A	19960110	CN 1994-190719	19940922
JP 08012579	A2	19960116	JP 1994-259309	19940928
JP 2759257	B2	19980528		
PRIORITY APPLN. INFO.:				
			JP 1993-241140	A 19930928
			JP 1994-114639	A 19940428
			WO 1994-JP1559	W 19940922

OTHER SOURCE(S): MARPAT 123:112079
GI




AB Title compds. [I; R = NR3R4; R1 = H, halo, alkyl, alkoxy, etc.; R2 = H, (halo)alkyl, alkoxy, etc.; R3, R4 = H, alkyl, alkanoyl, alkoxycarbonyl, substituted CH2Ph, heterocyclylalkenyl, etc.; m = 0 or 1; n = 0; r = 1 or 2] were prepared. Thus, benzofuroxan was cyclocondensed with MeOCH2CO2Et and the product converted in 2 steps to I (R2 = Me, m = 1, n = r = 0) (II; R = OR) which was amidated by 3-aminomethylbenzofuran to give II (3-benzofurylaminomethyl). II (R = HCH2CH2CR5Me, R5 = 2-benzofuryl) gave 2-deoxyglucose uptake of rat striated muscle L6 cells 24% of controls at 10-6mol (sic).


IT 165731-11-3P 165731-94-2P 165731-97-5P
165732-06-9P 165732-55-8P 165733-20-0P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(preparation of quinoxaline-2-carboxamides as antidiabetics)
RN 165731-11-3 CAPLUS
CN 2-Quinoxalinecarboxamide, N-[[4-(hydroxyphenyl)methyl]-3-methyl- (9CI) (CA INDEX NAME)




RN 165731-94-2 CAPLUS
CN 2-Quinoxalinecarboxamide, N-[[3-(4-methoxyphenyl)propyl]-3-methyl- (9CI) (CA INDEX NAME)




RN 165731-97-5 CAPLUS
CN 2-Quinoxalinecarboxamide, 3-methyl-N-[[4-[2-(4-morpholinyl)-2-oxoethoxy]phenyl]methyl]- (9CI) (CA INDEX NAME)




RN 165732-06-9 CAPLUS
CN 2-Quinoxalinecarboxamide, 3-methyl-N-(3-phenyl-2-propenyl)- (9CI) (CA INDEX NAME)



RN 165732-55-8 CAPLUS
CN Acetic acid, 4-[[[(3-methyl-2-quinoxaliny)carbonyl]amino]methyl]phenoxy]-, methyl ester (9CI) (CA INDEX NAME)



RN 165733-20-0 CAPLUS
CN Benzoic acid, 4-[[[(3-methyl-2-quinoxaliny)carbonyl]amino]methyl]-, methyl ester (9CI) (CA INDEX NAME)




IT 112369-35-4P 112369-37-6P 165731-03-3P
165731-04-4P 165731-16-8P 165731-17-9P
165731-18-0P 165731-19-1P 165731-20-4P
165731-21-5P 165731-22-6P 165731-23-7P
165731-24-8P 165731-91-9P 165731-92-0P
165731-93-1P 165731-95-3P 165731-96-4P
165731-98-6P 165732-01-4P 165732-04-7P
165732-05-8P 165732-07-0P 165732-08-1P
165732-09-2P 165732-10-5P 165732-11-6P
165732-12-7P 165732-13-8P 165732-14-9P
165732-16-1P 165732-17-2P 165732-21-8P
165732-22-9P 165732-23-0P 165732-24-1P
165732-25-2P 165732-26-3P 165732-27-4P
165732-28-5P 165732-29-6P 165732-30-9P


165732-31-0P 165732-32-1P 165732-33-2P
165732-34-3P 165732-35-4P 165732-36-5P
165732-37-6P 165732-38-8P 165732-40-1P
165732-41-2P 165732-42-3P 165732-43-4P
165732-44-5P 165732-45-6P 165732-46-7P
165732-47-8P 165732-48-9P 165732-49-0P
165732-50-3P 165732-51-4P 165732-52-5P
165732-53-6P 165732-54-7P 165732-56-9P
165732-57-0P 165732-58-1P 165732-59-2P
165732-60-5P 165732-61-6P 165732-62-7P
165732-64-9P 165732-67-2P 165732-68-3P
165732-69-4P 165732-70-7P 165732-71-8P
165732-72-9P 165732-73-0P 165732-74-1P
165732-75-2P 165732-76-3P 165732-77-4P
165732-78-5P 165732-80-9P 165732-81-0P
165732-83-2P 165732-84-3P 165732-85-4P
165732-88-7P 165732-89-8P 165733-00-6P
165733-01-7P 165733-07-3P 165733-08-4P
165733-09-5P 165733-10-8P 165733-11-9P
165733-15-3P 165733-16-4P 165733-93-7P
165733-94-8P 165733-95-9P 165733-96-0P
165733-97-1P 165733-98-2P 165734-02-1P
165734-03-2P 165734-04-3P 165734-07-6P
165734-08-7P 165734-10-1P 165734-18-9P
165734-19-0P 165734-20-3P 165734-21-4P
165734-26-9P 165734-71-4P 165734-78-1P
165734-79-2P 165737-61-1P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of quinoxaline-2-carboxamides as antidiabetics)


112369-35-4 CAPLUS
CN 2-Quinoxalinecarboxamide, 3-methyl-N-(phenylmethyl)- (9CI) (CA INDEX NAME)



RN 112369-37-6 CAPLUS
CN 2-Quinoxalinecarboxamide, 3-methyl-N-(3-phenylpropyl)-, 4-oxide (9CI) (CA INDEX NAME)




RN 165731-03-3 CAPLUS
CN 2-Quinoxalinecarboxamide, 3-methyl-N-[[4-[2-(4-morpholinyl)-2-oxoethoxy]phenyl]methyl]-, 4-oxide (9CI) (CA INDEX NAME)




RN 165731-04-4 CAPLUS
CN 2-Quinoxalinecarboxamide, N,3-dimethyl-N-(3-phenyl-2-propenyl)-, (E)- (9CI) (CA INDEX NAME)


Double bond geometry as shown.




RN 165731-16-8 CAPLUS
CN Acetic acid, 4-[[[(3-methyl-2-quinoxaliny)carbonyl]amino]methyl]phenoxy]- (9CI) (CA INDEX NAME)




RN 165731-17-9 CAPLUS
CN 2-Quinoxalinecarboxamide, N-[[4-[2-[(2-furanylmethyl)amino]-2-oxoethoxy]phenyl]methyl]-3-methyl- (9CI) (CA INDEX NAME)




RN 165731-18-0 CAPLUS
CN 2-Quinoxalinecarboxamide, N-[[4-[2-[(2-methoxyethyl)amino]-2-oxoethoxy]phenyl]methyl]-3-methyl- (9CI) (CA INDEX NAME)




RN 165731-19-1 CAPLUS
CN 2-Quinoxalinecarboxamide, N-[[3-bromo-4-(2-(4-morpholinyl)-2-oxoethoxy)phenyl]methyl]-3-methyl- (9CI) (CA INDEX NAME)




RN 165731-20-4 CAPLUS
CN 2-Quinoxalinecarboxamide, N-[[4-(hydroxymethyl)phenyl]methyl]-3-methyl- (9CI) (CA INDEX NAME)




RN 165731-21-5 CAPLUS
CN 2-Quinoxalinecarboxamide, N-[[4-(2-hydroxyethoxy)phenyl]methyl]-3-methyl- (9CI) (CA INDEX NAME)




RN 165731-22-6 CAPLUS
CN 2-Quinoxalinecarboxamide, N-[[4-(2-chloroethoxy)phenyl]methyl]-3-methyl- (9CI) (CA INDEX NAME)




RN 165731-23-7 CAPLUS
CN 2-Quinoxalinecarboxamide, 3-methyl-N-[[4-(2-(4-morpholinyl)ethoxy)phenyl]methyl]-, monohydrochloride (9CI) (CA INDEX NAME)




RN 165731-24-8 CAPLUS
CN 2-Quinoxalinecarboxamide, N-[[4-(acetylphenyl)methyl]-3-methyl-, 4-oxide (9CI) (CA INDEX NAME)




RN 165731-91-9 CAPLUS
CN 2-Quinoxalinecarboxamide, 3-methyl-N-(3-phenyl-2-propenyl)-, 4-oxide (9CI) (CA INDEX NAME)




RN 165731-92-0 CAPLUS
CN 2-Quinoxalinecarboxamide, 3-methyl-N-(3-phenyl-2-propenyl)-, 1-oxide (9CI) (CA INDEX NAME)




RN 165731-93-1 CAPLUS
CN 2-Quinoxalinecarboxamide, 3-methyl-N-(3-phenylpropyl)- (9CI) (CA INDEX NAME)




RN 165731-95-3 CAPLUS
CN 2-Quinoxalinecarboxamide, N-[[3-(4-(dimethylamino)phenyl)propyl]-3-methyl- (9CI) (CA INDEX NAME)




RN 165731-96-4 CAPLUS
CN 2-Quinoxalinecarboxamide, N-[[4-(methoxyphenyl)methyl]-3-methyl- (9CI) (CA INDEX NAME)




RN 165731-98-6 CAPLUS
CN 2-Quinoxalinecarboxamide, N-[[4-(2-(ethylamino)-2-oxoethoxy)phenyl]methyl]-3-methyl- (9CI) (CA INDEX NAME)




RN 165732-01-4 CAPLUS
CN 2-Quinoxalinecarboxamide, N-(cyclohexylmethyl)-3-methyl- (9CI) (CA INDEX NAME)




RN 165732-04-7 CAPLUS
CN 2-Quinoxalinecarboxamide, N-[[3-(methoxyphenyl)methyl]-3-methyl- (9CI) (CA INDEX NAME)




RN 165732-05-8 CAPLUS
CN 2-Quinoxalinecarboxamide, N-[[3-(3,4-dimethoxyphenyl)-2-propenyl]-3-methyl- (9CI) (CA INDEX NAME)




RN 165732-07-0 CAPLUS
CN 2-Quinoxalinecarboxamide, N-[[2-(chlorophenyl)methyl]-3-methyl- (9CI) (CA INDEX NAME)



RN 165732-08-1 CAPLUS
CN 2-Quinoxalinecarboxamide, N-[[2-(4-methoxyphenyl)ethyl]-3-methyl- (9CI) (CA INDEX NAME)




RN 165732-09-2 CAPLUS
CN 2-Quinoxalinecarboxamide, N-[[2-(methoxyphenyl)methyl]-3-methyl- (9CI) (CA INDEX NAME)




RN 165732-10-5 CAPLUS
CN 2-Quinoxalinecarboxamide, 3-methyl-N-[[4-(nitrophenyl)methyl]- (9CI) (CA INDEX NAME)


(INDEX NAME)




RN 165732-11-6 CAPLUS
CN 2-Quinoxalinecarboxamide, N-[(3,4-dimethoxyphenyl)methyl]-3-methyl-, (9CI) (CA INDEX NAME)




RN 165732-12-7 CAPLUS
CN 2-Quinoxalinecarboxamide, N-[3-(2-chlorophenyl)-2-propenyl]-3-methyl-, (9CI) (CA INDEX NAME)




RN 165732-13-8 CAPLUS
CN 2-Quinoxalinecarboxamide, N-[3-(2-chlorophenyl)-2-propenyl]-3-methyl-, 4-oxide (9CI) (CA INDEX NAME)




RN 165732-14-9 CAPLUS
CN 2-Quinoxalinecarboxamide, N-[(4-methoxyphenyl)methyl]-3-methyl-, 4-oxide (9CI) (CA INDEX NAME)



RN 165732-16-1 CAPLUS
CN 2-Quinoxalinecarboxamide, N-[(2-fluorophenyl)methyl]-3-methyl-, 4-oxide (9CI) (CA INDEX NAME)




RN 165732-17-2 CAPLUS
CN 2-Quinoxalinecarboxamide, N-[(2-naphthalenyl)methyl]-, 4-oxide (9CI) (CA INDEX NAME)



RN 165732-21-8 CAPLUS
CN 2-Quinoxalinecarboxamide, N-[3-(4-(dimethylamino)phenyl)propyl]-3-methyl-, 4-oxide, ethanedioate (1:1) (9CI) (CA INDEX NAME)

CN 1

CRN 165732-20-7
CMF C21 H24 N4 O2




CN 2

CRN 144-62-7


CMF C2 H2 O4




RN 165732-22-9 CAPLUS
CN 2-Quinoxalinecarboxamide, N-[(4-hydroxyphenyl)methyl]-3-methyl-, 4-oxide (9CI) (CA INDEX NAME)




RN 165732-23-0 CAPLUS
CN 2-Quinoxalinecarboxamide, N-[(4-(2-(ethylamino)-2-oxoethoxy)phenyl)methyl]-3-methyl-, 4-oxide (9CI) (CA INDEX NAME)



RN 165732-24-1 CAPLUS
CN 2-Quinoxalinecarboxamide, N-[(4-chlorophenyl)methyl]-3-methyl-, (9CI) (CA INDEX NAME)




RN 165732-25-2 CAPLUS
CN 2-Quinoxalinecarboxamide, N-[3-(4-methoxyphenyl)-2-propenyl]-3-methyl-, 4-oxide (9CI) (CA INDEX NAME)




RN 165732-26-3 CAPLUS


CN 2-Quinoxalinecarboxamide, N-[3-(4-methoxyphenyl)-2-propenyl]-3-methyl-, 4-oxide (9CI) (CA INDEX NAME)




RN 165732-27-4 CAPLUS
CN 2-Quinoxalinecarboxamide, N-[3-(2-methoxyphenyl)-2-propenyl]-3-methyl-, (9CI) (CA INDEX NAME)




RN 165732-28-5 CAPLUS
CN 2-Quinoxalinecarboxamide, N-[3-(2-nitrophenyl)-2-propenyl]-, 4-oxide (9CI) (CA INDEX NAME)




RN 165732-29-6 CAPLUS
CN 2-Quinoxalinecarboxamide, N-[3-(2-methoxyphenyl)-2-propenyl]-3-methyl-, 4-oxide (9CI) (CA INDEX NAME)




RN 165732-30-9 CAPLUS
CN 2-Quinoxalinecarboxamide, N-[(4-(hydroxymethyl)phenyl)methyl]-3-methyl-, 4-oxide (9CI) (CA INDEX NAME)




RN 165732-31-0 CAPLUS
CN 2-Quinoxalinecarboxamide, N-[[4-[2-(3-hydroxy-1-pyrrolidinyl)-2-oxoethoxy]phenyl]methyl]-3-methyl-, 4-oxide (9CI) (CA INDEX NAME)




RN 165732-32-1 CAPLUS
CN 2-Quinoxalinecarboxamide, N-[[4-[2-[[4-(4-methoxyphenyl)methyl]amino]-2-oxoethoxy]phenyl]methyl]-3-methyl-, 4-oxide (9CI) (CA INDEX NAME)




RN 165732-33-2 CAPLUS
CN 2-Quinoxalinecarboxamide, 3-methyl-N-[[4-[4-(4-morpholinyl)-4-oxobutoxy]phenyl]methyl]-, 4-oxide (9CI) (CA INDEX NAME)




RN 165732-34-3 CAPLUS
CN 2-Quinoxalinecarboxamide, N-[[4-[2-(diethylamino)-2-oxoethoxy]phenyl]methyl]-3-methyl-, 4-oxide (9CI) (CA INDEX NAME)




RN 165732-35-4 CAPLUS
CN 2-Quinoxalinecarboxamide, N-[[4-[2-(bis(2-hydroxyethyl)amino)-2-oxoethoxy]phenyl]methyl]-3-methyl-, 4-oxide (9CI) (CA INDEX NAME)




RN 165732-36-5 CAPLUS
CN 2-Quinoxalinecarboxamide, N-[[4-[2-[[4-(4-methoxyphenyl)methyl]amino]-2-oxoethoxy]phenyl]methyl]-3-methyl-, 4-oxide (9CI) (CA INDEX NAME)




RN 165732-37-6 CAPLUS
CN 2-Quinoxalinecarboxamide, N-[[4-[2-[[4-(4-methoxyphenyl)methyl]amino]-2-oxoethoxy]phenyl]methyl]-3-methyl-, 4-oxide (9CI) (CA INDEX NAME)




RN 165732-39-8 CAPLUS
CN 2-Quinoxalinecarboxamide, N-[[4-(ethylphenyl)methyl]-3-methyl-, 4-oxide (9CI) (CA INDEX NAME)




RN 165732-40-1 CAPLUS
CN 2-Quinoxalinecarboxamide, 3-methyl-N-[[4-[(2-methyl-2-propenyl)oxy]phenyl]methyl]-, 4-oxide (9CI) (CA INDEX NAME)




RN 165732-41-2 CAPLUS
CN 2-Quinoxalinecarboxamide, N-[[3-[2-(4-morpholinyl)-2-oxoethoxy]phenyl]methyl]-, 4-oxide (9CI) (CA INDEX NAME)




RN 165732-42-3 CAPLUS
CN 2-Quinoxalinecarboxamide, 3-methyl-N-[[3-[2-(4-morpholinyl)-2-oxoethoxy]phenyl]methyl]-, 4-oxide (9CI) (CA INDEX NAME)




RN 165732-43-4 CAPLUS
CN 2-Quinoxalinecarboxamide, N-[[3-[2-[(2-furanyl)methyl]amino]-2-oxoethoxy]phenyl]methyl]-3-methyl-, 4-oxide (9CI) (CA INDEX NAME)



RN 165732-44-5 CAPLUS
CN 2-Quinoxalinecarboxamide, N-[[3-[2-[(2-furanyl)methyl]amino]-2-oxoethoxy]phenyl]methyl]-3-methyl-, 4-oxide (9CI) (CA INDEX NAME)




RN 165732-45-6 CAPLUS
CN 2-Quinoxalinecarboxamide, 3-methyl-N-[[3-[2-oxo-2-(4-(phenylmethyl)-1-piperazinyl)ethoxy]phenyl]methyl]-, 4-oxide, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 165732-46-7 CAPLUS
CN 2-Quinoxalinecarboxamide, 3-methyl-N-[[3-[2-oxo-2-(4-(phenylmethyl)-1-piperazinyl)ethoxy]phenyl]methyl]-, 4-oxide, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 165732-47-8 CAPLUS
CN 2-Quinoxalinecarboxamide, 3-methyl-N-[[3-[2-(4-methyl-1-piperazinyl)-2-oxoethoxy]phenyl]methyl]-, 4-oxide, monohydrochloride (9CI) (CA INDEX NAME)


(NAME)



● HCl


RN 165732-46-9 CAPLUS

CN 2-Quinoxalinecarboxamide, 3-methyl-N-[[3-[2-(4-methyl-1-piperazinyl)-2-oxoethoxy]phenyl]methyl]- (9CI) (CA INDEX NAME)




RN 165732-49-0 CAPLUS

CN 2-Quinoxalinecarboxamide, 3-methyl-N-[[3-(4-morpholinylcarbonyl)phenyl]methyl]-, 4-oxide (9CI) (CA INDEX NAME)




RN 165732-50-3 CAPLUS

CN 2-Quinoxalinecarboxamide, 3-methyl-N-[[3-(4-morpholinylcarbonyl)phenyl]methyl]- (9CI) (CA INDEX NAME)




RN 165732-53-4 CAPLUS

CN 2-Quinoxalinecarboxamide, N-[[3-bromo-4-[2-(4-morpholinyl)-2-oxoethoxy]phenyl]methyl]-3-methyl-, 4-oxide (9CI) (CA INDEX NAME)




RN 165732-52-5 CAPLUS

CN 2-Quinoxalinecarboxamide, 3-methyl-N-[[4-[2-oxo-2-(1-piperidinyl)ethoxy]phenyl]methyl]-, 4-oxide (9CI) (CA INDEX NAME)




RN 165732-53-6 CAPLUS

CN 2-Quinoxalinecarboxamide, 3-methyl-N-[[4-[2-oxo-2-(1-piperidinyl)ethoxy]phenyl]methyl]- (9CI) (CA INDEX NAME)




RN 165732-54-7 CAPLUS

CN Acetic acid, 4-[[[3-methyl-4-oxido-2-quinoxaliny]carbonyl]amino]methyl]phenoxy]-, methyl ester (9CI) (CA INDEX NAME)




RN 165732-56-9 CAPLUS

CN 2-Quinoxalinecarboxamide, 3-methyl-N-[[2-[2-(4-morpholinyl)-2-oxoethoxy]phenyl]methyl]-, 4-oxide (9CI) (CA INDEX NAME)




RN 165732-57-0 CAPLUS

CN 2-Quinoxalinecarboxamide, 3-methyl-N-[[2-[2-(4-morpholinyl)-2-oxoethoxy]phenyl]methyl]- (9CI) (CA INDEX NAME)




RN 165732-58-1 CAPLUS

CN 2-Quinoxalinecarboxamide, N-[[4-[2-(2-methoxyethyl)amino]-2-oxoethoxy]phenyl]methyl]-3-methyl-, 4-oxide (9CI) (CA INDEX NAME)




RN 165732-59-2 CAPLUS

CN 2-Quinoxalinecarboxamide, 3-methyl-N-[[4-(phenylmethoxy)phenyl]methyl]-, 4-oxide (9CI) (CA INDEX NAME)




RN 165732-60-5 CAPLUS

CN 2-Quinoxalinecarboxamide, N-[[4-(dimethylamino)phenyl]methyl]-3-methyl-, 4-oxide (9CI) (CA INDEX NAME)




RN 165732-61-6 CAPLUS

CN Benzoic acid, 4-[[[3-methyl-4-oxido-2-quinoxaliny]carbonyl]amino]methyl]-, methyl ester (9CI) (CA INDEX NAME)




RN 165732-62-7 CAPLUS

CN 2-Quinoxalinecarboxamide, 3-methyl-N-[[2-(4-morpholinyl)-2-oxoethoxy]phenyl]methyl]-, 4-oxide (9CI) (CA INDEX NAME)




RN 165732-64-9 CAPLUS

CN 2-Quinoxalinecarboxamide, N-[[3,4-dimethoxyphenyl]methyl]-3-methyl-, 4-oxide (9CI) (CA INDEX NAME)




RN 165732-67-2 CAPLUS


CN 2-Quinoxalinecarboxamide, N-[[3-[[4-ethylphenyl]methoxy]phenyl]methyl]-3-methyl-, 4-oxide (9CI) (CA INDEX NAME)




RN 165732-68-3 CAPLUS
CN 2-Quinoxalinecarboxamide, N-([3-[2-(diethylamino)-2-oxoethoxy]phenyl]methyl)-3-methyl-, 4-oxide (9CI) (CA INDEX NAME)




RN 165732-69-4 CAPLUS
CN 2-Quinoxalinecarboxamide, N-([3-[2-(diethylamino)-2-oxoethoxy]phenyl]methyl)-3-methyl-, 4-oxide (9CI) (CA INDEX NAME)




RN 165732-70-7 CAPLUS
CN 2-Quinoxalinecarboxamide, N-([3-[2-(diethylamino)-2-oxoethoxy]phenyl]methyl)-3-methyl-, 4-oxide (9CI) (CA INDEX NAME)




RN 165732-71-8 CAPLUS
CN 2-Quinoxalinecarboxamide, N-([3-[2-(diethylamino)-2-oxoethoxy]phenyl]methyl)-3-methyl-, 4-oxide (9CI) (CA INDEX NAME)




RN 165732-72-9 CAPLUS
CN 2-Quinoxalinecarboxamide, N-([3-[2-(diethylamino)-2-oxoethoxy]phenyl]methyl)-3-methyl-, 4-oxide (9CI) (CA INDEX NAME)




RN 165732-73-0 CAPLUS
CN 2-Quinoxalinecarboxamide, N-([3-[2-(diethylamino)-2-oxoethoxy]phenyl]methyl)-3-methyl-, 4-oxide (9CI) (CA INDEX NAME)




RN 165732-74-1 CAPLUS
CN 2-Quinoxalinecarboxamide, N-([3-[2-(diethylamino)-2-oxoethoxy]phenyl]methyl)-3-methyl-, 4-oxide (9CI) (CA INDEX NAME)




RN 165732-75-2 CAPLUS
CN 2-Quinoxalinecarboxamide, N-([3-[2-(diethylamino)-2-oxoethoxy]phenyl]methyl)-3-methyl-, 4-oxide (9CI) (CA INDEX NAME)




RN 165732-76-3 CAPLUS
CN 2-Quinoxalinecarboxamide, N-([3-[2-(diethylamino)-2-oxoethoxy]phenyl]methyl)-3-methyl-, 4-oxide (9CI) (CA INDEX NAME)




RN 165732-77-4 CAPLUS
CN 2-Quinoxalinecarboxamide, N-([3-[2-(diethylamino)-2-oxoethoxy]phenyl]methyl)-3-methyl-, 4-oxide (9CI) (CA INDEX NAME)




RN 165732-78-5 CAPLUS
CN 2-Quinoxalinecarboxamide, N-([3-[2-(diethylamino)-2-oxoethoxy]phenyl]methyl)-3-methyl-, 4-oxide (9CI) (CA INDEX NAME)




RN 165732-80-9 CAPLUS
CN 2-Quinoxalinecarboxamide, N-([3-[2-(diethylamino)-2-oxoethoxy]phenyl]methyl)-3-methyl-, 4-oxide (9CI) (CA INDEX NAME)



RN 165732-81-0 CAPLUS
CN 2-Quinoxalinecarboxamide, N-([3-[2-(diethylamino)-2-oxoethoxy]phenyl]methyl)-3-methyl-, 4-oxide (9CI) (CA INDEX NAME)




RN 165732-83-2 CAPLUS
CN 2-Quinoxalinecarboxamide, N-([3-[2-(diethylamino)-2-oxoethoxy]phenyl]methyl)-3-methyl-, 4-oxide (9CI) (CA INDEX NAME)




● HCl


RN 165732-84-3 CAPLUS
CN 2-Quinoxalinecarboxamide, N-([3-[2-(diethylamino)-2-oxoethoxy]phenyl]methyl)-3-methyl-, 4-oxide (9CI) (CA INDEX NAME)




RN 165732-85-4 CAPLUS
CN 2-Quinoxalinecarboxamide, N-([3-[2-(diethylamino)-2-oxoethoxy]phenyl]methyl)-3-methyl-, 4-oxide (9CI) (CA INDEX NAME)




RN 165732-88-7 CAPLUS
CN 2-Quinoxalinecarboxamide, N,3-dimethyl-N-(3-phenyl-2-propenyl)- (9CI) (CA INDEX NAME)




RN 165732-89-8 CAPLUS
CN 2-Quinoxalinecarboxamide, 3-methyl-N-[2-methyl-3-(4-(1-methylethyl)phenyl)-2-propenyl]-, 4-oxide (9CI) (CA INDEX NAME)




RN 165733-00-6 CAPLUS
CN 2-Quinoxalinecarboxamide, N-[3-(4-methoxyphenyl)propyl]-3-phenyl- (9CI) (CA INDEX NAME)




RN 165733-01-7 CAPLUS
CN 2-Quinoxalinecarboxamide, N-[3-(4-methoxyphenyl)propyl]-, 4-oxide (9CI) (CA INDEX NAME)




RN 165733-07-3 CAPLUS
CN 2-Quinoxalinecarboxamide, 3-ethyl-N-[3-(4-methoxyphenyl)propyl]-, 4-oxide (9CI) (CA INDEX NAME)




RN 165733-08-4 CAPLUS
CN 2-Quinoxalinecarboxamide, N-[3-(4-methoxyphenyl)propyl]-3-(1-methylethyl)- (9CI) (CA INDEX NAME)




RN 165733-09-5 CAPLUS
CN 2-Quinoxalinecarboxamide, 3-ethyl-N-[3-(4-methoxyphenyl)propyl]- (9CI) (CA INDEX NAME)



RN 165733-10-8 CAPLUS
CN 2-Quinoxalinecarboxamide, N-[3-(4-methoxyphenyl)propyl]-3-phenyl-, 4-oxide (9CI) (CA INDEX NAME)




RN 165733-11-9 CAPLUS
CN 2-Quinoxalinecarboxamide, N-[3-(4-methoxyphenyl)propyl]- (9CI) (CA INDEX NAME)



RN 165733-15-3 CAPLUS
CN 2-Quinoxalinecarboxamide, 3-(4-morpholinylmethyl)-N-(3-phenyl-2-propenyl)-, ethanedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 165733-14-2
CMF C23 H24 N4 O2




CM 2


CRN 144-62-7
CMF C2 H2 O4




RN 165733-16-4 CAPLUS
CN 2-Quinoxalinecarboxamide, 3-(1H-imidazol-1-ylmethyl)-N-(3-phenyl-2-propenyl)- (9CI) (CA INDEX NAME)




RN 165733-93-7 CAPLUS
CN 2-Quinoxalinecarboxamide, N-[3-(2-methoxyphenyl)-2-butenyl]-3-methyl-, 4-oxide (9CI) (CA INDEX NAME)




RN 165733-94-8 CAPLUS
CN 2-Quinoxalinecarboxamide, N-[3-(3-methoxyphenyl)-2-butenyl]-3-methyl-, 4-oxide (9CI) (CA INDEX NAME)




RN 165733-95-9 CAPLUS
CN 2-Quinoxalinecarboxamide, 3-methyl-N-[3-(4-(trifluoromethyl)phenyl)-2-butenyl]-, 4-oxide (9CI) (CA INDEX NAME)




RN 165733-96-0 CAPLUS
CN 2-Quinoxalinecarboxamide, 3-methyl-N-[3-(3-(trifluoromethyl)phenyl)-2-butenyl]-, 4-oxide (9CI) (CA INDEX NAME)




RN 165733-97-1 CAPLUS
CN 2-Quinoxalinecarboxamide, 3-methyl-N-[3-(phenyl-2-butenyl)-, 4-oxide (9CI)
(CA INDEX NAME)




RN 165733-98-2 CAPLUS
CN 2-Quinoxalinecarboxamide, N-[3-[3-(acetylamino)phenyl]-2-butenyl]-3-methyl-, 4-oxide (9CI) (CA INDEX NAME)




RN 165734-02-1 CAPLUS
CN 2-Quinoxalinecarboxamide, N-[3-[2-(methoxyphenyl)-3-oxopropyl]-3-methyl-, 4-oxide (9CI) (CA INDEX NAME)




RN 165734-03-2 CAPLUS
CN 2-Quinoxalinecarboxamide, 3-methyl-N-[3-[2-(trifluoromethyl)phenyl]-2-butenyl]-, 4-oxide (9CI) (CA INDEX NAME)




RN 165734-04-3 CAPLUS
CN 2-Quinoxalinecarboxamide, N-[3-[4-(acetylamino)phenyl]-2-butenyl]-3-methyl-, 4-oxide (9CI) (CA INDEX NAME)




RN 165734-07-6 CAPLUS
CN 2-Quinoxalinecarboxamide, N-[3-[2-methoxyphenyl]-3-oxopropyl]-3-methyl-, 4-oxide (9CI) (CA INDEX NAME)




RN 165734-08-7 CAPLUS
CN 2-Quinoxalinecarboxamide, N-[3-(hydroxyimino)-3-(2-methoxyphenyl)propyl]-3-methyl-, 4-oxide (9CI) (CA INDEX NAME)




RN 165734-10-1 CAPLUS
CN 2-Quinoxalinecarboxamide, 3-methyl-N-[3-[4-[[1-oxo-3-phenyl-2-propenyl]amino]phenyl]-2-butenyl]-, 4-oxide (9CI) (CA INDEX NAME)




RN 165734-18-9 CAPLUS
CN 2-Quinoxalinecarboxamide, N-[3-[3-(hydroxyphenyl)-2-butenyl]-3-methyl-, 4-oxide (9CI) (CA INDEX NAME)




RN 165734-19-0 CAPLUS
CN 2-Quinoxalinecarboxamide, N-[3-[2-(4-morpholinyl)-2-oxoethoxy]phenyl]-2-butenyl]-3-methyl-, 4-oxide (9CI) (CA INDEX NAME)




RN 165734-20-3 CAPLUS
CN 2-Quinoxalinecarboxamide, N-[3-[3-[2-(diethylamino)-2-oxoethoxy]phenyl]-2-butenyl]-3-methyl-, 4-oxide (9CI) (CA INDEX NAME)




RN 165734-21-4 CAPLUS
CN 2-Quinoxalinecarboxamide, 3-methyl-N-[3-[2-methyl-2-propenyl]oxy]phenyl]-2-butenyl]-, 4-oxide (9CI) (CA INDEX NAME)




RN 165734-26-9 CAPLUS
CN 2-Quinoxalinecarboxamide, N-[3-[3-(methoxymethoxy)phenyl]-2-butenyl]-3-methyl-, 4-oxide (9CI) (CA INDEX NAME)




RN 165734-71-4 CAPLUS
CN 2-Quinoxalinecarboxamide, N-[3-[2-(2,3-dihydro-1-oxo-1H-inden-2-yl)methyl]-3-methyl-, 4-oxide (9CI) (CA INDEX NAME)




RN 165734-78-1 CAPLUS
CN 2-Quinoxalinecarboxamide, N-[3-[2-(2,3-dihydro-1-oxo-1H-inden-2-yl)methyl]-3-methyl-, 4-oxide (9CI) (CA INDEX NAME)




RN 165734-79-2 CAPLUS
CN 2-Quinoxalinecarboxamide, N-[3-[2-(2,3-dihydro-1-oxo-1H-inden-2-yl)methyl]-3-methyl-, 4-oxide (9CI) (CA INDEX NAME)



RN 165737-61-1 CAPLUS
CN 2-Quinoxalinecarboxamide, 3-methyl-N-((4-(2-(4-morpholinylethoxy)phenyl)methyl)-(9CI) (CA INDEX NAME)



IT 165733-19-7P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of quinoxaline-2-carboxamides as antidiabetics)
RN 165733-19-7 CAPLUS
CN 2-Quinoxalinecarboxamide, N-((3-bromo-4-hydroxyphenyl)methyl)-3-methyl-(9CI) (CA INDEX NAME)




L5 ANSWER 168 OF 283 CAPLUS COPYRIGHT 2006 ACS ON STN
ACCESSION NUMBER: 1995:257705 CAPLUS
DOCUMENT NUMBER: 122:31342
TITLE: Preparation of anilide derivatives as tumor multidrug resistance inhibitors
INVENTOR(S): Dumaitre, Bernard Andre; Dodic, Nerina; Daugan, Alain
PATENT ASSIGNEE(S): Claude Marie; Pianetti, Pascal Maurice Charle
SOURCE: Laboratoires Glaxo S.A., Fr.
PCT Int. Appl., 82 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9401408	A1	19940120	WO 1993-EP1802	19930708
W: AT, AU, BB, BG, BR, BY, CA, CH, CZ, DE, DK, ES, FI, GB, HU, JP, KR, KR, KZ, LK, LU, MG, MN, MM, NL, NO, NZ, PL, PT, RD, RU, SD, SE, SK, UA, US, VN				


RN: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG
AU 9345671 A1 19940131 AU 1993-45671 19930708
EP 649410 A1 19950426 EP 1993-915865 19930708
EP 649410 B1 19970502
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE
JP 06508974 T2 19960924 JP 1993-502977 19930708
AT 152443 E 19970515 AT 1993-915865 19930708
ES 2103479 T3 19970916 ES 1993-915865 19930708
US 5663179 A 19970902 US 1994-356323 19941229
GB 1993-14667 A 19920710
GB 1992-14668 A 19920710
GB 1992-14675 A 19920710
WO 1993-EP1802 A 19930708

OTHER SOURCE(S): MARPAT 122:31342
OI




AB Title compds. [1; R = ZCONH2IABCH2; A = O, S, bond, NH, etc.; B = (hydroxy)alkylene; R1 = H, alkyl; R2 = H, halo, alkyl, alkoxy, alkylthio; R3, R6 = H, alkoxy; R4 = H, alkyl, alkoxy; R5 = H; R1R5 = CH2, CH2CH2; Z = heterocyclyl, (substituted) 3-(PhCO)C6H4, etc.; Z1 = (substituted) 1,3- or 1,4-phenylene; m = 1 or 2] were prepared. Thus, 2-quinoxalinecarboxylic acid was condensed with 4-[3-(1,2,3,4-tetrahydro-6,7-dimethoxy-2-isoquinolinyl)propyl]benzenesamine to give N-[4-[3-(1,2,3,4-tetrahydro-6,7-dimethoxy-2-isoquinolinyl)propyl]phenyl]-2-quinoxalinecarboxamide. I had EC50 of <1 μM for reversal of multidrug resistance of CHRC5 cells in vitro.


IT 159780-66-2P 159780-78-6P 159780-82-2P
159780-83-3P 159780-84-4P 159780-85-5P
159780-86-6P 159780-87-7P 159781-06-3P
159781-07-4P 159781-13-2P 159804-79-2P
159804-81-6P 159804-82-7P 159839-01-7P
159839-02-8P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of, as multidrug resistance inhibitor)
RN 159780-66-2 CAPLUS
CN 2-Quinoxalinecarboxamide, N-[4-[3-(3,4-dihydro-6,7-dimethoxy-2(1H)-isoquinolinyl)propyl]phenyl]- (9CI) (CA INDEX NAME)




RN 159780-78-6 CAPLUS
CN 2-Quinoxalinecarboxamide, N-[4-[3-(3,4-dihydro-6,7-dimethoxy-2(1H)-isoquinolinyl)butyl]phenyl]-6,7-dimethyl- (9CI) (CA INDEX NAME)




RN 159780-82-2 CAPLUS
CN 2-Quinoxalinecarboxamide, N-[4-[4-((3,4-dimethoxyphenyl)methyl)methylaminobutyl]phenyl]- (9CI) (CA INDEX NAME)




RN 159780-83-3 CAPLUS
CN 2-Quinoxalinecarboxamide, N-[4-[4-((3,4-dihydro-6,7-dimethoxy-2(1H)-isoquinolinyl)butyl]phenyl]- (9CI) (CA INDEX NAME)




RN 159780-84-4 CAPLUS
CN 2-Quinoxalinecarboxamide, N-[4-[3-(3,4-dihydro-6,7-dimethoxy-2(1H)-isoquinolinyl)propoxy]phenyl]- (9CI) (CA INDEX NAME)




RN 159780-85-5 CAPLUS
CN 2-Quinoxalinecarboxamide, N-[4-[3-(3,4-dihydro-6,7-dimethoxy-2(1H)-isoquinolinyl)propoxy]phenyl]-3-methoxy-6,7-dimethyl- (9CI) (CA INDEX NAME)




RN 159780-86-6 CAPLUS
CN 2-Quinoxalinecarboxamide, N-[4-[3-(3,4-dihydro-6,7-dimethoxy-2(1H)-isoquinolinyl)propyl]phenyl]-3-methoxy-6,7-dimethyl- (9CI) (CA INDEX NAME)




RN 159780-87-7 CAPLUS
CN 2-Quinoxalinecarboxamide, N-[4-[3-(3,4-dihydro-6,7-dimethoxy-2(1H)-isoquinolinyl)butyl]phenyl]-3-methyl- (9CI) (CA INDEX NAME)




RN 159781-06-3 CAPLUS
CN 2-Quinoxalinecarboxamide, N-[4-[4-((3,4-dihydro-6,7-dimethoxy-2(1H)-isoquinolinyl)butoxy]phenyl]- (9CI) (CA INDEX NAME)




RN 159781-07-4 CAPLUS
CN 2-Quinoxalinecarboxamide, N-[4-[4-((3,4-dihydro-6,7-dimethoxy-2(1H)-isoquinolinyl)butoxy]phenyl]-3-ethoxy- (9CI) (CA INDEX NAME)



RN 159781-13-2 CAPLUS
CN 2-Quinoxalinecarboxamide, N-[4-{3-(3,4-dihydro-6,7-dimethoxy-2(1H)-isoquinolinyl)-2-hydroxypropoxy}phenyl]- (9CI) (CA INDEX NAME)




RN 159804-79-2 CAPLUS
CN 2-Quinoxalinecarboxamide, N-[4-{3-(3,4-dihydro-6,7-dimethoxy-2(1H)-isoquinolinyl)propoxy}phenyl]-6(or 7)-methyl- (9CI) (CA INDEX NAME)




D1-Me

RN 159804-81-6 CAPLUS
CN 2-Quinoxalinecarboxamide, N-[4-{3-(3,4-dihydro-6,7-dimethoxy-2(1H)-isoquinolinyl)propoxy}phenyl]-6(or 7)-methoxy- (9CI) (CA INDEX NAME)




D1-O-Me

RN 159804-82-7 CAPLUS
CN 2-Quinoxalinecarboxamide, N-[4-{3-(3,4-dihydro-6,7-dimethoxy-2(1H)-isoquinolinyl)butoxy}phenyl]-6(or 7)-methyl- (9CI) (CA INDEX NAME)




D1-Me

RN 159839-01-7 CAPLUS
CN 2-Quinoxalinecarboxamide, N-[4-{3-(3,4-dihydro-6,7-dimethoxy-2(1H)-isoquinolinyl)propyl}phenyl]-6(or 7)-methyl- (9CI) (CA INDEX NAME)




D1-Me

RN 159839-02-8 CAPLUS
CN 2-Quinoxalinecarboxamide, N-[4-{3-(3,4-dihydro-6,7-dimethoxy-2(1H)-isoquinolinyl)butyl}phenyl]-6(or 7)-methoxy- (9CI) (CA INDEX NAME)



D1-O-Me


L5 ANSWER 169 OF 283 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 1994:605305 CAPLUS
DOCUMENT NUMBER: 121:205305
TITLE: Curtius degradation of quinoxaline acid azides
AUTHOR(S): Ammar, Y.A.; Mohamed, Y.A.; El-Sharief, A.M.; Zahran, M.A.
CORPORATE SOURCE: Fac. Sci., Al-Azhar Univ., Cairo, Egypt
SOURCE: Egyptian Journal of Chemistry (1992), Volume Date 1991, 34(4), 361-9
CODEN: EGJCAJ; ISSN: 0367-0422
DOCUMENT TYPE: Journal
LANGUAGE: English
OTHER SOURCE(S): CASREACT 121:205305
GI




AB Curtius rearrangement of mono acid azides(I; R=H,Me) proceeded via an isocyanate intermediate followed by cyclization to give the anhydride derivs.(II; R as above). Condensation of I with primary amines gave urea derivs, as intermediates which cyclize to give alloxazine derivs.(III; R=H,Me; R1=cyclohexyl, Ph, p-OMeC6H4, p-MeC6H4). Reactions of I with secondary amines produced the urea derivs. (IV; R=H,Me; R1= piperidinyl, morpholino). Treatment of I with alics. caused addition on the isocyanate group to give IV (R=H,Me; R1=OMe, OEt). The reactions of I with amines or alics. proceed via Curtius rearrangement.

IT 37648-58-1P 37648-59-2P 149976-94-3P
149977-03-7P 157950-48-6P 157950-51-1P
157950-52-2P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)


RN 37648-58-1 CAPLUS
CN 2-Quinoxalinecarboxylic acid, 3-[(phenylamino)carbonyl]- (9CI) (CA INDEX NAME)




RN 37648-59-2 CAPLUS
CN 2,3-Quinoxalinedicarboxamide, N,N'-diphenyl- (9CI) (CA INDEX NAME)




RN 149976-94-3 CAPLUS
CN 2-Quinoxalinecarboxylic acid, 6,7-dimethyl-3-[(phenylamino)carbonyl]- (9CI) (CA INDEX NAME)





RN 149977-03-7 CAPLUS
CN 2-Quinoxalinecarboxylic acid, 3-[[[(4-methoxyphenyl)amino]carbonyl]-6,7-dimethyl- (9CI) (CA INDEX NAME)




RN 157950-48-6 CAPLUS
CN 2-Quinoxalinecarboxylic acid, 3-[[[(4-methoxyphenyl)amino]carbonyl]- (9CI) (CA INDEX NAME)




RN 157950-51-1 CAPLUS
CN 2,3-Quinoxalinedicarboxamide, N,N'-dicyclohexyl- (9CI) (CA INDEX NAME)




RN 157950-52-2 CAPLUS
CN 2,3-Quinoxalinedicarboxamide, N,N'-bis(4-chlorophenyl)- (9CI) (CA INDEX NAME)



LS ANSWER 170 OF 283 CAPLUS COPYRIGHT 2006 ACS on STN
 ACCESSION NUMBER: 1994:298496 CAPLUS
 DOCUMENT NUMBER: 120:298496
 TITLE: A facile, convenient and selective homolytic carbonylation of heteroaromatic bases
 AUTHOR(S): Minisci, Francesco
 CORPORATE SOURCE: Dip. Chim., Politec., Milano, 20133, Italy
 SOURCE: Heterocycles (1993), 36(12), 2687-96
 CODEN: HETCYA; ISSN: 0365-5414
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 OTHER SOURCE(S): CASREACT 120:298496
 AB Oxidative decarboxylation of oxalic acid monoamides provides carbonyl radicals, which are useful for the selective carbonylation of protonated heteroarom. bases. This reaction represents the first general and selective method for the N-alkyl or N-arylcabonylation of heterosarom. bases. Compared to alkoxycarbonylation, this reaction is much more effective and selective, due to more favorable polar and enthalpic effects. The importance of steric effects is also emphasized.
 IT 155129-19-2P 155129-19-4P
 RL: SPN (Synthetic preparation); PREP (Preparation) (preparation of)
 RN 155129-17-2 CAPLUS
 CN 2-Quinoxalinecarboxamide, N-(4-chlorophenyl)- (9CI) (CA INDEX NAME)



RN 155129-19-4 CAPLUS
 CN 2-Quinoxalinecarboxamide, N-cyclohexyl- (9CI) (CA INDEX NAME)




LS ANSWER 171 OF 283 CAPLUS COPYRIGHT 2006 ACS on STN
 ACCESSION NUMBER: 1994:290102 CAPLUS
 DOCUMENT NUMBER: 120:290102
 TITLE: Peptide derivatives for thrombin receptor antagonists

INVENTOR(S): Scarborough, Robert M.
 PATENT ASSIGNEE(S): Cor Therapeutics, Inc., USA
 SOURCE: PCT Int. Appl., 35 pp.
 CODEN: P1XXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
MO 9403479	A1	19940217	MO 1993-US6428	19930708
W: AT, AU, BB, BG, BR, BY, CA, CH, CZ, DE, DK, ES, FI, GB, HU, JP, KP, KR, KZ, LK, LU, MG, MN, MW, NL, NO, NZ, PL, PT, RO, RU, SD, SE, SK, UA, US, VN				
RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CP, CO, CI, CN, CA, CN, GB, ML, MR, NE, SN, TD, TO				
IL 106197	A1	19991130	IL 1993-106197	19930630
EP 656008	A1	19950607	EP 1993-917028	19930708
EP 656008	B1	20000315		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
JP 07506115	T2	19950706	JP 1993-505310	19930708
AU 656022	B2	19960627	AU 1993-46685	19930708
AU 934685	A1	19940303		
AT 190625	E	20000415	AT 1993-917028	19930708
CA 2140543	C	20010410	CA 1993-2140543	19930708
US 5866681	A	19990202	US 1995-407468	19950320
PRIORITY APPL. INFO.:				
US 1992-922340 A2 19920710				
US 1993-80748 A2 19930628				
MO 1993-US6428 W 19930708				

OTHER SOURCE(S): MARPAT 120:290102
 AB Peptide derive. (Markush included) serving as thrombin receptor antagonists are disclosed, which bear specificity for the cellular thrombin receptor without interfering with the catalytic activities of thrombin. Synthesis of (N,N-di-n-pentyl-Phe)-Cha-Cha-Arg-Lys-NH₂ (Cha is cyclohexylalanine) and of other peptides of the invention is described. IC50 values for 60 compds. are included.
 IT 155147-20-7
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); BIOL (Biological study) (thrombin receptor antagonist activity of)
 RN 155147-28-7 CAPLUS
 CN L-Lysineamide, 3-cyclohexyl-N-(2-quinoxalinylicarbonyl)-L-alanyl-3-cyclohexyl-L-alanyl-L-arginyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.




LS ANSWER 172 OF 283 CAPLUS COPYRIGHT 2006 ACS on STN
 ACCESSION NUMBER: 1994:191634 CAPLUS
 DOCUMENT NUMBER: 120:191634
 TITLE: The reactions of benzofuroxan with carbonyl compounds on the surface of silica catalysts
 AUTHOR(S): Takabetske, Tohru; Hasegawa, Yumiko; Hasegawa, Minoru
 CORPORATE SOURCE: Coll. Pharm., Nihon Univ., Funabashi, 274, Japan
 SOURCE: Journal of Heterocyclic Chemistry (1993), 30(6), 1477-9
 CODEN: JHTCAD; ISSN: 0022-152X
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 OTHER SOURCE(S): CASREACT 120:191634
 AB The cyclocondensations of benzofuroxan with carbonyl compds. were smoothly and efficiently carried out by the adsorption of the components on the surface of silica gel or a mol. sieve to form a 2,3-disubstituted quinoxaline 1,4-dioxide. When the reactions using a mol. sieve 3A (powder) were carried out at 90°, the actual reaction times were reduced to 0.5-2 h. Although Duerckheimer has reported the isolation of only the 7-substituted quinoxaline 1,4-dioxide when 5-methoxybenzofuroxan was allowed to react with Et acetoacetate, it produced only the 6-methoxy isomer as the reaction product by the authors' method.
 IT 23433-48-9P 104705-39-7P 111888-44-9P
 RL: SPN (Synthetic preparation); PREP (Preparation) (preparation of)
 RN 23433-48-9 CAPLUS
 CN 2-Quinoxalinecarboxamide, N-(2-methoxyphenyl)-3-methyl-, 1,4-dioxide (9CI) (CA INDEX NAME)




RN 104705-39-7 CAPLUS
 CN 2-Quinoxalinecarboxamide, N,3-diphenyl-, 1,4-dioxide (9CI) (CA INDEX NAME)




RN 111888-44-9 CAPLUS
 CN 2-Quinoxalinecarboxamide, N-(4-methoxyphenyl)-3-methyl-, 1,4-dioxide (9CI) (CA INDEX NAME)



RN 111888-45-0 CAPLUS
 CN 2-Quinoxalinecarboxamide, N-(4-chlorophenyl)-3-methyl-, 1,4-dioxide (9CI) (CA INDEX NAME)



RN 111888-46-1 CAPLUS
 CN 2-Quinoxalinecarboxamide, 3-methyl-N-(2-methylphenyl)-, 1,4-dioxide (9CI) (CA INDEX NAME)




LS ANSWER 173 OF 283 CAPLUS COPYRIGHT 2006 ACS on STN
 ACCESSION NUMBER: 1994:186611 CAPLUS
 DOCUMENT NUMBER: 120:186611
 TITLE: Fluorescent Substrates for Potential Use in Enzyme-Linked Immunosorbent Assay of Membrane-Bound Nucleic Acids
 AUTHOR(S): Fujita, Satoshi; Momiya, Masayoshi; Kondo, Yasumitsu; Kagiya, Naoto; Hori, Samuel H.; Toru, Takeshi
 CORPORATE SOURCE: Aisin Cosmos RD Co. Ltd., Sapporo, 060, Japan
 SOURCE: Analytical Chemistry (1994), 66(8), 1347-53
 CODEN: ANCHAM; ISSN: 0003-2700
 DOCUMENT TYPE: Journal
 LANGUAGE: English

AB A number of phosphorylated fluorochromes were synthesized and tested for the alkaline phosphatase-linked fluorescence assay of membrane-bound nucleic acids. 3-Hydroxy-N,2'-biphenyl-2-naphthalenecarboxamide phosphate ester (HBNP) was found to be the most suitable for the assay. Nonfluorescent HBNP is hydrolyzed by phospholipase bound to the probe DNA to the highly fluorescent 3-hydroxy-N,2'-biphenyl-2-naphthalenecarboxamide (HBN). HBN is insol. enough in aqueous medium to precipitate on the nylon membrane. Spots

containing as little as 5 fg of λ DNA can be successfully detected on the membrane with HENP.

IT 153696-03-4P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (preparation and reaction with alkaline phosphatase in ELISA for DNA and fluorescence of product of, structure in relation to)

RN 153696-03-4 CAPLUS
 CN 2-Quinoxalinecarboxamide, N-(3,5-dimethylphenyl)-3,4-dihydro-3-oxo- (9CI)
 (CA INDEX NAME)




L5 ANSWER 174 OF 283 CAPLUS COPYRIGHT 2006 ACS ON STN
 ACCESSION NUMBER: 1993:580281 CAPLUS
 DOCUMENT NUMBER: 119:160219
 TITLE: Spectral characteristics of the reaction products of 5-phenyl-2,3,4-furantrione with o-diamines
 AUTHOR(S): Rashed, Nagwa; Mousaad, Ahmed; Mousa, Adel; El Ashry, El Sayed H.
 CORPORATE SOURCE: Fac. Sci., Alexandria Univ., Alexandria, Egypt
 SOURCE: Spectroscopy Letters (1993), 26(6), 975-95
 CODEN: SPLEBX; ISSN: 0038-7010
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *


AB The ¹H and ¹³C NMR and mass spectra of 2-(2-amino-4,5-dimethylphenylcarbamoyl)-3-(hydroxyphenylmethyl)-6,7-dimethylquinoxaline, 3-(hydroxyphenylmethyl)-6,7-dimethylquinoxalin-2-carboxylic acid, 3-(hydroxyphenylmethyl)-6,7-dimethylquinoxalin-2-carboxylic acid phenylhydrazide, 3-[2-hydroxy-2-phenyl-1-(phenylhydrazono)ethyl]-6,7-dimethyl-2-[1H]-quinoxalinone, 2,3-dihydro-6,7-dimethyl-3-phenylhydrazono-2-phenylfuro[2,3-b]quinoxaline, 3-(hydroxyphenylmethyl)-6,7-dimethyl-1-phenylflavazole, and 3-(acetoxypheylmethyl)-6,7-dimethyl-1-phenylflavazole (I-VII, resp., R = Me) have been studied.

IT 150240-24-7P
 RL: PREP (Properties); SPN (Synthetic preparation); PREP (Preparation)
 (preparation and spectra of)

RN 150240-24-7 CAPLUS
 CN 2-Quinoxalinecarboxamide, N-(2-amino-4,5-dimethylphenyl)-3-(hydroxyphenylmethyl)-6,7-dimethyl- (9CI) (CA INDEX NAME)



L5 ANSWER 175 OF 283 CAPLUS COPYRIGHT 2006 ACS ON STN
 ACCESSION NUMBER: 1993:560219 CAPLUS
 DOCUMENT NUMBER: 119:160219
 TITLE: A facile synthesis and reactions of 6,7-dimethylquinoxaline-2,3-dicarboximides
 AUTHOR(S): Mohamed, Yehia A.; Ammar, Youery A.; El-Sharief, Ahmed M. S.; Zahran, Medhat A.
 CORPORATE SOURCE: Fac. Sci., Al-Azhar Univ., Naser, Egypt
 SOURCE: Afinidad (1993), 50(444), 123-6
 CODEN: AFINAE; ISSN: 0001-9704
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 OTHER SOURCE(S): CASREACT 119:160219
 GI




AB The cyclocondensation of 4,5-Me₂C₆H₂(NH₂)₂ with Na dihydroxytartarate in H₂O gave 68% 6,7-dimethyl-2,3-quinoxalinedicarboxylic acid, which was dehydrated in refluxing Ac₂O to give the anhydride I. Treatment of I with 4-RC₆H₄NH₂ (R = H, Me, MeO, Br, Cl) gave the amides II and treatment with R₁OH (R₁ = Me, Et, ClCH₂CH₂, Me₂CH, Ph, 2-MeC₆H₄) gave the esters III. II cyclized in refluxing Ac₂O to give dicarboximides IV. IV (R = H, Me, MeO) cyclized with H₂NNH₂ to give dioxopyridazinoquinoxaline V. A number of other reactions of 6,7-dimethylquinoxaline-2,3-dicarboxylic acid and -dicarboximides are also reported.


IT 149976-94-3P 149977-02-6P 149977-03-7P

149977-04-8P 149977-05-9P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (preparation and cyclodehydration of)


RN 149976-94-3 CAPLUS
 CN 2-Quinoxalinecarboxylic acid, 6,7-dimethyl-3-[(phenylamino)carbonyl]- (9CI) (CA INDEX NAME)




RN 149977-02-6 CAPLUS
 CN 2-Quinoxalinecarboxylic acid, 6,7-dimethyl-3-[[[4-methylphenyl]amino]carbonyl]- (9CI) (CA INDEX NAME)




RN 149977-03-7 CAPLUS
 CN 2-Quinoxalinecarboxylic acid, 3-[[[4-methoxyphenyl]amino]carbonyl]-6,7-dimethyl- (9CI) (CA INDEX NAME)



RN 149977-04-8 CAPLUS
 CN 2-Quinoxalinecarboxylic acid, 3-[[[4-bromophenyl]amino]carbonyl]-6,7-dimethyl- (9CI) (CA INDEX NAME)




RN 149977-05-9 CAPLUS
 CN 2-Quinoxalinecarboxylic acid, 3-[[[4-chlorophenyl]amino]carbonyl]-6,7-dimethyl- (9CI) (CA INDEX NAME)





IT 149976-95-4P 149976-97-6P 149977-06-0P
 149977-07-1P 149977-08-2P 149977-14-0P
 149977-15-1P 149977-16-2P 149977-17-3P
 149977-18-4P 149977-19-5P 149977-20-6P
 149977-21-9P 149977-22-0P
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (preparation of)


RN 149976-95-4 CAPLUS
 CN 2-Quinoxalinecarboxamide, N-cyclohexyl-6,7-dimethyl- (9CI) (CA INDEX NAME)




RN 149976-97-6 CAPLUS
 CN 2,3-Quinoxalinedicarboxamide, N-cyclohexyl-N'-(4-methoxyphenyl)-6,7-dimethyl- (9CI) (CA INDEX NAME)




RN 149977-06-0 CAPLUS
 CN 2-Quinoxalinecarboxamide, 6,7-dimethyl-N-(4-methylphenyl)- (9CI) (CA INDEX NAME)




RN 149977-07-1 CAPLUS
 CN 2-Quinoxalinecarboxamide, N-(4-methoxyphenyl)-6,7-dimethyl- (9CI) (CA INDEX NAME)




RN 149977-08-2 CAPLUS
CN 2-Quinoxalinedicarboxamide, N-(4-chlorophenyl)-6,7-dimethyl- (9CI) (CA INDEX NAME)




RN 149977-14-0 CAPLUS
CN 2,3-Quinoxalinedicarboxamide, N-(4-methoxyphenyl)-6,7-dimethyl-N'-phenyl- (9CI) (CA INDEX NAME)




RN 149977-15-1 CAPLUS
CN 2,3-Quinoxalinedicarboxamide, N-(4-methoxyphenyl)-6,7-dimethyl-N'-(4-methylphenyl)- (9CI) (CA INDEX NAME)





RN 149977-16-2 CAPLUS
CN 2-Quinoxalinedicarboxamide, N-(4-methoxyphenyl)-6,7-dimethyl-3-(1-piperidinylcarbonyl)- (9CI) (CA INDEX NAME)




RN 149977-17-3 CAPLUS
CN 2-Quinoxalinedicarboxamide, N-(4-methoxyphenyl)-6,7-dimethyl-3-(4-morpholinylcarbonyl)- (9CI) (CA INDEX NAME)




RN 149977-18-4 CAPLUS
CN 2,3-Quinoxalinedicarboxamide, N-(4-chlorophenyl)-N'-cyclohexyl-6,7-dimethyl- (9CI) (CA INDEX NAME)




RN 149977-19-5 CAPLUS
CN 2,3-Quinoxalinedicarboxamide, N-(4-chlorophenyl)-6,7-dimethyl-N'-(4-methylphenyl)- (9CI) (CA INDEX NAME)




RN 149977-20-8 CAPLUS
CN 2,3-Quinoxalinedicarboxamide, N-(4-chlorophenyl)-N'-(4-methoxyphenyl)-6,7-dimethyl- (9CI) (CA INDEX NAME)



RN 149977-21-9 CAPLUS
CN 2-Quinoxalinedicarboxamide, N-(4-chlorophenyl)-6,7-dimethyl-3-(1-piperidinylcarbonyl)- (9CI) (CA INDEX NAME)




RN 149977-22-0 CAPLUS
CN 2-Quinoxalinedicarboxamide, N-(4-chlorophenyl)-6,7-dimethyl-3-(4-morpholinylcarbonyl)- (9CI) (CA INDEX NAME)



L5 ANSWER 176 OF 283 CAPLUS COPYRIGHT 2006 ACS ON STN
ACCESSION NUMBER: 1993:101927 CAPLUS
DOCUMENT NUMBER: 118:101927
TITLE: Preparation of N-arylsulfonyl-3,4-dihydro-3-oxo-
quinoxaline-2-carboxamides and analogs as
neuroprotectants
INVENTOR(S): Hays, Sheryl Jeanne; Johnson, Graham; Lescosky,
Leonard Joseph; Malone, Thomas Charles; Novak, Perry
Michael
PATENT ASSIGNEE(S): Warner-Lambert Co., USA
SOURCE: PCT Int. Appl., 104 pp.
CODEN: PIKX02
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9211245	A1	19920709	WO 1991-US8586	19911122
W: AU, CA, FI, JP, KR, NO, US				
RM: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LU, NL, SE				
AU 9190493	A1	19920722	AU 1991-90493	19911122
ZA 9110018	A	19930621	ZA 1991-10018	19911219


PRIORITY APPLN. INFO.: US 1990-631139 A2 19901220
WO 1991-US8586 A 19911122
OTHER SOURCE(S): MARPAT 118:101927
CI




AB Title compds. (I; R1,R2,R11,R12 = H, alkyl, halo, CF3, cyano, etc.; X = NR6SO2R3, NR6R3, NR6OR3, etc.; R3 = H, alkyl, alkenyl, aryl, etc.; R6 = H, alkyl; Y = O, S) were prepared. Thus, 4,6-dichloro-2-nitroaniline was condensed with ClCOCH2CO2Et and the product cyclized to give, after PCl3 treatment of the N-oxide and saponification quinoxalinecarboxylate II (R1 =

Cl, R2 = H (III; X = OH) which was condensed with PhSO2NH2 to give III (X = NHSO2Ph). II (R1 = H, R2 = Cl, X = NHSO2R3,R3 = 1H-inden-5-yl) gave 100% inhibition of glycine binding at NMDA receptors at 5.00 x 10⁻⁵ M in vitro.


IT 143948-06-5P 143948-09-8P 143948-16-7P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of, as neuroprotectant)
RN 143948-06-5 CAPLUS
CN 2-Quinoxalinedicarboxamide, N-benzoyl-6,7-dichloro-3,4-dihydro-3-oxo- (9CI) (CA INDEX NAME)




RN 143948-09-8 CAPLUS
CN Benzeneacetic acid, α-[[[6,7-dichloro-3,4-dihydro-3-oxo-2-quinoxaliny]carbonyl]amino]- (9CI) (CA INDEX NAME)



RN 143948-16-7 CAPLUS
CN 2-Quinoxalinedicarboxamide, 6,7-dichloro-3,4-dihydro-3-oxo-N-(phenylmethyl)- (9CI) (CA INDEX NAME)




L5 ANSWER 177 OF 283 CAPLUS COPYRIGHT 2006 ACS on STN
 ACCESSION NUMBER: 1992:571375 CAPLUS
 DOCUMENT NUMBER: 117:171375
 TITLE: Synthesis and reactions of 6-methylquinoxaline-2,3-dicarboxylic acid
 AUTHOR(S): Ammar, Y. A.
 CORPORATE SOURCE: Fac. Sci., Al-Azhar Univ., Nasr, Egypt
 SOURCE: Delta Journal of Science (1990), 14(2), 528-39
 CODEN: DJSCES; ISSN: 1012-5965
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 GI




AB Condensation of 6-methylquinoxaline-2,3-dicarboxylic anhydride (I, X = O) with RNH2 (R = Ph, 4-MeC6H4, 4-MeOC6H4, 4-ClC6H4, 4-PhNHCO6H4) under different conditions gave quinoxalinecarboxamides II (R1 = H, CO2H). Cyclodehydration of II (R1 = CO2H) with acetic anhydride furnished I (X = NH) (III). Reactions of selected examples of III with sodium hydroxide, sodium ethoxide, amines, and hydrazine hydrate yielded II (R1 = CO2H), II (R = Ph, R1 = CO2Et), quinoxalines IV (R2 = CONHR4, R3 = COR5, R4 = H, OMe, R5 = cyclohexylamino, 4-MeOC6H4NH, NMe2, 4-morpholinyl, etc.; R2R3 = CONHNHCO), resp. Reaction of II (X = O) with alcs. gave the corresponding half esters.


IT 143663-25-6P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (preparation and cyclodehydration of)
 RN 143663-25-6 CAPLUS
 CN 2-Quinoxalinecarboxylic acid, 6-methyl-3-[[[4-(phenylamino)phenyl]amino]carbonyl]- (9CI) (CA INDEX NAME)




IT 143663-17-6P 143663-18-7P 143663-19-8P
 143663-20-1P 143663-30-3P 143663-31-4P
 143663-32-5P 143663-33-6P 143663-34-7P
 143663-35-8P 143663-36-9P
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (preparation of)
 RN 143663-17-6 CAPLUS
 CN 2-Quinoxalinecarboxamide, 7-methyl-N-phenyl- (9CI) (CA INDEX NAME)




RN 143663-18-7 CAPLUS
 CN 2-Quinoxalinecarboxamide, 7-methyl-N-(4-methylphenyl)- (9CI) (CA INDEX NAME)




RN 143663-19-8 CAPLUS
 CN 2-Quinoxalinecarboxamide, N-(4-methoxyphenyl)-7-methyl- (9CI) (CA INDEX NAME)




RN 143663-20-1 CAPLUS
 CN 2-Quinoxalinecarboxamide, N-(4-chlorophenyl)-7-methyl- (9CI) (CA INDEX NAME)




RN 143663-30-3 CAPLUS
 CN 2-Quinoxalinecarboxylic acid, 6-methyl-3-[(phenylamino)carbonyl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 143663-31-4 CAPLUS
 CN 2,3-Quinoxalinedicarboxamide, N3-cyclohexyl-6-methyl-N2-phenyl- (9CI) (CA INDEX NAME)




RN 143663-32-5 CAPLUS
 CN 2,3-Quinoxalinedicarboxamide, N3-(4-methoxyphenyl)-6-methyl-N2-phenyl- (9CI) (CA INDEX NAME)




RN 143663-33-6 CAPLUS
 CN 2,3-Quinoxalinedicarboxamide, N3,N3,6-trimethyl-N2-phenyl- (9CI) (CA INDEX NAME)




RN 143663-34-7 CAPLUS
 CN 2-Quinoxalinecarboxamide, 6-methyl-3-(4-morpholinylcarbonyl)-N-phenyl- (9CI) (CA INDEX NAME)




RN 143663-35-8 CAPLUS
 CN 2,3-Quinoxalinedicarboxamide, N2-(4-methoxyphenyl)-6-methyl-N3-(4-methylphenyl)- (9CI) (CA INDEX NAME)



RN 143663-36-9 CAPLUS
 CN 2,3-Quinoxalinedicarboxamide, N3-(4-chlorophenyl)-N2-(4-methoxyphenyl)-6-methyl- (9CI) (CA INDEX NAME)




IT 143663-21-2P 143663-22-3P 143663-23-4P
 143663-24-5P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (preparation, decarboxylation, and cyclodehydration of)
 RN 143663-21-2 CAPLUS
 CN 2-Quinoxalinecarboxylic acid, 6-methyl-3-[(phenylamino)carbonyl]- (9CI) (CA INDEX NAME)




RN 143663-22-3 CAPLUS

CN 2-Quinoxalinecarboxylic acid, 6-methyl-3-[[[4-methylphenyl]amino]carbonyl]- (9CI) (CA INDEX NAME)




RN 143663-23-4 CAPLUS

CN 2-Quinoxalinecarboxylic acid, 3-[[[4-methoxyphenyl]amino]carbonyl]-6-methyl- (9CI) (CA INDEX NAME)



RN 143663-24-5 CAPLUS

CN 2-Quinoxalinecarboxylic acid, 3-[[[4-chlorophenyl]amino]carbonyl]-6-methyl- (9CI) (CA INDEX NAME)



L5 ANSWER 176 OF 283 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 1992:426191 CAPLUS

DOCUMENT NUMBER: 117:26191

TITLE: Process for preparation of β -lactam antibiotics

INVENTOR(S): Jaehrling, Renate; Henklein, Peter; Scharfenberg, Peter; Teubner, Herbert; Steimecke, Guenter

PATENT ASSIGNEE(S): Akademie der Wissenschaften der DDR, Germany

SOURCE: Ger. (East), 26 pp.

DOCUMENT TYPE: Patent

LANGUAGE: German

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
DD 295630	A5	19911107	DD 1987-304606	19870703
			DD 1987-304606	19870703

PRIORITY APPLN. INFO.: MARPAT 117:26191

OTHER SOURCE(S): For diagram(s), see printed CA issue.

AB β -Lactam antibiotics ACONRD [I; D = β -lactam-containing group; R = H, alkyl, protecting group; ACO = acyl component of carboxylic acid ACO2H] were prepared by reaction of ACO2NB (NB = 5-norbornene-2,3-dicarboximide) with β -lactam HNRD. Using this method, D-II was prepared from ampicillin and an active ester.


IT 142060-44-4P

RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of, via amidation of norbornedicarboximide ester)

RN 142060-44-4 CAPLUS

CN 4-Thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid, 3,3-dimethyl-7-oxo-6-[[phenyl[[2-quinoxalinecarboxyl]amino]acetyl]amino]-, [2S-[2a,5a,6 β (S*)]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L5 ANSWER 179 OF 283 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 1992:194754 CAPLUS

DOCUMENT NUMBER: 116:194754

TITLE: Mode of formation of quinoxaline versus 2[[1H]-quinoxalinone rings from dehydro-D-erythorbic acid

AUTHOR(S): Mousaad, Ahmed; Rashed, Nagwa; Abdel Hamid, Hamida; El Kilany, Yelde; El Ashry, El Sayed H.

CORPORATE SOURCE: Fac. Sci., Alexandria Univ., Alexandria, Egypt


SOURCE: Carbohydrate Research (1992), 225(1), 59-66

CODEN: CRBRAT; ISSN: 0008-6215

DOCUMENT TYPE: Journal

LANGUAGE: English

GI



AB The mode of formation of the quinoxaline vs. 2[[1H]-quinoxalinone rings by the reaction of o-diamines with dehydro-D-erythorbic acid was investigated. The study was carried out by using one and two molar equivalents of 1,2-diamino-4,5-dimethylbenzene (I) to give 6,7-dimethyl-3-(1-oxo-D-erythro-2,3,4-trihydroxybutyl)-2[[1H]-quinoxalinone (III) and 2-(2-amino-4,5-dimethylphenylcarbamoyl)-3-(D-erythro-glycerol-1-yl)-6,7-dimethylquinoxaline (II), resp. The former product exists predominantly as the two furanose anomers IV. Sequential reaction of II with I was studied, and the location of each diamine in the product was deduced by using 1H-NMR spectroscopy. A mechanism for the reaction is proposed.

IT 140840-32-0P


RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation and acetylation of)

RN 140840-32-0 CAPLUS

CN 2-Quinoxalinecarboxamide, N-[2-(acetylamino)-4,5-dimethylphenyl]-6,7-dimethyl-3-(1,2,3-trihydroxypropyl)-, [S-(R*,S*)]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 140840-37-5P


RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation and hydrolysis and lactamization of)

RN 140840-37-5 CAPLUS

CN 2-Quinoxalinecarboxamide, N-(2-aminophenyl)-6,7-dimethyl-3-(1,2,3-trihydroxypropyl)-, [S-(R*,S*)]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 140840-33-1P


RL: SPN (Synthetic preparation); PREP (Preparation)

(preparation of)

RN 140840-33-1 CAPLUS

CN 2-Quinoxalinecarboxamide, N-[2-(acetylamino)-4,5-dimethylphenyl]-6,7-dimethyl-3-(1,2,3-tris(acetyloxy)propyl)-, [S-(R*,S*)]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 140840-31-9P


RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation, acetylation, and hydrolysis-lactamization of)

RN 140840-31-9 CAPLUS

CN 2-Quinoxalinecarboxamide, N-(2-amino-4,5-dimethylphenyl)-6,7-dimethyl-3-(1,2,3-trihydroxypropyl)-, [S-(R*,S*)]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L5 ANSWER 180 OF 283

ACCESSION NUMBER: 1992:20792 CAPLUS

DOCUMENT NUMBER: 116:20792

TITLE: Preparation of N-[(alkoxyphenyl)ethyl]carboxamides as nervous system agents

INVENTOR(S): Andrieux, Jean; Houssin, Raymond; Yous, Said;

Guardiola, Beatrice; Lesieur, Daniel

PATENT ASSIGNEE(S): ADIR et Cie., Fr.


SOURCE: Eur. Pat. Appl., 37 pp.

CODEN: EPXADW


DOCUMENT TYPE: Patent
LANGUAGE: French
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 447285	A1	19910918	EP 1991-400526	19910227
EP 447285	B1	19930512		
FR 2658818	A1	19910830	FR 1990-2393	19900227
FR 2658818	B1	19931231		
CA 2036876	AA	19910828	CA 1991-2036876	19910222
CA 2036876	C	19980818		
AU 9171375	A1	19910829	AU 1991-71375	19910226
AU 9171375	B2	19930518		
ZA 9101403	A	19911127	ZA 1991-1403	19910226
US 5194614	A	19930316	US 1991-661425	19910226
AT 89263	E	19930515	AT 1991-400526	19910227
ES 2059069	T3	19941101	ES 1991-400526	19910227
JP 07048331	A2	19950221	JP 1991-33192	19910227
US 5225442	A	19930706	US 1992-816466	19920103
US 5318994	A	19940607	US 1992-970578	19921103
PRIORITY APPL. INFO.:			FR 1990-2393	A 19900227
			US 1991-661425	A3 19910226
			EP 1991-400526	A 19910227
			US 1992-816466	A3 19920103

OTHER SOURCE(S): MARPAT 116:20792
OI



I



II

AB Title compds. [I: R = alkyl; R1 = H, alkyl; R2 = H, (halo)alkyl, (halo)cycloalkyl, aralkyl, (hetero)aryl, etc.; R1R2 = atoms to complete a ring], having high affinity for melatonin receptors, were prepared. Thus, 7-methoxy-1-tetralone was converted in 7 steps to 2-(7-methoxynaphthalen-1-yl)ethylamine which was condensed with PhCH2COCl to give title compound II. Certain I had K_d = 5.5 × 10⁻¹³ (no units given) for binding at melatonin receptors, vs. 6.3 × 10⁻¹¹ for melatonin itself.


IT 138112-94-4P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of, as nervous system agent)

RN 138112-94-4 CAPLUS

CN 2-Quinoxalinecarboxamide, N-[2-(7-methoxy-1-naphthalenyl)ethyl]- (9CI)
(CA INDEX NAME)

(CA INDEX NAME)

Absolute stereochemistry.




RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(prepn. and coupling of, with ampicillin)

IT 133206-51-6P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
(preparation of, as antibacterial)


RN 133206-51-6 CAPLUS

CN 4-Thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid, 6-[[[3,4-dihydro-3-oxo-2-quinolaliny]carbonyl]amino]phenylacetamido]-3,3-dimethyl-7-oxo-, [2S-[2α,5α,6β(S*)]]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



L5 ANSWER 182 OF 283 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 1991:559094 CAPLUS
DOCUMENT NUMBER: 115:559094
TITLES:
Synthesis and reactions of some new
thieno[2,3-b]quinoxalines and their related compounds
Mahgoub, S. A.
Fac. Sci., Assiut Univ., Assiut, Egypt
Phosphorus, Sulfur and Silicon and the Related
Elements (1991), 61(1-2), 151-60
CODEN: PSSLRK; ISSN: 1042-6507
DOCUMENT TYPE: Journal
LANGUAGE: English
OI




I



L5 ANSWER 181 OF 283 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 1991:631981 CAPLUS
DOCUMENT NUMBER: 115:231981
TITLES:
Preparation of acylamino-β-lactams
Scharfenberg, Peter; Jaehrling, Renate; Henklein,
Peter; Haber, Hanks; Teubner, Herbert; Steinbecke,
Quenter
Institut fuer Pharmakologische Forschung, Ger. Dem.
Rep.
Ger. (East), 30 pp.
CODEN: GEXKAS
Patent
German
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
DD 279887	A1	19900620	DD 1987-304622	19870703
PRIORITY APPL. INFO.:			DD 1987-304622	19870703
OTHER SOURCE(S):			MARPAT 115:231981	

OI



I

AB ACONRD (ACO = acyl; R = H, alkyl, protecting group; D = β-lactam-containing residue), specifically naphthyridone D-I, useful as antibacterials (no data), were prepared by coupling of ACO2X (X = 5-norbornen-2,3-dicarboximide residue) with HNRR. I and 8 addnl. ampicillin coupling products were prepared

IT 133206-57-2P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation and coupling of, with aminopenicillanic acid)

RN 133206-57-2 CAPLUS


CN Benzenesacetic acid, α-[[[3,4-dihydro-3-oxo-2-quinolaliny]carbonyl]amino]-, (4-nitrophenyl)methyl ester, (R)- (9CI)

AB Several thienoxinolines, e.g. I [R = cyano, R1 = NH2, NHAC; R = COMe, R1 = NH2; R1 = CONHCH=N, C(NH2):C(NH)CONH; etc.] have been prepared. Thus, 2-chloroquinoline-3-carbonitrile reacted with H2NC(S)NH2 in EtOH to give 3-cyano-2(1H)-quinolalinetione (II). II cyclocondensed with BrCH2COCH4R2 (R2 = H, 4-Cl, 4-Me) to give I (R = COCH4R2, R1 = NH2). II also reacted with ClCH2CHN to give I (R = cyano, R1 = NH2) (III). III cyclocondensed with NCCH2CO2Et to give I [R1 = C(NH2):C(NH)CONH].


IT 136228-93-8P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)

RN 136228-93-8 CAPLUS

CN 2-Quinoxalinecarboxamide, N-phenyl-3-(phenylamino)- (9CI) (CA INDEX NAME)



L5 ANSWER 183 OF 283 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 1990:478334 CAPLUS
DOCUMENT NUMBER: 113:78334
TITLES:
An improved and efficient synthesis of
quinoxalinecarboxamide 1,4-dioxides from benzofuroxan
and acetacetamides in the presence of calcium salts
Stumm, G.; Niclas, H. J.
Cent. Inst. Org. Chem., Acad. Sci. GDR, Berlin,
GDR-1199, Ger. Dem. Rep.
Journal fuer Praktische Chemie (Leipzig) (1989),
331(5), 736-44
CODEN: JPCEAD; ISSN: 0021-8383
DOCUMENT TYPE: Journal
LANGUAGE: English
OTHER SOURCE(S): CASREACT 113:78334
OI




I

AB Cyclocondensation reaction of benzofuroxan with MeCOCH2CONRR1 (R = H, R1 = H, Me, Pr, CHMe2, Bu, CH2CH2OH, Ph, C6H4OMe-o, C6H4OMe-p, 1-naphthyl, 2-naphthyl; R = R1 = Me, Et, CH2CH2OH) in the presence of HOCH2CH2NH2 and CaCl2 or Ca(NO3)2 gave 53-96% dioxoquinoxalinecarboxamides I.


IT 23433-48-9P 31983-89-8P 111888-44-9P
128613-90-7P 128615-91-8P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)

RN 23433-48-9 CAPLUS


CN 2-Quinoxalinecarboxamide, N-[2-methoxyphenyl]-3-methyl-, 1,4-dioxide (9CI)
(CA INDEX NAME)




RN 31983-69-8 CAPLUS
CN 2-Quinoxalinecarboxamide, 3-methyl-N-phenyl-, 1,4-dioxide (9CI) (CA INDEX NAME)



RN 111888-44-9 CAPLUS
CN 2-Quinoxalinecarboxamide, N-(4-methoxyphenyl)-3-methyl-, 1,4-dioxide (9CI) (CA INDEX NAME)



RN 128615-90-7 CAPLUS
CN 2-Quinoxalinecarboxamide, 3-methyl-N-1-naphthalenyl-, 1,4-dioxide (9CI) (CA INDEX NAME)




RN 128615-91-8 CAPLUS
CN 2-Quinoxalinecarboxamide, 3-methyl-N-2-naphthalenyl-, 1,4-dioxide (9CI) (CA INDEX NAME)

morpholinoethyl) and their pharmaceutically acceptable salts, useful as antihypertensives (no data) were prepared (2R,4S,5S)-6-Cyclohexyl-5-amino-2-(2-chloro-2'-propenyl)-γ-hexanolactone hydrochloride (165.5 mg) was coupled with 97.8 mg 5-chloroindole-2-carboxylic acid in the presence of N-methylmorpholine, N-hydroxybenzotriazole and dicyclohexylcarbodiimide in CH₂Cl₂ to give 226 mg (2R,4S,5S)-1 (HET = 5-chloroindol-2-yl; R₁ = cyclohexyl; R₂ = Cl;CH₂; R₃ = Me).


IT 124185-16-8P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses) (preparation of, as antihypertensive)

RN 124185-16-8 CAPLUS
CN 2-Quinoxalinecarboxamide, N-[1-(cyclohexylmethyl)-2-hydroxy-6-methyl-4-[(methylamino)carbonyl]heptyl]-3,4-dihydro-3-oxo-, [1S-(1R*,2R*,4S*)]-(9CI) (CA INDEX NAME)

Absolute stereochemistry:








L5 ANSWER 185 OF 283 CAPLUS COPYRIGHT 2006 ACS ON STN
ACCESSION NUMBER: 1988:56059 CAPLUS
DOCUMENT NUMBER: 108:56059
TITLE: Synthesis and spectroscopic studies on some new substituted 2-quinoxalinecarboxamides and their N-oxides
AUTHOR(S): Sabri, Salim S.; El-Abadlah, Mustafa M.; Al-Bitar, Bassam A.
CORPORATE SOURCE: Fac. Sci., Jordan Univ., Amman, Jordan
SOURCE: Heterocycles (1987), 26(3), 699-711
CODEN: HETCYM; ISSN: 0385-5414
DOCUMENT TYPE: Journal
LANGUAGE: English
OTHER SOURCE(S): CASREACT 108:56059
OI



L5 ANSWER 184 OF 283 CAPLUS COPYRIGHT 2006 ACS ON STN
ACCESSION NUMBER: 1990:35678 CAPLUS
DOCUMENT NUMBER: 112:35678
TITLE: Preparation of heterocyclic nonpeptidic renin inhibitors as antihypertensives
INVENTOR(S): Rosati, Robert Louis
PATENT ASSIGNER(S): Pfizer Inc., USA
SOURCE: Eur. Pat. Appl., 21 pp.
CODEN: EPKADW
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 321192	A2	19890621	EP 1988-311798	19881214
EP 321192	A3	19910130		
EP 321192	B1	19931027		
R: AT, BE, CH, DE, ES, FR, GB, GR, IT, LI, LU, NL, SE				
US 4923864	A	19900508	US 1988-261878	19881024
JP 01250345	A2	19891005	JP 1988-311642	19881212
JP 06092366	B4	19941116		
PL 152507	B1	19910131	PL 1988-276363	19881212
CS 274671	B2	19910915	CS 1988-8203	19881212
ZA 8809307	A	19900829	ZA 1988-9307	19881213
CA 1314545	A1	19930216	CA 1988-588722	19881213
HU 48277	A2	19890529	HU 1988-6423	19881214
HU 201564	B	19901128		
AU 8826881	A1	19890615	AU 1988-26881	19881214
AU 593181	B2	19900201		
FI 8805783	A	19890616	FI 1988-5783	19881214
FI 88295	B	19930115		
FI 88295	C	19930426		
NO 8805549	A	19890616	NO 1988-5549	19881214
NO 172935	B	19930621		
NO 172935	C	19930929		
CN 1034366	A	19890802	CN 1988-108575	19881214
CN 1025676	B	19940817		
DK 8806948	A	19890811	DK 1988-6948	19881214
DD 283381	A5	19901010	DD 1988-323142	19881214
SU 1651786	A3	19910523	SU 1988-4613032	19881214
AT 96433	E	19931115	AT 1988-311798	19881214
ES 2059540	T3	19941116	ES 1988-311798	19881214
PRIORITY APPL. INFO.:			US 1987-132373	A 19871215
			EP 1988-311798	A 19881214


OTHER SOURCE(S): CASREACT 112:35678; MARPAT 112:35678
AB HET-COHNCHRIC(OH)CH₂CH₂CONHR₃ [I; HET = hydroquinolinyl, imidazopyridyl, hydroxyquinoxalyl, dichloropyrrolyl, pyrrolopyridyl, (un)substituted indolyl; R₁ = C₆-6 cycloalkyl, Me₂CH; R₂ = C₃-5 alkyl, Ph, Me₂CH; Me₂C-CH, haloalkyl, hydroxy C₁-3 alkyl, amino C₁-4 alkyl; R₃ = C₁-6 alkyl,




AB (Phenylcarbamoyl)quinoxaline dioxides I (R = H, Me; n = 0-4), oxides II and III (R = H, Me; n = 1-4), and nonoxigenated analogs IV (R = H, Me; n = 1,3) were prepared. Thus, MeCOCH₂CONHCH₂CH₂Ph reacted with benzofuran (V) in Et₃N-MeOH to give 80% I (R = Me, n = 1). The C(3)-Me protons in dioxides I (R = Me) resonate at a higher field (δ = 2.45-2.80) than those of quinoxalines IV (R = Me) (δ = 3.0). The observed upfield shift for the C(3)-Me protons is at a maximum when 2 methylene carbons sep. the Ph group from the carbonyl function. The NMR of II (R = Me) show a comparable trend, whereas isomeric oxides III (R = Me) closely resemble IV. A comparative NMR study of I-IV (R = H) is also presented.

IT 83821-63-OP 112369-45-6P
RL: SPN (Synthetic preparation); PREP (Preparation) (preparation and deoxygenations of)


RN 83821-63-0 CAPLUS
CN 2-Quinoxalinecarboxamide, 3-methyl-N-(phenylmethyl)-, 1,4-dioxide (9CI) (CA INDEX NAME)




RN 112369-45-6 CAPLUS
CN 2-Quinoxalinecarboxamide, 3-methyl-N-(2-phenylethyl)-, 1,4-dioxide (9CI) (CA INDEX NAME)




IT 59834-00-3P 112369-33-2P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
 (Reactant or reagent)
 (preparation and selective deoxygenation of)
 RN 59834-00-3 CAPLUS
 CN 2-Quinoxalinecarboxamide, N-(2-phenylethyl)-, 1,4-dioxide (9CI) (CA INDEX
 NAME)




RN 112369-33-2 CAPLUS
 CN 2-Quinoxalinecarboxamide, N-(phenylmethyl)-, 1,4-dioxide (9CI) (CA INDEX
 NAME)




IT 112369-44-5P
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (preparation and selective deoxygenations of)
 RN 112369-44-5 CAPLUS
 CN 2-Quinoxalinecarboxamide, 3-methyl-N-(3-phenylpropyl)-, 1,4-dioxide (9CI)
 (CA INDEX NAME)




IT 7066-32-2P 11983-89-8P 59833-89-5P
 106477-28-5P 112369-27-4P 112369-28-5P
 112369-29-6P 112369-30-9P 112369-32-1P
 112369-34-3P 112369-35-4P 112369-37-6P
 112369-38-7P 112369-39-8P 112369-41-2P
 112369-42-3P 112369-43-4P
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (preparation of)
 RN 7066-32-2 CAPLUS
 CN 2-Quinoxalinecarboxamide, N-(phenylmethyl)- (9CI) (CA INDEX NAME)




RN 11983-89-8 CAPLUS
 CN 2-Quinoxalinecarboxamide, 3-methyl-N-phenyl-, 1,4-dioxide (9CI) (CA INDEX
 NAME)




RN 59833-89-5 CAPLUS
 CN 2-Quinoxalinecarboxamide, N-(2-phenylethyl)-, 1-oxide (9CI) (CA INDEX
 NAME)




RN 106477-28-5 CAPLUS
 CN 2-Quinoxalinecarboxamide, N-phenyl-, 1,4-dioxide (9CI) (CA INDEX NAME)




RN 112369-27-4 CAPLUS
 CN 2-Quinoxalinecarboxamide, N-(2-phenylethyl)- (9CI) (CA INDEX NAME)




RN 112369-28-5 CAPLUS
 CN 2-Quinoxalinecarboxamide, N-(2-phenylethyl)-, 4-oxide (9CI) (CA INDEX
 NAME)




RN 112369-29-6 CAPLUS
 CN 2-Quinoxalinecarboxamide, N-(phenylmethyl)-, 4-oxide (9CI) (CA INDEX
 NAME)




RN 112369-30-9 CAPLUS
 CN 2-Quinoxalinecarboxamide, N-(phenylmethyl)-, 1-oxide (9CI) (CA INDEX
 NAME)




RN 112369-32-1 CAPLUS
 CN 2-Quinoxalinecarboxamide, N-(3-phenylpropyl)-, 1,4-dioxide (9CI) (CA
 INDEX NAME)




RN 112369-34-3 CAPLUS
 CN 2-Quinoxalinecarboxamide, 3-methyl-N-(2-phenylethyl)- (9CI) (CA INDEX
 NAME)




RN 112369-35-4 CAPLUS
 CN 2-Quinoxalinecarboxamide, 3-methyl-N-(phenylmethyl)- (9CI) (CA INDEX
 NAME)




RN 112369-37-6 CAPLUS
 CN 2-Quinoxalinecarboxamide, 3-methyl-N-(3-phenylpropyl)-, 4-oxide (9CI) (CA
 INDEX NAME)




RN 112369-38-7 CAPLUS
CN 2-Quinoxalinecarboxamide, 3-methyl-N-(2-phenylethyl)-, 4-oxide (9CI) (CA INDEX NAME)




RN 112369-39-8 CAPLUS
CN 2-Quinoxalinecarboxamide, 3-methyl-N-(phenylmethyl)-, 4-oxide (9CI) (CA INDEX NAME)




RN 112369-41-2 CAPLUS
CN 2-Quinoxalinecarboxamide, 3-methyl-N-(3-phenylpropyl)-, 1-oxide (9CI) (CA INDEX NAME)




RN 112369-42-3 CAPLUS
CN 2-Quinoxalinecarboxamide, 3-methyl-N-(2-phenylethyl)-, 1-oxide (9CI) (CA INDEX NAME)




RN 112369-43-4 CAPLUS
CN 2-Quinoxalinecarboxamide, 3-methyl-N-(phenylmethyl)-, 1-oxide (9CI) (CA INDEX NAME)




L5 ANSWER 186 OF 283 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 1988:21841 CAPLUS
DOCUMENT NUMBER: 108:21841
TITLE: A new synthesis of 2,3-disubstituted quinoxaline 1,4-dioxides catalyzed by molecular sieves
AUTHOR(S): Takabatake, Toru; Hasegawa, Minoru
CORPORATE SOURCE: Coll. Sci. Technol., Nihon Univ., Tokyo, 101, Japan
SOURCE: Journal of Heterocyclic Chemistry (1987), 24(2), 529-30
CODEN: JHCTAD; ISSN: 0022-152X
DOCUMENT TYPE: Journal
LANGUAGE: English
OTHER SOURCE(S): CASREACT 108:21841
OI




AB Benzofuroxan was treated with R1OCH2COR2 (R1 = Me, CH2CO2Me, 4-O2NC6H4, Ph; R2 = Ph, OMe, OEt, NHPh, NHC6H4OMe-2 or -4, NHC6H4Cl-2, NHC6H4Me-4) in MeOH containing zeolites to yield quinoxaline dioxides I.
IT 23433-48-9P 31983-89-8P 104705-39-7P
111888-44-9P 111888-45-0P 111888-46-1P
RL: SPN (Synthetic preparation); PREP (Preparation)
RN 23433-48-9 CAPLUS
CN 2-Quinoxalinecarboxamide, N-(2-methoxyphenyl)-3-methyl-, 1,4-dioxide (9CI) (CA INDEX NAME)




RN 31983-89-8 CAPLUS
CN 2-Quinoxalinecarboxamide, 3-methyl-N-phenyl-, 1,4-dioxide (9CI) (CA INDEX NAME)




RN 104705-39-7 CAPLUS
CN 2-Quinoxalinecarboxamide, N,3-diphenyl-, 1,4-dioxide (9CI) (CA INDEX NAME)




RN 111888-44-9 CAPLUS
CN 2-Quinoxalinecarboxamide, N-(4-methoxyphenyl)-3-methyl-, 1,4-dioxide (9CI) (CA INDEX NAME)




RN 111888-45-0 CAPLUS
CN 2-Quinoxalinecarboxamide, N-(4-chlorophenyl)-3-methyl-, 1,4-dioxide (9CI) (CA INDEX NAME)



RN 111888-46-1 CAPLUS
CN 2-Quinoxalinecarboxamide, 3-methyl-N-(2-methylphenyl)-, 1,4-dioxide (9CI) (CA INDEX NAME)




L5 ANSWER 187 OF 283 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 1987:51555 CAPLUS
DOCUMENT NUMBER: 107:11555
TITLE: Reactivity of 3H-pyrimido[5,4-c][1,2,5]oxadiazin-3-one towards carbanions: synthesis of pteridine-2,4-diones
AUTHOR(S): Giori, P.; Poli, T.; Veronese, A. C.; Vicentini, C. B.; Manfrini, M.; Guarneri, M.
CORPORATE SOURCE: Dip. Sci. Farm., Univ. Ferrara, Ferrara, 44100, Italy
SOURCE: Journal of Heterocyclic Chemistry (1986), 23(6), 1661-5
CODEN: JHCTAD; ISSN: 0022-152X
DOCUMENT TYPE: Journal
LANGUAGE: English
OTHER SOURCE(S): CASREACT 107:11555
OI




AB The reaction of pyrimidooxadiazin-3-one (I) with carbanions prepared in situ from R1CH2 (R = Ac, Bz, CO2Me, CO2Et, cyano; R1 = Ac, Bz, CO2Me, CO2Et, cyano, CONHPh, CONHCH2Ph) afforded 6,7-disubstituted pteridine-2,4-diones II (R2 = Me, Ph, OH, NH2) in good yields. The reaction mechanism involving the initial attack by carbanion at the oxadiazinone nitrogen atom bonded to oxygen, is proposed and discussed.
IT 109879-40-5P 109879-41-6P
RL: SPN (Synthetic preparation); PREP (Preparation)
RN 109879-40-5 CAPLUS


CN 6-Pteridinecarboxamide, 1,2,3,4-tetrahydro-1,3,7-trimethyl-2,4-dioxo-N-phenyl- (9CI) (CA INDEX NAME)



RN 109879-41-6 CAPLUS
CN 6-Pteridinecarboxamide, 1,2,3,4-tetrahydro-1,3,7-trimethyl-2,4-dioxo-N-(phenylmethyl)- (9CI) (CA INDEX NAME)



L5 ANSWER 188 OF 283 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 1987:439040 CAPLUS
DOCUMENT NUMBER: 107:39040
TITLE: Carbon-13 NMR studies on some quinoxaline amino esters and their N-oxides
AUTHOR(S): Sabri, Salim S.; El-Abadelah, Mustafa M.; Tashtoush, Hasan I.; Duddeck, Helmut
CORPORATE SOURCE: Fac. Sci., Jordan Univ., Amman, Jordan
SOURCE: Heterocycles (1986), 24(11), 3169-80
CODEN: HETCYM; ISSN: 0385-5414
DOCUMENT TYPE: Journal
LANGUAGE: English
OI




AB 13C NMR spectra of quinoxaline (I), of its mono- and dioxides, and of quinoxalyl-substituted amino esters II (R1 = H, Me; R2 = Me, Ph, CH2Ph), and of their mono- and dioxides were recorded. The effects of N-oxide substituents on the 13C NMR chemical shifts and on the 13C-1H coupling consts. depended upon the substituents at C-2 and C-3. The substituent effects were discussed in terms of mesomeric states and intramol. H bonding.

IT 62973-10-8 62973-21-1 65926-49-0

74200-01-4 74200-11-6 74200-15-0
74200-19-4 74200-23-0 109084-22-3
109084-23-3


RL: PRP (Properties)
(Carbon-13 NMR spectrum of)
RN 62973-10-8 CAPLUS
CN L-Phenylalanine, N-[(3-methyl-1,4-dioxido-2-quinoxaliny)carbonyl]-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 62973-21-1 CAPLUS
CN L-Phenylalanine, N-[(3-methyl-2-quinoxaliny)carbonyl]-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 65926-49-0 CAPLUS
CN L-Phenylalanine, N-(2-quinoxaliny)carbonyl)-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 74200-01-4 CAPLUS
CN L-Phenylalanine, N-[(1,4-dioxido-2-quinoxaliny)carbonyl]-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 74200-11-6 CAPLUS
CN L-Phenylalanine, N-[(4-oxido-2-quinoxaliny)carbonyl]-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 74200-15-0 CAPLUS
CN L-Phenylalanine, N-[(1-oxido-2-quinoxaliny)carbonyl]-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 74200-19-4 CAPLUS
CN L-Phenylalanine, N-[(3-methyl-4-oxido-2-quinoxaliny)carbonyl]-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 74200-23-0 CAPLUS
CN L-Phenylalanine, N-[(3-methyl-1-oxido-2-quinoxaliny)carbonyl]-, methyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.




RN 109084-22-2 CAPLUS
CN Benzenesacetic acid, alpha-[(2-quinoxaliny)carbonyl]amino)-, methyl ester (9CI) (CA INDEX NAME)



RN 109084-23-3 CAPLUS
CN Benzenesacetic acid, alpha-[(1-methyl-1,4-dioxido-2-quinoxaliny)carbonyl]amino)-, methyl ester (9CI) (CA INDEX NAME)



L5 ANSWER 189 OF 283 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 1987:176333 CAPLUS
DOCUMENT NUMBER: 106:176333
TITLE: Structure of the reaction products of dehydro-D-isoascorbic acid with ortho diamines
AUTHOR(S): El Ashry, E. S. M.; El Kilany, Y.; El Shimy, N.; Huckerby, T. N.
CORPORATE SOURCE: Fac. Sci., Alexandria Univ., Alexandria, Egypt
SOURCE: Scientia Pharmaceutica (1986), 54(2), 121-5
CODEN: SCPHAA; ISSN: 0036-8709
DOCUMENT TYPE: Journal
LANGUAGE: English
OI




AB The structure of the reaction products I and II of dehydro-D-isoascorbic acid III with o-phenylenediamine (1 and 2 mol. resp.) was reinvestigated based on ¹H-NMR spectroscopy and spin decoupling technique.

IT 107823-76-7P 107850-72-6P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)


RN 107823-76-7 CAPLUS
CN 2-Quinoxalinecarboxamide, N-[2-(acetylamino)phenyl]-3-(1,2,3-trihydroxypropyl)-, [S-(R*,S*)]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 107850-72-6 CAPLUS
CN 2-Quinoxalinecarboxamide, N-[2-(acetylamino)phenyl]-3-(1,2,3-trihydroxypropyl)-, [S-(R*,S*)]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



IT 92983-92-1P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation, hydrolysis and acetylation of)

RN 92983-92-1 CAPLUS
CN 2-Quinoxalinecarboxamide, N-(2-aminophenyl)-3-(1,2,3-trihydroxypropyl)-, [S-(R*,S*)]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L5 ANSWER 190 OF 283 CAPLUS COPYRIGHT 2006 ACS ON STN

ACCESSION NUMBER: 1987:102117 CAPLUS

DOCUMENT NUMBER: 106:102117

TITLE: α-Oxodicarboxylic acid chloride imide chlorides

in the synthesis of heterocycles. I

Capuano, Lilly; Hell, Wolfgang; Wamprecht, Christian

Fachber. 14, Org. Chem., Univ. Saarlandes,

Saarbrücken, D-6600, Fed. Rep. Ger.

Liebigs Annalen der Chemie (1986), (1), 132-41


CODEN: LACHDI; ISSN: 0170-2041

DOCUMENT TYPE: Journal

LANGUAGE: German

OTHER SOURCE(S): CASREACT 106:102117

GI




AB The title compds. (I) were prepared by α-addition of dicarboxylic acid dichlorides [ClCOCOC1, R12C(COCl)2 (R1 = Me, Et), furan-3,4-dicarbonyl chloride, pyridine-2,3-dicarbonyl chloride, pyrazine-2,3-dicarbonyl chloride and o-ClCOC6H4COCl] to RCN (R = cyclohexyl, p-MeC6H4SO2CH2, Me3C). I [e.g., ClCOC12COC(NR)Cl and II (X = Y = CH, N; X = CH, Y = N)] were characterized by high reactivity of the terminal carbons and readily underwent cyclization with hydrazines, amines, or water, affording imino derivs. of pyrazole, pyridazine, pyrrole, isoquinoline, naphthyridine, or pyridopyridazine (e.g., III-V).

IT 106943-56-0P
RL: PRP (Properties); SPN (Synthetic preparation); PREP (Preparation)
(preparation and spectra of)

RN 106943-56-0 CAPLUS

CN 2-Quinoxalinecarboxamide, N-cyclohexyl-3,4-dihydro-3-oxo- (9CI) (CA INDEX NAME)



L5 ANSWER 191 OF 283 CAPLUS COPYRIGHT 2006 ACS ON STN

ACCESSION NUMBER: 1987:67258 CAPLUS

DOCUMENT NUMBER: 106:67258

TITLE: Reactivity of pyrazolo[4,3-c][1,2,5]oxadiazin-3(5H)-ones toward C-nucleophiles: synthesis of pyrazolo[3,4-b]pyrazines

Giori, P.; Veronesi, A. C.; Poli, T.; Vicentini, C.

B.; Manfredi, M.; Guarnieri, M.

Ist. Chim. Farm., Univ. Ferrara, Ferrara, 44100, Italy

Journal of Heterocyclic Chemistry (1986), 23(2), 585-8


CODEN: JHTCAD; ISSN: 0022-152X

DOCUMENT TYPE: Journal

LANGUAGE: English

OTHER SOURCE(S): CASREACT 106:67258

GI




AB Stirring pyrazolooxadiazines I (R = Me, Ph) with CH2R1R2 (R1, R2 = Ac, Bz, CO2Me, CO2Et, cyano, CONHPh, CONHCH2Ph) in THF in the presence of NaH gave 5,7,9-trisubstituted pyrazolopyrazines II.

IT 106538-02-7P 106538-03-8P 106538-04-9P

RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)


RN 106538-02-7 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyrazine-5-carboxamide, 3,6-dimethyl-N,1-diphenyl- (9CI) (CA INDEX NAME)




RN 106538-03-8 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyrazine-5-carboxamide, 1,3,6-trimethyl-N-phenyl- (9CI) (CA INDEX NAME)




RN 106538-04-9 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyrazine-5-carboxamide, 3,6-dimethyl-1-phenyl-N-(phenylmethyl)- (9CI) (CA INDEX NAME)




RN 106538-05-0 CAPLUS


CN 18-Pyrazolo[3,4-b]pyrazine-5-carboxamide, 1,3,6-trimethyl-N-(phenylmethyl)- (9CI) (CA INDEX NAME)




L5 ANSWER 192 OF 283 CAPLUS COPYRIGHT 2006 ACS ON STN
 ACCESSION NUMBER: 1986:627198 CAPLUS
 DOCUMENT NUMBER: 105:227198
 TITLE: Heterocycles from carbohydrate precursors. Part 29. Reaction of dehydro-L-ascorbic acid analogs with o-phenylenediamine
 AUTHOR(S): El Ashry, El-Sayed H.; Abdel Rahman, Mohamed A.; El Kilany, Yehia; El-Sayed, Nagwa
 CORPORATE SOURCE: Fac. Sci., Alexandria Univ., Alexandria, Egypt
 SOURCE: Carbohydrate Research (1986), 153(1), 146-9
 CODEN: CRBRAT; ISSN: 0008-6215
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 OTHER SOURCE(S): CASREACT 105:227198
 GI




AB Reaction of triazolybutanolide I (0.5 g) with o-C6H4(NH2)2 (0.8 g) in MeOH 10 min at reflux gave 83% quinoxaline derivative II, whose structure was determined by IR and mass spectroscopy.
 IT 105362-44-SP
 RL: PRP (Properties); SPN (Synthetic preparation); PREP (Preparation) (preparation and structure of)
 RN 105362-44-5 CAPLUS
 CN 2-Quinoxalinecarboxamide, N-(2-aminophenyl)-3-[hydroxy(2-phenyl-2H-1,2,3-triazol-4-yl)methyl]- (9CI) (CA INDEX NAME)



L5 ANSWER 193 OF 283 CAPLUS COPYRIGHT 2006 ACS ON STN
 ACCESSION NUMBER: 1986:572384 CAPLUS
 DOCUMENT NUMBER: 105:172384
 TITLE: Reactions of benzofuroxan with 1,3-diketones or β-ketoesters on silica gel or alumina
 AUTHOR(S): Hasegawa, Minoru; Takabatake, Tohru
 CORPORATE SOURCE: Coll. Sci. Technol., Nihon Univ., Tokyo, 101, Japan
 SOURCE: Synthese (1985), (10), 936
 CODEN: SYNTHF; ISSN: 0039-7081
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 OTHER SOURCE(S): CASREACT 105:172384
 GI




AB The cyclocondensation of benzofuroxan I with RCOCH2COR1 (R, R1 = Me, Ph, OMe, OEt, NHPh, C6H4NO2-4, CH2CO2Me) in the presence of silica gel (adsorption of the components on silica gel) yielded a convenient method for the synthesis of quinoxaline oxides II.
 IT 104705-39-7P
 RL: SPN (Synthetic preparation); PREP (Preparation) (preparation of)
 RN 104705-39-7 CAPLUS
 CN 2-Quinoxalinecarboxamide, N,3-diphenyl-, 1,4-dioxide (9CI) (CA INDEX NAME)




L5 ANSWER 194 OF 283 CAPLUS COPYRIGHT 2006 ACS ON STN

ACCESSION NUMBER: 1986:497422 CAPLUS
 DOCUMENT NUMBER: 105:97422
 TITLE: Structure of the reaction product of 4-hydroxy-2,3-dioxo-4-phenylbutanoic acid 1,4-lactone with o-phenylenediamine
 AUTHOR(S): Coxon, Bruce; Dahn, Hans; Khadem, Hassan S. El; Swartz, David L.
 CORPORATE SOURCE: Cent. Anal. Chem., Natl. Meas. Lab., Washington, DC, 20234, USA
 SOURCE: Carbohydrate Research (1985), 142(1), 1-10
 CODEN: CRBRAT; ISSN: 0008-6215
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 OTHER SOURCE(S): CASREACT 105:97422
 GI



AB Examination of the structure of the yellow product, obtained by treating 4-phenyl-2,3-dioxobutylolactone I with 2 mol of o-phenylenediamine (II), by high-resolution IR-, 13C-, and 15N-NMR spectroscopy, as well as by electron-impact mass spectrometry, confirmed without ambiguity the structure of the product as the quinoxaline amide III. When I is treated with II, the Schiff base is first formed, which is then converted into a quinoxaline lactone IV. The excess of II then converted IV into the yellow product III.
 IT 806-91-7P
 RL: FORM (Formation, nonpreparative); PREP (Preparation) (formation of, by condensation of phenyldioxobutylolactone with phenylenediamine)
 RN 806-91-7 CAPLUS
 CN 2-Quinoxalinecarboxamide, N-(2-aminophenyl)-3-(hydroxyphenylmethyl)- (9CI) (CA INDEX NAME)




L5 ANSWER 195 OF 283 CAPLUS COPYRIGHT 2006 ACS ON STN
 ACCESSION NUMBER: 1986:224624 CAPLUS
 DOCUMENT NUMBER: 104:224624


TITLE: N-Cycloheptenyl amides
 INVENTOR(S): Tomioka, Hiroki; Oishi, Tadashi; Takahashi, Junya; Sasaki, Mitsuru; Hirata, Naonori
 PATENT ASSIGNEE(S): Sumitomo Chemical Co., Ltd., Japan
 SOURCE: Jpn. Kokai Tokkyo Koho, 19 pp.
 CODEN: JKXXAF
 DOCUMENT TYPE: Patent
 LANGUAGE: Japanese
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 60224663	A2	19851109	JP 1984-82724	19840423
JP 05012339	B4	19930217		

PRIORITY APPL. INFO.: JP 1984-82724 19840423
 GI




AB The title compds. [I, R1 = H, alkenyl, aryl, alkynyl, cycloalkyl, cycloalkenyl, (substituted)alkyl; R2 = H, alkenyl, (substituted)cycloalkyl, (substituted)cycloalkenyl, aryl, etc.; X = O, S, NH], useful as insecticides (effective at 50 g/10 are without damage to plants), were prepared. Thus, 0.93 g EtOCCl was added to a mixture of 1.11 g 3-cycloheptenylamine, 1.01 g Et3N, and 10 mL CHCl3 at 0-5° and the resulting mixture stirred at 20° for 3 h to give 1.5 g I (R1 = H, R2 = Et, X = O).
 IT 95996-15-3P
 RL: AGR (Agricultural use); BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation); USES (Uses) (preparation of, as insecticide)
 RN 95996-15-9 CAPLUS
 CN 2-Quinoxalinecarboxamide, N-2-cyclohepten-1-yl- (9CI) (CA INDEX NAME)




L5 ANSWER 196 OF 283 CAPLUS COPYRIGHT 2006 ACS ON STN
 ACCESSION NUMBER: 1986:143964 CAPLUS
 DOCUMENT NUMBER: 104:143964
 TITLE: Acid amides as soil microbicides
 INVENTOR(S): Tomioka, Hiroki; Oishi, Tadashi; Takahashi, Junya; Sasaki, Mitsuru; Hirata, Naonori
 PATENT ASSIGNEE(S): Sumitomo Chemical Co., Ltd., Japan
 SOURCE: Jpn. Kokai Tokkyo Koho, 13 pp.
 CODEN: JKXXAF
 DOCUMENT TYPE: Patent
 LANGUAGE: Japanese
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO. KIND DATE APPLICATION NO. DATE
JP 60214706 A2 19851028 JP 1984-68733 19840405
PRIORITY APPLN. INFO.: JP 1984-68733 19840405
GI




AB Acid amides I [R1 = H, alkenyl, aryl, alkyl, etc.; R2 = H, alkynyl, (un)substituted cycloalkyl, etc.; Z = O, S, NH] are soil microbicides. Syntheses of I are given. Thus, the preemergence soil incorporation of I (R1 = H; R2 = Me; Z = O) at 50 g/10 are, controlled Fusarium oxysporum on Japanese white radish.

IT 95996-15-9P
RL: AGR (Agricultural use); BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation); USES (Uses) (preparation and microbicide activity of)
RN 95996-15-9 CAPLUS
CN 2-Quinoxalinecarboxamide, N-2-cyclohepten-1-yl- (9CI) (CA INDEX NAME)




L5 ANSWER 197 OF 283 CAPLUS COPYRIGHT 2006 ACS ON STN
ACCESSION NUMBER: 1986:68883 CAPLUS
DOCUMENT NUMBER: 104:68883
TITLE: Quinoxaline-2-thiocarboxamides
INVENTOR(S): Sarodnick, Gerhard; Viola, Horst; Kempter, Gerhard; Mayer, Roland; Klepel, Manfred
PATENT ASSIGNEE(S): VEB Fahlberg-List, Ger. Dem. Rep.
SOURCE: Ger. (East), 4 pp.
CODEN: GEXXAS
DOCUMENT TYPE: Patent
LANGUAGE: German
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:


PATENT NO. KIND DATE APPLICATION NO. DATE
DD 220602 A1 19850403 DD 1983-254754 19830913
PRIORITY APPLN. INFO.: DD 1983-254754 19830913
OTHER SOURCE(S): CASREACT 104:68883
GI




AB The title compds. [I; R1, R2 = H, (un)substituted alkyl, cycloalkyl, aralkyl; R1R2N = heterocyclyl; R3 = H, alkyl, aryl, heteroaryl, OR; R4 = alkoxy, aryloxy, halo, cyano, NO2, R3], intermediates for preparation of bioactive compds., were prepared by aminolysis of 2-quinoxalinecarbothioates. Thus, EUREZ was added to a refluxing solution of Me 3-methyl-2-quinoxalinecarbothioate in heptane to give 95% I (R1 = R4 = H, R2 = Et, R3 = Me).
IT 100010-67-1P 100010-70-6P 100010-76-2P
100010-78-4P
RL: SPN (Synthetic preparation); PREP (Preparation) (preparation of)
RN 100010-67-1 CAPLUS
CN 2-Quinoxalinecarbothioamide, N-cyclohexyl-3-methyl- (9CI) (CA INDEX NAME)




RN 100010-70-6 CAPLUS
CN 2-Quinoxalinecarbothioamide, N-cyclohexyl-3-phenyl- (9CI) (CA INDEX NAME)



RN 100010-76-2 CAPLUS
CN 2-Quinoxalinecarbothioamide, 3-methyl-N-(phenylmethyl)- (9CI) (CA INDEX NAME)




RN 100010-78-4 CAPLUS
CN 2-Quinoxalinecarbothioamide, 3-phenyl-N-(phenylmethyl)- (9CI) (CA INDEX NAME)



L5 ANSWER 198 OF 283 CAPLUS COPYRIGHT 2006 ACS ON STN
ACCESSION NUMBER: 1985:571456 CAPLUS
DOCUMENT NUMBER: 103:171456
TITLE: Comparative QSAR of antibacterial dihydrofolate reductase inhibitors
AUTHOR(S): Coats, Eugene A.; Gentsher, Clara S.; Smith, Carl C.
CORPORATE SOURCE: Coll. Pharm., Univ. Cincinnati, Cincinnati, OH, USA
SOURCE: QSAR Des. Bioact. Compd. (1984), 71-85. Editor(s): Kuchar, M. Prouse; Barcelona, Spain.
CODEN: 53SIAU
DOCUMENT TYPE: Conference
LANGUAGE: English
AB The quant. structure-activity relationship (QSAR) of pteridines, pyrimidines, triazines, and quinoxalines with regard to inhibition of dihydrofolate reductase (DHFR) [9002-03-3] of Lactobacillus casei was studied. The results were interpreted in light of the known x-ray crystal structure of the ternary complex of L. casei DHFR with methotrexate and NADPH and with reference to previously conducted QSAR studies on isolated L. casei DHFR. The correlations obtained for pteridines, pyrimidines, and phenyltriazines provide a logical extension of the known methotrexate L. casei-DHFR interactions. In case of quinoxalines, however, the results of QSAR do not match with the available conceptualization of inhibitor-active site interaction; the possible modes of quinoxaline-DHFR interaction thus remain as conjecture or hypothesis until further exptl. data are available.

IT 39707-65-0
RL: BIOL (Biological study) (dihydrofolate reductase inhibition by, QSAR of)
RN 39707-65-0 CAPLUS
CN L-Glutamic acid, N-[4-[(2,4-diamino-6-pteridinyl)carbonyl]amino]benzoyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L5 ANSWER 199 OF 283 CAPLUS COPYRIGHT 2006 ACS ON STN
ACCESSION NUMBER: 1985:418390 CAPLUS
DOCUMENT NUMBER: 103:18390
TITLE: A soil-disease-controlling agent
INVENTOR(S): Tomioka, Hiroki; Oishi, Tadao; Takahashi, Junya; Sasaki, Mitsuru; Hirata, Naonori
PATENT ASSIGNEE(S): Sumitomo Chemical Co., Ltd., Japan
SOURCE: Eur. Pat. Appl., 36 pp.
CODEN: EPXKDW
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:


PATENT NO. KIND DATE APPLICATION NO. DATE

EP 128006 A2 19841212 EP 1984-303640 19840530
EP 128006 A3 19860409
EP 128006 B1 19910918
R: CH, DE, FR, GB, IT, LI, NL
JP 5922403 A2 19841214 JP 1983-97545 19830531
JP 59225101 A2 19841218 JP 1983-99959 19830603
JP 59227845 A2 19841221 JP 1983-103949 19830609
JP 04065826 B4 19921021 JP 1983-106233 19830613
JP 59231068 A2 19841225 JP 1983-150853 19830817
JP 04002588 B4 19920120 JP 1983-151117 19830818
JP 60041602 A2 19850305 US 1984-610789 19840516
JP 60042304 A2 19850306 AU 1984-28856 19840530
AU 4709052 A 19871124
AU 8428856 A1 19841206 CA 1984-455433 19840530
AU 576503 B2 19880901 US 1987-66735 19870625
CA 1261839 A1 19890926 JP 1983-97545 A 19830531
US 5075488 A 19911224 JP 1983-99959 A 19830603
JP 1983-103949 A 19830609
JP 1983-106233 A 19830613
JP 1983-150853 A 19830817
JP 1983-151117 A 19830818
US 1984-610789 A3 19840516


PRIORITY APPLN. INFO.:

OTHER SOURCE(S): CASREACT 103:18390; MARPAT 103:18390
AB 2-Cycloalkenylamine deriva. and salts are fungicides for preventing or controlling plant diseases caused by pathogenic soil fungi. Thus, such compds. controlled Fusarium oxysporum on radish, F. oxysporum conglutinae on cabbage, F. oxysporum cucumerinum on cucumbers, Verticillium albo-atrum on eggplant, and clubroot of Chinese cabbage, etc. N-(2-Cyclohexenyl)glycine Et ester (I) [95995-43-0] at 300 g/are as a soil drench completely controlled F. oxysporum in Japanese radish in container expts. in the greenhouse. I was prepared by reaction of Et bromoacetate [105-36-2] with 2-cyclohexenylamine [1541-25-9] in a mixture with triethylamine and CHCl3. Preparation of various deriva. are described.

IT 95996-15-9P 95996-75-1P
RL: AGR (Agricultural use); BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation); USES (Uses) (preparation and fungicidal activity of)
RN 95996-15-9 CAPLUS
CN 2-Quinoxalinecarboxamide, N-2-cyclohexen-1-yl- (9CI) (CA INDEX NAME)




RN 95996-75-1 CAPLUS
CN 2-Quinoxalinecarboxamide, N-2-cyclohexen-1-yl- (9CI) (CA INDEX NAME)




L5 ANSWER 200 OF 283 CAPLUS COPYRIGHT 2006 ACS ON STN

ACCESSION NUMBER: 1985:185401 CAPLUS
 DOCUMENT NUMBER: 102:185401
 TITLE: Condensation of o-phenylenediamine with dehydro-L-ascorbic acid derivatives and analogs
 AUTHOR(S): Teujimoto, Yuji; Ohmori, Mitsuaki; Takagi, Masanosuke
 CORPORATE SOURCE: Dep. Hyg. Chem., Osaka City Inst. Public Health Environ. Sci., Osaka, 543, Japan
 SOURCE: Carbohydrate Research (1985), 138(1), 148-52
 CODEN: CRBRAT; ISSN: 0008-6215
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 OTHER SOURCE(S): CASREACT 102:185401
 Q1




AB Oxidation of L-ascorbic acid analogs I (R = Me, O, CH(OH)CH₂COO(CH₂)₁₄Me) followed by treatment with excess o-C₆H₄(NH₂)₂ gave the corresponding quinoxalines II in 63, 31, and 40% yield, resp. In the case of I (R = O) 31% quinoxaline III was also obtained. Hydrolysis of II (R = Me) with aqueous HCl gave III (R = Me). III (R = Me) on treatment with o-C₆H₄(NH₂)₂ gave II (R = Me). In the condensation of oxidized I with excess o-C₆H₄(NH₂)₂, the intermediacy of quinoxaline IV was confirmed by PhNHNH₂ trapping. In the condensation of oxidized I with o-C₆H₄(NH₂)₂ the major pathway is the formation of IV and the minor one is the formation of III.

IT 96103-24-1P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (preparation and elimination reaction of)
 RN 96103-24-1 CAPLUS
 CN 2-Quinoxalinecarboxamide, N-(2-aminophenyl)-3-(1-hydroxyethyl)- (9CI) (CA INDEX NAME)




IT 96103-25-2P 96109-44-3P
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (preparation of)
 RN 96103-25-2 CAPLUS
 CN 2-Quinoxalinecarboxamide, N-(2-aminophenyl)-3-[(2,2-dimethyl-1,3-dioxolan-4-yl)hydroxyethyl]-, [S-(R*,R*)]- (9CI) (CA INDEX NAME)
 Absolute stereochemistry.




RN 96109-44-3 CAPLUS
 CN Hexadecanoic acid, 3-[3-[(2-aminophenyl)amino]carbonyl]-2-quinoxaliny]-2,3-dihydroxypropyl ester, [S-(R*,R*)]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




L5 ANSWER 201 OF 283 CAPLUS COPYRIGHT 2006 ACS ON STN
 ACCESSION NUMBER: 1984:611620 CAPLUS
 DOCUMENT NUMBER: 101:211620
 TITLE: Some quinoxaline derivatives from dehydro-D-arabino-ascorbic acid
 AUTHOR(S): El Sekily, Mohamed Ali; Mancy, Sohila; Fahmy, Kamel
 CORPORATE SOURCE: Fac. Sci., Alexandria Univ., Alexandria, Egypt
 SOURCE: Carbohydrate Research (1984), 133(2), 324-8
 CODEN: CRBRAT; ISSN: 0008-6215
 DOCUMENT TYPE: Journal

LANGUAGE: English
 Q1




AB Oxidation of D-arabino-ascorbic acid with an equimolar amount of p-benzoquinone in MeOH-H₂O at room temperature, followed by condensation with 2 equivalent of o-C₆H₄(NH₂)₂ gave quinoxalinecarboxanilide I. Acid hydrolysis of I gave quinoxaline lactone II (R₁ = R₂ = OH). The latter was converted into III [R₁ = R₂ = OAc, OBz; R₁ = tosyloxy, Br, R₂ = OH] and into hydrazides II [R = Ph, 4-O₂NC₆H₄, 2,4-(O₂N)₂C₆H₃].

IT 92983-95-4P
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (preparation of)
 RN 92983-95-4 CAPLUS
 CN 2-Quinoxalinecarboxamide, N-(2-aminophenyl)-3-formyl- (9CI) (CA INDEX NAME)




IT 92983-92-1P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (preparation, oxidation, and hydrolysis of)
 RN 92983-92-1 CAPLUS
 CN 2-Quinoxalinecarboxamide, N-(2-aminophenyl)-3-(1,2,3-trihydroxypropyl)-, [S-(R*,S*)]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




L5 ANSWER 202 OF 283 CAPLUS COPYRIGHT 2006 ACS ON STN
 ACCESSION NUMBER: 1984:551813 CAPLUS
 DOCUMENT NUMBER: 101:151813
 TITLE: Potential antiallergic agents. V. Synthesis of N'-phenylquinoxaline-2,3-dicarboximide
 AUTHOR(S): Liu, Kang Chien; Shih, Bi Jane
 CORPORATE SOURCE: Dep. Pharm., Natl. Def. Med. Cent., Taipei, Taiwan
 SOURCE: Taiwan Yaxue Zazhi (1983), 35(2), 171-3
 CODEN: JTPHAA; ISSN: 0366-4520
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 Q1




AB The title compound (I), useful as the anti-allergic agent (no data), was prepared from 2,1,3-benzoxadiazole (II). II was heated with MeO₂C.tlplbond.CO₂Me in xylene to give quinoxaline derivative III (R = OMe), the latter and PhNH₂ gave III (R = NHPh), and the diamide product was heated in Dowtherm A to give I. o-Phenylenediamine was heated with H₂SeO₃ to yield II.

IT 37648-59-2P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (preparation and cyclocondensation of)
 RN 37648-59-2 CAPLUS
 CN 2,3-Quinoxalinedicarboxamide, N,N'-diphenyl- (9CI) (CA INDEX NAME)




L5 ANSWER 203 OF 283 CAPLUS COPYRIGHT 2006 ACS on STM
 ACCESSION NUMBER: 1984:156569 CAPLUS
 DOCUMENT NUMBER: 100:156569
 TITLE: Syntheses and antibacterial activity of some new N-(3-methyl-2-quinoxaloyl) amino alcohols and amine 1,4-dioxides
 AUTHOR(S): Sabri, Salim S.; El-Abdelah, Mustafa M.; Ovais, Wejib M.
 CORPORATE SOURCE: Fac. Sci., Jordan Univ., Amman, Jordan
 SOURCE: Journal of Chemical and Engineering Data (1984), 29(2), 229-31
 CODEN: JCEAAX; ISSN: 0021-9568
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 OTHER SOURCE(S): CASREACT 100:156569
 GI




AB The syntheses and the in vitro and in vivo antibacterial activities of a series of N-(3-methyl-2-quinoxaloyl) amino alcohols and amine 1,4-dioxides, and their deoxygenated analogs are described. The quinoxaline 1,4-dioxide derivative of the naturally occurring (-)-ephedrine I was the most potent antibacterial agent of the series. The presence of a hydroxy group and a tertiary amide appears to be associated with enhancement of the antibacterial action.

IT 81485-17-8P 88996-67-2P 88996-68-3P
 88996-69-4P 88996-70-7P 88996-74-1P
 89063-57-0P
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
 (preparation and bactericidal activity of)
 RN 81485-17-8 CAPLUS
 CN 2-Quinoxalinecarboxamide, N-[(1S,2R)-2-hydroxy-1-methyl-2-phenylethyl]-N,3-dimethyl-, 1,4-dioxide (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 88996-67-2 CAPLUS
 CN 2-Quinoxalinecarboxamide, 3-methyl-N-tricyclo[3.3.1.1^{3,7}]dec-1-yl-, 1,4-dioxide (9CI) (CA INDEX NAME)




RN 88996-68-3 CAPLUS
 CN 2-Quinoxalinecarboxamide, 3-methyl-N-tricyclo[3.3.1.1^{3,7}]dec-2-yl-, 1,4-dioxide (9CI) (CA INDEX NAME)




RN 88996-69-4 CAPLUS
 CN 2-Quinoxalinecarboxamide, 3-methyl-N-(1-phenylethyl)-, 1,4-dioxide, (R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 88996-70-7 CAPLUS
 CN 2-Quinoxalinecarboxamide, 3-methyl-N-(1-phenylethyl)-, 1,4-dioxide, (S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 88996-74-1 CAPLUS
 CN 2-Quinoxalinecarboxamide, N-[1-(hydroxymethyl)-2-phenylethyl]-3-methyl-, 1,4-dioxide, (S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 89063-57-0 CAPLUS
 CN 2-Quinoxalinecarboxamide, N-(2-hydroxy-1-methyl-2-phenylethyl)-N,3-dimethyl-, 1,4-dioxide, (R*,S*)- (9CI) (CA INDEX NAME)


Relative stereochemistry.



IT 88996-81-0P 88996-82-1P 88996-83-2P
 88996-84-3P 88996-88-7P 88996-89-8P
 89063-58-1P
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (preparation of)
 RN 88996-81-0 CAPLUS
 CN 2-Quinoxalinecarboxamide, 3-methyl-N-tricyclo[3.3.1.1^{3,7}]dec-1-yl- (9CI) (CA INDEX NAME)




RN 88996-82-1 CAPLUS
 CN 2-Quinoxalinecarboxamide, 3-methyl-N-tricyclo[3.3.1.1^{3,7}]dec-2-yl- (9CI) (CA INDEX NAME)



RN 88996-83-2 CAPLUS
 CN 2-Quinoxalinecarboxamide, 3-methyl-N-(1-phenylethyl)-, (R)- (9CI) (CA INDEX NAME)


INDEX NAME

Absolute stereochemistry.




RN 88996-84-3 CAPLUS
 CN 2-Quinoxalinecarboxamide, 3-methyl-N-(1-phenylethyl)-, (S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 88996-88-7 CAPLUS
 CN 2-Quinoxalinecarboxamide, N-(2-hydroxy-1-methyl-2-phenylethyl)-N,3-dimethyl-, [R-(R*,S*)]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 88996-89-8 CAPLUS
 CN 2-Quinoxalinecarboxamide, N-[1-(hydroxymethyl)-2-phenylethyl]-3-methyl-, (S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 89063-58-1 CAPLUS
 CN 2-Quinoxalinecarboxamide, N-(2-hydroxy-1-methyl-2-phenylethyl)-N,3-dimethyl-, (R*,S*)- (9CI) (CA INDEX NAME)

Relative stereochemistry.




LS ANSWER 204 OF 283 CAPLUS COPYRIGHT 2006 ACS ON STN
 ACCESSION NUMBER: 1984:121017 CAPLUS
 DOCUMENT NUMBER: 100:121017
 TITLE: Brominated analogs of quinoxaline, dioxidine and 3-(hydroxymethyl)quinoxaline-2-carboxamide di-N-oxides
 AUTHOR(S): Misatova, I. S.; Elina, A. S.; Solov'eva, N. P.; Polukhina, L. M.; Moskalenko, N. Yu.; Perashin, G. N.
 CORPORATE SOURCE: Vses. Nauchno-Issled. Khim.-Farm. Inst., Moscow, USSR
 SOURCE: Khimiko-Farmatsevticheskii Zhurnal (1983), 17(11), 1307-12
 CODEN: KHFZAN; ISSN: 0023-1134
 DOCUMENT TYPE: Journal
 LANGUAGE: Russian
 OTHER SOURCE(S): CASREACT 100:121017
 GI




AB Bromination of dimethylquinoxaline derivative I (R = Me) gave I (R = CH₂Br), which reacted with AcOH-NH₂ to give I (R = CH₂OAc); hydrolysis of this gave I (R = CH₂OH). The reaction of benzofuroxan II with MeCOCH₂CO₂Et gave quinoxalines III (R = H, R₁ = Br; R = Br, R₁ = H). Bromination of III (R = H, R₁ = Br) (IIa) followed by reaction with Ac₂O gives IV. Reaction of IIIa with Na₂SO₄ gives V; esterification of V, followed by reaction with Ac₂O, gave VI. The multistep conversion of IIIa to VII (R = H, Me, allyl, CH₂CH₂Ph, NH₂, etc.) was also carried out.
 IT 89142-24-5P 89142-25-6P 89142-27-8P
 RL: SPN (Synthetic preparation); PREP (Preparation) (preparation of)

and II. A reaction scheme of I with II is presented and the characteristics of the reactions are discussed.
 IT 87661-79-8P
 RL: SPN (Synthetic preparation); PREP (Preparation) (preparation and polarogram of)
 RN 87661-79-8 CAPLUS
 CN 2-Quinoxalinecarboxamide, N-(2-aminophenyl)-3-(1,2,3-trihydroxypropyl)-, [S-(R*,R*)]- (9CI) (CA INDEX NAME)
 Absolute stereochemistry.




LS ANSWER 206 OF 283 CAPLUS COPYRIGHT 2006 ACS ON STN
 ACCESSION NUMBER: 1983:11106 CAPLUS
 DOCUMENT NUMBER: 98:11106
 TITLE: 1,2-Dihydroxypropylidene[3,4-b]pyrazines: structure-activity relationships
 AUTHOR(S): Temple, Carroll, Jr.; Wheeler, Glynn P.; Elliott, Robert D.; Rose, Jerry D.; Comber, Robert N.; Montgomery, John A.
 CORPORATE SOURCE: Kettering-Meyer Lab., South. Res. Inst., Birmingham, AL, 35255, USA
 SOURCE: Journal of Medicinal Chemistry (1983), 26(1), 91-5
 CODEN: JMCMAH; ISSN: 0022-2623
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 OTHER SOURCE(S): CASREACT 98:11106
 AB Thirty-one 1,2-dihydroxypropylidene[3,4-b]pyrazine analogs, some of which were synthesized, were tested for neoplasia-inhibiting activity. Apparently, the neoplasia-inhibiting activity of 1,2-dihydroxypropylidene[3,4-b]pyrazines is diminished by addition of N to the 1-position or interchange of the 3-N and 1-CH₃ oxidation to the corresponding heteroatom system, reduction to the corresponding tetrahydro derivative, replacement of the 4-amino group with other substituents, replacement of the aryl moiety at the 6-position with a Me group, replacement of the 8-NH with NMe, and opening the pyrazine ring. In contrast, activity was increased by the substitution of a Me group at the 7-position.
 IT 83269-14-1P
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USSS (Uses) (preparation and neoplasia-inhibiting activity of)
 RN 83269-14-1 CAPLUS
 CN Carbanic acid, [5-amino-3-[(methylphenylamino)carbonyl]pyrido[3,4-b]pyrazin-7-yl]-, ethyl ester (9CI) (CA INDEX NAME)


RN 89142-24-5 CAPLUS
 CN 2-Quinoxalinecarboxamide, 7-bromo-N-(2-(3,4-dimethoxyphenyl)ethyl)-3-(hydroxymethyl)-, 1,4-dioxide (9CI) (CA INDEX NAME)




RN 89142-25-6 CAPLUS
 CN 2-Quinoxalinecarboxamide, 7-bromo-N-(2-(1-cyclohexen-1-yl)ethyl)-3-(hydroxymethyl)-, 1,4-dioxide (9CI) (CA INDEX NAME)



RN 89142-27-8 CAPLUS
 CN 2-Quinoxalinecarboxamide, 7-bromo-3-(hydroxymethyl)-N-(2-phenylethyl)-, 1,4-dioxide (9CI) (CA INDEX NAME)




LS ANSWER 205 OF 283 CAPLUS COPYRIGHT 2006 ACS ON STN
 ACCESSION NUMBER: 1983:576198 CAPLUS
 DOCUMENT NUMBER: 99:176198
 TITLE: Further polarographic studies on the condensation products of dehydro-L-ascorbic acid with o-phenylenediamine in acetate buffer, pH 3.6
 AUTHOR(S): Ohmori, Mitsuaki; Tadjimoto, Yujii; Takegi, Masanosuke
 CORPORATE SOURCE: Coll. Agric., Univ. Osaka, Sakai, 591, Japan
 SOURCE: Bulletin of the Chemical Society of Japan (1983), 56(7), 2033-6
 CODEN: BCSJAB; ISSN: 0009-2673
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 AB Three polarog. reduction waves, which appear when dehydro-L-ascorbic acid (I) is treated with o-phenylenediamine (II) in acetate buffer, pH 3.6, were reinvestigated by comparing with those of the synthesized products from I



LS ANSWER 207 OF 283 CAPLUS COPYRIGHT 2006 ACS ON STN
 ACCESSION NUMBER: 1983:4563 CAPLUS
 DOCUMENT NUMBER: 98:4563
 TITLE: Quinoxaline derivatives
 INVENTOR(S): Isidorides, Costas W.; Haddadin, Makhuf J.
 PATENT ASSIGNEE(S): Research Corp., USA
 SOURCE: U.S., 24 pp. Cont.-in-part of U.S. Ser. No. 691,252, abandoned.
 CODEN: USXXAM
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 3
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 4343942	A	19820810	US 1969-883577	19691209
CA 923131	A1	19730320	CA 1967-4478	19671107
GB 1308370	A	19730228	GB 1970-47202	19701005
NL 157302	B	19760717	NL 1972-8887	19720628
DK 7800142	A	19780112	DK 1978-142	19780112
US 4866175	A	19850912	US 1979-29344	19790412
PRIORITY APPL. INFO.:			US 1966-592729	A2 19661108
			NL 1967-14882	A2 19671102
			US 1967-691252	A2 19671218
			DK 1967-5535	A 19671107
			US 1969-883577	A 19691209
			CA 1970-933131	A5 19701118
			US 1977-843510	A1 19771008


OTHER SOURCE(S): CASREACT 98:4563
 GI




AB Bactericidal quinoxaline dioxides I (R, R₁ = H, alkyl; R₂ = F₃C, H₂NSO₂, MeNSO₂, Me₂NSO₂) and II (R₃ = alkoxy, aryloxy, PhCH₂O, H₂NR₄ (R₄, R₅ = H, alkyl, Ph); R₂ = H, Cl, F, Me, MeO, F₃C, H₂NSO₂, MeNSO₂) and III (R₂ = as before) were prepared. Thus, condensation of benzofuroxan with Me₂CO in

refluxing MeCN containing pyrrolidine gave 2-methylquinoxaline dioxide which possessed a min. inhibitory concentration of 50 µg/mL against *Pasteurella multocida*.


IT 23433-48-9P 23433-76-3P 31887-83-9P
 31983-89-8P 83821-63-0P
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (preparation of)
 RN 23433-48-9 CAPLUS
 CN 2-Quinoxalinecarboxamide, N-(2-methoxyphenyl)-3-methyl-, 1,4-dioxide (9CI)
 (CA INDEX NAME)




RN 23433-76-3 CAPLUS
 CN 2-Quinoxalinecarboxamide, N-cyclohexyl-3-methyl-, 1,4-dioxide (6CI, 9CI)
 (CA INDEX NAME)




RN 31887-83-9 CAPLUS
 CN 2-Quinoxalinecarboxamide, 3-methyl-N-(4-methylphenyl)-, 1,4-dioxide (9CI)
 (CA INDEX NAME)




RN 31983-89-8 CAPLUS
 CN 2-Quinoxalinecarboxamide, 3-methyl-N-phenyl-, 1,4-dioxide (9CI) (CA INDEX NAME)



RN 83821-63-0 CAPLUS
 CN 2-Quinoxalinecarboxamide, 3-methyl-N-(phenylmethyl)-, 1,4-dioxide (9CI)
 (CA INDEX NAME)



L5 ANSWER 208 OF 283 CAPLUS COPYRIGHT 2006 ACS ON STM
 ACCESSION NUMBER: 1982:194867 CAPLUS
 DOCUMENT NUMBER: 96:194867
 TITLE: Microbial mutagenicity and toxicity of newly synthesized heterocyclic N-oxides
 AUTHOR(S): Al-Mossawi, M. A. J.; Salem, A. A.; Salama, M.; Anani, A.
 CORPORATE SOURCE: Kuwait Inst. Sci. Res., Safat, Kuwait
 SOURCE: Environment International (1981), 5(3), 141-4
 CODEN: ENVIDV; ISSN: 0160-4120
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 GI




AB Newly synthesized heterocyclic N-oxides were tested for their mutagenicity using the Ames test. DX1 (I) [81485-16-9] was potentially mutagenic in *Salmonella typhimurium* TA 100 and 98 with and without the S-9 mixture WO 25 [81485-17-8] And WO 20 [81485-16-7], being structurally related to I, did not show any genetic change in the strains used. The antibiotic activity of these chems. was also tested using gram-neg. and gram-pos. bacteria. I had more killing effect in gram-pos. bacteria than WO 25 and WO 20.

IT 81485-16-7 81485-17-8
 RL: ADV (Adverse effect, including toxicity); BIOL (Biological study)


(mutagenicity and toxicity of)

RN 81485-16-7 CAPLUS
 CN D-Phenylalanine, N-[[[3-[[[(1S,2R)-2-hydroxy-1-methyl-2-phenylethyl]methylamino]carbonyl]-2-methyl-1,4-dioxido-6-quinoxaliny]carbonyl]- (9CI) (CA INDEX NAME)



RN 81485-17-8 CAPLUS
 CN 2-Quinoxalinecarboxamide, N-[[[3-[[[(1S,2R)-2-hydroxy-1-methyl-2-phenylethyl]-N,3-dimethyl-, 1,4-dioxide (9CI) (CA INDEX NAME)

Absolute stereochemistry.




L5 ANSWER 209 OF 283 CAPLUS COPYRIGHT 2006 ACS ON STM
 ACCESSION NUMBER: 1981:208098 CAPLUS
 DOCUMENT NUMBER: 94:208098
 TITLE: Deoxygenation and x-ray photoelectron studies on some quinoxalines and their N-oxides
 AUTHOR(S): El-Abadelah, Mustafa M.; Anani, Ali A.; Khan, Zahida H.; Hassan, A. M.; Kacrib, Ali
 CORPORATE SOURCE: Mater. Sci. Appl. Dep., Kuwait Inst. Sci. Res., Kuwait
 SOURCE: Journal of Heterocyclic Chemistry (1980), 17(8), 1671-80
 CODEN: JHTCAD; ISSN: 0022-152X
 DOCUMENT TYPE: Journal
 LANGUAGE: English

AB Deoxygenation results of some quinoxaline dioxides with PCl_3 are presented and compared with previous deoxygenations with other reagents. Differentiation between isomeric quinoxaline oxides using XPS is also discussed.

IT 62973-08-4 62973-10-8 74200-00-3
 74200-01-4
 RL: RCT (Reactant); RACT (Reactant or reagent)
 (deoxygenation of)


RN 62973-08-4 CAPLUS
 CN Benzenecetic acid, α -[[[3-methyl-1,4-dioxido-2-quinoxaliny]carbonyl]amino]-, methyl ester, (S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 62973-10-8 CAPLUS
 CN L-Phenylalanine, N-[[[3-methyl-1,4-dioxido-2-quinoxaliny]carbonyl]-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 74200-00-3 CAPLUS
 CN Benzenecetic acid, α -[[[3-methyl-1,4-dioxido-2-quinoxaliny]carbonyl]amino]-, methyl ester, (S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 74200-01-4 CAPLUS
 CN L-Phenylalanine, N-[[[3-methyl-1,4-dioxido-2-quinoxaliny]carbonyl]-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




IT 74200-11-6P 74200-14-9P 74200-15-0P
74200-18-3P 74200-19-4P 74200-22-9P
74200-23-0P
RL: PRP (Properties); SPN (Synthetic preparation); PREP (Preparation)
(preparation and RGR of)
RN 74200-11-6 CAPLUS
CN L-Phenylalanine, N-[(4-oxido-2-quinoxaliny)carbonyl]-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 74200-14-9 CAPLUS
CN Benzeneacetic acid, α -[[(1-oxido-2-quinoxaliny)carbonyl]amino]-, methyl ester, (S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 74200-15-0 CAPLUS
CN L-Phenylalanine, N-[(1-oxido-2-quinoxaliny)carbonyl]-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 74200-18-3 CAPLUS
CN Benzeneacetic acid, α -[[(3-methyl-4-oxido-2-quinoxaliny)carbonyl]amino]-, methyl ester, (S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 74200-19-4 CAPLUS
CN L-Phenylalanine, N-[(3-methyl-4-oxido-2-quinoxaliny)carbonyl]-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 74200-22-9 CAPLUS
CN Benzeneacetic acid, α -[[(3-methyl-1-oxido-2-quinoxaliny)carbonyl]amino]-, methyl ester, (S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 74200-31-0 CAPLUS
CN L-Phenylalanine, N-[(3-methyl-1-oxido-2-quinoxaliny)carbonyl]-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L5 ANSWER 210 OF 283 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 1981:30470 CAPLUS
DOCUMENT NUMBER: 94:30470


TITLE: Synthesis of quinoxaline- and indole-2,3-dicarboxylic acid imides
AUTHOR(S): Augustin, M.; Koehler, M.; Faust, J.; Al-Holly, M. M.
CORPORATE SOURCE: Sekk. Chem., Martin Luther Univ., Halle-Wittenberg,
DDR-402, Ger. Dem. Rep.
SOURCE: Tetrahedron (1980), 36(12), 1801-5
CODEN: TETRA; ISSN: 0040-4020
DOCUMENT TYPE: Journal
LANGUAGE: German
OTHER SOURCE(S): CASREACT 94:30470
OI




AB The maleimides I (R = H, R1 = Cl, R2R3 = NPh, NMe) reacted with NaN3 (Me2CO/H2O, room temperature, 10 min) to give the indole-2,3-dicarboxylic acid imides II (RR1 = NH, R2R3 = NPh, NMe) (33 and 24%, resp.). These reacted readily with nucleophiles to give a range of 6-methylindole-2,3-dicarboxylic acid imides. In high yield (53-92%). E.g., I (RR1 = NH, R2R3 = NPh) with MeOH (10 min) gave 90% I (RR1 = NH, R2 = NHPh, R3 = OMe). The quinoxaline-2,3-dicarboxylic acid imides II (R = Ph, Me) were prepared similarly. Treatment of II (R = Ph) with aqueous NH3 gave the intermediate III (R = CO2NH2) which either hydrolyzed to the acid-imide or decarboxylated to the crystalline monoamide III (R = H).

IT 37648-58-1P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)


RN 37648-58-1 CAPLUS
CN 2-Quinoxalinecarboxylic acid, 3-[(phenylamino)carbonyl]- (9CI) (CA INDEX NAME)



IT 37648-63-8P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)
RN 37648-63-8 CAPLUS
CN 2-Quinoxalinecarboxamide, N-phenyl- (9CI) (CA INDEX NAME)




IT 76039-52-6P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation, hydrolysis, and decarboxylation of)
RN 76039-52-6 CAPLUS
CN 2-Quinoxalinecarboxylic acid, 3-[(phenylamino)carbonyl]-, monoammonium salt (9CI) (CA INDEX NAME)



• NH3

L5 ANSWER 211 OF 283 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 1980:514423 CAPLUS
DOCUMENT NUMBER: 93:114423
TITLE: Studies on β -lactam antibiotics. V. Synthesis of 6-[D(-)- α -(acylamino)-4-hydroxyphenylacetamido]penicillanic acids and antibacterial activity
AUTHOR(S): Tobiki, Hisao; Yamada, Hirotsada; Tanno, Norihiko; Shimizu, Kozo; Kida, Yasuko; Noguchi, Hiroshi; Komatsu, Toshitsuki; Nakagawa, Takemasa
CORPORATE SOURCE: Pharm. Div., Sumitomo Chem. Co., Ltd., Takarazuka, Japan
SOURCE: Yakugaku Zasshi (1980), 100(2), 133-9
CODEN: YKKZAJ; ISSN: 0031-6903
DOCUMENT TYPE: Journal
LANGUAGE: Japanese
OI




AB 6-[p-(-)- α -(Acylamino)-4-hydroxyphenylacetamido]penicillanic acid Na salts I (R = N heterocyclyl) were prepared by reacting amoxicillin with the active esters of N-containing heterocyclic compds. These penicillins were tested for in vitro bactericidal activities. Structure-activity relationships were discussed. I (R = 4-hydroxy-3-quinolyl) and I (R =

4-hydroxy-1,4-naphthylidene-3-yl (II) and 3,6-substituted deriva.] had potent antibacterial activity against *E. coli*, *K. pneumoniae*, *P. mirabilis*, and *P. aeruginosa*. II exhibited the highest activity against *P. aeruginosa*, its MIC being 1.56 µg/mL.

IT 74700-51-9P
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
 (preparation and bactericidal activity of)


RN 74700-51-9 CAPLUS
 CN 4-Thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid, 6-[[[(3,4-dihydro-3-oxo-2-quinoxaliny)carbonyl]amino](4-hydroxyphenyl)acetyl]amino]-3,3-dimethyl-7-oxo-, monosodium salt, [2S-[2 α,5α,6β(8*)]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● Na

L5 ANSWER 213 OF 283 CAPLUS COPYRIGHT 2006 ACS ON STN
 ACCESSION NUMBER: 1980:495178 CAPLUS
 DOCUMENT NUMBER: 93:95178
 TITLE: Studies on β-lactam antibiotics. III. Synthesis of 6-[D(-)-α-(acylamino)phenylacetamido]penicillanic acid and antibacterial activity
 AUTHOR(S): Tobiki, Hisao; Yamada, Hirotsugu; Nakatsuka, Iwao; Shino, Kozo; Eda, Yasuko; Noguchi, Hiroshi; Komatsu, Toshiki; Nakagome, Takenari
 CORPORATE SOURCE: Pharm. Div., Sumitomo Chem. Co., Ltd., Takarazuka, Japan
 SOURCE: Yakugaku Zasshi (1980), 100(1), 38-48
 CODEN: YKKZAJ; ISSN: 0031-6903
 DOCUMENT TYPE: Journal
 LANGUAGE: Japanese
 OT




AB Thirty-four title compds. I (R = 2-pyridyl, substituted pyridyl, substituted pyridazinyl, substituted pyrimidinyl, etc.; M = H, K, Na) were prepared by treating ampicillin with the appropriate acylating deriva. of ROCH. I were tested against *Staphylococcus aureus*, *Escherichia coli*, *Klebsiella pneumoniae*, *Proteus mirabilis* and *Pseudomonas aeruginosa*.

IT 74557-65-6P
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
 (preparation and antibacterial activity of)

RN 74557-65-6 CAPLUS
 CN 4-Thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid, 6-[[[(3,4-dihydro-3-oxo-2-quinoxaliny)carbonyl]amino]phenylacetyl]amino]-3,3-dimethyl-7-oxo-, monopotassium salt, [2S-[2 α,5α,6β(8*)]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● K


L5 ANSWER 213 OF 283 CAPLUS COPYRIGHT 2006 ACS ON STN
 ACCESSION NUMBER: 1980:490734 CAPLUS
 DOCUMENT NUMBER: 93:90734
 TITLE: A simple radioassay for dihydrofolate synthetase activity in *Escherichia coli* and its application to an inhibition study of new pterate analogs
 AUTHOR(S): Ho, Richard I.
 CORPORATE SOURCE: Novo Lab. Inc., Wilton, CT, 06897, USA
 SOURCE: Methods in Enzymology (1980), 66(Vitam. Coenzymes, Pt. 8), 576-81
 CODEN: MENZAU; ISSN: 0076-6879
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 AB A radioassay for dihydrofolate synthetase activity in *E. coli* is described in which dihydropterate acid and L-glutamic-U-14C acid are incubated, together with the appropriate cofactors, buffers and salts, with the enzyme for 30 min at 37°, and the products were separated on Whatman 3 MM paper. Removal of endogenous folates and other undesirable compds. from crude exts. of *E. coli* before assay is also described. Studies of the kinetics of inhibition of the enzyme by 8 pterate analogs showed the structural requirements for active inhibitors. Of the 8 inhibitors tested, 4 were active, and their Ki values were: dihydropterate acid 1.4 × 10⁻⁵M, dihydro-10-thiopterate acid 4.0 × 10⁻⁵M, dihydrofolic acid 1.1 × 10⁻⁴M, and dihydroisopterate acid 1.7 × 10⁻⁴M. These were all competitive inhibitors.

IT 39707-60-3
 RL: BIOL (Biological study)
 (dihydrofolate synthetase inhibition in relation to)

RN 39707-60-3 CAPLUS
 CN Benzeneacetic acid, 4-[[[(2-amino-1,4-dihydro-4-oxo-6-pteridinyl)carbonyl]amino]- (9CI) (CA INDEX NAME)



L5 ANSWER 214 OF 283 CAPLUS COPYRIGHT 2006 ACS ON STN
 ACCESSION NUMBER: 1980:446583 CAPLUS
 DOCUMENT NUMBER: 93:46583
 TITLE: Selective monodeoxygenation of quinoxaline-amino acid and ester dioxides
 AUTHOR(S): El Abdelah, M. M.; Sabri, S. S.; Tashetoush, H. I.
 CORPORATE SOURCE: Kuwait Inst. Sci. Res., Kuwait, Kuwait
 SOURCE: Tetrahedron (1979), 35(21), 2571-6
 CODEN: TETRAH; ISSN: 0040-4020
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 OT




AB The selective monodeoxygenation of the title compds. by (MeO)3P is reported. In the amino ester dioxides, e.g. I, the N-1 O was removed, whereas in the corresponding series lacking the C-3 Me, the N-4 O was selectively removed. (MeO)3P requires doubling of the N-oxide function for deoxygenation as the corresponding monoxides were not deoxygenated. Alkaline Na2S2O4 removed the N-1 O in both series of dioxides as well as the parent carboxylic acid dioxide, contradicting A. S. Elina and O. Yu. Magidson (1955).

IT 65926-47-8
 RL: RCT (Reactant); RACT (Reactant or reagent)
 (oxidation of, by peroxide)

RN 65926-47-8 CAPLUS
 CN Benzeneacetic acid, α-[[[(2-quinoxaliny)carbonyl]amino]-, methyl ester, (S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




IT 74200-10-5P 74200-11-6P 74200-14-9P
 74200-15-0P 74200-18-3P 74200-19-4P

74200-22-9P 74200-23-0P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (preparation and deoxygenation of)


RN 74200-10-5 CAPLUS
 CN Benzeneacetic acid, α-[[[(4-oxido-2-quinoxaliny)carbonyl]amino]-, methyl ester, (S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 74200-11-6 CAPLUS
 CN L-Phenylalanine, N-[[[(4-oxido-2-quinoxaliny)carbonyl]-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 74200-14-9 CAPLUS
 CN Benzeneacetic acid, α-[[[(1-oxido-2-quinoxaliny)carbonyl]amino]-, methyl ester, (S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 74200-15-0 CAPLUS
 CN L-Phenylalanine, N-[[[(1-oxido-2-quinoxaliny)carbonyl]-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 74200-18-3 CAPLUS
CN Benzeneacetic acid, α -[(3-methyl-4-oxido-2-quinoxaliny)carbonyl]amino]-, methyl ester, (S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 74200-19-4 CAPLUS
CN L-Phenylalanine, N-[(3-methyl-4-oxido-2-quinoxaliny)carbonyl]-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 74200-22-9 CAPLUS
CN Benzeneacetic acid, α -[(3-methyl-1-oxido-2-quinoxaliny)carbonyl]amino]-, methyl ester, (S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 74200-23-0 CAPLUS
CN L-Phenylalanine, N-[(3-methyl-1-oxido-2-quinoxaliny)carbonyl]-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




IT 62973-07-3P 62973-08-4P 62973-09-5P
62973-10-8P 74200-04-7P 74200-05-8P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation and selective deoxygenation of)
RN 62973-07-3 CAPLUS
CN Benzeneacetic acid, α -[(3-methyl-1,4-dioxido-2-quinoxaliny)carbonyl]amino]-, (S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 62973-08-4 CAPLUS
CN Benzeneacetic acid, α -[(3-methyl-1,4-dioxido-2-quinoxaliny)carbonyl]amino]-, methyl ester, (S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 62973-09-5 CAPLUS
CN L-Phenylalanine, N-[(3-methyl-1,4-dioxido-2-quinoxaliny)carbonyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 62973-10-8 CAPLUS
CN L-Phenylalanine, N-[(3-methyl-1,4-dioxido-2-quinoxaliny)carbonyl]-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 74200-04-7 CAPLUS
CN Benzeneacetic acid, α -[(1,4-dioxido-2-quinoxaliny)carbonyl]amino]-, (S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 74200-05-8 CAPLUS
CN L-Phenylalanine, N-[(1,4-dioxido-2-quinoxaliny)carbonyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



IT 74200-00-3P 74200-01-4P


RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation, deoxygenation, and deesterification of)
RN 74200-00-3 CAPLUS
CN Benzeneacetic acid, α -[(1,4-dioxido-2-quinoxaliny)carbonyl]amino]-, methyl ester, (S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 74200-01-4 CAPLUS
CN L-Phenylalanine, N-[(1,4-dioxido-2-quinoxaliny)carbonyl]-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L5 ANSWER 215 OF 283 CAPLUS COPYRIGHT 2006 ACS ON STN
ACCESSION NUMBER: 1979:54905 CAPLUS
DOCUMENT NUMBER: 90:54905
TITLE: Ethyl amidinoacetates in the synthesis of pyrazines
AUTHOR(S): Keir, William F.; MacLennan, Alexander H.; Wood, Hamish C. S.
CORPORATE SOURCE: Paisley Coll. Technol., Paisley, UK
SOURCE: Journal of the Chemical Society, Perkin Transactions 1: Organic and Bio-Organic Chemistry (1972-1999) (1978), (9), 1002-6
CODEN: JCPR84; ISSN: 0300-922X
DOCUMENT TYPE: Journal
LANGUAGE: English
OTHER SOURCE(S): CASREACT 90:54905
OI



AB Treating EtO2CCN2C(OEt):NH.HCl with 2 equiv NH3/EtOH followed by

nitrosation or coupling with PhN₂• gave 70% EtO₂CCHRC(NH₂):NH (I, R = NO) and 50% I (R = N₂Ph), resp. Reduction of I (R = NO, N₂Ph) gave 87% I (R = NH₂) which on cyclization with 1,2-dicarbonyl reagents gave 22-61.3% pyrazinecarboxylates II (R = OEt, R₁ = NO, R₂ = H, CH₂Ph, Ph; R = OEt, R₁ = N₂Ph, R₂ = H). Cyclization of I (R = NH₂) and EtO₂CCHRC(NH₂):NH with phenylglyoxal gave 39 and 54% II (R = OEt, R₁ = NO, R₂ = Ph; R = R₁ = NH₂, R₂ = H, resp.). Treating the pyrazinecarboxylates with amines gave the corresponding N-alkylamides.


IT 68884-11-7P 68884-14-OP

RL: SPH (Synthetic preparation); PREP (Preparation)

(preparation of)


RN 68884-11-7 CAPLUS

CN 2-Quinoxalinecarboxamide, 3-amino-5,6,7,8-tetrahydro-N-(phenylmethyl)- (9CI) (CA INDEX NAME)



RN 68884-14-0 CAPLUS

CN 2-Quinoxalinecarboxamide, 3-amino-N-cyclohexyl-5,6,7,8-tetrahydro- (9CI) (CA INDEX NAME)



L5 ANSWER 216 OF 283 CAPLUS COPYRIGHT 2006 ACS ON STN

ACCESSION NUMBER: 1979:38909 CAPLUS

DOCUMENT NUMBER: 90:38909

TITLE: 6-(2-Acylamino-2-arylacetyl)penicillanic acids
INVENTOR(S): Morita, Yoshiharu; Oya, Junichi; Shirasaka, Tadashi
PATENT ASSIGNEE(S): Mitsubishi Chemical Industries Co., Ltd., Japan
SOURCE: Ger. Offen., 18 pp.
CODEN: GWIXEX

DOCUMENT TYPE: Patent

LANGUAGE: German

FAMILY ACC. NUM. COUNT: 1


PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
DE 2808301	A1	19781012	DE 1978-2808301	19780227
JP 53124295	A2	19781030	JP 1977-38227	19770404
US 4164577	A	19790814	US 1978-880132	19780222
GB 1566849	A	19800508	GB 1978-7125	19780222
FR 2386546	A1	19781103	FR 1978-7812	19780317
			JP 1977-38227	A 19770404

PRIORITY APPL. INFO.:

OTHER SOURCE(S): MARPAT 90:38909

GI



I

AB Penicillins I (R = H, Me, Et; R₁ = H, OH; X = CH, N, CCl, CBr) were prepared by acylating ampicillin or amoxicillin. Thus, 838 mg amoxicillin-3H₂O was treated with 382 mg 3-hydroxypyridine-2-carboxylic acid and BuEtCHCO₂K to give 449 mg K salt of I (R = H, R₁ = OH, X = CH), which had min. inhibitory concentration against *Pseudomonas aeruginosa* M-16 0.78 mg/mL.

IT 68021-44-3P 68021-45-4P 68021-46-5P

68021-47-6P 68021-48-7P 68021-49-8P

68767-99-7P 68768-00-3P 68832-14-4P

68832-15-5P


RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)

(preparation and bactericidal activity of)

RN 68021-44-3 CAPLUS

CN 4-Thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid, 6-[[[(3,4-dihydro-3-oxopyridine-2,3-bispyrazin-2-yl)carbonyl]amino]phenylacetyl]amino]-3,3-dimethyl-7-oxo-, monopotassium salt, [2S-[2 α,5α,6β(S*)]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




• K

RN 68021-45-4 CAPLUS

CN 4-Thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid, 6-[[[(3,4-dihydro-3-oxopyridine-2,3-bispyrazin-2-yl)carbonyl]amino]phenylacetyl]amino]-3,3-dimethyl-7-oxo-, monopotassium salt, [2S-[2 α,5α,6β(S*)]]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.




Absolute stereochemistry.




Absolute stereochemistry.




Absolute stereochemistry.




Absolute stereochemistry.



Absolute stereochemistry.




Absolute stereochemistry.



Absolute stereochemistry.




Absolute stereochemistry.



● K

RN 68767-99-7 CAPLUS
CN 4-Thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid, 6-[[[[(7-bromo-3,4-dihydro-6-methyl-3-oxopyrido[2,3-b]pyrazin-2-yl)carbonyl]amino]phenyl]acetyl]amino]-3,3-dimethyl-7-oxo-, monopotassium salt, [2S-[2α,5α,6β(S*)]]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● K

RN 68768-00-3 CAPLUS
CN 4-Thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid, 6-[[[[(7-bromo-3,4-dihydro-6-methyl-3-oxopyrido[2,3-b]pyrazin-2-yl)carbonyl]amino]phenyl]acetyl]amino]-3,3-dimethyl-7-oxo-, monopotassium salt, [2S-[2α,5α,6β(S*)]]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● K

RN 68832-14-4 CAPLUS
CN 4-Thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid, 6-[[[[(1,7-dihydro-7-oxo-6-pteridinyl)carbonyl]amino]phenyl]acetyl]amino]-3,3-dimethyl-7-oxo-, monopotassium salt, [2S-[2α,5α,6β(S*)]]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● K

RN 68832-15-5 CAPLUS
CN 4-Thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid, 6-[[[[(1,7-dihydro-7-oxo-6-pteridinyl)carbonyl]amino]phenyl]acetyl]amino]-3,3-dimethyl-7-oxo-, monopotassium salt, [2S-[2α,5α,6β(S*)]]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● K

L5 ANSWER 217 OF 283 CAPLUS COPYRIGHT 2006 ACS ON STN
ACCESSION NUMBER: 1978:597572 CAPLUS
DOCUMENT NUMBER: 89:197572
TITLE: 6[D-2-(7-Hydroxypteridine-6-carboxamido)-2-phenylacetamid]penicillanate salts
INVENTOR(S): Morita, Yoshiharu; Oya, Junichi; Shirasaka, Tadashi
PATENT ASSIGNEE(S): Mitsubishi Chemical Industries Co., Ltd., Japan
SOURCE: Jpn. Kokai Tokkyo Koho, 4 pp.
CODEN: JKXXAF
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 53077091	A2	19780708	JP 1976-151405	19761216
PRIORITY APPLN. INFO.:			JP 1976-151405	A 19761216




AB Antibacterial title salts I (R = Ph, p-hydroxyphenyl), effective against *Pseudomonas aeruginosa* at <1.56 μg/mL level. were prepared by acylating ampicillin or amoxicillin. Thus, 2 mmol 7-hydroxypteridine-6-carboxylic acid was activated with 2.2 mmol N,N'-carbonyldiimidazole in DMF, stirred with 2 mmol ampicillin Et3N salt at room temperature 3 h, and treated with K 2-ethylhexanoate in BuOH to give 47% I (R = Ph).

IT RL: SPN (Synthetic preparation); PREP (Preparation) (preparation of)

RN 68165-27-5 CAPLUS
CN 4-Thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid, 6-[[[[(1,7-dihydro-7-oxo-6-pteridinyl)carbonyl]amino]phenyl]acetyl]amino]-3,3-dimethyl-7-oxo-,

monopotassium salt, [2S-[2α,5α,6β]]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● K

RN 68165-28-6 CAPLUS
CN 4-Thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid, 6-[[[[(1,7-dihydro-7-oxo-6-pteridinyl)carbonyl]amino]phenyl]acetyl]amino]-3,3-dimethyl-7-oxo-, monopotassium salt, [2S-[2α,5α,6β]]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● K

L5 ANSWER 218 OF 283 CAPLUS COPYRIGHT 2006 ACS ON STN
ACCESSION NUMBER: 1978:579993 CAPLUS
DOCUMENT NUMBER: 89:179993
TITLE: Penicillin derivatives
INVENTOR(S): Morita, Yoshimi; Oya, Junichi; Shirasaka, Tadashi
PATENT ASSIGNEE(S): Mitsubishi Chemical Industries Co., Ltd., Japan
SOURCE: Jpn. Kokai Tokkyo Koho, 7 pp.
CODEN: JKXXAF
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE




AB Penicillin deriva. I [R, R1 = H, H; Cl, H; Cl, OH; Br, H; Br, OH] were prepared by reaction of II or their deriva. with III or their reactive deriva. followed by conversion to the K salts. I had antibacterial activity against gram pos. and neg. bacteria; the data were given against *Pseudomonas aeruginosa* in comparison with sulbenicillin. Thus, a mixture of 382 mg II (R = H) and 365 mg N,N'-carbonyldiimidazole in DMF was stirred 1.5 h with ice cooling, a mixture of 898 mg III (R1 = OH) and 0.278 mL Et3N in DMF added, the whole stirred 3 h at room temperature, and treated with K 2-ethylhexanoate in BuOH to give 443 mg D-I (R = H, R1 = OH).

IT 68021-44-3P 68021-45-4P 68021-46-5P
 68021-47-6P 68021-48-7P 68021-49-8P
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (preparation of)

RN 68021-44-3 CAPLUS
 CN 4-Thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid, 6-[[[(3,4-dihydro-3-oxopyrido[2,3-b]pyrazin-2-yl)carbonyl]amino]phenylacetyl]amino]-3,3-dimethyl-7-oxo-, monopotassium salt, [2S-[2 α,5α,6β(S*)]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● K

RN 68021-45-4 CAPLUS

CN 4-Thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid, 6-[[[(3,4-dihydro-3-oxopyrido[2,3-b]pyrazin-2-yl)carbonyl]amino]phenylacetyl]amino]-3,3-dimethyl-7-oxo-, monopotassium salt, [2S-[2 α,5α,6β(S*)]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● K

RN 68021-46-5 CAPLUS

CN 4-Thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid, 6-[[[(7-chloro-3,4-dihydro-3-oxopyrido[2,3-b]pyrazin-2-yl)carbonyl]amino]phenylacetyl]amino]-3,3-dimethyl-7-oxo-, monopotassium salt, [2S-[2 α,5α,6β(S*)]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● K

RN 68021-47-6 CAPLUS

CN 4-Thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid, 6-[[[(7-chloro-3,4-dihydro-3-oxopyrido[2,3-b]pyrazin-2-yl)carbonyl]amino]phenylacetyl]amino]-3,3-dimethyl-7-oxo-, monopotassium salt, [2S-[2 α,5α,6β(S*)]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● K

RN 68021-48-7 CAPLUS

CN 4-Thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid, 6-[[[(7-bromo-3,4-dihydro-3-oxopyrido[2,3-b]pyrazin-2-yl)carbonyl]amino]phenylacetyl]amino]-3,3-dimethyl-7-oxo-, monopotassium salt, [2S-[2 α,5α,6β(S*)]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● K

RN 68021-49-8 CAPLUS

CN 4-Thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid, 6-[[[(7-bromo-3,4-dihydro-3-oxopyrido[2,3-b]pyrazin-2-yl)carbonyl]amino]phenylacetyl]amino]-3,3-dimethyl-7-oxo-, monopotassium salt, [2S-[2 α,5α,6β(S*)]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● K

L5 ANSWER 219 OF 263

ACCESSION NUMBER:

DOCUMENT NUMBER:

TITLE:

AUTHOR(S):

CORPORATE SOURCE:

SOURCE:

DOCUMENT TYPE:

LANGUAGE:

Q1

CAPLUS COPYRIGHT 2006 ACS on STM

1978:121693 CAPLUS

88:121693

Optical shift PMR spectroscopic studies on some

quinoxaline amino esters and dipeptides

El-Abdelah, Mustafa M.; Sabri, Salim S.; Tabba, Hani

D.; Duddeck, Helmut


Chem. Dep., Univ. Jordan, Amman, Jordan

Journal of Heterocyclic Chemistry (1977), 14(5), 871-6

CODEN: JHCTAD; ISSN: 0022-152X

Journal


English



AB Optishift 1H-NMR spectra measurements on N-(2-quinoxaloyl)- α-amino esters I (R = H, Me; R1 = Me, CH2Ph) indicate that their L-isomers are optically pure. Such measurements also show that the Eu atom in the Eu(tfc)3 [tris(3-trifluoromethylhydroxymethylene-d-camphorato)europium] preferentially complexes with the amide carbonyl. Similar optishift 1H-NMR studies on model quinoxaline-dipeptide esters II (R2, R3 = H, CH2Ph) and their di-N-oxides reveal that the amino-terminal α-amino acid suffers appreciable racemization during the coupling process with triphenylphosphite-pyridine, whereas not detectable racemization is observed with diphenylphosphoryl azide. A Bystrov's model is suggested for the quinoxaline-dipeptide-Eu complexes studied. The benzylic protons of phenylalanine and the iso-Pr methyls in their quinoxaline deriva. show signal splitting due to diastereotopy in the presence of St(tfc)3.


IT 62973-19-7 62973-21-1
 RL: PRP (Properties)
 (NMR of, isomerism in relation to)
 RN 62973-19-7 CAPLUS
 CN Benzenecetic acid, α -[[(3-methyl-2-quinoxaliny)carbonyl]amino]-, methyl ester, (S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 62973-21-1 CAPLUS
 CN L-Phenylalanine, N-[(3-methyl-2-quinoxaliny)carbonyl]-, methyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



IT 65926-47-8P 65926-48-9P 65926-49-0P
 65926-50-3P 65926-54-7P 65926-56-9P
 65926-59-2P 65926-60-5P 65942-04-3P
 109084-22-2P
 RL: PRP (Properties); SPN (Synthetic preparation); PREP (Preparation)
 (preparation and NMR of, isomerism in relation to)


RN 65926-47-8 CAPLUS
 CN Benzenecetic acid, α -[(2-quinoxaliny)carbonyl]amino]-, methyl ester, (S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 65926-48-9 CAPLUS
 CN Glycine, N-[N-[(3-methyl-2-quinoxaliny)carbonyl]amino]-, methyl ester, (R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 65926-59-2 CAPLUS
 CN Glycine, N-[N-[(3-methyl-2-quinoxaliny)carbonyl]amino]-, methyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.




RN 65926-60-5 CAPLUS
 CN Glycine, N-[N-[(3-methyl-2-quinoxaliny)carbonyl]amino]-, methyl ester (9CI) (CA INDEX NAME)



RN 65942-04-3 CAPLUS
 CN Benzenecetic acid, α -[[(3-methyl-2-quinoxaliny)carbonyl]amino]-, methyl ester (9CI) (CA INDEX NAME)




RN 109084-22-2 CAPLUS
 CN Benzenecetic acid, α -[(2-quinoxaliny)carbonyl]amino]-, methyl ester (9CI) (CA INDEX NAME)




RN 65926-49-0 CAPLUS
 CN L-Phenylalanine, N-(2-quinoxaliny)carbonyl]-, methyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 65926-50-3 CAPLUS
 CN Phenylalanine, N-(2-quinoxaliny)carbonyl]-, methyl ester (9CI) (CA INDEX NAME)



RN 65926-54-7 CAPLUS
 CN Phenylalanine, N-[(3-methyl-2-quinoxaliny)carbonyl]-, methyl ester (9CI) (CA INDEX NAME)



RN 65926-56-9 CAPLUS
 CN Glycine, N-[N-[(3-methyl-1,4-dioxido-2-quinoxaliny)carbonyl]-L-phenylalanyl]-, methyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



LS ANSWER 220 OF 283 CAPLUS COPYRIGHT 2006 ACS ON STN
 ACCESSION NUMBER: 1977:552275 CAPLUS
 DOCUMENT NUMBER: 87:152275
 TITLE: 3-Substituted quinoxaline-2-carboxamide 1,4-dioxides
 INVENTOR(S): Dirlam, John P.
 PATENT ASSIGNEE(S): Pfizer Inc., USA
 SOURCE: U.S., 19 pp.
 CODEN: USXXAM
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 2
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 4039540	A	19770802	US 1975-632219	19751117
DK 7501712	A	19751108	DK 1975-1712	19750421
DK 140940	B	19791210		
DK 140940	C	19800519		
AU 7580530	A1	19761028	AU 1975-80530	19750424
ES 437053	A1	19770116	ES 1975-437053	19750426
BE 828745	A1	19751105	BE 1975-1006643	19750505
FI 7501328	A	19751108	FI 1975-1328	19750506
NL 7505292	A	19751111	NL 1975-5292	19750506
JP 50160286	A2	19751225	JP 1975-54193	19750506
GB 1450518	A	19760922	GB 1975-19058	19750506
FR 2269949	A1	19751205	FR 1975-14453	19750507
AT 7503510	A	19770715	AT 1975-3510	19750507
DK 7800485	A	19780202	DK 1978-485	19780202
PRIORITY APPL. INFO.:			US 1974-467718	A2 19740507
			DK 1975-1712	A 19750421

GI




AB Quinoxalinecarboxamide dioxides 1 (R = amino, R1 = substituted alkylthio, alkylsulfonfyl, alkylsulfonfyl) (76 compds.) were prepared. Thus, 1 (R = NHMe, R1 = Br) was treated with Me3N, 1 (R1 = N-Me3Br-) treated with H2SCH2CH2OH to give 1 (R = NHMe, R1 = SCH2CH2OH), which had min inhibitory concentration against Streptococcus pyogenes and Escherichia coli 0.781 μ g/ml.


IT 58050-68-3P
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
 (preparation and bactericidal activity of)

RN 58050-68-3 CAPLUS
 CN 2-Quinoxalinecarboxamide, 3-[[[(2-hydroxyethyl)sulfonfyl]methyl]-N-

(phenylmethyl)-, 1,4-dioxide (9CI) (CA INDEX NAME)




L5 ANSWER 221 OF 283 CAPLUS COPYRIGHT 2006 ACS ON STN
ACCESSION NUMBER: 1977:51727 CAPLUS
DOCUMENT NUMBER: 87:151727
TITLE: Amides and thioamides of squaric acid: syntheses and reactions
AUTHOR(S): Ehrhardt, Heinz; Huenig, Siegfried; Puetter, Hermann
CORPORATE SOURCE: Inst. Org. Chem., Univ. Wuerzburg, Wuerzburg, Fed. Rep. Ger.
SOURCE: Chemische Berichte (1977), 110(7), 2506-33
CODEN: CHEM; ISSN: 0009-2940
DOCUMENT TYPE: Journal
LANGUAGE: German
OTHER SOURCE(S): CASREACT 87:151727
OI




AB Squaric acid (I) 1,2- and 1,3-diamides were prepared by amidation of I or its derivs., e.g., the di-Et ester (II) or the dichloride. E.g., II reacted with tert-BuNH₂, C₆H₄(NH₂)₂-o, or PhNHMe to give, resp., III, the cyclobut[b]quinoxalinedione IV, and V, the latter via the ester amide. Diamides derived from primary amines undergo N-alkylation. Treatment of 1,2-diamides derived from secondary amines with P₄S₁₀ gave the dithiodiamides, which are S-methylated by treatment with P₂S₅Me. IV with p-benzoquinone in DMF gave the dihydro derivative, the cyclobutane ring of which can be opened by protolysis. Oxidation of IV N,N-di-Me derivative with p-benzoquinone in MeCN containing HClO₄ gave the radical cation.

IT 37648-63-8P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)
RN 37648-63-8 CAPLUS
CN 2-Quinoxalinecarboxamide, N-phenyl- (9CI) (CA INDEX NAME)




L5 ANSWER 222 OF 283 CAPLUS COPYRIGHT 2006 ACS ON STN
ACCESSION NUMBER: 1977:517808 CAPLUS
DOCUMENT NUMBER: 87:117808
TITLE: Investigations on a series of nitrogen heterocycles. New semisynthetic penicillins of the quinoxaline class
AUTHOR(S): Saucier, Tatiana; Zotti, V.; Cojocaru, Zenaide; Zvorișteanu, Virginia
CORPORATE SOURCE: Inst. Med. Farm., Iasi, Rom.
SOURCE: Revista Medico-Chirurgicala (1977), 81(1), 99-103
CODEN: RMNRM; ISSN: 0300-8738
DOCUMENT TYPE: Journal
LANGUAGE: Romanian
OI




AB Penicillins I {NRR1 = pyrrolidino, 4-methylpiperazino, morpholino, piperidino, antipyrinylamino, 2-pyridylamino, NHC₆H₄CO₂CH₂CH₂NEt₂, 4-(5-methoxy-2-pyrimidinylaminosulfonyl)anilino} were prepared by acylating 6-aminopenicillanic acid. I had min. inhibitory concns. against penicillin-resistant Staphylococcus at 0.4-25 µg/mL.

IT 64120-14-5 64120-15-6
RL: RCT (Reactant); RACT (Reactant or reagent)
(acylation of aminopenicillanic acid by)
RN 64120-14-5 CAPLUS
CN Benzoic acid, 4-[[[4-(chlorocarbonyl)-2-quinoxaliny]carbonyl]amino]-, 2-(diethylamino)ethyl ester (9CI) (CA INDEX NAME)




RN 64120-15-6 CAPLUS
CN 2-Quinoxalinecarboxyl chloride, 3-[[[4-[[[5-methoxy-2-pyridinyl]amino]sulfonyl]phenyl]amino]carbonyl]- (9CI) (CA INDEX NAME)




IT 64120-06-5P 64120-07-6P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
(preparation and bactericidal activity of)
RN 64120-06-5 CAPLUS
CN 4-Thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid, 6-[[[3-[[[4-[[[2-(diethylamino)ethoxy]carbonyl]phenyl]amino]carbonyl]-2-quinoxaliny]carbonyl]amino]-3,3-dimethyl-7-oxo-, [2S-(2α,5α,6β)]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 64120-07-6 CAPLUS
CN 4-Thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid, 6-[[[3-[[[4-[[[2-(diethylamino)ethoxy]carbonyl]phenyl]amino]carbonyl]-2-quinoxaliny]carbonyl]amino]-3,3-dimethyl-7-oxo-, [2S-(2α,5α,6β)]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L5 ANSWER 223 OF 283 CAPLUS COPYRIGHT 2006 ACS ON STN
ACCESSION NUMBER: 1977:406113 CAPLUS
DOCUMENT NUMBER: 87:6313
TITLE: Synthesis and chiroptical properties of some N-(3-methyl-2-quinoxaloyl) L-amino acids and their dioxides
AUTHOR(S): El-Abdelah, M. M.; Sabri, S. S.; Nazer, M. Z.; Za'atar, M. F.
CORPORATE SOURCE: Chem. Dep., Jordan Univ., Amman, Jordan
SOURCE: Tetrahedron (1976), 32(23), 2931-8
CODEN: TETRA; ISSN: 0040-4020
DOCUMENT TYPE: Journal
LANGUAGE: English
OI




AB 1,4-Dioxides of N-(3-methyl-2-quinoxaloyl) L-α-amino acids and esters were prepared by reaction of benzofuroxan with N-acetoacetyl L-α-amino acids and esters, resp. in Et₃N-MeOH at room temperature. Reduction of the 1,4-dioxides of the acids with Na₂S₂O₄ gave the corresponding methylquinoxaline derivs. which on esterification gave the corresponding esters. Thus, reaction of benzofuroxan with MeCOCH₂CONHCHRCO₂R₁ (R = Me, Ph, R₁ = H, Me) gave 51-81% I (X = NO). Reduction of I (X = NO, R = Me, Ph, R₁ = H) gave 56-63% I (X = N) which on methylation gave 59-90% I (R₁ = Me). The quinoxaline derivs. I (X = N) of aliphatic and aromatic L-α-amino acids exhibit enantiomeric CD spectra in EtOH as well as in ethanolic KOH. However, the corresponding quinoxaline-1,4-dioxide derivs. I (X = NO) of the L-α-aliphatic and L-α-aromatic amino acids show, in organic solvents, similar CD spectra. This behavior is attributed to differences in conformational equilibrium in both the quinoxaline and the quinoxaline-1,4-dioxide series. NMR and mass spectra of these compds. are discussed.

IT 62973-24-4P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)


RN 62973-24-4 CAPLUS
CN L-Tyrosine, N-[(3-methyl-1,4-dioxido-2-quinoxaliny)carbonyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




IT 62973-07-3P 62973-08-4P 62973-09-5P
62973-10-0P 62973-18-6P 62973-19-7P
62973-20-0P 62973-21-1P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation, CD, and UV spectrum of)
RN 62973-07-3 CAPLUS
CN Benzenesacetic acid, α -[[(3-methyl-1,4-dioxido-2-quinoxaliny)carbonyl]amino]-, (S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 62973-08-4 CAPLUS
CN Benzenesacetic acid, α -[[(3-methyl-1,4-dioxido-2-quinoxaliny)carbonyl]amino]-, methyl ester, (S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 62973-09-5 CAPLUS
CN L-Phenylalanine, N-[(3-methyl-1,4-dioxido-2-quinoxaliny)carbonyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 62973-10-8 CAPLUS
CN L-Phenylalanine, N-[(3-methyl-1,4-dioxido-2-quinoxaliny)carbonyl]-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 62973-18-6 CAPLUS
CN Benzenesacetic acid, α -[[(3-methyl-2-quinoxaliny)carbonyl]amino]-, (S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 62973-19-7 CAPLUS
CN Benzenesacetic acid, α -[[(3-methyl-2-quinoxaliny)carbonyl]amino]-, methyl ester, (S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 62973-20-0 CAPLUS
CN L-Phenylalanine, N-[(3-methyl-2-quinoxaliny)carbonyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 62973-21-1 CAPLUS
CN L-Phenylalanine, N-[(3-methyl-2-quinoxaliny)carbonyl]-, methyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



L5 ANSWER 224 OF 283 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 1977:189920 CAPLUS
DOCUMENT NUMBER: 86:189920
TITLE: Penicilline
INVENTOR(S): Yamada, Hirotsada; Tobiki, Hideo; Nakatsuka, Iwao;
Tanno, Norihiko; Shimago, Kozo; Nakagome, Takenari
PATENT ASSIGNEE(S): Sumitomo Chemical Co., Ltd., Japan
SOURCE: U.S., 11 pp. Division of U.S. 3,945,995.
CODEN: USXXAM
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 4005075	A	19770125	US 1975-610754	19750905
JP 49125387	A2	19741130	JP 1973-39358	19730405
JP 57051837	B4	19821104		
US 3945995	A	19760323	US 1974-458417	19740405
			JP 1973-39358	A 19730405
			US 1974-458417	A3 19740405


PRIORITY APPL. INFO.:
OTHER SOURCE(S): CASREACT 86:189920
GI



AB Penicilline I (RR1 = atoms required to complete a N heterocycle; R2 = Ph, 4-HOC6H4, 3-HOC6H4, 1,4-cyclohexadienyl) (28 compds.) were prepared by deacylating benzylpenicillin esters, acylating 6-aminopenicillanates with H2NCH(R2)CO2H derivative, and acylating the amine group with heterocyclic carbonyl chloride or N-hydroxysuccinimide ester. 1 had min. inhibitory


concns. against Staphylococcus aureus 209P of 0.2-3.13 μ g/ml.
IT 62734-96-7
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); BIOL (Biological study)
(bactericidal activity of)
RN 62734-96-7 CAPLUS
CN 4-Thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid, 6-[[[(3,4-dihydro-3-oxo-2-quinoxaliny)carbonyl]amino]phenylacetyl]amino]-3,3-dimethyl-7-oxo-, monosodium salt, [2S-[2 α ,5 α ,6 β (S*)]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● Na


L5 ANSWER 225 OF 283 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 1976:559009 CAPLUS
DOCUMENT NUMBER: 85:159009
TITLE: Structure and reactivity of the covalent hydrates in the alloxazine series
AUTHOR(S): Koziol, Jacek; Hennerich, Peter
CORPORATE SOURCE: Inst. Towarozn., Akad. Skon., Poznan, Pol.
SOURCE: Justus Liebigs Annalen der Chemie (1976), (7-8), 1276-88
CODEN: JIACBF; ISSN: 0075-4617
DOCUMENT TYPE: Journal
LANGUAGE: German
GI




AB Alloxazines (I; R = H, Me, PhCH2) form stable hydrates with structure II (R as above). II are methylated at the O with ring opening to III. Acid-base properties, mechanism of formation and decomposition, and uv, ir, and 1H-NMR spectral data are in agreement with structure II.

IT 60735-48-0P
RL: SPN (Synthetic preparation); PREP (Preparation)


(preparation of)
RN 60735-48-0 CAPLUS
CN Carbanic acid, [6,7-dimethyl-3-[[[phenylmethyl]amino]carbonyl]-2-quinoxaliny]]-, methyl ester (9CI) (CA INDEX NAME)




L5 ANSWER 226 OF 283 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 1976:463031 CAPLUS
DOCUMENT NUMBER: 85:63031
TITLE: Synthesis, structure and biological properties of N-oxides of some 2-substituted quinoxalines and pyrazines
AUTHOR(S): Elina, A. S.; Musatova, I. S.; Peresleni, E. M.; Padeiskaya, E. N.
CORPORATE SOURCE: Vses. Nauchno-Issled. Khim.-Farm. Inst. im. Ordzhonikidze, Moscow, USSR
SOURCE: Khimiya Oterotoksicheskikh Soedinenii (1976), (2), 278-83
CODEN: KQSSAQ; ISSN: 0132-6244
DOCUMENT TYPE: Journal
LANGUAGE: Russian
OTHER SOURCE(S): CASREACT 85:63031
OI




AB Quinoxaline monooxides and dioxides [I, II, R = H, NH2, OH, CH2CH(OH)CH2CH2, CH2CH2Ph, CH2CH2Ph, CH2CH2Ph, 3,4-dimethoxyphenethyl, (CH2)4NMe2, (CH2)3OH, (CH2)6OH], useful as bactericides and antitubercular substances, were prepared in 61.4-98% yields by treatment of the corresponding Me esters with amines and NH3.
IT 59833-89-5P 59833-90-8P 59833-91-9P
59833-95-3P 59834-00-3P 59834-01-4P
59859-93-7P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
(preparation and bactericidal activity of)
RN 59833-89-5 CAPLUS
CN 2-Quinoxalinecarboxamide, N-(2-phenylethyl)-, 1-oxide (9CI) (CA INDEX NAME)



RN 59834-01-4 CAPLUS
CN 2-Quinoxalinecarboxamide, N-(1-phenylethyl)-, 1,4-dioxide (9CI) (CA INDEX NAME)




RN 59859-93-7 CAPLUS
CN 2-Quinoxalinecarboxamide, N-[2-(3,4-dimethoxyphenyl)ethyl]-, 1,4-dioxide (9CI) (CA INDEX NAME)




IT 59833-87-3P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)


RN 59833-87-3 CAPLUS
CN 2-Quinoxalinecarboxamide, N-(1-methyl-2-phenylethyl)-, 1-oxide (9CI) (CA INDEX NAME)




L5 ANSWER 227 OF 283 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 1976:44159 CAPLUS
DOCUMENT NUMBER: 84:44159




RN 59833-90-8 CAPLUS
CN 2-Quinoxalinecarboxamide, N-(1-phenylethyl)-, 1-oxide (9CI) (CA INDEX NAME)



RN 59833-91-9 CAPLUS
CN 2-Quinoxalinecarboxamide, N-[2-(3,4-dimethoxyphenyl)ethyl]-, 1-oxide (9CI) (CA INDEX NAME)



RN 59833-95-3 CAPLUS
CN 2-Quinoxalinecarboxamide, N-(1-methyl-2-phenylethyl)-, 1,4-dioxide (9CI) (CA INDEX NAME)



RN 59834-00-3 CAPLUS
CN 2-Quinoxalinecarboxamide, N-(2-phenylethyl)-, 1,4-dioxide (9CI) (CA INDEX NAME)

TITLE: 3-Substituted quinoxaline-2-carboxamide-1,4-dioxides
INVENTOR(S): Dirlam, John P.
PATENT ASSIGNER(S): Pfizer Inc., USA
SOURCE: Ger. Offen., 47 pp.
CODEN: GWXXBX
DOCUMENT TYPE: Patent
LANGUAGE: German
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
DE 2520545	A1	19751120	DE 1975-2520545	19750506
DK 7501712	A	19751108	DK 1975-1712	19750421
DK 140940	B	19791210		
DK 140940	C	19800519		
AU 7580530	A1	19761028	AU 1975-80530	19750424
ES 437053	A1	19770116	ES 1975-437053	19750426
BE 828745	A1	19751105	BE 1975-1006643	19750506
FI 7501328	A	19751108	FI 1975-1328	19750506
NL 7505292	A	19751111	NL 1975-5292	19750506
JP 50160286	A2	19751225	JP 1975-54193	19750506
GB 1450518	A	19760922	GB 1975-19058	19750506
FR 2269949	A1	19751205	FR 1975-14453	19750507
AT 7503510	A	19770715	AT 1975-3510	19750507
DK 7800485	A	19780202	DK 1978-485	19780202
PRIORITY APPL. INFO.:			US 1974-467718	A 19740507
			DK 1975-1712	A 19750421

GI For diagram(s), see printed CA Issue.

AB Quinoxalines I (R = H, alkyl, hydroxyalkyl, aminoalkyl, R1 = H; R = R1 Me; R2 hydroxyalkyl, aminoalkyl; n = 0, 2) were prepared. Thus II (R3 = Br) was treated with Me3M and II (R3 = N-Me3Br-) treated with HSC2H2OH to give I (R = Me, R1 = H, R2 = CH2CH2OH, n = 0), which had a min. inhibitory concentration against Streptococcus pyogenes and Escherichia coli of 0.781 µg/ml.

IT 59850-48-3P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
(preparation and bactericidal activity of)

RN 59850-48-3 CAPLUS
CN 2-Quinoxalinecarboxamide, 3-[[[2-(hydroxyethyl)sulfonyl]methyl]-N-(phenylmethyl)-, 1,4-dioxide (9CI) (CA INDEX NAME)



L5 ANSWER 228 OF 283 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 1975:606241 CAPLUS
DOCUMENT NUMBER: 83:206241
TITLE: Penicillins
INVENTOR(S): Yamada, Hirotsada; Tobiki, Hisao; Tanno, Norihiko; Shimago, Kozo; Okamura, Kouzoku; Ueda, Shinzi; Nakagome, Takemasa
PATENT ASSIGNER(S): Sumitomo Chemical Co., Ltd., Japan


SOURCE: Ger. Offen., 18 pp.
CODEN: GWXXBX
DOCUMENT TYPE: Patent
LANGUAGE: German
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
DE 2504609	A1	19750814	DE 1975-2504609	19750204
JP 50106989	A2	19750812	JP 1974-14692	19740204
JP 57061760	B4	19821325		
AU 7577708	A1	19760729	AU 1975-77708	19750129
CA 1070295	A1	19800122	CA 1975-218925	19750129
GB 1493475	A	19771130	GB 1975-4117	19750130
NO 7500325	A	19750805	NO 1975-125	19750203
SE 7501155	A	19750805	SE 1975-1155	19750203
FR 2259604	A1	19750829	FR 1975-3317	19750203
HU 169936	P	19770228	HU 1975-SU888	19750203
BE 825171	A1	19750804	BE 1975-153049	19750204
NL 7501326	A	19750806	NL 1975-1326	19750204
DK 7500375	A	19751013	DK 1975-175	19750204
CH 609058	A	19790215	CH 1975-1291	19750204
			JP 1974-14692	A 19740204

PRIORITY APPL. INFO.:

GI For diagram(s), see printed CA issue.
AB Antibiotic penicillanic and deriva. (I, R = 1-cyclohexan-1-yl, MeCHCH₂, R₁ = H; R = 1,4-cyclohexadien-1-yl, R₁ = H, Me₂N) were obtained by condensation of an appropriately substituted acetamidopenicillanic acid with a 1,5-naphthyridinecarboxylate. Addnl. obtained were II and III.
IT 57391-05-6P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)
RN 57391-05-6 CAPLUS
CN 4-Thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid, 6-[[[(3,4-dihydro-3-oxo-2-quinoxaliny)carbonyl]amino]acetyl]amino]-3,3-dimethyl-7-oxo-, [2S-[2a,5a,6b(8*)]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L5 ANSWER 229 OF 283 CAPLUS COPYRIGHT 2006 ACS ON STN
ACCESSION NUMBER: 1975:579047 CAPLUS
DOCUMENT NUMBER: 83:179047
TITLE: Penicillins
INVENTOR(S): Tobiki, Hisao; Yamada, Hirotsada; Nakatsuka, Iwao;
Shimago, Kozo; Okano, Shigeru; Nakagome, Takenari;
Komatsu, Toshiaki; Isawa, Akio; Noguchi, Hiroshi; Eda,
Yasuko
PATENT ASSIGNEE(S): Sumitomo Chemical Co., Ltd., Japan

SOURCE: Ger. Offen., 47 pp.
CODEN: GWXXBX
DOCUMENT TYPE: Patent
LANGUAGE: German
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
DE 2461526	A1	19750710	DE 1974-2461526	19741227
DE 2461526	C2	19841122		
JP 50095694	A2	19750731	JP 1974-1799	19731227
JP 58007637	B4	19830210		
SE 416731	B	19810202	SE 1974-15913	19741216
SE 416731	C	19810514		
NO 7404662	A	19750610	NO 1974-4662	19741223
NO 148336	B	19830613		
NO 148336	C	19830921		
CA 1036154	A1	19780808	CA 1974-216654	19741223
US 3992371	A	19761116	US 1974-536181	19741224
GB 1488173	A	19771005	GB 1974-55848	19741224
CH 618175	A	19800715	CH 1974-17311	19741224
SE 823881	A1	19750627	SE 1974-151946	19741227
NL 7416965	A	19750701	NL 1974-16965	19741227
FR 2255898	A1	19750725	FR 1974-43165	19741227
FR 2255898	B1	19820625		
DK 7406836	A	19750825	DK 1974-6836	19741227
AU 7477020	A1	19760701	AU 1974-77020	19741231
			JP 1974-1799	A 19731227

PRIORITY APPL. INFO.:

CASREACT 83:179047
GI For diagram(s), see printed CA issue.
AB Penicillins I (R = OH, OCO₂Et, OCO₂Me₃, SH; R₁ = 3-NH₂, 4-NH₂, 4-OMe, 4-NMe₂, 3-NHAc, 4-NHSEt, 3-Cl, 3-Cl, 4-Me, 3-F, R₂ = H; R₁ = 4-OH, R₂ = 3-Me, 3-OH, 3-NO₂, 3-NH₂, 3-OMe; X = atoms required to complete a condensed N heterocycle) (64 compds.) were prepared. Thus, I (R = OH, R₁ = 3-NH₂, R₂ = H, X = 2,3-pyridylnitrilometheno) was prepared by esterifying 4-hydroxy-1,5-naphthyridine-3-carboxylic acid with N-hydroxysuccinimide and acylating D-α,α-diaminobenzylpenicillin triethylamine salt with the ester.
IT 57008-46-5P 57008-81-8P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
(preparation and bactericidal activity of)
RN 57008-46-5 CAPLUS
CN 4-Thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid, 6-[[[(3-aminophenyl)]][(3,4-dihydro-3-oxo-2-quinoxaliny)carbonyl]amino]acetyl]amino]-3,3-dimethyl-7-oxo-, monosodium salt, [2S-[2a,5a,6b(8*)]]- (9CI) (CA INDEX NAME)



Absolute stereochemistry.

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
DE 2416449	C2	19821007		
JP 49125387	A2	19741130	JP 1973-39358	19730405
JP 57051837	B4	19821104		
HU 168314	P	19760328	HU 1974-SU855	19740403
CH 594681	A	19780131	CH 1974-4656	19740403
FR 2224112	A1	19741031	FR 1974-12029	19740404
NO 145576	B	19820111	NO 1974-1227	19740404
NO 145576	C	19820421		
SE 422942	B	19820405	SE 1974-4565	19740404
SE 422942	C	19821202		
BE 813356	A1	19741007	BE 1974-142894	19740405
NL 7404879	A	19741008	NL 1974-4679	19740405
DD 110502	C	19741220	DD 1974-177716	19740405
ZA 7402186	A	19750528	ZA 1974-2186	19740405
AU 7467613	A1	19751009	AU 1974-67613	19740405
GB 1470188	A	19770414	GB 1974-15142	19740405
DK 145157	B	19820920	DK 1974-1922	19740405
SE 7701826	A	19770218	SE 1977-1836	19770218
SE 422943	B	19820405		
SE 422943	C	19820715		

PRIORITY APPL. INFO.:

GI For diagram(s), see printed CA issue.
AB Penicillin salts I (R = Ph, p-HOC₆H₄, m-HOC₆H₄, 1,4-cyclohexadienyl, R₂ = 6,9,4-hydroxy-3-pyridyl, 4-hydroxy-3-cinnolyl, 3-hydroxy-4-pyridazinyl, 4-hydroxy-5-pyrimidinyl, A, B) (28 compds.) were tested for bacterial inhibition. I were prepared from II (R₂ = PhCOCH₂, R₃ = PhCH₂CO) (III). Thus, III.HCl was treated with P halide in CH₂Cl₂ and 4-methylmorpholine (IV) at -25°, stirred 30 min, then treated with MeOH and IV 2 hr at -17° to -10° to give II (R₂ = PhCOCH₂, R₃ = H). This was treated with D-H₂NCHPhCOCl.HCl to give II (R₂ = PhCOCH₂, R₃ = D-H₂NCHPhCO), which was treated with succinimide 4-hydroxy-1,5-naphthyridine-3-carboxylate and the product saponified with NaSH to give I (R₁ = A, R = Ph). Min. inhibitory concns. were <0.05 to 200 γ/ml.
IT 54403-68-8
RL: PROC (Process)
(bacteria inhibition of)
RN 54403-68-8 CAPLUS
CN 4-Thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid, 6-[[[(3,4-dihydro-3-oxo-2-quinoxaliny)carbonyl]amino]phenylacetyl]amino]-3,3-dimethyl-7-oxo-, [2S-[2a,5a,6b(8*)]]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



Absolute stereochemistry.

RN 57008-81-8 CAPLUS
CN 4-Thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid, 6-[[[(3,4-dihydro-3-oxo-2-quinoxaliny)carbonyl]amino]acetyl]amino]-3,3-dimethyl-7-oxo-, monosodium salt, [2S-[2a,5a,6b(8*)]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L5 ANSWER 230 OF 283 CAPLUS COPYRIGHT 2006 ACS ON STN
ACCESSION NUMBER: 1975:43402 CAPLUS
DOCUMENT NUMBER: 82:43402
TITLE: Penicillins and their salts
INVENTOR(S): Tobiki, Hisao; Yamada, Hirotsada; Shimago, Kozo;
Nakatsuka, Iwao; Nakagome, Takenari; Tanno, Norihiko
PATENT ASSIGNEE(S): Sumitomo Chemical Co., Ltd.
SOURCE: Ger. Offen., 33 pp.
CODEN: GWXXBX
DOCUMENT TYPE: Patent
LANGUAGE: German
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
DE 2416449	A1	19741024	DE 1974-2416449	19740404


L5 ANSWER 231 OF 283 CAPLUS COPYRIGHT 2006 ACS ON STN
ACCESSION NUMBER: 1974:146108 CAPLUS
DOCUMENT NUMBER: 80:146108
TITLE: Redox reaction with 2-chloromethylquinoxaline di-N-oxide
AUTHOR(S): Sholzer, U.; Heitzer, H.; Seng, F.; Ley, K.
CORPORATE SOURCE: Zentralbereich Zent. Forsch.-Wiss. Hauptlab., Bayer A.-G., Leverkusen, Fed. Rep. Ger.
SYNTHESIS (1974), (4), 296-8
SOURCE:

DOCUMENT TYPE: CODEN: SYNTBF; ISSN: 0039-7881
Journal
German


AB Quinoxaline deriv. I (R = Me, Et, Pr, (CH₂)₁₁Me, cyclohexyl, C₆H₄Cl-p; R₁ = cyclohexyl, (CH₂)₁₁Me, Bu, Et, Pr, C₆H₄CO₂-p) were formed in 31-86% yield by treating the quinoxaline di-N-oxides II with 2 moles R₁NH₂. I were easily hydrolyzed to the dicarboximides. The pyrroloquinoxalines III (R₂ = morpholino, piperidino, pyrrolidino) were obtained in 60-86% yield by treating 2-chloro-methyl-3-cyanoquinoxaline di-N-oxide with 2 moles of the amine.

IT 24836-32-6 52398-26-2
RL: RCT (Reactant); RACT (Reactant or reagent)
(reaction of, with amines)

RN 24836-32-6 CAPLUS
CN 2-Quinoxalinecarboxamide, 3-(chloromethyl)-N-cyclohexyl-, 1,4-dioxide (8CI, 9CI) (CA INDEX NAME)




RN 52398-26-2 CAPLUS
CN 2-Quinoxalinecarboxamide, 3-(chloromethyl)-N-(4-chlorophenyl)-, 1,4-dioxide (9CI) (CA INDEX NAME)




L5 ANSWER 232 OF 283 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 1973:432274 CAPLUS
DOCUMENT NUMBER: 79:32274
TITLE: Synthesis of pteridine-6-carboxamides. 9-Oxofolic acid and 9-oxoaminopterin
AUTHOR(S): Nair, M. G.; Baugh, Charles M.
CORPORATE SOURCE: Nutr. Program, Univ. Alabama, Birmingham, AL, USA
SOURCE: Journal of Organic Chemistry (1973), 38(12), 2185-9
CODEN: JOCEAH; ISSN: 0022-3263
DOCUMENT TYPE: Journal
LANGUAGE: English

AB A new method for the preparation of several 7-unsubstituted pteridine-6-carboxamides is reported. This method was used for the synthesis of 9-oxofolic acid and 9-oxoaminopterin as well as γ-glutamyl derive. These procedures utilize the mixed anhydride of a pteridine-6-carboxylic acid with F₃CCO₂H. The activated pteridines are stable enough to permit removal of excess (F₃CCO)₂O and F₃CCO₂H followed by direct coupling to nucleophiles such as amines and amino acids. The preparation of α-amino-p-toluic acid is also reported.

RN 39707-63-5 CAPLUS
CN 6-Pteridinecarboxamide, 2-amino-N-(4-bromophenyl)-1,4-dihydro-4-oxo- (9CI) (CA INDEX NAME)




RN 39707-63-6 CAPLUS
CN Benzoic acid, 4-[[[(2,4-diamino-6-pteridinyl)carbonyl]amino]- (9CI) (CA INDEX NAME)




RN 39707-65-8 CAPLUS
CN L-Glutamic acid, N-[4-[[[(2,4-diamino-6-pteridinyl)carbonyl]amino]benzoyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 39707-66-9 CAPLUS
CN Benzoic acid, 4-[[[(2-amino-1,4-dihydro-4-oxo-6-pteridinyl)carbonyl]amino]methyl]- (9CI) (CA INDEX NAME)




L5 ANSWER 233 OF 283 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 1973:147994 CAPLUS

IT 39707-68-1
RL: RCT (Reactant); RACT (Reactant or reagent)
(deacetylation of)


RN 39707-68-1 CAPLUS
CN L-Glutamic acid, N-[4-[[[2,4-bis[[[trifluoroacetyl]amino]-6-pteridinyl]carbonyl]amino]benzoyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




IT 39707-60-3P 39707-61-4P 39707-62-5P
39707-63-6P 39707-65-8P 39707-66-9P
RL: SPH (Synthetic preparation); PREP (Preparation)
(preparation of)

RN 39707-60-3 CAPLUS
CN Benzoic acid, 4-[[[(2-amino-1,4-dihydro-4-oxo-6-pteridinyl)carbonyl]amino]- (9CI) (CA INDEX NAME)



RN 39707-61-4 CAPLUS
CN L-Glutamic acid, N-[4-[[[2-amino-1,4-dihydro-4-oxo-6-pteridinyl)carbonyl]amino]benzoyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



DOCUMENT NUMBER: 78:147994
TITLE: 1-Hydroxy-3-oxobenzimidazoles, quinoxaline di-N-oxides, and benzimidazole mono- and di-N-oxides
PATENT ASSIGNEE(S): Research Corp.
SOURCE: Brit., 36 pp. Addn. to Brit. 1,215,815 (CA 74; 141873b).
CODEN: BRXXAA
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 3
PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
GB 1308370	A	19730228	GB 1970-47202	19701005
US 4343942	A	19820810	US 1969-883577	19691209
			US 1969-883577	A 19691209
			US 1966-592729	A2 19661108
			NL 1967-14862	A 19671102
			US 1967-691252	A2 19671218

GI For diagram(s), see printed CA Issue.

AB The title compds., useful in the control of pathogenic microorganisms, were prepared from benzofuroxans and compds. containing activated methylene groups. Specific bases used for certain reactants were described. E.g. stirring 6.8 g benzofuroxan, 5.0 g MeCOCH₂CO₂Me, and 2.96 g PrNH₂ in THF overnight gave 0.33 g 3-methyl-3-acetylquinoxaline di-N-oxide. Forty-nine of the quinoxaline oxides (I, R, R₁ = H, OMe, CF₃, Me, halogen, SO₂NH₂ and derivs.; R₂, R₃ = H, alkyl) were similarly prepared from equimolar amts. of benzofuroxan and MeCOCH₂-CONR₂R₃ in THF containing Et₂NH.

IT 41153-40-6P
RL: SPH (Synthetic preparation); PREP (Preparation)
(preparation of)

RN 41153-40-6 CAPLUS
CN 2-Quinoxalinecarboxamide, N-2,4,6-cycloheptatrien-1-yl-3-methyl-, 1,4-dioxide (9CI) (CA INDEX NAME)



L5 ANSWER 234 OF 283 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 1973:43523 CAPLUS
DOCUMENT NUMBER: 78:43523
TITLE: Antimicrobial 3-carbamoyl-2-formimidoylquinoxaline 1,4-dioxides
INVENTOR(S): Seng, Florin; Ley, Kurt; Metzger, Karl Georg
PATENT ASSIGNEE(S): Farbenfabriken Bayer A.-G.
SOURCE: Ger. Offen., 30 pp.
CODEN: GWXXBX
DOCUMENT TYPE: Patent
LANGUAGE: German
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
------------	------	------	-----------------	------

DE 2122572 A 19721123 DE 1971-2122572 19710507
 US 3839326 A 19741001 US 1972-249121 19720501
 CA 980772 A1 19751230 CA 1972-140949 19720501
 AU 7241857 A1 19731108 AU 1972-41857 19720503
 NL 7206031 A 19721109 NL 1972-6031 19720504
 IL 39358 A1 19760229 IL 1972-39358 19720504
 BE 783084 A1 19721106 BE 1972-117157 19720505
 FR 2137585 A5 19721229 FR 1972-16234 19720505
 FR 2137585 B1 19751226
 ZA 7203066 A 19730228 ZA 1972-3066 19720505
 HU 163998 P 19731228 HU 1972-BAD742 19720505
 GB 1365441 A 19740904 GB 1972-21035 19720505
 SE 401832 C 19780907 SE 1972-5970 19720505
 ES 402484 A1 19750316 ES 1972-402484 19720506
 PL 88122 P 19760831 PL 1972-155218 19720506
 US 3896222 A 19750722 US 1973-399445 19730920
 US 3957987 A 19760518 US 1974-509325 19740926
 DE 1971-2122572 A 19710507
 US 1972-249121 A3 19720501
 US 1973-399445 A3 19730930


PRIORITY APPLN. INFO.:

GI For diagram(s), see printed CA Issue.
 AB Thirty-seven title compds. (I; R = NOH, NHCOSMe2, NHCOR3 with R3 = OMe, OEt, OCH2CH2OH, NH2, morpholino, 4-pyridyl; R1 = H, Me, Et; R2 = Me, Pr, Et, CHMe2, CH2CH2OH, CH2CH2OMe, cyclohexyl; or NR1R2 = piperidino, morpholino, 1-pyrrolidinyl) were prepared by reaction of I (R = Cl2) with H2NOH or H2NHCOR3 (X = O or S). I had inhibiting activities against gram-neg. and gram-pos. bacteria and were used as growth-promoting agents in chicken feed. Thus, I (R = H2, R1 = H, R2 = Me) was chlorinated with Cl in AcOH at 80-5° to give 80% I (R = Cl2, R1 = H, R2 = Me), which with H2NHCOR3 in EtOH-H2O in the presence of Me2NE for 5 hr gave 78.5% I (R = NHCOR3, R1 = H, R2 = Me).

IT 39577-91-8P
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (preparation of)
 RN 39577-91-8 CAPLUS
 CN Hydrazinecarboxylic acid, [3-[(cyclohexylamino)carbonyl]-1,4-dioxido-2-quinoxaliny]methylene-, methyl ester (9CI) (CA INDEX NAME)



IT 39576-46-0
 RL: RCT (Reactant); RACT (Reactant or reagent)
 (reaction of, with acyl hydrazines)
 RN 39576-46-0 CAPLUS
 CN 2-Quinoxalinecarboxamide, N-cyclohexyl-3-(dichloromethyl)-, 1,4-dioxide (9CI) (CA INDEX NAME)



LS ANSWER 235 OF 283 CAPLUS COPYRIGHT 2006 ACS on STN
 ACCESSION NUMBER: 1972:488541 CAPLUS
 DOCUMENT NUMBER: 77:88541
 TITLE: Quinoxaline di-N-oxides
 INVENTOR(S): Ley, Kurt; Eholter, Ulrich; Mast, Roland; Seng, Florin
 PATENT ASSIGNER(S): Farbenfabriken Bayer A.-G.
 SOURCE: U.S., 25 pp.
 CODEN: USKXAM
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 3660398	A	19720502	US 1970-24422	19700407
PRIORITY APPLN. INFO.:			US 1970-24422	A 19700407
AB				

Benzofuran N-oxide, Me2CO, and BuNH2 gave 2-methylquinoxaline di-N-oxide (I, R = R1 = H, R2 = Me) after 5 hr at room temperature. Similarly prepared were


.apprx.118 quinoxaline di-N-oxide deriva. (e.g., I, R = R1 = H, R2 = Ph; R = H, R1R2 = (CH2)4; R = R2 = Me, R1 = H; II). The products were herbicides.

IT 23433-47-8P 23433-48-9P 23433-49-0P
 23433-50-3P 23433-51-4P 23433-52-5P
 23433-53-6P 23433-54-7P 23433-55-8P
 23433-56-9P 23433-57-0P 23433-71-8P
 23433-76-3P 23523-93-5P 37937-30-7P
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (preparation of)


RN 23433-47-8 CAPLUS
 CN 2-Quinoxalinecarboxamide, N-(4-chloro-2,5-dimethoxyphenyl)-3-methyl-, 1,4-dioxide (9CI) (CA INDEX NAME)




RN 23433-48-9 CAPLUS
 CN 2-Quinoxalinecarboxamide, N-(2-methoxyphenyl)-3-methyl-, 1,4-dioxide (9CI) (CA INDEX NAME)




RN 23433-49-0 CAPLUS
 CN 2-Quinoxalinecarboxamide, N-(2-chlorophenyl)-3-methyl-, 1,4-dioxide (9CI) (CA INDEX NAME)




RN 23433-50-3 CAPLUS
 CN 2-Quinoxalinecarboxamide, 6-chloro-3-methyl-N-phenyl-, 1,4-dioxide (9CI) (CA INDEX NAME)




RN 23433-51-4 CAPLUS
 CN 2-Quinoxalinecarboxamide, 6-chloro-N-(2-chlorophenyl)-3-methyl-, 1,4-dioxide (9CI) (CA INDEX NAME)




RN 23433-52-5 CAPLUS
 CN 2-Quinoxalinecarboxamide, 6-chloro-N-(4-chloro-2,5-dimethoxyphenyl)-3-methyl-, 1,4-dioxide (9CI) (CA INDEX NAME)




RN 23433-53-6 CAPLUS
 CN 2-Quinoxalinecarboxamide, 6-chloro-3-methyl-N-(2-methylphenyl)-, 1,4-dioxide (9CI) (CA INDEX NAME)




RN 23433-54-7 CAPLUS
 CN 2-Quinoxalinecarboxamide, 6-chloro-N-(2,4-dimethylphenyl)-3-methyl-, 1,4-dioxide (9CI) (CA INDEX NAME)




RN 23433-55-8 CAPLUS
 CN 2-Quinoxalinecarboxamide, 6-chloro-N-(2-methoxyphenyl)-3-methyl-, 1,4-dioxide (9CI) (CA INDEX NAME)




RN 23433-56-9 CAPLUS
 CN 2-Quinoxalinecarboxamide, 6-chloro-N-(4-chloro-2-methylphenyl)-3-methyl-, 1,4-dioxide (9CI) (CA INDEX NAME)




RN 23433-57-0 CAPLUS
CN 2-Quinoxalinecarboxamide, N-(4-(aminosulfonyl)phenyl)-3-methyl-, 1,4-dioxide (9CI) (CA INDEX NAME)




RN 23433-71-8 CAPLUS
CN 2-Quinoxalinecarboxamide, N-(2,6-dimethylphenyl)-3-methyl-, 1,4-dioxide (9CI) (CA INDEX NAME)




RN 23433-76-3 CAPLUS
CN 2-Quinoxalinecarboxamide, N-cyclohexyl-3-methyl-, 1,4-dioxide (8CI, 9CI) (CA INDEX NAME)




RN 23523-93-5 CAPLUS
CN 2-Quinoxalinecarboxamide, N-(4-chloro-2-methylphenyl)-3-methyl-, 1,4-dioxide (9CI) (CA INDEX NAME)




RN 37937-10-7 CAPLUS
CN 2-Quinoxalinecarboxamide, 6-chloro-N-(3,4-dichlorophenyl)-3-methyl-, 1,4-dioxide (9CI) (CA INDEX NAME)




L5 ANSWER 236 OF 283 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 1972:461947 CAPLUS
DOCUMENT NUMBER: 77:61947
TITLE: 3-Arylamino-1-arylpyrrolidine-2,5-diones and their N-nitroso compounds. II. Properties. New heterocyclization reaction
AUTHOR(S): Burmistrov, S. I.; Kul'chitskaya, N. E.; Romanenko, V. D.
CORPORATE SOURCE: Dnepropetr. Khim.-Tekhnol. Inst., Dnepropetrovsk, USSR
SOURCE: Zhurnal Organicheskoi Khimii (1972), 8(5), 1095-100
CODEN: ZORJAE; ISSN: 0514-7492
DOCUMENT TYPE: Journal
LANGUAGE: Russian
GI For diagram(s), see printed CA Issue.
AB Cyclodehydration of 11 title nitrosamines (I, R = Ph, substituted Ph; R = Ph, substituted Ph, PhCH₂) at 100-20° in Ac₂O afforded the corresponding quinoxaline deriva. (II) in 40-60% yield instead of the expected sydnone analogs. Alkaline hydrolysis of II (R = H; R₁ = Ph, C₆H₄Me-p, C₆H₄OMe-p) gave the corresponding 2,3-quinoxalinedicarboxylic acid mono-N-arylamides (III), which were converted back to II by Ac₂O; III were also prepared from 2,3-quinoxalinedicarboxylic anhydride and R₁NH₂. Similarly, II gave bis-N-arylamides with the resp. R₁NH₂. Refluxing III in quinoline containing Cu powder yielded 68% 2-quinoxalinedicarboxylic acid.
IT 37648-58-1P 37648-59-2P 37648-60-5P
37648-61-6P 37648-63-8P
RL: SPN (Synthetic preparation); PREP (Preparation)
RN 37648-58-1 CAPLUS
CN 2-Quinoxalinecarboxylic acid, 3-{(phenylamino)carbonyl}- (9CI) (CA INDEX NAME)




RN 37648-59-2 CAPLUS
CN 2,3-Quinoxalinedicarboxamide, N,N'-diphenyl- (9CI) (CA INDEX NAME)




RN 37648-60-5 CAPLUS
CN 2,3-Quinoxalinedicarboxamide, N,N'-bis(4-methylphenyl)- (9CI) (CA INDEX NAME)




RN 37648-61-6 CAPLUS
CN 2,3-Quinoxalinedicarboxamide, N,N'-bis(4-methoxyphenyl)- (9CI) (CA INDEX NAME)




RN 37648-63-8 CAPLUS
CN 2-Quinoxalinecarboxamide, N-phenyl- (9CI) (CA INDEX NAME)



L5 ANSWER 237 OF 283 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 1972:448392 CAPLUS
DOCUMENT NUMBER: 77:448392
TITLE: New oral antidiabetic drugs. III
AUTHOR(S): Ambrogli, V.; Bloch, K.; Daturi, S.; Logemann, W.; Parenti, M. A.; Tommasini, R.
CORPORATE SOURCE: Ric. Ter., Ist. Carlo Erba, Milan, Italy
SOURCE: Arzneimittel-Forschung (1972), 22(3), 542-4
CODEN: ARZNFJ; ISSN: 0004-4172
DOCUMENT TYPE: Journal
LANGUAGE: English
AB Eleven p-RCONHCH₂CH₂-C₆H₄SO₂NHCONHR₁ (I, R = 5-methyl-2-pyrazinyl, 5,6-dimethyl-2-pyrazinyl, 2-quinolyl, or 2-quinoxalyl; R₁ = piperidino, 4-methylpiperidino, 2,6-dimethylpiperidino, 1-azepinyl, or 3-azabicyclo[3.2.2]non-3-yl) were prepared by reaction of p-RCONHCH₂CH₂CH₂C₆H₄SO₂NH₂ with ClCON₂Me via p-RCONH-CH₂CH₂C₆H₄SO₂NHCO₂Me followed by R₁NH₂. Most I had a high hypoglycemic activities at low oral doses in mice and rats.
IT 35149-17-8P 35237-88-8P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
RN 35149-17-8 CAPLUS
CN 2-Quinoxalinecarboxamide, N-[2-{4-[[[3-azabicyclo[3.2.2]non-3-ylamino]carbonyl]amino]sulfonyl]phenyl]ethyl]- (9CI) (CA INDEX NAME)




RN 35237-88-8 CAPLUS
CN 2-Quinoxalinecarboxamide, N-[2-{4-[[[3-azabicyclo[3.2.2]non-3-ylamino]carbonyl]amino]sulfonyl]phenyl]ethyl]- (9CI) (CA INDEX NAME)



IT 37512-89-3P
RL: SPN (Synthetic preparation); PREP (Preparation)
RN 37512-89-3 CAPLUS

CN 2-Quinoxalinecarboxamide, N-[2-[4-[[[(methylamino)carbonyl]amino]sulfonyl]phenyl]ethyl]- (9CI) (CA INDEX NAME)




LS ANSWER 238 OF 283 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 1972:434581 CAPLUS
DOCUMENT NUMBER: 77:34572
TITLE: Antibacterial and protozoacidal 3-(2-hydroxyethyl)-2-carbamoylquinoxaline 1,4-dioxides
INVENTOR(S): Hartung, Herbert; Duerckheimer, Walter; Raether, Wolfgang; Schrinner, Elmar
PATENT ASSIGNER(S): Farbwerke Hoechst A.-G.
SOURCE: Ger. Offen., 15 pp.
CODEN: GWXBXB
DOCUMENT TYPE: Patent
LANGUAGE: German
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
DE 2052359	A	19720427	DE 1970-2052359	19701024
DE 1970-2052359	A	19701024		


PRIORITY APPLN. INFO.:
GI For diagram(s), see printed CA Issue.
AB Fifty title compds. [I; R = H or Me; R1 = H, MeO, or Me or RR1 = OCH2O; R2 = H, R3 = e.g. H, alkyl, alkoxy(aryl) or NR2R3 = piperidino, morpholino, or 4-methyl-1-piperazinyl; R4 = e.g. alkyl, aryl, or 3-pyridyl] were prepared by esterification of the alc. II. I were used in the treatment of amebiasis in hamsters. Thus, II (R-R3 = H) obtained by formylation of Et 3-methyl-2-quinoxalinecarboxylate dioxides via 3-(2-hydroxyethyl)-2-quinoxalinecarboxylic acid 1,4-dioxides was treated with Ac2O in pyridine at 50° for 10 min to give 88% I (R-R3 = H, R4 = Me).

IT 36789-64-7P 36789-71-6P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)
RN 36789-64-7 CAPLUS
CN 2-Quinoxalinecarboxamide, 3-[2-(acetyloxy)ethyl]-N-(phenylmethyl)-, 1,4-dioxide (9CI) (CA INDEX NAME)




RN 36789-71-6 CAPLUS
CN 2-Quinoxalinecarboxamide, 3-[2-(acetyloxy)ethyl]-7-methoxy-N-(phenylmethyl)-, 1,4-dioxide (9CI) (CA INDEX NAME)


RN 37742-41-9 CAPLUS
CN 2-Quinoxalinecarboxamide, 3-(2-hydroxyethyl)-N-(2-methylcyclohexyl)-, 1,4-dioxide (9CI) (CA INDEX NAME)



RN 37742-42-0 CAPLUS
CN 2-Quinoxalinecarboxamide, 3-(2-hydroxyethyl)-N-(phenylmethyl)-, 1,4-dioxide (9CI) (CA INDEX NAME)




RN 37742-60-2 CAPLUS
CN 2-Quinoxalinecarboxamide, 3-(2-hydroxyethyl)-7-methoxy-N-(phenylmethyl)-, 1,4-dioxide (9CI) (CA INDEX NAME)



LS ANSWER 240 OF 283 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 1972:25312 CAPLUS
DOCUMENT NUMBER: 76:25312
TITLE: Hypoglycemic (acylaminoethyl)phenylsulfonyl ureas
INVENTOR(S): Ambrogio, Vittorio; Logemann, Willy; Parenti, Marcantonio; Tommasin, Raffaele
PATENT ASSIGNER(S): Erba, Carlo, S. p. A.
SOURCE: Ger. Offen., 19 pp.
CODEN: GWXBXB
DOCUMENT TYPE: Patent
LANGUAGE: German
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
DE 2052359	A	19720427	DE 1970-2052359	19701024
DE 1970-2052359	A	19701024		




LS ANSWER 239 OF 283 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 1972:434572 CAPLUS
DOCUMENT NUMBER: 77:34572
TITLE: Antibacterial and protozoacidal 3-(2-hydroxyethyl)-2-carbamoylquinoxaline 1,4-dioxides
INVENTOR(S): Hartung, Herbert; Duerckheimer, Walter; Raether, Wolfgang; Schrinner, Elmar
PATENT ASSIGNER(S): Farbwerke Hoechst A.-G.
SOURCE: Ger. Offen., 20 pp.
CODEN: GWXBXB
DOCUMENT TYPE: Patent
LANGUAGE: German
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
DE 2052279	A	19720427	DE 1970-2052279	19701024
DE 1970-2052279	A	19701024		

PRIORITY APPLN. INFO.:
GI For diagram(s), see printed CA Issue.
AB Forty-one title compds. [I; R = H or Me; R1 = H, MeO, or Me; RR1 = OCH2O; R2 = H; R3 = (for example) H, Me, C12H25 cyclohexyl, CH2Ph, CH2CH=CH2, (CH2)3OH, CH2CH2NH2, NH2, OH, MeO2CCH2, or H2NCOCH2; NR2R3 = piperidino, morpholino, or 4-methyl-1-piperazinyl] were prepared by reaction of 3-methyl-2-(alkoxycarbonyl)quinoxaline 1,4-dioxides with CH2O, cyclization of the 3-(2-hydroxyethyl)-3-carboxy deriva. via lactones (II), and reaction with amines. I had antibacterial and protozoacidal activity in mice and golden hamsters. Thus, 760 ml 40% methanolic Triton B was added to 496 g 3-methyl-2-(ethoxycarbonyl)-quinoxaline 1,4-dioxide and 60 g paraformaldehyde in dioxane to give 200 g 3-(2-hydroxyethyl)-2-carboxyquinoxaline 1,4-dioxide, which (200 g) on reaction with HCl (g) in EtOH at 0° gave 150 g II (R = R1 = H) (III). Reaction of III with NH3-saturated EtOH at 0° gave 93% I (R-R3 = H).


IT 37742-40-8P 37742-41-9P 37742-42-0P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)
RN 37742-40-8 CAPLUS
CN 2-Quinoxalinecarboxamide, N-cyclohexyl-3-(2-hydroxyethyl)-, 1,4-dioxide (9CI) (CA INDEX NAME)




PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
DE 2114629	A	19711021	DE 1971-2114629	19710326
US 3819633	A	19740625	US 1971-126893	19710322
FR 2085759	A1	19711231	FR 1971-10914	19710329
FR 2085759	A5	19711231		
BE 764998	A1	19710930	BE 1971-101556	19710330
CA 957687	A1	19741112	CA 1971-109207	19710331
HU 162749	P	19730428	HU 1971-CA302	19710401
GB 1289240	A	19720913	GB 1971-1289240	19710419

PRIORITY APPLN. INFO.:
IT 1970-22739 A 19700401
IT 1970-29767 A 19700916
IT 1971-19717 A 19710125
IT 1971-19718 A 19710125
AB p-RCONHCH2CH2C6H4SO2NHCONHR1 (I) were prepared by reaction of p-RCONHCH2CH2C6H4SO2NH2 (II) with OCHNR1, or p-RCONHCH2CH2C6H4SO2NHCO2Me with R1NH2, or of p-H2NCH2CH2C6H4SO2NHCONHR1 with RCOCl. Thus, 3.17 g 2-quinolinecarboxylic acid in Me2CO and Et3N reacted with ClCO2Et 15 min at -5° and then with p-H2NCH2CH2C6H4SO2NH2 in H2O 4 hr at room temperature to give 5.1 g II (R = 2-quinolyl). This (3.56 g) reacted in Me2CO and aqueous NaOH with cyclohexyl isocyanate over night at room temperature to give I (R = 2-quinolyl, R1 = cyclohexyl). Similarly prepared were 20 addnl. I, e.g. (R and R1 given): 3-isoquinolyl, cyclohexyl [III]; 4-cinnolyl, 1-azacyclohept-1-yl, 2-quinolalanyl, 3-sabicyclo[3.2.2]non-3-yl. Some I were tested in 16 hr fasting rabbits, e.g. 0.3 mg III/kg decreased the blood glucose level 3 and 6 hr after oral administration by 33 and 52%, resp.


IT 30961-30-9P 33289-00-8P 35148-82-4P
35149-17-8P 35149-18-9P 35237-88-8P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)
RN 30961-30-9 CAPLUS
CN 2-Quinoxalinecarboxamide, N-[2-[4-[[[(cyclohexylamino)carbonyl]amino]sulfonyl]phenyl]ethyl]- (9CI) (CA INDEX NAME)




RN 33289-00-8 CAPLUS
CN 2-Quinoxalinecarboxamide, N-[2-[4-[[[(aminosulfonyl)phenyl]ethyl]- (9CI) (CA INDEX NAME)




RN 35148-82-4 CAPLUS
CN 2-Quinoxalinecarboxamide, 3-chloro-N-[2-[4-[[[(cyclohexylamino)carbonyl]amino]sulfonyl]phenyl]ethyl]- (9CI) (CA INDEX NAME)




RN 35149-17-8 CAPLUS
CN 2-Quinoxalinecarboxamide, N-[2-[4-[[[(3-azabicyclo[3.2.2]non-3-ylamino)carbonyl]amino]sulfonyl]phenyl]ethyl]- (9CI) (CA INDEX NAME)



RN 35149-18-9 CAPLUS
CN 2-Quinoxalinecarboxamide, N-[2-[4-[[[(cyclohexylamino)carbonyl]amino]sulfonyl]phenyl]ethyl]-6,7-dimethyl- (9CI) (CA INDEX NAME)




RN 35237-88-6 CAPLUS
CN 2-Quinoxalinecarboxamide, N-[2-[4-[[[(hexahydro-1H-azepin-1-yl)amino]carbonyl]amino]sulfonyl]phenyl]ethyl]- (9CI) (CA INDEX NAME)




L5 ANSWER 241 OF 283 CAPLUS COPYRIGHT 2006 ACS ON STN
ACCESSION NUMBER: 1971:551759 CAPLUS
DOCUMENT NUMBER: 75:151759
TITLE: N-Oxides of the quinoxaline series. XXI. Synthesis and properties of N-oxides and N,N'-dioxides of some 2-substituted quinoxalines
AUTHOR(S): Sline, A. S.; Musatova, I. S.; Teyrul'nikova, L. G.
CORPORATE SOURCE: Vses. Nauchno-Issled. Khim.-Farm. Inst. im. Ordzhonikidze, Moscow, USSR
SOURCE: Khimiko-Farmatsvicheskii Zhurnal (1971), 5(8), 6-12
CODEN: KHFZAN; ISSN: 0033-1134
DOCUMENT TYPE: Journal

LANGUAGE: Russian
GI For diagram(s), see printed CA Issue.
AB The title quinoxalines, including I and II, were prepared employing conventional chemical techniques.
IT 34118-05-3P
RL: SPN (Synthetic preparation); PREP (Preparation)
RN 34118-05-3 CAPLUS
CN 2-Quinoxalinecarboxamide, N-(alpha-methylphenethyl)-, 4-oxide (8CI) (CA INDEX NAME)




L5 ANSWER 242 OF 283 CAPLUS COPYRIGHT 2006 ACS ON STN
ACCESSION NUMBER: 1971:488572 CAPLUS
DOCUMENT NUMBER: 75:88572
TITLE: New oral antidiabetic drugs. II
AUTHOR(S): Ambrogio, V.; Bloch, Konrad; Corti, P.; Daturi, S.; Logemann, W.; Parenti, M. A.; Tomasini, R.
CORPORATE SOURCE: Ist. Carlo Erba Ric. Ter., Milan, Italy
SOURCE: Arzneimittel-Forschung (1971), 21(2), 204-8
CODEN: ARZNAD; ISSN: 0004-4172
DOCUMENT TYPE: Journal
LANGUAGE: English
GI For diagram(s), see printed CA Issue.
AB 1-V were prepared from the appropriate heterocyclic carboxylic acids and p-(beta-aminoethyl)benzenesulfonamide and treating the product with cyclohexyl isocyanate. Ten of 17 new sulfonylureas had some antidiabetic activity in mice, and only 5 of these, N-(4-[beta-(quinoxaline-2-carboxamido)ethyl]benzenesulfonyl)-N'-cyclohexylurea (I), N-(4-[beta-(isoquinoline-3-carboxamido)ethyl]benzenesulfonyl)-N'-cyclohexylurea (II), N-(4-[beta-(quinoline-2-carboxamido)ethyl]benzenesulfonyl)-N'-cyclohexylurea (III), N-(4-[beta-(benzofuran-2-carboxamido)ethyl]benzenesulfonyl)-N'-cyclohexylurea (IV), and N-(5-[beta-(5-chlorobenzofuran-2-carboxamido)ethyl]benzenesulfonyl)-N'-cyclohexylurea (V), were active in rats producing 44, 40, 42, 28, and 22%, resp., hypoglycemic effect at 7.5 mg/kg, orally.

IT 30961-30-9P 33289-00-8P
RL: SPN (Synthetic preparation); PREP (Preparation)
RN 30961-30-9 CAPLUS
CN 2-Quinoxalinecarboxamide, N-[2-[4-[[[(cyclohexylamino)carbonyl]amino]sulfonyl]phenyl]ethyl]- (9CI) (CA INDEX NAME)




RN 33289-00-8 CAPLUS
CN 2-Quinoxalinecarboxamide, N-[2-[4-[[[(aminosulfonyl]phenyl]ethyl]- (9CI) (CA INDEX NAME)



L5 ANSWER 243 OF 283 CAPLUS COPYRIGHT 2006 ACS ON STN
ACCESSION NUMBER: 1971:421112 CAPLUS
DOCUMENT NUMBER: 75:21112
TITLE: Polyimides based on pyrazinetetracarboxylic dianhydride and some related model compounds
AUTHOR(S): Vaughan, George B.; Rose, Jerry C.; Brown, Gordon P.
CORPORATE SOURCE: Mellon Inst., Carnegie-Mellon Univ., Pittsburgh, PA, USA
SOURCE: Journal of Polymer Science, Polymer Chemistry Edition (1971), 9(4), 1117-38
CODEN: JPLCAT; ISSN: 0449-296X
DOCUMENT TYPE: Journal
LANGUAGE: English

GI For diagram(s), see printed CA Issue.
AB Pyrazinetetracarboxylic dianhydride (I) condensed with heterocyclic diamines which did not contain an N-N linkage gave polyimides with a lower mol. weight and thermal stability than the corresponding polypyromellitimides as a result of synthesis problems arising from the low reactivity of the diamines and the ready decarboxylation of pyrazinecarboxylic acids. The IR spectra of model compds. indicated the proposed condensate structure had recurring amideimide units rather than a complete polyimide structure. Unsuccessful polymers were attempted by condensation of I with 3,5-diamino-1,2,4-oxadiazole, 3,4-diamino-1,2,5-oxadiazole, 2,4-diamino-6-methyl-s-triazine, and 2,6-diaminopyridine.

IT 34139-54-3P
RL: SPN (Synthetic preparation); PREP (Preparation)
RN 34139-54-3 CAPLUS
CN 2,3-Pyrazinedicarboximide, N-phenyl-5-(phenylcarbamoyl)- (8CI) (CA INDEX NAME)




L5 ANSWER 244 OF 283 CAPLUS COPYRIGHT 2006 ACS ON STN
ACCESSION NUMBER: 1971:141873 CAPLUS
DOCUMENT NUMBER: 74:141873
TITLE: Antibacterial quinoxaline-di-N-oxides and benzimidazole mono- and di-N-oxides
INVENTOR(S): Issidorides, Costas H.; Haddadin, Makhluf J.
PATENT ASSIGNER(S): Research Corp.

SOURCE: Brit., 16 pp.
CODEN: BRXXAA
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
GB 1215815		19701216	GB	19671220

AB Benzofuran 1-oxide (I) was refluxed with MeCOEt in MeCN in the presence of morpholine to give 2,3-dimethylquinoxaline 1,4-dioxide. Over 40 quinoxaline 1,4-dioxides were prepared similarly. I reacted with EtNO₂ and Et₂NH in THF to give 1-hydroxy-2-methylbenzimidazole 3-oxide. Five addnl. 1-hydroxybenzimidazole 3-oxides were similarly prepared. I reacted with iso-PrNO₂ and Et₂NH in THF to give 2,2-dimethyl-2H-benzimidazole 1,3-dioxide (II). The 2-ethyl-2-methyl and 2,2-pentamethylene analogs of II were similarly prepared. Some phenazine 5,10-dioxides were also prepared. The quinoxaline 1,4-dioxides were virucides and bactericides.


IT 33433-48-9P 33433-76-3P 31887-83-9P
RL: SPN (Synthetic preparation); PREP (Preparation)
RN 33433-48-9 CAPLUS
CN 2-Quinoxalinecarboxamide, N-(2-methoxyphenyl)-3-methyl-, 1,4-dioxide (9CI) (CA INDEX NAME)




RN 23433-76-3 CAPLUS
CN 2-Quinoxalinecarboxamide, N-cyclohexyl-3-methyl-, 1,4-dioxide (8CI, 9CI) (CA INDEX NAME)



RN 31887-83-9 CAPLUS
CN 2-Quinoxalinecarboxamide, 3-methyl-N-(4-methylphenyl)-, 1,4-dioxide (9CI) (CA INDEX NAME)



RN 31983-69-8 CAPLUS
CN 2-Quinoxalinecarboxamide, 1-methyl-N-phenyl-, 1,4-dioxide (9CI) (CA INDEX NAME)




L5 ANSWER 245 OF 283 CAPLUS COPYRIGHT 2006 ACS ON STN
ACCESSION NUMBER: 1971:112057 CAPLUS
DOCUMENT NUMBER: 74:112057
TITLE: Antibacterial 3-methyl-2-quinoxalinecarboxamide di-N-oxides
INVENTOR(S): Abuel-Haj, Marwan J.; Cronin, Timothy H.
PATENT ASSIGNEE(S): Pfizer Inc.
SOURCE: Ger. Offen., 53 pp.
CODEN: GWXXBX
DOCUMENT TYPE: Patent
LANGUAGE: German
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
DE 2035460	A	19710211	DE 1970-2035480	19700717
US 3635972	A	19720116	US 1969-643810	19690722
BR 6915087	A0	19730419	BR 1969-215087	19691215
BR 6915236	A0	19730223	BR 1969-215238	19691217
GB 1325501	A	19730801	GB 1970-33489	19700709
FR 2059542	A5	19710604	FR 1970-26396	19700717
FR 2059542	B1	19751128		
CA 978949	A1	19751202	CA 1970-48694	19700721
CA 979455	A1	19751209	CA 1970-48695	19700721
PRIORITY APPLN. INFO.:			US 1969-643775	A 19690722
			US 1969-643810	A 19690722
			US 1970-6550	A 19700128

GI For diagram(s), see printed CA Issue.
AB Antibacterial and growth-promoting title compds. (I) were prepared by reaction of benzofuroxane (II) with diketene and HNR₁R₂. Thus, reaction of 4.2 g diketene in Et₂O, DMF saturated with MeNH₂, and 6.8 g II (R₂ = R₃ = H) 12 hr at room temperature gave 4.5 g I (R = Me, R₁ = R₂ = R₃ = H). Among approx. 130 compds. similarly prepared were I (R, R₁, R₂, and R₃ given): H, Me, Cl, Cl; H, Et, H, OMe; Et, Et, H, Cl; (RR₁R₂ =) morpholino, H, H.
IT 31683-22-4P 31683-23-5P 31687-83-9P


RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)
RN 31683-22-4 CAPLUS
CN 2-Quinoxalinecarboxy-p-toluidide, 6-methoxy-3-methyl-, 1,4-dioxide (8CI) (CA INDEX NAME)



RN 31683-23-5 CAPLUS
CN 2-Quinoxalinecarboxy-p-toluidide, 6-chloro-3-methyl-, 1,4-dioxide (8CI) (CA INDEX NAME)




RN 31687-83-9 CAPLUS
CN 2-Quinoxalinecarboxamide, 3-methyl-N-(4-methylphenyl)-, 1,4-dioxide (9CI) (CA INDEX NAME)




L5 ANSWER 246 OF 283 CAPLUS COPYRIGHT 2006 ACS ON STN
ACCESSION NUMBER: 1971:42082 CAPLUS
DOCUMENT NUMBER: 74:42082
TITLE: Structure and color of the Schiff bases of anilides of the aliphatic mono- and diketocides
AUTHOR(S): Moszew, Jan; Moskal, Aleksandra
CORPORATE SOURCE: Univ. Jagiellonian, Cracow, Pol.
SOURCE: Zeszyty Naukowe Uniwersytetu Jagiellonskiego, Prace Chemiczne (1970), No. 15, 117-31
CODEN: ZJWCAQ; ISSN: 0083-4319
DOCUMENT TYPE: Journal
LANGUAGE: Polish
AB The condensation of aliphatic carboxylic acid anilides and anilides of acetoacetic acid anil with p-nitroso-N,N-dimethylaniline (I) gave

intensely colored single and double Schiff bases having quinonediimine structures. Condensation of the aliphatic carboxylic acid anilides and anilides of acetoacetic acid anil with nitrosobenzene (II) gave colorless products. Absorption spectra of various anilindides of acetoacetic acid confirm the tautomeric keto imine-enamine equilibrium. Acid hydrolysis of the condensation products of I and II gave anil anilides of α,β-dioxobutyric acid. These compds. were strongly colored and readily bind water to form colorless hydrates.


IT 30296-01-6P 30296-02-7P 30296-03-8P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)
RN 30296-01-6 CAPLUS
CN 2-Quinoxalinecarboxanilide, 3-methyl-, (8CI) (CA INDEX NAME)



RN 30296-02-7 CAPLUS
CN 2-Quinoxalinecarbox-p-aniside, 3-methyl-, (8CI) (CA INDEX NAME)



RN 30296-03-8 CAPLUS
CN 2-Quinoxalinecarboxanilide, 4'-bromo-3-methyl-, (8CI) (CA INDEX NAME)




L5 ANSWER 247 OF 283 CAPLUS COPYRIGHT 2006 ACS ON STN
ACCESSION NUMBER: 1970:445539 CAPLUS
DOCUMENT NUMBER: 73:445539
TITLE: Antibacterial 2-hydroxymethyl-3-carbamoylquinoxaline N,N'-dioxides
INVENTOR(S): Seng, Florian; Ley, Kurt; Metzger, Karl O.
PATENT ASSIGNEE(S): Farbenfabriken Bayer A.-G.
SOURCE: Ger. Offen., 24 pp.
CODEN: GWXXBX
DOCUMENT TYPE: Patent
LANGUAGE: German
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
DE 2035460	A	19710211	DE 1970-2035480	19700717
US 3635972	A	19720116	US 1969-643810	19690722
BR 6915087	A0	19730419	BR 1969-215087	19691215
BR 6915236	A0	19730223	BR 1969-215238	19691217
GB 1325501	A	19730801	GB 1970-33489	19700709
FR 2059542	A5	19710604	FR 1970-26396	19700717
FR 2059542	B1	19751128		
CA 978949	A1	19751202	CA 1970-48694	19700721
CA 979455	A1	19751209	CA 1970-48695	19700721
PRIORITY APPLN. INFO.:			US 1969-643775	A 19690722
			US 1969-643810	A 19690722
			US 1970-6550	A 19700128


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
DE 1813918	A	19700625	DE 1968-1813918	19681211
DE 1813918	C3	19700215		
CH 523263	A	19720531	CH 1969-523263	19691114
IL 33364	A1	19730730	IL 1969-33364	19691114
GB 1254340	A	19711117	GB 1969-1254340	19691125
US 3682902	A	19720808	US 1969-880968	19691128
DK 126654	B	19730806	DK 1969-6393	19691202
FI 51163	B	19760802	FI 1969-3491	19691202
BR 6914788	A0	19730308	BR 1969-214788	19691205
BR 6914663	A	19700615	NL 1969-18463	19691209
NL 125186	B	19720731	NO 1969-4878	19691210
SE 356300	B	19730521	SE 1969-17049	19691210
BE 742970	A	19700611	BE 1969-742970	19691211
FR 2025909	A5	19700910	FR 1969-43010	19691211
FR 2025909	B1	19730713		
AT 294105	B	19711110	AT 1969-11529	19691211
US 3801711	A	19740402	US 1971-181245	19710916
PRIORITY APPLN. INFO.:			DE 1968-1813918	A 19681211
			US 1969-880968	A3 19691128

GI For diagram(s), see printed CA Issue.
AB Antibacterial title compds. (I), suitable as feed additives, were prepared by reaction of II and R₁R₂NH. Thus, reaction of II (R = H) with morpholine in C₆H₆ 10 hr gave 91.7% I (R = H, (NR₁R₂ =) morpholino). Similarly prepared were the following I (R, R₁, and R₂ given): H, Me, Me; H, H, H, H, Me; H, H, Et; H, H, Pr; H, H, iso-Pr; H, H, cyclohexyl; H, H, HOCH₂CH₂; H, H, MeCH₂CH₂; H, H, PhCH₂; H, H, CH₂CH₂CH₂; H, H, NH₂; H, H, NHOH; H, H, MeCH(OH)CH₂; H, H, MeCH(OH)CH₂CH₂; H, H, HO(CH₂)₃; and the following I (R and NR₁R₂ given): Me, morpholino; Cl, morpholino; N, pyrrolidino; H, 4-methylpiperazino. Formulations containing I as active components were described.

IT 27520-10-1 27520-12-3
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); BIOL (Biological study) (bactericidal activity of)
RN 27520-10-1 CAPLUS
CN 2-Quinoxalinecarboxamide, N-benzyl-3-(hydroxymethyl)-, 1,4-dioxide (8CI) (CA INDEX NAME)




RN 27520-12-3 CAPLUS
CN 2-Quinoxalinecarboxamide, N-benzyl-3-(hydroxymethyl)-, 1,4-dioxide (8CI) (CA INDEX NAME)



L5 ANSWER 248 OF 283 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 1970:3509 CAPLUS
DOCUMENT NUMBER: 72:3509
TITLE: Bactericidal 2-halomethyl-3-amidoquinazoline
1,4-N-oxides
INVENTOR(S): Ley, Kurt; Eholzer, Ulrich; Mast, Roland; Metzger,
Karl G.; Fritsche, Dieter
PATENT ASSIGNEE(S): Farbenfabriken Bayer A.-G.
SOURCE: S. African, 20 pp.
CODEN: SFXKAS
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
ZA 6806098		19690226		
PRIORITY APPL. INFO.:	DE	19671004		
GI For diagram(s), see printed CA Issue.				
AB Bactericidal activities and preps. of the title comds., I (R = Cl or Br, R1 = H, Me or Et; R2 = Me, Et, H, Pr, MeCH ₂ , Bu, Me ₂ C, Cl ₂ H ₂ , CH ₂ CH ₂ OMe or CH ₂ CH ₂ OAc, (R1R2 = (CH ₂) ₄ or (CH ₂) ₅) are described. For example, 380 g MeNH ₂ in 2 l. MeOH was treated with 830 ml diketene at -10 to 0°, stirred 2 hr at 35°, treated with 1360 g benzofuroxan followed by 30 moles NH ₃ at <45° and stirred 6-8 hr at 40-5° to give, on cooling, 72.3% I (R = R1 = H, R2 = Me) (II), m. 218° (decomposition). Chlorination of 233 g II in 700 ml CHCl ₃ with 90 g Cl gave 68% I (R = Cl, R1 = H, R2 = Me), m. 195-6°.				
IT 24836-32-6P				
RL: SPN (Synthetic preparation); PREP (Preparation) (preparation of)				
RN 24836-32-6 CAPLUS				
CN 2-Quinoxalinecarboxamide, 3-(chloromethyl)-N-cyclohexyl-, 1,4-dioxide (8CI, 9CI) (CA INDEX NAME)				




L5 ANSWER 249 OF 283 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 1969:470643 CAPLUS
DOCUMENT NUMBER: 71:70643
TITLE: Quinoxaline di-N-oxides
PATENT ASSIGNEE(S): Farbenfabriken Bayer A.-G.
SOURCE: Fr., 21 pp.
CODEN: FRXXAK
DOCUMENT TYPE: Patent
LANGUAGE: French
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
------------	------	------	-----------------	------


FR 1521907 19680419 FR
DE 1670693 DE
DE 1670730 DE
GB 1187991 GB
PRIORITY APPL. INFO.:

19660504
19660810


GI For diagram(s), see printed CA Issue.
The title comds. useful as intermediates in the preparation of pharmaceuticals and plant protection agents are prepared by reacting benzofuroxans with a ketone and an amine, or with a Schiff base. Addg. 73 g. BuNH₂ dropwise to a solution of the benzofuroxan (I) in 450 ml. Me₂CO at 20-30°, stirring 5 hrs. at room temperature and cooling to 0° gave 77 g. II (R2 = X = H, R1 = Me), m. 171° (EtOH). Similar treatment of 136 g. I and 66.5 g. MeCOEt (III) in 500 ml. MeOH with 119 g. cyclohexylamine at 30° gave 140 g. II (X = H, R1 = R2 = Me) (IV), m. 188-9° decomposition (EtOH). IV was also obtained (260 g.) by passing NH₃ into a mixture of 204 g. I, 119 g. III, and 700 ml. MeOH at 50° for 8 hrs. By similar methods were prepared the following II (X, R1, R2, m.p., and % yield given): H, Me, Et, 141-2°, prepared both from Et₂CO and MeCOPr in 84 and 88.5% yield resp.; H, Me, ClO₂H₂, 111-13°, 80; H, Me, Cl₂H₂, 111-13°, 77-80; H, Ph, B, 209-10°, 56-7; Cl, Me, H, 190-1°, -; Cl, Me, Me, 179-6°, 71.5-91; Cl, Me, Et, 142-4°, 73; Cl, Me, ClO₂H₂, 79-80°, 71.5; Cl, Me, Cl₂H₂, 82-3°, 64-85; Me, Me, H, 183-4° (decomposition), 49; Me, Me, Me, 155-6°, 77.5; Me, Me, Et, 150-2°, 55; MeO, Me, Me, 196-8°, 88.5; MeO, Me, Cl₂H₂, 77-8°, 81.5; EtO, Me, H, 202° (decomposition), 24; EtO, Me, Me, 160-2°, 84; EtO, Me, Et, 167-8°, 56.5; EtO, Et, Me, 174-5°, 50.5; EtO, Me, Cl₂H₂, 97-8°, 84.5; MeO₂C, Cl₂H₂, Me, 90-1°, 61.5. To a solution of 27.2 g. I in 100 ml. MeOH was added 35.6 g. cyclohexylidene(cyclohexyl)amine dropwise at 35°. After stirring for a further hr., cooling gave 22 g. V, m. 182-3°. By treatment of a mixture of 68 g. I, 91 g. cyclododecanone, and 400 ml. EtOH at 50° with 40 g. BuNH₂ and heating at 60° 2 hrs. 90 g. VI (X = H) (VII), m. 132-3°, was obtained. VII was also prepared in 60% yield from I and cyclodecylidene(cyclohexyl)amine at 50° and in 83.5% yield using NH₃ in place of BuNH₂. Similarly were prepared VI (X = Cl), m. 122-4° (54-77.5% yield), VI (X = Me), m. 144-6° (60%), and VI (X = EtO), m. 202-4° (43-61%). To a solution of 13.6 g. I and 13 g. AcOEt in 50 ml. MeOH at 40° was added 8 g. BuNH₂ dropwise and the mixture heated at 50° 4 hrs. to give 10 g. II (X = H, R1 = Me, R2 = EtO₂C), m. 134-6° (MeOH). Other quinoxaline dioxides VIII similarly prepared were (R1, R2, R3, R4, R5, m.p. and % yield given): Me, Me, H, H, 4-ClC₆H₄NHCO, 248°, 74.5; Me, Me, Me, Me, 164-6°, 41; Me, Me, H, 2-pyridylsulfonamide, H, 234° (decomposition), 62.6; Me, Me, Br, H, 189-90°, 62.5; Me, Me, MeO₂C, H, 185-6°, 68.6; Me, ClO₂H₂, H, MeO, 97-9°, 89; Me, ClO₂H₂, H, EtO, 84-6°, 39; Me, Cl₂H₂, Me, H, Me, 75-6°, 37; Me, Cl₂H₂, H, H, Me, 91-3°, 60; Me, CH₂CONH₂, H, H, MeO, 238°, 51; Me, CH₂CONHPh, H, H, H, 220-1° (decomposition), 82.5; Me, 3,4-Cl₂C₆H₃NHCOCH₂, H, H, H, 220°, 84; Me, CO₂Et, H, H, Cl, 178-9°, 37.5; Me, 3,4-Cl₂C₆H₃NHCOCH₂, H, H, Cl, 183-4°, 77.5; Me, 4,2,5-Cl₃C₆H₂NHCO, H, H, H, 227-8° (decomposition), 50; Me, 2-MeOC₆H₄NHCO, H, H, H, 190-1°, 53; Me, 2,4-Me₂(Cl)C₆H₃NHCO, H, H, H, 207°, 46; Me, 2-ClC₆H₄NHCO, H, H, H, 208-9°, 30; Me, PhNHCO, H, H, Cl, 206-7°, 55; Me, 2-ClC₆H₄NHCO, H, H, Cl, 185-6°, 46; Me, 4,2,5-Cl₃(MeO)C₆H₂NHCO, H, H, Cl, 224-5° (decomposition), 44; Me, 2-MeOC₆H₄NHCO, H, H, Cl, 197-8°, 32; Me, 2,4-MeOC₆H₃NHCO, H, H, Cl, 180-1°, 45; Me, 2-MeOC₆H₄NHCO, H, H, Cl, 150-2°, 30.5; Me, 2,4-Me₂(Cl)C₆H₃NHCO, H, H, Cl, 209°, 32; Me, 4-H₂N₂O₂C₆H₄NHCO, H, H, H, 254° (decomposition), 62; Me, pyrrolidinocarbonyl, H, H, EtO, 132-3°, 67.5; Me, piperidinocarbonyl, H, H, Me, 135° (decomposition), 69; Me, Cl₂H₂NHCO, H, H, H, 151-2°, 71; Me, Cl₂H₂NHCO, H, H, Me 150-1°, 52; Me, Cl₂H₂NHCO, H, H, EtO, 152-4°, 58; Me, Cl₂H₂NHCO, H, H, Cl,




RN 23433-48-9 CAPLUS
CN 2-Quinoxalinecarboxamide, N-(2-methoxyphenyl)-3-methyl-, 1,4-dioxide (9CI) (CA INDEX NAME)



RN 23433-49-0 CAPLUS
CN 2-Quinoxalinecarboxamide, N-(2-chlorophenyl)-3-methyl-, 1,4-dioxide (9CI) (CA INDEX NAME)




RN 23433-50-3 CAPLUS
CN 2-Quinoxalinecarboxamide, 6-chloro-3-methyl-N-phenyl-, 1,4-dioxide (9CI) (CA INDEX NAME)




RN 23433-51-4 CAPLUS
CN 2-Quinoxalinecarboxamide, 6-chloro-N-(2-chlorophenyl)-3-methyl-, 1,4-dioxide (9CI) (CA INDEX NAME)

155-6°, 34; Me, N-morpholinocarbonyl, H, H, H, 204-5° (decomposition), 20; Me, H₂NCO, H, H, H, 245° (decomposition), 33; Me, 4-methyl-2-pyrimidinylaminocarbonyl, H, H, Cl, 220° (decomposition), 20; Me, 2-benzothiazolylaminocarbonyl, H, H, H, 222° (decomposition), 45. Addg. 8 g. BuNH₂ dropwise at 40° to a solution of 16.6 g. 5-methoxybenzofuroxan and 28.1 g. acetylacetosobenzamide, stirring at 40° 4 hrs. and cooling gave 28 g. 3-carboxybenzamide of 2-methyl-7-methoxyquinoxaline 4-di-N-oxide, m. 211-2° decomposition (Me₂NCHO-EtOH). IX (R = H) methanolate, m. 235° (decomposition) (Me₂NCHO-MeOH) was similarly prepared in 5.9 g. yield from 2.72 g. I, 5.8 g. dihydrotestosterone, and 2.2 g. BuNH₂ in 45 ml. MeOH at 60°. Also, prepared were IX (R = Cl) methanolate, m. 251° (decomposition), 42.5% yield; IX (R = MeO) 2H₂O, m. 230° (decomposition), 53%; X, m. 224-5° (decomposition), in 17.5% yield from N-(2-phenylbenzo-1,2,3-triazole-5-yl)acetylacetamide; II (R1 = Me, X = H, R2 = 2-pyridylaminocarbonyl), m. 218° (decomposition), 34%; II (R1 = Me, X = H, R2 = 2,6-Me₂C₆H₃NHCO), m. 234° (decomposition), 72.5%; II (R1 = Me, X = H, R2 = 2-thiazolylaminocarbonyl), m. 212-13° (decomposition), 33%; XI (R = Cl), m. 25° (decomposition), 65.5% (from H₂N⁺ diacetateocetyl piperazine); XI (R = EtO), m. 267° (decomposition), 84%; XI (R = Me), m. 250° (decomposition), 85%; II (R1 = Me, X = H, R2 = cyclohexylaminocarbonyl), m. 205° 68%; II (R1 = Me, X = Cl, R2 = CMe-(NOH)), m. 222-3° (Me₂NCHO-MeCN), 73.5% yield (from 2-oximino-3-pentanone); II (R1 = Me, X = H, R2 = CMe-(NOH)), m. 219° (decomposition), 58.5%; II (R1 = Me, R2 = Ph, X = H), m. 194° 6°, 72%; II (R1 = Me, R2 = Ph, X = Cl), m. 162-3°, 77%; II (R1 = Me, R2 = Ac, X = Cl), m. 170-1°, 57.5%; II (R1 = Me, R2 = Ac, X = EtO), m. 178-80°, 43%; II (R1 = Me, R2 = N-morpholinomethyl, X = H), m. 138-9°, 69% (from 1-morpholino-3-butanone); XII (R = H). Me₂NCHO, m. 202-4°, 42% [from Cl₂-2-decalone, 5-chlorobenzofuroxan (XIII), and BuNH₂]. Into a solution of 50 g. 2-oximino-cyclododecan-1-one (m. 73-5°) and 40 g. XIII in 200 ml. MeOH at 50° was passed NH₃ gas 5 hrs. to give 47 g. Na salt of XIV, crystallized from MeOH-Me₂CO. Acidification with AcOH gave XIV, m. 197-9° (MeOH). The following II were also prepared (R1, R2, X, m.p., and % yield given): Me, PhCH(CN)CH₂, EtO, 173-3°, 37.4; Me, EtNH-CO, H, 208-9°, 70; H₂NCO, H₂NCO, H, 217° (decomposition), 81; H₂NCO, H₂NCO, MeO, 222° (decomposition), 73; H₂NCO, H₂NCO, EtO, 218° (decomposition), 54; H₂NCO, H₂NCO, Cl, 300° (decomposition), 69; Me, HON-CHCH₂, Me, 234° (decomposition), 51; Me, HON-CHCH₂, MeO, 220° (decomposition), 55; Me, H₂NCO, Me, 223° (decomposition), 56; Me, H, MeO, 245° (decomposition), 56; Me, H, Et, 227° (decomposition), 31; Me, H, piperidylcarbonyl, H, 178°, 60; Me, N-pyrrolidinocarbonyl, H, 185°, 63; Me, iso-Pr, H, 184°, 73; Me, iso-Pr, Cl, 158°, 75; Me, iso-Pr, Me, 148°, 69; Me, iso-Pr, MeO, 212°, 60; Me, iso-Pr, EtO, 174°, 65; Me, HON-CHCH₂, EtO, 222° (decomposition), 52; Me, HON-CHCH₂, H₂NCO, 231° (decomposition), 55; Me, H₂NCO, Cl, 232° (decomposition), 40. XII (R = H). XI (R = H).


IT 23433-47-8P 23433-48-9P 23433-49-0P
23433-50-3P 23433-51-4P 23433-52-5P
23433-53-6P 23433-54-7P 23433-55-8P
23433-56-9P 23433-57-0P 23433-58-1P
23433-71-8P 23433-76-3P 23433-93-5P
RL: SPN (Synthetic preparation); PREP (Preparation) (preparation of)
Rn 23433-47-8 CAPLUS
CN 2-Quinoxalinecarboxamide, N-(4-chloro-2,5-dimethoxyphenyl)-3-methyl-, 1,4-dioxide (9CI) (CA INDEX NAME)




RN 23433-52-5 CAPLUS
CN 2-Quinoxalinecarboxamide, 6-chloro-N-(4-chloro-2,5-dimethoxyphenyl)-3-methyl-, 1,4-dioxide (9CI) (CA INDEX NAME)




RN 23433-53-6 CAPLUS
CN 2-Quinoxalinecarboxamide, 6-chloro-3-methyl-N-(2-methylphenyl)-, 1,4-dioxide (9CI) (CA INDEX NAME)




RN 23433-54-7 CAPLUS
CN 2-Quinoxalinecarboxamide, 6-chloro-N-(2,4-dimethylphenyl)-3-methyl-, 1,4-dioxide (9CI) (CA INDEX NAME)




RN 23433-55-8 CAPLUS
CN 2-Quinoxalinecarboxamide, 6-chloro-N-(2-methoxyphenyl)-3-methyl-, 1,4-dioxide (9CI) (CA INDEX NAME)




RN 23433-56-9 CAPLUS
CN 2-Quinoxalinecarboxamide, 6-chloro-N-(4-chloro-2-methylphenyl)-3-methyl-, 1,4-dioxide (9CI) (CA INDEX NAME)




RN 23433-57-0 CAPLUS
CN 2-Quinoxalinecarboxamide, N-[4-(aminosulfonyl)phenyl]-3-methyl-, 1,4-dioxide (9CI) (CA INDEX NAME)




RN 23433-58-1 CAPLUS
CN 2-Quinoxalinecarboxanilide, 6-methoxy-3-methyl-4'-(phenylazo)-, 1,4-dioxide (8CI) (CA INDEX NAME)




RN 23433-71-8 CAPLUS
CN 2-Quinoxalinecarboxamide, N-(2,6-dimethylphenyl)-3-methyl-, 1,4-dioxide (9CI) (CA INDEX NAME)



RN 23433-76-3 CAPLUS
CN 2-Quinoxalinecarboxamide, N-cyclohexyl-3-methyl-, 1,4-dioxide (8CI, 9CI) (CA INDEX NAME)




RN 23523-93-5 CAPLUS
CN 2-Quinoxalinecarboxamide, N-(4-chloro-2-methylphenyl)-3-methyl-, 1,4-dioxide (9CI) (CA INDEX NAME)




L5 ANSWER 250 OF 283 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 1968:467333 CAPLUS
DOCUMENT NUMBER: 69:57333
TITLE: Pteridines. V. Some analogs of 4,7-diamino-2-phenyl-6-pteridinecarboxamide
AUTHOR(S): Weinstein, Joseph; Dunoff, Roberta Y.; Williams, June G.
CORPORATE SOURCE: Smith Kline and French Lab., Philadelphia, PA, USA
SOURCE: Journal of Medicinal Chemistry (1968), 11(3), 542-8
CODEN: JMCMAR; ISSN: 0022-2623
DOCUMENT TYPE: Journal
LANGUAGE: English
AB A series of 4,7-diamino-6-pteridinecarboxamides were prepared either by reaction of the appropriate 2-substituted 4,6-diamino-5-nitrosopyrimidine with the required N-substituted cyanoacetamide or by aminolysis of ethyl 4,7-diamino-2-phenyl-6-pteridinecarboxylate. The ester was prepared from 8c cyanoacetate and 4,6-diamino-5-nitroso-2-phenylpyrimidine and was also unexpectedly obtained when the same pyrimidine was treated with diphenyl sulfoacetate, cyanoacetylurea, or cyanoacetylurethan in the presence of NaCN. A series of 4-amino-7-hydroxy-2-phenyl-6-pteridinecarboxamide analogs was prepared from the corresponding ester. 17 references.

IT 19148-08-4P 19970-93-5P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)
RN 19148-08-4 CAPLUS
CN 6-Pteridinecarboxanilide, 4,7-diamino-2-phenyl- (8CI) (CA INDEX NAME)




RN 19970-93-5 CAPLUS
CN 6-Pteridinecarboxamide, 4,7-diamino-N-benzyl-2-phenyl- (6CI, 8CI) (CA INDEX NAME)




L5 ANSWER 251 OF 283 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 1968:452104 CAPLUS
DOCUMENT NUMBER: 69:52104
TITLE: Pteridines. XII. Structure-activity relation of some pteridine diuretics
AUTHOR(S): Weinstein, Joseph; Wilson, James W.; Wiebelhaus, Virgil D.; Maass, Alfred R.; Brennan, Francis T.; Sosnowski, Genevieve
CORPORATE SOURCE: Res. and Develop. Div., Smith Kline and French Lab., Philadelphia, PA, USA
SOURCE: Journal of Medicinal Chemistry (1968), 11(3), 573-9
CODEN: JMCMAR; ISSN: 0022-2623
DOCUMENT TYPE: Journal
LANGUAGE: English
AB The diuretic activity of pteridines related to 2,4,7-triamino-6-phenylpteridine (triamterene), 2,4-diamino-6,7-dimethylpteridine (I), and 4,7-diamino-2-phenyl-pteridine-6-carboxamide was studied in the saline-loaded and sodium-deficient rat. A limited number of related pyrimidopyrimidines were similarly studied. Some of the compounds related to triamterene and I not only cause Na⁺ excretion but also conserve K⁺. All the 2-phenylpteridines that were studied which are active natriuretic agents also cause K⁺ excretion. In the triamterene series, replacement of any of the amino groups by either a large amine or a nonbasic group other than H leads to reduction of diuretic activity. Replacement of the Ph by a small, nonbasic group gives active diuretic agents, but an aromatic (or heteroaromatic) group seems desirable for highest activity. Some variation in the substitution pattern on the pteridine ring is permissible as demonstrated by the activity of the triamterene isomers. The 7-Ph isomer is outstanding as a blocker of K⁺ excretion.


IT 19148-08-4
RL: RCT (Reactant); RACT (Reactant or reagent)
(as diuretic)
RN 19148-08-4 CAPLUS
CN 6-Pteridinecarboxanilide, 4,7-diamino-2-phenyl- (8CI) (CA INDEX NAME)




L5 ANSWER 252 OF 283 CAPLUS COPYRIGHT 2006 ACS ON STN
 ACCESSION NUMBER: 1967:403074 CAPLUS
 DOCUMENT NUMBER: 67:3074
 TITLE: Pteridinecarboxamide diuretics. II. Reaction of 4,6-diamino-5-nitrosopyrimidines with N-substituted cyanoacetamides
 AUTHOR(S): Osdene, Thomas S.; Santilli, Arthur A.; McCordle, Lee E.; Rosenthal, Marvin E.
 CORPORATE SOURCE: Res. and Develop. Div., Wyeth Labs. Inc., Radnor, PA, USA
 SOURCE: Journal of Medicinal Chemistry (1967), 10(2), 165-7
 CODEN: JMCMAR; ISSN: 0022-2623
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 GI For diagram(s), see printed CA Issue.
 AB cf. CA 65: 12204g. Several new 4,6-diamino-2-substituted 5-nitrosopyrimidines and N-substituted 2-cyanoacetamides were prepared and used as intermediates in the base-catalyzed preparation of a number of 4,7-diamino-2-substituted N-substituted 6-pteridinecarboxamides as shown. Many of these pteridines had diuretic activity in rats after oral administration. Increased activity was associated with certain specific structural characteristics. The more active compds. were those in which the 2 position of the pteridine nucleus bears an aromatic group, preferably phenyl or p-chlorophenyl, and in which the carbonyl N bears a 2-dialkylaminoethyl or 2-(N-heterocyclic amino)ethyl group, e.g., 2-diethylaminoethyl or 2-morpholinoethyl.
 IT 13053-06-OP 13206-68-3P 15029-90-OP
 15048-48-3P 15057-67-7P 15057-68-8P
 15163-86-7P 15163-89-OP 15341-52-3P
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (preparation of)
 RN 13053-06-0 CAPLUS
 CN Benzoic acid, 4-[[[4,7-diamino-2-phenyl-6-pteridinyl]carbonyl]amino]-, ethyl ester (9CI) (CA INDEX NAME)




RN 13206-68-3 CAPLUS
 CN 6-Pteridinecarboxamide, 4,7-diamino-N-cyclopropyl-2-phenyl- (7CI, 8CI) (CA INDEX NAME)




RN 15029-90-0 CAPLUS
 CN 6-Pteridinecarboxamide, 4,7-diamino-N-cyclohexyl-2-p-tolyl- (7CI, 8CI) (CA INDEX NAME)




RN 15048-48-3 CAPLUS
 CN 6-Pteridinecarboxamide, 4,7-diamino-N-cyclohexyl-N-methyl-2-phenyl- (7CI, 8CI) (CA INDEX NAME)



RN 15057-67-7 CAPLUS
 CN 6-Pteridinecarboxamide, 4,7-diamino-N-cyclopentyl-2-phenyl- (7CI, 8CI) (CA INDEX NAME)




RN 15057-68-8 CAPLUS
 CN 6-Pteridinecarboxamide, 4,7-diamino-N-cyclohexyl-2-phenyl- (7CI, 8CI) (CA INDEX NAME)




RN 15163-86-7 CAPLUS
 CN 6-Pteridinecarboxamide, 2,4,7-triamino-N-cycloheptyl- (8CI) (CA INDEX NAME)


NAME)



RN 15163-89-0 CAPLUS
 CN 6-Pteridinecarboxamide, 4,7-diamino-N-cyclooctyl-2-phenyl- (7CI, 8CI) (CA INDEX NAME)



RN 15341-52-3 CAPLUS
 CN 6-Pteridinecarboxamide, 4,7-diamino-N-cycloheptyl-2-phenyl- (7CI, 8CI) (CA INDEX NAME)



L5 ANSWER 253 OF 283 CAPLUS COPYRIGHT 2006 ACS ON STN
 ACCESSION NUMBER: 1967:10929 CAPLUS
 DOCUMENT NUMBER: 66:10929
 TITLE: Improved penicillins
 INVENTOR(S): Houseley, John R.; Richards, Hugh Colin; Spooner, David F.
 PATENT ASSIGNEE(S): Boots Pure Drug Co. Ltd.
 SOURCE: Brit., 11 pp.
 CODEN: BRXXAA
 PATENT: Patent
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
GB 967890		19660721	GB	19611207

GI For diagram(s), see printed CA Issue.
 AB New penicillins and non-toxic salts represented by the general formula Ia are described. R represents a vicinally bound divalent heterocyclic radical. Therapeutic compds. containing these compds. with an inert diluent or carrier may be in the form of solids, suspensions, tablets, lozenges, ointments, creams or powders. 3-Carboxy-2-quinoxalinylnicillin may be used as a parenteral injection to combat bovine mastitis. For example, 2,3-quinoxalinedicarboxylic anhydride (0.83 g.) was added during 2 min. to a suspension of 0.896 g. 6-aminopenicillanic acid in 2.5 cc. HCONMe2 and 1.75 cc. of NEt3 which had been stirred at 0° 2 hrs. Stirring at

0° was continued 35 min., the semi-solid mass filtered, and the residue washed with dry acetone and dry Et2O to give the monohydrate bis(triethylamine) salt of 3-carboxy-2-quinoxalinylnicillin (I), m. 135-7° (decomposition), α 20 D 142° (c 0.376, H2O). 2,3-Quinoxalinedicarboxylic anhydride (1.99 g.) and 2.16 g. 6-aminopenicillanic acid were allowed to react in 15 cc. HCONMe2 and 4.2 cc. NEt3 as described. The addition of dry Et2O (50 cc.) precipitated an oil

which was separated and dissolved in 10 cc. of H2O. This aqueous solution was washed with Et2O, chilled, and acidified with shaking in the presence of Et2O again. The ethereal exts. were washed with H2O, dried, and then treated with benzylamine to give a solid which was washed with Et2O, washed with dry Et2O, and dried in vacuo to give an isomeric mixture of the dibenzylamine salts of 3-carboxy-2-quinolylpenicillin and 2-carboxy-3-quinolylpenicillin, m. 154-7° (decomposition), α 20 D 141° (c 0.5, H2O). Also, 440 cc. HCONMe2 and 96 cc. redistd. aqueous azeotrope of NEt3 (b. 76°, 90% by weight base) was cooled to 0.3° in a 2-l. flask with stirring, 43.2 g. 6-aminopenicillanic acid added, the mixture stirred 15 min., 40 g. 2,3-quinoxalinedicarboxylic anhydride added over 2 hrs., and stirring at 0.3° continued 2 hrs. more during which time the product began to precipitate. Me2CO (1320 cc.) was added with stirring and the mixture kept at 0.3° overnight to give I, m. 135-7° (decomposition), α 20 D 136°. Colorimetric assay with hydroxylamine against benzylpenicillin corresponded to a purity of 110%. The di-Na salt-H2O (III) of I, m. 253-4° (decomposition), α 20 D 175° (H2O). Similarly, 0.7 cc. NEt3 was added to a stirred solution of 0.835 g. 2,3-pyridinedicarboxylic acid in 50 cc. dry tetrahydrofuran, the solution cooled to 0°, 0.5 cc. ethyl chloroformate added dropwise, and stirring continued at 0° 1 hr. After cooling to -30°, the mixture was filtered and the filtrate added to an aqueous solution of K 6-aminopenicillanate. This mixture was stirred

1.5 hrs. during which time it came to room temperature, the solvent evaporated at 30°/3 mm., and the last traces of H2O were removed by azeotropic distillation with BuOH under the same conditions to give an isomeric mixture of K

3-carboxy-2-pyridylpenicillanate and K 2-carboxy-3-pyridylpenicillanate, m. 190-5° (decomposition); hydroxylamine assay indicated 100% purity. The same method was used to effect the conversion of 3,4-pyridinedicarboxylic acid to an isomeric mixture of K 3-carboxy-4-pyridylpenicillanate and K 4-carboxy-3-pyridylpenicillanate, m. 170-80° (decomposition). The purity was about 80% (hydroxylamine assay). A solution of Na 6-aminopenicillanate was prepared from 1.4 g. of the acid and 2.5 g. NaHCO3 in 25 cc. H2O and 5 cc. Me2CO cooled to 0°. A solution of 3-benzoyloxycarbonyl-2-quinoxalinedicarboxylic chloride (prepared by refluxing 2 g. 3-benzoyloxycarbonyl-2-quinoxalinedicarboxylic acid with 1.5 ml. SOCl2 30 min. and evaporating the excess SOCl2 in vacuo) in 10 cc. dry Me2CO was added to the stirred solution of the above Na salt dropwise during 10 min., the temperature kept at 0° 5 min. more, 5 cc. MeCOBu-iso added, and the mixture stirred for 15 min. more, during which time it reached room temperature. After discarding the organic layer, the aqueous phase was covered with 50 cc. ether and acidified with 2N HCl, and the ethereal extract washed with 10 cc. H2O, dried, evaporated under reduced pressure to 10 cc., and cooled to 0° to precipitate 3-benzoyloxycarbonyl-2-quinoxalinylnicillin, m. 167-70° (decomposition). Also, 0.5 cc. ethyl chloroformate was added dropwise to a stirred solution of 1.23 g. 3-ethoxycarbonyl-2-quinoxalinedicarboxylic acid and 0.7 cc. NEt3 in 50 cc. dry tetrahydrofuran at 0°, the mixture stirred at 0° 1 hr., cooled to -30°, and filtered, the filtrate added to a stirred aqueous solution of K 6-aminopenicillanate, stirring continued 1.5 hrs., and the solvent evaporated in vacuo to yield crude K 3-ethoxycarbonyl-2-quinoxalinylnicillin, m. 210-15° (decomposition), purity 86% (hydroxylamine assay). This

procedure was used to convert a number of hemi-esters and hemi-amides of 2,3-quinoxalinedicarboxylic acid to the K salts of the following esters of 3-carboxy-2-quinoxalinylnicillin (alc. moiety, m.p. (decomposition), and % purity (hydroxylamine assay) given): Pr, 200-10°, 73; iso-Pr, 205-10°, 100; Bu, 150-60°, 71; n-decyl, 230-5°, 73; Et2NHC2H2, 200-10°, 94; cyclohexyl, 155-6°, -; Ph, 205-10°, 74; benzyl, 130-5°, 100. Also prepared were the K salts of the following amides of 3-carboxy-2-quinoxalinylnicillin (amine moiety, m.p. (decomposition), and % purity (hydroxylamine assay) given): NH2, 180-90°, 56; Et2N, 210-15°, 75; PrNH, 140-50°, 41; piperidino, 200-10°, 97; PhNH, 205-10°, 50; N-methylanilino, 193-9°, 95. 3-Methoxy-2-quinoxalinedicarboxylic acid (1.16 g.) was converted to its K salt and then treated with K 6-aminopenicillinate by the last procedure. Instead of evaporating the solvent, a further amount of

H2O

(20 cc.) and Et2O (50 cc.) were added, the mixture was well shaken, the aqueous phase separated, covered with 30 cc. of Et2O, cooled with ice, and acidified with 2N HCl with vigorous shaking, the ethereal extract washed with H2O and extracted with 0.5 g. of NaHCO3 in 20 cc. of Et2O, the ethereal layer discarded, MeCOBu-iso added to the aqueous phase, which was then chilled with ice and acidified with 2N HCl, and the organic layer was separated, washed with 20 cc. H2O four times, dried, and treated with K 2-ethylhexanoate in MeCOBu-iso (6.74 by weight) until there was no further turbidity to give 3-methoxycarbonyl-2-quinoxalinylnicillin, m. 210-20°, 95% pure (hydroxylamine assay). The ir absorption spectra of all the penicillins prepared were characteristic of a β -lactam ring system. Descriptions of pharmaceutical formulations were given.

IT

13233-25-5P 13255-86-2P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)


RN

13233-25-5 CAPLUS

CN

4-Thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid, 3,3-dimethyl-6-[3-(methylphenylcarbamoyl)-2-quinoxalinedicarboxamido]-7-oxo-, monopotassium salt (8CI) (CA INDEX NAME)

Absolute stereochemistry.




• K

RN 13255-86-2 CAPLUS

CN

4-Thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid, 3,3-dimethyl-7-oxo-6-[3-(phenylcarbamoyl)-2-quinoxalinedicarboxamido]-, monopotassium salt (7CI, 8CI) (CA INDEX NAME)

Absolute stereochemistry.



• K

L5 ANSWER 254 OF 283

ACCESSION NUMBER:

DOCUMENT NUMBER:

ORIGINAL REFERENCE NO.:

TITLE:

INVENTOR(S):

PATENT ASSIGNEE(S):

SOURCE:

DOCUMENT TYPE:

LANGUAGE:

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
GB 1039379		19660817	GB	19630923

GI For diagram(s), see printed CA Issue.

AB Dyes of the general formula R₁NH₂, where R is the residue of an azo,

anthraquinone, or phthalocyanine (Pc) dye, gives fast shades on cellulose fibers from a bath containing an acid-binding agent. They can also be used on wool and polyamide fibers. For example, a solution of 9.3 parts tri-Na salt of 1-(4-sulfonylphenyl)-3-carboxy-4-(3-amino-4-sulfonylphenylazo)-5-pyrazolone in 200 parts water is added to a suspension of 4.15 parts QCOCl (I) in a mixture of 200 parts H2O and 40 parts ice, stirred at 5-10° until no further addition of Na2CO3 is required to keep the pH at 6, salted with 100 parts of NaCl, filtered, and dried to give a product containing 0.9 atom organically bound Cl per mol., which dyes cotton (fast yellow shades). Similarly, other amino dyes were acylated with I (R₁NH2 and shade given): CuPc(SO3Na)2(SO2NH2)2(SO2NHC6H4NH2)-3, greenish blue (II); CuPc(SO3Na)2(SO2NHC6H4NH2)-3, greenish blue; III, blue; 4-H2NHC6H4NHC6H3(OH)Me-2,5, yellow. II boiled with aqueous Na2SO3 gave the 2-sulfoquinoxaline-3-carboxyl analog with similar properties.

IT


5815-92-9, 2,7-Naphthalenedisulfonic acid, 5-(3-chloro-2-quinoxalinedicarboxamido)-4-hydroxy-3-[(6-hydroxy-m-tolyl)azo]-5-oxo-1-(p-sulfonylphenyl)azo)- (7CI, 8CI) (CA INDEX NAME)

RN 5815-92-9 CAPLUS

CN

2,7-Naphthalenedisulfonic acid, 5-(3-chloro-2-quinoxalinedicarboxamido)-4-hydroxy-3-[(6-hydroxy-m-tolyl)azo]-5-oxo-1-(p-sulfonylphenyl)azo)- (7CI, 8CI) (CA INDEX NAME)


PAGE 1-A



RN 5815-93-0 CAPLUS

CN


2-Quinoxalinedicarboxanilide, 3-chloro-4'-[(6-hydroxy-m-tolyl)azo]- (7CI, 8CI) (CA INDEX NAME)



RN 10572-52-8 CAPLUS

CN


2-Pyrazoline-3-carboxylic acid, 4-[(3-(3-chloro-2-quinoxalinedicarboxamido)-4-sulfonylphenyl)azo]-5-oxo-1-(p-sulfonylphenyl)azo)- (7CI, 8CI) (CA INDEX NAME)



RN 108513-08-2 CAPLUS

CN

Copper, [dihydrogen 3'-[(3-chloro-2-quinoxalinedicarboxamido)phenyl]sulfonyl]-3'-[(3-chloro-2-quinoxalinedicarboxamido)phenyl]sulfonyl]-3'-phthalocyaninedisulfonate(2-)- (7CI) (CA INDEX NAME)



• 2 H+

PAGE 2-A

L5 ANSWER 255 OF 283

ACCESSION NUMBER:

DOCUMENT NUMBER:

ORIGINAL REFERENCE NO.:

TITLE:

PATENT ASSIGNEE(S):

SOURCE:

DOCUMENT TYPE:

LANGUAGE:

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
FR 1410533		19650910	FR	19640917

AB Azo dyes containing a ClCH:CHSO2- or Cl2CHCH2SO2-group and useful for dyeing

cellulose fibers (I) fast shades were prepared. Thus, 331.5 parts 2,5-Cl(Cl2CHCH2SO2)C6H3NH2 was diazotized and coupled with 460 parts 1,8,3,6-HO(AcNH)C10H4-(SO3H)2 while maintaining pH 7.5-8 by adding Na2CO3, salted, the precipitate filtered and dried to give a red powder, which dyed I


red

shades. Similarly, the following dyes were prepared (amine, coupling component and shade on I given): 3-ClCH:CHSO2-C6H4NH2 (II), 1,8,3,6-HO [4,2,5-Cl(Me)2C6H2SO2NH] C10H4 (SO3H)2 (III), red; 3-Cl2CHCH2SO2C6H4NH2 (IV), red; IV, 2,3,6-HOClOHS (SO3H)2, orange; II, 1,8,5,7-HO(H2N)C10H4-(SO3H)2 (V), violet red; IV, 1,8,3,6-H2N(HO)C10H4-(SO3H)2, blue; 2,5-Me(ClCH:CHSO2)C6H3NH2, V, violet red; II, 1-(4-sulfonylphenyl)-3-methyl-5-pyrazolone, yellow; IV, 1,4,8-HOClOHS-(SO3H)2, red orange; II, 1-(2-chloro-4-sulfonylphenyl)-3-methyl-5-pyrazolone, yellow; II, 1-(4-sulfonylphenyl)-3-carbomethoxy-5-pyrazolone, yellow; II, 1-(6-sulfo-2-naphthyl)-3-methyl-5-pyrazolone, reddish yellow.

IT


5815-92-9, 2,7-Naphthalenedisulfonic acid, 5-(3-chloro-2-

quinoxalinecarboxamido)-4-hydroxy-3-[(o-sulfonyl)azo]-
(preparation of)
RN 5815-92-9 CAPLUS
CN 2,7-Naphthalenedisulfonic acid, 5-(3-chloro-2-quinoxalinecarboxamido)-4-
hydroxy-3-[(o-sulfonyl)azo]- (7CI, 8CI) (CA INDEX NAME)




L5 ANSWER 256 OF 283 CAPLUS COPYRIGHT 2006 ACS ON STN
ACCESSION NUMBER: 1966:456810 CAPLUS
DOCUMENT NUMBER: 65:56810
ORIGINAL REFERENCE NO.: 65:105889-h,10589a-b
TITLE: N-Benzylamide of quinoxaline-2,3-dicarboxylic acid
AUTHOR(S): Cesari, Adriana
SOURCE: Annali dell'Istituto Superiore di Sanita (1965),
119-120, 555-9
CODEN: AISSAN; ISSN: 0021-2571
DOCUMENT TYPE: Journal
LANGUAGE: Italian
GI For diagram(s), see printed CA Issue.
AB To a boiling suspension of 9.5 g. quinoxaline-2,3-dicarboxylic anhydride
(I) in 300 ml. absolute EtOH, 16 g. PhCH2NH2 (III) was added, the mixture
refluxed 1 hr., the solvent evaporated in vacuo, and the residue taken up in
H2O and Et2O, to give 12 g. crude benzylamine salt of quinoxaline-2,3-
carboxamic acid (III), m. 182-4° (Me2CO); the crude product was
dissolved in warm H2O, the solution filtered, and acidified with HCl, to give
10.5 g. free III, m. 172° (decomposition) (alc.). III (6.5 g.) was
treated with 50 cc. SO2Cl2, after 30 min. 300 ml. CHCl3 was added, the
mixture refluxed until the solid was completely dissolved, and the solvent
evaporated to give 4.8 g. N-benzylamide (IV) of quinoxaline-2,3-dicarboxylic
acid, m. 270-2° (C6H6). Pyrolysis of III was accomplished by
refluxing the compound in xylene 1 hr. and evaporating the solvent in vacuo, to
give a residue of quinoxaline-2-carboxybenzylamide, m. 150-2°
(MeOH). Quinoxaline-2,3-dicarboxylic acid monamide was heated in vacuo
to 165° for 20 min. and to 205° for another 10 min., to give
quinoxaline-2-carboxamide, m. 198° (AcOH). A mixture of 3.9 g. I and
4.2 g. PCl5 was gradually heated to 185°, cooled to 150°
when the reaction began, kept for 3 hrs. at this temperature, and POC13 was
evaporated in vacuo to give 3 g. quinoxaline-2,3-dicarboxylic acid chloride
(V), m. 85-7° (ligroine). To a solution of 2.5 g. V in 15 ml. anhydrous
C6H6, 3 g. II in 50 ml. C6H6 was added slowly, with gentle heating, the
mixture was heated 30 min. on a water bath, cooled, the precipitate filtered
off,
and washed with H2O, to give 2.6 g. crude quinoxaline-2,3-dicarboxamide,
m. 190° (alc.). From the mother liquor 0.2 g. IV was isolated by
evaporation of the solvent and recrystn. of the residue in C6H6.
IT 7066-31-1, 2-Quinoxalinecarboxylic acid, 3-(benzylcarbamoyl)-
7066-32-2, 2-Quinoxalinecarboxamide, N-benzyl- 7066-35-5
2,3-Quinoxalinedicarboxamide, N,N'-dibenzyl- 13564-72-2,
Benzylamine, compound with 3-(benzylcarbamoyl)-2-quinoxalinecarboxylic acid
(1:1)
(preparation of)


RN 7066-31-1 CAPLUS
CN 2-Quinoxalinecarboxylic acid, 3-(benzylcarbamoyl)- (7CI, 8CI) (CA INDEX NAME)



RN 7066-32-2 CAPLUS
CN 2-Quinoxalinecarboxamide, N-(phenylmethyl)- (9CI) (CA INDEX NAME)




RN 7066-35-5 CAPLUS
CN 2,3-Quinoxalinedicarboxamide, N,N'-dibenzyl- (7CI, 8CI) (CA INDEX NAME)



RN 13564-72-2 CAPLUS
CN 2-Quinoxalinecarboxylic acid, 3-(benzylcarbamoyl)-, compd. with
benzylamine (1:1) (8CI) (CA INDEX NAME)

CN 1

CRN 7066-31-1
CMF C17 H13 N3 O3




CN 2

CRN 100-46-9
CMF C7 H9 N


H2N-CH2-Ph

L5 ANSWER 257 OF 283 CAPLUS COPYRIGHT 2006 ACS ON STN
ACCESSION NUMBER: 1966:456809 CAPLUS
DOCUMENT NUMBER: 65:56809
ORIGINAL REFERENCE NO.: 65:10588e-g
TITLE: Quinoxaline derivatives. IX. An unusual chlorine
substitution in quinoxaline N-oxides. Its scope and
limitations
AUTHOR(S): Ahmad, Yusuf; Habib, M. S.; Ziauddin; Bakhtiar,
Bushra
CORPORATE SOURCE: Chem. Res. Div., Pakistan Council Sci. Ind. Res.,
Karachi
SOURCE: Journal of Organic Chemistry (1966), 31(8), 2613-16
CODEN: JOCEAH; ISSN: 0022-3263
DOCUMENT TYPE: Journal
LANGUAGE: English
AB cf. CA 64, 5092f. An O function at C-3 in quinoxaline 1-oxides was shown
to control the nucleophilic Cl substitution at C-6 observed when these
N-oxides are heated with AlCl3 or ethanolic HCl. In its absence the Cl
substitution (a) fails to take place as evidenced in the case of
2,3-diphenylquinoxaline 1-oxide and 1,4-dioxide; (b) if it takes place as
in the case of 2,3-dimethylquinoxaline 1-oxide and 1,4-dioxide is directed
to the Me groups; (c) takes place at a position adjacent to the N-oxide if
it is previously unoccupied. 17 references.
IT 7066-32-2, 2-Quinoxalinecarboxamide, N-benzyl-
(preparation of)
RN 7066-32-2 CAPLUS
CN 2-Quinoxalinecarboxamide, N-(phenylmethyl)- (9CI) (CA INDEX NAME)



L5 ANSWER 258 OF 283 CAPLUS COPYRIGHT 2006 ACS ON STN
ACCESSION NUMBER: 1966:438025 CAPLUS
DOCUMENT NUMBER: 65:38025
ORIGINAL REFERENCE NO.: 65:7035f-g
TITLE: Polarographic study of pteridines
AUTHOR(S): LaPidus, Milton; Rosenthal, Marvin S.
CORPORATE SOURCE: Myeth Labs., Inc., Radnor, PA
SOURCE: Journal of Pharmaceutical Sciences (1966), 55(6),
555-60
CODEN: JPMSAE; ISSN: 0022-3549
DOCUMENT TYPE: Journal
LANGUAGE: English
AB The electronegativity of the half-wave potentials of a series of pteridine
congeners was found to be related to the substituent groups. The
2,4,7-tri-aminopteridines, 7-substituted 4-amino-2-aryl-6-
pteridinecarboxamides, and 4,7-diamino-2-aryl-6-pteridinecarboxamides were
characterized, in that order, by decreasingly lower electroneg. half-wave
potentials.
IT 13206-68-3, 6-Pteridinecarboxamide, 4,7-diamino-N-cyclopropyl-2-
phenyl-
(polarography of)
RN 13206-68-3 CAPLUS

CN 6-Pteridinecarboxamide, 4,7-diamino-N-cyclopropyl-2-phenyl- (7CI, 8CI)
(CA INDEX NAME)




L5 ANSWER 259 OF 283 CAPLUS COPYRIGHT 2006 ACS ON STN
ACCESSION NUMBER: 1966:105013 CAPLUS
DOCUMENT NUMBER: 64:105013
ORIGINAL REFERENCE NO.: 64:19843h,19844a-b
TITLE: Reactive dyes containing chloroquinoxaline groups
INVENTOR(S): Benz, Jakob
PATENT ASSIGNEE(S): Sandos Ltd.
SOURCE: 55 pp.
DOCUMENT TYPE: Patent
LANGUAGE: Unavailable
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
BE 656696	---	19650401	BE	---
FR 1420687	---	---	FR	---
PRIORITY APPLN. INFO.:	---	---	CH	19631213

GI For diagram(s), see printed CA Issue.
AB (Throughout this abstract O is a 2-chloroquinoxaline-3-carbonyl group).
Azo, anthraquinone, and phthalocyanine (Pc) dyes containing a QNH group and
useful for dyeing cellulose and polyamide fibers were prepared. Thus, 25
parts OCl (prepared by treatment of QNH with SOCl2, m. 117-19°) was
added to a solution of 43.3 parts 2,5,7,6-H2N(HO)(NaO3S)C10H4N:NC6H4SO3Na-2
in 400 parts H2O, the mixture stirred, neutralized with Na2CO3 solution, 20
parts NaCl added, and the precipitate filtered and dried at 50-70° to give a
fast orange dye for cotton. Similarly, the following dyes were prepared
(reactants and shade given): 2,4-H2N(QNH)C6H3SO3H (1) -
1-(2,5-dichloro-4-sulfonylphenyl)-3-methyl-5-pyrazolone, greenish yellow on
rayon; 1-amino-4-(4-aminoanilino) anthraquinone-2,7-disulfonic acid,
condensed with QCl, blue on cotton; Cu phthalocyanine-x-sulfon(4-
amino)anilide sulfonic acid, condensed with QCl, turquoise blue on cotton;
4,6,8,2-(NaO3S)3C10H4N:NC6H4NH2-4, OCl, reddish yellow on cotton; 1
+ 1,6,3,6,2-H2N(HO)(NaO3S)2C10H3N:NC6H4NH2-4, gray-green on
cellulose fiber; 1 + 1,4,7-HOC10H5(SO3Na)2, scarlet on cotton;
2-HO3SC6H4NH2 - 1,8,3,6-QNH(HO)C10H4(SO3H)2, red on cotton;
5,2-Me(HO)C6H3N:NC6H4NH2-4, OCl, yellow on polyamide fibers.
IT 5815-77-0, 2-Naphthalenesulfonic acid, 7-(3-chloro-2-
quinoxalinecarboxamido)-4-hydroxy-3-[(o-sulfonyl)azo]-
5815-78-1, Sulfonic acid, N-[(3-chloro-2-quinoxalinecarboxamido)carbonyl]-
2-[(1,2,5-dichloro-4-sulfonylphenyl)-3-methyl-5-oxo-2-pyrazolin-4-yl]azo]-
5815-79-2, 1,3,5-Naphthalenesulfonic acid, 7-[[p-(3-chloro-2-
quinoxalinecarboxamido)phenyl]azo]- 5815-92-9,
2,7-Naphthalenedisulfonic acid, 5-(3-chloro-2-quinoxalinecarboxamido)-4-
hydroxy-3-[(o-sulfonyl)azo]- 5815-27-1, 2,7-
Anthracenedisulfonic acid, 1-amino-4-[p-(3-chloro-2-
quinoxalinecarboxamido)anilino]-9,10-dihydro-9,10-dioxo- 7381-45-5
2,7-Naphthalenedisulfonic acid, 4-amino-6-[[p-(3-chloro-2-
quinoxalinecarboxamido)phenyl]azo]-3-[[5-(3-chloro-2-
quinoxalinecarboxamido)-2-sulfonylphenyl]azo]-5-hydroxy- 36600-58-9
1,6-Naphthalenedisulfonic acid, [[5-(3-chloro-2-quinoxalinecarboxamido)-
2-sulfonylphenyl]azo]-4-hydroxy-


(preparation of)
 RN 5815-77-0 CAPLUS
 CN 2-Naphthalenesulfonic acid, 7-[(3-chloro-2-quinoxalyl)carboxamido]-4-hydroxy-3-[(o-sulfonyl)azo]- (7CI, 8CI) (CA INDEX NAME)




RN 5815-78-1 CAPLUS
 CN Sulfanilic acid, N-[(3-chloro-2-quinoxalyl)carboxamido]-2-[[1-(2,5-dichloro-4-sulfonyl)-3-methyl-5-oxo-2-pyrazolin-4-yl]azo]- (7CI, 8CI) (CA INDEX NAME)




RN 5815-79-2 CAPLUS
 CN 1,3,5-Naphthalenesulfonic acid, 7-[[p-(3-chloro-2-quinoxalyl)carboxamido]phenyl]azo]- (7CI, 8CI) (CA INDEX NAME)




RN 5815-92-9 CAPLUS
 CN 2,7-Naphthalenedisulfonic acid, 5-(3-chloro-2-quinoxalyl)carboxamido)-4-hydroxy-3-[(o-sulfonyl)azo]- (7CI, 8CI) (CA INDEX NAME)



RN 6565-27-1 CAPLUS
 CN 2,7-Anthracenedisulfonic acid, 1-amino-4-[[p-(3-chloro-2-quinoxalyl)carboxamido]anilino]-9,10-dihydro-9,10-dioxo- (7CI, 8CI) (CA INDEX NAME)




RN 7381-45-5 CAPLUS
 CN 2,7-Naphthalenedisulfonic acid, 4-amino-6-[[p-(3-chloro-2-quinoxalyl)carboxamido]phenyl]azo]-3-[[5-(3-chloro-2-quinoxalyl)carboxamido]-2-sulfonylphenyl]azo]-5-hydroxy- (7CI, 8CI) (CA INDEX NAME)




PAGE 1-A

PAGE 1-B



RN 30600-58-9 CAPLUS
 CN 1,6-Naphthalenedisulfonic acid, [[5-[[3-chloro-2-quinoxalyl)carboxamido]amino]-2-sulfonylphenyl]azo]-4-hydroxy- (9CI) (CA INDEX NAME)




L5 ANSWER 260 OF 283 CAPLUS COPYRIGHT 2006 ACS ON STN
 ACCESSION NUMBER: 1966:76026 CAPLUS
 DOCUMENT NUMBER: 64:76026
 ORIGINAL REFERENCE NO.: 64:14263a-b
 TITLE: Quinoxaline studies. XIII. N-(2-Quinoxalyl)- α -amino acids
 AUTHOR(S): Gerchakov, Shlomo; Whitman, Peter J.; Schultz, Harry P.
 CORPORATE SOURCE: Univ. of Miami, Coral Gables, FL
 SOURCE: Journal of Medicinal Chemistry (1966), 9(2), 266-8
 CODEN: JMCMAR; ISSN: 0022-2623
 DOCUMENT TYPE: Journal
 LANGUAGE: English

AB cf. CA 60, 10683h. A mix of α -amino acid, 5% aqueous NaHCO₃ and 2-quinoxalyl chloride was stirred at 25° until the first-formed red color became pale yellow. Acidification of the decolorized solution then yielded the title compds. UV data are given.

IT 5570-04-7, Alanine, 3-phenyl-N-(2-quinoxalyl)carboxamido)-, L- (preparation of)
 RN 5570-04-7 CAPLUS
 CN Alanine, 3-phenyl-N-(2-quinoxalyl)carboxamido)-, L- (8CI) (CA INDEX NAME)


Absolute stereochemistry.



L5 ANSWER 261 OF 283 CAPLUS COPYRIGHT 2006 ACS ON STN
 ACCESSION NUMBER: 1966:76025 CAPLUS
 DOCUMENT NUMBER: 64:76025
 ORIGINAL REFERENCE NO.: 64:14262g-h, 14263a
 TITLE: Cytosolic alkoxy and hydroxy amino acids. V. Synthesis of β -[5-bis(2-chloroethyl)amino]-2-hydroxyphenyl]-DL-alanine
 AUTHOR(S): Straukas, J.; Degutis, J.
 CORPORATE SOURCE: Lietuvos TSR Mokslu Akad. Darbai, Ser. B (1965), (4), 55-9


DOCUMENT TYPE: Journal
 LANGUAGE: Russian
 AB cf. CA 64, 14124c. Synthesis of the title compound (I) was done as follows. Acylating 5-nitro-2-hydroxybenzyl chloride with Ac₂O using H₂SO₄ as catalyst gave 2-acetoxy-5-nitrobenzyl chloride (II), m. 76.5-8.0°. Condensation of II with di-Et acetamidomalonate gave di-Et acetamido(2-acetoxy-5-nitrobenzyl)malonate (III), m. 195-7° (decomposition). Reduction of the nitro group of III yielded di-Et acetamido(5-amino-2-acetoxybenzyl)malonate (IV) m. 180-2° (decomposition). IV with ethylene oxide was converted to di-Et acetamido(2-acetoxy-5-bis(2-hydroxyethyl)aminobenzyl)malonate (V), an oil. Di-Et acetamido(2-acetoxy-5-bis(2-chloroethyl)aminobenzyl)malonate (VI) was obtained by dissolving 1 g. V in 10 ml. CHCl₃ and adding 1 g. PCl₅ in increments during a 15-min. period. After boiling 3 hrs., the solvent and most of the PCl₅ was removed in vacuo. The residue was dissolved in CHCl₃ and poured on ice. The material was neutralized with saturated NaHCO₃ solution to pH 5 and dried over MgSO₄. The product was obtained as an oil after purification on an Al₂O₃ column. Treatment of VI with concentrated HCl yielded I, as the HCl salt, which decomposed >90°.
 IT 5570-04-7, Alanine, 3-phenyl-N-(2-quinoxalyl)carboxamido)-, L- (preparation of)
 RN 5570-04-7 CAPLUS
 CN Alanine, 3-phenyl-N-(2-quinoxalyl)carboxamido)-, L- (8CI) (CA INDEX NAME)

Absolute stereochemistry.




L5 ANSWER 262 OF 283 CAPLUS COPYRIGHT 2006 ACS ON STN
 ACCESSION NUMBER: 1966:27558 CAPLUS
 DOCUMENT NUMBER: 64:27558
 ORIGINAL REFERENCE NO.: 64:5092f-h, 5093a-c
 TITLE: Quinoxaline derivatives. VIII. The effect of electron-donating groups on the formation of certain quinoxalinecarboxaniline N-oxides and their rearrangement
 AUTHOR(S): Ahmad, Yusuf; Habib, M. S.; Iqbal, M.; Qureshi, M. Ikram; Ziauddin
 CORPORATE SOURCE: Pakistan Council Sci. Ind. Res., Karachi
 SOURCE: Canadian Journal of Chemistry (1965), 43(12), 3424-8
 CODEN: CJCHAG; ISSN: 0008-4042
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 GI For diagram(s), see printed CA issue.
 AB cf. CA 63, 18083d. Introduction of methyl or methoxy groups into the benzene ring of quinoxaline-carboxanilide (Ia), makes the resulting anilides less prone to abnormal oxidation. Normal N-oxides (IIa and IIb) were obtained from the anilides Ib and Ic in which the cyclic >NH was unprotected. The methyl-substituted anilides Id and Ie, however, on oxidation with peracetic acid gave the dioxo derivatives (IIId and IIId) instead of the N-oxides (IIc and IId). (I), (II), (III), (R = R₁ = R₂ = H); (IIb), (R = R₁ = Me, R₂ = H); (Ic), (R = R₁ = MeO, R₂ = H, R₃ = Me); (Id), (R = R₁ = R₂ = Me, R₃ = H); (Ie), (R = R₁ = Me, R₂ = R₃ = H); (II), (R = R₁ = MeO, R₂ = Me, R₃ = H); (Ig), (R = R₁ = Me, R₂ = R₃ = H); (IIa), (R = R₁ = R₂ = Me, R₃ = H); (IIb), (R = R₁ = MeO, R₂ = H, R₃ = Me); (IIc), (R = R₁ = R₂ = Me, R₃ = H); (IId), (R = R₁ = MeO, R₂ = R₃ = H); (IIe), (R = R₁ = MeO, R₂ = Me, R₃ = H); (IIIf), (R = R₁ = MeO, R₂ = R₃ = H)

RN 809-28-9 CAPLUS
CN 2-Quinoxalinedicarboxanilide, 2'-acetamido-3-(α -hydroxybenzyl)- (7CI,
ACI) (CA INDEX NAME)




LS ANSWER 265 OF 283 CAPLUS COPYRIGHT 2006 ACS on STN
 ACCESSION NUMBER: 1965:1099 CAPLUS
 DOCUMENT NUMBER: 62:1099
 ORIGINAL REFERENCE NO.: 62:560a-b
 TITLE: Quinoxaline derivatives. II. Direct synthesis of 1,2-dihydroquinoxalines
 AUTHOR(S): Ahmad, Yusuf; Habib, M. S.; Iqbal, M.; Qureshi, M. Ikram
 CORPORATE SOURCE: Pakistan Council Sci. Ind. Res., Karachi
 SOURCE: Journal of the Chemical Society (1964), (Oct.), 4056-7
 CODEN: JCSOAS; ISSN: 0368-1769
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 OI For diagram(s), see printed CA Issue.
 AB The appropriate o-phenylenediamine (0.5 g.) and 1 cc. EtCH(CO₂Et)₂ in 25 cc. EtOH refluxed 1 hr. yielded 50-80% the corresponding I, which was also obtained from the corresponding quinoxaline by refluxing 0.1 g. 1 hr. with 0.2 g. Na₂SO₄ in 50% aqueous EtOH (70-90% yields).
 IT 1230-49-5, 2-Quinoxalinecarboxy-p-toluide, 3,4-dihydro-3-oxo- (preparation of)
 RN 1230-49-5 CAPLUS
 CN 2-Quinoxalinecarboxy-p-toluide, 3,4-dihydro-3-oxo- (7CI, 8CI) (CA INDEX NAME)




LS ANSWER 266 OF 283 CAPLUS COPYRIGHT 2006 ACS on STN
 ACCESSION NUMBER: 1965:1098 CAPLUS
 DOCUMENT NUMBER: 62:1098
 ORIGINAL REFERENCE NO.: 62:559h, 560a
 TITLE: Quinoxaline derivatives. I. Intramolecular rearrangement of certain quinoxalinecarboxanilides to spiroindoles
 AUTHOR(S): Ahmad, Yusuf; Habib, M. S.; Iqbal, M.; Qureshi, M. Ikram
 CORPORATE SOURCE: Pakistan Council Sci. Ind. Res., Karachi
 SOURCE: Journal of the Chemical Society (1964), (Oct.), 4053-6
 CODEN: JCSOAS; ISSN: 0368-1769
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 OTHER SOURCE(S): CASREACT 62:1098
 OI For diagram(s), see printed CA Issue.
 AB A series of I was converted into II by boiling with HCl-EtOH. When R₂ was electron-releasing, the reaction did not occur on treatment of I with


concentrated H₂SO₄ at room temperature
 IT 37648-63-8, 2-Quinoxalinecarboxanilide (derivate, rearrangements of)
 RN 37648-63-8 CAPLUS
 CN 2-Quinoxalinecarboxamide, N-phenyl- (9CI) (CA INDEX NAME)




IT 1230-49-5, 2-Quinoxalinecarboxy-p-toluide, 3,4-dihydro-3-oxo-
 1233-88-1, 2-Quinoxalinecarboxanilide, 3,4-dihydro-6,7-dimethyl-3-oxo-
 1237-73-6, 2-Quinoxalinecarboxanilide, 3,4-dihydro-N,6,7-trimethyl-3-oxo-
 1240-73-9, 2-Quinoxalinecarboxanilide, 3,4-dihydro-6,7-dimethoxy-3-oxo-
 1243-50-1, 2-Quinoxalinecarboxanilide, 3,4-dihydro-6,7-dimethoxy-N-methyl-3-oxo-
 (preparation of)
 RN 1230-49-5 CAPLUS
 CN 2-Quinoxalinecarboxy-p-toluide, 3,4-dihydro-3-oxo- (7CI, 8CI) (CA INDEX NAME)



RN 1233-88-1 CAPLUS
 CN 2-Quinoxalinecarboxanilide, 3,4-dihydro-6,7-dimethyl-3-oxo- (7CI, 8CI) (CA INDEX NAME)




RN 1237-73-6 CAPLUS
 CN 2-Quinoxalinecarboxanilide, 3,4-dihydro-N,6,7-trimethyl-3-oxo- (8CI) (CA INDEX NAME)




RN 1240-73-9 CAPLUS
 CN 2-Quinoxalinecarboxanilide, 3,4-dihydro-6,7-dimethoxy-3-oxo- (7CI, 8CI)

(CA INDEX NAME)



RN 1243-50-1 CAPLUS
 CN 2-Quinoxalinecarboxanilide, 3,4-dihydro-6,7-dimethoxy-N-methyl-3-oxo- (7CI, 8CI) (CA INDEX NAME)




LS ANSWER 267 OF 283 CAPLUS COPYRIGHT 2006 ACS on STN
 ACCESSION NUMBER: 1964:476590 CAPLUS
 DOCUMENT NUMBER: 61:76590
 ORIGINAL REFERENCE NO.: 61:13186a-g
 TITLE: Penicillins
 INVENTOR(S): Houseley, John R.; Richards, Hugh C.; Spooner, David F.
 PATENT ASSIGNEE(S): Boots Pure Drug Co. Ltd.
 SOURCE: 14 pp.
 DOCUMENT TYPE: Patent
 LANGUAGE: Unavailable
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
GB 867890	19640826	GB	19611207
PRIORITY APPL. INFO.:			GB	19611207

AB The preparation of the title compds. (I) is described. Thus, quinoxaline-2,3-dicarboxylic acid anhydride was added during 2 min. to an equimolar amount of 6-aminopenicillanic acid (III) suspended in HCONMe₂ and Et₃N previously stirred for 2 h. at 0° the mixture stirred 35 min. at 0° and the semisolid filtered off and washed with dry acetone and ether to give the diEt₃N salt of 3-carboxyquinoxalin-2-ylpenicillin-H₂O (III) m. 135-7° (decomposition), [α]_D²⁰ 142° (c 0.376, H₂O). III was dissolved in distilled H₂O and treated with saturated NaOAc to give the corresponding diacid salt dihydrate (IV), m. 253-4° (decomposition) [α]_D²⁰ 175° (H₂O). Similarly prepared were 3-carboxy-6,7-di-methylquinoxalin-2-ylpenicillin di-Et₃N salt, m. 178° (decomposition), and an isomeric mixture (V) of dibenzylamine salts of 3-carboxyquinoxalin-2-yl- and 2-carboxyquinoxalin-2-ylpenicillins, m. 154-7° (decomposition), [α]_D²⁰ 141° (c 0.5, H₂O). V was isolated by adding ether to the reaction mixture, dissolving the precipitated oil in H₂O, washing the aqueous extract with ether, chilling, acidifying to pH 2, shaking with ether, washing the ether extract with H₂O, drying over MgSO₄, and adding benzylamine to pH 8. An isomeric mixture of K 3-carboxypyrid-2-yl- and 2-carboxypyrid-3-ylpenicillanates, m. 190-5° (decomposition), was prepared by adding 0.5 mL. ClCO₂Et dropwise at

0° with stirring over 1 h. to a solution containing equimolar amts. of Et₃N and pyridine-2,3-dicarboxylic acid in dry THF, cooling to -30°, filtering off Et₃N.HCl, adding an aqueous solution of K 6-aminopenicillanate (prepared from 1.08 g. II and 4.5 mL. 1.1N KOH), stirring to ambient temperature, distilling solvent at 30° in vacuo and H₂O by azeotropic with 2 mL. BuOH. The following penicillanates were similarly prepared (decomposition point and % purity by NH₂OH assay): di-K 3-carboxypyrazin-2-yl, 195-200°, 80; K 3-carboxy-5,6-dimethylpyrazin-2-yl, 205-10°, 80; isomeric mixture of K 3-carboxypyrid-4-yl and 4-carboxypyrid-3-yl, 170-80°, 80. K salts of the following 3-carboxyquinoxalin-2-ylpenicillin esters were prepared: Et, 210-15°, 85; Pr, 200-10° 73; iso-Pr, 205-10° 100; Bu, 150-60°, 71; n-decyl, 210-5°, 73; Et₃NCH₂CH₂NH₂, 200-10°, 94; cyclohexyl, 155-6°, -; Ph, 205-10°, 78; PhCH₂, 130-5°, 100. Analogous amides were prepared: amide, 180-90°, 56; diethylamide, 210-15° 75; propylamide, 140-50°, 41; piperidine, 200-10° 97; anilide, 205-10°, 50; N-methylanilide, 193-99°, 95. K 3-methoxycarboxyquinoxalin-2-ylpenicillin, m. 210-20°, 95% purity, was isolated by adding H₂O and ether to the reaction mixture, shaking, separating the aqueous phase, covering with ether, ice-cooling, and acidifying with 2N HCl. The ether extract was washed with H₂O, extracted with NaHCO₃, the ether discarded, iso-BuCOMe added to the aqueous phase which was chilled and acidified with 2N HCl, organic layer separated, washed with H₂O, and dried over MgSO₄, aqueous K 2-ethylhexanoate added until no further turbidity was produced, and the precipitate dried in vacuo over P₂O₅. 3-Benzoyloxycarbonylquinoxalin-2-ylpenicillin, m. 167-70° (decomposition), was prepared by adding a 3-benzoyloxycarbonylquinoxaline-2-carbonyl chloride solution in dry acetone to an Na 6-aminopenicillanate solution (prepared from 1.4 g. II, 2.5 g. Na₂CO₃, 25 mL. H₂O, and 5 mL. acetone) at 0° with stirring followed by iso-BuCOMe, stirring to ambient temperature, separating Organic layer, covering aqueous phase with ether, acidifying with 2N HCl, washing ether extract with H₂O, drying over MgSO₄ and evaporating in vacuo to 10 mL. (approx.). Details of activity of I when given orally or s.c. in mice against penicillin-resistant bacteria are given.
 IT 1233-25-5, 4-Thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid, 3,3-dimethyl-6-[3-(methylphenylcarbamoyl)-2-quinoxalinecarboxamido]-7-oxo-, potassium salt 1235-86-2, 4-Thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid, 3,3-dimethyl-7-oxo-6-[3-(phenylcarbamoyl)-2-quinoxalinecarboxamido]-, potassium salt
 (preparation of)
 RN 1233-25-5 CAPLUS
 CN 4-Thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid, 3,3-dimethyl-6-[3-(methylphenylcarbamoyl)-2-quinoxalinecarboxamido]-7-oxo-, monopotassium salt (8CI) (CA INDEX NAME)


Absolute stereochemistry.



● K

RN 13255-86-2 CAPLUS
 CN 4-Thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid, 3,3-dimethyl-7-oxo-6-[3-(phenylcarbamoyl)-2-quinoxalinedicarboxamido]-, monopotassium salt (7CI, 8CI) (CA INDEX NAME)

Absolute stereochemistry.



● K

L5 ANSWER 268 OF 283 CAPLUS COPYRIGHT 2006 ACS on STN
 ACCESSION NUMBER: 1964:454900 CAPLUS
 DOCUMENT NUMBER: 61:54900
 ORIGINAL REFERENCE NO.: 61:9512b-e
 TITLE: N-Cycloalkylpteridinecarboxamides
 INVENTOR(S): Oedene, Thomas S.; Santilli, Arthur A.
 PATENT ASSIGNEE(S): American Home Products Corp.
 SOURCE: 3 pp.
 DOCUMENT TYPE: Patent
 LANGUAGE: Unavailable
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 3138595		19640623	US	19621203
NL 294818			NL	

GI For diagram(s), see printed CA issue.

AB The title comds. were prepared by heating in an anhydrous neutral polar solvent a 4,6-diamino-5-nitroso-2-arylpyrimidine (I) with a

2-cyano-N-cycloalkylacetamide (II) in the presence of a basic catalyst. Thus, 10 g. cyclopropylamine was added to a solution of 20.3 g. NCH₂CO₂Et in 25 ml. absolute EtOH, the mixture refluxed 3 hrs. and kept overnight to give 13.3 g. (crude) cyclic NCH₂CO₂Et (CH₂)_n (I) (R = H, n = 2) (IV), m. 103.5-5° (EtOH). Similarly prepared were III (R = Me, n = 2, and m.p. given): H, 4, 87-8.5° (cyclohexane-C₆H₆); H, 5, 94-6° (EtOH-H₂O); H, 7, 74-5.5° (EtOH-H₂O) and Me, 5, 84° (cyclohexane). I (R = Ph) (6.45 g.) was added to a solution of 0.2 g. Na in 500 ml. absolute EtOH, the


mixture brought to reflux, treated with 4 g. IV, and refluxed addnl. 15 min., the precipitate dissolved in HCO₂Me₂ and the solution treated with H₂O to give

V (n = 2, R = H, R' = Ph), m. 342-8. Similarly prepared were V (n, R, R', and m.p. given): 4, H, Ph, 344-6.5°; 5, H, Ph, 350-5°; 6, H, Ph, 350-2°; 7, H, Ph, 332-3°; 5, Me, Ph, 327.5-8.5°;


5, H, p-tolyl, 360°. The title comds., useful in exptl. pharmacology, can be administered in a wide variety of oral and parenteral unit dosage forms singly or in admixt. with other active comds.

IT 13206-68-3, 6-Pteridinecarboxamide, 4,7-diamino-N-cyclopropyl-2-phenyl- 15029-90-0, 6-Pteridinecarboxamide, 4,7-diamino-N-cyclohexyl-2-p-tolyl- 15048-48-3, 6-Pteridinecarboxamide, 4,7-diamino-N-cyclohexyl-N-methyl-2-phenyl- 15057-67-7, 6-Pteridinecarboxamide, 4,7-diamino-N-cyclopentyl-2-phenyl- 15057-68-8, 6-Pteridinecarboxamide, 4,7-diamino-N-cyclohexyl-2-phenyl- 15163-89-0, 6-Pteridinecarboxamide, 4,7-diamino-N-cyclooctyl-2-phenyl- 15341-52-3, 6-Pteridinecarboxamide, 4,7-diamino-N-cycloheptyl-2-phenyl-


RN (preparation of)
 CN 6-Pteridinecarboxamide, 4,7-diamino-N-cyclopropyl-2-phenyl- (7CI, 8CI) (CA INDEX NAME)




RN 15029-90-0 CAPLUS
 CN 6-Pteridinecarboxamide, 4,7-diamino-N-cyclohexyl-2-p-tolyl- (7CI, 8CI) (CA INDEX NAME)




RN 15048-48-3 CAPLUS
 CN 6-Pteridinecarboxamide, 4,7-diamino-N-cyclohexyl-N-methyl-2-phenyl- (7CI, 8CI) (CA INDEX NAME)




RN 15057-67-7 CAPLUS
 CN 6-Pteridinecarboxamide, 4,7-diamino-N-cyclopentyl-2-phenyl- (7CI, 8CI) (CA INDEX NAME)




RN 15057-68-8 CAPLUS
 CN 6-Pteridinecarboxamide, 4,7-diamino-N-cyclohexyl-2-phenyl- (7CI, 8CI) (CA INDEX NAME)



RN 15163-89-0 CAPLUS
 CN 6-Pteridinecarboxamide, 4,7-diamino-N-cyclooctyl-2-phenyl- (7CI, 8CI) (CA INDEX NAME)



RN 15341-52-3 CAPLUS
 CN 6-Pteridinecarboxamide, 4,7-diamino-N-cycloheptyl-2-phenyl- (7CI, 8CI) (CA INDEX NAME)



L5 ANSWER 269 OF 283 CAPLUS COPYRIGHT 2006 ACS on STN
 ACCESSION NUMBER: 1963:456940 CAPLUS
 DOCUMENT NUMBER: 59:56940

ORIGINAL REFERENCE NO.: 59:10497f-h, 10498a-b
 TITLE: Quinacillin, a new penicillin with unusual properties
 AUTHOR(S): Richards, H. C.; Housley, J. R.; Spooner, D. F.
 CORPORATE SOURCE: Boots Pure Drug Co., Nottingham, UK
 SOURCE: Nature (London, United Kingdom) (1963), 199(4891), 354-6
 CODEN: NATUAS; ISSN: 0028-0836

DOCUMENT TYPE: Journal

LANGUAGE: Unavailable


AB cf. CA 53, 13264c. In search of penicillins resistant to staphylococcal penicillinase hydrolysis, (carboxymethyl)phenylbenzylpenicillin was prepared with min. inhibitory concentration (1/μL) against Staphylococcus aureus designated as highly penicillin-resistant >500, mod. penicillin-resistant 33.3, and penicillin-sensitive 0.01. Other semisynthetic penicillins were tested (side chain acid, min. inhibitory concns. as above given, resp.): 2-pyridine carboxylic 500, 11.1, 0.4; 3-pyridinecarboxylic >500, 100, 1.2; 4-pyridinecarboxylic 500, 100, 0.4; 3-methyl-2-pyridinecarboxylic 500, 33.3, 0.4; 6-methyl-2-pyridinecarboxylic 500, 3.7, 0.4; 2-quinolinecarboxylic 500, 1.2, 0.04; 2,3-pyridinedicarboxylic 11.1, 11.1, 3.7; 2,3-pyrazinedicarboxylic 33.3, 11.1, 1.2; 5,6-dimethyl-2,3-pyrazinedicarboxylic 33.3, 11.1, 3.7; 2,3-quinolinedicarboxylic 0.4, 0.4, 0.4; 2,3-quinoxalinedicarboxylic 0.4, 0.4, 0.4; 6,7-dimethyl-2,3-quinoxalinedicarboxylic 11.1, 3.7, 3.7; 6,7-dichloro-2,3-quinoxalinedicarboxylic 33.3, 11.1, 3.7. The di-Ha salt of 3-carboxy-2-quinoxalinedicarboxylic penicillin (quinacillin) (IV) is prepared by condensation of 2,3-quinoxalinedicarboxylic anhydride with 6-aminopenicillanic acid in HCO₂Me₂ and Et₃N and separated from Me₂CO as the bis(triethylammonium) salt monohydrate, m.p. 135-7° (decompose), [α]_D²⁰ + 142 (c 0.376, H₂O). An aqueous solution of the salt heated with saturated NaOH gives IV as cream colored needles dried in vacuo at 40°, m. 260° (decompose) containing 9% H₂O. Anhydrous IV prepared by drying at 100° at 2 mm. m. 261-2° (decompose) and [α]_D²³ + 183.5 (H₂O) very hygroscopic and acquiring bright yellow color in sunlight, stable for 2 mo at 0°, half life 12 days at 37°, half life in 50% EtOH 0.1N HCl, 250 min. and deep violet chelate forms with Fe(II) and a red color with Cu(I). Bacteriostatic activity of several dilns. in agar, peptone yeast extract, glucose containing 10% ox serum at pH 7.0 inoculated

with 0.01 mL culture and incubated for 24 h. at 37 gave min. inhibitory concns. in 1/μL. as follows: Staphylococcus aureus 0.15-0.62, Streptococcus pyogenes 3.7, Streptococcus (groups, B, C, D, 5 species) 3.7- >100, Diplococcus pneumoniae 3.7, Corynebacterium (4 species) 3.7-11.1, Sarcina lutea 11.1, Bacillus (6 species) 33.3, Lactobacillus (3 species) >100, Bordetella parapertussis >100, Neisseria catarrhalis >100, Escherichia coli >100, Proteus (4 species) >100, Salmonella (6 species) >100, Shigella (3 species) >100, Pseudomonas (2 species) >100. Bacteriostatic activity compared with benzylpenicillin against 50 strains of S. aureus from clin. sources at concns. 1.2 1/μL or greater at pH 7.0 showed no growth while benzylpenicillin showed growth at 1.2, 50, and 100 1/μL. Min. inhibitory concentration in 1/μL of some ester and amide derivs. against S. aureus were given.

IT 101698-85-5, 4-Thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid, 3,3-dimethyl-7-oxo-6-[3-(phenylcarbamoyl)-2-quinoxalinedicarboxamido]- 103820-23-1, 4-Thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid, 3,3-dimethyl-6-[3-(methylphenylcarbamoyl)-2-quinoxalinedicarboxamido]-7-oxo- (preparation of)


RN 101698-85-5 CAPLUS
 CN 4-Thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid, 3,3-dimethyl-7-oxo-6-[3-(phenylcarbamoyl)-2-quinoxalinedicarboxamido]- (7CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 103820-23-1 CAPLUS
4-Thia-1,2-cyclo[3.2.0]heptane-3-carboxylic acid, 3,3-dimethyl-6-[3-(methylphenylcarbamoyl)-2-quinoxalinecarboxamido]-7-oxo- (7CI) (CA INDEX NAME)

Absolute stereochemistry.




LS ANSWER 270 OF 283 CAPLUS COPYRIGHT 2006 ACS ON STN
ACCESSION NUMBER: 1961:73333 CAPLUS
DOCUMENT NUMBER: 58:73333
ORIGINAL REFERENCE NO.: 58:12556a-h
TITLE: Synthetic approaches to quinoxaline antibiotics. Synthesis of bisquinoxaloyl derivatives
AUTHOR(S): Koppel, Henry C.; Honigberg, Irwin L.; Springer, Robert M.; Cheng, C. C.
CORPORATE SOURCE: Midwest Res. Inst., Kansas City, MO
SOURCE: Journal of Organic Chemistry (1963), 28, 1119-22
CODEN: JOCEAH; ISSN: 0022-3263
DOCUMENT TYPE: Journal
LANGUAGE: Unavailable
GI For diagram(s), see printed CA issue.
AB A number of model compounds, similar to quinoxaline antibiotics were prepared. Refluxing 20 g. 2-quinoxalinecarboxylic acid 40 min. in 100 ml. SOCI2 gave 79% 2-quinoxaloyl chloride (I), needles, m. 112-13° (petr. ether). A solution of 1 equivalent NET3 and 0.5 equivalent appropriate diamine added dropwise to a stirred refluxing solution of 1 equivalent I in tetrahydrofuran, and the mixture refluxed 15 min. gave the following II (R, X, yield, m.p., and crystallization solvent given): NH(CH2)3NH, 40, 225-7°, HCONMe2H2O; NH(CH2)5NH, 49, 186-7°, EtOAc; NH(CH2)6NH, 59, 153-4°, EtOH-H2O; NH(CH2)10NH, 50, 109° (decomposition), MeOH; and piperazine-1,4-diyl, 60, decomposition above 250°, HCONMe2-H2O. A solution of 19.3 g. I in 75 ml. EtOH added dropwise to a stirred mixture of 13.9 g. Et ester of glycine-HCl in 75 ml. H2O and 200 ml. CH2Cl2 at 10°,

5.2 g. MeO added during this addition in 3 equal portions, the mixture stirred 30 min., 5 ml. pyridine added, and the mixture stirred 5 min. gave 87% III (R = H, X = OH), light pink needles, m. 89-91°. Solns. of 13.0 g. I in 100 ml. Me2CO and of 2.8 g. MeOH in 50 ml. H2O added simultaneously and dropwise to a stirred solution of 5.3 g. glycine, 2.8 g. NaOH, 50 ml. H2O, and 100 ml. Me2CO at 0°, the pH adjusted to 9 after the addition, and the mixture stirred 1 hr. at room temperature and adjusted to pH 1 gave 56% III (R = H, X = OH), needles, sublimed 215°, decompose 226°. III (R = CH2OH, X = OH), needles, decomposing 274°, was similarly prepared in 59% yield from 25.2 g. dl-serine and 47.0 g. I. Anhydrous H2N4 (1.92 g.) added at 70° to a solution of 7.5 g. III (R = H, X = OH) in 125 ml. EtOH, and the mixture stirred 1 hr. gave 90% III (R = H, X = NHCH2), decomposing 215°. 1,3-Diaminopropane (1.8 g.) added to a solution of 13.0 g. III (R = CH2OH, X = OH) in 150 ml. HCONMe2, 10.3 g. N,N'-dicyclohexylcarbodiimide then added, and the mixture stirred 4 hrs. gave 30% N,N'-dicyclohexyl-N- (N''-2-quinoxalinecarboxyl-dl-seryl)urea, m. 169-71°. Et chlorocarbonate (1 equivalent) in 25 ml. toluene added with stirring to a mixture of 1 equivalent N-carboxybenzylglycine acid, 1 equivalent

NET3, and 250 ml. toluene at -5°, the mixture held 30 min. at -5°, 0.5 equivalent diamine in 25 ml. toluene added, and the mixture kept at room temperature overnight gave the following (PhCH2OOCNHCHCO)2Z [Z = NH(CH2)3NH] (IV) (R, X, % yield, m.p., and crystallization solvent given): H, 62, 177-8°, 95% EtOH; H, 5, 51, 174-5°, 95% EtOH-MeOH; H, 6, 50, 170-1°, aqueous sol.; H, 10, 44, 171-2°, HCONMe2-95% EtOH; CH2Me2, 3, 49, decompose above 175°, 95% EtOH; CH2Me2, 6, 60, 194-6°, HCONMe2-MeOH; and CH2Ph, 5, 54, decompose above 170°, HCONMe2-H2O. A mixture of 0.05 mole IV, 1 g. 10% Pd-C, and 100 ml. 95% EtOH containing 20 drops HOAc hydrogenated 4 hrs. at 70° and 70 lb./sq. in., the oily product taken up in 50 ml. 95% EtOH, 0.2 mole NET3, added, the resulting solution added dropwise to a refluxing stirred solution of 0.1 mole I in 400 ml. tetrahydrofuran, and the mixture refluxed 15 min. gave the following V [Z = NH(CH2)3NH] (R, X, % yield, m.p., and crystallization solvent given): H, 3, 17, decompose above 200°, p-dioxane; H, 5, 10, decompose above 240°, HCONMe2-H2O; H, 6, 11, decompose 257°, HCONMe2H2O; H, 10, 8, 228-9°, HCONMe2H2O; and CH2Ph, 5, 12, decompose above 170°, MeOH.

IT 7149-60-2, 2-Quinoxalinecarboxamide, N,N'-[pentamethylenebis(iminocarbonylphenethylidene)]bis- (preparation of)
RN 7149-60-2 CAPLUS
CN 2-Quinoxalinecarboxamide, N,N'-[5,5-pentenediylbis(imino[2-oxo-1-(phenylmethyl)-2,1-ethanediyl])]bis- (9CI) (CA INDEX NAME)



LS ANSWER 271 OF 283 CAPLUS COPYRIGHT 2006 ACS ON STN
ACCESSION NUMBER: 1961:73333 CAPLUS
DOCUMENT NUMBER: 58:53333
ORIGINAL REFERENCE NO.: 58:9094g-h, 9095a-g
TITLE: 3,5-Diaminopyrazine-2,6-dicarboxamides
INVENTOR(S): Daglish, Anthony F.; Vonderwahl, R.; Tillotson, G. A.
PATENT ASSIGNEE(S): J. R. Geigy A.-G.
SOURCE: 8 pp.
DOCUMENT TYPE: Patent
LANGUAGE: Unavailable

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
DE 1087609		19600825	DE	
CH 358807			CH	
CH 358808			CH	
US 3043780		1962	US	
US 3175900		1965	US	
US 3201315		1965	US	


PRIORITY APPLN. INFO.:
GI For diagram(s), see printed CA issue.
AB 1,3-Diethyl-4-amino-5-nitrosouracil (I) 212 and 1,3-diethyl-4-aminouracil 183 in AcOH 750 refluxed 3 h. with stirring, cooled, and filtered yielded 3,2,5,6-bis-[1,3-diethyl-2,4-dioxo-1,2,3,4-tetrahydro]-1,4-pyrimidino] pyrazine 320 parts (II), m. 235.5-36° (75% AcOH). II 10, EtOH 200 parts, and N NaOH 300 volume parts, refluxed 2.5 h., cooled, and filtered gave 3,5-bis(ethylaminopyrazine-2,6-bis(ethylcarboxamide)) 7.5 parts, m. 133-4° (EtOH). In the same manner as II were prepared the following IV (R1, R2, R3, R4 and m.p. given): Pr, Pr, Pr, 150-1°; Bu, Bu, Bu, Bu (V), 115-16°; Me, Me, Me, Me (VI), 390°. Saponification of IV gave the corresponding VII (R1, R2, R3, R4, and m.p. given): Pr, Pr, Pr, 96-7°; Bu, Bu, Bu, Bu, 89-91°; Me, Me, Me, Me (VIIa), 332-3° and 1,3-dipropyl-4-aminouracil 42 in AcOH 180 refluxed 3 h. with stirring, cooled, diluted with H2O, and filtered gave IV (R1 = R2 = Et, R3 = R4 = Pr) 70 parts, m. 150-1° (EtOH); a portion 10 saponified in the usual manner gave VII (R1 = R2 = Et, R3 = R4 = Pr) 7.2 parts, m. 91-2°. In the same manner were prepared IV (R1 = R2 = Me, R3 = R4 = Pr), m. 169-9.5°, and IV (R1 = R2 = Me, R3 = R4 = Et) (VIII), m. 253-4°, and saponified to VII (R1 = R2 = Me, R3 = R4 = Pr), m. 136-7° and VII (R1 = R2 = Me, R3 = R4 = Et), m. 169-70°. resp. 1,3-Dimethyl-4-aminouracil (IX) 31 and 5-NO derivative 40 of IX in AcOH 200 refluxed 3 h. gave VI 51 parts, m. 390° (75% EtOH). VI 51 and a solution 152 of KOH 200 in EtOH 2400 refluxed 6 h. yielded VIIa.0.5H2O 117 parts, m. 214° (decomposition). VIIa.0.5H2O 20 and SOCI2 150 kept 45 min. at room temperature and evaporated, the residue added slowly with cooling

to PhNH2 10 and dry C5H5N 400 parts, stirred overnight, steam distilled to remove the C5H5N, and filtered yielded X (R1 = R2 = R3 = Me, R4 = NHPh), light yellow crystals, m. 198-8.5° (EtOH). Similarly were prepared the following X with R1 = R2 = R3 = Me (R4 = m.p., and color of fluorescence given): NH2, 290-2°, violet-blue; NHCH2CH2OH, 210-10.5°, violet-blue; NHPr, 218-19°, violet-blue; NHSt, 197-8.5°, violet-blue; NHCH2Ph, 218-20°, blue-violet; NHCH2CH2Ph, 76-8°, blue-violet; m-NHCH2CH2OMe, 126.5-27°, blue; NHBu, 194-6°, violet-blue; p-NHCH2CH2OMe, 252-4°, blue; NHCH2CH2CH2, 194-5.5°, violet-blue; NHCH2CH2CH2, 121-21.5°, violet-blue; PhNH, 237-8°, blue-violet; NHMe2, 128-9°, violet; NHCH2Me, 188-90°, violet-blue; 2-pyridylamino, 223-4°, blue-violet; NHCH2Me, 204-5°, violet-blue; p-NHCH2CH2OMe, 211-12.5°, blue-violet; o-NHCH2CH2OMe, 194-5°, blue-violet; m-NHCH2CH2OMe, 172-3°, blue-violet; p-ClCH2CH2NH, 261-2.5°, blue-violet; m-ClCH2CH2NH, 185-7°, blue-violet; 3,4-Cl2CH2CH2NH, 216-17°, violet-blue; m-HO2CCH2CH2NH, 268-70°; m-HO3SCCH2CH2NH, -, violet-blue; p-HO3SCCH2CH2NH, -, violet-blue; m-(p-MeC6H4)602NH)C6H4NH, 226-7° violet-blue; m-H2NO2SCCH2CH2NH, 234-6°, violet-blue; morpholino, 155-6°, violet-blue; NHCH2Me, 175-7°, violet-blue; NH(CH2)3OH, 147-9°, violet blue; 3-pyridylamino, 209-11°, blue-violet; 3,4-dimethyl-1-phenylpyrazolylamino, 267-9°, blue-violet; 2-thiazolylamino, 262-3°, blue-violet; 1-phenyl-3-pyrazolylamino, 236-8°, blue-violet; 6-quinolylamino, 232-4°, blue-violet; NHCONHPh, 233-4°, blue; NHCONHCH2Ph, 190-1°, violet-blue; NHCONHMe, 215-17°, violet-blue. Similarly were prepared the following XII (R1, R2, R3, and m.p. given): PhCH2, PhCH2, PhCH2, 161-2°; Et, Et, Et

(XIII), 174-5°. XIII was converted in the usual manner to the anilide, m. 146.5-7.5°, and to the N-(2-pyridyl)amide, m. 108-9°. VIII 57, KOH 45, and EtOH 500 refluxed 6 h. and evaporated, and the residue acidified with dilute HCl gave XII (R1 = R2 = Et, R3 = Me) (XIV) 43 parts, m. 160-2°. XIV 20 treated 45 min. with SOCI2 100 and evaporated, and the residue stirred overnight with concentrated NH4OH 300

and EtOH 100 and filtered gave amide of XIV 16 parts, m. 223-4° (EtOH). Similarly were prepared the N-Et, N-Pr, and N-PhCH2 amides, m. 162-4°, 84-6°, and 87-9°, resp., of XIV. VI 10 and PhCH2NH2 300 refluxed 24 h., cooled, diluted with H2O, and filtered yielded 3,2-(1,3,4-dimethyl-2,4-dioxo-1,2,3,4-tetrahydro-1,4-pyrimidino)-5-methylamino-6- (Ar. benzylcarbamoyl)pyrazine 9 parts, m. 204-5° (EtOH). 1,3-Dibutyl-4-aminouracil (XV) 48 and 5-NO derivative 54 of XV in H2SO4 300 refluxed 3 h. with stirring, cooled, and filtered, and the residue in EtOH 1200 refluxed 2 h. with N NaOH 1800 and filtered gave V 66 parts, needles, m. 115-16° (EtOH).

IT 93651-15, 7-Pteridinecarboxamide, N-benzyl-1,2,3,4-tetrahydro-1,3-dimethyl-6-(methylamino)-2,4-dioxo- (preparation of)
RN 93651-15-1 CAPLUS
CN 7-Pteridinecarboxamide, N-benzyl-1,2,3,4-tetrahydro-1,3-dimethyl-6-(methylamino)-2,4-dioxo- (7CI) (CA INDEX NAME)



LS ANSWER 272 OF 283 CAPLUS COPYRIGHT 2006 ACS ON STN
ACCESSION NUMBER: 1962:404005 CAPLUS
DOCUMENT NUMBER: 57:4005
ORIGINAL REFERENCE NO.: 57:820e-h
TITLE: Rearrangement of certain quinoxalinecarboxanilides to spiro compounds
AUTHOR(S): Habib, M. S.; Rees, C. W.
CORPORATE SOURCE: Univ. London
SOURCE: Journal of the Chemical Society (1962) 123-50
CODEN: JCSOAP; ISSN: 0368-1769
DOCUMENT TYPE: Journal
LANGUAGE: Unavailable
OTHER SOURCE(S): CASREACT 57:4005
AB 3,4-Dihydro-4-methyl-2-(N-methyl-N-phenylcarbamoyl)-3-oxoquinoxaline (I) isomerized to 1,2,2',3,3',4'-hexahydro-1',4'-dimethyl-2',3'-dioxoquinoxaline-2'-spiro-3'-indole (II) very rapidly in concentrated H2SO4 at 0° and more slowly in hot alc. HCl. The mechanism of this rearrangement was very similar to that previously reported (CA 55, 1636g) for its 1-oxide though the spiro lactam formed here was not further decomposed; the scope of this rearrangement was similarly limited. An intermediate of the type postulated previously for the N-oxide rearrangement in H2SO4, the 1,2',3',4'-hexahydro-1'-hydroxy-1',4'-dimethyl-2',3'-dioxoquinoxaline-2'-spiro-3'-indole (III), was isolated by making use of the slower reaction in alc. HCl. I (8 g.) gave 3.5 g. II, alc. solvate, m. 243°. 3,4-Dihydro-2-(N-methyl-N-phenylcarbamoyl)-3-oxoquinoxaline (IV) (6 g.) gave 2 g. 1,2,2',3,3',4'-hexahydro-1'-methyl-2',3'-dioxoquinoxaline-2'-spiro-3'-indole-H2O (V), m. 244°. Methylation of IV with Me2SO4 and 2N NaOH for 16 hrs. gave II. 3,4-Dihydro-4-methyl-2-(N-phenylcarbamoyl)-3-oxoquinoxaline gave


1,2,3,4,2',3' hexahydro-4-methyl-2',3 - dioxoquinoxaline - 2 - spiro - x - sulfonic acid-2H₂O, m. 267-70°. This material gave a crystalline precipitate with S-benzylthiuronium chloride. II (1 g.), 10 ml. concentrated HCl, and 10 ml. alc. refluxed 6 hrs., evaporated, the residue poured into H₂O, basified, and the precipitate crystallized gave 0.1 g.

3,4-dihydro-4-methyl-2-(o-methylaminophenyl)-3-oxoquinoxaline, m. 142-4°. 3,4-Dihydro-4-methyl-2-(N-methyl-N-phenylcarbamoyl)-3-oxopyrazine 1-oxide (1 g.) in 25 ml. alc. saturated with HCl, refluxed 3 hrs., evaporated, and refrigerated gave 0.75 g. III, m. 186-8°.

IT 37648-63-8. 2-Quinoxalinecarboxanilide (deriva., rearrangements of)

RN 37648-63-8 CAPLUS

CN 2-Quinoxalinecarboxamide, N-phenyl- (9CI) (CA INDEX NAME)



L5 ANSWER 273 OF 283 CAPLUS COPYRIGHT 2006 ACS ON STN
ACCESSION NUMBER: 1962:46026 CAPLUS
DOCUMENT NUMBER: 56:46026
ORIGINAL REFERENCE NO.: 56:4713g-i
TITLE: Rearrangement of certain quinoxalinecarboxanilides. Isolation of an intermediate in a related N-oxido rearrangement

AUTHOR(S): Habib, M. S.; Rees, C. W.
CORPORATE SOURCE: King's Coll., London
SOURCE: Proc. Chem. Soc. (1961) 167-8
DOCUMENT TYPE: Journal
LANGUAGE: Unavailable


GI For diagram(s), see printed CA Issue.

AB The spiro lactam I was isolated as intermediate in the transformation of II (R = CONHMe) (III) with cold H₂SO₄ into I (R = o-MeNHC(SH₄)) (IV). III 1-oxide also gave IV with cold H₂SO₄. An N-hydroxy spiro lactam was isolated and shown to be an intermediate in the rearrangement of V into VI. The N-hydroxy spiro lactam and V were converted by acid into VI, providing support for a proposed acid-catalyzed mechanism for the transformation of the N-oxide through the corresponding spiro compound

IT 92872-03-2. 2-Quinoxalinecarboxanilide, 3,4-dihydro-N-methyl-3-oxo- (preparation of)

RN 92872-03-2 CAPLUS

CN 2-Quinoxalinecarboxanilide, 3,4-dihydro-N-methyl-3-oxo- (7CI) (CA INDEX NAME)




L5 ANSWER 274 OF 283 CAPLUS COPYRIGHT 2006 ACS ON STN
ACCESSION NUMBER: 1961:54385 CAPLUS


4,7-diamino-N-p-butoxybenzyl-2-phenyl- 103381-60-3.
6-Pteridinecarboxamide, 7-amino-N-benzyl-4-dibutylamino-2-phenyl- 108843-86-3, 6-Pteridinecarboxamide, 4,7-diamino-N-benzyl-2-(4-hydroxy-3-nitrophenyl)- 108977-52-2, 6-Pteridinecarboxamide, 4,7-diamino-2-(2-amino-4-chlorophenyl)-N-benzyl- 109553-77-7, 6-Pteridinecarboxamide, 4,7-diamino-N-benzyl-2-[2-thienyl]- 109553-78-8, 6-Pteridinecarboxamide, 4,7-diamino-N-benzyl-2-[3-thienyl]- 110151-30-9, 6-Pteridinecarboxamide, 4,7-diamino-N-benzyl-2-m-tolyl- 110151-31-0, 6-Pteridinecarboxamide, 4,7-diamino-N-m-methylbenzyl-2-phenyl- 110151-32-1, 6-Pteridinecarboxamide, 4,7-diamino-N-benzyl-2-(p-methoxyphenyl)- 110330-85-9, 6-Pteridinecarboxamide, 4,7-diamino-N-(p-methoxyphenethyl)-2-phenyl- 115915-26-9, 6-Pteridinecarboxamide, 4,7-diamino-N-(n-butylphenethyl)-2-phenyl- 115915-98-5, 6-Pteridinecarboxamide, 4,7-diamino-N-(p-butylphenethyl)-2-phenyl- (preparation of)

RN 19970-93-5 CAPLUS


CN 6-Pteridinecarboxamide, 4,7-diamino-N-benzyl-2-phenyl- (6CI, 8CI) (CA INDEX NAME)



RN 102006-65-5 CAPLUS
CN 6-Pteridinecarboxamide, 4,7-diamino-N-benzyl-2-(p-chlorophenyl)- (6CI) (CA INDEX NAME)



RN 102006-66-6 CAPLUS
CN 6-Pteridinecarboxamide, 4,7-diamino-N-p-chlorobenzyl-2-phenyl- (6CI) (CA INDEX NAME)



RN 102317-82-8 CAPLUS
CN 6-Pteridinecarboxamide, 7-amino-N-benzyl-4-methylamino-2-phenyl- (6CI) (CA INDEX NAME)




DOCUMENT NUMBER: 55:54385
ORIGINAL REFERENCE NO.: 55:104821,10483a-e
TITLE: 2-Aryl-4,7-diamino-N-alkyl-6-pteridinecarboxamides
INVENTOR(S): Weinstein, Joseph
PATENT ASSIGNEE(S): Smith, Kline & French Laboratories
DOCUMENT TYPE: Patent
LANGUAGE: Unavailable
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2963478		19601206	US	
GB 894384			GB	

AB The title compds. were prepared by treating 2-aryl-4,6-diamino-5-nitropyrimidines with N-alkyl-α-cyanoacetamide. Thus, a solution of 24.4 g. 4-(2-aminoethyl)pyridine and 19.8 g. Me α-cyanoacetate in 100 ml. EtOH was stirred 4 hrs. at room temperature, refluxed 2 hrs., cooled, the mixture filtered, and recrystd. from EtOH to give α-cyano-N-(4-pyridylethyl)acetamide (I). A solution of 12.8 g. I and 12.5 g. 2-phenyl-4,6-diamino-5-nitropyrimidine in 200 ml. HCONMe₂ was heated to reflux, 3 g. MeONa added, the solution refluxed 5 min., cooled, H₂O added, and the precipitate collected to give 2-phenyl-4,7-diamino-N-(4-pyridylethyl)-6-pteridinecarboxamide (II). The following other N-substituted 2-phenyl-4,7-diamino-6-pteridinecarboxamides were prepared in a similar manner (N-substituent given) (no const. given): benzyl, m. 314-18° (HCONMe₂); phenethyl; 2-furyl-ethyl; p-methoxyphenethyl; β-methylphenethyl; α-butylphenethyl; m-methylbenzyl; p-chlorobenzyl; p-butylphenethyl; p-butoxybenzyl; o-nitrophenethyl; 3-thienylethyl; 6-phenylhexyl. To a solution of 4.65 g. p-anisidine-HCl in 50 ml. MeOH was added 5.55 g. Ag isonitrosomalmonitrile, the mixture stirred 1 hr., filtered, the filtrate evaporated in vacuo at 30-40°, and the residue boiled 15 min. in 60 ml. 2:1 mixture 2-methyl-5-ethylpyridine and 2-picoline to give 2-(p-methoxyphenyl)-4,6-diamino-5-nitropyrimidine (III), green. Other 2-substituted 4,6-diamino-5-nitropyrimidines prepared in an analogous manner were (2-substituent given): p-chlorophenyl; 3'-thienyl; o-amino-p-chlorophenyl; 2'-thienyl; m-tolyl; m-nitro-p-hydroxyphenyl. Treatment of III with N-benzyl-α-cyanoacetamide (IV) and MeONa in HCONMe₂ gave 2-(p-methoxyphenyl)-4,7-diamino-N-benzyl-6-pteridinecarboxamide (HCONMe₂). Other 2-substituted 4,7-diamino-N-benzyl-6-pteridinecarboxamides prepared in an analogous manner were (2-substituent given): p-chlorophenyl; 3'-thienyl; o-amino-p-chlorophenyl; 2'-thienyl; m-tolyl; m-nitro-p-hydroxyphenyl. A solution of 10 g. 2-phenyl-4-methylamino-6-aminopyrimidine in 200 ml. 10% AcOH was heated to 90°, the solution filtered, the filtrate cooled to 0°, 5 g. NaNO₂ in H₂O added, the mixture allowed to stand 1 hr., and filtered to give 2-phenyl-4-methylamino-5-nitroso-6-aminopyrimidine (V). V treated with IV and MeONa in HCONMe₂ gave 2-phenyl-4-methylamino-7-amino-N-benzyl-6-pteridinecarboxamide (HCONMe₂). In a similar manner 2-phenyl-4-dimethylamino-7-amino-N-benzyl-6-pteridinecarboxamide and 2-phenyl-4-dibutylamino-7-amino-N-benzyl-6-pteridinecarboxamide were prepared. The compds. have diuretic and natriuretic activity with a low order of side effects.


IT 19970-93-5. 6-Pteridinecarboxamide, 4,7-diamino-N-benzyl-2-phenyl- 102006-65-5, 6-Pteridinecarboxamide, 4,7-diamino-N-benzyl-2-(p-chlorophenyl)- 102006-66-6, 6-Pteridinecarboxamide, 4,7-diamino-N-p-chlorobenzyl-2-phenyl- 102317-82-8, 6-Pteridinecarboxamide, 7-amino-N-benzyl-4-methylamino-2-phenyl- 102317-83-9, 6-Pteridinecarboxamide, 4,7-diamino-N-phenethyl-2-phenyl- 102460-23-1, 6-Pteridinecarboxamide, 7-amino-N-benzyl-4-dimethylamino-2-phenyl- 102460-24-2, 6-Pteridinecarboxamide, 4,7-diamino-N-(β-methylphenethyl)-2-phenyl- 102477-72-5, 6-Pteridinecarboxamide, 4,7-diamino-N-(o-nitrophenethyl)-2-phenyl- 102950-32-3, 6-Pteridinecarboxamide,




RN 102317-83-9 CAPLUS
CN 6-Pteridinecarboxamide, 4,7-diamino-N-phenethyl-2-phenyl- (6CI) (CA INDEX NAME)




RN 102460-23-1 CAPLUS
CN 6-Pteridinecarboxamide, 7-amino-N-benzyl-4-dimethylamino-2-phenyl- (6CI) (CA INDEX NAME)




RN 102460-24-2 CAPLUS
CN 6-Pteridinecarboxamide, 4,7-diamino-N-(β-methylphenethyl)-2-phenyl- (6CI) (CA INDEX NAME)




RN 102477-72-5 CAPLUS
CN 6-Pteridinecarboxamide, 4,7-diamino-N-(o-nitrophenethyl)-2-phenyl- (6CI) (CA INDEX NAME)




RN 102950-32-3 CAPLUS
CN 6-Pteridinecarboxamide, 4,7-diamino-N-p-butoxybenzyl-2-phenyl- (6CI) (CA INDEX NAME)




RN 103281-60-3 CAPLUS
CN 6-Pteridinecarboxamide, 7-amino-N-benzyl-4-dibutylamino-2-phenyl- (6CI) (CA INDEX NAME)




RN 108843-86-3 CAPLUS
CN 6-Pteridinecarboxamide, 4,7-diamino-N-benzyl-2-(4-hydroxy-3-nitrophenyl)- (6CI) (CA INDEX NAME)




RN 108977-52-2 CAPLUS
CN 6-Pteridinecarboxamide, 4,7-diamino-2-(2-amino-4-chlorophenyl)-N-benzyl- (6CI) (CA INDEX NAME)




RN 109553-77-7 CAPLUS
CN 6-Pteridinecarboxamide, 4,7-diamino-N-benzyl-2-(2-thienyl)- (6CI) (CA INDEX NAME)




RN 109553-78-8 CAPLUS
CN 6-Pteridinecarboxamide, 4,7-diamino-N-benzyl-2-(3-thienyl)- (6CI) (CA INDEX NAME)




RN 110151-30-9 CAPLUS
CN 6-Pteridinecarboxamide, 4,7-diamino-N-benzyl-2-m-tolyl- (6CI) (CA INDEX NAME)



RN 110151-31-0 CAPLUS
CN 6-Pteridinecarboxamide, 4,7-diamino-N-m-methylbenzyl-2-phenyl- (6CI) (CA INDEX NAME)




RN 110151-32-1 CAPLUS
CN 6-Pteridinecarboxamide, 4,7-diamino-N-benzyl-2-(p-methoxyphenyl)- (6CI) (CA INDEX NAME)




RN 110330-65-9 CAPLUS


CN 6-Pteridinecarboxamide, 4,7-diamino-N-(p-methoxyphenethyl)-2-phenyl- (6CI) (CA INDEX NAME)



RN 115915-26-9 CAPLUS
CN 6-Pteridinecarboxamide, 4,7-diamino-N-(n-butylphenethyl)-2-phenyl- (6CI) (CA INDEX NAME)




RN 115915-90-5 CAPLUS
CN 6-Pteridinecarboxamide, 4,7-diamino-N-(p-butylphenethyl)-2-phenyl- (6CI) (CA INDEX NAME)




LS ANSWER 275 OF 283 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 1961:8148 CAPLUS
DOCUMENT NUMBER: 55:8148
ORIGINAL REFERENCE NO.: 55:1638g-i.1639a-g
TITLE: Oxidation of 3-hydroxyquinoxaline-2-carboxanilide and its N-methyl derivatives
AUTHOR(S): Habib, M. S.; Rees, C. W.
CORPORATE SOURCE: Univ. London
SOURCE: Journal of the Chemical Society (1960) 3386-92
CODEN: JCSOAS; ISSN: 0368-1769
DOCUMENT TYPE: Journal
LANGUAGE: Unavailable
OTHER SOURCE(S): CASREACT 55:8148
AB 3,4-Dihydro-4-methyl-3-oxoquinoxaline-2-carboxy-N-methylanilide (I) was oxidized by peracids to the 1-oxide (II), but on removal of either or both of the N-Me groups, the oxidation took a different course, the carboxamide groups being replaced by OH groups to form the 2,3-dihydroxyquinoxaline, with no N-oxides detectable under a variety of conditions. The mechanism of these abnormal oxidns. was discussed. 4-Acetyl-3,4-dihydro-3-oxoquinoxaline-2-carboxy-N-methylanilide (III) formed an N-oxide (IV) normally, which underwent the H2SO4 rearrangement described elsewhere. The isomeric mono-N-oxides of quinoxaline-2-carboxy-N-methylanilide were prepared and characterized. 3-Hydroxyquinoxaline-2-carboxylic acid chloride (from 3 g. acid and SOCl2) suspended in C6H6, the mixture treated slowly with 10 ml. PhNHMe in 15 ml. C6H6, the mixture washed with 2N HCl, and the

solid crystallized gave 3.1 g. 3-hydroxyquinoxaline-2-carboxy-N-methylanilide (V), m. 242° (alc.). V (0.5 g.) and 5 ml. AcCl refluxed 24 hrs. gave 0.5 g. III, m. 216° (alc.). III (1.2 g.), 6 ml. AcOH, and 1.2 ml. 30% H2O2 heated at 55°, 2 further lots of 0.6 ml. H2O2 added after 20 and 40 hrs., after 60 hrs. total heating the AcOH removed, the residual gum extracted with alc., the alc. solution concentrated, and diluted with H2O gave 0.6 g. IV, cubes, m. 216-17° (C6H6-CHCl3). 3,4-Dihydro-4-methyl-3-oxoquinoxaline-2-carboxanilide (Va) (0.5 g.) and 5 ml. Ac2O refluxed 24 hrs., the mixture cooled, and the product crystallized gave 0.4 g. Ac derivative, which with H2O2 and AcOH 72 hrs. at 55° gave 50% 3,4-dihydro-2-hydroxy-4-methyl-3-oxoquinoxaline (VI), m. 283-4°. VI was obtained in 50% yield by a similar oxidation of Et 3,4-dihydro-4-methyl-3-oxoquinoxaline-2-carboxylate. 3-Hydroxyquinoxaline-2-carboxanilide (VII), V, and Va (1 g.) were treated with the oxidizing agent at the temperature and for the time shown in the following list. The products were isolated by removing volatile components in vacuo and purifying. 2,3-Dihydroxyquinoxaline (VIII) was identified by comparison of its infrared spectrum with that prepared from o-phenylenediamine and Et oxalate. VI was identified by m.p. The following results were obtained (compound, temperature, time in hrs., AcOH in ml., ml. 30% H2O2, ml. 40% AcOH in AcOH, % H2O2H in CHCl3 in ml., and products given): VII, 20°, 48, 2, -, 3, -, 88 VII; VII, 36°, 36, 4, -, 1.5, -, 65% VII; VII, 45°, 28, -, -, 2, -, 67% VII; VII, 76°, 2, -, -, 1.5, -, 78% VII; VII, 56°, 60, 5, 2, -, -, 75% VIII; VII, 65°, 20, 4, -, 4, -, 80% VIII; VII, 100°, 0.3, -, -, 5, -, 55% VIII; V, 20°, 48, 8, -, 3, -, 70% V; V, 43°, 18, 10, -, 1.5, -, 70% V; V, 55°, 18, -, -, 3, -, 80% V; V, 40°, 72, 10, 3.5, -, -, 50% VIII; V, 40°, 72, 9.5, -, 3.5, -, V and VIII; V, 20°, 72, -, -, -, 10, 40% V, 10% VIII; V, 20°, 240, -, -, -, 35, VIII and tar; V, 65°, 50, 5, 4, -, -, 75% VIII; Va, 20°, 48, 4, -, 4, -, 100% Va; Va, 40° 72, 10, 2.5, -, -, 60% 3,4-dihydro-2-hydroxy-4-methyl-3-oxoquinoxaline (IX); Va, 56°, 72, 5, 2, -, -, 70% IX; Va, 65°, 42, 5, 2, -, -, 75% IX. The following results were obtained on heating the comds. with 10% AcOH in AcOH 24 hrs. at 65°. VIII was recovered quant., II was recovered in 66% yield, the residue being tar. PhNCO was converted almost quant. into (PhNH)2CO, m. 240°. Va was converted into VI in high yield. VII was converted into VIII and a tar. Va treated with excess 10% H2O2, 10% H2O2 in 2N NaOH, or 2N NaOH 24 hrs. at 65° was recovered in over 90% yield in each experiment VIII (3 g.), 1 ml. Me2SO4, and 75 ml. 2N NaOH shaken together 2 hrs. at room temperature, the solid on acidification collected, dried, extracted with Me2CO, evaporated, and the residue crystallized gave 12% VI. IV added portionwise to 2 ml. concentrated H2SO4, the mixture left 20 min. at room temperature, poured on ice, filtered, the filtrate neutralized, the solid extracted with C6H6, and crystallized gave 0.02 g. 4-acetyl-3,4-dihydro-2-(o-methylaminophenyl)-3-oxoquinoxaline, m. 204-5°. The C6H6 exts. afforded 0.102 g. 3-hydroxy-2-(o-methylaminophenyl)quinoxaline (X), m. 221-2° (aqueous HCOOH). X with Me2SO4 gave 3,4-dihydro-4-methyl-2-(o-methylaminophenyl)-3-oxoquinoxaline, m. 130°. Quinoxaline-2-carboxanilide (1 g.), 2 ml. AcOH, and 40% H2O2 yielded 0.67 g. 1,4-dioxide (XI), leaflets, m. 211°. XI (0.2 g.) in 2 ml. CHCl3 left overnight at room temperature with 0.4 ml. PCl3 gave 0.15 g. quinoxaline-2-carboxanilide, m. 159°. Quinoxaline-2-carboxy-N-methylanilide (0.4 g.), 2.5 ml. AcOH, and 1.27 ml. 30% H2O2 heated 16 hrs. at 55° and the mixture evaporated in vacuo gave 0.55 g. 4-oxide (XII), yellow needles, m. 150°. XII (0.2 g.), 2 ml. CHCl3, and 0.4 ml. PCl3 left 16 hrs. at room temperature gave 0.14 g. quinoxaline-2-carboxy-N-methylanilide, m. 124°. The 1-oxide treated identically was unchanged. IT 37448-63-8, 2-Quinoxalinecarboxanilide


(oxidation of, and oxides)
RN 17648-63-8 CAPLUS
CN 2-Quinoxalinecarboxanilide, N-phenyl- (9CI) (CA INDEX NAME)




IT 92872-03-2, 2-Quinoxalinecarboxanilide, 3-hydroxy-N-methyl-
101117-57-1, 2-Quinoxalinecarboxanilide, N-methyl-, oxides
109039-05-6, 2-Quinoxalinecarboxanilide, N-methyl-, oxides
(preparation of)
RN 92872-03-2 CAPLUS
CN 2-Quinoxalinecarboxanilide, 3,4-dihydro-N-methyl-3-oxo- (7CI) (CA INDEX NAME)



RN 101117-57-1 CAPLUS
CN 2-Quinoxalinecarboxanilide, N-methyl- (6CI) (CA INDEX NAME)



RN 109039-05-6 CAPLUS
CN 2-Quinoxalinecarboxanilide, N-methyl-, 1-oxide (6CI) (CA INDEX NAME)



LS ANSWER 276 OF 283 CAPLUS COPYRIGHT 2006 ACS ON STN
ACCESSION NUMBER: 1961:8147 CAPLUS
DOCUMENT NUMBER: 55:8147
ORIGINAL REFERENCE NO.: 55:1638a-g
TITLE: Reduction of 3-hydroxyquinoxaline-2-carboxylic acid
and derivatives with sodium dithionite
AUTHOR(S): Habib, M. S.; Rees, C. W.
CORPORATE SOURCE: Univ. London


SOURCE: Journal of the Chemical Society (1960) 2384-6
CODEN: JCSOAS; ISSN: 0368-1769

DOCUMENT TYPE: Journal
LANGUAGE: Unavailable
AB


The reactivity of 3-hydroxyquinoxaline-2-carboxylic acid towards Na dithionite was parallel to that of the corresponding 1-oxides towards H2SO4. The ready formation of the corresponding 1,2-dihydro compds. provided further evidence of the powerfully electrophilic nature of C-2 in certain of these compds. The following procedure was used for reduction. The compound (0.2 g.) and 0.3 g. Na dithionite in 10 ml. 50% aqueous alc. refluxed 0.75 hr., the alc. removed, and the product crystallized gave 72-98% yields. 3,4-Dihydro-4-methyl-3-oxopyrazine-2-carboxy-N-methylanilide 1-oxide gave the corresponding base, m. 188°. Quinoxaline-2-carboxy-N-methylanilide 1,4-dioxide gave quinoxaline-2-carboxy-N-methylanilide (I), m. 128°. With use of the amount of Na dithionite calculated for the removal of one O atom, a mixture of starting material and I was isolated. 3-Hydroxyquinoxaline-2-carboxylic acid gave after adjustment to pH 2.5, 1,2-dihydro-3-hydroxyquinoxaline-2-carboxylic acid-H2O, m. 152° (decomposition). 3-Hydroxyquinoxaline-2-carboxanilide (Ia) gave yellow needles of 1,2-dihydro-3-hydroxyquinoxaline-2-carboxanilide, m. 208°. This compound was reconverted into the starting material in 0.5 hr. at 240° in air. 3,4-Dihydro-4-methyl-3-oxoquinoxaline-2-carboxanilide (II) gave 1,2,3,4-tetrahydro-4-methyl-3-oxoquinoxaline-2-carboxylanilide, yellow needles, m. 161°. 3,4-Dihydro-4-methyl-3-oxoquinoxaline-2-carboxy-N-methylanilide and its 1-oxide both yielded 1,2,3,4-tetrahydro-4-methyl-3-oxoquinoxaline-2-carboxy-N-methylanilide, m. 188°. 3,4-Dihydro-4-methyl-3-oxoquinoxaline-2-carboxy-N,N-diphenylanilide, m. 178°. The following compds. were not reduced under the standard conditions: 3,4-dihydro-4-methyl-3-oxopyrazine-2-carboxy-N-methylanilide, quinoxaline-2-carboxy-N-methylanilide, 3-aminoquinoxaline-2-carboxy-N-methylanilide (III), 2-hydroxyquinoxaline, and 3,4-dihydro-4-methyl-2-(o-methylaminophenyl)-3-oxoquinoxaline. Ia was prepared from 3-hydroxyquinoxaline-2-carboxylic acid, yellow needles, m. 340-3° (decomposition). 3,4-Dihydro-4-methyl-3-oxoquinoxaline-2-carboxanilide (2 g.) refluxed 13 hrs. with 15 ml. PhNH2, the mixture cooled, poured into 2N HCl, and crystallized gave 1.9 g. II, yellow needles, m. 193-5° (alc.). Ia with Me2SO4 gave 73% II. 3,4-Dihydro-4-methyl-3-oxoquinoxaline-2-carboxyl chloride (from 7 g. acid) added portionwise to excess PhNH2 in C6H6, the mixture heated 15 min., and the product washed gave 36% II. Phenylphosphazoneanilide (from 3.8 ml. PhNH2 and 0.64 g. PCl3) refluxed 1 hr. with 2 g. 3-aminoquinoxaline-2-carboxylic acid in dry PhMe, the mixture filtered, the residue extracted with hot PhMe, and evaporated gave 1.2 g. 3-aminoquinoxaline-2-carboxanilide, yellow crystals, m. 213° (alc.). (PhMeN)3P (from 4.3 ml. PhNHMe and 0.64 g. PCl3) refluxed 20 min. with 2 g. 3-aminoquinoxaline-2-carboxylic acid in 40 ml. PhMe, the solvent removed, the tarry residue extracted with alc., and the alc. solution evaporated gave 0.69 g. III, m. 157° (H2O).

IT 100881-39-8, 2-Quinoxalinecarboxanilide, 3-amino-
101117-57-1, 2-Quinoxalinecarboxanilide, N-methyl-
106951-40-0, 2-Quinoxalinecarboxanilide, N-methyl-, 1,4-dioxide
(preparation of)


RN 100881-39-8 CAPLUS
CN 2-Quinoxalinecarboxanilide, 3-amino- (6CI) (CA INDEX NAME)




RN 101117-57-1 CAPLUS
CN 2-Quinoxalinecarboxanilide, N-methyl- (6CI) (CA INDEX NAME)



RN 106951-40-0 CAPLUS
CN 2-Quinoxalinecarboxanilide, N-methyl-, 1,4-dioxide (6CI) (CA INDEX NAME)



IT 101351-88-6, 2-Quinoxalinecarboxanilide, 3-amino-N-methyl-
(reduction of)
RN 101351-88-6 CAPLUS
CN 2-Quinoxalinecarboxanilide, 3-amino-N-methyl- (6CI) (CA INDEX NAME)



LS ANSWER 277 OF 283 CAPLUS COPYRIGHT 2006 ACS ON STN
ACCESSION NUMBER: 1961:8146 CAPLUS
DOCUMENT NUMBER: 55:8146
ORIGINAL REFERENCE NO.: 55:1634i, 1635a-i, 1636a-i, 1637a-i, 1638a
TITLE: Mechanism and scope of an N-oxide rearrangement
AUTHOR(S): Habib, M. S.; Rees, C. W.
CORPORATE SOURCE: Univ. London
SOURCE: Journal of the Chemical Society (1960) 3371-83
CODEN: JCSOAS; ISSN: 0368-1769
DOCUMENT TYPE: Journal
LANGUAGE: Unavailable

AB The mechanism of the very rapid reaction of 3,4-dihydro-4-methyl-2-(N-methyl-N-phenylcarbamoyl)-3-oxoquinoxaline 1-oxide (I) in concentrated H2SO4 at 0° was elucidated. A novel N → ortho rearrangement of the heterocyclic aryl group occurred with simultaneous loss of CO2. This proceeded by intramolecular electrophilic substitution of an o-position of the anilide by the carbamoyl-bearing C in the conjugate acid. This C atom proved to be insufficiently electrophilic for the rearrangement to occur in most heterocyclic systems investigated; thus the scope of the reaction was severely limited and it was extended only to the corresponding pyrazine compds. (PhMeN)3P (Ia) was stored at room temperature in the absence

moisture. Phenylphosphazoneanilide (II) was prepared and heated 0.5 h. on the steam bath, the anilinium chloride collected, and the solvent removed in vacuo to give product ready for use. The general method for the preparation of N-oxides was as follows. In general, 1 g. base, 2 ml. AcOH, and 3 ml. 40% AcOH was heated 16 h. at 60°, the AcOH removed, the residue dissolved in CHCl3, neutralized, the solution filtered, dried, evaporated, and the N-oxide purified by crystallization. Picolinic acid (3.1 g.) and 8 g. PhNH2 8.5 h. at 120-5° gave 2.65 g. picolinanilide (III), yellow needles, m. 76° (ligroine). Picolinic acid (3 g.) was converted to the acid chloride and then to 40% III. This yield was increased to 90% if the acid chloride was distilled before addition of PhNH2. II (from 37.4 g. PhNH2) refluxed 3 h. with 10 g. picolinic acid in 100 ml. dry PhMe gave 48% III. III gave 84% picolinanilide 1-oxide (IV), m. 181-5° (EtOAc). Acid chloride (from 20 g. picolinic acid) and 45 ml. SOCl2 in 100 ml. C6H6 treated dropwise below 30° with 65 ml. PhNHMe in C6H6, the solution refluxed 3 h., cooled, neutralized, extracted with CHCl3, and distilled gave

20.1 g. N-methylpicolinanilide (V), m. 54° (ligroine); plicate m. 161°. Ia was obtained from 10.7 g. PhNHMe and 2.3 g. PCl3 in dry PhMe, 4.5 g. picolinic acid in 100 ml. PhMe added, the mixture refluxed 2 h., and crystallized to give 1.5 g. V. V gave 84% N-methylpicolinanilide 1-oxide, cubes, m. 144° (EtOAc); plicate m. 152°. 3-Aminopicolinic acid (9 g.) diazotized, the mixture refluxed, cooled, the pH adjusted to 3-4 with NaOH, the H2O distilled, the yellow mass dried at 100°, and extracted with alc. gave 7.8 g. 3-hydroxypicolinic acid (VI), m. 211-12° (decomposition). The phosphazone compound from 7.5 g. PhNH2 and 1.8 g. PCl3 and 1.8 g. VI in 50 ml. PhMe refluxed 2 h., the solution filtered, the PhMe removed, and the residue extracted with ligroine gave 18% 3-hydroxypicolinic acid, needles, m. 89°. VI yielded 76% 3-hydroxypicolinic acid 1-oxide, m. 94-5° (ligroine). Ia and 2 g. VI in 100 ml. PhMe refluxed 15 min., the dried residue extracted with ligroine, the aqueous filtrate neutralized and extracted with CHCl3, the solution dried, evaporated, and the residue extracted with ligroine gave 1.9 g. 3-hydroxy-N-methylpicolinanilide (VII), m. 154°. VII was converted in 95% yield into the 1-oxide, m. 263-5° (decomposition). Ia (from 1.2 ml. PCl3 and 8 ml. PhNHMe) and 3.5 g. quinaldic acid in 30 ml. PhMe refluxed 1 h., the solution decanted, and the residue extracted with hot PhMe gave 4 g. N-methylquinaldinanilide (VIII), needles, m. 109° (ligroine). VIII was converted into 1-oxide, m. 153-4° (H2O). 3-Hydroxy-2-methylquinoline (3.2 g.), 6 g. AcOH, and 6.4 g. BzH heated 3 h. at 155-60°, the mixture diluted with 50 ml. alc., and the solid collected gave 3.2 g. 3-acetoxy-2-styrylquinoline (IX), yellow needles, m. 130° (alc.). IX (3.2 g.) and 32 ml. 6N HCl refluxed 1 h., the mixture cooled, added to an excess of hot aqueous NaOH, and the solution neutralized gave 2.5 g. 3-hydroxy-2-styrylquinoline (X), orange beads, m. 206-7° (decomposition) (alc.). X (7 g.) was benzoylated to yield 8.3 g. 2-styryl-3-quinolyl benzoate, needles, m. 178° (alc.). X (2 g.) methylated with CH2N2 [from 21 g. N-(p-toluenesulfonyl)methylnitrosamine] gave 2 g. 3-methoxy-2-methylquinoline, b16 172-4°; plicate m. 227° (decomposition). Methylation of 6.5 g. X in 300 ml. alc. gave 6.2 g. 3-methoxy-2-styrylquinoline (XI); plicate, yellow needles, m. 228° (alc.). XI (2.2 g.) in 70 ml. CSH5N and 10 ml. H2O treated at 2-5° with 2.5 g. KMnO4 in 45 ml. H2O, the mixture stirred 45 min. at this temperature then 2.5 h. at room temperature, the MnO2 filtered off, extracted with 0.1N NaOH, the filtrates concentrated, cooled, and the filtrate brought to pH 2.5 gave 0.3 g. 3-methoxyquinoxaline-2-carboxylic acid hydrate (XII), m. 112-5° (decomposition). Demethylation of XII with HI was accomplished by decarboxylation to give 3-hydroxyquinoxaline, m. 196°. XII was readily decarboxylated to give 2-methoxyquinoxaline; plicate m. 220-2° (alc.). Ia (from 7.1 g. PhNHMe and 1.1 ml. PCl3) refluxed 1 h. with 2.5 g. 1,6-dihydro-6-oxopyrazine-3-carboxylic acid in 22 ml. PhMe and the product extracted with alc. gave 2 g. 3-hydroxy-6-(N-methyl-N-phenylcarbamoyl)pyridazine (XIII), m. 158° (H2O). XIII (4.5 g.)

276 mμ (c 1400). [The compound, m. 224°, reported by Kubling and Kaselitz, Ber. 39, 1314 (1906) as "Methylaminophenylamino-alloxansäure" is considered by C.-L. to be hydrated VI. VI.0.5H₂O becomes anhydrous only at 110° in vacuo. I, VI, AcCl, and Ac₂O gave the 1-Ac derivative (VII), needles, m. 284° (from H₂O). 3,4-Dihydro-4-methyl-3-oxo-2-quinoxalinecarboxamide (VIII), was unaffected by AcCl-Ac₂O, hence the Ac derivative of VIII reported by K. and K. (loc. cit.) was probably VII. VII (0.13 g.) and MeI in Me₂CO-K₂CO₃ gave 0.083 g. 1-Ac derivative, prisms, m. 206° (from MeOH), of 1. VI and CH₂N₂ in Et₂O gave the 3',4'-Me₂ derivative (IX), m. 272-3° (from aqueous HCOONMe₂), which with MeI in Me₂CO and K₂CO₃ as above gave 1. 3-Hydroxy-2-quinoxalinecarboxamide (6.2 g.) and aqueous Na₂CO₃ warmed to effect solution and acidified with 12N HCl gave 5

9. 1,2,3,4-tetrahydro-3-oxoquinoxaline-2-epi-5'-hydantoin-0.5H₂O (X), fine needles, m. 250° (decomposition) (from aqueous EtOH or HCOONMe₂). λ_{max} 225, 301 mμ (c 21,600, 4000). λ_{min} 279 mμ (c 2800), described by Bednarsky and Marchlewski (C.A. 33, 4936) as the isomeric ureide. X (1 g.) and CH₂N₂ gave the 3',4'-Me₂ derivative, m. 272-3°, along with a gum presumed to be the isomeric 3-methoxy-3'-methyl compound 3,4-Dihydro-3-oxo-4-phenyl-2-quinoxalinecarboxamide (0.1 g.) in 40 cc. boiling H₂O containing 1.5 equivs. Na₂CO₃, filtered and the filtrate acidified with 2N H₂SO₄ gave 0.09 g. 1,2,3,4-tetrahydro-3-oxo-4-phenylquinoxaline-2-epi-5'-hydantoin, m. 225-5° (decomposition) (from aqueous EtOH) [cf. "Phenylaminophenylamino-alloxansäure described by K. and K. (loc. cit.)]. 3-Methoxy-2-quinoxalinecarboxamide, λ_{max} 246, 309, 340 mμ (c 20, 100, 6500, 5200). m. 225°, was rapidly hydrolyzed by warm aqueous Na₂CO₃ to the carboxylic acid, m. 140-2° (decomposition), which with CH₂N₂ gave the Me ester, m. 107°. Et 3-hydroxy-2-quinoxalinecarboxylate (XI) in a little MeOH and concentrated aqueous NH₃ gave


the amide (XII), m. 308° (decomposition); similarly, 2 g. XI and 20 cc. 25% MeNH₂ kept 8 hrs. at room temperature and the whole treated with excess 12N HCl gave 1.6 g. N-methylamide (XIII), m. 310-11° (decomposition) (from aqueous MeOH). XII (1 g.) and 10 cc. PhNH₂ refluxed 8-10 hrs., cooled, and added to excess 2N HCl gave 1.4 g. 2-carboxanilide, m. 340° (decomposition) (from aqueous HCOONMe₂). XII (3.6 g.), 4 g. anhydrous K₂CO₃, 2.0 cc. Me₂SO₄,

and 100 cc. Me₂CO refluxed 3 hrs., the solid material filtered, and the solid treated with 2N HCl gave 2.2 g. 3,4-dihydro-4-methyl-3-oxo-2-quinoxalinecarboxamide (XIII), yellow needles, m. 254-5° (from H₂O). λ_{max} 234, 301, 370 mμ (c 21,000, 7300, 5200). λ_{min} 262, 332 mμ (c 2200, 3200), unaffected by further treatment with Me₂SO₄. II (4.5 g.) and 1 equivalent BuO₂CCl in dry CHCl₃ gave a mixed anhydride (XIV); XIV with 1 equivalent Et₃N kept 10 min. at 0-10°, a one-third aliquot treated with an excess of Me₂NH, the mixture kept 14 hrs., washed with 2N HCl, aqueous NaHCO₃, and H₂O, and the


CHCl₃ solution then evaporated gave 0.32 g. N,N-dimethylamide, m. 115° (from C₆H₆-petr. ether), λ_{max} 232, 288, 353 mμ (c 23,000, 6800, 4800). λ_{min} 218, 264, 317 mμ (c 16,100, 4800, 4300). XIII and MeOH gave 3,4-dihydro-N,4-dimethyl-3-oxo-2-quinoxalinecarboxamide-H₂O, (XV), pale yellow needles, m. 167-8° (from MeOH). λ_{max} 234, 302, 369 mμ (c 20,500, 8900, 6200), λ_{min} 262 and 332 mμ (c 2100, 4200), also obtained by hydrolyzing I or by treating XIV as above with MeNH₂. The acid chloride from II and SOCl₂ in C₆H₆ as above treated with PhNHMe gave 75% N-methylamide (XVI), m. 169° (from C₆H₆-petr. ether), λ_{max} 232, 292, 354 mμ (c 20,500, 8800, 6700). λ_{min} 218, 264, 318 mμ (c 14,500, 3000, 4200); XIV and PhNHMe also gave XVI. XI (1 g.), o-C₆H₄(NH₂)₂, 8 cc. EtOH, and 2.5 cc. 1:1 AcOH-H₂O heated 20 hrs. at 100°, and the solid collected and extracted with 100 ml. boiling EtOH to remove the color gave 0.7 g. 2,2'-spirodi-(1,2,3,4-tetrahydro-3-oxoquinoxaline) (XVII), white powder, m. above 375°. λ_{max} 237, 301-2 mμ (c 47,700,

10,200). λ_{min} 275 mμ (c 5200). XVII (0.5 g.) heated 6 hrs. on the steam bath with AcCl-Ac₂O gave 0.15 2'-acetamido-3-acetoxy-2-quinoxalinecarboxanilide, yellow needles, m. 230° (decomposition). λ_{max} 232, 314, 352 mμ (c 33,300, 9400, 900). λ_{min} 264, 332, mμ (c 5100, 8800).

IT 101893-49-6, 2-Quinoxalinecarboxanilide, 2'-acetamido-3-hydroxy-, acetate (preparation of)
RN 101893-49-6 CAPLUS
CN 2-Quinoxalinecarboxanilide, 2'-acetamido-3-hydroxy-, acetate (6CI) (CA INDEX NAME)



L5 ANSWER 279 OF 283 CAPLUS COPYRIGHT 2006 ACS ON STN
ACCESSION NUMBER: 1956:64392 CAPLUS
DOCUMENT NUMBER: 50:64392
ORIGINAL REFERENCE NO.: 50:11981f-g
TITLE: Peptidolike polyoxo compounds. III. Synthesis of β-phenyl-α,β-dioxopropionanilide
AUTHOR(S): Balenovic, K.; Lacan, M.
CORPORATE SOURCE: Univ. Zagreb, Yugoslavia
SOURCE: Arhiv Kem. (1955), 27, 219-20
DOCUMENT TYPE: Journal
LANGUAGES: Unavailable
AB OF C.A. 50, 810f(in English). Adding 0.6 ml. 33% NaOH to a boiling solution of 4.5 g. p-ONC₆H₄NMe₂ and 7.2 g. BzCH₂CONHPh in 40 ml. EtOH, refluxing 5 min., keeping 1 hr. at -20°, and crystallizing the separated crystals from absolute EtOH gave 5.8 g. p-Me₂N₂C₆H₄N.CBzCONHPh (I), m. 191-2°. I (4.2 g.) triturated with 80 ml. 23% H₂SO₄ at 0° and kept 2 hrs. gives 1.7 g. BzCOC₆H₄NHPh, m. 115° (from C₆H₆); this with o-C₆H₄(NH₂)₂ gave the quinoxaline derivative, m. 179-80° (from C₆H₆).
IT 857757-46-1, 2-Quinoxalinecarboxanilide, 3-phenyl- (preparation of)
RN 857757-46-1 CAPLUS
CN 2-Quinoxalinecarboxanilide, 3-phenyl- (5CI) (CA INDEX NAME)



L5 ANSWER 280 OF 283 CAPLUS COPYRIGHT 2006 ACS ON STN
ACCESSION NUMBER: 1953:44613 CAPLUS
DOCUMENT NUMBER: 47:44613
ORIGINAL REFERENCE NO.: 47:7508a-1, 7509a-e
TITLE: Experimental chemotherapy of tuberculosis. II. The synthesis of pyrazinamides and related compounds
AUTHOR(S): Kuehner, S.; Dabalian, H.; Sanjurjo, J. L.; Bach, F. L., Jr.; Safir, S. R.; Smith, V. K., Jr.; Williams, J. H.


CORPORATE SOURCE: American Cyanamid Co., Stamford, CT
SOURCE: Journal of the American Chemical Society (1952), 74, 3617-21
CODEN: JACSAT; ISSN: 0002-7863
DOCUMENT TYPE: Journal
LANGUAGES: Unavailable
AB cf. C.A. 43, 5025b. To 5.0 g. 2-aminothiazole was added slowly a suspension of 3.5 g. freshly prepared pyrazinoyl chloride (I) in 15 cc. EtOAc, the mixture heated 10 min. on a steam bath, the supernatant hot EtOAc decanted, the residue heated again with 15 cc. EtOAc, the procedure repeated, the combined EtOAc-layers were evaporated to dryness, and the solid, yellow residue washed with cold H₂O, filtered, dried, and recrystd. from hot EtOAc to give 3.0 g. (60%) N-(2-thiazolyl)pyrazinamide, m. 187-9°. By the same procedure were prepared the following N-mono- or N,N-disubstituted pyrazinamides (substituent given): Me, m. 105°; Me₂, m. 70-2°; Bu 20%, b₃ 167-70°; Cl₆H₁₃ 50%, m. 85-7° (from C₆H₆-EtOH); PhCH₂, m. 116-18°; Ph 55-60%, m. 127-30°; p-ClC₆H₄ 60%, m. 145-5°; o-ClC₆H₄ 60%, m. 135-6°; m-ClC₆H₄ 60%, m. 145-7°; 2-pyridyl, 65%, m. 138-40°; 3-pyridyl 62%, m. 185-6°; 1-piperidyl 80%, m. 68-9° (from Me₂CO); 3-quinoxalyl 76%, m. 205-6°; and 2-pyrazinyl 40%, m. 190-2°. Et N-pyrazinoyl-β-alanate (II) (1 g.) in 25 cc. MeOH saturated with NH₃ at 0° gave 55% β-(N'-pyrazinoyl)amino-L-propanoic acid, m. 206-8° Me pyrazinoate (III) (5.0 g.), 7.5 g. HO(CH₂)₂NHCH₂CH₂NH₂, and 30 cc. absolute EtOH refluxed 60 hrs. gave 84% N-(2-hydroxyethyl)-N'-pyrazinoylthylene-diamine, m. 107-8°. Similarly were prepared from III and iso-BuNH₂, N-isobutylpyrazinamide, m. 63-4° (from C₆H₆-EtOH); and from III and p-MeOC₆H₄CH₂NH₂, 50% N-(p-methoxybenzyl)pyrazinamide m. 134-6°. By ammonolysis of the appropriate, substituted pyrazinoates were prepared the following substituted pyrazinamides (substituents given): 6-Me, 83%, m. 204-5° (from EtOH); 3-H₂N, 50%, m. 237-9°; 3-amino-6-bromo (IV) 80%, m. 215-17°; 3-HO, m. 265° (decomposition). 2,3-Pyrazinedicarboxamide (V) m. 240°, (decomposition); 2,6-isomer, 90%, m. 300° (decomposition); 6-Me derivative of IV, 80%, m. 215-17°. To 15 g. H₂N(CH₂)₂CH₂CH₂NH₂ and 5.2 g. NaOH in 100 cc. ice-cold H₂O were added simultaneously during 30 min. with stirring 9 g. NaOH in 50 cc. H₂O and 10 g. I in 50 cc. C₆H₆, the mixture was stirred 30 min. at room

temperature, the C₆H₆ removed in vacuo, and the resulting aqueous solution acidified with 6N HCl to give 7.5 g. 5-pyrazinoyl-L-pentenoic acid, 200-1°. By the same procedure but with NaHCO₃ were prepared 70% di-Et N-pyrazinoyl-L-aspartate, m. 64-5°, and 50% II, m. 87-9°. Cyanopyrazine (VI), b₆-7 86-7°, (21.9 g.) in 125 cc. dry Et₂O and 8.4 g. absolute MeOH saturated with HCl at 0° and the mixture let stand 15 hrs. at room temperature gave 25.6 g. Me pyrazinimidate-2HCl, m. above 150° (with darkening and decomposition); this was added to 600 cc. ice-cold 8% alc. NH₃, the mixture shaken 1 day at room temperature, filtered, the filtrate evaporated to dryness in vacuo, and the solid residue boiled briefly with 125 cc. Me₂CO, filtered, and crystallized from EtOH to give 6 g. pyrazinecarboxanilide-HCl, m. 215-18° (decomposition); picrate, m. 221-4°. VI (15 g.) in 200 cc. saturated, alc. NH₃ saturated with H₂S and the mixture let stand overnight at room temperature yielded 90% thiocarbonyl-pyrazine, m. 195-6°. To 13.8 g. III and 7 g. NH₂OH.HCl in 50 cc. ice-water was added 16 cc. 12.5 N NaOH, and the mixture let stand 15 min. in an ice bath and neutralized with HCl to give 72% pyrazinohydrazonic acid, m. 163-5° (from H₂O), gives a wine color with alc. FeCl₃. Pyrazinamide (VII) (21 g.), 84 cc. AcOH, and 210 cc. 30% H₂O₂ heated 34 hrs. at 56° gave 45% pyrazinoic acid 4-oxide, m. 292-3° (decomposition) (from AcOH), also obtained by similar oxidation of VI. VII (10 g.) and 17 g. MeI refluxed 12 hrs. in 100 cc. MeOH yielded 38% 3-carbamyl-1-methylpyrazinone iodide (VIII), m. 192-202° (from H₂O). VII (4 g.) refluxed 1.25 hrs. with 20 cc. Ac₂O gave 55% N-Ac derivative (IX), of VII, m. 92-7°. VII (15 g.), 18 cc. aqueous CH₂O, and 0.2 g.

K₂CO₃ heated on a steam bath until a clear solution was formed yielded 80% N-(hydroxymethyl)pyrazinamide, m. 129-36.5°. 1-Phenylsulfonyl-2-pyrazinoylhydrazine (X) 85% was obtained from PhSO₂Cl and pyrazinoic acid hydrazide (XI), m. 169°. Dry X (109.18 g.) and 18 g. finely powdered Na₂CO₃ heated at 150-70° and 35 mm. pressure, and the vapors bubbled through 34 aqueous H₂NC(S)NH₂ gave 9% pyrazinaldehyde thiosemicarbazone (XII), m. 237-9° (decomposition). XI (2.5 g.) and 3.3 g. p-AC₆H₄CH₂CHO in 100 cc. absolute EtOH refluxed 5 min. yielded 92% pyrazinoic acid (p-acetamidobenzylidene)hydrazide, m. above 250°. To Me₂MI (from 50 g. MeI and 9 g. Mg) in 100 cc. dry Et₂O was added dropwise over 20 min. 13 g. VI in 150 cc. Et₂O, and the mixture poured on ice and acidified to give 77% acetylpyrazine (XIII), m. 76-8° (from Et₂O); thiosemicarbazone (XIV), 67%, m. 226-7° (decomposition); oxime, 50%, m. 113-15° (sublimed at 100° and 0.05 mm.). Powdered S (1.5 g.) in 15 cc. concentrated NH₄OH saturated with H₂S, 3.0 g. XIII, and 12 cc. dioxane

heated 24 hrs. in a sealed tube at 170° gave 0.2 g. pyrazinacetamide, m. 108-10° (from EtOH-petr. ether). XIII (12.2 g.), 5.2 g. S, and 15 cc. morpholine refluxed 6 hrs. yielded 80% 4-(2-pyrazinylthioacetyl)morpholine, m. 92-3°. HCl passed through 29.6 g. pyrazinylidiazomethyl ketone (XV) in 600 cc. dry Et₂O until the evolution ceased gave 30% chloroacetylpyrazine, m. 85-6°. Thiosemicarbazones, 30%, m. 222-4°. To 30 cc. glacial AcOH was added at 50° in portions 5.4 g. XV, and, after all the N had been evolved, 0.5 g. KOAc, the mixture heated 1 hr. at 100°, and the AcOH distilled off in vacuo to yield 10% (acetoxyacetyl)pyrazine, m. 67-8°. VI (5.1 g.), 3.3 g. Na₂S, 10 cc. glacial AcOH and 15 cc. iso-PrOH autoclaved 5 days at 150° gave 30% 5-pyrazinyl-1H-tetrazole, m. 192-4°. Concentrated aqueous soln. of 2-aminopyrazine and KSCN mixed and acidified during 1 hr. with 1 molar equivalent HCl gave 80% 1-pyrazinyl-2-thiourea, m. 128°. PhONa (36 g.) and 36 g. chloropyrazine refluxed 13 hrs. yielded 72% Ph pyrazinyl ether, m. 50-2°. 3-Methyl-2-quinoxalinecarboxaldehyde thiosemicarbazone (XVI), m. 251-2° (decomposition) was obtained in 30% yield by refluxing the components 2 hrs. in absolute EtOH. All above mentioned pyrazine derivs. were tested in a standardized mouse test for T. B. activity at the arbitrary level of 0.2% of diet (8 mg./day), with survival as a criterion. VII, m. 189-91°, was highly active, and IX and XII showed a slight activity. All others were inactive; IV, V, VIII, X, XI, XIII, and XIV were also toxic. The following addnl. pyrazine derivs. (substituents and m.p.s. given) were also tested and found inactive: 702H, 225-6°; C(OAc).NH₂.2HCl, 180°; CO₂-Me.HCl, 46°; 6,2-Me(HO₂C), 138-40°; 2,3-(HO₂C) 2, 179-82°; 2,3-CO₂CONH₂, m. 245°; and 6,2,3-Me(HO₂C) 2, 43-4°. XVI, 2-chloro-3-quinoxalinecarboxamide (XVII), m. 207-9°, and its N-PhCH₂ derivative did not exhibit T.B. activity in the above test.


IT 858478-60-1, 2-Quinoxalinecarboxamide, N-benzyl-3-chloro- (preparation of)
RN 858478-60-1 CAPLUS
CN 2-Quinoxalinecarboxamide, N-benzyl-3-chloro- (5CI) (CA INDEX NAME)




L5 ANSWER 281 OF 283 CAPLUS COPYRIGHT 2006 ACS ON STN
ACCESSION NUMBER: 1949:30025 CAPLUS
DOCUMENT NUMBER: 43:30025

ORIGINAL REFERENCE NO.: 42:6402a-b
 TITLE: Some structural analogs antagonistic to pteroylglutamic acid
 AUTHOR(S): Woolley, D. W.; Pringle, A.
 CORPORATE SOURCE: Rockefeller Inst. for Med. Research, New York, NY
 JOURNAL: Journal of Biological Chemistry (1948), 174, 327-33
 CODEN: JBCHA3; ISSN: 0021-9258
 DOCUMENT TYPE: Journal
 LANGUAGE: Unavailable

AB A complex product (II) is prepared by condensation of o-phenylenediamine, dibromopropionaldehyde, and p-aminobenzoylglutamic acid. Quinoxaline-2-carboxyl-p-aminobenzoylglutamic acid (II) is prepared from p-aminobenzoylglutamic acid and quinoxaline-2-carboxyl chloride. 2-Amino-4,7-dihydroxypteridine-6-carboxyl-p-aminobenzoylglutamic acid (III) is obtained from the condensation of the acid chloride of isoxanthopterincarboxylic acid with the Na salt of p-aminobenzoylglutamic acid and precipitation at a pH of 3-4. Acidification of III ppt. 2-Amino-4,7-dihydroxypteridine-6-carboxyl-p-aminobenzoylglutamic acid (IV). These structural analogs of pteroylglutamic acid (V) inhibit the growth of certain bacteria, III being the most active. The amount of analog required for inhibition increases as the amount of V is increased. These analogs are more effective against Lactobacillus casei than against Streptococcus faecalis, and are more effective against other microorganisms which do not require V as a growth factor. Administration of 10 γ of V protects a rat against an otherwise fatal dose of 10 mg. of III.
 IT 857757-44-9, 2-Quinoxalinecarboxanilide, 4'-[1,3-dicarboxypropylcarbamoyl]- 860693-29-4, Benzoic acid, p-(2-amino-4,7-dihydroxy-6-pteridinecarboxamido)- (preparation of)
 RN 857757-44-9 CAPLUS
 CN INDEX NAME NOT YET ASSIGNED




RN 860693-29-4 CAPLUS
 CN Benzoic acid, p-(2-amino-4,7-dihydroxy-6-pteridinecarboxamido)- (SCI) (CA INDEX NAME)



L5 ANSWER 282 OF 283 CAPLUS COPYRIGHT 2006 ACS ON STN
 ACCESSION NUMBER: 1938:56548 CAPLUS
 DOCUMENT NUMBER: 32:56548
 ORIGINAL REFERENCE NO.: 32:79161,7917a-1
 TITLE: Alkaline degradation of tetrahydroxybutylquinoxaline and some quinoxaline derivatives
 AUTHOR(S): Maurer, Kurt; Boettger, Bernhard

RN 37648-63-8 CAPLUS
 CN 2-Quinoxalinecarboxamide, N-phenyl- (9CI) (CA INDEX NAME)




L5 ANSWER 283 OF 283 CAPLUS COPYRIGHT 2006 ACS ON STN
 ACCESSION NUMBER: 1938:8731 CAPLUS
 DOCUMENT NUMBER: 32:8731
 ORIGINAL REFERENCE NO.: 32:1265a-g
 TITLE: The phthaloyl reaction. The action of the anhydride of α,β -quinoxalinedicarboxylic acid on o-phenylenediamine

Crippa, Olinio B.; Aguzzi, Augusto
 SOURCE: Gazzetta Chimica Italiana (1937), 67, 352-8
 CODEN: GCITA9; ISSN: 0016-5603
 DOCUMENT TYPE: Journal
 LANGUAGE: Unavailable
 GI For diagram(s), see printed CA issue.
 AB The condensation of α,β -quinoxalinedicarboxylic acid anhydride (I) with o-C₆H₄(NH₂)₂ (II) was studied to learn the behavior, hitherto unknown, of a cyclic anhydride combined with a heterocyclic system and at the same time to extend a previous investigation on quinoxalines. Knowledge of structural relations and other exptl. results suggested that there action would not follow the normal course of phthaloylation. The expts. show that the condensation actually does differ from the usual phthaloylation, apparently as a result of the influence of the pyrazine ring, the cyclolamide group being particularly labile. I (2 g.) and II (2.4 g.) in absolute EtOH (100 cc.) refluxed for 0.5 hr. turn yellow, then ruby-red. After filtering, the combined filtrates and washings let stand for several days give β -[(o-aminophenylamido)quinoxaline- α -carboxylic acid o-H₂N-C₆H₄-N-CO-CO₂H (III), yellow, m. 168°, amphoteric. Acidification of its alkaline solns. gives an immediate white precipitate which soon turns yellow and yields III, perhaps in the more stable form of the internal NH salt. The EtOH-insol. residue in the preparation of III yields from boiling AcOH a pale yellow compound (IV), m. 186-87°, also amphoteric (though more acidic and less basic than III). With increase in the proportion of II to I, the yield of IV diminishes progressively. This fact, in conjunction with its chemical properties, makes it possible that the formula of IV is C₆H₄(NHCO₂C₆H₄N-CO-CO₂H)₂, which would be genetically analogous to III. This will be studied further. I (2 g.) and o-AcNH-C₆H₄-NH₂ (1.6 g.) in absolute EtOH refluxed yield β -[(o-acetylamino)phenylamido]quinoxaline- α -carboxylic acid, o-AcNH-C₆H₄-NHCO₂C₆H₄-N-CO-CO₂H (V), pale yellow, m. 217°. It is also formed by heating III with AcCl (2 parts by weight), III or V and excess Ac₂O heated for 10 min. yield quinoxaloylene- α,β -cyclo[(o-acetylamino)phenyl]imide (VI), m. 310-15°. The best yield is obtained by simple dehydration of V rather than of III, for with the latter acetylation of the free NH₂ group also takes place. This reaction is analogous to the transformation o-AcNH-C₆H₄-NH₂ (VI) of o-aminophthalimide compds. into the corresponding benzoyleneazolidine derivs. by Ac₂O [cf. and Galimberti, C. A. 25, 3363; 27, 3463]. In other words, in the reaction of I and II, the cyclic imide is formed only by subsequent dehydration by Ac₂O. Moreover, since, dehydration is accompanied by acetylation, and because the NH₂ group is thus rendered inactive, there is no opportunity for the formation of a quinoxaloylenebenzoinazole compound to be formed.
 IT 855874-27-0, 2-Quinoxalinecarboxylic acid, 3-(o-


SOURCE: Ber. (1938), 71B, 1383-91
 DOCUMENT TYPE: Journal
 LANGUAGE: Unavailable
 GI For diagram(s), see printed CA issue.
 AB Tetrahydroxybutylquinoxaline (I) with acids changes, without loss of C but with elimination of water, into a new ring system, glucosidone (C. A. 31, 8512.5). Its behavior toward alkalis is quite different. No condensation occurs but the side chain is degraded and there is finally obtained, through various intermediate products, quinoxaline- α -carboxylic acid (II). Since colored substances are formed in the course of the reaction, an attempt was made to isolate some of the intermediate products. Treated in pyridine with NaOMe under strictly defined conditions, I gives a red amorphous product (III); under different conditions, II is obtained in good yield. III is practically insol. except in concentrated mineral acids and alkalis, in which it dissolves with deep red color. The alkaline solution is decolorized by atmospheric O with formation of
 II. III forms with PhNHNH₂ an osazone (IV), to which is assigned the structure C₆H₄N:CH:CR:N (V) (R = C:(N₂Ph)CH:N₂Ph), and on acetylation a colorless monoacetate, Cl₂H₂OON₂ (VI), whose easy saponification shows that it is an O-Ac derivative VI reduces cold Fehling solution instantly, which makes the presence of a free CHO group very probable and hence it is assigned the structure V with R = CH(CHO)COAc. Although it contains an asym. C atom it is optically inactive; racemization probably takes place during the long treatment with alkali. With aromatic primary amines (aniline, toluidine, xylidine) III forms well crystallized red derivs., all of which behave very much alike. The aniline compound (VII) dissolves in concentrated acids with indigo-blue color changing to red on addition of water, in alkalis with deep red color. Solns. in organic solvents fluoresce strongly. With oxidizing agents these solns. turn yellow and the fluorescence disappears; dehydrogenation occurs, the red VII being 1,2-dihydroquinoxalylglycolaldehyde anil, C₆H₄N:CH:CH₂NH (R = CH(CH₂NPh)OH), and the yellow compound the dehydro product (VIII) corresponding to V. The structure of VII is confirmed by the oxidative degradation of VII in alkaline solution to II and PhNC. The free HO group is detected by acetylation but dehydrogenation also occurs and the product (IX) is the acetate of VIII; it can also be obtained by acetylation of VIII. As Schiff bases of α -HO aldehydes, VII and VIII give with PhNHNH₂ the same osazone (IV). Furthermore, both slowly change in solution into a pyrazine, (X, R = C₆H₄N:CH:CH₂N). The action of alkali on I therefore consists in elimination of 2 C atoms from the side chain with formation of quinoxalylglycolaldehyde which is reduced by other cleavage products to the 1,2-dihydroaldehyde (III). II always being formed as a 2nd cleavage product in varying amts. III (9 g. from 30 g. I suspended in 80 cc. pyridine and heated 2 hrs. on the water bath with 6 g. Na in 80 cc. MeOH), m. 138-44° (decomposition); if the mixture is boiled 6 hrs., the chief product is II. IV, yellow, m. 243°. VI, m. 117°, is soluble in alkalis with red color. VII (1.6 g. from 2 g. III), m. 188°. IX, m. 134°. VIII, m. 208°, dissolves in AcOH with blood-red color, in H₂SO₄ with a greenish color changed to deep blue by a drop of water and to red by more water; it is insol. in alkali. X, orange, m. 253°, is indifferent toward dilute acids and alkalis, evolves a PhNC odor with boiling concentrated alkalis and gives PhNH₂ on distillation with Zn dust.

Toluidine analog of VII, m. 150°; of VIII, m. 187°; of X, m. 276°. II (70% from 10 g. I, suspended in 600 cc. of 6% H₂O₂, treated below 80° with 24 g. solid NaOH and heated 1 hr. at 80°), m. 210°; ferrous salt, blue-violet leaflets; aniline salt, m. 156°; chloride, from II and SOCl₂, m. 115°; anilide, m. 180°, is hydrogenated with Pd in AcOH to the tetrahydro derivative, dark yellow m. 154°; toluidide, faintly yellow, m. 150°; 1,3,4-xylidide, m. 132°; Et ester, m. 85°.
 IT 37648-63-8, 2-Quinoxalinecarboxanilide (preparation of)


acetamidophenylcarbamyl)- 855874-64-5, 2-Quinoxalinecarboxylic acid, 3,3'-(o-phenylenebis(iminocarbonyl))di- 855874-66-7, 2-Quinoxalinecarboxylic acid, 3-(o-aminophenylcarbamyl)- (preparation of)
 RN 855874-27-0 CAPLUS
 CN 2-Quinoxalinecarboxylic acid, 3-(o-acetamidophenylcarbamyl)- (4CI) (CA INDEX NAME)



RN 855874-64-5 CAPLUS
 CN 2-Quinoxalinecarboxylic acid, 3,3'-(o-phenylenebis(iminocarbonyl))di- (4CI) (CA INDEX NAME)



RN 855874-66-7 CAPLUS
 CN 2-Quinoxalinecarboxylic acid, 3-(o-aminophenylcarbamyl)- (4CI) (CA INDEX NAME)



== LOG HOLD
 COST IN U.S. DOLLARS
 FULL ESTIMATED COST
 DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)
 CA SUBSCRIBER PRICE
 SINCE FILE
 ENTRY
 TOTAL
 1311.59
 1500.07
 SINCE FILE
 ENTRY
 TOTAL
 -174.75
 -174.75
 SESSION WILL BE HELD FOR 60 MINUTES
 STN INTERNATIONAL SESSION SUSPENDED AT 08:44:28 ON 28 FEB 2006